



# 2017 Scientific Report

# HSCSP Research Institute Board of Trustees

## President

Enric Argelagüés Vidal

## Secretary

Joaquim Jornet Porta

## Members

**Managing Director,**  
**Hospital de la Santa Creu i Sant Pau**

Alberto Salazar Soler

**Designated by the Hospital de la Santa Creu  
i Sant Pau Foundation**

Francisco Blanco Vaca  
Josep M. Forcada i Casanovas  
Jordi Sierra Gil

**Designated by the Generalitat de Catalunya**

Antonio L. Andreu Periz  
Francesc Subirada Curcó

**Designated by the Autonomous University  
of Barcelona**

Manuel Armengol Carrasco  
Antonio Escartín Siquier

**Designated by the Board of the Research Institute  
of Sant Pau Hospital**

Antoni Esteve Cruella  
Josep M. Ventura Ferrero

# IIB Sant Pau Steering Committee

## Chair

Alberto Salazar Soler

**Managing Director,**  
**Hospital de la Santa Creu i Sant Pau Healthcare  
Management Foundation**

## Members

Jordi Bachs i Ferrer  
Hospital de la Santa Creu i Sant Pau  
Private Foundation

Armand Sánchez  
Autonomous University of Barcelona

Lina Badimon Maestro  
Catalan Institute of Cardiovascular Sciences

Helena Isábal Roca  
Puigvert Foundation

Joan Garcia López  
Blood and Tissue Bank

Xavier Bonfill i Cosp  
Iberoamerican Cochrane Centre

Jaume Sellàrès Sallas  
Barcelona-Sardenya Primary Care Centre

Carme Borrell Thió  
Public Health Agency of Barcelona

Jaume Kulisevsky Bojarski  
Hospital de la Santa Creu i Sant Pau  
Research Institute

# Summary

## IIB Sant Pau · 2017 Scientific Report

- 04** Presentation
- 06** IIB Sant Pau Entities
- 08** Vertical Areas of Research
- 09** Transversal Areas of Research
- 09** Associated Groups
- 10** Organization Chart
- 12** Financial Data
- 14** Publications with an Impact Factor and Quartile
- 15** Research Resources
- 16** Research Training
- 17** Innovation Activity
- 22** Clinical Guidelines
- 24** Research Scientific Support and Technical Services

### **34** Areas of Research

- 36** Area 1. Cardiovascular Diseases
- 68** Area 2. Genetic, Metabolic and Inflammatory Diseases
- 112** Area 3. Haematological and Oncological Diseases
- 134** Area 4. Neurological, Mental Disorders and Ageing
- 176** Area 5. Uronephrology and Experimental Surgery
- 190** Area T1. Epidemiology, Public Health and Healthcare Services
- 222** Area T2. Molecular, Genomic, Cellular and Kinetic-Dynamic Bases for Diseases and their Treatment
- 234** Associated Groups

# Presentation



The present Annual Report is a mirror which reflects the scientific outputs and outcomes of IR-IIB Sant Pau (Instituto de Investigación Biosanitaria del Hospital Universitario de la Santa Creu i Sant Pau). It provides an opportunity to recognize the efforts and achievements of our researchers organized in 55 excellence groups and 21 associated clinical groups, and is therefore essential to the continued evaluation of our Institution. In addition to acting as the key instrument for evaluating the scientific impact of our research, the Annual Report is also a basic tool for working within our own network and to make available external visibility, as it provides a record of the activities carried out, in particular the projects undertaken, methods employed and results obtained. Our scientific activity is structured into seven research areas, five Vertical Areas (Cardiovascular Diseases; Genetic, Metabolic and Inflammatory Diseases; Hematological and Oncological Diseases; Neurological and Mental Disorders; and Uronephrology and Experimental Surgery) and two Transversal Lines (Epidemiology, Public Health and Healthcare Services; and Molecular, Genomic, Cellular and Kinetic-Dynamic Bases for Diseases and their Treatment).

Over the years, we have maintained a progressive growth of our scientific activity, without this year being an exception. Thus, once again this year, I congratulate all members for the magnificent performed work and the achieved results.

In 2017, IIB Sant Pau researchers published 1167 documents of which 866 were originals articles with an overall impact factor that reached 5.170 points, generously exceeding the 4,000-point threshold that we have achieved in the last years. There was also a consolidation in the quality of the source journals, with a mean impact factor of 5,0695 and with more than 56% of the manuscripts published in journals in the first quartile of their subject area.

Again this year, our clinical research activity continues to be very active, which keeps us as one of the most active centres in the country in clinical trials. More specifically, 204 new contracts for clinical trials were signed in 2017.

Regarding innovation, 5 new patents were presented and two were conferred in 2017. Thus, until December 2017, the IR- IIB Sant Pau had 13 conferred patents and 12 in process of resolution. Moreover, one start-up (Nanoligent S.L) and 2 Spin-off (Glycardial Diagnostics S.L and Blumentech S.L) were created in 2017.

Much work has yet to be done in order to reach IR-IIB's projected level of internationalization and participation in European research projects. A great part of the proposals for the new Strategic Plan 2019-2023 is presently focused to planning IIB's future strategies for reaching this goal. Thus, the challenges that lie ahead continued to be the increased awareness of opportunities for IR-IIB research groups to succeed within the context of European and international programs and a greater level of participation in European collaborative projects as either partners or coordinators.

The transfer of knowledge acquired thanks to the Research Institute-IIB Sant Pau must lead to improved clinical practice and advances that can be applied to the community. Although we cannot expect immediate results, we anticipate that the opening of the Experimental Research Building of the IR-IIB Sant Pau will bring about critical change in the every-day life of our researchers and will facilitate the continuous growing of the scientific quality of our groups.

Throughout the year, the IR-IIB and its groups also organized several workshops, courses, seminars and conferences. The outreach activities of the IR-IIB allow the network to reach its main goal of promoting quality research in the many areas of interest of our Institute by transferring knowledge to and from its researchers and by communicating its activities and findings to a variety of audiences.

Once again, thanks to the high quality of our researchers and the commitment of all the personnel of the IR – IIB Sant Pau that represents the best guarantee of continued success, we are optimistic about the future of our research activities that ultimately seeks to improve the health of the citizens.

**Jaume Kulisevsky**  
Scientific Director IIB Sant Pau

# IIB Sant Pau Entities

## Hospital de la Santa Creu i Sant Pau Healthcare Management Foundation



The Hospital de la Santa Creu i Sant Pau Healthcare Management Foundation (HSCSP Healthcare Management Foundation) is a high-technology specialist care hospital performing patient care, teaching and research activities in the clinical, epidemiological and healthcare services fields. It offers accredited specialist and undergraduate health science training courses.

## Hospital de la Santa Creu i Sant Pau Research Institute



The Hospital de la Santa Creu i Sant Pau Research Institute (HSCSP RI) promotes, manages and communicates biomedical research conducted in the HSCSP. It raises and manages funds and other resources for health science research in the basic, clinical, epidemiological and healthcare service fields.

## Hospital de la Santa Creu i Sant Pau Private Foundation



The Hospital de la Santa Creu i Sant Pau Private Foundation (HSCSP Private Foundation), which owns the HSCSP, is responsible for building, improving and maintaining buildings and premises used for medical care and associated and complementary activities.

## Autonomous University of Barcelona (UAB) - Ageing Institute



The UAB, a leading university renowned for quality and innovation in research, coordinates an influential scientific and technological centre, called Esfera UAB, responsible for promoting new business projects. The UAB also projects its productive activity in such a way as to disseminate new knowledge in society.

The Ageing Institute, attached to this university, is a non-profit foundation governed by a board of trustees formed by the UAB, the UAB Foundation and the Agrupació Mútua del Comerç i de la Indústria. Its mission is to improve knowledge of different aspects related to ageing with the aim of enhancing the quality of life of older people and promoting actions that contribute to adapting society and people to the challenges of demographic change.



### Catalan Institute of Cardiovascular Sciences (ICCC)

The ICCC performs basic and clinical research into cardiovascular and heart diseases. The fact that it competes successfully at the international level enables it to avail of the infrastructure necessary to transfer basic research to the development of therapies and diagnostic methods, ultimately improving medical care for patients.



### Puigvert Foundation

The Puigvert Foundation has the aim of deepening medical knowledge and perfecting medical techniques in the field of research and treatment of urinary and male reproductive system disorders and diseases. More specifically, it performs urology, nephrology and andrology research, focusing particularly on medical care, teaching, training and studies.



### Iberoamerican Cochrane Centre

This independent, not-for-profit organization has as its main aim the promotion of medical practice based on the best available scientific evidence. To this end, it ensures that valid, useful, up-to-date and thoroughly reviewed information is made available for clinical and healthcare decision making.



### Barcelona-Sardenya Primary Care Centre

Part of the public healthcare system, this teaching and care centre provides primary care services in its catchment area of Barcelona and has a research unit which performs clinical trials and epidemiology studies.



### Public Health Agency of Barcelona

This autonomous body, created by the Barcelona Health Consortium, has as its main mission to analyse and monitor the health of the population of Barcelona with a view to improving health and preventing risk. It is also responsible for epidemiological surveillance and the provision of medical care to substance abusers. It has an excellent track record in the public health and applied research fields.



### Blood and Tissue Bank

The Blood and Tissue Bank is a public healthcare body which carries out patient care, teaching and research activities in the blood transfusion and tissue bank fields.

# Vertical Areas of Research



## Cardiovascular Diseases

The incorporation of new technologies that facilitate molecular profiling and gene regulation has led to innovative research into heart disease. The great diversity of the groups in this area gives research varied perspectives, whether in developing or testing the effectiveness of new biomarkers (as in the investigation of the metabolic and genetic bases of diseases) or improving the range of results and possible applications in short-term therapies.




## Genetic, Metabolic and Inflammatory Diseases

Identifying the genes and mutations responsible for genetic diseases is an essential component of knowledge and understanding of the physiological bases of metabolic pathways and also in the development of new forms of treatment for common diseases affecting large proportions of the population, such as diabetes and obesity, known but with a hereditary diseases, infectious diseases (AIDS, tuberculosis, etc) and rare diseases (not well known but with a devastating impact on those affected).



## Haematological and Oncological Diseases

A broad range of research is conducted in this area, particularly in head-and-neck, breast, ovary, colorectal and haematological cancers, among others. Research covers a wide range of fields, with disciplines that include nanomedicine, new anticancer agents and predictive molecular markers. Initiatives of specific relevance include the GAIT (Genetic Analysis of Idiopathic Thrombophilia) project, a world pioneer in the identification of genes influencing the risk of thromboembolic disease, and research into antitumour immunotherapy in animals and humans.



## Neurological, Mental Disorders and Ageing

This area covers research in a broad range of disciplines. Besides the study of ageing and the most common neurodegenerative disorders such as Alzheimer and Parkinson, neurological research is also focused on stroke, neuroimmunology and neuromuscular diseases. Research into cognitive, affective, psychotic and personality disorders ranges from identification and evaluation of new therapeutic targets to neurogenesis and the effects of deep-brain stimulation. Research in this field has the support of the Drug Research Centre, which assesses the effectiveness of new drugs and therapies in humans.



## Uronephrology and Experimental Surgery

IIB Sant Pau promotes experimental surgery in the knowledge that this area has a promising future both as an independent research line and as a complement to general surgery. This interdisciplinary approach provides valuable new insights and ensures techniques and procedures of great clinical relevance. Current areas of interest include the development of minimally invasive techniques and the application of deep-brain stimulation in different pathologies. In the fields of andrology, urology and nephrology research, the Puigvert Foundation is a leading centre in Spain.

# Transversal Areas of Research



## Epidemiology, Public Health and Healthcare Services

Research in these fields aims to determine the magnitude and distribution and identify the determinants of public health problems in order to evaluate the effectiveness and efficiency of public interventions and prevention practices. This area also aims to reduce patient risk and make healthcare safer by promoting evidence-based medical practice and ensuring the use of conscious, explicit and rational decision making concerning patient care.



## Molecular, Genomic, Cellular and Kinetic-Dynamic Bases for Diseases and their Treatment


This area focuses on the structure of proteins associated with neurodegenerative diseases and inflammatory processes and on factors linked to the innate immune system. Research is also conducted in the area of osteoporosis, ageing-related macular degeneration and coagulation-cascade factors closely linked to cardiovascular disease and haemophilia. Such studies are vital to the understanding of diseases of the heart, blood and nervous systems and to advances in the fields of cancer and epidemiology.

# Associated Groups



This area includes HSCSP Research Institute groups that do not form part of IIB Sant Pau because they have not, as yet, been accredited by the External Scientific Committee.

# Organization Chart



## Steering Committee

### Chair

Dr. Alberto Salazar  
Hospital de la Santa Creu i Sant Pau Healthcare Management Foundation

### Members

Dr. Jordi Bachs  
Hospital de la Santa Creu i Sant Pau Private Foundation  
  
Dr. Lluís Tort  
Autonomous University of Barcelona  
  
Dr. Lina Badimon  
Catalan Institute of Cardiovascular Sciences  
  
Dr. Helena Isábal  
Puigvert Foundation  
  
Dr. Joan Garcia  
Blood and Tissue Bank  
  
Dr. Xavier Bonfill  
Iberoamerican Cochrane Centre  
  
Dr. Carme Borrell  
Public Health Agency of Barcelona  
  
Mr. Jaume Sellarès  
Barcelona-Sardenya Primary Care Centre  
  
Dr. Jaume Kulisevsky  
Hospital de la Santa Creu i Sant Pau Research Institute

## Executive Committee

### Chair

Dr. Jaume Kulisevsky  
IIB Sant Pau Manager

### Representatives of Associated Entities

Dr. Manel Trias  
Autonomous University of Barcelona  
  
Dr. Ramon Mangues  
Hospital de la Santa Creu i Sant Pau Research Institute  
  
Dr. Xavier Bonfill  
Iberoamerican Cochrane Centre  
  
Dr. Juan Cinca  
Hospital de la Santa Creu i Sant Pau Healthcare Management Foundation  
  
Dr. Alessandro Sionis  
Hospital de la Santa Creu i Sant Pau Private Foundation  
  
Dr. Lina Badimon  
Catalan Institute of Cardiovascular Sciences  
  
Dr. Helena Isabal  
Puigvert Foundation  
  
Dr. Joan Garcia  
Blood and Tissue Bank  
  
Dr. Maica Rodríguez  
Public Health Agency of Barcelona  
  
Dr. Carlos Brotons  
Barcelona-Sardenya Primary Care Centre

## Internal Scientific Committee

### Chair

Dr. Jaume Kulisevsky  
IIB Sant Pau Manager

### Vice-Chair

Dr. Antonio López Pousa  
Chair, Clinical Research Ethics Committee

### 4 members designated by the IIB Sant Pau Manager

Dra. Lina Badimon  
Molecular Pathology and Therapeutic of Ischaemic and Atherothrombotic Diseases

Dr. Alex Bayes  
Molecular physiology of the synapse

Dr. Sílvia Mateu  
Puigvert Foundation

Dr. Carlos Brotons  
Barcelona-Sardenya Care Research Centre

### 2 members each representing IIB Sant Pau thematic areas

#### Cardiovascular Diseases

Dr. Juan Cinca Cuscallola  
Clinical and translational cardiology

Dr. José Martínez  
Atherosclerosis and vascular biology

#### Genetic, Metabolic, Inflammatory and Infectious Diseases

Dr. Cándido Juárez  
Inflammatory diseases

Dr. Carlos Guarner  
Digestive diseases

### Haematological and Oncological Diseases

Dr. Miquel Quer  
Ear, nose and throat cancers

Dr. Agustí Barnadas  
Clinical oncology

### Neurological, Mental Disorders and Ageing

Dr. Alberto Lleó  
Neurobiology of dementia

Dra. María J. Portella  
Clinical psychiatry

### Uronephrology and Experimental Surgery

Dr. José Ballarín  
Nephrology research

Dr. Manel Trias  
General and digestive surgery

### Epidemiology, Public Health and Healthcare Services

Dr. Carles Ariza  
Evaluation of public health policies and programmes

Dr. Gerard Urrútia  
Clinical epidemiology and healthcare services

### Molecular, Genomic, Cellular and Kinetic-Dynamic Bases for Diseases and Treatments

Dr. José Manuel Soria  
Genomics and bioinformatics for genetically complex disease

Dra. Marta Valle  
Pharmacokinetic/pharmacodynamic modelling and simulation

## External Scientific Committee

Dr. José López-Barneo  
Physiology professor  
Institute of Biomedicine of Seville (Spain)

Dr. Ángel María Carracedo  
Genomic medicine group researcher  
Institute of Legal Medicine  
Faculty of Medicine and Dentistry  
Santiago de Compostela University (Spain)

Dr. José Palacios  
Head of the pathology/anatomy Department  
Ramón y Cajal Hospital (Madrid, Spain)

Dr. Agustín Gómez de la Cámara  
Clinical epidemiology group researcher  
Doce de Octubre Teaching Hospital (Madrid, Spain)

Dr. John Louis McGregor  
Director of Research-INSERM Unit 689  
Cardiovascular Research Centre-Lariboisière Hospital (Paris, France)

Dr. Jordi Alonso  
Health Services Research Unit  
Hospital del Mar Municipal  
Institute for Medical Research (Barcelona, Spain)

Mr. Guillem López Casasnovas  
Professor  
Faculty of Economics and Business Sciences  
Pompeu Fabra University (Barcelona, Spain)

## Management Team

### Scientific & Management Director

Dr. Jaume Kulisevsky

### Financial Director

Esther Zamora

### Deputy Director

Miriam Ors

# Financial Data




Next we highlight some economic data. The first chart shows the evolution of the public and private funds raised by the IIB San Pau during the period 2006-2017. The Income Statement for 2017 are displayed in the following page.

As a relevant event in 2017, on 31 December, the “Institut Català de Ciències Cardiovasculars” was dissolved by global assignment of its assets and liabilities, with effect from 01/01/2018, to the “Fundació Institut de Recerca del Hospital de la Santa Creu i Sant Pau”.

**Esther Zamora**  
Financial Director

## Public/Private Income Summary 2006-2017




## Income Statement year ending 31 December 2017

Income from activities	16.049.341,80
Services	5.228.002,36
Collaborations with partners and sponsors	2.742.355,22
Government grants	7.203.741,68
Other grants, donations and legacies	959.842,50
Repayment of grants, donations, etc	-84.599,96
Stocks and supplies	-1.449.504,87
Material and equipment for activities	-1.449.504,87
Grants awarded and other expenses	-23.000,00
Personnel expenditure	-8.875.073,29
Salaries	-6.843.074,97
Social security	-2.031.998,32
Other operating expenses	-5.610.389,28
External services	-4.960.623,75
Taxes	-65.100,43
Loss, deterioration and variation in provisions for operations	30.792,09
Other operating expenses	-615.457,19
Depreciation of fixed assets	-934.322,61
Grants, donations and bequests transferred to results	663.698,50
Other gains/losses	204.111,75
<b>OPERATIONAL PROFIT/LOSS</b>	<b>24.862,00</b>
Financial income	157.311,80
Financial expenditure	-159.147,08
<b>FINANCIAL PROFIT/LOSS</b>	<b>-2.683,66</b>
<b>OVERALL PROFIT/LOSS</b>	<b>22.178,34</b>


*In euros*

# Publications with an Impact Factor and Quartile

## Production status



## Indexed publications by quartile



# Research Resources

Centre	Active		Granted	
	2016	2017	2016	2017
AGAUR (Agència de Gestió d'Ajuts Universitats i Recerca)	24	24	—	1
Comissió Europea	3	3	—	1
Projectes americans	—	—	—	1
Fundació Infermeria i Societat	1	3	2	1
Fundació Marató TV3	12	14	2	3
Fundación Mutua Madrileña (FMM)	2	1	—	1
Fundació Josep Carreras Internacional	—	1	1	—
ISCIII (Instituto de Salud Carlos III)	99	111	28	29
MINECO (Ministerio de Economía y Competitividad)	7	6	3	—
Ministerio de Sanidad, Servicios Sociales e Igualdad	5	5	2	—
SEPAR (Sociedad Española de Neumología y Cirugía Torácica)	3	2	—	—
AECC (Asociación Española Contra el Cáncer)	5	4	—	—
SOCAP (Societat Catalana de Pneumologia)	1	—	—	—
Sociedad Española de Diabetes	1	—	—	—
Fundació Catalana de Pneumologia	3	1	—	1
Sociedad Española de Cardiología	1	—	—	—
AFM Telethon	1	—	—	—
Societat Catalana de Psiquiatria i Salut Mental	1	—	—	—
GILEAD	—	1	1*	—
Grupo Español de Investigación en Sarcomas	1	1	—	—
Fed Esp de Enfermedades Raras / Fund Isabel Gemio / Fed Esp de Enfermedades Neuromusculares	1	1	—	—
Fundació Privada de l'Hospital de la Santa Creu i Sant Pau	6	7	7	—
Col·legi de Farmacèutics de Barcelona	1	—	—	—
Fundación y Sociedad Española de Arteriosclerosis	1	1	—	—
European Society of Cardiology	1	1	—	—
Fundació Víctor Grífols i Lucas	1	—	—	1
Fundació Ramon Pla Armengol	1	1	—	—
Institució CERCA	1	1	1	—
Fundación BBVA	—	1	1	—
BIOCAT	—	1	1	—
Grupo Español de Oncología Genitourinaria	—	1	1	—
Fundació Privada Daniel Bravo-Andreu	1	1	—	—
Foundation International Guillain-Barré	1	—	—	—
Fundación Española para el Fomento de la Investigación de la Esclerosis Lateral Amiotrófica	—	—	—	1
Acadèmia de Ciències Mèdiques	—	—	—	1
Departament de Salut (Generalitat de Catalunya)	—	—	—	8
	185	193	50	49

\* A project has resigned.

\*\* Five projects have resigned.

# Research Training

Centre	Active		Granted	
	2016	2017	2016	2017
AGAUR (Agència de Gestió d'Ajuts Universitats i Recerca)	5	6	2	3*
Departament de Salut (Generalitat de Catalunya)	1	1	–	–
MEC (Ministerio de Educación, Cultura y Deporte)	–	–	–	1
MINECO (Ministerio de Economía y Competitividad)	3	3	1	3*
ISCIII (Instituto de Salud Carlos III)	34	30	12	15**
Fundación Casa del Corazón	1	–	–	–
Projectes americans	1	1	–	–
Fundació Privada de l'Hospital de la Santa Creu i Sant Pau	3	10	10	–
SEPAR (Sociedad Española de Neumología y Cirugía Torácica)	–	1	1	–
SOCAP (Societat Catalana de Pneumologia)	–	1	1	1
FUCAP (Fundació Catalana de Pneumologia)	–	1	1	–
FEHH (Fundación Española de Hematología y Hemoterapia)	–	1	1	–
AECC (Asociación Española Contra el Cáncer)	–	1	1	1
Departament de Salut (Generalitat de Catalunya)	–	–	–	5
	48	56	30	29

\* A project has resigned.

\*\* Five projects have resigned.

# Innovation Activity

## Innovation funnel 2017



The Transfer and Innovation Unit manages the innovation projects developed at the Institute, from the capture and evaluation of the opportunities, to their development, implementation and/or transfer to the market. The chart below shows the innovation projects portfolio according to their phase and typology as of December 31, 2017. The Results of Innovation are detailed in the following pages.

**Miriam Ors Riera**

Director of the Technology Transfer and Innovation Unit  
Deputy Director of Research Institute



Source: Hospital de la Santa Creu i Sant Pau Research Institute

# Patents

Title	HSCSP RI author(s)	Territory	Application number	Filing date	Status	Grant number	Grant date
Marcadores para la miocardiopatía dilatada	David de Gonzalo	-	201700749	24/11/2017	In process	-	-
Genetic biomarker profiles for endurance sport suitability	José Manuel Soria	-	EP17382799.9	27/11/2017	In process	-	-
Nanostructured proteins and uses thereof	Ramon Mangues	-	EP17169722.0	05/05/2017	In process	-	-
Therapeutic nanoconjugates and uses thereof	Ramon Mangues	-	EP17382461.6	14/07/2017	In process	-	-
New therapeutic compounds targeting the androgen receptor	Pablo Fuentes	GB	GB1701887.0	05/02/2017	In process	-	-
Systems and methods to assess infarcted myocardial tissue by measuring electrical impedance during the cardiac cycle	Juan Maria Cinca; Gerard Amorós; Esther Jorge	-	PCT/EP2016/056933	30/03/2016	In process	-	-
Dispositivo para simular una operación endoscópica vía orificio natural	Ramon Rovira	-	PCT/EP2016/080572	12/12/2016	In process	-	-
Methods and kits for the diagnosis and risk stratification of patients with ischemia	Lina Badimon Maestro; Judit Cubedo Ràfols; Teresa Padró Capmany	-	PCT/EP2017/058768	12/04/2016	In process	-	-
Prevention and/or treatment of ischemia or ischemia / reperfusion injury	Lina Badimon Maestro; Judit Cubero Ràfols; Gemma Vilahur García; Teresa Padró Capmany	-	PCT/EP2017/056027	14/06/2016	In process	-	-
Procedimiento y dispositivo para el aprendizaje y entrenamiento de operaciones de cirugía laparoscópica e intervenciones similares	Ramon Rovira	Spain	P201331528	16/10/2013	Granted	ES2534140B1	17/04/2015
Methods and reagents for efficient and targeted delivery of therapeutic molecules to CXCR4 cells	Ramon Mangues; Ugutz Unzueta; Virtudes Céspedes; Isolda Casanova (CIBER)	Australia	2012206533	19/07/2012	Granted	-	18/12/2017
Methods and reagents for efficient and targeted delivery of therapeutic molecules to CXCR4 cells	Ramon Mangues; Ugutz Unzueta; Virtudes Céspedes; Isolda Casanova (CIBER)	Israel	227442	13/01/2012	In process	-	-

Title	HSCSP RI author(s)	Territory	Application number	Filing date	Status	Grant number	Grant date
Methods and reagents for efficient and targeted delivery of therapeutic molecules to CXCR4 cells	Ramon Mangues; Ugutz Unzueta; Virtudes Céspedes; Isolda Casanova (CIBER)	Europe	EP12704711.6	13/01/2012	In process	-	-
Methods and reagents for efficient and targeted delivery of therapeutic molecules to CXCR4 cells	Ramon Mangues; Ugutz Unzueta; Virtudes Céspedes; Isolda Casanova (CIBER)	USA	US 13/979560	03/04/2014	Granted	US 20140094404 A1	28/02/2017
LRP1 as key receptor for the transfer of sterified cholesterol from very-low-density lipoproteins (VLDL) to ischaemic cardiac muscle	Vicenta Llorente Cortés; Lina Badimon Maestro;	USA	US14129446	29/06/2011	Granted	US 9096671 B2	08/04/2015
LRP1 as key receptor for the transfer of sterified cholesterol from very-low-density lipoproteins (VLDL) to ischaemic cardiac muscle	Vicenta Llorente Cortés; Lina Badimon Maestro;	Europe	12804028.4	29/06/2011	Granted	EP2728005B1	22/08/2018
Conjugates comprising nanoparticles coated with platinum containing compounds	Òscar Gallego	Japan	JP2011540141	13/06/2011	Granted	P1133JP00	07/01/2016
Conjugates comprising nanoparticles coated with platinum containing compounds	Òscar Gallego	Canada	CA2745972	06/06/2011	Granted	CA2745972	11/04/2016
Conjugates comprising nanoparticles coated with platinum containing compounds	Òscar Gallego	Israel	il213408	06/06/2011	In process	-	-
Conjugates comprising nanoparticles coated with platinum containing compounds	Òscar Gallego	Turkey	P1133TREP	06/06/2011	Granted	TR 2014 11735 T4	23/02/2016
Conjugates comprising nanoparticles coated with platinum containing compounds	Òscar Gallego	Europe	EP20090768395	15/12/2009	Granted	EP2379114B1	09/07/2014
Conjugates comprising nanoparticles coated with platinum containing compounds	Òscar Gallego	USA	US13140347	15/12/2009	Granted	US9023370 B2	20/12/2015
Blood-based assay for dysferlinopathies	Isabel Illa; Eduard Gallardo	Canada	2468431	26/05/2004	Granted	CA2468431C	28/06/2011
Blood-based assay for dysferlinopathies	Isabel Illa; Eduard Gallardo	USA	US10/306662	27/11/2002	Granted	US7172858B2	06/02/2007
Blood-based assay for dysferlinopathies	Isabel Illa; Eduard Gallardo	Japan	JP2003547654A	27/11/2002	Granted	JP4282483B2	24/06/2009

## Spin off

Tax number	Business name	HSCSP RI Entrepreneur	Type	Constitution date	Licensed technology	Status
B-66970088	Nanoligent S.L.	Manuel Rodríguez	Start-up	13/03/2017	New therapeutic product in the oncology area, especially in the treatment of metastasis.	Active
B-67079186	Glycardial Diagnostics S.L.	Lina Badimon, Teresa Padró, Judit Cubedo, Gemma Vilahur	Spin-off	15/09/2017	Apo J-Glyc as a novel biomarker for the diagnosis and prognosis of myocardial ischemia	Active
B-66963257	Blumentech S.L.	Jordi Riba	Spin-off	01/03/2017	Pharmacological therapies for psychiatric and neurological patients	Active
B-66663303	Surgitrainer S.L.	Ramon Rovira	Start-up	15/03/2016	Method and device for learning and training operations laparoscopic surgery and similar procedures	Active

## Other IP

Type	Title	Author(s)	Register date
Trademark registration	m-HEART	MªAntonia Mangues;Mar Gomis	19/05/2017
Notary registration	DUO QUEST Clinical Scale	Antonia Campolongo	08/04/2016
Notary registration	Memory Unit Database	Daniel Alcolea; Juan Fortea	30/09/2015
Notary registration	PARKINSON DISEASE COGNITIVE FUNCTIONAL RATING SCALE (PD-CFRS)	Jaime Kulisevsky; Javier Pagonabarraga	17/07/2015
Notary registration	PARKINSON'S DISEASE - COGNITIVE RATING SCALE (PD-CRS)	Jaime Kulisevsky; Javier Pagonabarraga	17/07/2015

# Technology Transfer Agreements

Year	Title Contract	Collaborator /Client	IP	Research group
2017	Acord de llicència patent	Nanoligent, SL	Ramon Mangues Bafalluy	Oncogènes i antitumorals
2017	Acord de transferència	Bluementech, SL	Jordi Riba Serrano	Neuropsicofarmacologia humana experimental
2017	Acord d'explotació	Nabelia, SL	Oscar Gallego Rubio	Recerca clínica en oncologia
2016	Llicència escala PD-CRS	Sanofi-Aventis	Jaime Kulisevsky Bojarski	Parkinson Disease and Movement Disorders
2016	Transferència DiGestEpiClin	Fundació Institut per l'Excel·lència Clínica i Sanitària	Xavier Bonfill Cosp	Clinical Epidemiology and Healthcare Services
2016	Tranferència Surgitrainer and Hystrainer	Surgitrainer SL	Ramon Rovira Negre	Reproductive Health
2015	Contracte llicència escala clínica	Eli Lilly & Co.	Jaime Kulisevsky Bojarski	Parkinson Disease and Movement Disorders
2015	Llincència escala clínica	Bracket Global LLC	Jaime Kulisevsky Bojarski	Parkinson Disease and Movement Disorders
2015	Cooperation treaty iFightDepression	European Alliance Against Depression e.V.	Maria J. Portella	Clinical Psychiatry
2014	License Agreement PREDI-NU Project	European Alliance Against Depression e.V.	Saiko Allende	Clinical Psychiatry

# Clinical Guidelines

1. Ariza J, Cobo J, Baraia-Etxaburu J et al. Executive summary of management of prosthetic joint infections. Clinical practice guidelines by the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). *Enferm Infecc Microbiol Clin.* 2017 Mar;35(3):189-195. doi: 10.1016/j.eimc.2016.08.012
2. Babjuk M, Bohle A, Burger M et al. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. *Eur Urol* 2017; 71(3):447-61. *Eur Urol.* 2017 Mar;71(3):447-461. doi: 10.1016/j.eurouro.2016.05.041. Epub 2016 Jun 17.
3. Capdevila J, Galofre JC, Grande E et al. Consensus on the management of advanced radioactive iodine-refractory differentiated thyroid cancer on behalf of the Spanish Society of Endocrinology Thyroid Cancer Working Group (GTSEEN) and Spanish Rare Cancer Working Group (GETHI). *Clin Transl Oncol.* 2017 Mar;19(3):279-287. doi: 10.1007/s12094-016-1554-5. Epub 2016 Oct 4.
4. de Witte T, Bowen D, Robin M et al. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. *Blood.* 2017 Mar 30;129(13):1753-1762. doi: 10.1182/blood-2016-06-724500. Epub 2017 Jan 17
5. Dodd K, Watchman K, Janicki MP et al. Consensus statement of the international summit on intellectual disability and Dementia related to post-diagnostic support. *Aging Ment Health.* 2017 Sep 7:1-10. doi: 10.1080/13607863.2017.1373065
6. Dohner H, Estey E, Grimwade D et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. *Blood.* 2017 Jan 26;129(4):424-447. doi: 10.1182/blood-2016-08-733196
7. Du Y, Carrio I, De Vincentis G et al. Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer. *Eur J Nucl Med Mol Imaging.* 2017 Sep;44(10):1671-1678. doi: 10.1007/s00259-017-3756-7
8. Engelborghs S, Niemantsverdriet E, Struyfs H et al. Consensus guidelines for lumbar puncture in patients with neurological diseases. *Alzheimers Dement (Amst).* 2017 May 18;8:111-126. doi: 10.1016/j.dadm.2017.04.007. eCollection 2017
9. Garcia-Iglesias P, Botargues JM, Feu Caballe F et al. Management of non variceal upper gastrointestinal bleeding: position statement of the Catalan Society of Gastroenterology. *Gastroenterol Hepatol.* 2017 May;40(5):363-374. doi: 10.1016/j.gastrohep.2016.11.009
10. Gonzalez A, Lluch A, Aba E et al. A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM). *Clin Transl Oncol.* 2017 May;19(5):616-624. doi: 10.1007/s12094-016-1571-4
11. Gonzalez-Billalabeitia E, Sepulveda JM, Maroto P et al. Consensus Recommendations from the Spanish Germ Cell Cancer Group on the Use of High-dose Chemotherapy in Germ Cell Cancer. *Eur Urol Focus.* 2017 Apr;3(2-3):280-286. doi: 10.1016/j.euf.2016.07.002
12. Isla D, Majem M, Vinolas N et al. A consensus statement on the gender perspective in lung cancer. *Clin Transl Oncol* 2017; 19(5):527-35. *Clin Transl Oncol.* 2017 May;19(5):527-535. doi: 10.1007/s12094-016-1578-x
13. Jimenez-Fonseca P, Carmona-Bayonas A, Calderon C et al. FOTROCAN Delphi consensus statement regarding the prevention and treatment of cancer-associated thrombosis in areas of uncertainty and low quality of evidence. *Clin Transl Oncol.* 2017 Aug;19(8):997-1009. doi: 10.1007/s12094-017-1632-3
14. Jimenez-Fonseca P, Gomez Saez JM, Santamaria Sandi J et al. Spanish consensus for the management of patients with anaplastic cell thyroid carcinoma. *Clin Transl Oncol.* 2017 Jan;19(1):12-20. doi: 10.1007/s12094-016-1506-0
15. Kamat AM, Colombel M, Sundi D et al. BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG. *Nat Rev Urol.* 2017 Apr;14(4):244-255. doi: 10.1038/nrurol.2017.16
16. Lip GYH, Collet JP, Caterina R et al. Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLEACE). *Europace.* 2017 Nov 1;19(11):1757-1758. doi: 10.1093/europace/eux240.

17. Lip GYH, Collet JP, de Caterina R et al. Antithrombotic Therapy in Atrial Fibrillation Associated with Valvular Heart Disease: Executive Summary of a Joint Consensus Document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, Endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLEACE). *Thromb Haemost.* 2017 Dec;117(12):2215-2236. doi: 10.1160/TH-17-10-0709
18. Lopez-Vina A, Giner J, Molina J et al. Multidisciplinary Consensus on the Nonadherence to Clinical Management of Inhaled Therapy in Spanish asthma patients. *Clin Ther.* 2017 Aug;39(8):1730-1745.e1. doi: 10.1016/j.clinthera.2017.06.010
19. Luquin MR, Kulisevsky J, Martinez-Martin P, Mir P, Tolosa ES. Consensus on the Definition of Advanced Parkinson's Disease: A Neurologists-Based Delphi Study (CEPA Study). *Parkinsons Dis.* 2017;2017:4047392. doi: 10.1155/2017/4047392
20. Manos M, Giralt J, Rueda A et al. Multidisciplinary management of head and neck cancer: First expert consensus using Delphi methodology from the Spanish Society for Head and Neck Cancer (part 1). *Oral Oncol.* 2017 Jul;70:58-64. doi: 10.1016/j.onaloncology.2017.04.004
21. Martin-Llahi M, Albillas A, Banares R et al. Vascular diseases of the liver. Clinical Guidelines from the Catalan Society of Digestology and the Spanish Association for the Study of the Liver. *Gastroenterol Hepatol.* 2017 Oct;40(8):538-580. doi: 10.1016/j.gastrohep.2017.03.011
22. Miravitles M, Alvarez-Gutierrez FJ, Calle M et al. Algorithm for identification of asthma-COPD overlap: consensus between the Spanish COPD and asthma guidelines. *Eur Respir J.* 2017 May 1;49(5). pii: 1700068. doi: 10.1183/13993003.00068-2017
23. Navarini AA, Burden AD, Capon F et al. European consensus statement on phenotypes of pustular psoriasis. *J Eur Acad Dermatol Venereol* 2017; 31(11):1792-9. *J Eur Acad Dermatol Venereol.* 2017 Nov;31(11):1792-1799. doi: 10.1111/jdv.14386
24. Pastor M, Lopez Pousa A, Del Barco E et al. SEOM clinical guideline in nasopharynx cancer (2017). *Clin Transl Oncol.* 2018 Jan;20(1):84-88. doi: 10.1007/s12094-017-1777-0
25. Pereira MP, Steinke S, Zeidler C et al. European academy of dermatology and venereology European prurigo project: expert consensus on the definition, classification and terminology of chronic prurigo. *J Eur Acad Dermatol Venereol.* 2018 Jul;32(7):1059-1065. doi: 10.1111/jdv.14570
26. Pernambuco L, Espelt A, Magalhaes HV Junior, Lima KC. Recommendations for elaboration, transcultural adaptation and validation process of tests in Speech, Hearing and Language Pathology. *Codas.* 2017 Jun 8;29(3):e20160217. doi: 10.1590/2317-1782/20172016217.
27. Plaza V, Alvarez F, Calle M et al. Consensus on the Asthma-COPD Overlap Syndrome (ACOS) Between the Spanish COPD Guidelines (GesEPOC) and the Spanish Guidelines on the Management of Asthma (GEMA). *Arch Bronconeumol.* 2017 Aug;53(8):443-449. doi: 10.1016/j.arbres.2017.04.002
28. Quirce S, Delgado J, Entrenas LM et al. Quality Indicators of Asthma Care Derived From the Spanish Guidelines for Asthma Management (GEMA 4.0): A Multidisciplinary Team Report. *J Investig Allergol Clin Immunol.* 2017;27(1):69-73. doi: 10.18176/jiaci.0121.
29. Redondo A, Bague S, Bernabeu D et al. Malignant bone tumors (other than Ewing's): clinical practice guidelines for diagnosis, treatment and follow-up by Spanish Group for Research on Sarcomas (GEIS). *Cancer Chemother Pharmacol.* 2017 Dec;80(6):1113-1131. doi: 10.1007/s00280-017-3436-0
30. Rochwerg B, Brochard L, Elliott MW et al. Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure. *Eur Respir J.* 2017 Aug 31;50(2). pii: 1602426. doi: 10.1183/13993003.02426-2016
31. Roupret M, Babjuk M, Comperat E et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2017 Update. *Eur Urol.* 2018 Jan;73(1):111-122. doi: 10.1016/j.eururo.2017.07.036
32. Vicente V, Martin A, Lecumberri R et al. [Clinical perspectives on the management of bleeding in patients on oral anticoagulants: the DECOVER Study (DElphi Consensus on oral COagulation and therapy action reVERsal)]. *Emergencias* 2017; 29(1):18-26. PMID: 28825264
33. Xaubet A, Molina-Molina M, Acosta O et al. Guidelines for the medical treatment of idiopathic pulmonary fibrosis. *Arch Bronconeumol.* 2017 May;53(5):263-269. doi: 10.1016/j.arbres.2016.12.011
34. Cámara Lorenzo A, Campolongo Perillo A, de Deus Fonticoba T et al. PROTOCOLO DE CUIDADOS DEL ESTOMA. IM&c S.A www. imc-sa.es , Deposito legal M-13003-2017 (2017)

# Research Scientific Support and Technical Services



**Manager:**  
Rosa M. Antonijoan  
rantonijoana@santpau.cat

**Coordinator:**  
Montserrat Ruiz  
MRuizB@santpau.cat

**Staff:**  
Elisenda Brunet  
M. Àngels Piera

## Clinical Trial Documentation Management

### Functions:

- > Manage and supervise all documentation associated with active clinical trials in the experimental phase and destruction of documentation for terminated clinical trials located in the external archive.
- > Store the supplies until the end of the studies, when they are destroyed or recycled.
- > Oversee and manage documentation of completed trials for the Centre for Drug Research (CIM)
- > Maintain and update the clinical workstation database and manage clinical studies.
- > Manage restricted access by clinical trial monitors to the clinical workstation.
- > Supervise data processing and management.
- > Coordinate researchers and monitors; draw up agendas for meetings and study monitoring.
- > Provide logistical support to the cold area and the clinical materials store associated with clinical trials in the experimental phase.
- > Ship biological samples to central laboratory services.

### Facilities:

Several areas have been designated to implement these functions:

- > Head office and administration area
- > Data processing and management area
- > Clinical trial monitoring meeting rooms
- > Documentation filing area
- > Cold room.
- > Archive.



**Coordinator:**  
Hilda Herrero  
hherrero@santpau.cat

**Staff:**  
Management Control Unit  
Soraya González, Sandra Parera,  
Laura San Martín

Administrative-Financial Unit  
Ana Espallargas, Cristina Requena,  
Núria García, Declan de la Fuente

Human Resources Unit  
Rafael Fernández

General Secretariat  
Rosa M. García  
Amanda García  
Marta Lorente  
Magda Sanz

## Research Institute Management

### Functions:

- > Management of HSCSP Research Institute and IIB Sant Pau finances: manage accounts and fiscal matters; design, administer and control budget-related issues; manage and monitor financial and material resources.
- > Management of public body funding requirements: fulfil obligations imposed by government and official regional and state entities; ensure compliance with current fiscal, financial, labour and legal regulations and with HSCSP Research Institute–IIB Sant Pau management policies.
- > Administration and management of activities, providing management support for research groups in different areas; project management, human resources, procurement, invoicing, control and monitoring of projects, general administration, management of services (courses, travel and continuing professional development).
- > Design, elaboration, development and maintenance of information systems for management area units, both for HSCSP Research Institute–IIB Sant Pau and research groups.



## Research Institute Projects Unit

### Functions:

- > Search of public and private funding, broadcast, assessment and review for the success of the application submission, send applications, register and monitoring until its resolution.
- > Registration of granted projects, economic monitoring of both national and international projects and agreements, costs validation (concept/balance), preparing annual and final reports, manage incidences, interlocutor with official entities.
- > Activity reports: scientific report, Board, Direction and others.
- > Internal and external audits from different financial entities.
- > Researchers: meetings for starting and managing projects.
- > Interaction with different transversal areas to implement the regulations of the calls.

**Coordinator:**  
Fabiola Fernández

**Staff:**  
Eva José  
Eva Rodríguez  
Amanda García  
Marta L oriente



**Coordinator:**  
Jordi Virgili  
[jvirgili@santpau.cat](mailto:jvirgili@santpau.cat)

**Staff:**  
Cati Pérez  
Montserrat Campmany

## Quality and Information Systems Unit

### Functions:

- > General:
  - Support management with strategic projects (accreditation, CERCA evaluation, biobank legalization, evaluation of research groups, etc).
  - Manage IIB Sant Pau research groups: creation, dissolution and changes in composition.
  - Implement the functional plan for the new research building.
  - Support management of the IIB Sant Pau Internal Scientific Committee, External Scientific Committee, Executive Committee and Delegate Committee.
  - Implement policies for the dissemination of research among the general public and especially among secondary pupils and health science university students.
  - Represent the HSCSP Research Institute before external organizations.
- > Quality:
  - Implement policies to improve quality under GLP, GCP, GMP, ISO 9001 and UNE 166002 standards.
  - Lead the quality assurance programme at CIM Sant Pau and in clinical trials where the HSCSP Research Institute acts as sponsor.
  - Oversee auditing for protocols, databases, experimental phases, facilities, processes and final reports for clinical trials.
- > Oversee supplier audits.
- > Monitor non-conformity in internal and external audits.
- > Draw up own SOPs and provide support for SOPs preparation by other units.
- > Establish mechanisms to assess quality and good scientific practices in IIB Sant Pau.
- > Information systems:
  - Design mechanisms and implement tools for the collection and organization of data and information to feed decision making.
  - Manage and transform information and data to contribute to the fulfillment of objectives and strategies.
  - Respond to external requests for data and information (statistical surveys, SIRECS, etc).
  - Implement policies to improve information systems.
  - Develop new indicators of use for the institution.
  - Update research group staff details on the intranet.
- > Biosafety Committee:
  - Management of the biosafety committee.



## Radioactivity Unit

### Functions:

- > The Radioactivity Unit provides groups with specific research laboratories in which to work with radioactive isotopes in liquid form. These areas are fully equipped and adapted for the handling of radioactive material and apply optimum measures for the safety and radioprotection of staff and the environment.
- > This area has been authorized by the nuclear safety authority and its staff supervise compliance with the corresponding laws, guidelines and regulations.

### > Services include support for:

- In vitro labelling of proteins, lipoproteins and liposomes.
- Cellular proliferation and toxicity.
- Nucleic acid labelling.
- Immunoassay techniques.
- Determination of enzymatic activities using radiolabelled substrates.
- Analysis and separation of labelled molecules.
- Metabolism in vitro and in vivo.

### Facilities:

The Radioactivity Unit has the following facilities:

- > 1 room for radioactive material storage.
- > 7 equipped laboratories, one of them refrigerated.
- > 1 room for gamma- and beta- counters.
- > 1 room for radioactive waste storage.
- > 1 room for controlled disposal of radioactive waste.
- > Radioactive liquid waste containers for controlled radioactive waste disposal.

### > Shielding accessories for radiation safety (table top shields, shielded containers, protective equipment, etc)

- > Portable radiation and environmental contamination detectors.
- > 1 ventilated rack for in vivo studies.
- > 2 chemical safety cabinets for gas extraction.
- > 1 vertical laminar air flow cabinet for cell cultures.
- > 1 CO<sub>2</sub> incubator for cell cultures.



## Centre for Drug Research (CIM Sant Pau)

### Functions:

Perform clinical drug trials and/or clinical research in compliance with methodological, ethical and legal requirements in the context of international GCP guidelines concerning:

- > Clinical trials that are not of therapeutic interest for participants (phase I, special populations, psychopathological research, biomarkers, proof of concept).
- > Clinical trials in neuropsychopharmacology.
- > Clinical trials in initial developmental phases.

### Coordinator:

Rosa M. Antonijoan

[rantonjoana@santpau.cat](mailto:rantonjoana@santpau.cat)

### Staff:

M. Rosa Ballester  
Judit Claramunt  
Susana Clos  
Sonia Coma  
M. Ángeles Funes  
Consuelo García  
Ignasi Gich  
Sandra Giménez  
Ana Gomis  
Mireia González  
David Martínez  
Joan Martínez  
Maribel Martínez  
Pura Martínez  
Esteve Mercader  
Sara Mora  
Montserrat Puntes

### Facilities:

Three separate work areas have been designated for the trials:

#### Healthcare:

- > Admission zone.
- > 24 beds distributed in 4 units: trials in healthy volunteers and patients.
- > 2 individual rooms for CNS studies.
- > Ambulatory zone.
- > 4 consulting rooms for complementary testing, mainly related to CNS.
- > 3 cubicles to evaluate psychomotor performance.

#### Logistical support:

- > Rest area for clinical trial participants with bathrooms and kitchen.
- > Areas for the preparation, centrifugation and separation of biological samples.
- > Cold room.
- > Archives.

#### Management, administration and data processing:

- > Offices.
- > Area for monitors.
- > IT equipment for clinical trial activities of a non-experimental nature.

## Communications Coordination Team

### Functions:

- > Coordinate IIB Sant Pau communications.
- > Prepare IIB Sant Pau annual reports and other communication materials.
- > Provide an effective news distribution service and generate positive media coverage.
- > Respond to media enquiries.
- > Update website content.

- > Establish standards concerning graphics and linguistic style to ensure visual uniformity in all IIB Sant Pau communications.

**Coordinator:**

Rosa M. Antonijoan

rantonjoana@santpau.cat

**Staff:**

Claudia E. Delgado

Enrique Peña

Edson Cedero Pico

Lucía Serna

## Clinical Research and Clinical Trials Unit (UICEC Sant Pau)

**Functions:**

It provides comprehensive support to researchers in the development of independent research projects (not sponsored by the pharmaceutical industry) on the methodological, regulatory, administrative, economic and practical aspects, subject to compliance with the ethical, good clinical practice and legislation.

UICEC Sant Pau is part of the Spanish Clinical Research Network (SCReN), a functional organization network to support the conduction of multi-center clinical trials.

**Knowledge management:**

- > One-stop information for independent research group projects.
- > Comprehensive assessment and project coordination.
- > Point of communication between researchers and technical units.
- > Pharmacovigilance activities for trials including drugs or medical devices.
- > Knowledge management:
  - Study of dimensionality and feasibility of projects.
  - Identification of each project needs.
  - Advice on the preparation of documentation: protocol, annexes, monitoring report, final report.
  - Advice on the submission of documentation to Spanish Agency for Medicines and Medical Devices (AEMPS), Ethics Committee for research with medicinal products (CEIm), Autonomous Communities (CCAA) and other relevant authorities.
  - Advice on project registration in public databases.
  - Identification of spinoff projects.
  - Advice on the presentation of research results.

**Methodological and statistical support unit:**

- > Advice on study design.
- > Data entry.
- > Data processing.
- > Development of statistical reports.
- > Electronic CRFs validation and management.
- > Documentation and reports.

**Documentation, archiving, monitoring and follow-up unit:**

- > Support in document creation: EudraCT application form and annexes / other application forms / evaluation forms / monitoring reports.
- > Support in the processing of initial applications, clarifications and amendments: AEMPS, CEIm, other health authorities regarding clinical trials, and other post-authorization studies.
- > Comprehensive monitoring of clinical trials and observational studies.
- > Management of initial, follow-up and final reports.
- > Development and file custody promoter (Master File), file preparation investigator.
- > Other communications to CEIC, autonomous communities and competent authorities.

**Unit of management and financial management:**

- > Management of clinical trials contracts with participating centers.
- > Management of collaboration agreements with laboratories / companies for funding.
- > Management of clinical trial-related contracts (CRO's, E-CRDs, statistics, etc.).
- > Management of clinical trial-related client and supplier invoices.
- > Management of clinical trial insurance policies.
- > Preparation of financial reports for the submission of studies to ethics committees.
- > Management of payment of fees to the competent authorities.



## Animal Experimentation Service

The Animal Experimentation Service is the area dedicated to the house and care of experimental animals, and to work with experimental procedures that use them. The SEA has the ISO 9001: 2015 certification and guarantees compliance with the legal and ethical laws related to the use of animals for experimentation and for other scientific purposes. It is officially registered as a breeding center, supplier and user of experimental animals (B9900067 and REGA ES080190036528), and it also has the authorization to house and work with Genetically Modified Organisms (A / ES / 08/21 and A / ES / 08 / I-14) . The staff of the SEA is also officially trained and accredited: Welfare and Animal Health Specialist, Advisor on Animal Welfare, Technicians and Caregivers.

Translational research needs responsible use of experimental animals and the reproducibility of results. The use of animals of high genetic and health quality and their use, maintenance and well-being in appropriate facilities are accurate to obtain these results. The SEA offers its services to keep the animals in the right conditions and also to advice and give specialized support to the researchers in the realization and design of the experimental procedures and techniques

### The SEA consists of 2 separate buildings:

> Conventional Facility, one floor area of 650m<sup>2</sup>, designed according to the requirements of Decret 214/1997 and R D 53/2013. It has the necessary facilities to house up to 40 pigs, 114 rabbits, 350 rats and 2500 mice in conventional conditions and 90 ratios and 2200 mice in SPF or Special Pathogen-Free conditions (individually ventilates cages in a positive pressure room).

The SEA facility has work halls for rodents and rabbits and 4 experimental operating theaters for pigs. It also has advanced medical equipment for small animals: bioluminescence (Hamamatsu), high frequency ultrasound (Veo2100), intravital microscope, flow measurement equipment and probes, ECG monitor, NIP equipment, mechanical ventilators , equipment of anesthesia with sebu / isoflurane, surgery microscopes... For the large animals the SEA has: multiparameter monitors, defibrillators, anesthesia equipment with sebu / isoflurane, mechanical ventilators, RX (Philips and Siemens) equipment, equipment Trans-echocardiography and transesophageal echocardiography (Philips iE33), intravascular echocardiography (Siemens Acuson), real-time 3D imaging equipment (CartoXP), radiofrequency ablation equipment, 12-lead ECG...

The operating theaters can be used to teach microsurgery courses, experimental surgery, medical equipment presentations...

> The Biomodule-SPF is a barrier area of 30m<sup>2</sup> that can house up to 400 immunodeprived mice. The entrance to the installation is through an air shower for people or a SAS of peroxide for materials. Work with animals is under biosafety hood, it has a preclinical in vivo image system for fluorescence and / or bioluminescence (IVIS Spectrum) and inhalatory anesthesia equipment.

### Director of the Animal Facility:

Dra. Laura Casaní (Designated Veterinarian, Animal Health and Welfare Advisor). ICCC  
lcasan@sanpau.cat  
estabulari@sanpau.cat

### Manager of the Animal Facility:

Sergi Florit (Animal Welfare Advisor)  
ICCC

### Animal Technicians:

Angel Juncosa. ICCC  
Margarita Domingo. IR  
Assistant: Fanny Cevallos. ICCC

## Transfer and Innovation Unit

innovacio@santpau.cat

**Coordinator:**

Miriam Ors  
mors@santpau.cat

**Staff:**

Gisela Gallego  
Marina Passarell

**Functions:**

- > Facilitate collaboration between institute's research groups and industry.
- > Support to public and private funding of technology development projects.
- > Support the submission of European projects.
- > Analysis of the business viability of technological projects.
- > Intellectual Property protection.
- > Technology Transfer.
- > Support the creation of spin-offs and start-ups.
- > Legal support to agreements with third parties.



**President:**

Antonio López Pousa  
alopezp@santpau.cat

**Vice-president:**

Gerard Urrutia  
GUrrutia@santpau.cat

**Secretary:**

Milagros Alonso  
MAlonsoMa@santpau.cat

**Members:**

Ester Amado  
Josep Corbella  
Francesc Jané  
Xavier León  
Dora Mejías  
Indalecio Morán  
Estela Moreno  
M. Virtudes Pacheco  
Javier Pagonabarraga  
Maria Teresa Ricart Basagaña  
Olegario Sotelo  
Miguel A. Viciana

## Ethics Committee for research with medicinal products (CEIm)

The Ethics Committee for research with medicinal products (CEIm) of the HSCSP Healthcare Management Foundation is an independent body that, according to the laws that accredit it, has the mission to ensure the protection of rights, safety and welfare of the subjects involved in a research study and provide

public assurance of that protection by reviewing the protocol, the suitability of the researchers, facilities, equipment and methods to be used in obtaining and documenting the informed consent of the subjects.

**Its specific functions are:**

- > Evaluate the methodological, ethical and legal aspects of:
  - Clinical trials with medicinal products and medical devices
  - Non interventional studies.
  - Pharmacogenetic and pharmacogenomic studies.
  - Studies evaluating surgical or psychological treatments.
  - Studies involving invasive procedures or the use of health data or biological samples.
- > Evaluate the relevant amendments in projects approved by the CEIm.
- > Conduct a follow up of clinical trials with medicinal products and medical devices, as well as the other approved research studies.



**Head of the technical secretariat:**  
Milagros Alonso  
[malonsoma@santpau.cat](mailto:malonsoma@santpau.cat)

**Administrative Staff:**  
Robert Caballero  
Marisol Mogollón  
Albert Querol

## Technical Secretariat of the CEIm

The Technical Secretariat of the CEIm is an independent agency whose mission is to protect the rights, safety and wellbeing of persons participating in HSCSP research projects which may entail physical or psychological harm. The Technical Secretariat of the CEIm evaluates the methodological, ethical and legal aspects

### Functions:

- > Receive, log and validate documentation for clinical research projects submitted to the Committee for evaluation.
- > Arrange and call Committee meetings, inform members of the agenda and provide them with copies of protocol summaries and patient informed consent and information sheets.
- > Prepare and submit reports to the Committee containing a methodological, ethical and legal description and analysis (and any other relevant information) of the research projects listed in agendas.
- > Act as a reference point in communications with and between researchers, sponsors, medical administrators and managers and healthcare authorities regarding all aspects of the activities of the Committee and of the research projects evaluated by the Committee.
- > Prepare and sign the reports of the Committee and communicate its decisions to the corresponding sponsors and researchers.
- > Prepare the minutes of meetings and distribute them to Committee members within the established period.
- > Manage all documentation associated with the operations and activities of the Committee and with the research projects evaluated by the Committee.
- > Manage contracts for all clinical studies to be performed at the HSCSP.
- > Certify the actions of the Committee.
- > Prepare the annual report of the Committee.
- > Ensure compliance with the SOPs of the Committee.

as well as any other relevant information regarding all research projects listed in the minutes of the Committee's meetings. It also advises researchers in the HSCSP and the HSCSP Research Institute regarding the preparation and presentation of clinical research projects.



## Biobank

The Biobank is a core facility for coordinating the collection, processing, store and transfer of human biological samples at the highest standard.

### It's comprised of three main sections:

- > Blood and fluids: samples of hematological neoplasias, respiratory, psychiatric and neurological diseases. The processing is performed in the biobank's BSL-2 laboratory.
- > Tumour bank: Tumoral and non-tumoral tissue samples from patients affected by a neoplasia.
- > Histopathology laboratory: tissue processing, paraffin and OCT-block preparation, block cutting (microtome and cryostat), automatic immunostaining, histological stainings, special stainings, FISH staining, tissue microarray, high-resolution slide scan.

### Equipment:

- > BSL-2 II A cabinet, inverted microscope, TC automated cell counter, refrigerated centrifuge, refrigerated microfuge, computer system for managing samples and data, automated molecular extraction (Qiacube, Qiagen), controlled freezing ramp
- > liquid nitrogen tanks, -20°C freezer, -80°C freezers with safety systems
- > Tissue processor VIP Jr (Sakura), paraffin tissue embedding console system (Sakura), microtome (Microm), cryostat (Leica), Automated Immunostaining System (DAKO AS 48), Semiautomatic tissue arrayer (Galileo), Digital slide scanner Pannoramic Midi (3DHistech), microwave tissue processor (KOS), multiobserver microscope with fluorescent light illumination system (Olympus)

### Grants:

- > HSCSP Research Institute. Biobank Network 2014-2017. Amount: 138,000 €
- > ICO Agreement (Oncology Director Plan for members of the Catalan Network of Tumour Banks) 15,000 €

## Genomics and Transcriptomics Platform

[sequenciacio\\_ir@santpau.cat](mailto:sequenciacio_ir@santpau.cat)  
[transcriptomica@santpau.cat](mailto:transcriptomica@santpau.cat)

**Coordinator:**  
 Elena Serrano  
[eserrano@santpau.cat](mailto:eserrano@santpau.cat)

### Equipment:

- > Affymetrix array platform (upgrade 7G).
- > 7900HT Real time quantitative PCR (Applied Biosystems)
- > Ion Torrent Personal Genome Machine, Ion OneTouch™ System
- > 3130xl Genetic Analyzer capillary electrophoresis sequencer
- > Bioanalyzer 2100, Nanodrop 2000

## Microscopy Platform

microscopia@santpau.cat

**Coordinator:**

Elena Serrano

eserrano@santpau.cat

**Technical Staff:**

Eva Companys

eCompanysa@santpau.cat

**Equipment:**

- > Confocal multispectral Leica SP5 AOBS with high-resolution scanning system and high-speed tandem scanning, FLIM/FCS modules and time-lapse incubation system.
- > Zeiss digital time-lapse epifluorescence microscope.

## Citomics Platform

citometria@santpau.cat

**Coordinator:**

Elena Serrano

eserrano@santpau.cat

**Technical Staff:**

Flow Cytometry Laboratory:

Marta Soler

msolerC@santpau.cat

Cell Culture Laboratory:

Rosa Antón

RAnton@santpau.cat

> **FLOW CYTOMETRY LABORATORY**

**Equipment:**

- > MACSQuant (Miltenyi Biotech) conventional flow cytometry.
- > FACSCalibur (BD) conventional flow cytometry.
- > FACSaria (BD) flow cytometry cell sorter.

> **CELL CULTURE LABORATORY**

**Equipment:**

- > CO<sub>2</sub> incubators, 2 hypoxia incubators (2-21% O<sub>2</sub>), IIA biosafety cabinets (BSL2), hypoxia cabinets (BSL1), Culture baths, inverted microscope with high-resolution colour camera, Refrigerated centrifuge, Fridge 4°C and freezer -20°C, Thermo-desinfector and autoclave.

## Equipment for General Use

**Coordinator:**

Elena Serrano

eserrano@santpau.cat

> **IMAGE ANALYSIS LABORATORY:**

**Equipment:**

- > Revolution 4200 microarray scanner (Vidar).
- > Image Station 4000MM Pro (Kodak) gel documentation: luminescence, fluorescence, absorption.

> **OTHER EQUIPMENT**

- > Precision weighing balances (Sartorius).
- > Infinite 200 (Tecan) microplate reader: spectrophotometer, fluorometer, luminometer.

# Areas of Research

36



Area 1  
Cardiovascular Diseases

68



Area 2  
Genetic, Metabolic and  
Inflammatory Diseases

112



Area 3  
Haematological and  
Oncological Diseases

134



Area 4  
Neurological,  
Mental Disorders and Ageing

176



Area 5  
Uronephrology  
and Experimental Surgery

**190**



Area T1

### Epidemiology, Public Health and Healthcare Services

**222**



Area T2

### Molecular, Genomic, Cellular and Kinetic-Dynamic Bases for Diseases and their Treatment

**234**



### Associated Groups

AREA 1

# Cardiovascular Disease

**38** Clinical and Translational Cardiology

**44** Thrombosis and Haemostasis

**46** Cardiovascular Biochemistry

**50** Angiology, Vascular Biology and Inflammation

**52** Molecular Pathology and Therapeutic of Ischaemic and Atherothrombotic Diseases

**58** Biomarkers for Cardiovascular Disease

**62** Atherosclerosis and Vascular Biology

**64** Regulation of Cardiac Rhythm and Contraction

**66** Lipids and Cardiovascular Pathology

# eases



# Clinical and Translational Cardiology



## Coordinator

Juan Cinca Cuscullola, FGS  
jcinca@santpau.cat

## Members

Alonso Martín, Concepción	FGS
Álvarez García, Jesús	FGS
Amorós Figueras, Gerard	IR
Anglí Ferrández, Laia	IR
Arzamendi Aizpurua, Dabit	FGS
Benabou Zdaou, Ibtissam	IR
Carreras Costa, Francesc	FGS
Fernández Martínez, Ana	IR
Ferrero Gregori, Andreu	IR
García-Moll Marimon, Xavier	FGS
Guerra Ramos, José M.	FGS
Jorge Vizuete, Esther	IR
Rivas Lasarte, Mercedes	FGS
Roig Mingüell, Eulàlia	FGS
Serra Peñaranda, Antoni	FGS
Sionis, Alessandro	FGS
Viñolas Prat, Xavier	FGS
Vives Borràs, Miquel	IR

## Main Lines of Research

- ▶ Electrophysiology and arrhythmias, clinical and experimental.
- ▶ Heart failure.
- ▶ Ischemic heart disease.
- ▶ Valvular heart disease.
- ▶ Cardiac imaging.
- ▶ Percutaneous valve repair.
- ▶ Bioengineering

## Challenges

### Electrophysiology

- ▶ Describe the mechanisms and clinical significance of the electrocardiographic alterations in patients with acute myocardial infarction, using translational research in pig heart models.
- ▶ Develop animal models for the study of left bundle branch block.
- ▶ Prognosis in patients with left circumflex coronary occlusion.
- ▶ Develop clinical applications of myocardial impedance in patients undergoing ablation of arrhythmias.

### Heart failure

- ▶ Develop new risk scores for ambulatory heart failure patients predicting death and rehospitalizations.
- ▶ Research on new biomarkers in patients with heart failure included in the Spanish registry Redinscor II (RIC) (1500 patients). Our group is the national coordinator.
- ▶ Develop new markers for early detection of cardiac graft rejection in transplanted patients.
- ▶ Develop palliative care programs for patients with advanced heart failure.

## Collaborations

### Collaborations with other IIB Sant Pau Groups

- ▶ Vicenta Llorente-Cortés, ICCC - CSIC.
- ▶ Leif Hove Madsen, ICCC - CSIC.
- ▶ Jordi Ordóñez Llanos, HSCSP - Biochemistry Laboratory.
- ▶ Antoni Capdevila, HSCSP - Radiodiagnostics.
- ▶ María Poca Sans, HSCSP - Digestive Disorders.
- ▶ Rafael Serra, HSCSP - Anaesthesiology.
- ▶ Enric Álvarez, HSCSP - Psychiatry.

### Ischaemic heart disease

- ▶ Settle a Program for patients with refractory angina.
- ▶ Treat complex atherosclerotic coronary artery lesions using international techniques.

### Valvular heart disease

- ▶ Implement new percutaneous techniques for the treatment of mitral valve regeneration and degenerative aortic stenosis.
- ▶ Implement devices for the treatment of prosthetic valve leak.

### Cardiac imaging

- ▶ Implement new imaging software analysis to detect structural abnormalities of the myocardium (fibrosis, necrosis).
- ▶ Implement new software analysis for fusion imaging in patients submitted to coronary interventions.
- ▶ Implement new percutaneous techniques for the treatment of mitral regurgitation in patients with heart failure or myocardial infarction.

### External Collaborations

Juan Cinca Cuscullola - RD12/0042-RIC (Cardiovascular Research Network)

Programme 6: Clinical and Translational Cardiology

- ▶ Alfredo Bardají Ruiz. Hospital Universitari Joan XXIII (Tarragona)
- ▶ Fernando Worner Díz. Hospital Universitari Arnau de Vilanova (Lleida)
- ▶ Andrés Grau Sepúlveda. Hospital Son Dureta (Palma de Mallorca)
- ▶ Xavier Rosell Ferrer. Universitat Politècnica Catalunya – UPC (Barcelona)

- ▶ Rafael Vázquez García. Hospital Universitario Virgen de Valme (Sevilla) / Hospital Puerta del Mar (Cádiz)
- ▶ Joaquín Lucena Romero. Instituto de Medicina Legal (Sevilla)
- ▶ José M. Cubero Gómez. Hospital Virgen del Rocío (Sevilla)
- ▶ Antonio Fernández Romero. CHARE Utrera SAS (Sevilla)
- ▶ Josep Brugada Terradellas. Hospital Clínic (Barcelona)
- ▶ Julián Pérez-Villacastín. Hospital Clínico San Carlos (Madrid)
- ▶ Juan Francisco Delgado Jiménez. Hospital 12 de Octubre (Madrid)
- ▶ José Luis Zamorano. Hospital Ramón y Cajal (Madrid)
- ▶ Mariano Valdés Chavarri. Hospital Universitario Virgen de la Arrixaca (Murcia)
- ▶ José Ramón González. Hospital Clínico Universitario (Santiago de Compostela)
- ▶ Luis Alonso-Pulpón Rivera. Hospital Puerta del Hierro (Madrid)
- ▶ Covadonga García González. Hospital Guadarrama (Madrid)
- ▶ José Miguel Rivera. Hospital La Fe (Valencia)
- ▶ Alfonso Castro Beiras. Complejo Hospitalario Universitario A Coruña
- ▶ Francisco Fernández Avilés. Hospital Gregorio Marañón (Madrid)
- ▶ Ignacio Flores Hernández. Centro Nacional de Investigaciones Cardiovasculares - CNIC (Madrid)

#### Programme 5: Arrhythmias

- ▶ Francisco Fernández Avilés. Hospital Gregorio Marañón (Madrid)
- ▶ Josep Brugada Terradellas. Hospital Clínic (Barcelona)
- ▶ Julián Pérez-Villacastín. Hospital Clínico San Carlos (Madrid)
- ▶ Juan Francisco Delgado Jiménez. Hospital 12 de Octubre (Madrid)
- ▶ Mariano Valdés Chavarri. Hospital Universitario Virgen de la Arrixaca (Murcia)
- ▶ David García-Dorado. Hospital Vall d'Hebron (Barcelona)
- ▶ Cándido Martín Luengo. Hospital Universitario de Salamanca
- ▶ Luis Rodríguez Padial. Complejo Hospitalario de Toledo
- ▶ Francisco Javier Chorro Gascó. Hospital Clínico de Valencia
- ▶ Francisco Sánchez Margallo. Centro de Cirugía de Mínima Invasión Jesús Usón de Cáceres

CB16/11/00276 - CIBER Enfermedades Cardiovasculares (CIBERCV), Registro Redinscor III

- ▶ Lisardo Bosca. Instituto de Investigaciones Biomédicas Alberto Sols (Madrid)
- ▶ Juan Delgado. Hospital 12 de Octubre (Madrid)
- ▶ Javier Díez. Centro de Investigación Médica Aplicada de Navarra
- ▶ José Ramón González-Juanatey. Hospital Clínico de Santiago de Compostela
- ▶ Julián Pérez Villacastín. Hospital Clínico San Carlos (Madrid)
- ▶ José Miguel Rivera. Hospital La Fe (Valencia)

- ▶ Antoni Bayés Genís. Hospital Germans Trias i Pujol de Badalona
- ▶ Pablo García Pavía. Hospital Puerta de Hierro (Madrid)
- ▶ Manuel Martínez Sellés. Hospital Gregorio Marañón (Madrid)
- ▶ J. Nuñez. Hospital Clínico de Valencia
- ▶ Domingo Pascual Figal. Hospital Virgen de la Arrixaca (Murcia)
- ▶ Alfredo Bardají Ruiz. Hospital Universitari Joan XXIII (Tarragona)
- ▶ Fernando Worner Diz. Hospital Universitari Arnau de Vilanova (Lleida)

#### Other collaborators

- ▶ Xavier Rosell, Departament d'Enginyeria Electrònica, Universitat Politècnica de Catalunya - UPC (Barcelona)
- ▶ Borja Ibáñez, Laboratorio Traslacional Imagen y Terapia Cardiovascular, Centro Nacional de Investigaciones Cardiovasculares Carlos III - CNIC (Madrid)
- ▶ Deborah Gil, Barcelona Supercomputing Center (Centro Nacional de Supercomputación-CVC, UAB Barcelona)
- ▶ Ignacio Cruz González. Hospital Universitario de Salamanca
- ▶ Reda Ibrahim, Montreal Heart Institute Adult Congenital Heart Center, Montreal (Canada)

#### Antoni Serra Peñaranda

##### TEAM

- ▶ Eulogio García. Hospital Clínico San Carlos (Madrid)
- ▶ Carlos Macaya Miguel. Hospital Clínico San Carlos (Madrid)
- ▶ Andrés Iníguez Romo. Complejo Hospitalario de Vigo

Euro CTO Club (chronic total occlusions (CTOs))

- ▶ Formed by 60 members, spread among all European countries

#### Eulàlia Roig MingueLL, Registro Nacional de Trasplante Cardiaco

- ▶ Clínica Universitaria de Navarra, Pamplona, Navarra
- ▶ Hospital Universitario Puerta de Hierro, Majadahonda, Madrid
- ▶ Hospital Universitario Marqués de Valdecilla, Santander, Cantabria
- ▶ Hospital Universitario Reina Sofía, Córdoba
- ▶ Hospital Universitario y Politécnico La Fe, Valencia
- ▶ Hospital General Universitario Gregorio Marañón, Madrid
- ▶ Fundación Jiménez Díaz, Madrid
- ▶ Hospital Universitario Virgen del Rocío, Sevilla
- ▶ Hospital Universitario 12 de Octubre, Madrid
- ▶ Hospital Universitario de A Coruña, A Coruña
- ▶ Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona
- ▶ Hospital Central de Asturias, Oviedo, Asturias
- ▶ Hospital Clínic i Provincial, Barcelona
- ▶ Hospital Universitario Virgen de la Arrixaca, El Palmar, Murcia
- ▶ Hospital Universitario Miguel Servet, Zaragoza
- ▶ Hospital Clínico Universitario, Valladolid

# Clinical and Translational Cardiology

## Collaborations

### Xavier Viñolas Prat, RETAC Group - European Network for the Treatment of Arrhythmias in Cardiology

- ▶ Philippe Lagrange. Clinique Saint Pierre (Perpignan)
- ▶ Benoît Guy-Moyat. Hospital Universitaire de Limoges (France)
- ▶ Franck Halimi. C.M.C. Parly II (Le Chesnay)
- ▶ Luc de Roy. Clinique Universitaire de Saint Godinne (Yvoir-Belgium)
- ▶ Serge Boveda. Clinique Pasteur (Toulouse)
- ▶ Julio Martí. Hospital del Mar (Barcelona)

▶ Pascal Defaye. Hospital Universitaire de Grenoble

▶ Antonio Curnis. Spedali Civili (Brescia-Italy)

▶ Marc Zimmermann. Hôpital de la Tour (Geneve-Switzerland)

### Alessandro Sionis, GREAT-Global Research on Acute Conditions Team

- ▶ International Network between 308 experts operating in the management of acute clinical conditions in the field of Emergency Medicine

## Active Grants

- ▶ Juan Cinca Cuscallola. Red Cardiovascular. RD12/0042/0002. Instituto de Salud Carlos III. Duration: 2013-2017. 594,532.28 €.
- ▶ Juan Cinca Cuscallola. Desarrollo preclínico de una nueva técnica para guiar la ablación eléctrica de las arritmias ventriculares en pacientes con infarto crónico mediante bioimpedancia. PI13/00765. Instituto de Salud Carlos III. Duration: 2014-2017. 140,250.00 €.
- ▶ Juan Cinca Cuscallola. A novel myocardial impedance mapping system for ablation of post-infarction ventricular arrhythmias in humans: A translational development. MARATO 20150830. Fundació La Marató de TV3. Duration: 2016-2019. 160,000.00 €.
- ▶ Maria Eulàlia Roig Mingueu. Adrenergic agonist Treatment in Patients with Chronic Heart Failure and Secondary Pulmonary Hypertension: a Randomized Placebo-Controlled Phase 2 Clinical Trial. MARATO 20151732. Fundació La Marató de TV3. Duration: 2016-2019. 119,500.00 €.
- ▶ Juan Cinca Cuscallola. Grup de Recerca Clínica i Translacional en Cardiologia - RCTCAR. 2014 SGR 620. Agència de Gestió d'Ajuts Universitaris i de Recerca. Duration: 2014-2017.

▶ Mercedes Rivas Lasarte. Eficàcia d'una estratègia de tractament guiada per ecografia pulmonar respecte a la pràctica clínica habitual en pacients amb insuficiència cardíaca. IR16-R1. Fundació Privada Hospital de la Santa Creu i Sant Pau. Duration: 2016-2017. 35,500.00 €.

▶ Juan Cinca Cuscallola. Translational development of myocardial electrical impedance mapping system to guided catheter ablation of infarction ventricular arrhythmias. DTS15/00099. Instituto de Salud Carlos III. Duration: 2016-2017. 100,100 €.

▶ Xavier Viñolas. RITMOCORE - Arrhythmias monitoring and comprehensive care. Horizon 2020. H2020-SCI-2016-CNET. European Commission. Agència de Qualitat i Avaluació Sanitàries (AQuAS). Duration: 2016-2020 . 903,875 €.

▶ Juan Cinca Cuscallola. Ciber Cardiovascular - CIBERCV. CB16/11/00276. Instituto de Salud Carlos III. Juan Cinca. Duration: 2017-2020. 71,029,00 €.

Note: Total amount granted to PI. It does not include indirect costs.

## Grants Awarded in 2017

- ▶ Juan Cinca Cuscallola. Tractament combinat contra el dany per reperfisió en l'infart de miocardi COMBAT-MI. SLT002/16/478. Departament de Salut. Duration: 2017-2019. 24,645.00 €.
- ▶ Mercedes Rivas Lasarte. Contractes de formació en recerca "Río Hortega" 2017. CM17/00028. Instituto de Salud Carlos III. Duration: 2018-2019. 53,732.00 €.
- ▶ Juan Cinca Cuscallola. Desarrollo de un modelo preclínico para la caracterización electrofisiológica y estructural del infarto de miocardio auricular. PI17/00069. Instituto de Salud Carlos III. Duration: 2018-2020. 66,000.00 €.

▶ José María Guerra Ramos, Caracterización Genética del Síndrome del QT Largo Asociado a Fármacos. PI17/00980, Instituto de Salud Carlos III. Duration: 2018-2020, 122,000.00 €.

Note: Total amount granted to PI. It does not include indirect costs.

## Patents

- ▶ Javier Rosell; Juan Cinca; Ramon Bragos; Gerard Amorós; Esther Jorge; Tomas Garcia; Benjamin Sanchez. Systems And Methods To Assess Infarcted Myocardial Tissue By Measuring Electrical Impedance During The Cardiac Cycle. PCT/EP2016/056933. International. 30/03/2016.

**\*TIF: 178.699 \*\*MIF: 3.8847**

Abu-Assi E., Sionis A., Nunez Gil I.J., Lidon R.M., Selection of the Best of 2016 in Acute Cardiovascular Care Selección de lo mejor del año 2016 en cuidados agudos cardiovasculares (2017) REV ESP CARDIOL, 70 (2), 127-128.

**IF: 3.408**

Alquezar A., Santalo M., Rizzi M., Gich I., Grau M., Sionis A., Ordóñez-Llanos J., Merce J., Martín A., Muñoz M., Povar J., Velilla J., Calmarza P., Temboury F., Ortiz C., Balaguer J., Carratalá A., Combined high-sensitivity copeptin and troponin T evaluation for the diagnosis of non-ST elevation acute coronary syndrome in the emergency department Evaluación de una estrategia diagnóstica combinada con copeptina y troponina T ultrasensibles en el infarto de miocardio sin elevación del segmento ST en los servicios de urgencias (2017) EMERGENCIAS, 29 (4), 237-244.

**IF: 2.363**

Alquezar-Arbe A., Sionis A., Ordóñez-Llanos J., Cardiac troponins: 25 years on the stage and still improving their clinical value (2017) CRIT REV CL LAB SCI, 54 (7-8), 551-571.

**IF: 6.442**

Alvarez M., Bertomeu-González V., Arcocha M.F., Morina P., Tercedor L., Ferrero de Loma A., Pachón M., García A., Pardo M., Datino T., Alonso C., Osca J., Nonfluoroscopic Catheter Ablation. Results From a Prospective Multi-center Registry Ablación con catéter no guiada por fluoroscopia. Resultados de un registro prospectivo multicéntrico (2017) REV ESP CARDIOL, 70 (9), 699-705.

**IF: 3.408**

Alvarez-García J., Salamanca-Bautista P., Ferrero-Gregori A., Montero-Perez-Barquero M., Puig T., Aramburu-Bodas O., Vazquez R., Formiga F., Delgado J., Arias-Jiménez J.L., Vives-Borras M., Cerqueiro Gonzalez J.M., Manzano L., Cinca J., Prognostic Impact of Physician Specialty on the Prognosis of Outpatients With Heart Failure: Propensity Matched Analysis of the REDINSCOR and RICA Registries Impacto pronóstico de la especialidad en el paciente ambulatorio con insuficiencia cardiaca: un análisis emparejado de los registros REDINSCOR y RICA (2017) REV ESP CARDIOL, 70 (5), 347-354.

**IF: 3.408**

Arribas F., Arribas F., Roldan I., Luis Merino J., Roldan V., Arenal A., Tamargo J., Ruiz-Granell R., Mont L., Anguita M., Marin F., Barrios Alonso V., Baron G., Esquivias, Cosin Sales J., Diaz Infante E., Escobar Cervantes C., Ferreiro Gutierrez J.L., Guerra Ramos J.M., Jimenez Candil F.J., Perez Castellano N., Sambola Ayala A., Tello Montoliu A., San Roman A., Alfonso F., Arribas F., Evangelista A., Ferreira I., Jimenez M., Marin F., de Isla

L.P., Rodriguez Padial L., Sanchez P.L., Sionis A., Vazquez R., Comments on the 2016 ESC Guidelines for the Management of Atrial Fibrillation Comentarios a la guía ESC 2016 sobre el diagnóstico y tratamiento de la fibrilación auricular (2017) REV ESP CARDIOL, 70 (1), 2-8.

**IF: 3.408**

Awamleh Garcia P., Alonso Martin J.J., Graupner Abad C., Jimenez Hernandez R.M., Curcio Ruigomez A., Talavera Calle P., Cristobal Varela C., Serrano Antolin J., Muniz J., Gomez Doblas J.J., Roig E., Prevalence of Electrocardiographic Patterns Associated With Sudden Cardiac Death in the Spanish Population Aged 40 Years or Older. Results of the OFRECE Study Prevalencia de patrones electrocardiográficos asociados a muerte súbita en la población española de 40 años o más. Resultados del estudio OFRECE (2017) REV ESP CARDIOL, 70 (10), 801-807.

**IF: 3.408**

Azzalini L., Dautov R., Ojeda S., Serra A., Benincasa S., Bellini B., Giannini F., Chavarria J., Gheorghe L.L., Pan M., Carlino M., Colombo A., Rinfret S., Long-term outcomes of rotational atherectomy for the percutaneous treatment of chronic total occlusions (2017) CATHETER CARDIO INTE, 89 (5), 820-828.

**IF: 2.370**

Azzalini L., Garcia-Moll X., On Contrast-Induced Acute Kidney Injury, Risk Prediction, and the Future of Predictive Model Development (2017) CAN J CARDIOL, 33 (6), 711-713.

**IF: 4.072**

Bardaji A., Leal M., Arrarte V., Garcia-Moll X., Perez de Isla L., Bueno H., Extended dual antiplatelet therapy after acute coronary syndrome in Spain: Results from the EPICOR study (2017) CARDIOVASC THER, 35 (2).

**IF: 2.179**

Carceller-Sindreu M., de Diego-Adelino J., Portella M.J., Garcia-Moll X., Figueras M., Fernandez-Vidal A., Queralto J.M., Puigdemont D., Alvarez E., Lack of relationship between plasma levels of escitalopram and QTc-interval length (2017) EUR ARCH PSY CLIN N, 267 (8), 815-822.

**IF: 3.390**

Carrasco-Chinchilla F., Estevez-Loureiro R., Andraka L., Arzamendi D., Freixa X., Suarez de Lezo J., Percutaneous Mitral Repair With MitraClip in Patients Treated With Transcatheter Aortic Valve Implantation Reparación mitral percutánea con MitraClip en pacientes tratados con implante percutáneo de válvula aórtica (2017) REV ESP CARDIOL, 70 (12), 1144-1145.

**IF: 3.408**

Cubedo J., Suades R., Padro T., Martin-Yuste V., Sabate-Tenás M., Cinca J., Sans-Rosello J., Sionis A., Badimon L., Erythrocyte-heme

proteins and STEMI: Implications in prognosis (2017) THROMB HAEMOSTASIS, 117 (10), 1970-1980.

**IF: 4.413**

Cutlip D.E., Garratt K.N., Novack V., Barakat M., Meraj P., Maillard L., Erglis A., Jauhar R., Popma J.J., Stoler R., Silber S., Cutlip D., Allaqaaband S., Caputo R., Beohar N., Brown D., Garratt K., Jauhar R., George J., Varghese V., Huth M., Larraín G., Lee T., Malik A., Martin S., McGarry T., Phillips C., Shah A., Stoler R., Ball M., Price R.J., Rossi J., Taylor C., Tolleson T., Nicholson W., Kesanakurthy S., Shoukfeh M., Finn A., Devireddy C., Shoultz C., Robbins M., Kiesz R., Menon P., Weilenmann D., Sievert H., Erglis A., Stankovic G., Berland J., Delarche N., Hirsch J.L., Maillard L., Shayne J., Serra A., Fernandez-Ortiz A., Monassier J.-P., Silber S., 9-Month Clinical and Angiographic Outcomes of the COBRA Polyzene-F NanoCoated Coronary Stent System (2017) JACC-CARDIOVASC INTE, 10 (2), 160-167.

**IF: 8.963**

Danzi G.B., Piccolo R., Chevalier B., Urban P., Fath-Ordoubadi F., Carrie D., Wiemer M., Serra A., Wijns W., Kala P., Stabile A., Ruiogomez J.G., Sagic D., Laanmets P., Strupp G., West N., Five-year clinical performance of a biodegradable polymer-coated biolimus-eluting stent in unselected patients (2017) HEART, 103 (2), 111-116.

**IF: 5.234**

De Gonzalo-Calvo D., Cenarro A., Garlaschelli K., Pellegatta F., Vilades D., Nasarre L., Camino-Lopez S., Crespo J., Carreras F., Leta R., Catapano A.L., Norata G.D., Civeira F., Llorente-Cortes V., Translating the microRNA signature of microvesicles derived from human coronary artery smooth muscle cells in patients with familial hypercholesterolemia and coronary artery disease (2017) J MOL CELL CARDIOL, 106, 55-67.

**IF: 5.123**

Di Marco A., Anguera I., Rodriguez M., Sionis A., Bayes-Genis A., Rodriguez J., Ariza-Sole A., Sanchez-Salado J.C., Diaz-Nuila M., Massotti M., Villuendas R., Dallaglio P., Gomez-Hospital J.A., Cequier A., Assessment of Smith Algorithms for the Diagnosis of Acute Myocardial Infarction in the Presence of Left Bundle Branch Block Evaluación de los algoritmos de Smith para el diagnóstico de infarto agudo de miocardio en presencia de bloqueo de rama izquierda del haz de His (2017) REV ESP CARDIOL, 70 (7), 559-566.

**IF: 3.408**

Estevez-Loureiro R., Freixa X., Arzamendi D., Perez de Prado A., Campante-Teles R., Melica B., Tarantini G., Musumeci G., Pan M., Transcatheter mitral valve interventions for mitral regurgitation, with special focus on MitraClip: The position of Spanish, Portuguese

# Clinical and Translational Cardiology

\*TIF: 178.699 \*\*MIF: 3.8847

and Italian interventional societies (2017) INT J CARDIOL, 243, 169-173.

**IF: 3.679**

Fam J.M., Ojeda S., Garbo R., Latib A., La Manna A., Vaquerizo B., Boukhris M., Vlachojannis G.J., Van Geuns R.-J., Ezhumalai B., Kawamoto H., Van Der Sijde J., Felix C., Pan M., Serdzo R., Bocuzzi G.G., De Paolis M., Sardella G., Mancone M., Tamburino C., Smits P.C., Di Mario C., Seth A., Serra A., Colombo A., Serruys P., Galassi A.R., Zijlstra F., Van Mieghem N.M., Diletti R., Thiele H., Everolimus-eluting bioresorbable vascular scaffolds for treatment of complex chronic total occlusions (2017) EUROINTERVENTION, 13 (3), 355-363.

**IF: 3.919**

Farré N., Lupon J., Roig E., Gonzalez-Costello J., Vila J., Perez S., de Antonio M., Solé-González E., Sánchez-Enrique C., Moliner P., Ruiz S., Enjuanes C., Mirabet S., Bayés-Genís A., Comin-Colet J.; GICCAT Investigators. Clinical characteristics, one-year change in ejection fraction and long-term outcomes in patients with heart failure with mid-range ejection fraction: a multicentre prospective observational study in Catalonia (Spain) (2017) BMJ OPEN. Dec 21;7(12):e018719.

**IF: 2.237**

Garcia E., Arzamendi D., Jimenez-Quevedo P., Sarnago F., Martí G., Sanchez-Recalde A., Lasa-Larraya G., Sancho M., Iniguez A., Goicoechea J., Garcia-San Roman K., Alonso-Briales J.H., Molina E., Calabuig J., Freixa X., Berenguer A., Valdes-Chavarri M., Vazquez N., Diaz J.F., Cruz-Gonzalez I., Outcomes and predictors of success and complications for paravalvular leak closure: An analysis of the Spanish realWorld paravalvular LEaks closure (HOLE) registry (2017) EUROINTERVENTION, 12 (16), 1962-1968.

**IF: 3.919**

Garcia-Cosio Carmena M.D., Roig Mingue E., Ferrero-Gregori A., Vazquez Garcia R., Delgado Jimenez J., Cinca J., Prognostic Implications of Functional Mitral Regurgitation in Patients With Heart Failure and Reduced Ejection Fraction Impacto de la insuficiencia mitral funcional en el pronóstico de pacientes con insuficiencia cardiaca y fracción de eyeción reducida (2017) REV ESP CARDIOL, 70 (9), 785-787.

**IF: 3.408**

Gheorghe L.L., Arzamendi D., Li C.H., Barros-Membrilla A.J., Munoz J.F.D., Penaranda A.S., How should i treat an asymptomatic aortic coarctation with a concomitant dissection of the descending aorta? (2017) EUROINTERVENTION, 12 (16), 2037-2040.

**IF: 3.919**

Gil-Cayuela C., Rosello-Lleti E., Tarazon E., Ortega A., Sandoval J., Martinez-Dolz L., Cinca J., Jorge E., Gonzalez-Juanatey J.R., Lago F.,

Rivera M., Portoles M., Thyroid hormone biosynthesis machinery is altered in the ischemic myocardium: An epigenomic study (2017) INT J CARDIOL, 243, 27-33.

**IF: 3.679**

Gomez-Otero I., Ferrero-Gregori A., Varela Roman A., Seijas Amigo J., Pascual-Figal D.A., Delgado Jimenez J., Alvarez-Garcia J., Fernandez-Aviles F., Worner Diz F., Alonso-Pulpon L., Cinca J., Gonzalez-Juanatey J.R., Mid-range Ejection Fraction Does Not Permit Risk Stratification Among Patients Hospitalized for Heart Failure La fracción de eyeción intermedia no permite estratificar el riesgo de los pacientes hospitalizados por insuficiencia cardiaca (2017) REV ESP CARDIOL, 70 (5), 338-346.

**IF: 3.408**

Hongisto M., Lassus J., Tarvasmaki T., Sionis A., Tolppanen H., Lindholm M.G., Banaszewski M., Parissis J., Spinar J., Silva-Cardoso J., Carubelli V., Di Somma S., Masip J., Harjola V.-P., Use of noninvasive and invasive mechanical ventilation in cardiogenic shock: A prospective multicenter study (2017) INT J CARDIOL, 230, 191-197.

**IF: 3.679**

Illatopa Cerna V., Descalzo M.L., Carreras Costa F., Diagnostic Usefulness of Cardiac MRI T1 Mapping in Ventricular Hypertrophy Utilidad diagnóstica del mapeo T1 por RM cardiaca en la hipertrofia ventricular (2017) REV ESP CARDIOL, 70 (3), 196-.

**IF: 5.166**

Jantti T., Tarvasmaki T., Harjola V.-P., Parissis J., Pulkki K., Sionis A., Silva-Cardoso J., Kober L., Banaszewski M., Spinar J., Fuhrmann V., Tolonen J., Carubelli V., diSomma S., Mebazaa A., Lassus J., Frequency and Prognostic Significance of Abnormal Liver Function Tests in Patients With Cardiogenic Shock (2017) AM J CARDIOL, 120 (7), 1090-1097.

**IF: 3.009**

Loughlin G., Avila P., Martinez-Ferrer J.B., Alzueta J., Vinolas X., Brugada J., Arizon J.M., Fernandez-Lozano I., Garcia-Campo E., Basterra N., Fernandez De La Concha J., Arenal A., Association of cardiac resynchronization therapy with the incidence of appropriate implantable cardiac defibrillator therapies in ischaemic and non-ischaemic cardiomyopathy (2017) EUROPACE, 19 (11), 1818-1825.

**IF: 4.537**

Masiero S., Connolly S.J., Birnie D., Neuzner J., Hohnloser S.H., Vinolas X., Kautzner J., O'Hara G., Vanerven L., Gadler F., Wang J., Mabo P., Glikson M., Kutyifa V., Wright D.J., Essebag V., Healey J.S., Wound haematoma following defibrillator implantation: Incidence and predictors in the Shockless Implant Evaluation (SIMPLE) trial (2017) EUROPACE, 19 (6), 1002-1006.

**IF: 4.537**

Millan X., Bouhout I., Nozza A., Samman K., Stevens L.-M., Lamarche Y., Serra A., Asgar A.W., El-Hamamsy I., Cartier R., Pellerin M., Noble S., Demers P., Ibrahim R., Jolicoeur E.M., Bouchard D., Surgery Versus Transcatheter Interventions for Significant Paravalvular Prosthetic Leaks (2017) JACC-CARDIOVASC INTE, 10 (19), 1959-1969.

**IF: 8.963**

Montero S., Ferrero-Gregori A., Cinca J., Guerra J.M., Long-term Outcome of Patients With Tachycardia-induced Cardiomyopathy After Recovery of Left Ventricular Function (2017) REV ESP CARDIOL.

**IF: 3.408**

Moscarella E., Spitaleri G., Brugaletta S., Senti Farrarons S., Pernigotti A., Ortega-Paz L., Cequier A., Iniguez A., Serra A., Jimenez-Quevedo P., Mainar V., Campo G., Tespili M., den Heijer P., Bethencourt A., Vazquez N., Valgimigli M., Seruys P.W., Sabate M., Impact of Body Mass Index on 5-Year Clinical Outcomes in Patients With ST-Segment Elevation Myocardial Infarction After Everolimus-Eluting or Bare-Metal Stent Implantation (2017) AM J CARDIOL, 120 (9), 1460-1466.

**IF: 3.009**

Nunez Gil I.J., Sionis A., Abu-Assi E., Lidon R.M., Selection of the Best of 2016 in Ischemic Heart Disease Selección de lo mejor del año 2016 en cardiopatía isquémica (2017) REV ESP CARDIOL, 70 (2), 125-126.

**IF: 3.408**

Ophof T., Remme C.A., Jorge E., Noriega F., Wiegerinck R.F., Tasiam A., Beekman L., Alvarez-Garcia J., Munoz-Guijosa C., Coronel R., Cinca J., Cardiac activation-repolarization patterns and ion channel expression mapping in intact isolated normal human hearts (2017) HEART RHYTHM, 14 (2), 265-272.

**IF: 4.152**

Ortega A., Tarazon E., Gil-Cayuela C., Garcia-Manzanares M., Martinez-Dolz L., Lago F., Gonzalez-Juanatey J.R., Cinca J., Jorge E., Portoles M., Rosello-Lleti E., Rivera M., Intercalated disc in failing hearts from patients with dilated cardiomyopathy: Its role in the depressed left ventricular function (2017) PLOS ONE, 12 (9).

**IF: 2.600**

Ortega-Paz L., Brugaletta S., Giacchi G., Ishida K., Cequier A., Iniguez A., Serra A., Jimenez-Quevedo P., Mainar V., Campo G., Tespili M., Den Heijer P., Valgimigli M., Seruys P.W., Sabate M., Cutlip D., Impact of stent overlapping on long-term clinical outcomes in patients with ST-segment elevation myocardial infarction: Insights from the five-year follow-up of the EXAMINATION trial (2017) EUROINTERVENTION, 13 (5), e557-e563.

**IF: 3.919**

## Scientific Production

## Other Publications

**\*TIF: 178.699 \*\*MIF: 3.8847**

Pascual-Figal D.A., Ferrero-Gregori A., Gomez-Otero I., Vazquez R., Delgado-Jimenez J., Alvarez-Garcia J., Gimeno-Blanes J.R., Worner-Diz F., Bardaji A., Alonso-Pulpon L., Gonzalez-Juanatey J.R., Cinca J., Mid-range left ventricular ejection fraction: Clinical profile and cause of death in ambulatory patients with chronic heart failure (2017) INT J CARDIOL, 240, 265-270.

**IF: 3.679**

Perez-Castellanos A., Martinez-Selles M., Mejia-Renteria H., Andres M., Sionis A., Almenandro-Delia M., Martin-Garcia A., Aguilera M.C., Pereyra E., Linares Vicente J.A., Garcia de la Villa B., Nunez-Gil I.J., Tako-tsubo Syndrome in Men: Rare, but With Poor Prognosis (2017) REV ESP CARDIOL.

**IF: 3.408**

Roberts P.R., Clementy N., Al Samadi F., Garweg C., Martinez-Sande J.L., Iacopino S., Johansen J.B., Vinolas Prat X., Kowal R.C., Klug D., Mont L., Steffel J., Li S., Van Osch D., El-Chami M.F., A leadless pacemaker in the real-world setting: The Micra Transcatheter Pacing System Post-Approval Registry (2017) HEART RHYTHM, 14 (9), 1375-1379.

**IF: 4.152**

Sans-Rosello J., Casals G., Rossello X., Gonzalez de la Presa B., Vila M., Duran-Cambrà A.,

Morales-Ruiz M., Ferrero-Gregori A., Jimenez W., Sionis A., Prognostic value of plasma apelin concentrations at admission in patients with ST-segment elevation acute myocardial infarction (2017) CLIN BIOCHEM, 50 (6), 279-284.

**IF: 2.420**

Soudah E., Casacuberta J., Gamez-Montero P.J., Perez J.S., Rodriguez-Cancio M., Raush G., Li C.H., Carreras F., Castilla R., Estimation of wall shear stress using 4D flow cardiovascular MRI and computational fluid dynamics (2017) J MECH MED BIOL, 17 (3).

**IF: 0.701**

Tolppanen H., Rivas-Lasarte M., Lassus J., Sans-Rosello J., Hartmann O., Lindholm M., Arrigo M., Tarvasmaki T., Kober L., Thiele H., Pulkki K., Spinar J., Parissis J., Banaszewski M., Silva-Cardoso J., Carubelli V., Sionis A., Harjola V.-P., Mebazaa A., Adrenomedullin: a marker of impaired hemodynamics, organ dysfunction, and poor prognosis in cardiogenic shock (2017) ANN INTENSIVE CARE, 7 (1).

**IF: 3.653**

Tolppanen H., Rivas-Lasarte M., Lassus J., Sadoune M., Gayat E., Pulkki K., Arrigo M., Krastinova E., Sionis A., Parissis J., Spinar J., Januzzi J., Harjola V.-P., Mebazaa A., Combined Measurement of Soluble ST2 and

Amino-Terminal Pro-B-Type Natriuretic Peptide Provides Early Assessment of Severity in Cardiogenic Shock Complicating Acute Coronary Syndrome (2017) CRIT CARE MED, 45 (7), e666-e673.

**IF: 6.092**

Vilahur G., Onate B., Cubedo J., Bejar M.T., Arderiu G., Pena E., Casani L., Gutierrez M., Capdevila A., Pons-Llado G., Carreras F., Hidalgo A., Badimon L., Allogenic adipose-derived stem cell therapy overcomes ischemia-induced microvessel rarefaction in the myocardium: Systems biology study (2017) STEM CELL RES THER, 8 (1).

**IF: 4.625**

Vives-Borras M., Moustafa A.-H., Alvarez-Garcia J., Ferrero-Gregori A., Balcells J., Garcia-Picart J., Serra-Penaranda A., Sionis A., Cinca J., Clinical and Prognostic Value of the Electrocardiogram in Patients With Acute Occlusion of the Left Circumflex Coronary Artery (2017) AM J CARDIOL, 120 (9), 1487-1494.

**IF: 3.009**

- Freixa X., Estévez-Loureiro R., Carrasco-Chinchilla F., Arzamendi D., Jiménez-Quevedo P., Nombela-Franco L., Cruz-González I., Amat-Santos I.J., Sabaté M. Initial Results of Combined MitraClip® Implantation and Left Atrial Appendage Occlusion (2017) J HEART VALVE DIS. Mar; 26(2): 169-174.

# Thrombosis and Haemostasis



## Coordinators

Souto Andrés, Joan Carles FGS  
jsouto@santpau.cat

## Members

Carrasco Exposito, Marina	FGS
Cerdà Urbano, Helia	FGS
Fontcuberta Boj, Jorge	FGS
Jiménez Peinado, Blanca	IR
Llobet Lorente, Maria Dolors	FGS
Martínez Álamo, Sílvia	IR
Mateo Arranz, Jose	FGS
Millon Caño, Juan Antonio	IR
Múñoz Lozano, Concepción	IR
Murillo Escoda, Joaquim	IR
Pujol Moix, Nuria	IR
Romero Román, Lidia	FGS
Tirado García, Isabel	FGS
Vallve Fornieles, Cristina	FGS
Vazquez Santiago, Miguel	IR
Vilalta Setó, Noelia	FGS

## Main Lines of Research

- ▶ Investigation of the genetic basis of venous and arterial thrombosis. GAIT-1 and GAIT-2 projects.
- ▶ Investigation of new antithrombotic drugs: thrombin inhibitors, molecules against activated factor X, low molecular weight heparin with oral activity, among others.
- ▶ Biomarkers of prothrombotic states in patients under 55 years with venous thromboembolic disease, acute ischaemic stroke, or acute myocardial infarction. VEREMA project.
- ▶ Applied clinical development of the self-management model of oral anticoagulant treatment. ORION project. Retrospective analysis of the clinical outcomes from

patient self-management of antivitamin-K treatment at the Hospital de Sant Pau. NCT3532724

- ▶ Mathematical models of prediction of the individual risk of thromboembolic disease in general population (RETROVE Project) and in cancer patients (MIRTO Project).

- ▶ CITA project. Centre for Antithrombotic Therapy Management. Research into a new ambulatory management model for patients receiving any kind of antithrombotic therapy (anti vitamin-K, new oral anticoagulants, low molecular weight heparins, antiplatelets) by incorporating new educational programmes, specialized nursing and new communication technologies.

## Challenges

- ▶ Study QTL detected in GAIT-1 families in relation to phenotypes of haemostasis with thrombosis risk (resistance to activated protein C, factor VIII, homocysteine, factor XII, body mass index and others).
- ▶ Replicate QTL related to thrombosis in GAIT-1 families by means of the linkage analysis using new GAIT-2 families.
- ▶ Conduct genome-wide association study (GWAS) of phenotypes involved in GAIT-1.
- ▶ GWAS of phenotypes included in GAIT-2.
- ▶ Analyse RNA expression in the GAIT-2 families.
- ▶ Investigate miRNA associated with thromboembolic disease in GAIT-2.
- ▶ To complete the recruitment of the cohorts included in MIRTO Project (Modelling the Individual Risk of Thrombosis in

Oncology), with the goal of establishing an individual risk score for venous thromboembolism (RETROVO sub-project) and for ischaemic stroke (SINO subproject) in patients with cancer.

- ▶ Research plasma proteins associated with the risk of venous thromboembolism by using high affinity proteomics developed at Karolinska Institutet. VEREMA project, joint collaboration between the European case-control studies VEBIOS (Sweden), RETROVE (from our unit) and MARTHA (France).
- ▶ Investigation on laboratory management of DOACs.
- ▶ Search for new universal laboratory methods for the assessment of any kind of oral anticoagulant (AVK and DOACs).
- ▶ To finish the recruitment of patients for the ORION project.

## Active Grants

- ▶ Joan Carles Souto Andrés. Red Cardiovascular. RD12/0042/0032. Instituto de Salud Carlos III. Duration: 2013-2017. 181,000.00 €.
- ▶ Joan Carles Souto Andrés. Continuación de la búsqueda de algoritmos aplicables en la clínica para definir el perfil individual de Riesgo de Enfermedad TRoMboembólica VEnosa (RETROVE). PI15/00269. Instituto de Salud Carlos III. Duration: 2016-2018. 86,500.00 €.

Note: Total amount granted to PI. It does not include indirect costs.

## Grants Awarded in 2017

- ▶ Concepción Muñoz Lozano, Predisposición genética a la trombosis en pacientes oncológicos (ONCOTHROMB). SLT002/16/00113. Departament de Salut. Duration: 2017-2019. 63,311.05 €.

Note: Total amount granted to PI. It does not include indirect costs.

## Theses

- ▶ Miguel Vázquez Santiago, Plaquetas y enfermedad tromboembólica. Aspectos genéticos, biológicos y clínicos. Universitat Autònoma de Barcelona. Directors: Juan Carlos Souto and Nuria Pujol-Moix. Date of defense: 26/09/2017.

## Collaborations

**Collaborations with other IIB Sant Pau Groups**

- ▶ Genomics of Complex Diseases (GAIT1, GAIT2, RETROVE, VEREMA and MIRTO Project).
- ▶ Stroke Unit (HERO and MIRTO Project).
- ▶ Vascular Surgery (GAIT2, genetics of venous insufficiency).
- ▶ Medical Oncology (MIRTO Project).
- ▶ Clinical Haematology (MIRTO Project).
- ▶ Digestive Diseases (HEPACO).

**External Collaborations**

- ▶ Cardiovascular Research Network (RIC).
- ▶ Karolinska Institutet, Stockholm, Sweden: GAIT2 and VEREMA.
- ▶ La Timone Hospital, Marseille, France: GAIT2 and VEREMA.

- ▶ Pierre and Marie Curie University, INSERM, UMR-S 1166, Paris, France: GAIT2 and VEREMA.
- ▶ Université de Genève, Switzerland: GAIT2.
- ▶ Texas Research Institute (formerly Southwest Foundation for Biomedical Research), San Antonio, USA: GAIT1 and GAIT2.
- ▶ Universitat Politècnica de Catalunya, Barcelona, Spain. Centre for Biomedical Engineering Research: RETROVE and MIRTO design.
- ▶ Thrombosis Group of the Spanish Medical Oncology Society (SEOM): ONCOTHROMB and MIRTO.
- ▶ Institut of Biological Psychiatry, Mental Health Snc. Hans. Roskilde (Denmark).
- ▶ Haematology Service of Hospital Sant Joan de Déu (Clinical modeling for the management of haemophilic patients and patients under self-management of VKA therapy)

**\*TIF: 27.083 \*\*MIF: 3.3853**

Barrios V, Egocheaga-Cabello M.I., Gallego-Cullere J, Ignacio-Garcia E., Manzano-Espinosa L, Martin-Martinez A, Mateo-Arranz J., Polo-Garcia J, Vargas-Ortega D, Healthcare resources and needs in anticoagulant therapy for patients with nonvalvular atrial fibrillation. SAMOA Study Recursos y necesidades asistenciales en el tratamiento anticoagulante de los pacientes con fibrilación auricular no valvular. Estudio SAMOA (2017) REV CLIN ESP, 217 (4), 193-200.

**IF: 0.796**

Borras N, Batlle J, Perez-Rodriguez A, Lopez-Fernandez M.F, Rodriguez-Trillo A, Loures E, Cid A.R, Bonanad S, Cabrera N, Moret A, et al. Molecular and clinical profile of von Willebrand disease in Spain (PCM-EVW-ES): Comprehensive genetic analysis by next-generation sequencing of 480 patients (2017) HAEMATOLOGICA, 102 (12), 2005-2014.

**IF: 8.725**

Jimenez-Fonseca P, Carmona-Bayonas A., Calderon C, Fontcuberta Boj J, Font C, Lecumberri R, Monreal M, Munoz Martin A.J, Otero R, Rubio A, Ruiz-Artacho P, Suarez Fernandez C, Colome E, Perez Segura P, FOTROCAN Delphi consensus statement

regarding the prevention and treatment of cancer-associated thrombosis in areas of uncertainty and low quality of evidence (2017) CLIN TRANSL ONCOL, 19 (8), 997-1009.

**IF: 2.339**

Llobet D, Tirado I, Vilalta N, Vallvé C, Oliver A, Vázquez-Santiago M, Mateo J, Millón J, Fontcuberta J, Souto JC. Low ADAMTS13 levels are associated with venous thrombosis risk in women. (2017) THROMB RES, 157, 38-40.

**IF: 2.779**

Martin-Fernandez L, Gavidia-Bovadilla G, Corrales I, Brunel H, Ramirez L, Lopez S, Souto J.C., Vidal F, Soria J.M., Next generation sequencing to dissect the genetic architecture of KNG1 and F11 loci using factor XI levels as an intermediate phenotype of thrombosis (2017) PLOS ONE, 12 (4), -.

**IF: 2.600**

Sennblad B, Basu S, Mazur J, Suchon P, Martinez-Perez A, Vlieg A.H, Truong V, Li Y, Gadin J.R., Tang W, Grossman V, de Haan H.G., Handin N, Silveira A, Souto J.C., Franco-Cereceda A, Morange P-E, Gagnon F, Soria J.M., Eriksson P, Hamsten A, Maegdefessel L, Rosendaal F.R., Wild P, Folsom A.R., Tregouet D.-A., Sabater-Lleal M, Ge-

nome-wide association study with additional genetic and post-transcriptional analyses reveals novel regulators of plasma factor XI levels (2017) HUM MOL GENET, 26 (3), 637-649.

**IF: 4.702**

Vázquez-Santiago M, Vilalta N, Ziyatdinov A, Cuevas B, Macho R, Pujol-Moix N, Carrasco M, Mateo J, Fontcuberta J, Soria JM, Souto JC. Platelet count and plateletcrit are associated with an increased risk of venous thrombosis in females. Results from the RETROVE study. (2017) THROMB RES, 157, 162-164.

**IF: 2.779**

Vicente V, Martin A, Lecumberri R, Coll-Vinent B, Suero C, Gonzalez-Porras J.R., Marco P, Mateo J, Roldan V, Soulard S, Crespo C, Camats M, Clinical perspectives on the management of bleeding in patients on oral anticoagulants: The DECOVER Study (Delphi Consensus on oral COagulation and therapy action reVERsa Perspectivas clínicas del manejo de la hemorragia en el paciente tratado con anticoagulante oral: Estudio DECOVER (2017) EMERGENCIAS, 29 (1), 18-26.

**IF: 2.363**

## Scientific Production

## Other Publications

- ▶ López S, Soria JM, Souto JC. Genética en trombosis. Ponencia en el XXXIII Congreso Nacional de la SETH. Málaga 2017. Libro de Ponencia y Comunicaciones. Arán Ediciones SL. DL: M-34026-2012. P 68-74.
- ▶ Pujol-Moix N, Español I, Hernández A, Vázquez Santiago M, Souto JC, Muñiz-Díaz E. Platelet Ultrastructural Morphology and Morphometry in 10 Patients with MYH9- Related Disease (2017) J Hematol Transfus, 5, 1065.

- ▶ Vilalta N, Vázquez-Santiago M, Cuevas B, Macho R, Remacha A, Carrasco M, Mateo J, Millón J, Soria JM, Souto JC. The relationship between leukocyte counts and venous thromboembolism: results from RETROVE Study (2017) BIOL MED (ALIGARH), 9, 4.
- ▶ Vilalta N, Tirado I, Mateo J, Romero L, Carrasco M, Souto JC, Fontcuberta J. The c.1787G>T and c.1787G>A mutations are not found in the prothrombin gene in a Spanish population. (2017) BIOL MED (ALIGARH), 9, 4.

# Cardiovascular Biochemistry



## Coordinator

Sánchez Quesada, José Luis    IR  
jsanchezq@santpau.cat

## Members

Benítez González, Sonia	IR
Bonet Marques, Rosa	FGS
Freixa Martín, Julia	FGS
García Osuna, Álvaro	FGS
Grau Agramunt, Margarita	FGS
Ordoñez Llanos, Jorge	FGS
Pérez Calleja, Raquel	FGS
Porcel Jabalera, Inmaculada	FGS
Puig Grifol, Núria	IR
Rivas Urbina, Andrea Patricia	IR

## Main Lines of Research

### Atherosclerosis mechanisms

- ▶ Mechanisms leading to lipoprotein aggregation in the arterial wall.
- ▶ Use of mimetic peptides derived from apoJ as therapeutic tools.
- ▶ Involvement of LDL(-) on lipid accumulation in cardiomyocytes associated to diabetes and obesity.
- ▶ Association of lipid accumulation in cardiomyocytes with heart failure.
- ▶ Inflammatory mechanisms induced by LDL(-) on monocytes from patients with diabetes.

### Diagnosis and Biomarkers

- ▶ Analysis of apolipoprotein J (apoJ) as a marker of CVR.
- ▶ Diagnosis of chronic or acute cardiovascular diseases.
- ▶ Development of algorithms for ruling-out acute coronary disease.
- ▶ Assessment of new biomarkers of acute cardiovascular disease: cardiac troponins, natriuretic peptides, ST-2.
- ▶ Development of methods for point-of-care biomarker measurement.
- ▶ Vulnerability markers in atheromatous plaque: electronegative LDL, LDL size, HDL function, myeloperoxidase, phospholipase.

## Challenges

- ▶ Determine the intracellular mechanisms involved in the inflammatory response induced by LDL(-) and the components of the particle that entail atherogenicity.
- ▶ Analyse the therapeutic potential of mimetic peptides derived from apoJ to delay the development of atherosclerosis in animal models.

- ▶ Demonstrate that electronegative LDL is a marker of vulnerable atheromatous plaque.
- ▶ Find new markers of cardiovascular risk in diseases such as diabetes, HIV or cardiac failure.

## Active Grants

- ▶ José Luis Sánchez Quesada. Contracte Programa d'Estabilització i Intensificació. CES12/023. Departament de Salut. Duration: 2013-2017. 120,000.00 €.
- ▶ José Luis Sánchez Quesada. Implicación de la apolipoproteína J (clusterina) en la arteriosclerosis. Utilización terapéutica de péptidos miméticos con actividad chaperona. PI13/00364. Instituto de Salud Carlos III. Duration: 2014-2017. 85,500.00 €.

- ▶ José Luis Sánchez Quesada. Relación de la grasa epicárdica, la función lipoproteica y la inflamación con el desarrollo de arteriosclerosis y miocardiopatía diabética. PI16/00471. Instituto de Salud Carlos III. Duration: 2017-2019. 131,500.00 €.
- ▶ Jorge Ordoñez Llanos. Red Cardiovascular. RD12/0042/0043. Instituto de Salud Carlos III. Duration: 2013-2017. 94,000.00 €.

Note: Total amount granted to PI. It does not include indirect costs.

### **Collaborations with other IIB Sant Pau Groups**

- ▶ Metabolic Bases of Cardiovascular Risk (Dr. F. Blanco Vaca).
- ▶ Endocrinology, Diabetes and Nutrition (Dr. A. Pérez).
- ▶ Angiology, Vascular Biology and Inflammation (Dr. M. Camacho).
- ▶ Clinical and Translational Cardiology (Dr. J. Cinca).
- ▶ Lipids and Cardiovascular Pathology (Dr. C. Llorente).
- ▶ Cerebrovascular Diseases (Dr. J. Martí Fàbregas).
- ▶ Clinical Psychiatry (Dra. M.J. Portella).
- ▶ Intensive Care Unit (Dr. A. Betbese).

### **External Collaborations**

#### **Research into atherosclerosis mechanisms**

- ▶ Dr. Petri Kovanen, Wihuri Research Institute, Helsinki, Finland.
- ▶ Dr. Kati Öörni, Wihuri Research Institute, Helsinki, Finland.
- ▶ Dr. Olga Gursky, Boston University School of Medicine, Boston, USA.
- ▶ Dr. Sandra Villegas Hernández, Biochemistry and Molecular Biology Department, Universitat Autònoma de Barcelona, Spain.
- ▶ Dr. Ferdinando Mannello. Department of Biomolecular Sciences, Section of Clinical Biochemistry and Molecular Genetics, University "Carlo Bo", Urbino, Italy
- ▶ Dr. Mar Hernández-Guillamon. Neurovascular Research Laboratory, Vall d'Hebron Research Institute; Universitat Autònoma de Barcelona, Spain.
- ▶ Dr. Ana Reis. Facultade de Ciencias da Universidade do Porto, Portugal.

#### **Research into diagnosis**

- ▶ Dr Daniel Podzamczer, HIV Unit, Infectious Disease Service, Bellvitge University Hospital, Barcelona, Spain (PATHER, ATADAR, SPIRAL and BICOMBO clinical trials).
- ▶ Dr. Joan Sabater-Riera, Critical Care Department, Bellvitge University Hospital, Barcelona, Spain.

▶ Formation and maintenance of a bank of samples within the Cardiovascular Research Network (RIC), Programme 6 (Clinical and Translational Heart Failure).

▶ Cardiovascular Research Network (RIC): Dr Francisco Marín, Cardiology, Hospital Virgen de Arrixaca, Murcia, Spain, 3-month stay by Dr Juan Antonio Vilchez (during a Rio Hortega contract) in our collaborative studies laboratory.

▶ Dr. Mariano Valdés, Virgen de Arrixaca University Hospital, Murcia (Spain), 3-week stay by Dr Carmen Puche in our collaborative studies laboratory.

▶ Dr. Laura Dos (D. Garcia-Dorado), Integrated Adult Congenital Heart Disease Unit of Vall d'Hebron University Hospital, Barcelona, Spain (Evedes study).

▶ Dr. Domingo Pascual-Figal, Cardiology Department, Virgen de la Arrixaca University Hospital, Murcia, Spain.

▶ Dr. Rafael Vázquez, Cardiology Service, Puerta del Mar University Hospital, Cádiz, Spain.

▶ Dr. Antoni Bayes-Genís, Cardiology Department, Germans Trias i Pujol University Hospital, Barcelona, Spain.

▶ IFCC Task Force on Clinical Applications of Cardiac Biomarkers (Dr Jordi Ordóñez-Llanos, member).

▶ Dr Fred S. Apple, Department of Laboratory Medicine and Pathology, University of Minnesota, USA.

▶ Dr Paul O. Collinson, Cardiovascular and Laboratory Departments, St. George's Hospital, London, UK.

▶ Dr Alan S. Jaffe, Mayo Clinic, Cardiovascular Division, Rochester, New York, USA.

▶ Dr James L. Januzzi, Cardiology Division, Massachusetts General Hospital, Boston, USA.

#### **Participation in multicentre studies in the field of heart failure**

- ▶ MUSIC (sudden death in heart failure) Risk Score, Spanish Society of Cardiology.
- ▶ MAGGIC (meta-analysis global group in chronic heart failure), European Society of Cardiology.

# Cardiovascular Biochemistry

\*TIF: 57.588 \*\*MIF: 4.4298

Alquezar A., Santalo M., Rizzi M., Gich I., Grau M., Sionis A., Ordonez-Llanos J., Merce J., Martin A., Munoz M., Povar J., Velilla J., Calmarza P., Temboury F., Ortiz C., Balaguer J., Carratala A., Combined high-sensitivity copeptin and troponin T evaluation for the diagnosis of non-ST elevation acute coronary syndrome in the emergency department Evaluación de una estrategia diagnóstica combinada con copeptina y troponina T ultrasensibles en el infarto de miocardio sin elevación del segmento ST en los servicios de urgencias (2017) EMERGENCIAS, 29 (4), 237-244.

**IF: 2.363**

Alquezar-Arbe A., Sionis A., Ordonez-Llanos J., Cardiac troponins: 25 years on the stage and still improving their clinical value (2017) CRIT REV CL LAB SCI, 54 (7-8), 551-571.

**IF: 6.442**

Apple F.S., Sandoval Y., Jaffe A.S., Ordonez-Llanos J., Cardiac troponin assays: Guide to understanding analytical characteristics and their impact on clinical care (2017) CLIN CHEM, 63 (1), 73-81.

**IF: 8.138**

Cedo L., Santos D., Roglans N., Julve J., Pallasses V., Rivas-Urbina A., Llorente-Cortes V., Laguna J.C., Blanco-Vaca F., Escola-Gil J.C., Human hepatic lipase overexpression in mice induces hepatic steatosis and obesity through promoting hepatic lipogenesis and white adipose tissue lipolysis and fatty acid uptake (2017) PLOS ONE, 12 (12).

**IF: 2.600**

Cuartero M., Ballus J., Sabater J., Perez X., Nin N., Ordonez-Llanos J., Betbese A.J., Cell-cycle arrest biomarkers in urine to predict acute kidney injury in septic and non-septic critically ill patients (2017) ANN INTENSIVE CARE, 7 (1).

**IF: 3.653**

Estruch M., Minambres I., Sanchez-Quesada J.L., Soler M., Perez A., Ordonez-Llanos J., Benitez S., Increased inflammatory effect of electronegative LDL and decreased protection by HDL in type 2 diabetic patients (2017) ATHEROSCLEROSIS, 265, 292-298.

**IF: 4.258**

Fernandez-De-Retana S., Cano-Sarabia M., Marazuela P., Sanchez-Quesada J.L., Garcia-Leon A., Montanola A., Montaner J., Maspoch D., Hernandez-Guillamon M., Characterization of ApoJ-reconstituted high-density lipoprotein (rHDL) nanodisc for the potential treatment of cerebral β-amyloidosis (2017) SCI REP-UK, 7 (1).

**IF: 3.745**

Ferrarini A., Righetti L., Martinez M.P., Fernandez-Lopez M., Mastrangelo A., Horcada J.P., Betbese A., Esteban A., Ordonez J., Gea J., Cabello J.R., Pellati F., Lorente J.A., Nin N., Ruperez F.J., Discriminant biomarkers of acute respiratory distress syndrome associated to H1N1 influenza identified by metabolomics HPLC-QTOF-MS/MS platform (2017) ELECTROPHORESIS, 38 (18), 2341-2348.

**IF: 2.081**

Jayaraman S., Sanchez-Quesada J.L., Gursky O., Triglyceride increase in the core of high-density lipoproteins augments apolipoprotein dissociation from the surface: Potential implications for treatment of apolipoprotein deposition diseases (2017) BBA-MOL BASIS DIS, 1863 (1), 200-210.

**IF: 5.4760**

Mccord J., Cabrera R., Lindahl B., Giannitsis E., Evans K., Nowak R., Frisoli T., Body R., Christ M., DeFilippi C.R., Christenson R.H., Jacobsen G., Alquezar A., Panteghini M., Melki D., Plebani M., Verschuren F., French J., Bendig G., Weiser S., Mueller C., Ordóñez-Llanos J., Prognostic utility of a modified HEART score in chest pain patients in the emergency de-

partment (2017) CIRC-CARDIOVASC QUAL, 10 (2).

**IF: 4.753**

Mueller-Hennenhen M., Mueller C., Giannitsis E., Biener M., Vafaie M., DeFilippi C.R., Christ M., Ordonez-Llanos J., Panteghini M., Plebani M., Verschuren F., Melki D., French J.K., Christenson R.H., Body R., McCord J., Dinkel C., Katus H.A., Lindahl B., Serial sampling of high-sensitivity cardiac troponin T may not be required for prediction of acute myocardial infarction diagnosis in chest pain patients with highly abnormal concentrations at presentation (2017) CLIN CHEM, 63 (2), 542-551.

**IF: 8.138**

Nowak R., Mueller C., Giannitsis E., Christ M., Ordonez-Llanos J., DeFilippi C., McCord J., Body R., Panteghini M., Jernberg T., Plebani M., Verschuren F., French J.K., Christenson R., Jacobsen G., Dinkel C., Lindahl B., High sensitivity cardiac troponin T in patients not having an acute coronary syndrome: results from the TRAPID-AMI study (2017) BIOMARKERS, 22 (8), 709-714.


**IF: 1.917**

Saenger A.K., Rodriguez-Fraga O., Ler R., Ordonez-Llanos J., Jaffe A.S., Goetze J.P., Apple F.S., Specificity of B-type natriuretic peptide assays: Cross-reactivity with different BNP, NT-proBNP, and proBNP peptides (2017) CLIN CHEM, 63 (1), 351-358.

**IF: 8.138**

Saumoy M., Tiraboschi J.M., Ordonez-Llanos J., Ribera E., Domingo P., Mallolas J., Curto J., Gatell J.M., Podzamczer D., Atherogenic properties of LDL particles after switching from Truvada or Kivexa plus lopinavir/r to lamivudine plus lopinavir/r: OLE-MET sub-study (2017) HIV CLIN TRIALS, 18 (2), 49-53.

**IF: 1.362**



# Angiology, Vascular Biology and Inflammation



## Coordinator

Vila Navarro, Luis FGS  
lvila@santpau.cat

## Members

Alcolea Ruiz, Sonia	IR
Bellmunt Montoya, Sergio	FGS
Camacho Pérez de Madrid, María Mercedes	IR
Dilme Muñoz, Jaume Félix	FGS
Escudero Rodríguez, José Román	FGS
Galán Arroyo, María	IR
Gallastegui Mozos, Teresa	IR
Gómez Jabalera, Efren	FGS
Navas Madroñal, Miquel	IR
Romero Carro, Josep Maria	FGS
Sola Font, Olga	IR
Soto Carricas, Begoña	FGS

## Main Lines of Research

### Cardiovascular Research

- ▶ Inflammatory mechanisms involved in vascular disorders.
- ▶ Genetic basis of vascular pathologies: atherothrombosis, aortic aneurism and chronic venous insufficiency.
- ▶ New, more effective targets. Research into pharmacologic targets for NSAIDs of cardiovascular interest.

### Cancer Research

- ▶ Role of inflammatory mediators in head and neck squamous carcinoma and in regulating gene expression in tumour relapse.

## Challenges

- ▶ Increase cooperation between clinicians and experimental researchers to enhance the translation level of our research by setting up training programmes for clinical physicians.
- ▶ Increase funding sources by establishing collaborations with the industrial sector.

- ▶ Improve research quality in terms of standard evaluation indexes.

## Collaborations

### Collaborations with other IIB Sant Pau Groups

- ▶ Ear, Nose and Throat Cancers (Xavier León, Jacinto Gracia and Miquel Quer).
- ▶ Genomics of Complex Diseases (José Manuel Soria, PI).
- ▶ Thrombosis and Haemostasis (Juan Carlos Souto, PI).
- ▶ Atherosclerosis and Vascular Biology (José Martínez, PI).
- ▶ Inflammation and Vascular Remodelling (Cristina Rodríguez, PI).
- ▶ General and Digestive Surgery (Eduard Targarona and Carmen Balagueré).
- ▶ Cerebrovascular Diseases (Joan Martí Fàbregas, PI; Pol Camps Renom, Elena Jiménez Xarrie)

### External Collaborations

- ▶ Dra. Mercedes Salaices. Universidad Autónoma de Madrid, Spain.
- ▶ Dr. Juan Miguel Redondo. CNIC, Madrid, Spain.
- ▶ Dr. Francesc-Xavier Avilés-Jurado. Otorhinolaryngology Department, Hospital Universitari de Tarragona Joan XXIII, Institut d'Investigació Sanitària Pere Virgili, Universitat Rovira i Virgili, Tarragona, Spain.
- ▶ Prueba piloto de un programa de cribado poblacional de aneurismas de aorta abdominal realizada en atención primaria mediante ecografía. PERIS: SLT 002/16/00441.

## Active Grants

- ▶ María Galán Arroyo. Contratos Miguel Servet I 2015. MS15/00126. Instituto de Salud Carlos III. Duration: 2016-2021. 202,500.00 €.
- ▶ María Galán Arroyo. Novel therapeutic strategies to limit the progression of abdominal aortic aneurysm: targeting endoplasmic reticulum and mitochondrial stress. CP15/00126. Instituto de Salud Carlos III. Duration: 2016-2018. 121,500.00 €.
- ▶ Luis Vila Navarro. Red Cardiovascular. RD12/0042/0051. Instituto de Salud Carlos III. Duration: 2013-2017. 201,869.56 €.

Note: Total amount granted to PI. It does not include indirect costs.

**Grants  
Awarded  
in 2017**

- María Galán Arroyo. Nuevas dianas terapéuticas para el tratamiento del AAA y de la cardiopatía hipertensiva: proteínas implicadas en el estrés del retículo y en la disfunción mitocondrial. PI17/01837. Instituto de Salud Carlos III. Duration: 2018-2020. 102,000.00 €.

- Mercedes Camacho. Grup de Recerca Consolidat SGR 1234. Generalitat de Catalunya. Duration: 2017-2019.

Note: Total amount granted to PI. It does not include indirect costs.

**Scientific Production**

**\*TIF: 25.392 \*\*MIF: 3.63**

Galan M., Varona S., Guadall A., Orriols M., Navas M., Aguiló S., De Diego A., Navarro M.A., Garcia-Dorado D., Rodriguez-Sinovas A., Martinez-Gonzalez J., Rodriguez C., Lysyl oxidase overexpression accelerates cardiac remodeling and aggravates angiotensin II-induced hypertrophy (2017) FASEB J, 31 (9), 3787-3799.

**IF: 5.595**

Gomez-Jabalera E., Bellmunt Montoya S., Fuentes-Camps E., Escudero Rodriguez J.R., Age-adjusted D-dimer for the diagnosis of deep vein thrombosis (2017) PHLEBOLOGY.

**IF: 1.513**

Marin-Garcia M., Benseny-Cases N., Camacho M., Suades J., Barnadas-Rodriguez R., Camacho Pérez De Madrid M., Low-toxicity metallosomes for biomedical applications by self-assembly of organometallic metallo-

surfactants and phospholipids (2017) CHEM COMMUN, 53 (60), 8455-8458.

**IF: 6.29**

Pardo L., Valero C., Lopez M., Garcia J., Camacho M., Quer M., Leon X., The prognostic value of pretreatment platelet count in patients with head and neck squamous cell carcinoma (2017) AURIS NASUS LARYNX, 44 (3), 313-318.

**IF: 1.387**

Soto B., Gallastegi-Mozos T., Rodríguez C., Martínez-González J., Escudero JR., Vila L., Camacho M., Circulating CCL20 as a New Biomarker of Abdominal Aortic Aneurysm (2017) Sci Rep, 7(1), 17331.

**IF: 4.259**

Soto B., Vila L., Dilme J.F., Escudero J.R., Bellmunt S., Camacho M., Increased Peak Wall Stress, but Not Maximum Diameter, Is Asso-

ciated with Symptomatic Abdominal Aortic Aneurysm (2017) EUR J VASC ENDOVASC, 54 (6), 706-711.

**IF: 3.877**

Valero C., Pardo L., Lopez M., Garcia J., Camacho M., Quer M., Leon X., Pretreatment count of peripheral neutrophils, monocytes, and lymphocytes as independent prognostic factor in patients with head and neck cancer (2017) HEAD NECK-J SCI SPEC, 39 (2), 219-226.

**IF: 2.471**

# Molecular Pathology and Therapeutic of Ischaemic and Atherothrombotic Diseases



## Coordinator

Badimon Maestro, Lina ICCC  
lbadimon@santpau.cat

## Members

Ardériu Marquès, Gemma	ICCC
Ben Aicha González,	
Soumaya	ICCC
Borrell Pagès, Maria	ICCC
Camino López, Sandra	ICCC
Cánovas Noé,	
María Ángeles	ICCC
Casaní Arazo, Laura	ICCC
Catalina García, Pablo	ICCC
Chiva Blanch, Gemma	ICCC
Crespo Asensio, Javier	ICCC
Escate Chávez,	
Oscar Rafael	ICCC
Florit Carbonell, Sergi	ICCC
Gallatin O'Callaghan,	
Alexandre	ICCC
García García, Olalla	ICCC
Gerbolés Freixas, Esther	ICCC
Huertas Segarra, Sònia	ICCC
Juan Babot, Josep Oriol	ICCC
Juncosa Rosalén,	
Ángel Luis	ICCC
Lambert Goitia, Carmen	ICCC
López Bernal, Sergio	ICCC
Moreno Gómez, Josep	ICCC
Nasarre Miarnau,	
Laura Rosa	ICCC
Segalés Aguilar, Estefania	ICCC
Velasco Murcia,	
María Ángeles	ICCC
Vilahur Garcia, Gemma	ICCC

## Main Lines of Research

- ▶ Physiopathological role of LRP family proteins in chronic diseases.
- ▶ Role of lipids and inflammation in atherosclerosis and ischemic heart disease.
- ▶ Vascular impact of ischaemia and angiogenesis in heart disease. Cell therapy.

- ▶ Research into new targets to inhibit the transformation of silent atherosclerosis into ischaemic syndromes: tissue-factor-mediated angiogenic switch.

## Challenges

- ▶ Broaden the experimental focus to include transgenic animal models with/without cardiovascular risk factors in order to proceed to in-depth analysis of molecules involved in the modulation of new proteins identified by post-genomic technologies and systems biology approaches.

- ▶ Maintain present scientific networks and establish new multidisciplinary collaborations.
- ▶ Increase international funding for the extension of new and established platforms in order to implement proposed activities.

## Active Grants

- ▶ Lina Badimon Maestro. Red de Terapia Celular (TerCel). RD16/0011/0018. Instituto de Salud Carlos III. Duration: 2017-2021. 66,502.00 €.
- ▶ Gemma Vilahur Garcia. L'administració intravenosa d'un inhibidor modificat de l'HMG-COA-reductasa: una prometedora estratègia cardioprotectora en la malaltia isquèmica del cor, desentranyar benefis i mecanismes d'acció. MARATO 20154310. Fundació La Marató de TV3. Duration: 2016-2019. 154,150.00 €.
- ▶ Maria Montserrat Borrell Pages. Aterotrombosis y su inhibición: LRP5/WNT en la respuesta aguda a la lesión vascular. PI16/02014. Instituto de Salud Carlos III. Duration: 2017-2019. 53,500.00 €.
- ▶ Carmen Lambert Goitia. Project SAF2013-42962 LB. BES2014-068269. Ministerio de Economía y Competitividad. Duration: 2015-2019. 83,900.00 €.
- ▶ Lina Badimon Maestro (CP IP). Factor tisular no-coagulante y angiogenesis terapéutica para reparar el tejido isquémico. SAF2016-76819-R. Ministerio de Economía y Competitividad. Duration: 2016-2019. 320,000.00 €.
- ▶ Gemma Chiva Blanch. Patología molecular i terapèutica de les malalties aterotrombòtiques i isquèmiques. IJCI-2015-26358. Ministerio de Economía y Competitividad. Duration: 2017-2019. 64,000.00 €.
- ▶ Lina Badimon Maestro. Investigación y desarrollo clínico de una nueva molécula para el control de peso y prevención de la obesidad. RTC-2016-5317-1. Ministerio de Economía y Competitividad. Duration: 2016-2018. 180,000.40 €.
- ▶ Gemma Vilahur Garcia. Remodelado estructural y funcional de las partículas HDL y su implicación en la salud cardiovascular: identificación de moduladores con potencial terapéutico. SAF2015-71653-R. Ministerio de Economía y Competitividad. Duration: 2016-2018. 90,000.00 €.
- ▶ Lina Badimon Maestro. Validación de un nuevo y original biomarcador, ApoJ-glyc, para el diagnóstico y la estratificación del riesgo en pacientes con isquemia miocárdica. DTS16/00194. Instituto de Salud Carlos III. Duration: 2017-2018. 70,500.00 €.
- ▶ Lina Badimon Maestro. Patología molecular i terapèutica de les malalties aterotrombòtiques. 2017 SGR 1480. Agència de Gestió d'Ajuts Universitaris i de Recerca. Duration: 2017-2019. 61,192.00 €.
- ▶ Lina Badimon Maestro. Identificación de nuevos biomarcadores en el manejo de la insuficiencia cardiaca. Sociedad Española de Cardiología (SEC). Duration: 2016-2017. 20,000 €.
- ▶ Lina Badimon Maestro. Moderate beer intake effects of the inflammasome pathway and TLR-mediated immunomodulation in humans. The European Foundation for Alcohol Research (ERAB Grants). Duration: 2017-2018. 65,000 €.
- ▶ Lina Badimon Maestro. CIBER Enfermedades Cardiovasculares. (CIBERCV). CB16/11/00411. Instituto de Salud Carlos III. 188,362 €.

Note: Total amount granted to PI. It does not include indirect costs.

### Collaborations with other IIB Sant Pau Groups

- ▶ Clinical and Translational Cardiology (PI: Juan Cinca).
- ▶ Biomarkers for Cardiovascular Disease (PI: Teresa Padró).
- ▶ Cerebrovascular Diseases (PI: Joan Martí Fàbregas).
- ▶ Endocrinology, Diabetes and Nutrition (PI: Alberto de Leiva).
- ▶ Pharmacological Research in Humans (PI: Rosa M. Antonijuan).
- ▶ Angiology, Vascular Biology and Inflammation (PI: Luis Vila)
- ▶ Radiodiagnostics (PI: Antoni Capdevila)
- ▶ Molecular Basis of Cardiovascular Risk (PI: Joan Carles Escolà)

### National Collaborations

- ▶ Department of Internal Medicine, Hospital Clínic, Barcelona (Ramón Estruch).
- ▶ Department of Cardiology, Thorax Institute, Hospital Clínic, University of Barcelona (Salvatore Brugaletta, Victoria Martín-Yuste, Clarissa Cola, Manel Sabaté).
- ▶ Fundación Hipercolesterolemia Familiar, Madrid (Pedro Mata, Rodrigo Alonso, Leopoldo Pérez-Isla).
- ▶ Cell Therapy Network (TerCel), RD12/0019.
- ▶ Cardiovascular Research Network (RIC), RD12/0042.
- ▶ Department of Cardiology, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia (MA Esteve-Pastor).
- ▶ Department of Cardiology, Hospital Universitario San Juan, Alicante (V. Bertomeu-Martínez).
- ▶ Department of Cardiology, Hospital La Paz, Madrid (I Roldán-Rabadán, R Peinado).
- ▶ Department of Cardiology (A Cequier-Fillat), Internal Medicine Service (F Formiga), Hospital de Bellvitge, Barcelona.
- ▶ Department of Cardiology, Hospital Universitario A Coruña, La Coruña (J Muñiz-García).
- ▶ Department of Cardiology, Hospital Universitario Reina Sofía, Córdoba (M. Anguita-Sánchez).
- ▶ Department of Preventive Medicine and Public Health, University of Valencia, Valencia (D. Corella).
- ▶ Human Nutrition Unit, Hospital Universitari Sant Joan, Institut d'Investigacions Sanitàries Pere Virgili, Universitat Rovira i Virgili, Reus (J Salas-Salvadó).
- ▶ Department of Cardiology, University Hospital Araba, Vitoria (F Arós).
- ▶ Department of Epidemiology and Public Health, University of Navarra, Pamplona (MA Martínez-González).
- ▶ Lipid Clinic, Endocrinology and Nutrition Service, Institut d'Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Hospital.
- ▶ Clinic, University of Barcelona, Barcelona, Spain (E Ros).

- ▶ Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona (M. Fitó).

- ▶ Servicio de Medicina Interna, Hospital Universitario La Paz, Madrid (MA Quesada, J Camacho Siles).
- ▶ Invasive Cardiology Department Puerta de Hierro Hospital, Majadahonda, Madrid, Spain (J Goicolea).
- ▶ Clinical Laboratory L'Hospitalet, Barcelona, Spain (G Padrós).

### International Collaborations

- ▶ Experimental, Diagnostic and Speciality Medicine, University of Bologna, Italy (Raffaele Bugiardini).
- ▶ School of Healthcare Science, John Dalton Building, Manchester Metropolitan University, UK (Mark Slevin).
- ▶ Atherothrombosis Research Unit, Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai School of Medicine, New York, USA (Juan José Badimon).
- ▶ Department of Clinical Biochemistry and Immunohematology, Faculty of Health Sciences, University of Talca, Chile (Ivan Palomo).
- ▶ Centre for Clinical Heart Research, Department of Cardiology, Oslo University Hospital Ullevål, Oslo, Norway (Ingebjørg Seljeflot).
- ▶ Department of Food and Nutrition, Universidade Federal de Santa Maria, Palmeira das Missões, Brazil; Program of Postgraduate in Gerontology, Universidade Federal de Santa Maria, Santa Maria, Brazil (Patricia Chagas).
- ▶ Department of Pharmacology, Catholic University School of Medicine, Rome, Italy (Carlo Patrono).
- ▶ Engineering and Materials Research Centre, Manchester Metropolitan University, Manchester, M1 5GD, United Kingdom (Amir Keshmiri).
- ▶ Department of NeuroFarBa, C.I.M.M.B.A., University of Florence, Viale Pieraccini, 6, Florence 50139, Italy (Elisabetta Cerbai).
- ▶ Department of Epidemiology and Prevention, IRCCS Istituto Neuropologico Mediterraneo Neuromed, 86077 Pozzilli, Italy (Giovanni de Gaetano).
- ▶ TACTICS - Transnational Alliance for Regenerative Therapies in Cardiovascular Syndromes (Fernández-Avilés F, Sanz-Ruiz R, Climent AM, Badimon L, Charron D, Fuster V, Janssens S, Kastrup J, Kim HS, Lüscher TF, Martin J, Menasché P, Simari R, Stone GW, Terzic A, Willerson JT, Wu J).
- ▶ Cardiology Department, University of Medicine and Pharmacy "Carol Davila" of Bucharest, Emergency Clinical Hospital of Bucharest, 8, Calea Floreasca, Sector 1, 014461 Bucuresti, Romania (Maria Dorobantu).
- ▶ Cardiovascular and Metabolic Diseases, Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Mölndal, Sweden (Leif Carlsson).
- ▶ Division of Hematology/Oncology, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, USA (Vladimir Y Bogdanov).

- ▶ Lina Badimon Maestro. Validation of apo j-glyc as a biomarker of ischemic damage, 2016 PROD 00043. Agència de Gestió d'Ajuts Universitaris i de Recerca. Duration: 2017-2019. 99,500.00 €.
- ▶ Gemma Arderiu Marquès. Enfermedad arterial periférica: potenciar la capacidad angiogénica de las células madre mesenqui-

males, PI17/01321. Instituto de Salud Carlos III. Duration: 2018-2020. 74,000.00 €.

Note: Total amount granted to PI. It does not include indirect costs.

# Molecular Pathology and Therapeutic of Ischaemic and Atherothrombotic Diseases

## Books or chapters with ISBN

- ▶ Badimon L, Tanner FC, Camici GG, Vilahur G. Pathophysiology of thrombosis (Section V / Chapter 18). In: Kramps R, Bäck M. ESC Textbook of Vascular Biology. Oxford University Press, United Kingdom; pp: 273-290; 2017. ISBN: 9780198755777.

## Awards

- ▶ Gemma Chiva 2017 Young Investigador Award for excellence in Clinical Research of the European Society for Clinical Investigation (ESCI).
- ▶ Lina Badimon. Visiting Professorship Manchester Metropolitan University (2017).
- ▶ Lina Badimon. Honorary Member of the Hungarian Society of Cardiology (2017).
- ▶ Lina Badimon. Member of the Scientific Advisory Board of the International Aspirin Foundation. England (2017).
- ▶ Lina Badimon. Member of the Scientific Advisory Committee of the Fundación GADEA para la Ciencia (2017).

## Patents

- ▶ Lina Badimon Maestro, Gemma Vilahur García. Prevention or reduction is ischemia-related damage. EP17164137. European Union. 31/03/2017.
- ▶ Lina Badimon Maestro, Judit Cubedo Ràfols, Teresa Padró Capmany. Methods and kits for the diagnosis and risk stratification of patients with ischemia. EP16382167.1. European Union. 12/04/2016.
- ▶ Lina Badimon Maestro, Judit Cubedo Ràfols, Gemma Vilahur García, Teresa Padró Capmany. Prevention and/or treatment of ischemia or ischemia/reperfusion injury. EP16382111.9. European Union. 14/03/2016.
- ▶ Lina Badimon Maestro, Gemma Vilahur García. Prevention and/or treatment of ischemia/reperfusion injury. 14382190.8-1464. European Union. 18/07/2014.
- ▶ Concepción Vicenta Llorente-Cortés, Lina Badimon Maestro. LRP1 as key receptor for the transfer of sterified cholesterol from very-low-density lipoproteins (VLDL) to ischaemic cardiac muscle. 12804028. International. 07/05/2014.
- ▶ Lina Badimon Maestro, Judit Cubedo Ràfols, Teresa Padró Capmany. Apolipoprotein J isoforms as biomarkers of organ damage. PCT/ES2011/070080. International. 26/08/2011.
- ▶ Lina Badimon Maestro, José Martínez González. Procedimiento de identificación de potenciales compuestos moduladores de la actividad de NOR-1, nueva diana diagnóstica y terapéutica de enfermedades cardiovasculares. 2288330. International. 26/08/2009.
- ▶ Lina Badimon Maestro, José Martínez González. Procedimiento de identificación de NOR-1 y/o NURR1 para el diagnóstico y seguimiento de enfermedades cardiovasculares. 200202901. National. 01/04/2005.
- ▶ Nuria Rubio Vidal, Jerónimo Blanco Fernández, Lina Badimon Maestro. Procedimiento de cultivo de células progenitoras humanas para el transplante autólogo. PCT/ES2004/070106. National. 01/01/2004.

## Transfer Products

- ▶ Co-founder of the Spin-Off "Glycardial Diagnostics SL" September 2017.

\*TIF: 336.259 \*\*MIF: 8.006

Arderiu G., Espinosa S., Pena E., Crespo J., Aledo R., Bogdanov V.Y., Badimon L., Tissue factor variants induce monocyte transformation and transdifferentiation into endothelial cell-like cells (2017) *J THROMB HAEMOST*, 15 (8), 1689-1703.

**IF: 4.899**

Badimon L., Cubedo J., Adipose tissue depots and inflammation: Effects on plasticity and residentmesenchymal stem cell function (2017) *CARDIOVASC RES*, 113 (9), 1064-1073.

**IF: 6.290**

Badimon L., Cubedo J., Hypercoagulability and atrial fibrillation: A two-way road? (2017) *EUR HEART J*, 38 (1), 51-52.

**IF: 23.425**

Badimon L., Vilahur G., Padro T., Systems biology approaches to understand the effects of nutrition and promote health (2017) *BRIT J CLIN PHARMACO*, 83 (1), 38-45.

**IF: 3.838**

Badimon L., Padro T., Cubedo J., Protein changes in non-LDL-lipoproteins in familial hypercholesterolemia: Implications in cardiovascular disease manifestation and outcome (2017) *CURR OPIN LIPIDOL*, 28 (5), 427-433.

**IF: 3.853**

Badimon L., Bugiardini R., Cenko E., Cubedo J., Dorobantu M., Duncker D.J., Estruch R., Milicic D., Tousoulis D., Vasiljevic Z., Vilahur G., De Wit C., Koller A., Position paper of the European Society of Cardiology-working group of coronary pathophysiology and microcirculation: Obesity and heart disease (2017) *EUR HEART J*, 38 (25), 1951-1958a.

**IF: 23.425**

Badimon L., Borrell-Pages M., Wnt signaling in the vessel wall (2017) *CURR OPIN HEMATOL*, 24 (3), 230-239.

**IF: 2.821**

Bugiardini R., Ricci B., Cenko E., Vasiljevic Z., Kedev S., Davidovic G., Zdravkovic M., Milicic D., Dilic M., Manfrini O., Koller A., Badimon L., Delayed care and mortality among women and men with myocardial infarction (2017) *J AM HEART ASSOC*, 6 (8).

**IF: 4.450**

Catapano A.L., Graham I., De Backer G., Wiklund O., Chapman M.J., Drexel H., Hoes A.W., Jennings C.S., Landmesser U., Pedersen T.R., Reiner Z., Riccardi G., Taskinen M.-R., Tokgozoglu L., Monique Verschuren W.M., Vlachopoulos C., Wood D.A., Luis Zamorano J., Cooney M.-T., Badimon L., Funck-Brentano C., Agewall S., Baron-Esquivias G., Boren J., Bruckert E., Cordero A., Corsini A., Giannuzzi P., Gueyffier F., Krstacic G., Lettino M., Lionis C., Lip G.Y.H., Marques-Vidal P., Milicic D., Pe-

dro-Botet J., Piepoli M.F., Rigopoulos A.G., Ruschitzka F., Tunon J., von Eckardstein A., Vrablik M., Weiss T.W., Williams B., Windecker S., Zimlichman R., 2016 ESC/EAS guidelines for the management of dyslipidemias Guía ESC/EAS 2016 sobre el tratamiento de las dislipemias (2017) *REV ESP CARDIOL*, 70 (2), 115.e-115.e.

**IF: 5.166**

Chagas P., Mazocco L., Piccoli J.D.C.E., Ardenghi T.M., Badimon L., Caramori P.R.A., Pellanda L., Gomes I., Schwanke C.H.A., Association of alcohol consumption with coronary artery disease severity (2017) *CLIN NUTR*, 36 (4), 1036-1039.

**IF: 5.496**

Chagas P., Badimon L., Augustin Schwanke C.H., Reply to letter to the editor: Epicardial adipose tissue, alcohol consumption, and coronary artery disease severity (2017) *CLIN NUTR*.

**IF: 5.496**

Chiva-Blanch G., Bratseth V., Ritschel V., Andersen G.O., Halvorsen S., Eritsland J., Arnesen H., Badimon L., Seljeflot I., Monocyte-derived circulating microparticles (CD14+, CD14+/CD11b+ and CD14+/CD142+) are related to long-term prognosis for cardiovascular mortality in STEMI patients (2017) *INT J CARDIOL*, 227, 876-881.

**IF: 4.034**

Chiva-Blanch G., Laake K., Myhre P., Bratseth V., Arnesen H., Solheim S., Badimon L., Seljeflot I., Platelet-, monocyte-derived & tissue factorcarrying circulating microparticles are related to acute myocardial infarction severity (2017) *PLOS ONE*, 12 (2).

**IF: 2.766**

Chiva-Blanch G., Badimon L., Effects of Polyphenol Intake on Metabolic Syndrome: Current Evidences from Human Trials (2017) *OXID MED CELL LONGEV*, 2017.

**IF: 4.936**

Cubedo J., Blasco A., Padro T., Ramaiola I., Juan-Babot O., Goicoechea J., Fernandez-Diaz J.A., Oteo J.F., Badimon L., Molecular signature of coronary stent thrombosis: Oxidative stress and innate immunity cells (2017) *THROMB HAEMOSTASIS*, 117 (9), 1816-1827.

**IF: 4.952**

Cubedo J., Padro T., Formiga F., Ferrer A., Padros G., Pena E., Badimon L., Inflammation and hemostasis in older octogenarians: implication in 5-year survival (2017) *TRANSL RES*, 185, 34-46.e9.

**IF: 4.880**

Cubedo J., Suades R., Padro T., Martin-Yuste V., Sabate-Tenas M., Cinca J., Sans-Rosello J., Sionis A., Badimon L., Erythrocyte-heme proteins and STEMI: Implications in progn-

sis (2017) *THROMB HAEMOSTASIS*, 117 (10), 1970-1980.

**IF: 4.952**

de Gonzalo-Calvo D., Cenarro A., Garlaschelli K., Pellegatta F., Vilades D., Nasarre L., Camino-Lopez S., Crespo J., Carreras F., Leta R., Catapano A.L., Norata G.D., Civeira F., Llorente-Cortes V., Translating the microRNA signature of microvesicles derived from human coronary artery smooth muscle cells in patients with familial hypercholesterolemia and coronary artery disease (2017) *J MOL CELL CARDIOL*, 106, 55-67.

**IF: 5.296**

Escate R., Padro T., Borrell-Pagès M., Suades R., Aledo R., Mata P., Badimon L., Macrophages of genetically characterized familial hypercholesterolemia patients show upregulation of LDL-receptor related proteins (2017) *J CELL MOL MED*, 21(3), 487-499.

**IF: 4.302**

Fernández-Avilés F., Sanz-Ruiz R., Climent AM., Badimon L., Charron D., Fuster V., Janssens S., Kastrup J., Kim HS., Lüscher TF., Martin J., Menasché P., Simari R., Stone GW., Terzic A., Willerson JT., Wu J.: the TACTICS (Transnational Alliance for Regenerative Therapies in Cardiovascular Syndromes) Writing Group. Global Position Paper on Cardiovascular Regenerative Medicine. Scientific Statement of the Transnational Alliance for Regenerative Therapies in Cardiovascular Syndromes (TACTICS) International Group for the Comprehensive Cardiovascular Application of Regenerative Medicinal Products (2017) *EUR HEART J* Sep 1, 38(33), 2532-2546.

**IF: 23.425**

Fuentes F., Alarcon M., Badimon L., Fuentes M., Klotz K.-N., Vilahur G., Kachler S., Padro T., Palomo I., Fuentes E., Guanosine exerts antiplatelet and antithrombotic properties through an adenosine-related cAMP-PKA signaling (2017) *INT J CARDIOL*, 248, 294-300.

**IF: 4.034**

Halvorsen S., Storey R.F., Rocca B., Sibbing D., Berg J.T., Grove E.L., Weiss T.W., Collet J.-P., Andreotti F., Gulba D.C., Lip G.Y.H., Husted S., Vilahur G., Morais J., Verheugt F.A., Lanas A., Salman R.A.-S., Steg P.G., Huber K., Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: Expert consensus paper of the European Society of cardiology working group on thrombosis (2017) *EUR HEART J*, 38 (19), 1455-1462.

**IF: 23.425**

Lambert C., Cubedo J., Padro T., Sanchez-Hernandez J., Antonjoan R.M., Perez A., Badimon L., Phytosterols and omega 3 supple-

# Molecular Pathology and Therapeutic of Ischaemic and Atherothrombotic Diseases

\*TIF: 336.259 \*\*MIF: 8.006

mentation exert novel regulatory effects on metabolic and inflammatory pathways: A proteomic study (2017) *NUTRIENTS*, 9 (6).

**IF: 4.196**

Lip G.Y.H., Collet J.P., Caterina R.D., Fauchier L., Lane D.A., Larsen T.B., Marin F., Morais J., Narasimhan C., Olshansky B., Pierard L., Potpara T., Sarrafzadegan N., Sliwa K., Varela G., Vilahur G., Weiss T., Boriani G., Rocca B., Gorenk B., Savelieva I., Sticherling C., Kudai-berdieva G., Chao T.-F., Violi F., Nair M., Zimmerman L., Piccini J., Storey R., Halvorsen S., Gorog D., Rubboli A., Chin A., Scott-Millar R., Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: A joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE) (2017) *EUROPACE*, 19 (11), 1757-1758.

**IF: 5.231**

Lip GYH, Collet JP, de Caterina R, Fauchier L, Lane DA, Larsen TB, Marin F, Morais J, Narasimhan C, Olshansky B, Pierard L, Potpara T, Sarrafzadegan N, Sliwa K, Varela G, Vilahur G, Weiss T, Boriani G, Rocca B. Antithrombotic Therapy in Atrial Fibrillation Associated with Valvular Heart Disease: Executive Summary of a Joint Consensus Document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, Endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE) (2017) *THROMB HAEMOSTASIS* Dec, 117(12), 2215-2236.

**IF: 4.952**

Moreno-Navarrete J.M., Jove M., Padro T., Boada J., Ortega F., Ricart W., Pamplona R., Badimon L., Portero-Otin M., Fernandez-Real J.M., Adipocyte lipopolysaccharide binding protein (LBP) is linked to a specific lipidomic signature (2017) *OBESITY*, 25 (2), 391-400.

**IF: 4.042**

Padro T., Cubedo J., Camino S., Bejar M.T., Ben-Aicha S., Mendieta G., Escola-Gil J.C., Escate R., Gutierrez M., Casani L., Badimon L., Vilahur G., Detrimental Effect of Hypercholesterolemia on High-Density Lipoprotein

Particle Remodeling in Pigs (2017) *J AM COLL CARDIOL*, 70 (2), 165-178.

**IF: 16.834**

Patrono C., Morais J., Baigent C., Collet J.-P., Fitzgerald D., Halvorsen S., Rocca B., Siegbahn A., Storey R.F., Vilahur G., Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis (2017) *J AM COLL CARDIOL*, 70 (14), 1760-1776.

**IF: 16.834**

Pena E., De La Torre R., Arderiu G., Slevin M., Badimon L., mCRP triggers angiogenesis by inducing F3 transcription and TF signalling in microvascular endothelial cells (2017) *THROMB HAEMOSTASIS*, 117 (2), 357-370.

**IF: 4.952**

Perez de Isla L., Alonso R., Mata N., Fernandez-Perez C., Muniz O., Diaz-Diaz J.L., Saltijeral A., Fuentes-Jimenez F., de Andres R., Zambon D., Piedeca M., Cepeda J.M., Mauri M., Galiana J., Brea A., Munoz-Torrero J.F.S., Padro T., Argueso R., Miramontes-Gonzalez J.P., Badimon L., Santos R.D., Watts G.F., Mata P., Predicting cardiovascular events in familial hypercholesterolemia: The SAFEHEART registry (Spanish Familial Hypercholesterolemia Cohort Study) (2017) *CIRCULATION*, 135 (22), 2133-2144.

**IF: 18.880**

Quifer-Rada P., Chiva-Blanch G., Jauregui O., Estruch R., Lamuela-Raventos R.M., A discovery-driven approach to elucidate urinary metabolome changes after a regular and moderate consumption of beer and nonalcoholic beer in subjects at high cardiovascular risk (2017) *MOL NUTR FOOD RES*, 61 (10).

**IF: 5.151**

Ricci B., Cenko E., Vasiljevic Z., Stankovic G., Kedev S., Kalpak O., Vavlukis M., Zdravkovic M., Hinic S., Milicic D., Manfrini O., Badimon L., Bugiardini R., Acute coronary syndrome: The risk to young women (2017) *J AM HEART ASSOC*, 6 (12).

**IF: 4.450**

Ridger V.C., Boulanger C.M., Angelillo-Scherer A., Badimon L., Blanc-Brude O., Bocheton-Piallat M.-L., Boillard E., Buzas E.I., Caporali A., Dignat-George F., Evans P.C., Lacroix R., Lutgens E., Ketelhuth D.F.J., Nieuwland R., Toti F., Tunon J., Weber C., Hoefer I.E., Lip G.Y.H., Werner N., Shantsila E., ten Cate H., Thomas M., Harrison P., Microvesicles in vascular homeostasis and diseases position paper of the European Society of Cardiology (ESC) working group on atherosclerosis and vascular biology (2017) *THROMB HAEMOSTASIS*, 117 (7), 1296-1316.

**IF: 4.952**

Saltijeral A., Perez de Isla L., Alonso R., Muniz O., Diaz-Diaz J.L., Fuentes F., Mata N., de An-

dres R., Diaz-Soto G., Pastor J., Pinilla J.M., Zambon D., Pinto X., Badimon L., Mata P., Attainment of LDL Cholesterol Treatment Goals in Children and Adolescents With Familial Hypercholesterolemia. The SAFEHEART Follow-up Registry Consecución de objetivos terapéuticos de colesterol LDL en niños y adolescentes con hipercolesterolemia familiar. Registro longitudinal SAFEHEART (2017) *REV ESP CARDIOL*, 70 (6), 444-450.

**IF: 5.166**

Vilahur G., High-density lipoprotein benefits beyond the cardiovascular system: A potential key role for modulating acquired immunity through cholesterol efflux (2017) *CARDIOVASC RES*, 113 (13), e51-e53.

**IF: 6.290**

Vilahur G., New role for CD36 in metastasis through fat intake (2017) *CARDIOVASC RES* Jun 1, 113(7), e16-e17.

**IF: 6.290**

Vilahur G., Relevance of low miR-30c-5p levels in atherogenesis: A promising predictive biomarker and potential therapeutic target (2017) *CARDIOVASC RES*, 113 (13), 1536-1537.

**IF: 6.290**

Vilahur G., Ben-Aicha S., Badimon L., New insights into the role of adipose tissue in thrombosis (2017) *CARDIOVASC RES*, 113 (9), 1046-1054.

**IF: 6.290**

Vilahur G., Gutierrez M., Casani L., Varela L., Capdevila A., Pons-Lladó G., Carreras F., Carlsson L., Hidalgo A., Badimon L., Response by Vilahur et al to letters regarding article, "Protective Effects of Ticagrelor on Myocardial Injury After Infarction" (2017) *CIRCULATION* Apr 25, 135(17), e1004-e1005.

**IF: 18.880**

Vilahur G., Onate B., Cubedo J., Bejar M.T., Arderiu G., Pena E., Casani L., Gutierrez M., Capdevila A., Pons-Lladó G., Carreras F., Hidalgo A., Badimon L., Allogenic adipose-derived stem cell therapy overcomes ischemia-induced microvessel rarefaction in the myocardium: Systems biology study (2017) *STEM CELL RES THER*, 8 (1).

**IF: 4.963**

Weber C., Badimon L., Mach F., van Der Vorst E.P.C., Therapeutic strategies for atherosclerosis and atherothrombosis: Past, present and future (2017) *THROMB HAEMOSTASIS*, 117 (7), 1258-1264.

**IF: 4.952**

Zamorano J.L., Lancellotti P., Rodriguez Muñoz D., Aboyans V., Asteggiano R., Galderisi M., Habib G., Lenihan D.J., Lip G.Y.H., Lyon A.R., Lopez Fernandez T., Mohty D., Piepoli

**Scientific Production****\*TIF: 336.259 \*\*MIF: 8.006**

M.F., Tamargo J., Torbicki A., Suter T.M., Zamorano J.L., Aboyans V., Achenbach S., Agewall S., Badimon L., Baron-Esquivias G., Baumgartner H., Bax J.J., Bueno H., Carerj S., Dean V., Erol C., Fitzsimons D., Gaemperli O., Kirchhof P., Kolh P., Lancellotti P., Lip G.Y.H., Nihoyannopoulos P., Piepoli M.F., Ponikows-

ki P., Roffi M., Torbicki A., Vaz Carneiro A., Windecker S., 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of

Cardiology (ESC) (2017) EUR J HEART FAIL, 19 (1), 9-42.

**IF: 10.683**

**Other Publications**

- ▶ Badimon L, Suades R, Arderiu G, Chiva-Blanch G, Peña E, Padro T. Microvesicles in atherosclerosis and angiogenesis: from bench to bedside and reverse. *Frontiers in Cardiovascular Medicine-Atherosclerosis and Vascular Medicine*. 18 December 2017.
- ▶ Badimon L, Vilahur G. Optimización del tratamiento antiagregante del paciente tras un infarto agudo de miocardio. Efectos cardioprotectores del ticagrelor. *Revista Española de Cardiología*, Supl. 17(B), 3-8; 2017.
- ▶ Padro T, Badimon L. Investigación en enfermedad cardiovascular femenina. *Diabetes Práctica* 08 (Supl Extr 5): 14-17; 2017.
- ▶ Badimon L. Fisiopatología de la pared arterial y papel del colesterol en el origen y progresión de la placa de ateroma. *Clinica e Investigación en Arteriosclerosis* 29 Supl 1: 4-8; 2017.

# Biomarkers for Cardiovascular Disease



## Coordinator

Padró Capmany, Teresa ICCC  
tpadro@santpau.cat

## Members

Baldellou Sebastián,	ICCC
Maria Isabel	ICCC
Catot Mayoral, Ona	ICCC
Díaz Riera, Elisa	ICCC
García Arguinzonis,	ICCC
Maisa Inés	ICCC
Gómez-Pardo Arellano,	ICCC
Montserrat	ICCC
Múñoz García, Natalia	ICCC
Peña Sendra, Esther	ICCC

## Main Lines of Research

- Identification of new biomarkers of atherothrombosis and ischaemic heart disease with potential use in diagnosis and prognosis research is based on cell culture studies, animal models of cardiovascular disease and human samples of patients with coronary heart disease risk factors.

## Challenges

- Advance research aiming to identify and characterize new biomarkers of tissue remodelling, vascular injury, atherothrombotic disease and/or ischaemic, coronary and cerebrovascular syndromes using postgenomic techniques.
- Generate new information on potential soluble biomarkers (serum, plasma, urine) and in microvesicles /exosomes circulating in blood/urine, as well as in blood and/or vascular cells through proteomic and lipidomic studies based on liquid chromatography and bidimensional electrophoresis, mass spectrometry (MALDI-TOF/TOF; linear ion trap) and antigen-antibody based assays, as well as transcriptomic studies (mRNA, miRNA) using arrays systems and real-time PCR.
- Validate biomarkers identified in the diagnosis and prognosis of cardiovascular and/or cerebrovascular disease using specific quantitative techniques (confocal microscope, ELISA, multiplex assays, etc).
- Characterize molecular and functional mechanisms for selected biomarkers in cardiovascular pathology and myocardial remodeling (biology of systems).

## Collaborations

### Collaborations with other IIB Sant Pau Groups

- Molecular Pathology and Therapeutic of Ischemic and Atherothrombotic Diseases (PI: Lina Badimon; Gemma Vilahur)
- Pharmacological Research in Humans (PI: Rosa M. Antonjoan)
- Clinical and Translational Cardiology (PI: Juan Cinca; Xavier Garcia-Moll, Alessandro Sionis)
- Molecular Basis Cardiovascular Risk (PI: Francisco Blanco Vaca; Joan Carles Escolà)

### National Collaborations

- Fundación Hipercolesterolemia Familiar. Madrid (Pedro Mata, Rodrigo Alonso, Leopoldo Pérez-Isla).
- Department of Internal Medicine. Hospital Clínic. Barcelona (Ramon Estruch).
- Internal Medicine Department Lipids and Vascular Risk Units, Bellvitge University Hospital, Hospital de Llobregat, Barcelona (Xavier Pinto).
- Internal Medicine Department, Bellvitge University Hospital, Hospital de Llobregat, Barcelona (Francesc Formiga).

- Department of Cardiology, Thorax Institute, Hospital Clínic, University of Barcelona, Spain (Salvatore Brugaletta, Victoria Martín-Yuste, Clarissa Cola, Manel Sabaté).

- Invasive Cardiology Department Puerta de Hierro Hospital. Majadahonda, Madrid (Javier Goicolea).

- Department of Rheumatology, Consorci Sanitari de Terrassa (CST), Terrassa, Barcelona (Carmen García-Gómez).

- Centre d'Atenció Primària Florida Sud. Direcció d'Atenció Primària Costa de Ponent-ICS. L'Hospitalet, Institut Universitari d'Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Barcelona, Spain (Juan José Rodríguez).

### International Collaborations

- Platelet Research Center, Faculty of Health Sciences, University of Talca, Chile (Ivan Palomo, Eduardo Fuentes).
- School of Healthcare Science, Manchester Metropolitan University, Manchester, United Kingdom (Mark Slevin).
- Division of Hematology/Oncology, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, USA (Vladimir Y Bogdanov).

## Active Grants

- ▶ Maria Teresa Padró Capmany. Diagnòstic precoç d'insuficiència renal durant insuficiència cardíaca aguda (EDRIAHF). MARATÓ 20153110. Fundació La Marató de TV3. Duration: 2016-2019. 155,700.00 €.
- ▶ Maria Teresa Padró Capmany. Remodelado miocárdico post-infarco: regulación por la matriz extracelular y el sistema-c3 del complemento. PI16/01915. Instituto de Salud Carlos III. Duration: 2017-2019. 141,500.00 €.

- ▶ Maria Teresa Padró Capmany (CO IP). Investigación y desarrollo clínico de una nueva molécula para el control de peso y prevención de la obesidad. RTC-2016-5317-1. Ministerio de Economía y Competitividad. Duration: 2016-2018.

Note: Total amount granted to PI. It does not include indirect costs.

## Patents

- ▶ Lina Badimon, Judit Cubedo, Teresa Padró. Methods and kits for the diagnosis and risk stratification of patients with ischemia. EP16382167.1. Priority: Europe. 12/04/2016.
- ▶ Lina Badimon, Judit Cubedo, Vilahur G, Teresa Padró. Prevention and/or treatment of ischemia or ischemia/reperfusion injury. EP16382111.9. Priority: Europe. 14/03/2016.

- ▶ Lina Badimon, Judit Cubedo, Teresa Padró. Apolipoprotein J isoforms as biomarkers of organ damage. P201030168. Priority: Spain. 26/08/2011.

## Transfer Products

- ▶ Co-founder of the Spin-Off "Glycardial Diagnostics SL". September 2017.

## \*TIF: 89.742 \*\*MIF: 6.4101

Arderiu G., Espinosa S., Pena E., Crespo J., Aledo R., Bogdanov V.Y., Badimon L., Tissue factor variants induce monocyte transformation and transdifferentiation into endothelial cell-like cells (2017) J THROMB HAEMOSTASIS, 15 (8), 1689-1703.

**IF: 4.899**

Badimon L., Vilahur G., Padró T., Systems biology approaches to understand the effects of nutrition and promote health (2017) BRIT J CLIN PHARMACO, 83 (1), 38-45.

**IF: 3.838**

Badimon L., Padró T., Cubedo J., Protein changes in non-LDL-lipoproteins in familial hypercholesterolemia: Implications in cardiovascular disease manifestation and outcome (2017) CURR OPIN LIPIDOL, 28 (5), 427-433.

**IF: 3.853**

Bourbon M., Alves A.C., Alonso R., Mata N., Aguiar P., Padró T., Mata P., Mutational analysis and genotype-phenotype relation in familial hypercholesterolemia: The SAFEHEART registry (2017) ATHEROSCLEROSIS, 262, 8-13.

**IF: 4.467**

Cubedo J., Padró T., Formiga F., Ferrer A., Padrós G., Pena E., Badimon L., Inflammation and hemostasis in older octogenarians: implication in 5-year survival (2017) TRANSL RES, 185, 34-46.e9.

**IF: 4.880**

Cubedo J., Blasco A., Padró T., Ramaiola I., Juan-Babot O., Goicolea J., Fernandez-Diaz J.A., Oteo J.F., Badimon L., Molecular signature of coronary stent thrombosis: Oxidative stress and innate immunity cells (2017) THROMB HAEMOSTASIS, 117 (9), 1816-1827.

**IF: 4.952**

Cubedo J., Suades R., Padró T., Martin-Yuste V., Sabate-Tenias M., Cinca J., Sans-Rosello J., Sionis A., Badimon L., Erythrocyte-heme proteins and STEM1: Implications in prognosis (2017) THROMB HAEMOSTASIS, 117 (10), 1970-1980.

**IF: 4.952**

Fuentes F., Alarcon M., Badimon L., Fuentes M., Klotz K.-N., Vilahur G., Kachler S., Padró T., Palomo I., Fuentes E., Guanosine exerts antiplatelet and antithrombotic properties through an adenosine-related cAMP-PKA signaling (2017) INT J CARDIOL, 248, 294-300.

**IF: 4.034**

Lambert C., Cubedo J., Padró T., Sanchez-Hernandez J., Antonijan R.M., Perez A., Badimon L., Phytosterols and omega 3 supplementation exert novel regulatory effects on metabolic and inflammatory pathways: A proteomic study (2017) NUTRIENTS, 9 (6).

**IF: 4.196**

Moreno-Navarrete J.M., Jove M., Padró T., Boada J., Ortega F., Ricart W., Pamplona R., Badimon L., Portero-Otin M., Fernandez-Real

J.M., Adipocyte lipopolysaccharide binding protein (LBP) is linked to a specific lipidomic signature (2017) OBESITY, 25 (2), 391-400.

**IF: 4.042**

Padro T., Cubedo J., Camino S., Bejar M.T., Ben-Aicha S., Mendieta G., Escola-Gil J.C., Escate R., Gutierrez M., Casani L., Badimon L., Vilahur G., Detrimental Effect of Hypercholesterolemia on High-Density Lipoprotein Particle Remodeling in Pigs (2017) J AM COLL CARDIOL, 70 (2), 165-178.

**IF: 16.834**

Pena E., De La Torre R., Arderiu G., Slevin M., Badimon L., mCRP triggers angiogenesis by inducing F3 transcription and TF signalling in microvascular endothelial cells (2017) THROMB HAEMOSTASIS, 117 (2), 357-370.

**IF: 4.952**

Perez de Isla L., Alonso R., Mata N., Fernandez-Perez C., Muniz O., Diaz-Diaz J.L., Saltijeral A., Fuentes-Jimenez F., de Andres R., Zambon D., Piedeca M., Cepeda J.M., Mauri M., Galiana J., Brea A., Munoz-Torrero J.F.S., Padró T., Argueso R., Miramontes-Gonzalez J.P., Badimon L., Santos R.D., Watts G.F., Mata P., Predicting cardiovascular events in familial hypercholesterolemia: The SAFEHEART registry (Spanish Familial Hypercholesterolemia Cohort Study) (2017) CIRCULATION, 135 (22), 2133-2144.

**IF: 18.880**

## Scientific Production

# Biomarkers for Cardiovascular Disease

\*TIF: 89.742 \*\*MIF: 6.4101


## Scientific Production

Vilahur G., Onate B., Cubedo J., Bejar M.T., Arderiu G., Peña E., Casani L., Gutierrez M., Capdevila A., Pons-Llado G., Carreras F., Hidalgo A., Badimon L., Allogenic adipose-derived stem cell therapy overcomes ischemia-induced microvessel rarefaction in the myocardium: Systems biology study (2017) STEM CELL RES THER, 8 (1).

IF: 4.963

## Other Publications

- ▶ Badimon L, Suades R, Arderiu G, Peña E, Chiva-Blanch G, Padró T. Microvesicles in Atherosclerosis and Angiogenesis: From Bench to Bedside and Reverse. FRONT CARDIOVASC MED. 2017 Dec 18; 4: 77.
- ▶ Padró T, Badimon L. Investigación en enfermedad cardiovascular femenina. DIABETES PRÁCTICA 08 (Supl Extr 5): 12-17; 2017.



# Atherosclerosis and Vascular Biology



## Coordinator

Martínez González, Jose CSIC  
jmartinezg@santpau.cat

## Members

Alonso Nieto, Judit	CIBERCV
Martí Pàmies, Íngrid	ICCC
Orriols Martins, Mar	CIBERCV
Varona Álvarez, Saray	CSIC



## Main Lines of Research

- ▶ Identification and characterization of master genes involved in the onset, development and complication of ischaemic heart disease (IHD), abdominal aortic aneurysm (AAA) and cardiac hypertrophy.
- ▶ Mechanisms involving nuclear receptors in IHD, AAA and cardiac hypertrophy.

- ▶ Identification and validation of new targets for diagnosis, prognosis and treatment of cardiovascular diseases.
- ▶ Development of new (genetically modified) animal models for IHD, AAA and cardiac hypertrophy.

## Challenges

- ▶ Incorporate new PhD and postdoctoral students as well as staff investigators to preserve the core group and implement new technical expertise and experimental approaches.
- ▶ Find affinities with other IIB Sant Pau groups in order to increase critical mass and imple-

ment joint strategies to optimize resources and access to alternative funding sources.

- ▶ Consolidate present relationships with national collaborators and expand our international collaborations.

## Collaborations

### Collaborations with other IIB Sant Pau Groups

- ▶ Inflammation and Vascular Remodelling (PI: Cristina Rodríguez).
- ▶ Angiology, Vascular Biology and Inflammation (PI: Luis Vila).
- ▶ Regulation of Cardiac Rhythm and Contraction (PI: Leif Hove-Madsen).

- ▶ Pablo García de Frutos (IIBB-CSIC).
- ▶ Francisco Marín. Hospital Clínico Universitario Virgen de la Arrixaca, Murcia.
- ▶ Jesús Osada. Universidad de Zaragoza.
- ▶ Mercedes Salices. Universidad Autónoma de Madrid, UAM.
- ▶ Vicente Andrés García. CNIC.
- ▶ Victoria Cachofeiro. Universidad Complutense de Madrid, UCM.
- ▶ Lisardo Boscá. Instituto de Investigaciones Biomédicas Alberto Sols, CSIC-UAM.

### External Collaborations

- ▶ Francisco Sánchez Madrid. Hospital de la Princesa-UAM.
- ▶ Alicia G. Arroyo. Centro Nacional de Investigaciones Cardiovasculares, CNIC.
- ▶ David García Dorado. Vall d'Hebron Research Institute, VHIR.
- ▶ Eduardo Rodríguez Boulan (Cornell University).
- ▶ Roxana Carare (University of Southampton).
- ▶ Anna Planas (IIBB-CSIC).

## Active Grants

- ▶ José Martínez González. The nuclear receptor NOR-1 in cardiac and vascular remodeling: analysis of pathological mechanisms and validation of new animal models useful for pre-clinical studies. MINECO SAF2015-64767-R. Duration: 2016-2018.
- ▶ José Martínez González, Francisco Sánchez Madrid. Immunoregulatory molecules and miRNAs as targets in coronary heart disease and acute coronary syndrome Fundació La Marató de TV3 (Ref. 20152330 31). Duration: 2016-2018.
- ▶ José Martínez González. CIBER de Enfermedades Cardiovasculares (Ref. grupo CB16/11/00257) ISCIII-MINECO. Duration: from 2017.

Note: Total amount granted to PI. It does not include indirect costs.

## Awards

- ▶ Martí-Pàmies I, Cañes L, Alonso J, Romero JM, Rodríguez C, Martínez-González J. Special mention for the oral communication: NOR1 en el aneurisma de aorta abdominal (AAA): generación de un nuevo modelo animal de AAA experimentalXXX Congreso de la Sociedad Española de Aterosclerosis (SEA). (31 May-2 June 2017, Cádiz)

## Theses

- ▶ Ingrid Martí Pàmies. NOR-1 en el remodelat cardiovascular: identificació de gens diana i caracterització d'animals transgènics per a NOR-1 com a models en patologies cardiovasculares. Universitat de Barcelona. Directors: José Martínez González, Cristina Rodríguez. Date of defense: 10/03/2017.

## Patents

- ▶ José Martínez González, Cristina Rodríguez Sinovas, Ingrid Martí Pàmies. Modelo animal para aneurisma aórtico y sus usos. P201631548. Spanish patent. 07/12/2016.

## Scientific Production

**\*TIF: 28.700 \*\*MIF: 5.74**

Galan M., Varona S., Guadall A., Orriols M., Navas M., Aguiló S., De Diego A., Navarro M.A., García-Dorado D., Rodriguez-Sinovas A., Martínez-González J., Rodriguez C., Lysyl oxidase overexpression accelerates cardiac remodeling and aggravates angiotensin II-induced hypertrophy (2017) FASEB J, 31 (9), 3787-3799.

**IF: 5.595**

Martínez-Revelles S., García-Redondo A.B., Avendano M.S., Varona S., Palao T., Orriols M., Roque F.R., Fortuno A., Touyz R.M., Martínez-González J., Salaices M., Rodriguez C., Briones A.M., Lysyl Oxidase Induces Vascular

Oxidative Stress and Contributes to Arterial Stiffness and Abnormal Elastin Structure in Hypertension: Role of p38MAPK (2017) ANTONIO REDOX SIGN, 27 (7), 379-397.

**IF: 6.530**

Marti-Pamies I., Canes L., Alonso J., Rodriguez C., Martínez-González J., The nuclear receptor NOR-1/NR4A3 regulates the multifunctional glycoprotein vitronectin in human vascular smooth muscle cells (2017) FASEB J, 31 (10), 4588-4599.

**IF: 5.595**

Orriols M., Gomez-Puerto M.C., Ten Dijke P., BMP type II receptor as a therapeutic target in pulmonary arterial hypertension (2017) CELL MOL LIFE SCI, 1-17.

**IF: 6.721**

Soto B., Gallastegi-Mozos T., Rodríguez C., Martínez-González J., Escudero JR, Vila L., Camacho M. Circulating CCL20 as a New Biomarker of Abdominal Aortic Aneurysm. (2017) SCI REP. 2017 Dec 11;7(1):17331.

**IF: 4.259**

## Other Publications

- ▶ Varona V, García-Redondo AB, Martínez-González J, Salaices M, Briones AM, Rodríguez C. La sobre expresión vascular de la lisil oxidasa altera la estructura de la matriz extracelular e induce estrés oxidativo. CLIN INVESTIG ARTERIOSCLER. 2017;29:157-165.

# Regulation of Cardiac Rhythm and Contraction



## Coordinator

Hove-Madsen , Leif  
l.madsen@santpau.cat

## Members

Llach Martínez, Ana  
Tarifa Lora, Carmen

CSIC

IR  
ICCC

## Main Lines of Research

- ▶ Receptor-mediated changes in intracellular calcium homeostasis in atrial fibrillation.
- ▶ Contribution of genetic variants to electrical remodelling and cardiac arrhythmogenesis.
- ▶ Effects of development and ageing on calcium handling in cardiac myocytes.
- ▶ Mathematical modeling of calcium homeostasis and electrical activity in cardiac myocytes.

## Challenges

The goal is to consolidate the group as a reference in research on calcium handling in atrial fibrillation and to establish it within other lines of research by including emerging technology and fields of research. Specifically we aim to:

- ▶ Develop computational tools and models to improve the analysis and understanding of intracellular calcium handling in cardiac myocytes.
- ▶ Incorporate emerging technology such as stretching and measurements of force development in single cardiomyocytes.
- ▶ Consolidate current national and international collaborations and establish new strategic collaborations within emerging fields of research such as the use of super-resolution fluorescence imaging (STORM, STED-techniques) and the detection and role of Reactive Oxygen Species in diseased cardiomyocytes.
- ▶ Achieve international funding for incorporation of scientific expertise and participation in multidisciplinary international research projects.

## Collaborations

### Collaborations with other IIB Sant Pau Groups

- ▶ Clinical and Translational Cardiology (PI: Juan Cinca)
- ▶ Lipids and Cardiovascular Pathology (PI: Vicenta Lorente)
- ▶ Atherosclerosis and Vascular Biology (PI: José Martínez)

### National Collaborations

- ▶ Diego Franco, Amelia Aranega. Departamento de Biología Experimental, Universidad de Jaén.
- ▶ Francisco Ciruela, Departament de Patología i Terapèutica Experimental, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Universitat de Barcelona.
- ▶ Blas Echebarria. Departament de Física Aplicada, Universitat Politècnica de Catalunya.
- ▶ Raul Benítez. Enginyeria de Sistemes, Automàtica i Informàtica Industrial, Universitat Politècnica de Catalunya.
- ▶ Vicente Andrés. Fisiopatología Cardiovascular Molecular y Genética, CNIC.
- ▶ Leif Hove-Madsen, Research Collaborator at the Spanish National Cardiovascular Research Network CIBERCV.

### International Collaborations

- ▶ SR Wayne Chen. Department of Physiology and Pharmacology, University of Calgary, Canada.
- ▶ Glen F Tibbits. Department of Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby & Child and Family Research Institute, Vancouver, Canada.
- ▶ Edwin Moore. Cardiovascular Research Group, University of British Columbia, Vancouver, Canada.

### Active Research Grants coordinated by Cardiac Rhythm and Contraction Group

- ▶ Marató TV3 2015-2030. Coordinated research project on "Adenosine receptors as new targets for the treatment of atrial fibrillation: Biomarker, Risk-Stratification and Therapy". 1/4/2016 - 31/3/2019.
- ▶ SAF2014-58286-C2-1-R. Coordinated research project on "Identification of molecular and Cellular Electrophysiological Risk factors That confer patients a high risk for Atrial fibrillation". 1/1/2015 -31/8/2018.
- ▶ SGR-2014-1465GRE. Emerging research group on "Analysis and Control of Cardiac Rhythm". 1/1/2015 - 31/12/2017.

**Grants  
Awarded  
in 2017**

- ▶ Ana Llach Martínez. Receptors de rianodina com a nova diana per al tractament de la fibril·lació auricular. SLT002/16/00074. Departament de Salut. Duration: 2017-2019. 103,907.80 €.

Note: Total amount granted to PI. It does not include indirect costs.

# Lipids and Cardiovascular Pathology



## Coordinator

Llorente Cortés,  
Concepción Vicenta  
cllorente@santpau.cat

## Members

Benítez Amaro, Aleyda	CSIC
Bornachea Gómez, Olga	CSIC
De Gonzalo Calvo, David	IR
Nasarre Miarnau, Laura Rosa	ICCC
Vea Badenes, Angela	IR

## Main Lines of Research

- ▶ Molecular mechanisms involved in the modulation of LRP1 by cardiovascular risk factors.
- ▶ Impact of LRP1 on vascular and myocardial cholesterol accumulation.
- ▶ Impact of lipoproteins on LRP1-Intracellular signal pathways under normoxic and hypoxic conditions.
- ▶ Alterations in LRP1 expression and LRP1-intracellular signal pathways in hypoxia/ischaemia in *in vitro* and *in vivo* models.
- ▶ Lipids and diabetic cardiomyopathy.
- ▶ Lipids and breast cancer.
- ▶ LRP1 and inflammation.
- ▶ Circulating non-coding RNAs as biomarkers of cardiovascular disease.
- ▶ Role of non-coding RNAs in vascular lipid accumulation.
- ▶ Role of non-coding RNAs in myocardial lipid accumulation.

## Challenges

- ▶ Integrate genomic and functional *in vivo* studies to validate LRP1 as a new therapeutic target in cardiometabolic diseases
- ▶ Maintain and amplify relationship with IIB Sant Pau groups regarding translation in this cardiometabolism.
- ▶ Maintain and strengthen national and international collaborations to set up future applications for European funding.
- ▶ Establish collaborations with companies with the aim of developing new products useful for prognosis, diagnosis and treatment of cardiometabolic diseases.

## Collaborations

### Collaborations with other IIB Sant Pau Groups

- ▶ Cardiovascular Biochemistry (PI: Jordi Ordóñez)
- ▶ Molecular Pathology and Therapeutic of Ischaemic and Atherothrombotic Diseases (PI: Lina Badimon)
- ▶ Clinical and Translational Cardiology (PI: Juan Cinca)
- ▶ Metabolic Bases of Cardiovascular Risk (PI: Francisco Blanco)
- ▶ Molecular Bases of Disease (PI: Pablo Fuentes)
- ▶ Clinical Oncology (PI: Agustí Barnadas)
- ▶ Enrique Lerma (researcher of Molecular Pathology of Gynecologic Cancer)

### National Collaborations

- ▶ Dr. Bayés-Genís. Grupo ICREC (Insuficiencia Cardiaca y Regeneración Cardiaca). Hospital Germans Trias i Pujol. Badalona.
- ▶ Eduardo Iglesias Gutiérrez. Grupo ITS (Intervenciones Traslacionales para la Salud). Universidad de Oviedo.
- ▶ Rocío Toro. Departamento de Medicina. Facultad de Medicina, Universidad de Cádiz.
- ▶ Antonio Zorzano. IRB Barcelona

Dolors Serra. Facultat de Farmàcia. Universitat de Barcelona

Joan Carles Laguna. Facultat de Farmàcia. Universitat de Barcelona

Eduard Sabidó. Centre de Regulació Genòmica. Barcelona

### International Collaborations

- ▶ Colette Lacabanne & Valerie Samouilhan. Group Physique des Polymères, Institut Carnot, CIRIMAT, Université Paul Sabatier. Toulouse, France.
- ▶ Max Bown. Vascular Surgery group. Department of Cardiovascular Sciences University of Leicester, New England.
- ▶ Fulvia Ortolani. Department of Experimental Clinical Medicine. Università degli Studi di Udine. Italy.
- ▶ Gustavo Alberto Chiabrando. CIBICI-CONICET/FCQ-Universidad Nacional de Córdoba, Argentina.
- ▶ Claudia Huesca Gómez. Departamento de Biomedicina Cardiovascular. Instituto Nacional de Cardiología "Ignacio Chávez". México D.F.

### Other Collaborations

- ▶ Teresa Tarragó. Iproteos. Parc Científic. Barcelona. Spain.

## Active Grants

- ▶ David de Gonzalo Calvo. Contractes "Sara Borrell" 2014. CD14/00109. Institut de Salud Carlos III. Duration: 2015-2017. 89,598.00 €.

Note: Total amount granted to PI. It does not include indirect costs.

## Grants Awarded in 2017

- ▶ Concepción Vicenta Llorente Cortés, Seguiment de la cohort poblacional de l'estudi REGICOR: tendències en la incidència de malaltia cardiovascular, en la prevalença de factors de risc, identificació de nous mecanismes i biomarcadors predictius, i avaluació d'estratègies de prevenció. SLT002/16/00088. Departament de Salut. Duration: 2017-2019. 106,212.00 €.

Note: Total amount granted to PI. It does not include indirect costs.

## Awards

- ▶ Extraordinary Doctorate Award of the academic year 2015-16 to the thesis by Elena Revuelta López.

## Scientific Production

Cedo L., Santos D., Roglans N., Julve J., Pal-lares V., Rivas-Urbina A., Llorente-Cortes V., Laguna J.C., Blanco-Vaca F., Escola-Gil J.C., Human hepatic lipase overexpression in mice induces hepatic steatosis and obesity through promoting hepatic lipogenesis and white adipose tissue lipolysis and fatty acid uptake (2017) PLOS ONE, 12 (12).

**IF: 2.600**

De Gonzalo-Calvo D., Quezada M., Campuzano O., Perez-Serra A., Broncano J., Ayala R., Ramos M., Llorente-Cortes V., Blasco-Turrión S., Morales F.J., Gonzalez P., Brugada R., Mangas A., Toro R., Familial dilated cardiomyopathy: A multidisciplinary entity, from basic screening to novel circulating biomarkers (2017) INT J CARDIOL, 228, 870-880.

**IF: 3.679**

**\*TIF: 23.534 \*\*MIF: 3.9223**

De Gonzalo-Calvo D., Cenarro A., Garlaschelli K., Pellegatta F., Vilades D., Nasarre L., Camino-Lopez S., Crespo J., Carreras F., Leta R., Catapano A.L., Norata G.D., Civeira F., Llorente-Cortes V., Translating the microRNA signature of microvesicles derived from human coronary artery smooth muscle cells in patients with familial hypercholesterolemia and coronary artery disease (2017) J MOL CELL CARDIOL, 106, 55-67.

**IF: 5.123**

De Gonzalo-Calvo D., Iglesias-Gutierrez E., Llorente-Cortes V., Epigenetic Biomarkers and Cardiovascular Disease: Circulating MicroRNAs Biomarcadores epigenéticos y enfermedad cardiovascular: los microARN circulantes (2017) REV ESP CARDIOL, 70 (9), 763-769.

**IF: 3.408**

De Gonzalo-Calvo D., Van Der Meer R.W., Rijzewijk L.J., Smit J.W.A., Revuelta-Lopez E., Nasarre L., Escola-Gil J.C., Lamb H.J., Llorente-Cortes V., Serum microRNA-1 and microRNA-133a levels reflect myocardial steatosis in uncomplicated type 2 diabetes (2017) SCI REP-UK, 7 (1).

**IF: 3.745**

Samouillan V., Revuelta-Lopez E., Soler-Botija C., Dandurand J., Benitez-Amaro A., Nasarre L., de Gonzalo-Calvo D., Bayes-Genis A., Lacabanne C., Llorente-Cortes V., Conformational and thermal characterization of left ventricle remodeling post-myocardial infarction (2017) BBA-MOL BASIS DIS, 1863 (6), 1500-1509.

**IF: 4.979**

AREA 2

# Genetic, Metabolic Inflammatory Disease

**70** Genetic Diseases

**72** Metabolic Bases of Cardiovascular Risk

**76** Inflammatory Diseases

**78** Endocrinology, Diabetes and Nutrition

**82** Pituitary Gland Disorders

**86** Digestive Diseases

# C and ases

**90** Microbiology and Infectious Diseases

**96** Multi-organ Damage

**100** Chronic Respiratory Diseases

**104** Research Group in HIV and AIDS

**108** Genome Instability and DNA Repair Syndromes

# Genetic Diseases



## Coordinator

Gallano Petit, Maria Pia FGS  
pgallano@santpau.cat

## Members

Aceiton Zabay, Montserrat	FGS
Alias Andreu, Laura	CIBERER
Baena Gimeno, Manel	FGS
Baiget Bastus, Montserrat	FGS
Barceló Rubira, María Jesús	FGS
Bernal Noguera, Sara	FGS
Companys Armengol, Eva María	IR
Cornet Ciurana, Mònica	FGS
Del Rio Conde, Elisabeth	FGS
González Quereda, Lidia	CIBERER
Iturbe Ferreiro, Ana Isabel	FGS
Lasa Laborde, Adriana María	FGS
Marcos Fa, Francesc Xavier	IR
Moron López, Sara	FGS
Ortiz Losada, Esther	IR
Rodríguez Fernández, María José	FGS
Salazar Blanco, Juliana	CIBERER
Vencesla García, Adoración	IR

## Main Lines of Research

- ▶ Study of the clinical heterogeneity of genetic autosomal recessive transmission of waist dystrophy and autosomal dominant transmission.
- ▶ Spinal atrophy and SMN genes:
  - Studies of molecular pathology, disease mechanisms and SMN gene expression.
  - Identification of modifying genes.
  - Study of biomarkers for validation processing in spinal muscular atrophy.
  - Study of the neuromuscular junction in human development.
  - Hereditary breast cancer and BRCA mutations:
    - Identification of mutations and genetic variants.
    - Molecular characterization of circulating tumor cells (CTCS) through expression profiles in patients with breast cancer.
- ▶ Analysis of free circulating tumor DNA (cfDNA) as a predictor of response to the treatment of breast cancer.
- ▶ Pharmacogenetics: adverse reactions to medications.
- ▶ Congenital coagulopathies: molecular pathology of haemophilias.
- ▶ Duchenne and Becker muscular dystrophy: molecular pathology of DMD gene.

## Challenges

### Pharmacogenetics

- ▶ Colorectal and lung cancer treatments.
- ▶ Chronic inflammatory disease treatment.
- ▶ HIV infection treatment.

### Muscular Dystrophies

- ▶ Post-transcriptional regulation of the dystrophin gene using nonsense-mediated decay analysis in DNA from patients with Duchenne muscular dystrophy.
- ▶ Genes associated with new phenotypic forms of limb girdle muscular dystrophy.
- ▶ Workflow development for the analysis of DMD gene by NGS techniques.

### Hereditary Breast/Ovarian Cancer

- ▶ DNA studies to classify DNA variants found in the BRCA genes as pathogenic or neutral.
- ▶ CTCs as prognostic markers in patients with locally advanced and disseminated breast cancer.
- ▶ Workflow development for the analysis of BRCA1 and BRCA2 genes by NGS techniques.

### Hereditary Motor Neurone Diseases

- ▶ Development of neuromuscular junction studies in health and disease.
- ▶ Broadening of the spectrum of motor neuron diseases to include bulbar and spinal muscular atrophy, distal muscular atrophies and amyotrophic lateral sclerosis.

## Awards

- ▶ Ana Sebio García. Young Investigator Award. Gastrointestinal Group of the European Organisation for Research and Treatment of Cancer.

## Grants Awarded in 2017

- ▶ Maria Pia Gallano Petit. Implementació de la medicina personalitzada basada en la genòmica en malalties minoritàries neurològiques no diagnosticades. SLT002/16/00174, Departament de Salut. Duration: 2017-2019. 12,000.00 €.

Note: Total amount granted to PI. It does not include indirect costs.

## Active Grants

- ▶ Ana Sebio García. Contratos Juan Rodés 2014. JR14/00006. Instituto de Salud Carlos III. Duration: 2015-2018. 135,000.00 €.
- ▶ Lidia González Quereda. Implementación de la secuenciación masiva en el estudio de las Miopatías Congénitas y los Síndromes Miasténicos congénitos: un modelo de investigación traslacional en enfermedades raras. FMM 2015. Fundación Mutua Madrileña. Duration: 2015-2018. 74,200.00 €.
- ▶ María Pia Gallano Petit. Implementación de la secuenciación masiva en el estudio de Miopatías Congénitas y Síndromes Miasténicos congénitos: un modelo de investigación traslacional en enfermedades raras. PI15/01898. Instituto de Salud Carlos III. Duration: 2016-2018. 56,500.00 €.
- ▶ Pau Riera Armengol. Marcadors farmacogenètics de resposta/resistència a les teràpies biològiques (anti-EGFR) en càncer colorectal. 2016 FI\_B 00368. Agència de Gestió d'Ajuts Universitaris i de Recerca. Duration: 2016-2019. 40,806.00 €.
- ▶ David Paez López-Bravo. Estudio farmacogenético fase II randomizado para evaluar eficacia y seguridad del esquema FOLFIRI con altas dosis de irinotecán (FOLFIRIAD) en pacientes con cáncer colorrectal metastásico de acuerdo con el genotipo UG-T1A 1. EC11-336. Ministerio de Sanidad y Política Social. Duration: 2015-2017. 13,965.97 €.

Note: Total amount granted to PI. It does not include indirect costs.

**\*TIF: 52.877 \*\*MIF: 5.287**

Arqueros C., Salazar J., Arranz M.J., Sebio A., Mora J., Sullivan I., Tobena M., Martin-Richard M., Barnadas A., Baiget M., Paez D., SPARC gene variants predict clinical outcome in locally advanced and metastatic pancreatic cancer patients (2017) MED ONCOL, 34 (8).  
**IF: 2.920**

Grasselli J., Elez E., Caratu G., Matito J., Santos C., Macarulla T., Vidal J., Garcia M., Vieitez J.M., Paez D., Falco E., Lopez Lopez C., Aranda E., Jones F., Sikri V., Nuciforo P., Fasani R., Tabernero J., Montagut C., Azuara D., Dienstmann R., Salazar R., Vivancos A., Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer (2017) ANN ONCOL, 28 (6), 1294-1301.  
**IF: 13.926**

Lorente A.M.R., Moreno-Cid M., Rodriguez M.J., Bueno G., Tenias J.M., Roman C., Arias A., Pascual A., Meta-analysis of validity of echogenic intracardiac foci for calculating the risk of Down syndrome in the second trimester of pregnancy (2017) TAIWAN J OBSTET GYNE, 56 (1), 16-22.  
**IF: 1.029**

Natera-de Benito D., Topf A., Vilchez J.J., Gonzalez-Quereda L., Dominguez-Carral J., Diaz-Manera J., Ortez C., Bestue M., Gallano P., Dusl M., Abicht A., Muller J.S., Senderek J., Garcia-Ribes A., Muelas N., Evangelista T., Azuma Y., McMacken G., Paipa Merchan A., Rodriguez Cruz P.M., Camacho A., Jimenez E., Miranda-Herrero M.C., Santana-Artiles A., Garcia-Campos O., Dominguez-Rubio R., Olive M., Colomer J., Beeson D., Lochmuller H., Nascimento A., Molecular characterization

of congenital myasthenic syndromes in Spain (2017) NEUROMUSCULAR DISORD, 27 (12), 1087-1098.

**IF: 2.487**

Paez D., Salazar R., Tabernero J., DPYD genotype-guided fluoropyrimidines dose: Is it ready for prime time? (2017) ANN ONCOL, 28 (12), 2913-2914.  
**IF: 13.926**

Perez-Gracia J.L., Sanmamed M.F., Bosch A., Patino-Garcia A., Schalper K.A., Segura V., Bellmunt J., Tabernero J., Sweeney C.J., Choueiri T.K., Martin M., Fusco J.P., Rodriguez-Ruiz M.E., Calvo A., Prior C., Paz-Ares L., Pio R., Gonzalez-Billalabentia E., Gonzalez Hernandez A., Paez D., Piulats J.M., Gurpide A., Andueza M., de Velasco G., Pazo R., Grande E., Nicolas P., Abad-Santos F., Garcia-Donas J., Castellano D., Pajares M.J., Suarez C., Colomer R., Montuenga L.M., Melero I., Strategies to design clinical studies to identify predictive biomarkers in cancer research (2017) CANCER TREAT REV, 53, 79-97.  
**IF: 8.122**

Sullivan I., Salazar J., Arqueros C., Andres M., Sebio A., Majem M., Szafranska J., Martinez E., Paez D., Lopez-Pousa A., Baiget M., Barnadas A., KRAS genetic variant as a prognostic factor for recurrence in resectable non-small cell lung cancer (2017) CLIN TRANSL ONCOL, 19 (7), 884-890.  
**IF: 2.392**

Vidal S., Brandi N., Pacheco P., Gerotina E., Blasco L., Trotta J.-R., Derdak S., Del Mar O'Callaghan M., Garcia-Cazorla A., et al. The utility of Next Generation Sequencing for

molecular diagnostics in Rett syndrome (2017) SCI REP-UK, 7 (1).

**IF: 4.122**

Vieitez I., Gallano P., Gonzalez-Quereda L., Borrego S., Marcos I., Millan J.M., Jairo T., Prior C., Molano J., Trujillo-Tiebas M.J., Gallego-Merlo J., Garcia-Barcina M., Fenollar M., Navarro C., Mutational spectrum of Duchenne muscular dystrophy in Spain: Study of 284 cases Espectro mutacional de la distrofia muscular de Duchenne en España: estudio de 284 casos (2017) NEUROLOGIA, 32 (6), 377-385.  
**IF: 1.938**

Villalba M., Lopez L., Redrado M., Ruiz T., de Aberasturi A.L., de la Roja N., Garcia D., Exposito F., de Andrea C., Alvarez-Fernandez E., Montuenga L., Rueda P., Rodriguez M.J., Calvo A., Development of biological tools to assess the role of TMPRSS4 and identification of novel tumor types with high expression of this prometastatic protein (2017) HISTOL HISTOPATHOL, 32 (9), 929-940.  
**IF: 2.015**

## Scientific Production

# Metabolic Bases of Cardiovascular Risk



## Coordinator

Blanco Vaca, Francisco FGS  
fblancova@santpau.cat

## Members

Cabrerizo Farré, Núria	IR
Cedo Gine, Lidia	CIBERDEM
Escola Gil, Juan Carlos	IR
Julve Gil, Josep	IR
Martín Campos, Jesús María	IR
Martínez Figueroa, Susana	FGS
Mendez Lara, Karen Alejandra	IR
Pérez Pérez, Antonio	FGS
Roig Martínez, Rosa	FGS
Santos Palacios, David	CIBERDEM
Tondo Colomer, Mireia	FGS

## Main Lines of Research

- ▶ HDL and susceptibility to diabetes, arteriosclerosis and breast cancer: this relationship is being analysed through the study of metabolic disorders, genetic modification, and dietary or drug intervention.
- ▶ Genetic determinants of metabolic factors of cardiovascular risk: dyslipidaemia, type 2 diabetes, hyperhomocysteinaemia.
- ▶ Positive health effects of phytosterols.

## Challenges

- ▶ To explore the effect of olive oil in reverse cholesterol transport in vivo and characterize the components responsible of this effect.
- ▶ Determine the pathogenic relevance of cholesterol metabolism impairment in diabetic retinopathy.
- ▶ To explore the anti-cancer mechanisms related to cholesterol metabolism, especially in breast and thyroid cancer.

## Collaborations

### Collaborations with other IIB Sant Pau Groups

- ▶ Dr. Annabel F. Valledor. Universitat de Barcelona. Barcelona, Spain.
- ▶ Dr. Luís Masana. Hospital Sant Joan de Reus and Universitat Rovira i Virgili and CIBERDEM. Reus, Spain.
- ▶ Dr. Manuel Vázquez-Carrera, Universitat de Barcelona and CIBERDEM. Barcelona, Spain.
- ▶ Dr. Joan Carles Laguna. Universitat de Barcelona. Barcelona, Spain.

### External Collaborations

- ▶ Dr. Jesús Osada. Universidad de Zaragoza and CIBEROBN. Zaragoza, Spain.
- ▶ Drs. Diego Gómez-Coronado and Miguel A. Lasunción. Hospital Ramón y Cajal and CIBEROBN, Madrid, Spain.
- ▶ Dr. Alberto Dávalos. IMDEA-Food. Madrid, Spain.
- ▶ Dr. Montserrat Fitó. IMIM and CIBEROBN. Barcelona, Spain.

- ▶ Dr. Jose Luis Martin-Ventura. Fundación Jimenez-Díaz and CIBERCV, Madrid, Spain.
- ▶ Drs. Fernando Civeira y Ana Cenarro. Hospital Clínico Universitario Miguel Servet and CIBERCV. Madrid, Spain.
- ▶ Dr. Petri Kovanen. Wihuri Research Institute. Helsinki, Finland.
- ▶ Dr. Matti Jauhainen. National Institute for Health and Welfare. Helsinki, Finland.
- ▶ Dr. Srinu Reddy. Department of Medicine, UCLA. CA, US

## Active Grants

- ▶ Josep Julve Gil. Contratos Miguel Servet 2013 - Tipo I. MS13/00070. Instituto de Salud Carlos III. Duration: 2014-2019. 202,500.00 €.
- ▶ Josep Julve Gil. Molecular studies of monogenic familial dyslipemias and construction of a diagnostic/prognosis criteria in mutation-negative patients with familial hypercholesterolemia. CP13/00070. Instituto de Salud Carlos III. Duration: 2014-2017. 121,500.00 €.
- ▶ Francisco Blanco Vaca. Avances en el diagnóstico molecular de pacientes con dislipemias hereditarias, con especial referencia a la base poligénica de algunas de ellas y a la hipercolesterolemia familiar. PI14/01648. Instituto de Salud Carlos III. Duration: 2015-2018. 76,500.00 €.
- ▶ Francisco Blanco Vaca. Preventing Premature Coronary Heart Disease in Catalonia by Expanding Familial Hypercholesterolemia Diagnosis. MARATO 20152431. Fundació La Marató de TV3. Duration: 2016-2019. 119,968.00 €.
- ▶ Josep Julve Gil. Análisis del efecto de la administración de nicotinamida sobre el peso corporal y las propiedades cuantitativas y cualitativas de las lipoproteínas y su relación con el desarrollo de arteriosclerosis en modelos experimentales. BIN 03/15. Fundació i Societat Espanyola d'Arteriosclerosis. Duration: 2016-2018. 8,181.82 €.
- ▶ Josep Julve Gil. Lipotoxicity and microvascular disease: contribution to myocardial damage in clinical and experimental models of diabetes. MARATO 201602.31. Fundació La Marató de TV3. Duration: 2017-2020. 108,000.00 €.
- ▶ Juan Carlos Escola Gil. Estudio de las alteraciones del metabolismo intracelular del colesterol en el cáncer de mama y carcinoma epitelial de tiroides: Evaluación de estrategias terapéuticas basadas en la HDL. PI16/00139. Instituto de Salud Carlos III. Duration: 2017-2019. 71,500.00 €.
- ▶ Karen Alejandra Méndez Lara. Estratègies terapèutiques i nutricionals basades en la millora de les funcions antioxidant i antiinflamatòria de les lipoproteïnes d'alta densitat (HDL) en la diabetis tipus 2 i el càncer de mama. 2014FI00171. Agència de Gestió d'Ajuts Universitaris i de Recerca. Duration: 2014-2017. 58,965.12 €.

Note: Total amount granted to PI. It does not include indirect costs.

# Metabolic Bases of Cardiovascular Risk

\*TIF: 81.284 \*\*MIF: 4.5158

Barcelo A., Morell-Garcia D., Salord N., Esquinas C., Perez G., Perez A., Monasterio C., Gasa M., Fortuna A.M., Montserrat J.M., Mayos M., A randomized controlled trial: branched-chain amino acid levels and glucose metabolism in patients with obesity and sleep apnea (2017) *J SLEEP RES*, 26 (6), 773-781.

**IF: 3.433**

Botteri G., Montori M., Guma A., Pizarro J., Cedo L., Escola-Gil J.C., Li D., Barroso E., Palomer X., Kohan A.B., Vazquez-Carrera M., VLDL and apolipoprotein CIII induce ER stress and inflammation and attenuate insulin signalling via Toll-like receptor 2 in mouse skeletal muscle cells (2017) *DIABETOLOGIA*, 60 (11), 2262-2273.

**IF: 6.206**

Cedo L., Blanco-Vaca F., Escola-Gil J.C., Antatherogenic potential of ezetimibe in sitosterolemia: Beyond plant sterols lowering (2017) *ATHEROSCLEROSIS*, 260, 94-96.

**IF: 4.467**

Cedo L., Santos D., Ludwig I.A., Silvennoinen R., Garcia-Leon A., Kaipiainen L., Carbo J.M., Valledor A.F., Gylling H., Motilva M.-J., Kovánen P.T., Lee-Rueckert M., Blanco-Vaca F., Escola-Gil J.C., Phytosterol-mediated inhibition of intestinal cholesterol absorption in mice is independent of liver X receptor (2017) *MOL NUTR FOOD RES*, 61 (9).

**IF: 5.151**

Cedo L., Santos D., Roglans N., Julve J., Pallares V., Rivas-Urbina A., Llorente-Cortes V., Laguna J.C., Blanco-Vaca F., Escola-Gil J.C., Human hepatic lipase overexpression in mice induces hepatic steatosis and obesity through promoting hepatic lipogenesis and white adipose tissue lipolysis and fatty acid uptake (2017) *PLOS ONE*, 12 (12).

**IF: 2.766**

Chehaibi K., le Maire L., Bradoni S., Escola J.C., Blanco-Vaca F., Slimane M.N., Effect of PPAR- $\beta/\delta$  agonist GW0742 treatment in the acute phase response and blood-brain barrier permeability following brain injury (2017) *TRANSL RES*, 182, 27-48.

**IF: 4.880**

De Gonzalo-Calvo D., Van Der Meer R.W., Rijzewijk L.J., Smit J.W.A., Revuelta-Lopez E., Nasarre L., Escola-Gil J.C., Lamb H.J., Llorente-Cortes V., Serum microRNA-1 and microRNA-133a levels reflect myocardial steatosis

in uncomplicated type 2 diabetes (2017) *SCI REP-UK*, 7 (1).

**IF: 4.122**

Erico T.L., Mendez-Lara K.A., Santos D., Cabrerizo N., Baila-Rueda L., Metso J., Cenarro A., Pardina E., Lecube A., Jauhainen M., Peinado-Onsurbe J., Escola-Gil J.C., Blanco-Vaca F., Julve J., LXR-dependent regulation of macrophage-specific reverse cholesterol transport is impaired in a model of genetic diabesity (2017) *TRANSL RES*, 186, 19-35.e5.

**IF: 4.880**

Estruch M., Minambres I., Sanchez-Quesada J.L., Soler M., Perez A., Ordóñez-Llanos J., Benítez S., Increased inflammatory effect of electronegative LDL and decreased protection by HDL in type 2 diabetic patients (2017) *ATHEROSCLEROSIS*, 265, 292-298.

**IF: 4.467**

Fernandez-De-Retana S., Cano-Sarabia M., Marazuela P., Sanchez-Quesada J.L., Garcia-Leon A., Montanola A., Montaner J., Maspoch D., Hernandez-Guillamon M., Characterization of ApoJ-reconstituted high-density lipoprotein (rHDL) nanodisc for the potential treatment of cerebral  $\beta$ -amyloidosis (2017) *SCI REP-UK*, 7 (1).

**IF: 4.122**

Lambert C., Cubedo J., Padro T., Sanchez-Hernandez J., Antonijoan R.M., Perez A., Badimon L., Phytosterols and omega 3 supplementation exert novel regulatory effects on metabolic and inflammatory pathways: A proteomic study (2017) *NUTRIENTS*, 9 (6).

**IF: 4.196**

Minambres I., Perez A., Is there a justification for classifying GLP-1 receptor agonists as basal and prandial? (2017) *DIABETOL METAB SYNDR*, 9 (1).

**IF: 2.413**

Padro T., Cubedo J., Camino S., Bejar M.T., Ben-Aicha S., Mendieta G., Escola-Gil J.C., Escate R., Gutierrez M., Casani L., Badimon L., Vilahur G., Detrimental Effect of Hypercholesterolemia on High-Density Lipoprotein Particle Remodeling in Pigs (2017) *J AM COLL CARDIOL*, 70 (2), 165-178.

**IF: 16.834**

Pardina E., Ferrer R., Rossell J., Ricart-Jane D., Mendez-Lara K.A., Baena-Fustegueras J.A.,

Lecube A., Julve J., Peinado-Onsurbe J., Hepatic CD36 downregulation parallels steatosis improvement in morbidly obese undergoing bariatric surgery (2017) *INT J OBESITY*, 41 (9), 1388-1393.

**IF: 5.151**

Reig-Rosello G., Contreras M.M., Suarez-Fernandez C., Gonzalez-Hernandez A., Cardona P., Pons-Amate J.M., Marti-Fabregas J., Vivancos J., Pose A., Diaz J.A., et al, Clinical profile and satisfaction with anticoagulated treatment in patients with non-valvular atrial fibrillation attended in internal medicine and neurology departments of Spain Perfil clínico y satisfacción con el tratamiento antiocoagulante en pacientes con fibrilación auricular no valvular atendidos en consultas de medicina interna y neurología de España (2017) *REV NEUROLOGIA*, 65 (8), 361-367.

**IF: 0.601**

Rial-Crestelo D., Santos-Recuero I., Julve J., Blanco-Vaca F., Torralba M., A novel homozygous mutation causing lecithin-cholesterol acyltransferase deficiency in a proband of Romanian origin with a record of extreme gestational hyperlipidemia (2017) *J CLIN LIPIIDOL*, 11 (6), 1475-1479.e3.

**IF: 3.580**

Royo-Bordonada M.A., Armario P., Lobos Bejarano J.M., Pedro-Botet J., Villar Alvarez F., Elosua R., Brotons Cuixart C., Cortes O., Serrano B., Camafort Babkowi M., Gil Nunez A., Perez A., Maiques A., de Santiago Nocito A., Castro A., Alegria E., Baeza C., Herranz M., Sans S., Campos P., Spanish adaptation of the 2016 European Guidelines on cardiovascular disease prevention in clinical practice Adaptación española de las guías europeas de 2016 sobre prevención de la enfermedad cardiovascular en la práctica clínica (2017) *GAC SANIT*, 31 (3), 255-268.

**IF: 1.581**

Schanton M., Maymo J., Perez-Perez A., Gambino Y., Maskin B., Duenas J.L., Sanchez-Margalef V., Varone C., Sp1 transcription factor is a modulator of estradiol leptin induction in placental cells (2017) *PLACENTA*, 57, 152-162.

**IF: 2.434**



# Inflammatory Diseases



## Coordinator

Juárez Rubio, Cándido FGS  
cjuarez@santpau.cat

## Members

Agustí Martí, Manuela	FGS
Alserawan de Lamo, Leticia	FGS
Baucells de la Peña, Andrés	FGS
Canto Naves, Elisabeth	IR
De la Calle Martín, Óscar	FGS
Mariscal Rodríguez, Anaís	FGS
Martínez Carretero, María Ángeles	FGS
Martínez Martínez, Laura	FGS
Moga Naranjo, María Esther	FGS
Ortiz de Juana, María Àngels	IR
Perea Soriano, Lidia	IR
Rubiales Robles, María Victoria	FGS
Vidal Alcorisa, Sílvia	IR
Zamora Atenza, Carlos	IR

## Main Lines of Research

- ▶ The role of the natural immune system in the development of autoimmune and inflammatory processes.
- ▶ Immunological response and clinical course in immunomodulator treatments.
- ▶ The role of autoantibodies, components of the adaptive immunity system, in the

pathogenesis of autoimmune processes and their use as diagnostic and prognostic markers in these diseases.

- ▶ Mechanisms involved in immunodeficiency.

## Challenges

- ▶ Role of cells, molecules and autoantibodies of the innate and adaptative immune response in the development and control of inflammatory processes, in the appearance of autoimmune phenomena, immunodeficiencies, infections, cardiovascular diseases and development of tumours.
- ▶ Role of TLR and STAT signalling in inflammatory diseases and response to superantigens.
- ▶ Study of mechanisms involved in immunodeficiency caused by alterations of molecular components.
- ▶ Analysis of the evolution of immunological parameters and their correlation with clinical response to treatment with immunomodulators.
- ▶ Composition of complex human biological fluids. Association with clinical parameters.

## Collaborations

### Collaborations with other IIB Sant Pau Groups

- ▶ Dr. C. Guarner and Dr. G. Soriano (Digestive Diseases and CIBER)
- ▶ Dra. Isabel Illa (Neurology)
- ▶ Dra. Esther Garcia-Planella (Digestive Diseases)
- ▶ Dr. Cesar Diaz-Torné (Reumatología)
- ▶ Dr. Plaza and Dr. Sibila (Chronic Respiratory Diseases)
- ▶ Dr. Lluís Puig (Dermatology)
- ▶ Dra. Majem i Dr. Barnades (Clinical Oncology)
- ▶ Dr. Maroto (Clinical Oncology)

### External Collaborations

- ▶ Dra. Manichanh (Digestive Pathology, Hospital Vall d'Hebron)
- ▶ Dra. Hernandez (Rheumatology, Hospital Clinic)
- ▶ Dr. Albert Selva i Dr. Moises Labrador (Allergology, Hospital Vall d'Hebron)
- ▶ Dr. Porcel (Internal Medicine, Hospital Arnau de Vilanova)
- ▶ Dr. Fernandez (Fundació Puigvert)
- ▶ Dra. Andia (Hospital Universitario de Cruces)
- ▶ Dra. Semnani i Dr. Nutman del NIAID-NIH (Bethesda, USA)
- ▶ Dra. Catalfamo del Georgetown University School of Medicine (Washington DC)

## Active Grants

- ▶ Sílvia Vidal Alcorisa. Estudio de la interacción entre el linfocito T y plaquetas: su aplicación en el desarrollo de una terapia celular para regular la respuesta inmune en la artritis reumatoide. PI14/00741. Instituto de Salud Carlos III. Duration: 2015-2017. 41,500.00 €.

lung cancer patients treated with immune checkpoint inhibitors. IR16-P6. Fundació Privada Hospital de la Santa Creu i Sant Pau. Duration: 2017-2017. 7,000.00 €.

Note: Total amount granted to PI. It does not include indirect costs.

- ▶ Sílvia Vidal Alcorisa. Platelet-leukocyte complex/interaction: a new biomarker for the immune-related adverse events in

**Grants  
Awarded  
in 2017**

- ▶ Sílvia Vidal Alcorisa. Caracterización de las plaquetas "educadas" en un entorno inflamatorio crónico para optimizar las terapias inmunoreguladoras con plaquetas. PI17/00072, Instituto de Salud Carlos III. Duration: 2018-2020. 47,500.00 €.

Note: Total amount granted to PI. It does not include indirect costs.

**Transfer Products**

- ▶ Sílvia Vidal Alcorisa. Análisis de los mecanismos inmunoreguladores de la Treg inducidos por tocilizumab en artritis reumatoide. Roche Farma, S.A.
- ▶ Sílvia Vidal Alcorisa Caracterización de los macrófagos y las células madre del cáncer en pacientes con cáncer de pulmón, mama y ovario. MERCK.
- ▶ Sílvia Vidal Alcorisa, Marga Majem. Fuentes de PD-1 y PD-L1 en el cáncer de pulmón no microcítico. BMS.
- ▶ Pablo Maroto Análisis del perfil inmunológico de las células tumorales y de los linfocitos en la orina de pacientes con cáncer de vejiga. Roche Farma, S.A.
- ▶ César Díaz-Torné. Systemic inflammation in patients with gout. Astra Grunenthal.

**Scientific Production**

**\*TIF: 38.733 \*\*MIF: 5.533**

Leiding J.W., Okada S., Hagin D., Abinun M., Shcherbina A., Balashov D.N., Kim V.H.D., Ovadia A., Guthery S.L., Pulsipher M., Lilic D., Devlin L.A., Christie S., Depner M., Fuchs S., van Royen-Kerkhof A., Lindemanns C., Petrovic A., Sullivan K.E., Bunin N., Kilic S.S., Arpacı F., Calle-Martin O.D.L., Martinez-Martinez L., Aldave J.C., Kobayashi M., Ohkawa T., Imai K., Iguchi A., Roifman C.M., Gennery A.R., Slatter M., Ochs H.D., Morio T., Torgerson T.R., Hematopoietic stem cell transplantation in patients with gain-of-function signal transducer and activator of transcription 1 mutations (2017) *J ALLERGY CLIN IMMUN*.

**IF: 13.258**

Martinez-Martinez L., Lleixa M.C., Boera-Carnicer G., Cortese A., Devaux J., Siles A., Rajabally Y., Martinez-Pineiro A., Carvajal A., Pardo J., Delmont E., Attarian S., Diaz-Manera J., Callegari I., Marchionni E., Franciotta D., Benedetti L., Lauria G., de la Calle Martin O., Juarez C., Illa I., Querol L., Anti-NF155 chronic in-

flammatory demyelinating polyradiculoneuropathy strongly associates to HLA-DRB15 (2017) *J NEUROINFLAMM*, 14 (1).

**IF: 5.193**

Nieto J.C., Zamora C., Canto E., Garcia-Planella E., Gordillo J., Ortiz M.A., Juarez C., Vidal S., CSF-1 regulates the function of monocytes in Crohn's disease patients in remission (2017) *SCI REP-UK*, 7 (1).

**IF: 4.122**

Sanchez E., Nieto J.C., Vidal S., Santiago A., Martinez X., Sancho F.J., Sancho-Bru P., Mirellis B., Corominola H., Juarez C., Manichanh C., Guarner C., Soriano G., Fermented milk containing *Lactobacillus paracasei* subsp. *paracasei* CNCM I-1518 reduces bacterial translocation in rats treated with carbon tetrachloride (2017) *SCI REP-UK*, 7.

**IF: 4.122**

Suarez-Calvet X., Gallardo E., Pinal-Fernandez I., De Luna N., Lleixa C., Diaz-Manera J., Rojas-Garcia R., Castellvi I., Martinez M.A.,

Grau J.M., Selva-O'Callaghan A., Illa I., RIG-I expression in perifascicular myofibers is a reliable biomarker of dermatomyositis (2017) *ARTHRITIS RES THER*, 19 (1).

**IF: 4.269**

Suarez-Cuartin G., Smith A., Abo-Leyah H., Rodrigo-Troyano A., Perea L., Vidal S., Plaza V., Fardon T.C., Sibila O., Chalmers J.D., Anti-Pseudomonas aeruginosa IgG antibodies and chronic airway infection in bronchiectasis (2017) *RESP MED*, 128, 1-6.

**IF: 3.230**

Zamora C., Canto E., Nieto J.C., Bardina J., Diaz-Torne C., Moya P., Magallares B., Ortiz M.A., Julia G., Juarez C., Llobet J.M., Vidal S., Binding of platelets to lymphocytes: A potential anti-inflammatory therapy in rheumatoid arthritis (2017) *J IMMUNOL*, 198 (8), 3099-3108.

**IF: 4.539**

**Other Publications**

- ▶ Crespo-Lessmann A., Mateus E., Torrejón M., Belda A., Giner J., Vidal S., Sibila O., Plaza V. Asthma with bronchial hypersecretion: expression of mucins and toll-like receptors in sputum and blood. *J Asthma Allergy*. 2017 Oct 12; 10: 269-276.

# Endocrinology, Diabetes and Nutrition



## Coordinator

Corcòy Pla, Rosa FGS  
rcorcoy@santpau.cat

## Members

Alcántara Aragón, Valeria	IR
Blanco Soto, Rosa María	CIBERBBN
Castilla Manjón, María José	IR
Chico Ballesteros, Ana Isabel	FGS
Cubero Marcos, José María	FGS
De Leiva Hidalgo, Alberto	FGS
Gil Millán, Pedro Alejandro	IR
González Blanco, Cintia	FGS
Lupiñez Barbero, Ascensión	IR
Martínez Bru, Cecilia	FGS
Martínez Roldán, María José	IR
Mato Matute, Eugenia	CIBERBBN
Navarro Cano, Gemma	FGS
Orellana Casado, Inmaculada	FGS
Pérez Pérez, Antonio	FGS

## Main Lines of Research

- ▶ Endocrine neoplasms: investigation of tumour dedifferentiation mechanisms through genomic, proteomic and bioinformatic procedures.
- ▶ Autoimmune diabetes mellitus (classic type 1 and LADA) and gestational diabetes.
- ▶ Telemedicine and intelligent systems for therapeutic optimization of diabetes mellitus.
- ▶ Prediction, prevention and optimization of the treatment of obesity, hyperlipidaemia, metabolic syndrome and complications.
- ▶ Diabetes and endocrine disorders in pregnancy.
- ▶ History of insulin: old and new controversies about the discovery of insulin.

## Challenges

### Endocrine Neoplasms

- ▶ Molecular markers of the epithelial lineage: expression of the ABCG2 gene/BCRP1 transporter.
- ▶ Transcriptomics and proteomics as prediction and prognosis instruments for epithelial thyroid cancer.
- ▶ Intramural CELL-NANO-THYROID project: investigation of human mesenchymal cell capacity as an instrument for administering anti-tumour cell drugs in the form of conjugated nanoparticles.
- ▶ Role of cholesterol & cholesterol metabolites in thyroid neoplasms differentiation.
- ▶ Assessment of glycated immunoglobulins as serologic markers of thyroid carcinoma.

tational diabetes at pre-conception, pregnancy, birth and postpartum stages.

### Technology, telemedicine and intelligent systems for therapeutic optimization of diabetes mellitus

- ▶ Technology in the treatment of diabetes with special focus in insulin (new insulins, pumps), and glucose measurement including sensors.
- ▶ Development of a technological platform for the prediction, prevention and treatment of obesity, DM, HTA, dyslipidemia and cardiometabolic risk.

### Optimization of the Treatment of Obesity, Hyperlipidaemia, Metabolic Syndrome and Complications

- ▶ Optimal treatment and prevention of cardiovascular risk associated with obesity, hyperlipidaemia, metabolic syndrome and diabetes mellitus 2.

### History of Insulin: Old and New Controversies about the Discovery of Insulin

- ▶ To investigate with documented evidence (heuristics) if European research on the development of pancreatic extracts achieved beneficial results in the ootherapy of both experimental and clinical diabetes.

## Theses

- ▶ Gabriela Monroy Rodríguez. Diabetes gestacional y la influencia de la lactancia en el metabolismo hidrocarbonado. Universitat Autònoma de Barcelona. Directors: Rosa Corcòy and Alberto de Leiva. Date of defense: 01/12/2017.
- ▶ Diana Ovejero Crespo. Descripció clínica, etiologia molecular i estudis fisiopatològics de la síndrome cutània esquelètica hipofosfatèmica: una malaltia mosaica de mutacions ras activadores, Universitat Autònoma de Barcelona. Directors: Ana Isabel Chico, Rosa Corcòy, Adolfo Díez, Alberto de Leiva. Date of defense: 18/06/2017.

**Collaborations****Collaborations with other IIB Sant Pau Groups**

- ▶ Oncogenesis and Antitumour Drugs (Ramon Mangues).
- ▶ Ophthalmology (Fernando Rodríguez Álvarez).
- ▶ Cardiovascular Biochemistry (Jorge Ordóñez, José Luis Quesada, Francisco Blanco).
- ▶ General and Digestive Surgery (Antonio Moral, Ignacio Pérez).
- ▶ Reproductive Health (Juan Adelantado).
- ▶ Metabolic Bases of Cardiovascular Risk (Francisco Blanco).

**External Collaborations****CIBER-BBN**

- ▶ Bioengineering and Telemedicine Group at the Universidad Politécnica de Madrid, Spain (GBT-UPM). PI: Enrique J. Gómez Aguilera.

- ▶ Biomedical Engineering Research Group at the Universidad de Sevilla, Spain (GIB-US). PI: Laura Roa Romero.

**CELL-NANO-THYROID**

- ▶ Molecular Oncology Group at HVH, PI: S. Schwartz, Jr.
- ▶ Development of New Drugs Group at the Universidad del País Vasco, Spain. PI: JL Pedraz.

**CONCEPTT: Women with Type 1 Diabetes in Pregnancy Trial****Vitamin D and Lifestyle Intervention for Gestational Diabetes Mellitus (GDM) Prevention (DALI) Consortium****Action LADA European Consortium****Active Grants**

- ▶ Cintia González Blanco. Intensificación y monitorización telemática personalizada de la modificación del estilo de vida en el tratamiento de la obesidad y la prevención del riesgo cardiometaobólico. PI12/00931. Instituto de Salud Carlos III. Duration: 2013-2017. 68,000.00 €.
- ▶ Valeria Alcántara Aragón. Intensificación y monitorización telemática personalizada de la modificación del estilo de vida en el tratamiento de la obesidad y la prevención del riesgo cardiometaobólico (PREDIRCAM 2). 2014FI00149. Agència de Gestió d'Ajuts Universitaris i de Recerca. Duration: 2014-2017. 60,465.12 €.
- ▶ Alberto de Leiva Hidalgo. Grup de Recerca en Endocrinologia, Diabetes i Metabolisme. 2014 SGR 569. Agència de Gestió d'Ajuts Universitaris i de Recerca. Duration: 2014-2017. 50,000.00 €.

- ▶ Ascension Lupiañez Barbero. Validació clínica de la plataforma tecnològica PREDIRCAM en l'etapa primerenca de la diabetis autoimmune tipus LADA. 2016 FI\_B 00211. Agència de Gestió d'Ajuts Universitaris i de Recerca. Duration: 2016-2019. 60,465.12 €.

- ▶ Valeria Alcántara Aragón. Impact of intermittent versus continuous walking on glucose control in type 2 diabetes. IR16-E4. Fundació Privada Hospital de la Santa Creu i Sant Pau. Duration: 2017-2017. 3,500.00 €.

- ▶ Rosa Corcoy. Novel markers of glycemic control in women with Type 1 diabetes in pregnancy. An ancillary study from the CONCEPTT randomised clinical trial. EFSD/Sanofi Research Grant Programme for innovative measurement of diabetes outcomes. Duration: 2017-2018. 60,000 €.

Note: Total amount granted to PI. It does not include indirect costs.

**Awards**

- ▶ Valeria Alcántara. Predircam 2- plataforma web para el soporte continuado en cambios de estilo de vida, tratamiento y seguimiento telemático de personas con obesidad y prevención de DM2. 3rd Award MSD 2017 to Innovation and Excellence in the approach of diabetic patients.

# Endocrinology, Diabetes and Nutrition

\*TIF: 102.487 \*\*MIF: 6.4054

## Scientific Production

- Barcelo A., Morell-Garcia D., Salord N., Esquinas C., Perez G., Perez A., Monasterio C., Gasa M., Fortuna A.M., Montserrat J.M., Mayos M., A randomized controlled trial: branched-chain amino acid levels and glucose metabolism in patients with obesity and sleep apnea (2017) *J SLEEP RES*, 26 (6), 773-781.  
**IF: 3.433**
- Caimari F., Valassi E., Garbayo P., Steffensen C., Santos A., Corcoy R., Webb S.M., Cushing's syndrome and pregnancy outcomes: a systematic review of published cases (2017) *ENDOCRINE*, 55 (2), 555-563.  
**IF: 3.179**
- Cedo L., Santos D., Roglans N., Julve J., Pallares V., Rivas-Urbina A., Llorente-Cortes V., Laguna J.C., Blanco-Vaca F., Escola-Gil J.C., Human hepatic lipase overexpression in mice induces hepatic steatosis and obesity through promoting hepatic lipogenesis and white adipose tissue lipolysis and fatty acid uptake (2017) *PLOS ONE*, 12 (12).  
**IF: 2.766**
- Egan A.M., Vellinga A., Harreiter J., Simmons D., Desoye G., Corcoy R., Adelantado J.M., Devlieger R., van Assche A., Galjaard S., Damm P., Mathiesen E.R., Jensen D.M., Andersen L., Lapolla A., Dalfra M.G., Bertolotto A., Mantaj U., Wender-Ozegowska E., Zawiejska A., Hill D., Jelsma J.G.M., Snoek F.J., Worda C., Bancher-Todesca D., van Poppel M.N.M., Kautzky-Willer A., Dunne F.P., Epidemiology of gestational diabetes mellitus according to IADPSG/WHO 2013 criteria among obese pregnant women in Europe (2017) *DIABETOLOGIA*, 60 (10), 1913-1921.  
**IF: 6.023**
- Estruch M., Minambres I., Sanchez-Quesada J.L., Soler M., Perez A., Ordonez-Llanos J., Benitez S., Increased inflammatory effect of electronegative LDL and decreased protection by HDL in type 2 diabetic patients (2017) *ATHEROSCLEROSIS*, 265, 292-298.  
**IF: 4.467**
- Feig D.S., Donovan L.E., Corcoy R., Murphy K.E., Amiel S.A., Hunt K.F., Asztalos E., Barrett J.F.R., Sanchez J.J., de Leiva A., Hod M., Jovanovic L., Keely E., McManus R., Hutton E.K., Meek C.L., Stewart Z.A., Wysocki T., O'Brien R., Ruedy K., Kollman C., Tomlinson G., Murphy H.R., Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial (2017) *LANCET*, 390 (10110), 2347-2359.  
**IF: 5.254**
- Jelsma J.G.M., Simmons D., Gobat N., Rollnick S., Blumska K., Jans G., Galjaard S., Desoye G., Corcoy R., Juarez F., Kautzky-Willer A., Harreiter J., van Assche A., Devlieger R., Timmerman D., Hill D., Damm P., Mathiesen E.R., Wender-Ozegowska E., Zawiejska A., Lapolla A., Dalfra M.G., del Prato S., Bertolotto A., Dunne F., Jensen D.M., Andersen L., Snoek F.J., van Poppel M.N.M., Is a motivational interviewing based lifestyle intervention for obese pregnant women across Europe implemented as planned? Process evaluation of the DALI study (2017) *BMC PREGNANCY CHILDB*, 17 (1).  
**IF: 2.331**
- Kumar A., de Leiva A., Latent autoimmune diabetes in adults (LADA) in Asian and European populations (2017) *DIABETES-METAB RES*, 33 (5).  
**IF: 3.904**
- Lambert C., Cubedo J., Padro T., Sanchez-Hernandez J., Antonijonan R.M., Perez A., Badimon L., Phytosterols and omega 3 supplementation exert novel regulatory effects on metabolic and inflammatory pathways: A proteomic study (2017) *NUTRIENTS*, 9 (6).  
**IF: 4.196**
- Minambres I., Perez A., Is there a justification for classifying GLP-1 receptor agonists as basal and prandial? (2017) *DIABETOL METAB SYNDR*, 9 (1).  
**IF: 2.413**
- Monroy G., Tundidor D., Orellana I., Garcia-Patterson A., Adelantado J.M., Corcoy R., Antenatal oral glucose tolerance test in women with gestational diabetes mellitus: Fasting plasma glucose is the best predictor of both large for-gestational-age newborns and postpartum glucose tolerance (2017) *MINERVA ENDOCRINOL*, 42 (4), 311-317.  
**IF: 1.260**
- Ramos A., Mendoza L.C., Rabasa F., Bolibar I., Puig T., Corcoy R., Case-control studies in diabetes. Do they really use a case-control design? (2017) *ACTA DIABETOL*, 54 (7), 631-634.  
**IF: 3.126**
- Royo-Bordonada M.A., Armario P., Lobos Bejarano J.M., Pedro-Botet J., Villar Alvarez F., Elosua R., Brotons Cuixart C., Cortes O., Serrano B., Camafort Babkowski M., Gil Nunez A., Perez A., Maiques A., de Santiago Nocito A., Castro A., Alegría E., Baeza C., Herranz M., Sans S., Campos P., Spanish adaptation of the 2016 European Guidelines on cardiovascular disease prevention in clinical practice Adaptación española de las guías europeas de 2016 sobre prevención de la enfermedad cardiovascular en la práctica clínica (2017) *GAC SANIT*, 31 (3), 255-268.  
**IF: 1.581**
- Sattler M.C., Jelsma J.G.M., Bogaerts A., Simmons D., Desoye G., Corcoy R., Adelantado J.M., Kautzky-Willer A., Harreiter J., van Assche F.A., Devlieger R., Jans G., Galjaard S., Hill D., Damm P., Mathiesen E.R., Wender-Ozegowska E., Zawiejska A., Blumska K., Lapolla A., Dalfra M.G., Bertolotto A., Dunne F., Jensen D.M., Andersen L.L.T., Snoek F.J., van Poppel M.N.M., Correlates of poor mental health in early pregnancy in obese European women (2017) *BMC PREGNANCY CHILDB*, 17 (1).  
**IF: 2.331**
- Schanton M., Maymo J., Perez-Perez A., Gambino Y., Maskin B., Duenas J.L., Sanchez-Margalef V., Varone C., Sp1 transcription factor is a modulator of estradiol leptin induction in placental cells (2017) *PLACENTA*, 57, 152-162.  
**IF: 2.434**
- Simmons D., Devlieger R., Van Assche A., Jans G., Galjaard S., Corcoy R., Adelantado J.M., Dunne F., Desoye G., Harreiter J., Kautzky-Willer A., Damm P., Mathiesen E.R., Jensen D.M., Andersen L., Lapolla A., Dalfra M.G., Bertolotto A., Wender-Ozegowska E., Zawiejska A., Hill D., Snoek F.J., Jelsma J.G.M., Van Poppel M.N.M., Effect of physical activity and/or healthy eating on gdm risk: The dali lifestyle study (2017) *J CLIN ENDOCR METAB*, 102 (3), 903-913.  
**IF: 5.789**



# Pituitary Gland Disorders



## Coordinator

Webb Youdale, Susana FGS  
swebb@santpau.cat

## Members

Resmini, Eugenia	CIBERER
Roig Garcia, Olga	IR
Santos Vives, Alicia	IR
Valassi, Elena	CIBERER

## Main Lines of Research

- ▶ ERCUSYN: European Registry on Cushing syndrome. Initiated with funding from SANCO, EU Public Health Programme.
- ▶ Role of myosteatosis in the development and persistence of residual muscular fragility in treated acromegaly and Cushing's syndrome. Study of the mechanisms involved.
- ▶ Spanish Molecular Registry of Pituitary Adenomas (REMAH study).
- ▶ Morbimortality, low-grade inflammation and cardiovascular risk in patients with acromegaly or Cushing syndrome.
- ▶ International consortium collaboration to identify genes and pathogenetic mechanisms involved in the development of craniopharyngiomas and pituitary adenomas.
- ▶ Neuroradiological, neuropsychological and clinical study of endogenous hypercortisolism: comparison of Cushing syndrome and chronic major depressive disorder.
- ▶ Validation of psychological properties of specific questionnaires to evaluate health-related quality of life (HRQoL) in Cushing syndrome and acromegaly.
- ▶ Study of bone microarchitecture and resistance and their predictors in patients with Cushing's syndrome and acromegaly in remission. A model to investigate the interaction between bone and body fat.
- ▶ Aetiology of cardiopathy in acromegaly and its relation to body composition.
- ▶ Role of telomeres in endocrine diseases.

## Challenges

- ▶ Investigate the neuropsychological, neuroradiological and clinical correlation of patients with endogenous hypercortisolism (due to Cushing syndrome or chronic major depressive disorder) or exogenous exposure to low-dose glucocorticoids (due to treatment of adrenal insufficiency or rheumatoid arthritis). Similar studies for acromegaly.
- ▶ Evaluate long-term morbidity and mortality in patients who have had Cushing syndrome or acromegaly in the last 35 years, especially bone quality, muscular dysfunction and quality of life
- ▶ Analyse and update the European database of patients with Cushing syndrome (ERCUSYN), which in 2017 included over 1600 patients from 57 centres in 36 countries.
- ▶ Conduct in vitro molecular analysis of operated pituitary adenomas within the REMAH (Molecular Registry of Pituitary Adenomas) study, sponsored by the Spanish Endocrinology and Nutrition Society.

## Active Grants

- ▶ Susan Webb Youdale. Estudio de microarquitectura y resistencia óseas y de factores que las determinan en el síndrome de Cushing o acromegalía en remisión. Modelo para investigar la interacción hueso-grasa corporal. PI14/00194. Instituto de Salud Carlos III. Duration: 2015-2019. 91,500.00 €.
- ▶ Susan Webb Youdale. Grup de Recerca de Malalties de la Hipòfisi i Grup CIBERER 747 (CIBER de Malalties Rares). 2014 SGR 355. Agència de Gestió d'Ajuts Universitaris i de Recerca. Duration: 2014-2017.

Note: Total amount granted to PI. It does not include indirect costs.

## Grants Awarded in 2017

- ▶ Elena Valassi. Role of myosteatosis in the development and persistence of residual muscular fragility in treated acromegaly and Cushing's syndrome. Study of the mechanisms involved. PI 17/00749. Duration: 2018-2020.

Note: Total amount granted to PI. It does not include indirect costs.

## Theses

- ▶ Patricia Pires Encuentra. Anomalías de la sustancia blanca cerebral en el síndrome de Cushing en relación a sintomatología psiquiátrica y rendimiento cognitivo. UAB. Directors: Susan M Webb, Beatriz Gómez Ansón. Date of defense: 19/09/2017.

## Collaborations

### **Collaborations with other IIB Sant Pau Groups**

- ▶ Martínez-Momblan MA, Santos A, Santesmases R, Campillo B, Guillaumet M, Serret M, Torres A, Abades M. Estudio longitudinal de la inserción laboral de los titulados de máster en enfermería. Revista ROL de Enfermería [Epub ahead of print]
- ▶ Collaboration with the Neuromuscular Research Group led by Dr Isabel Illa, specifically with Dr Jordi Manero, to evaluate muscle in patients treated for acromegaly and Cushing syndrome.

### **External Collaborations**

- ▶ Bilateral research between E Resmini and Richard Lee of Baltimore University, Departments of Psychiatry and Medicine, the Johns Hopkins University School of Medicine. It has generated the publication Resmini E., Santos A., Aulinás A., Webb S.M., Reduced DNA methylation of FKBP5 in Cushing's syndrome. (2016) ENDOCRINE, 54 (3), 768-77.
- ▶ Genetic, molecular and clinical characterisation of craniopharyngioma. St Bartholomew's Hospital and The London Charity Hospital. With Dr. Carles Gaston-Massuet.
- ▶ Participation in the project of Personalized Medicine of the ISCIII. Improved and efficient therapy of acromegaly by implementation of a personalized and predictive algorithm including functional analysis, imaging and genomic information (number PMP 15/00027). Global PI: Manel Puig Domingo. Participating PIs:
- ▶ IGTP Group/CIBERER GP: Manel Puig Domingo (PI)
- ▶ Sant Pau Group/CIBERER 747: Susan Webb (PI), E Resmini, E Valassi, A Santos, I Crespo, A Aulinás
- ▶ IDIBAPS/Clinic Group/CIBERER GV: Irene Halperin (PI)
- ▶ Hospital de la Ribera Group (Alzira): Carmiña Fajardo (PI)
- ▶ Hospital de la Princesa Group (Madrid)/CIBERER GP: Mónica Marazuela (PI)
- ▶ Complejo Hospitalario de Santiago de Compostela Group: Ignacio Bernabéu (PI)
- ▶ Hospital Universitario de Alicante/CIBERER GV: Antonio Picó (PI)
- ▶ IMS Health: Montserrat Roset (PI)
- ▶ Silent corticotrope adenomas: Are they a subtype of more aggressive non-functioning pituitary adenomas? Project funded by CIBERER in the competitive call on Translational Medicine, 2015-2016. PI: Antonio Picó (Alacant). Participating Units: U747-S. Webb (S Pau); U725A-L. Castaño (Bilbao); GCV 13\_Picó (Alacant); GCV 11\_Halperin (H Clinic Barcelona); GCV 12\_Marazuela (Hosp Princesa, Madrid); GCV 14\_Puig (Hospital GTiP, Badalona); GCV 15\_Soto (HUV Rocío Sevilla).

# Pituitary Gland Disorders

## Scientific Production

\*TIF: 47.76 \*\*MIF: 3.411

Aulinas A., Crespo I., Vilades D., Leta R., Urgell E., Biagetti B., Webb S.M., Valassi E., Cystatin-C and epicardial adipose tissue as noninvasive predictors of cardiovascular risk in acromegaly (2017) CLIN ENDOCRINOL, 86 (2), 214-222.

**IF: 3.077**

Caimari F., Valassi E., Garbayo P., Steffensen C., Santos A., Corcaya R., Webb S.M., Cushing's syndrome and pregnancy outcomes: a systematic review of published cases (2017) ENDOCRINE, 55 (2), 555-563.

**IF: 3.179**

Crespo I., Valassi E., Webb S.M., Update on quality of life in patients with acromegaly (2017) PITUITARY, 20 (1), 185-188.

**IF: 2.730**

Ibanez-Costa A., Lopez-Sanchez L.M., Gahete M.D., Rivero-Cortes E., Vazquez-Borrego M.C., Galvez M.A., De La Riva A., Venegas-Moreno E., Jimenez-Reina L., Moreno-Carazo A., Tinahones F.J., Maraver-Selfa S., Japon M.A., Garcia-Arnes J.A., Soto-Moreno A., Webb S.M., Kineman R.D., Culler M.D., Castano J.P., Luque R.M., BIM-23A760 influences key functional endpoints in pituitary adenomas and normal pituitaries: Molecular mechanisms underlying the differential response in adenomas (2017) SCI REP-UK, 7.

**IF: 4.122**

Kyriakakis N., Lynch J., Gilbey S.G., Webb S.M., Murray R.D., Impaired quality of life in patients with treated acromegaly despite long-term biochemically stable disease: Re-

sults from a 5-years prospective study (2017) CLIN ENDOCRINOL, 86 (6), 806-815.

**IF: 3.077**

Pires P., Santos A., Vives-Gilabert Y., Webb S.M., Sainz-Ruiz A., Resmini E., Crespo I., de Juan-Delago M., Gomez-Anson B., White matter involvement on DTI-MRI in Cushing's syndrome relates to mood disturbances and processing speed: a case-control study (2017) PITUITARY, 20 (3), 340-348.

**IF: 2.730**

Santos A., Resmini E., Pascual J.C., Crespo I., Webb S.M., Psychiatric Symptoms in Patients with Cushing's Syndrome: Prevalence, Diagnosis and Management (2017) DRUGS, 77 (8), 829-842.

**IF: 4.690**

Santos A., Granell E., Gomez-Anson B., Crespo I., Pires P., Vives-Gilabert Y., Valassi E., Webb S.M., Resmini E., Depression and Anxiety Scores Are Associated with Amygdala Volume in Cushing's Syndrome: Preliminary Study (2017) BIOMED RES INT, 2017.

**IF: 2.583**

Sesmilo G., Resmini E., Sambo M., Blanco C., Calvo F., Pazos F., Fernandez-Catalina P., Martinez De Icaya P., Paramo C., Fajardo C., Marazuela M., Alvarez-Escola C., Diez J.J., Perea V., Prevalence of acromegaly in patients with symptoms of sleep apnea (2017) PLOS ONE, 12 (9).

**IF: 2.766**

Valassi E., Crespo I., Keevil B.G., Aulinas A., Urgell E., Santos A., Trainer P.J., Webb S.M.,

Affective alterations in patients with Cushing's syndrome in remission are associated with decreased BDNF and cortisone levels (2017) EUR J ENDOCRINOL, 176 (2), 221-231.

**IF: 4.333**

Valassi E., Franz H., Brue T., Feelders R.A., Neete-Maier R., Tsagarakis S., Webb S.M., Yaneva M., Reincke M., Droste M., Diagnostic tests for Cushing's syndrome differ from published guidelines: Data from ERCUSYN (2017) EUR J ENDOCRINOL, 176 (5), 613-624.

**IF: 4.333**

Valassi E., Aulinas A., Glad C.A.M., Johansson G., Ragnarsson O., Webb S.M., A polymorphism in the CYP17A1 gene influences the therapeutic response to steroidogenesis inhibitors in Cushing's syndrome (2017) CLIN ENDOCRINOL, 87 (5), 433-439.

**IF: 3.077**

van der Lely A.J., Gomez R., Pleil A., Badia X., Brue T., Buchfelder M., Burman P., Clemons D., Ghigo E., Jorgensen J.O.L., Luger A., van der Lans-Bussemaker J., Webb S.M., Strasburger C.J., Development of ACRODAT®, a new software medical device to assess disease activity in patients with acromegaly (2017) PITUITARY, 20 (6), 692-701.

**IF: 2.730**

Webb S.M., Crespo I., Santos A., Resmini E., Aulinas A., Valassi E., Quality of life tools for the management of pituitary disease (2017) EUR J ENDOCRINOL, 177 (1), R13-R26.

**IF: 4.333**



# Digestive Diseases


**Coordinator**

Guarner Aguilar, Carlos FGS  
cguarner@santpau.cat

**Members**

Alvarado Tapias,	
Edilmar Auxiliadora	FGS
Ardevol Ribalta, Alba	CIBEREHD
Bertoletti, Federico	FGS
Colan Hernández, Juan	FGS
Concepción Martín,	
Maria del Mar	FGS
Diez Cuadrado,	
Francisco Javier	FGS
Escuredo Rodríguez,	
Bibiana	FGS
Gallego Moya, Adolfo	FGS
García Guix, Marta	FGS
Garcia Planella, Esther	FGS
Gely Vila, Cristina	IR
Gómez Oliva, Cristina	FGS
González Juan, Dolores	FGS
Gordillo Abalos, Jorge	FGS
Guarner Argente, Carlos	FGS
Llao Guardia, Jordina	IR
Lozano Martínez,	
Gloria Andrea	FGS
Menso, María Magdalena	FGS
Murzi Pulgar, Marianette C.	FGS
Oblitas Susaníbar, Elida	FGS
Pernas Canadell,	
Juan Carlos	FGS
Poca Sans, Maria	FGS
Roman Abal, Eva Maria	IR
Sainz Saenz-Torre, Sergio	FGS
Sánchez Ardid,	
Elisabet	CIBEREHD
Soriano Pastor, Germán	FGS
Torras Colell, Javier	FGS
Villanueva Sánchez, Càndid	FGS

**Main Lines of Research**
**Experimental research**

- ▶ Experimental rat model of cirrhosis and ascites.
- ▶ Mechanisms and prevention of bacterial translocation in rats with cirrhosis.
- ▶ Experimental model of spontaneous and induced bacterial peritonitis: physiopathology and treatment.
- ▶ MiRNAs expression profile in inflammatory bowel disease after stimulation with toll-like receptor ligands.

**Clinical investigation**

- ▶ Physiopathology, diagnosis, treatment and prevention of bacterial infections, ascites and hepatorenal syndrome in cirrhosis.
- ▶ Diagnosis and treatment of hepatic encephalopathy in cirrhosis.
- ▶ Cognitive impairment, falls and quality of life in patients with cirrhosis.

▶ Physiopathology, diagnosis, treatment and prevention of digestive haemorrhage due to portal hypertension of non-varicose origin.

▶ Diagnosis and treatment of chronic hepatitis B and C.

▶ Diagnosis and treatment of hepatocarcinoma.

▶ Physiopathology, diagnosis and treatment of intestinal inflammatory disease (inflammatory bowel disease).

▶ Diagnosis and treatment in advanced gastrointestinal endoscopy.

▶ Diagnosis and treatment of acute pancreatitis.

▶ Prevention of acute post-ERCP pancreatitis.

▶ Chronic pancreatitis and pancreatic neoplasms: molecular studies, early detection and treatment.

**Challenges**

- ▶ Consolidate the CIBEREHD, CIBER, Instituto de Salud Carlos III research group by studying complications in cirrhosis.
- ▶ Grup de Recerca de Complicacions de la Cirrosis Hepàtica. Universitat Autònoma de Barcelona
- ▶ Consolidated research group of the Generalitat de Catalunya (SGR)
- ▶ Expand the hepatology research lab and develop new research.
- ▶ Consolidate the portal hypertension research group.

▶ Consolidate the pancreatic illness research line.

▶ Consolidate the inflammatory bowel disease research line.

▶ Consolidate the polyps and colon cancer research line.

▶ Develop a digestive endoscopy research line.

**Active Grants**

- ▶ Carlos Guarner Argente. Ensayo clínico multicéntrico, aleatorizado y doble ciego sobre el uso de antibiótico profiláctico en la punción por ecoendoscopia de lesiones quísticas del páncreas. PI13/00609. Instituto de Salud Carlos III. Duration: 2014-2018. 33,750.00 €.
- ▶ Carlos Guarner Aguilar. Estudio de las alteraciones de la barrera intestinal en la cirrosis hepática. PI14/00680. Instituto de Salud Carlos III. Duration: 2015-2019. 81,500.00 €.
- ▶ Càndid Villanueva Sánchez. Evolución de la circulación colateral portosistémica y la hiperdinamia asociadas a hipertensión portal con el tratamiento etiológico de la

cirrosis. Influencia en el desarrollo de complicaciones. PI16/01992. Instituto de Salud Carlos III. Duration: 2017-2019. 101,500.00 €.

▶ Edilmar Auxiliadora Alvarado Tapias. Ajuts per a contractes de formació "Río Hortega" 2016. CM16/00133. Instituto de Salud Carlos III. Duration: 2017-2019. 53,732.00 €.

▶ Roman Abal, Eva Maria. Papel de la deficiencia de la vitamina D en los eventos clave de la cirrosis hepática e impacto de su suplementación. Beca Fondo de Investigación Sanitaria (Instituto de Salud Carlos III) PI16/00920

Note: Total amount granted to PI. It does not include indirect costs.

**Collaborations****Collaborations with other IIB Sant Pau Groups****IIB-Sant Pau, Institut de Recerca**

Genetic, Metabolic and Inflammatory Diseases research area:

- ▶ Dr. Cándido Juárez (Inflammatory Diseases)
- ▶ Dr. Pere Coll (Microbiology and Infectious Diseases)
- ▶ Dra. Pia Gallano and Dr. Jordi Surrallés (Genetic Research)
- ▶ Dr. Alberto de Leiva (Endocrinology, Diabetes and Nutrition)

Neurological, Mental Disorders and Ageing:

- ▶ Dra. Beatriz Gómez Ansón (Neuroradiology)

Molecular, Genomic, Cellular and Kinetic-Dynamic bases for Diseases and their Treatment:

- ▶ Dr. Juan Garcia (Banc de Sang i Teixits, Generation of advanced therapy medicines)

Associated Groups:

- ▶ Dr. Lluís Puig (Dermatology)

**Fundació de Gestió Sanitària Hospital de la Santa Creu i Sant Pau**

- ▶ Physical Medicine and Rehabilitation

**Intitut Català de Ciències Cardiovasculars**

- ▶ Dr. Laura Casani (Service for external use of Animal Experimentation Unit (UEA))

**External Collaborations****National collaborations**

- ▶ CIBER Groups: CIBEREHD:Dr. Albillos, Dr. Frances, Dr. Bosch, Dr. Bruix, Dr. Cabré, Dr. Forns, Dr. Genesca, Dr. Andrade, Dr. Romero Gómez, Dr. Bañares, among others..); CIBERSAM: Dr. Gish; CIBERER: Dr. Pia Gallano.
- ▶ Instituto de Productos Lácteos Asturias (IPLA).
- ▶ Danone Nutricia Research, Barcelona, Spain.
- ▶ Gastrointestinal Oncology Group of the Spanish Gastroenterological Association.
- ▶ Spanish Collaborative Group for the Study of the Use of Hepatitis C Direct-Acting Drugs.

- ▶ Spanish DILI registry.

- ▶ SportDiet Collaborative Group.

- ▶ BLEPS Study Group. Spanish Collaborative Group for the Study of the Use of Hepatitis C Direct-Acting Drugs.

- ▶ Variceal Bleeding Study Group.

- ▶ Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU).

- ▶ ENEIDA project.

- ▶ Spanish Microscopic Colitis Group (SMCG).

- ▶ EndoCAR group of the Spanish Gastroenterological Association and Spanish Digestive Endoscopy Society.

**International collaborations**

- ▶ Cleveland Abu Dhabi.
- ▶ University of Bologna Italia.
- ▶ EF Clif European Foundation for the study of chronic liver failure.
- ▶ CANONIC study investigators of the EASL-CLIF Consortium and the European Foundation for the Study of Chronic Liver Failure (EF-CLIF).
- ▶ Danone Nutricia Research.
- ▶ EPICOLON Consortium, Lynch Syndrome prediction model validation study group.
- ▶ BLEPS study group.
- ▶ Variceal Bleeding Study Group.
- ▶ European Study Group on Cystic Tumors of the Pancreas.
- ▶ Gilead
- ▶ Shionogi Group
- ▶ Actial
- ▶ Mendes
- ▶ Quintiles
- ▶ Tobira
- ▶ Boehringer Ingelheim

**Awards**

- ▶ Award for the best oral communication: Eva M. Román. Estudio del efecto de un probiótico multiespecies sobre la función cognitiva, el riesgo de caídas y la respuesta inflamatoria en los pacientes con cirrosis. Congrés de la Societat Catalana de Digestologia (SCD) Lleida 2017.

- ▶ Award for the best oral communication in clinical uses: Eva M. Román. Estudio del efecto de un probiótico multiespecies sobre la función cognitiva, el riesgo de caídas y la respuesta inflamatoria en los pacientes con cirrosis. VIII Workshop de la Sociedad Española sobre Probióticos y Prebióticos (SEPYP). Santiago de Compostela, 22-24 february de 2017.

**Theses**

- ▶ Alan Colomo Ordoñez, Hemorragia digestiva alta: prevención y tratamiento. Universitat Autònoma de Barcelona, Director: Càndid Villanueva Sánchez. Date of defense: 20/01/2017.

# Digestive Diseases

Books or  
chapters  
with ISBN

- Soriano G, Sánchez E, Poca M, Román E y Guarner C. Probióticos y prebióticos en las enfermedades hepáticas. Probióticos, prebióticos y salud: Evidencia científica. Sociedad Española de Probióticos y Prebióticos. Edit. Ergon. 2017. ISBN: 978-84-16732-09-8.

**\*TIF: 210.592 \*\*MIF: 7.7997**

Berzigotti A., Albillas A., Villanueva C., Genesca J., Ardevol A., Augustin S., Calleja J.L., Banares R., Garcia-Pagan J.C., Mesonero F., Bosch J., Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: The SportDiet study (2017) *HEPATOLOGY*, 65 (4), 1293-1305.

**IF: 14.079**

Calleja J.L., Crespo J., Rincon D., Ruiz-Antoran B., Fernandez I., Perello C., Gea F., Lens S., Garcia-Samaniego J., Sacristan B., Garcia-Eliz M., Llerena S., Pascasio J.M., Turnes J., Torras X., Morillas R.M., Llaneras J., Serra M.A., Diago M., Rodriguez C.F., Ampuero J., Jorquera F., Simon M.A., Arenas J., Navascues C.A., Banares R., Munoz R., Albillas A., Marino Z., Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort (2017) *J HEPATOL*, 66 (6), 1138-1148.

**IF: 14.911**

Casanova M.J., Chaparro M., Garcia-Sanchez V., Nantes O., Leo E., Rojas-Feria M., Jauregui-Amezaga A., Garcia-Lopez S., Huguet J.M., Arguelles-Arias F., et al., Evolution after Anti-TNF Discontinuation in Patients with Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study (2017) *AM J GASTROENTEROL*, 112 (1), 120-131.

**IF: 10.231**

Colan-Hernandez J., Aldana A., Conception M., Chavez K., Gomez C., Mendez-bocanegra A., Martinez-Guillen M., Sendino O., Villanueva C., Llach J., Guarner-Argente C., Cardenas A., Guarner C., Optimal timing for a second ERCP after failure of initial biliary cannulation following precut sphincterotomy: an analysis of experience at two tertiary centers (2017) *SURG ENDOSC*, 31 (9), 3711-3717.

**IF: 3.54**

Domenech E., Garcia V., Iborra M., Gutierrez A., Garcia-Lopez S., Martin Arranz M.D., Garcia-Planella E., Calvo M., Castro L., Minguez M., Taxonera C., Julia B., Cea-Calvo L., Romero C., Barreiro-De Acosta M., Incidence and Management of Recurrence in Patients with Crohn's Disease Who Have Undergone Intestinal Resection: The Practicrohn Study (2017) *INFLAMM BOWEL DIS*, 23 (10), 1840-1846.

**IF: 4.347**

Escorsell À, Pavel O, Cárdenas A, Morillas R, Llop E, Villanueva C, García-Pagan JC, Bosch J. Reply. *HEPATOLOGY*. 2017 Jun; 65(6): 2121-2122.

**IF: 14.079**

García-Iglesias P, Botargues JM, Feu Caballé F, Villanueva Sánchez C, Calvet Calvo X, Brullet Benítez E, Cánovas Moreno G, Fort Martorell E, Gallach Montero M, Gené Tous E, Hidalgo Rosas JM, Lago Macía A, Nieto Rodríguez A, Papo Berger M, Planella de Rubinat M, Saló Rich J, Campo Fernández de Los Ríos R. Management of non variceal upper gastrointestinal bleeding: position statement of the Catalan Society of Gastroenterology. *GASTROENTEROL HEPATOL*. 2017 May; 40(5): 363-374.

**IF: 1.078**

Garcia-Planella E, Mañosa M, Chaparro M, Beltrán B, Barreiro-de-Acosta M, Gordillo J, Ricart E, Bermejo F, García-Sánchez V, Piquerias M, Llaó J, Gisbert JP, Cabré E, Domènech E. Serial semi-quantitative measurement of fecal calprotectin in patients with ulcerative colitis in remission; PRECUCAL study group Investigators. *SCAND J GASTROENTEROL*. 2018 Feb; 53(2): 152-157.

**IF: 2.629**

Garriga C, Manzanares-Laya S, García de Olalla P, Gorrindo P, Lens S, Solà R, Martínez-Rebollar M, Laguno M, Navarro J, Torras X, Gurgui M, Barberá MJ, Quer J, Masdeu E, Simón P, Ros M, de Andrés A, Cayllà JA. Evolution of acute hepatitis C virus infection in a large European city: Trends and new patterns. *PLoS One*. 2017 Nov 14; 12(11): e0187893.

**IF: 2.766**

Gomez-Rubio P, Zock J.-P, Rava M, Marquez M, Sharp L, Hidalgo M, Carrato A, Ilzarbe L, Michalski C, Molero X, Farre A, Perea J, Greenhalf W, O'Rorke M, Tardon A, Gress T, Barbera V, Crnogorac-Jurcevic T, Dominguez-Munoz E, Munoz-Bellvis L, Alvarez-Urturi C, Balcells J, Barneo L, Costello E, Guillen-Ponce C, Kleeff J, Kong B, Lawlor R, Lohr M, Mora J, Murray L, O'Driscoll D, Peñalve P, Poves I, Scarpa A, Real F.X., Malats N, Reduced risk of pancreatic cancer associated with asthma and nasal allergies (2017) *GUT*, 66 (2), 314-322.

**IF: 17.016**

González-Colominas E, Londoño MC, Morillas RM, Torras X, Mojáil S, Lens S, López D, Gallego A, Mariño Z, Ardèvol M, Pagès N, Solà R, Carrión JA. Potential drug-drug interactions of OMBITASVIR, PARITAPREVIR/ritonavir ± DASABUVIR ± ribavirin in clinical practice. *J Gastroenterol Hepatol*. 2017 Oct 10.

**IF: 1.078**

Graupera I., Coll M., Pose E., Elia C., Piano S., Sola E., Blaya D., Huelin P., Sole C., Moreira R., De Prada G., Fabrellas N., Juanola A., Morales-Ruiz M., Sancho-Bru P., Villanueva C., Gines P., Adipocyte fatty-acid binding protein is overexpressed in cirrhosis and correlates with clinical outcomes (2017) *SCI REP-UK*, 7 (1).

**IF: 4.122**

Lens S., Fernandez I., Rodriguez-Tajes S., Hontangas V., Vergara M., Forne M., Calleja J.L., Diago M., Llaneras J., Llerena S., Torras X., Sacristan B., Roget M., Fernandez-Rodriguez C.M., Navascues M.C., Fuentes J., Sanchez-Ruano J.-J., Simon M.-A., Saez-Rouyela F., Baliellas C., Morillas R., Forns X., Interferon-Free Therapy in Elderly Patients with Advanced Liver Disease (2017) *AM J GASTROENTEROL*, 112 (9), 1400-1409.

**IF: 10.231**

Maas A.I.R., Menon D.K., Adelson P.D., Andelic N., Bell M.J., Belli A., Bragge P., Brazinova A., Buki A., Chesnut R.M., et al., Traumatic brain injury: integrated approaches to improve prevention, clinical care, and research (2017) *LANCET NEUROL*, 16 (12), 987-1048.

**IF: 27.138**

Marino Z., Pascasio-Acevedo J.M., Gallego A., Diago M., Baliellas C., Morillas R., Prieto M., Moreno J.M., Sanchez-Antolin G., Vergara M., et al., High efficacy of Sofosbuvir plus Simeprevir in a large cohort of Spanish cirrhotic patients infected with genotypes 1 and 4 (2017) *LIVER INT*, 37 (12), 1823-1832.

**IF: 4.500**

Martín-Llahí M, Albillas A, Bañares R, Berzigotti A, García-Criado MÁ, Genescà J, Hernández-Gea V, Llop-Herrera E, Masnou-Ridaura H, Mateo J, Navascués CA, Puente Á, Romero-Gutiérrez M, Simón-Talero M, Téllez L, Turon F, Villanueva C, Zarzbeitia R, García-Pagán JC. Vascular diseases of the liver. Clinical Guidelines from the Catalan Society of

**\*TIF: 210.592 \*\*MIF: 7.7997**

Digestology and the Spanish Association for the Study of the Liver. *GASTROENTEROL HEPATOL.* 2017 Oct; 40(8): 538-580.

**IF: 1.078**

Nieto J.C., Zamora C., Canto E., Garcia-Planella E., Gordillo J., Ortiz M.A., Juarez C., Vidal S., CSF-1 regulates the function of monocytes in Crohn's disease patients in remission (2017) *SCI REP-UK*, 7 (1).

**IF: 4.122**

Ordas I., Domenech E., Manosa M., Garcia-Sanchez V., Iglesias-Flores E., Penalva M., Canas-Ventura A., Merino O., Fernandez-Banares F., Gomollon F., Vera M., Gutierrez A., Garcia-Planella E., Chaparro M., Aguas M., Gento E., Munoz F., Aguirresarobe M., Munoz C., Fernandez L., Calvet X., Jimenez C.E., Montoro M.A., Mir A., De Castro M.L., Garcia-Sepulcre M.F., Bermejo F., Panes J., Esteve M., Long-Term Efficacy and Safety of Cyclosporine in a Cohort of Steroid-Refractory Acute Severe Ulcerative Colitis Patients from the ENEIDA Registry (1989-2013): A Nationwide Multicenter Study (2017) *AM J GASTROENTEROL*, 112 (11), 1709-1718.

**IF: 10.231**

Perelló C., Carrión JA., Ruiz-Antorán B., Crespo J., Turnes J., Llaneras J., Lens S., Delgado M., García-Samaniego J., García-Paredes F., et al. Effectiveness and safety of ombitasvir, paritaprevir, ritonavir ± dasabuvir ± ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection. *J VIRAL HEPAT.* 2017 Mar; 24(3): 226-237.

**IF: 4.237**

Perrotti P.P., Aterido A., Fernandez-Nebro A., Canete J.D., Ferrandiz C., Tornero J., Gisbert J.P., Domenech E., Fernandez-Gutierrez B., Gomollon F., Garcia-Planella E., Fernandez E., Sanmarti R., Gratacos J., Martinez-Taboada

V.M., Rodriguez-Rodriguez L., Palau N., Tortosa R., Corbeto M.L., Lasanta M.L., Marsal S., Julia A., Genetic variation associated with cardiovascular risk in autoimmune diseases (2017) *PLOS ONE*, 12 (10).

**IF: 2.766**

Rodriguez de Lope C., Reig M., Matilla A., Ferrer M.T., Duenas E., Minguez B., F. Castro-agudin J., Ortiz I., Pascual S., Lledo J.L., Gallego A., Arenas J.I., Aracil C., Forne M., Munoz C., Pons F., Sala M., Inarraegui M., Martin-Llahi M., Andreu V., Garre C., Rendon P., Fuentes J., Crespo J., Rodriguez M., Bruix J., Varela M., Clinical characteristics of hepatocellular carcinoma in Spain. Comparison with the 2008-2009 period and analysis of the causes of diagnosis out of screening programs. Analysis of 686 cases in 73 centers Características clínicas del carcinoma hepatocelular en España. Comparación con el período 2008-2009 y análisis de las causas del diagnóstico fuera de cribado. Estudio de 686 casos en 73 centros (2017) *MED CLIN-BARCELONA*, 149 (2), 61-71.

**IF: 1.168**

Sanchez E., Nieto J.C., Vidal S., Santiago A., Martinez X., Sancho F.J., Sancho-Bru P., Mirelis B., Corominola H., Juarez C., Manichanh C., Guarner C., Soriano G., Fermented milk containing *Lactobacillus paracasei* subsp. *paracasei* CNCM I-1518 reduces bacterial translocation in rats treated with carbon tetrachloride (2017) *SCI REP-UK*, 7.

**IF: 4.122**

Soriano G., Bajaj J.S., Grading the range of hepatic encephalopathy from overt to covert: Animals to the rescue! (2017) *HEPATOL-OLOGY*, 66 (1), 10-12.

**IF: 14.079**

Taxonera C., Rodriguez C., Bertoletti F., Menchen L., Arribas J., Sierra M., Arias L.,

Martinez-Montiel P., Juan A., Iglesias E., Algabea A., Mancenido N., Rivero M., Barreiro-De Acosta M., Lopez-Serrano P., Arguelles-Arias F., Gutierrez A., Busquets D., Gisbert J.P., Olivares D., Calvo M., Alba C., Garcia-Planella E., Cabriada J.L., Lopez-Sanroman A., Sicilia B., Domenech E., Olivares S., Bermejo F., Chaparro M., Perez-Calle J.L., Munoz C., Higuera R., Merino O., Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis (2017) *INFLAMM BOWEL DIS*, 23 (8), 1394-1402.

**IF: 4.347**

Villanueva C., Graupera I., Aracil C., Alvarado E., Minana J., Puente A., Hernandez-Gea V., Ardevol A., Pavel O., Colomo A., Concepcion M., Poca M., Torras X., Rene J.M., Guarner C., A randomized trial to assess whether portal pressure guided therapy to prevent variceal rebleeding improves survival in cirrhosis (2017) *HEPATOLOGY*, 65 (5), 1693-1707.

**IF: 14.079**

Villanueva C., Graupera I., Alvarado E. Reply. *HEPATOLOGY*. 2017 Oct; 66(4): 1363-1364.

**IF: 14.079**

Zamora C., Canto E., Nieto J.C., Bardina J., Diaz-Torne C., Moya P., Magallares B., Ortiz M.A., Julia G., Juarez C., Llobet J.M., Vidal S., Binding of platelets to lymphocytes: A potential anti-inflammatory therapy in rheumatoid arthritis (2017) *J IMMUNOL*, 198 (8), 3099-3108.

**IF: 4.539**

- Abades M., Campillo B., Guillaumet M., Santesmases R., Hernández E., Román E. Inserción laboral de los titulados en enfermería de una escuela universitaria de enfermería (2009-2016). *Revista Enfermería Docente*. 2017; 109:12-18.
- Sánchez-Martínez MA, García-Planella E, Laiz A, Puig L. Inflammatory Bowel Disease: Joint Management in Gastroenterology and Dermatology. *ACTAS DERMOSIFILIOGR*. 2017 Apr; 108(3): 184-191.

# Microbiology and Infectious Diseases



## Coordinator

Coll Figa, Pere  
FGS  
pcoll@santpau.cat

## Members

Cortes Palacios, Ana Pilar	FGS
Cotura Vidal, María Ángeles	FGS
De Benito Hernández, María Natividad	FGS
Españoł Fran, Montserrat	FGS
Espinal Marín, Paula Andrea	IR
Fernández Arévalo, Anna	IR
Fernández Ramírez, Judith	IR
Fontanet Giralt, Àngels	FGS
Galvez Deltoro, María Luz	FGS
García Sarasola, Ana	IR
Gómez Martínez, Laura	FGS
Guirado Perich, Lluís F. PUIGVERT	
Gurgui Ferrer, Mercedes	FGS
Iglesias Torrens, Yaidelys	IR
Lamarca Soria, Maria Karuna	IR
López-Contreras González, Joaquín	FGS
Margall Coscojuela, Núria	FGS
Martín Andrés, Esther	FGS
Millan Revilla, Lucía	IR
Mirelis Otero, Beatriz	FGS
Miró Cardona, Elisenda	FGS
Muñoz Batet, Carmen	FGS
Mur Arizón, Isabel	FGS
Navarro Risueño, Ferran	FGS
Pomar Solchaga, Virginia	FGS
Prim Bosch, Núria	FGS
Rabella García, Núria	FGS
Rivera Martínez, María Alba	FGS
Rodríguez Navarro, Judith	IR
Rubio Bueno, Marc	IR
Sambeat Domènech, Maria Antònia	FGS
Sánchez Morillo, Alba	IR
Sánchez Reus, Fernando	FGS

## Main Lines of Research

### Clinical Microbiology

- ▶ Study of resistance mechanisms.
- ▶ Tuberculosis, epidemiology and antituberculosis resistance mechanisms.
- ▶ Molecular biology applications in infectious disease detection, taxonomy and epidemiology.
- ▶ Medical care projects.

### Kidney Transplantation

- ▶ Biomarkers for BKV in urine samples.
- ▶ T CD8+ immunity from CMV in renal transplant patients treated with Thymoglobulin.
- ▶ Medical care projects.

### Infectious Pathologies

- ▶ Restricted-use policies for antibiotic and antimicrobial agents and suitable use of antimicrobial agents.
- ▶ Study of infections associated with foreign bodies (joint prostheses, catheters, cardiac prostheses and pacemakers).
- ▶ Study of infections due to multiresistant microorganisms or requiring isolation.
- ▶ Tuberculosis.

## Challenges

### Clinical Microbiology

- ▶ Detection and characterization of Leishmanias from clinical samples.
- ▶ Study of molecular epidemiology (population and clonality studies in bacteria, mycobacteria, fungi and viruses).
- ▶ Molecular bases of bacterial resistance to antibiotics, vectors that convey resistance genes (plasmids, transposons, integrons, phages).
- ▶ The use of molecular techniques in diagnosis of infectious diseases.
- ▶ Research related to bacteraemia and endocarditis, nosocomial infections, prosthetic joint infections, central nervous system infections and tuberculosis.

### Tuberculosis, Epidemiology and Resistance Mechanisms

- ▶ Prospective monitoring of primary and acquired Mycobacterium tuberculosis resistance to first-second-line drugs.
- ▶ Molecular detection of resistance using a molecular antibiogram.
- ▶ Study of the epidemiology and spread of resistant strains and assessment of the impact of immigration and the contribution of new Mycobacterium tuberculosis families (Beijing, EAI, CAS).

### Molecular Biology Applications to Infectious Disease Detection, Taxonomy and Epidemiology

- ▶ Study of the usefulness of the 16S RNA gene for microbiological diagnosis and molecular identification.

- ▶ Genotype characterization of Cryptosporidium spp. oocysts from stool samples collected by the HSCSP Microbiology Unit.

### Medical Care

- ▶ Government Health Department agreement (ongoing) regarding the development of epidemiological surveillance support functions for nosocomial infections and flaccid paralysis.
- ▶ Study of mycoses in depth, especially invasive fusariosis and aspergillosis and respiratory tract viral infections in patients with onco-haematological diseases.
- ▶ Multicentre studies of HIV (ongoing).
- ▶ Monitoring of congenital infection in pregnant women with Chagas disease.

### Kidney Surgery

- ▶ Biomarkers for BKV in urine sample: Determination of a diagnostic and prognostic biomarker in urine by proteomics of nephropathy by BK virus in renal transplant receptors, sponsored by the Infectious Diseases Department, Vall d'Hebron University Hospital, Barcelona, Spain.
- ▶ Estudio de la cinética de la Inmunidad T CD8+frente a CMV en trasplantados renales tratados con Timoglobulina. Financiación: Convocatoria de ayudas de la Fundación, Proyecto y Salud de la Junta de Andalucía.
- ▶ Ensayo clínico de suspensión de la profilaxis con valganciclovir en trasplantados renales CMV-seropositivo que mantienen la inmunidad celular CD8+ CMV-específica tras recibir timoglobulina. Financiación: Convocatoria de Ayudas Proyectos de Investigación de Salud del ISC III. FIS (PI15/00402)

**Challenges****Infectious Pathologies****Restricted-use Antibiotic and Antimicrobial Policies**

- ▶ To minimize resistance, reduce cost and improve compliance with surgical prophylaxis (at the time of administration) through suitable use of antimicrobial agents.

**Epidemic Cutbreaks and Infections Caused by Multiresistant Microorganisms and Microorganisms Requiring Isolation**

- ▶ To study epidemiology for our hospital.
- ▶ To reduce incidence.
- ▶ To prevent/contain epidemic outbreaks and work with the Microbiology Unit in epidemiology and molecular studies.

**Infections Associated with Foreign Bodies (Joint Prostheses, Catheters, Cardiac Prostheses, Pacemakers)**

- ▶ To reduce incidence.
- ▶ To develop effective conservative treatment regimes.

**Infections in Transplant Patients (Heart, Haemopoietic Progenitors)**

- ▶ To study current epidemiology.
- ▶ To assess the efficacy of prophylaxis and other preventive measures.

**Tuberculosis**

- ▶ To cooperate with studies of resistance and with new treatment regimes for tuberculosis.

**Other Projects**

To continue with the Government Health Department agreement regarding the development of support functions as follows:

- ▶ Epidemiological surveillance of nosocomial infections (VINCat).
- ▶ Tuberculosis control: Barcelona-Dreta Tuberculosis Operations Committee (coordinator: Dr Sambeat).
- ▶ New influenza control: Barcelona-Dreta Epidemiological Surveillance Operations Committee (coordinator: Dr López-Contreras).
- ▶ Database for monitoring CMV infections after renal transplantation.
- ▶ Database for monitoring BK virus infections after renal transplantation.
- ▶ Observational and multicentre case-controlled (1:2) study to compare the evolution of renal transplantation in patients with HIV infection (Dr Canal, Dr Facundo and Dr Serra), sponsored by the Andalusian Organ and Tissue Transplantation Society.

**Collaborations****Active Grants**

- ▶ Estudio de la cinética de la Inmunidad T CD8+frente a CMV en trasplantados renales tratados con Timoglobulina. Convocatoria de ayudas de la Fundación, Proyecto y Salud de la Junta de Andalucía.
- ▶ Ensayo clínico de suspensión de la profilaxis con valganciclovir en trasplantados renales CMV-seropositivo que mantienen la inmunidad celular CD8+ CMV-específica tras recibir timoglobulina. Convocatoria de Ayudas Proyectos de Investigación de Salud del ISC III. FIS (PI15/00402)

**External Collaborations**

- ▶ Montserrat Gállego Culleré Sección de Parasitología, Dep. de Biología, Sanitat I Media Ambient, Facultat de Farmàcia. Universitat de Barcelona. Topic: Chagas and leishmaniasis
- ▶ Alejandro Gabriel Schijman Laboratorio de Biología molecular de la enfermedad de Chagas (LabMECh). Instituto de Investigaciones en Ingeniería Genética y Biología Molecular (INGEBI-CONICET). Buenos Aires, Argentina. Topic: Chagas
- ▶ Renaud Piarroux Université Aix-Marseille, INSERM-IRD-AMU UMR 912, Marseille, France. Topic: Leishmaniasis. Characterization
- ▶ Patrick Bastien, Laurence Lachaud. Département de Parasitologie-Mycologie, Centre National de Référence des Leishmanioses, Centre Hospitalier Universitaire de Montpellier, France. Topic: Leishmaniasis. Characterization

- ▶ Francisco Bolás Fernández. Departamento de Parasitología. Universidad Complutense de Madrid (UCM). Topic: Leishmaniasis
- ▶ Marcia Dalastra Laurenti. Universidade de São Paulo (USP). Brasil. Topic: Tegumentary leishmaniasis
- ▶ Mary Cruz Torrico de Solano. Parasitology laboratory –Medicin Faculty. Universidad Mayor de San Simón and Laboratorio de Investigación-Fundación CEADES de Cochabamba, Bolivia. Topic: Leishmaniasis in Bolivia.
- ▶ Dr. Kathryn Harris. Great Ormond Street Hospital (Camelia Botnar Laboratories). Londres, UK. Topic: Epidemiology of Mycobacterium abscessus complex using whole genome sequencing. Interhuman transmission?
- ▶ Aurora Garcia Fernández. Instituto Superiore di Sanità. Department of Infectious Diseases. Rome, Italy. Topic: Epidemiology of enteropathogenic bacteria.
- ▶ Alessandra Carattoli. Instituto Superiore di Sanità. Department of Infectious Diseases. Rome, Italy. Topic: Characterization of plasmids
- ▶ Maite Muniesa. Departament de Genètica, Microbiologia i estadística, Universitat de Barcelona. Topic: Presence of phages in clinical samples
- ▶ Carlos Balsalobre and Cristina Madrid. Departament de Genètica, Microbiologia i estadística, Universitat de Barcelona. Topic: Campylobacteriosis
- ▶ Alex Friedrik and Silvia Garcia-Cobos. University Medical Center (UMCG) Groningen, The Nederlands. Topic: Whole genome sequence in carbapenemase-producing Enterobacteriaceae.

# Microbiology and Infectious Diseases

## Active Grants

- ▶ Pere Coll Figa. Conveni Dpt. Salut - Dr. Coll (IR). Desenvolupar conjuntament funcions de vigilància epidemiològica de les infeccions nosocomials i la poliomielitis (Vigilància de les paràlisis flaccides). Dpt. Salut - Coll. Departament de Salut. Duration: 2011-2017. 104,670.49 €.
- ▶ Pere Coll Figa. Red Española de Investigación en Patología Infecciosa. RD12/0015/0017. Instituto de Salud Carlos III. Duration: 2013-2017. 212,100.41 €.
- ▶ Pere Domingo Pedrol. Red de sida (RIS). RD12/0017/0014. Instituto de Salud Carlos III. Duration: 2013-2017. 121,000.00 €.
- ▶ Paula Andrea Espinal Marin. Contratos Sara Borrell 2015. CD15/00017. Instituto de Salud Carlos III. Duration: 2016-2019. 80,598.00 €.
- ▶ Maria Natividad de Benito Hernández. Optimización de la profilaxis quirúrgica antimicrobiana en los pacientes a los que se implanta una prótesis articular electiva en España. PI15/01026. Instituto de Salud Carlos III. Duration: 2016-2018. 59,000.00 €.
- ▶ Ferran Navarro Risueño. Presencia de bacteriófagos en muestras clínicas estériles e interferencia de los mismos en el diagnóstico microbiológico de las infecciones. PI16/00158. Instituto de Salud Carlos III. Duration: 2017-2019. 66,000.00 €.
- ▶ Pere Coll Figa. Grup de Recerca en Patologia Infecciosa i Microbiologia Clínica. 2014 SGR 333. Agència de Gestió d'Àjuts Universitaris i de Recerca. Duration: 2014-2017.

Note: Total amount granted to PI. It does not include indirect costs.

## Grants Awarded in 2017

- ▶ María Natividad de Benito Hernández, Factors de risc i prevenció de les infeccions del peu diabètic: paper del control glicèmic i el microbioma de l'úlcera. SLT002/16/00089. Departament de Salut. Duration: 2017-2019. 58,714.20 €.
- ▶ Paula Andrea Espinal Marín. Movilidad AES-Instituto Superior de Sanita. Departament of Infectious Diseases, Rome, Italy., MV17/00046. Instituto de Salud Carlos III. Duration: 2018, 11,895.00 €.

Note: Total amount granted to PI. It does not include indirect costs.

## Theses

- ▶ Alba Abras Feliu. Utilidad de diferentes técnicas serológicas y moleculares en el diagnóstico y seguimiento de la enfermedad de Chagas y en la caracterización de *Tripanosoma cruzi*, UAB. Directors: Montse Gállego and Carme Muñoz. Date of defense: 08/03/2017.

## Scientific Production

### \*TIF: 292.394 \*\*MIF: 4.564

Abras A., Gallego M., Munoz C., Juiz N.A., Ramirez J.C., Cura C.I., Tebar S., Fernández-Arevalo A., Pinazo M.-J., de la Torre L., Posada E., Navarro F., Espinal P., Ballart C., Portus M., Gascon J., Schijman A.G., Identification of *Trypanosoma cruzi* Discrete Typing Units (DTUs) in Latin-American migrants in Barcelona (Spain) (2017) PARASITOL INT, 66 (2), 83-88.

**IF: 1.7440**

Abras A., Munoz C., Ballart C., Berenguer P., Llovet T., Herrero M., Tebar S., Pinazo M.-J., Posada E., Martí C., Fumado V., Bosch J., Coll O., Juncosa T., Ginovart G., Armengol J., Gascon J., Portus M., Gallego M., Towards a new strategy for diagnosis of congenital *Trypanosoma cruzi* infection (2017) J CLIN MICROBIOLOGY, 55 (5), 1396-1407.

**IF: 4.054**

Alvarez-Del Arco D., Fakoya I., Thomadakis C., Pantazis N., Touloumi G., Gennotte A.-F., Zuure F., Barros H., Staehelin C., Gopel S., et al. High levels of postmigration HIV acquisition within nine European countries (2017) AIDS, 31 (14), 1979-1988.

**IF: 4.914**

Ariza J., Cobo J., Baraia-Etxaburu J., de Benito N., Bori G., Cabo J., Corona P., Esteban J.,

Horcajada J.P., Lora-Tamayo J., Murillo O., Palomino J., Parra J., Pigrau C., del Pozo J.L., Riera M., Rodriguez D., Sanchez-Somolinos M., Soriano A., del Toro M.D., de la Torre B., Executive summary of management of prosthetic joint infections. Clinical practice guidelines by the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) Resumen ejecutivo de tratamiento de las infecciones de prótesis articulares. Guía clínica práctica de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (2017) ENFERM INFEC MICR CL, 35 (3), 189-195.

**IF: 1.707**

Boix-Palop L., Nicolas C., Xercavins M., Riera M., Prim N., Freixas N., Perez J., Calvo E., *Bacillus* species pseudo-outbreak: construction works and collateral damage (2017) J HOSP INFECT, 95 (1), 118-122.

**IF: 3.354**

Cabrerizo M., Diaz-Cerio M., Munoz-Almagro C., Rabella N., Tarrago D., Romero M.P., Pena M.J., Calvo C., Rey-Cao S., Moreno-Docon A., Martinez-Rienda I., Otero A., Trallero G., Molecular epidemiology of enterovirus and parechovirus infections according to patient age over a 4-year

period in Spain (2017) J MED VIROL, 89 (3), 435-442.

**IF: 1.988**

Cabrerizo M., Garcia-Iniguez J.P., Munell F., Amado A., Madurga-Revilla P., Rodrigo C., Perez S., Martinez- Sapina A., Anton A., Suarez G., Rabella N., del Campo V., Otero A., Masa-Calles J., First Cases of Severe Flaccid Paralysis Associated with Enterovirus D68 Infection in Spain, 2015-2016 (2017) PEDIATR INFECT DIS J.

**IF: 2.305**

Cabrerizo M., Ojeda E., Megias G., Cilla A., Aranzamendi M., Romero M.P., Calvo Rey C., Martin del Valle F., Santos M.J., Munoz Almagro C., Launes C., Casas D., Valero A., Moreno Docon A., Menasalvas A.I., Garcia Costa J., Reis Iglesias L., Perez Ruiz M., Sanbonmatsu S., Salmeron M.J., Santos Perez J.L., Perez C., Poch Paez J., Rabella N., del Cuerpo M., Moliner E., Marin P., Martinez Sapina A., Navascues A., Viguria N., Rey Cao S., Portugues M.M., Gonzalez Duran M.L., Hernandez A., Rivaya B., Menendez M., Cabrerozo M., Otero A., Gonzalez R., Fedele G., Perez Perea N., Saiz M., Importance of enteroviruses in neuro-paediatrics: From polioviruses to other enteroviruses Importancia de los enterovirus

**\*TIF: 292.394 \*\*MIF: 4.564**

en neuropediatría: De los poliovirus a otros enterovirus (2017) REV NEUROLOGIA, 64, S35-S38.

**IF: 0.601**

Clotet S., Matas L., Pomar V., Casademont J., Acute mediastinitis as a rare complication of an infectious mononucleosis Mediastinitis aguda como complicación atípica de una mononucleosis infecciosa (2017) ENFERM INFEC MICR CL.

**IF: 1.707**

De Mendoza C., Cabezas T., Caballero E., Requena S., Amengual M.J., Penaranda M., Saez A., Tellez R., Lozano A.B., Trevino A., et al., HIV type 2 epidemic in Spain: Challenges and missing opportunities (2017) AIDS, 31 (10), 1353-1364.

**IF: 4.914**

De Mendoza C., Caballero E., Aguilera A., Requena S., De Lejarazu R.O., Piron M., Gonzalez R., Jimenez A., Roc L., Trevino A., et al., Human T-lymphotropic virus type 1 infection and disease in Spain (2017) AIDS, 31 (12), 1653-1663.

**IF: 4.914**

Del Barrio-Tofino E., Lopez-Causape C., Cabot G., Rivera A., Benito N., Segura C., Montero M.M., Sorli L., Tubau F., Gomez-Zorrilla S., Tomo N., Dura-Navarro R., Viedma E., Resino-Foz E., Fernandez-Martinez M., Gonzalez-Rico C., Alejo-Cancho I., Martinez J.A., Labayru-Echverria C., Duenas C., Ayestaran I., Zamorano L., Martinez-Martinez L., Horcajada J.P., Oliver A., Genomics and susceptibility profiles of extensively drug-resistant pseudomonas aeruginosa isolates from Spain (2017) ANTIMICROB AGENTS CH, 61 (11).

**IF: 4.255**

Delgado-Valverde M., Valiente-Mendez A., Torres E., Almirante B., Gomez-Zorrilla S., Borrell N., Aller-Garcia A.I., Gurgui M., Almela M., Sanz M., Bou G., Martinez-Martinez L., Canton R., Lepe J.A., Causse M., Gutierrez-Gutierrez B., Pascual A., Rodriguez-Bano J., Cueto M., Planes-Reig A.M., Tubau-Quintano F., Pena C., de Alegria C.R., Morosini M.I., Shan A., Cisneros J.M., Corzo J.E., Prim N., Galan M.E., Garcia-Alvarez L., Gracia-Ahufinger I., Guzman-Puche J., Torre-Cisneros J., MIC of amoxicillin/clavulanate according to CLSI and EUCAST: Discrepancies and clinical impact in patients with bloodstream infections due to Enterobacteriaceae (2017) J ANTIMICROB CHEMOTH, 72 (5), 1478-1487.

**IF: 5.217**

Espinal P., Miro E., Ramoneda L., Flores M., Rivera A., Coll P., Navarro F., Characterization of the Genetic Environment of the blaVEB-4 Gene, Associated with a Transposable Region in a *Proteus mirabilis* Clinical Isolate (2017) MICROB DRUG RESIST, 23 (7), 833-837.

**IF: 2.344**

Esteban-Cantos A., Aracil B., Bautista V., Ortega A., Lara N., Saez D., Fernandez-Romero S., Perez-Vazquez M., Navarro F., Grundmann H., Campos J., Oteo J., Alarcon T., Barba I., Cercenado E., De Miguel M.A., De Miguel D., Fontanals D., Fleites A.M., Sanchez-Romero I., Solis S., Gimeno A., Hernandez J.M., Martinez-Lopez J., Alos J.I., Arias M., Yague G., De Baranda C.S., Cordon L.A., Leiva J., Perez-Moreno M.O., The carbapenemase-producing Klebsiella pneumoniae population is distinct and more clonal than the carbapenem-susceptible population (2017) ANTIMICROB AGENTS CH, 61 (4).

**IF: 4.255**

Fernandez-Cruz A., Munoz P., Sandoval C., Farinas C., Gutierrez-Cuadra M., Pericas Pulido J.M., Miro J.M., Goenaga-Sanchez M.A., De Alarcon A., Bonache-Bernal F., et al., Infective endocarditis in patients with cancer: A consequence of invasive procedures or a harbinger of neoplasm? A prospective, multicenter cohort (2017) MEDICINE, 96 (38).

**IF: 2.028**

Furlano M., Barreiro Y., Marti T., Facundo C., Ruiz-Garcia C., DaSilva I., Ayasreh N., Cabrerizo-Lopez C., Ballarin J., Ars E., Torra R., Renal angiomyolipoma bleeding in a patient with TSC2/PKD1 contiguous gene syndrome after 17 years of renal replacement therapy Sangrado de angiomiolipoma renal en paciente con síndrome de genes contiguos (TSC2/PKD1) tras 17 años de tratamiento renal sustitutivo (2017) NEFROLOGIA, 37 (1), 87-92.

**IF: 1.167**

Furlano M., Barreiro Y., Marti T., Facundo C., Ruiz-Garcia C., DaSilva I., Ayasreh N., Cabrerizo-Lopez C., Ballarin J., Ars E., Torra R., Renal angiomyolipoma bleeding in a patient with TSC2/PKD1 contiguous gene syndrome after 17 years of renal replacement therapy (2017) NEFROLOGIA.

**IF: 1.167**

Gallego-Escuredo J.M., Lamarca M.K., Villarroya J., Domingo J.C., Mateo M.G., Gutierrez M.D.M., Vidal F., Villarroya F., Domingo P., Giralt M., High FGF21 levels are associated with altered bone homeostasis in HIV-1-infected patients (2017) METABOLISM, 71, 163-170.

**IF: 5.963**

Garin N., Zurita B., Velasco C., Feliu A., Gutierrez M., Masip M., Mangues M.A., Prevalence and clinical impact of recreational drug consumption in people living with HIV on treatment: A cross-sectional study (2017) BMJ OPEN, 7 (1).

**IF: 2.413**

Garriga C., Manzanares-Laya S., Garcia De Olalla P., Gorriindo P., Lens S., Sola R., Martinez-Rebollar M., Laguno M., Navarro J., Tor-

ras X., Gurgui M., Barbera M.-J., Quer J., Masdeu E., Simon P., Ros M., De Andres A., Cayla J.A., Evolution of acute hepatitis C virus infection in a large European city: Trends and new patterns (2017) PLOS ONE, 12 (11).

**IF: 2.766**

Gatell J.M., Assoumou L., Moyle G., Waters L., Johnson M., Domingo P., Fox J., Martinez E., Stellbrink H.-J., Guaraldi G., Masia M., Gompels M., De Wit S., Florence E., Esser S., Raffi F., Pozniak A.L., Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk (2017) AIDS, 31 (18), 2503-2514.

**IF: 4.914**

Glenwright H., Pohl S., Navarro F., Miro E., Jimenez G., Blanch A.R., Harwood C.R., The identification of intrinsic chloramphenicol and tetracycline resistance genes in members of the *Bacillus cereus* group (sensu lato) (2017) FRONT MICROBIOL, 7 (JAN).

**IF: 4.019**

Gomez-Ambrosi J., Gallego-Escuredo J.M., Catalan V., Rodriguez A., Domingo P., Moncada R., Valenti V., Salvador J., Giralt M., Villarroya F., Fruhbeck G., FGF19 and FGF21 serum concentrations in human obesity and type 2 diabetes behave differently after diet- or surgically-induced weight loss (2017) CLIN NUTR, 36 (3), 861-868.

**IF: 5.496**

Gudiol C., Royo-Cebrecos C., Tebe C., Abdala E., Akova M., Alvarez R., Maestro-De La Calle G., Cano A., Cervera C., Clemente W.T., Martin-Davila P., Freifeld A., Gomez L., Gottlieb T., Gurgui M., Herrera F., Manzur A., Maschmeyer G., Meije Y., Montejo M., Peghin M., Rodriguez-Bano J., Ruiz-Camps I., Sukiennik T.C., Carratala J., Clinical efficacy of  $\beta$ -lactam/ $\beta$ -lactamase inhibitor combinations for the treatment of bloodstream infection due to extended-spectrum  $\beta$ -lactamaseproducing Enterobacteriaceae in haematological patients with neutropenia: A study protocol for a retrospective observational study (BICAR) (2017) BMJ OPEN, 7 (1).

**IF: 2.413**

Gudiol C., Royo-Cebrecos C., Abdala E., Akova M., Alvarez R., De La Calle G.M., Cano A., Cervera C., Clemente W.T., Martin-Davila P., Freifeld A., Gomez L., Gottlieb T., Gurgui M., Herrera F., Manzur A., Maschmeyer G., Meije Y., Montejo M., Peghin M., Rodriguez-Bano J., Ruiz-Camps I., Sukiennik T.C., Tebe C., Carratala J., Efficacy of  $\beta$ -lactam/ $\beta$ -lactamase inhibitor combinations for the treatment of bloodstream infection due to extended-spectrum- $\beta$ -lactamase-producing enterobacteriaceae in hematological patients

# Microbiology and Infectious Diseases

## Scientific Production

with neutropenia (2017) ANTIMICROB AGENTS CH, 61 (8).

**IF: 4.255**

Guembe M., Perez-Granda M.J., Capdevila J.A., Barberan J., Pinilla B., Martin-Rabadan P., Bouza E., Millan J., Perez de Oteyza C., Muino A., et al., Nationwide study on peripheral-venous-catheter-associated-bloodstream infections in internal medicine departments (2017) J HOSP INFECT, 97 (3), 260-266.

**IF: 3.354**

Guillen-Gomez E., Dasilva I., Silva I., Arce Y., Facundo C., Ars E., Breda A., Ortiz A., Guirado L., Ballarin J.A., Diaz-Encarnacion M.M., Early Macrophage Infiltration and Sustained Inflammation in Kidneys From Deceased Donors Are Associated With Long-Term Renal Function (2017) AM J TRANSPLANT, 17 (3), 733-743.

**IF: 6.493**

Gutierrez-Gutierrez B., Salamanca E., de Cueto M., Hsueh P.-R., Viale P., Pano-Pardo J.R., Venditti M., Tumbarello M., Daikos G., Cantor R., et al., Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study (2017) LANCET INFECT DIS, 17 (7), 726-734.

**IF: 25.148**

Harris P.N.A., Pezzani M.D., Gutierrez-Gutierrez B., Viale P., Hsueh P.-R., Ruiz-Garbazosa P., Venditti M., Tumbarello M., Navarro-Francisco C., Calbo E., et al., Geographical variation in therapy for bloodstream infections due to multidrug-resistant Enterobacteriaceae: a post-hoc analysis of the INCREMENT study (2017) INT J ANTIMICROB AG, 50 (5), 664-672.

**IF: 4.253**

Lachaud L., Fernandez-Arevalo A., Norman A.-C., Lami P., Nabet C., Donnadieu J.L., Piarroux M., Djenad F., Cassagne C., Ravel C., Tebar S., Llovet T., Blanchet D., Demar M., Harrat Z., Aoun K., Bastien P., Munoz C., Gallego M., Piarroux R., Identification of Leishmania by matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry using a free web-based application and a dedicated mass-spectral library (2017) J CLIN MICROBIOL, 55 (10), 2924-2933.

**IF: 4.054**

Lopez M., Mayer C., Fernandez-Garcia L., Blasco L., Muras A., Ruiz F.M., Bou G., Otero A., Tomas M., Rodriguez-Bano J., et al., Quorum sensing network in clinical strains of *A. baumannii*: AidA is a new quorum quenching enzyme (2017) PLOS ONE, 12 (3).

**IF: 2.766**

Lopez-Hernandez I., Alonso N., Fernandez-Martinez M., Zamorano L., Rivera A., Oli-

**\*TIF: 292.394 \*\*MIF: 4.564**

ver A., Conejo M.C., Martinez-Martinez L., Navarro F., Pascual A., Activity of ceftazidime-avibactam against multidrug-resistant Enterobacteriaceae expressing combined mechanisms of resistance Actividad de ceftazidima/avibactam en enterobacterias multirresistentes con mecanismos de resistencia combinados (2017) ENFERM INFEC MICR CL, 35 (8), 499-504.

**IF: 1.707**

Lora-Tamayo J., Senneville E., Ribera A., Bernard L., Dupon M., Zeller V., Li H.K., Arvieux C., Clauss M., Uckay I., et al., The not-so-good prognosis of streptococcal periprosthetic joint infection managed by implant retention: The results of a large multicenter study (2017) CLIN INFECT DIS, 64 (12), 1742-1752.

**IF: 9.117**

Machuca J., Aguero J., Miro E., Conejo M.D.C., Oteo J., Bou G., Gonzalez-Lopez J.J., Oliver A., Navarro F., Pascual A., Martinez-Martinez L., Prevalence of quinolone resistance mechanisms in Enterobacteriaceae producing acquired AmpC β-lactamases and/or carbapenemases in Spain Prevalencia en España de mecanismos de resistencia a quinolonas en enterobacterias productoras de betalactamas de clase C adquiridas y/o carbapenemases (2017) ENFERM INFEC MICR CL, 35 (8), 487-492.

**IF: 1.707**

Martinez-Castillo A., P. Quiros, F. Navarro, E. Miro, M. Muniesa. (2017). Erratum for Martinez-Castillo et al., Shiga Toxin 2-Encoding Bacteriophages in Human Fecal Samples from Healthy Individuals. APPL ENVIRON MICROBIOL. 2017 Aug 1;83(16). pii: e01408-17.

**IF: 3.633**

Martinez-Sanchez N., Seoane-Collazo P., Contreras C., Varela L., Villarroya J., Rial-Pensado E., Buque X., Aurrekoetxea I., Delgado T.C., Vazquez-Martinez R., Gonzalez-Garcia I., Roa J., Whittle A.J., Gomez-Santos B., Velagapudi V., Tung Y.C.L., Morgan D.A., Voshol P.J., Martinez de Morentin P.B., Lopez-Gonzalez T., Linares-Pose L., Gonzalez F., Chatterjee K., Sobrino T., Medina-Gomez G., Davis R.J., Casals N., Oresic M., Coll A.P., Vidal-Puig A., Mittag J., Tena-Sempere M., Malagon M.M., Dieguez C., Martinez-Chantar M.L., Aspichueta P., Rahmouni K., Nogueiras R., Sabio G., Villarroya F., Lopez M., Hypothalamic AMPK-ER Stress-JNK1 Axis Mediates the Central Actions of Thyroid Hormones on Energy Balance (2017) CELL METAB, 26 (1), 212-229.e12.

**IF: 20.565**

Masia M., Padilla S., Moreno S., Barber X., Iribarren J.A., Del Romero J., Gomez-Sirvent J.L., Rivero M., Vidal F., Campins A.A., et al., Prediction of long-term outcomes of HIV-in-

fected patients developing non-AIDS events using a multistate approach (2017) PLOS ONE, 12 (9).

**IF: 2.766**

Meije Y., Martinez-Montauti J., Cayla J.A., Loureiro J., Ortega L., Clemente M., Sanz X., Ricart M., Santoma M.J., Coll P., Sierra M., Calsina M., Vaque M., Ruiz-Camps I., Lopez-Sanchez C., Montes M., Ayestaran A., Carratala J., Orcau A., Healthcare-Associated Mycobacterium bovis -Bacille Calmette-Guérin (BCG) Infection in Cancer Patients Without Prior BCG Instillation (2017) CLIN INFECT DIS, 65 (7), 1136-1143.

**IF: 9.117**

Millan O., Budde K., Sommerer C., Aliart I., Rissling O., Bardaji B., Matz M., Zeier M., Silva I., Guirado L., Brunet M., Urinary miR-155-5p and CXCL10 as prognostic and predictive biomarkers of rejection, graft outcome and treatment response in kidney transplantation (2017) BRIT J CLIN PHARMACO, 83 (12), 2636-2650.

**IF: 3.838**

Navarro F., M. Muniesa. Phages in the Human Body. FRONT MICROBIOL 2017; 8: 566.

**IF: 4.019**

Negredo E., Estrada V., Domingo P., Gutierrez M.D., Mateo G.M., Puig J., Bonjoch A., Ornelas A., Echeverria P., Estany C., Toro J., Clotet B., Switching from a ritonavir-boosted PI to dolutegravir as an alternative strategy in virologically suppressed HIV-infected individuals (2017) J ANTIMICROB CHEMOTH, 72 (3), 844-849.

**IF: 5.217**

Palacios-Baena Z.R., Gutierrez-Gutierrez B., De Cueto M., Viale P., Venditti M., Hernandez-Torres A., Oliver A., Martinez-Martinez L., Calbo E., Pintado V., Gasch O., Almirante B., Antonio Lepe J., Pitout J., Akova M., Pena-Miralles C., Schwaber M.J., Tumbarello M., Tacconelli E., Origuen J., Prim N., Bou G., Gimarellou H., Bermejo J., Hamprecht A., Perez F., Almela M., Lowman W., Hsueh P.-R., Navarro-San Francisco C., Torre-Cisneros J., Carmeli Y., Bonomo R.A., Paterson D.L., Pascual A., Rodriguez-Bano J., Development and validation of the INCREMENT-ESBL predictive score for mortality in patients with bloodstream infections due to extended-spectrum-β-lactamase-producing Enterobacteriaceae (2017) J ANTIMICROB CHEMOTH, 72 (3), 906-913.

**IF: 5.217**

Palacios-Baena Z.R., Gutierrez-Gutierrez B., Calbo E., Almirante B., Viale P., Oliver A., Pintado V., Gasch O., Martinez-Martinez L., Pitout J., et al., Empiric Therapy with Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: Re-

**\*TIF: 292.394 \*\*MIF: 4.564**

sults from the INCREMENT Cohort (2017) CLIN INFECT DIS, 65 (10), 1615-1623.

**IF: 9.117**

Perez-Molina J.A., Rubio R., Rivero A., Pasquau J., Suarez-Lozano I., Riera M., Estebanez M., Palacios R., Sanz-Moreno J., Troya J., et al., Simplification to dual therapy (atazanavir/ritonavir/lamivudine) versus standard triple therapy [atazanavir/ritonavir/two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study) (2017) J ANTIMICROB CHEMOTH, 72 (1), 246-253.

**IF: 5.217**

Pomar V., Benito N., Lopez-Contreras J., Coll P., Gurgui M., Domingo P., Characteristics and outcome of spontaneous bacterial meningitis in patients with cancer compared to patients without cancer (2017) MEDICINE, 96 (19).

**IF: 2.028**

Prim N., A. Rivera, P. Coll, B. Mirelis. Intrinsic resistance versus intrinsic resistome: are we talking about the same concept? Reply to 'Resistance to polymyxins in Gram-negative organisms'. (2017). INT J ANTIMICROB AGENTS, 50(2):281.

**IF: 4.253**

Prim N., Turbau M., Rivera A., Rodriguez-Navarro J., Coll P., Mirelis B., Prevalence of colistin resistance in clinical isolates of Enterobacteriaceae: A four-year cross-sectional study (2017) J INFECTION, 75 (6), 493-498.

**IF: 4.603**

Pulido F., Ribera E., Lagarde M., Perez-Valero I., Palacios R., Iribarren J.A., Payeras A., Domingo P., Sanz J., Cervero M., Curran A., Rodriguez-Gomez F.J., Tellez M.J., Ryan P., Barrufet P., Knobel H., Rivero A., Alejos B., Yllescas M., Arribas J.R., Dual Therapy with Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy with Darunavir and Ritonavir Plus Tenovofir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Non-inferiority DUAL-GESIDA 8014-RIS-EST45 Trial (2017) CLIN INFECT DIS, 65 (12), 2112-2118.

**IF: 9.117**

Ramos-Martinez A., Vicente-Lopez N., Sanchez-Romero I., Padilla B., Merino-Amador P., Garnacho-Montero J., Ruiz-Camps I., Montejano M., Salavert M., Mensa J., et al., Epidemiology and prognosis of candidaemia in elderly patients (2017) MYCOSES, 60 (12), 808-817.

**IF: 2.793**

Requena S., Trevino A., Cabezas T., Garcia-Delgado R., Amengual M.J., Lozano A.B., Penaranda M., Fernandez J.M., Soriano V., de Mendoza C., et al., Drug resistance mutations in HIV-2 patients failing raltegravir and

influence on dolutegravir response (2017) J ANTIMICROB CHEMOTH, 72 (7), 2083-2088.

**IF: 5.217**

Risslegger B., Zoran T., Lackner M., Aigner M., Sanchez-Reus F., Rezusta A., Chowdhary A., Taj-Aldeen S.J., Arendrup M.C., Oliveri S., et al., A prospective international Aspergillus terreus survey: an EFISG, ISHAM and ECMM joint study (2017) CLIN MICROBIOL INFEC, 23 (10), 776.e1-776.e5.

**IF: 5.394**

Rodriguez Faba O., Palou J., Vila Reyes H., Guirado L., Palazzetti A., Gontero P., Vigués F., Garcia-Olaverri J., Fernandez Gomez J.M., Olsburg J., Terrone C., Figueiredo A., Burgos J., Lledo E., Breda A., Treatment options and predictive factors for recurrence and cancer-specific mortality in bladder cancer after renal transplantation: A multi-institutional analysis Opciones terapéuticas y factores predictivos de recurrencia y mortalidad cáncer-específica en pacientes con tumor vesical después de trasplante renal: análisis multiinstitucional (2017) ACTAS UROL ESP, 41 (10), 639-645.

**IF: 1.260**

Rueda C., Puig-Asensio M., Guinea J., Almirante B., Cuenca-Estrella M., Zaragoza O., Padilla B., Munoz P., Guinea J., Pano Pardo J.R., et al., Evaluation of the possible influence of trailing and paradoxical effects on the clinical outcome of patients with candidemia (2017) CLIN MICROBIOL INFEC, 23 (1), 49.e1-49.e8.

**IF: 5.394**

Rueda F., Eich C., Cordobilla B., Domingo P., Acosta G., Albericio F., Cruz L.J., Domingo J.C., Effect of TLR ligands co-encapsulated with multiepitopic antigen in nanoliposomes targeted to human DCs via Fc receptor for cancer vaccines (2017) IMMUNOBIOLOGY, 222 (11), 989-997.

**IF: 2.873**

Sanchez E., Nieto J.C., Vidal S., Santiago A., Martinez X., Sancho F.J., Sancho-Bru P., Mirelis B., Corominola H., Juarez C., Manichanh C., Guarner C., Soriano G., Fermented milk containing Lactobacillus paracasei subsp. paracasei CNCM I-1518 reduces bacterial translocation in rats treated with carbon tetrachloride (2017) SCI REP-UK, 7.

**IF: 4.122**

San-Juan R., Fernandez-Ruiz M., Gasch O., Camoëz M., Lopez-Medrano F., Dominguez M.A., Almirante B., Padilla B., Pujol M., Aguado J.M., et al., High vancomycin MICs predict the development of infective endocarditis in patients with catheter-related bacteraemia due to methicillin-resistant Staphylococcus aureus (2017) J ANTIMICROB CHEMOTH, 72 (7), 2102-2109.

**IF: 5.217**

Saumoy M., Llibre J.M., Terron A., Knobel H., Arribas J.R., Domingo P., Arroyo-Manzano D., Rivero A., Moreno S., Podzamczer D., Short Communication: Maraviroc Once-Daily: Experience in Routine Clinical Practice (2017) AIDS RES HUM RETROV, 33 (1), 29-32.

**IF: 1.935**

Saumoy M., Tiraboschi J.M., Ordonez-Llanos J., Ribera E., Domingo P., Mallolas J., Curto J., Gatell J.M., Podzamczer D., Atherogenic properties of LDL particles after switching from Truvada or Kivexa plus lopinavir/r to lamivudine plus lopinavir/r: OLE-MET sub-study (2017) HIV CLIN TRIALS, 18 (2), 49-53.

**IF: 1.379**

Sorli L., Luque S., Segura C., Campillo N., Montero M., Esteve E., Herrera S., Benito N., Alvarez-Lerma F., Grau S., Horcajada J.P., Impact of colistin plasma levels on the clinical outcome of patients with infections caused by extremely drug-resistant Pseudomonas aeruginosa (2017) BMC INFECT DIS, 17 (1).

**IF: 2.620**

Teira R., Vidal F., Munoz-Sánchez P., Geijo P., Viciana P., Ribera E., Domingo P., Castaño M., Martínez E., Roca B., Puig T., Estrada V., Deig E., Galindo M., de la Fuente B., Lozano F., Montero M., Muñoz-Sanz A., Sanchez T., Terron A., Romero-Palacios A., Lacalle J., Garrido M., Suarez-Lozano I., Very low level viraemia and risk of virological failure in treated HIV-1-infected patients (2017) HIV MED, 18 (3), 196-203.

**IF: 2.932**

Temkin E., Torre-Cisneros J., Beovic B., Benito N., Giannella M., Gilarranz R., Jeremiah C., Loches B., MacHuca I., Jimenez-Martin M.J., Martinez J.A., Mora-Rillo M., Navas E., Osthoff M., Pozo J.C., Ramos J.C.R., Rodriguez M., Sanchez-Garcia M., Viale P., Wolff M., Carmeli Y., Ceftazidime-avibactam as salvage therapy for infections caused by carbapenem-resistant organisms (2017) ANTIMICROB AGENTS CH, 61 (2).

**IF: 4.255**

Villarroya F., Gavalda-Navarro A., Peyrou M., Villarroya J., Giralt M., The Lives and Times of Brown Adipokines (2017) TRENDS ENDOCRIN MET, 28 (12), 855-867.

**IF: 10.769**

Wouthuyzen-Bakker M., Benito N., Soriano A., The effect of preoperative antimicrobial prophylaxis on intraoperative culture results in patients with a suspected or confirmed prosthetic joint infection: A systematic review (2017) J CLIN MICROBIOL, 55 (9), 2765-2774.

**IF: 4.054**

# Multi-organ Damage



## Coordinator

Casademont Pou, Jordi FGS  
jcasademont@santpau.cat

## Members

Arroyo Díaz, Juan Antonio	FGS
Ballart Roig, Judith	IR
Barceló Trias, Montserrat	FGS
Benet Gusta, María Teresa	IR
Castella Rovira, Marta	IR
Castellví Barranco, Iván	FGS
Díaz Torné, César	FGS
Filella Agullo, David	FGS
Francia Santamaría, Esther	FGS
Hernández de Sosa, Nerea	FGS
Herrera Bachs, Silvia	IR
Jurado González, Susana	IR
Laiz Alonso, Ana María	FGS
Magallares López, Berta Paula	IR
Malouf Sierra, Jorge	IR
Mascaró Lamarca, Jordi	FGS
Matas Pericas, Laia	FGS
Millan Arciniegas, Ana Milena	IR
Moya Alvarado, Patricia	IR
Ponte Márquez, Paola Helena	IR
Ruiz Hidalgo, Domingo	FGS
Torres Bonafonte, Olga Herminia	FGS

## Main Lines of Research

### Bone Metabolism and Osteoporosis

- ▶ Analysis of genetic influence on osteoporosis by means of aggregation studies in families of three or more generations with a minimum of 15 members.
- ▶ Bone structure study with quantitative CT of hip and spine, analysing the contribution of trabecular and cortical components using HRCT.
- ▶ Description of fat values and percentages in a normal population (in collaboration with the HIV Unit and CETIR Medical Group).
- ▶ Analysis of the influence of an intervention (physical exercise) on changes in the muscle compartment of patients with cirrhosis measured by DXA and HRQCT (in collaboration with the Gastroenterology Department).
- ▶ Description of bone structure in patients with a history of acromegaly assessed by DXA and HRQCT.

### Hypertension and Vascular Risk

- ▶ Hypertension and quality of life.
- ▶ Refractory hypertension.
- ▶ Use of alirocumab in hypercholesterolemia.

### Clinical Management, Internal Medicine and Geriatrics

- ▶ Health care quality indexes (mortality, readmissions, etc).
- ▶ Perioperative medicine.
- ▶ Potentially inappropriate prescribing to older patients admitted to hospital.
- ▶ Central Sensitization Syndromes.

### Rheumatology and Rheumatoid Arthritis

- ▶ Immunomodulation due to anti-CD20 (rituximab) treatment and study of polymorphisms.

## Challenges

- ▶ To establish stable work relations between the HSCSP Bone Metabolism and Genomics of Complex Diseases Groups and the Bone Metabolism Unit of Hospital del Mar Medical Research Institute and the Faculty of Biology of the University of Barcelona.

- ▶ Pharmacokinetics of methotrexate.
- ▶ Evaluation of baricitinib in patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to methotrexate or antiTNF therapy.
- ▶ Evaluation of tofacitinib in patients with moderately to severely active rheumatoid arthritis with inadequate response to biologic DMARD.
- ▶ Evaluation of the JAK-STAT pathway in patients with rheumatoid arthritis treated with tocilizumab.

### Systemic Sclerosis

- ▶ Capillaroscopy patterns and correlation with auto-antibodies and pulmonary function tests.
- ▶ Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study.
- ▶ Use of endothelin receptor antagonism to prevent pulmonary arterial hypertension (in collaboration with Vall d'Hebron University Hospital, Barcelona, Spain).
- ▶ Genetic studies in systemic sclerosis and collaboration with DUO Registry and LAUDES study.
- ▶ Study of capillaroscopy patterns in diffuse connective tissue diseases: QuanticAP study.

### Gout

- ▶ Epidemiology of hyperuricaemia and gout.

### Sjögren Syndrome

- ▶ Clinical and epidemiological findings in Spanish patients with primary Sjögren syndrome (in collaboration with Spanish Society of Rheumatology).

**Collaborations****Collaborations with other IIB Sant Pau Groups**

- ▶ Digestive Diseases (Dr Germán Soriano). Study by densitometry and ergospirometry of the effects of an exercise programme in overweight patients with liver cirrhosis.
- ▶ Orthopaedic Surgery and Traumatology Service (Dr José Carlos González Rodríguez). Randomized, double-blind, placebo-controlled clinical trial of parallel groups assessing the efficacy of subcutaneous denosumab for periprosthetic resorption decrease in patients with total knee prosthesis, IIB-SP-DEN-2012-24, Eudra No: 2012-001285-15.
- ▶ Cardiovascular Risk Group (Dr Laiz Matas). Longitudinal epidemiological study for the assessment of arterial stiffness in patients with renal insufficiency and treatment with vitamin D3 and vitamin D analogues, IIBSP- VIT-2013-138.

**External Collaborations**

- ▶ Dr Luis del Rio. Standardized measures of different tissues using dual-energy X-ray absorptiometry, CETIR Medical Group, Barcelona, Spain.
- ▶ Internal Medicine Pneumonia Study (ENEMI), coordinated by the Hospital General Universitario Gregorio Marañón, Madrid, Spain.

**Active Grants**

- ▶ Jordi Casademont Pou. Estudio GAO: de los fenotipos intermedios al análisis global del genoma. PI14/01036. Instituto de Salud Carlos III. Duration: 2015-2018. 76,000.00 €.

Note: Total amount granted to PI. It does not include indirect costs.

**Theses**

- ▶ Ainhoa Simon Estrada. Adult Attachment Styles in American and Spanish Patients with Fibromyalgia and Rheumatoid Arthritis: a Cross-Sectional Study. Universitat Autònoma de Barcelona. Director: Jordi Casademont. Date of defense: 20/09/2017.
- ▶ Matas Pericas, Laia. Risc cardiovascular en pacients que consulten a urgències d'un hospital general amb un accident vascular agut. Universitat Autònoma de Barcelona. Directors: Juan Antonio Arroyo Díaz, Alex Roca-Cusachs Coll. Date of defense: 26/06/2017.

# Multi-organ Damage

**\*TIF: 189.688 \*\*MIF: 8.247**

Bone H.G., Wagman R.B., Brandi M.L., Brown J.P., Chapurlat R., Cummings S.R., Czerwinski E., Fahrleitner-Pammer A., Kendler D.L., Lip-puner K., Reginster J.-Y., Roux C., Malouf J., Bradley M.N., Daizadeh N.S., Wang A., Dakin P., Pannacciulli N., Dempster D.W., Papapoulos S., 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension (2017) *LANCET DIABETES ENDO*, 5 (7), 513-523.

**IF: 19.313**

Bossini-Castillo L., Campillo-Davo D., Lopez-Isac E., Carmona F.D., Simeon C.P., Carreira P., Callejas-Rubio J.L., Castellvi I., Fernandez-Nebro A., Rodriguez-Rodriguez L., Rubio-Rivas M., Garcia-Hernandez F.J., Madronero A.B., Beretta L., Santaniello A., Lunardi C., Airo P., Hoffmann-Vold A.-M., Kreuter A., Riemarken G., Witte T., Hunzelmann N., Vonk M.C., Voskuyl A.E., De Vries-Bouwstra J., Shiels P., Herrick A., Worthington J., Radstake T.R.D.J., Martin J., An MIF promoter polymorphism is associated with susceptibility to pulmonary arterial hypertension in diffuse cutaneous systemic sclerosis (2017) *J RHEUMATOL*, 44 (10), 1453-1457.

**IF: 3.470**

Casademont J., Healthcare systems and alcohol consumption - can they coexist? Sistema sanitario y consumo de alcohol. ¿Es posible la convivencia? (2017) *REV CLIN ESP*, 217 (7), 394-395.

**IF: 1.184**

Casademont J., RECALMIN II: Information for improving the country's Internal Medicine Services RECALMIN II: información para la mejora de los Servicios de Medicina Interna del país (2017) *REV CLIN ESP*, 217 (8), 462-463.

**IF: 1.184**

Cebolla A., Campos D., Galiana L., Oliver A., Tomas J.M., Feliu-Soler A., Soler J., Garcia-Campayo J., Demarzo M., Banos R.M., Exploring relations among mindfulness facets and various meditation practices: Do they work in different ways? (2017) *CONSCIOUS COGN*, 49, 172-180.

**IF: 2.272**

Clotet S., Matas L., Pomar V., Casademont J., Acute mediastinitis as a rare complication of an infectious mononucleosis Mediastinitis aguda como complicación atípica de una mononucleosis infecciosa (2017) *ENFERM INFEC MICR CL*.

**IF: 1.707**

De-Ugarte L., Caro-Molina E., Rodriguez-Sanz M., Garcia-Perez M.A., Olmos J.M., Sosa-Henriquez M., Perez-Cano R., Gomez-Alonso C., Del Rio L., Mateo-Agudo J., Blazquez-Cabre-

ra J.A., Gonzalez-Macias J., Pino-Montes J.D., Munoz-Torres M., Diaz-Curiel M., Malouf J., Cano A., Perez-Castrillon J.L., Nogues X., Garcia-Giralt N., Dlez-Perez A., SNPs in bone-related miRNAs are associated with the osteoporotic phenotype (2017) *SCI REP-UK*, 7 (1).

**IF: 4.122**

Feliu-Soler A., Pascual J.C., Elices M., Martin-Blanco A., Carmona C., Cebolla A., Simon V., Soler J., Fostering Self-Compassion and Loving-Kindness in Patients With Borderline Personality Disorder: A Randomized Pilot Study (2017) *CLIN PSYCHOL PSYCHOT*, 24 (1), 278-286.

**IF: 2.508**

Guembe M., Perez-Granda M.J., Capdevila J.A., Barberan J., Pinilla B., Martin-Rabadan P., Bouza E., Millan J., Perez de Oteyza C., Muino A., Villalba M., Cuenca C., Castano J.G., Delgado C.M., Zamorano S., Gomez B., Collado J.M., Salinas M.T., Amat A.S., Lazaro J.R., del Villar Sordo V., del Valle Sanchez M., Benach A.F., Vidal E., Albiach L., Agud Aparicio J.M., Saez de Adana Arromiz E., Casademont i Pou J., Solchaga V.P., Castellon F.E., Obanos T.R., Egurbide Arberas M.V., Arana J.N., Lopez E.G., Gaviria A.Z., Clemente I.N., Ruiz P.C., Salomo A.C., Iftimie S.M., Castillo A.M., Barbera Farre J.R., Laveria A.O., Ribera M.C., Pallares N.B., Suarez P.C., Cepeda Piorno F.J., Andres N.A., Rodriguez Tarazona R.E., Rodriguez Zapata M.M., Costa Cerdá M.A., Nationwide study on peripheral-venous-catheter-associated-bloodstream infections in internal medicine departments (2017) *J HOSP INFECT*, 97 (3), 260-266.

**IF: 3.354**

Humbert L., Martelli Y., Fonolla R., Steghofer M., Di Gregorio S., Malouf J., Romera J., Barquer L.M.D.R., 3D-DXA: Assessing the Femoral Shape, the Trabecular Macrostructure and the Cortex in 3D from DXA images (2017) *IEEE T MED IMAGING*, 36 (1), 27-39.

**IF: 6.131**

Kendler D.L., Marin F., Zerbini C.A.F., Russo L.A., Greenspan S.L., Zikan V., Bagur A., Malouf-Sierra J., Lakatos P., Fahrleitner-Pammer A., Lespessailles E., Minisola S., Body J.J., Geusens P., Moricke R., Lopez-Romero P., Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): A multicentre, double-blind, double-dummy, randomised controlled trial (2017) *LANCET*.

**IF: 53.254**

Laiz A., Malouf J., Marin A., Longobardi V., de Caso J., Farrerons J., Casademont J., Impact of 3-monthly vitamin D supplementation plus exercise on survival after surgery for osteoporotic hip fracture in adult patients over 50 years: A pragmatic randomized,

partially blinded, controlled trial (2017) *J NUTR HEALTH AGING*, 21 (4), 413-420.

**IF: 2.868**

Langdahl B.L., Libanati C., Crittenden D.B., Bolognesi M.A., Brown J.P., Daizadeh N.S., Dokoupilova E., Engelke K., Finkelstein J.S., Genant H.K., Goemaere S., Hyldstrup L., Jordar-Gimeno E., Keaveny T.M., Kendler D., Lakatos P., Maddox J., Malouf J., Massari F.E., Molina J.F., Ulla M.R., Grauer A., Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial (2017) *LANCET*, 390 (10102), 1585-1594.

**IF: 53.254**

Lopez-Ferrer A., Laiz A., Puig L., The safety of ustekinumab for the treatment of psoriatic arthritis (2017) *EXPERT OPIN DRUG SAF*, 16 (6), 733-742.

**IF: 3.156**

Malouf-Sierra J., Tarantino U., Garcia-Hernandez P.A., Corradini C., Overgaard S., Stepan J.J., Borris L., Lespessailles E., Frihagen F., Papavasiliou K., Petto H., Aspenberg P., Caeiro J.R., Marin F., Effect of Teriparatide or Risedronate in Elderly Patients With a Recent Pectrochanteric Hip Fracture: Final Results of a 78-Week Randomized Clinical Trial (2017) *J BONE MINER RES*, 32 (5), 1040-1051.

**IF: 6.314**

Marquez P.H.P., Torres O.H., San-Jose A., Vidal X., Agusti A., Formiga F., Lopez-Soto A., Ramirez-Duque N., Fernandez-Moyano A., Garcia-Moreno J., Arroyo J.A., Ruiz D., San-Jose A., Agusti A., Vidal X., Aguilera C., Ballarin E., Perez E., Barbe J., Bocanegra C.P., Toscano A., Pal C., Teixidor T., Fernandez-Moyano A., Hernandez M.G., de la Rosa Morales R., Martinez M.N.B., Lopez-Soto A., Bosch X., Palau M.J., Rovira J., Navarro M., Formiga F., Chivite D., Roson B., Vallano A., Cabot C., Garcia J., Ballesteros I., Torres O.H., Ruiz D., Turbau M., Ponte P., Ortiz G., Ramirez-Duque N., Cobas P.-C.R., Gil P., Potentially Inappropriate Antihypertensive Prescriptions to Elderly Patients: Results of a Prospective, Observational Study (2017) *DRUG AGING*, 34 (6), 453-466.

**IF: 2.381**

Masanés F., Rojano I., Luque X., Salva A., Serra-Rexach J.A., Artaza I., Formiga F., Cuesta F., Lopez Soto A., Ruiz D., Cruz-Jentoft A.J., Cut-off points for muscle mass — not grip strength or gait speed — determine variations in sarcopenia prevalence (2017) *J NUTR HEALTH AGING*, 21 (7), 825-829.

**IF: 2.868**

**Scientific Production****Other Publications****\*TIF: 189.688 \*\*MIF: 8.247**

Nolla J.M., Martin E., Llamas P., Manero J., de la Serna A.R., Fernandez-Miera M.F., Rodriguez M., Lopez J.M., Ivanova A., Aragon B., An estimate of the cost of administering intravenous biological agents in Spanish day hospitals (2017) THER CLIN RISK MANAG, 13, 325-334.

**IF: 1.995**

Rivas-Cobas P.C., Ramirez-Duque N., Gomez Hernandez M., Garcia J., Agusti A., Vidal X., Formiga F., Lopez-Soto A., Torres O.H., San-Jose A., Characteristics of potentially inappropriate prescribing of drugs in elderly polypathological patients Características del uso inadecuado de medicamentos en pacientes pluripatológicos de edad avanzada (2017) GAC SANIT, 31 (4), 327-331.

**IF: 1.581**

Rua-Figueroa I., Lopez-Longo J., Galindo-Izquierdo M., Calvo-Alen J., Del Campo V., Olive-Marques A., Perez-Vicente S., Fernandez-Nebro A., Andres M., Erazquin C., Tomero E., Horcada L., Uriarte E., Freire M., Montilla C., Sanchez-Atrio A., Santos G., Bo-

teanu A., Diez-Alvarez E., Narvaez J., Martinez-Taboada V., Silva-Fernandez L., Ruiz-Lucea E., Andreu J.L., Hernandez-Beriain J.A., Gantes M., Hernandez-Cruz B., Perez-Veengas J., Peondon-Espanol A., Marras C., Ibanez-Barcelo M., Bonilla G., Torrente V., Castellvi I., Alegre J.J., Calvet J., Marenco J.L., Raya E., Vazquez T., Quevedo V., Munoz-Fernandez S., Rodriguez-Gomez M., Ibanez J., Pego-Reigosa J.M., Incidence, associated factors and clinical impact of severe infections in a large, multicentric cohort of patients with systemic lupus erythematosus (2017) SEMIN ARTHRITIS RHEU, 47 (1), 38-45.

**IF: 4.356**

Suarez-Calvet X., Gallardo E., Pinal-Fernandez I., De Luna N., Lleixa C., Diaz-Manera J., Rojas-Garcia R., Castellvi I., Martinez M.A., Grau J.M., Selva-O'Callaghan A., Illa I., RIG-I expression in perifascicular myofibers is a reliable biomarker of dermatomyositis (2017) ARTHRITIS RES THER, 19 (1).

**IF: 4.269**

Torres Bonafonte O.H., Gil Olivas E., Perez Macho E., Pacho Pacho C., Mateo Roca M., Casademont Pou J., Ruiz Hidalgo D., Predictors of drug-resistant pathogens in community-onset pneumonia: Are factors considered in health-care-associated pneumonia useful in the emergency department? Predictores de patógenos resistentes en las neumonías procedentes de la comunidad: ¿Es útil en urgencias el concepto de neumonía asociada a cuidados sanitarios? (2017) EMERGENCIAS, 29 (5), 306-312.

**IF: 3.608**

Zamora C., Canto E., Nieto J.C., Bardina J., Diaz-Torne C., Moya P., Magallares B., Ortiz M.A., Julia G., Juarez C., Llobet J.M., Vidal S., Binding of platelets to lymphocytes: A potential anti-inflammatory therapy in rheumatoid arthritis (2017) J IMMUNOL, 198 (8), 3099-3108.

**IF: 4.539**

- Casademont J. Resolución voluntaria de mini-casos de fisiopatología y semiología clínica: una nueva experiencia docente. Educ Med. 2017; 18(2): 121-24.

# Chronic Respiratory Diseases


**Coordinator**

Plaza Moral, Vicente  
vplaza@santpau.cat

FGS

**Members**

Alonso León, Ana María	FGS
Anton Albisu,	
Pedro Antonio	FGS
Bigorra Rodríguez, Teresa	IR
Brienza, Sonia Nadia	IR
Burrel Deicke, Cristina	FGS
Castillo Villegas, Diego	FGS
Cisneros Anto, Josep Lluís	FGS
Crespo Lessmann,	
Astrid del Carmen	FGS
Curto Sánchez, Elena	IR
Feliu Ropero, Anna	IR
Fortuna Gutiérrez,	
Ana María	FGS
García Moral, Alba	FGS
Giménez Badía, Sandra	FGS
Giménez Palleiro, Ana María	FGS
Giner Donaire, Jordi	FGS
Güell Rous, Maria Rosa	FGS
Lapuente Torrents, Ana María	IR
Mateus Medina, Eder Fredy	IR
Mayos Pérez, Mercedes	FGS
Miralda Galán, Rosa María	FGS
Morante Vélez, Fátima	FGS
Osuna Gómez, Rubén	IR
Pajares Ruiz, Virginia	FGS
Paz del Río, Luis Daniel	FGS
Peiró Fàbregas, Meritxell	FGS
Peñacoba Toribio, Patricia	IR
Perea Soriano, Lidia	IR
Puy Rion, Maria Carme	FGS
Ramos Barbón, David	FGS
Rodrigo Troyano, Ana María	IR
Segura Medina, Macarena	FGS
Sibila Vidal, Oriol	FGS
Solanes Garcia, Íngrid	FGS
Soto Retes,	
Lorena Concepción	FGS
Torregó Fernández, Alfonso	FGS
Torrejón Lazaro, Montserrat	FGS
Ujaldón Miró, Cristina	IR

**Main Lines of Research**
**Asthma**

- ▶ Asthma exacerbations.
- ▶ Severe asthma.
- ▶ Good clinical practice guidelines for asthma.
- ▶ Bronchial inflammation.
- ▶ Experimental asthma and pathogenic mechanisms.
- ▶ Multicentre biobank specializing in bronchial biopsies for research into asthma.
- ▶ Bronchial thermoplasty.
- ▶ Clinical trials.

**COPD and Respiratory Failure**

- ▶ Non-invasive mechanical ventilation.
- ▶ Respiratory rehabilitation.
- ▶ Pathophysiology.
- ▶ Exacerbation.

**Obstructive Sleep Apnoea (OSA)**

- ▶ Physiology and clinical, diagnostic and treatment consequences of sleep disorders.
- ▶ Obesity-hypoventilation syndrome.
- ▶ Analysis of airway inflammation in patients with OSA.

**Challenges**

- ▶ Consolidate a leading clinical trial unit in respiratory diseases.
- ▶ Capture pre-clinical development contracts from the pharmaceutical and biotech industry, using the capabilities of our basic research lab and experimental animal models.
- ▶ Recruit research trainees seeking a doctoral degree.

- ▶ Support the development of multidisciplinary research networks such as the Barcelona Respiratory Network and the Programme for Integrated Research for Asthma of the Spanish Society of Pneumology and Thoracic Surgery (SEPAR), and collaborate with or become involved in existing networks such as CIBER-Respiratory Disorders.

**Collaborations**
**Collaborations with other IIB Sant Pau Groups**

- ▶ Ear, Nose and Throat Cancers (collaboration of Dr. V. Plaza in the EPONA study).
- ▶ Genetics and Vascular Surgery Departments (collaboration of Dr. V. Plaza in the TAGA study).

**External Collaborations**

- ▶ Dr. V. Plaza. Emergent Asthma Group, SEPAR.
- ▶ Dr. V. Plaza. INASMA Group.
- ▶ Drs. V. Plaza and D. Ramos Barbón. Integrated Research Programme (PII) for Asthma, SEPAR.
- ▶ Drs. V. Plaza and D. Ramos Barbón. Group associated with CIBER-Respiratory.
- ▶ Drs. V. Plaza and D. Ramos Barbón. Severe Heterogenous Asthma Research collaboration, Patient-centered (SHARP) of the European Respiratory Society
- ▶ Dr. D. Castillo Villegas. National Institute for Rare Diseases, Instituto de Salud Carlos III, Madrid, Spain.

- ▶ Dr. D. Castillo Villegas. International Working Group on Langerhans Cell Histiocytosis and EUROHISTIONET.
- ▶ Dr. D. Ramos Barbón (PI). Multicentre Biobank of Bronchial Biopsies for Asthma Research, with collaborators as follows:
  - Dr. Carlos Martínez Rivera from Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
  - Dr. Antolín López Viña from Hospital Universitario Puerta de Hierro, Madrid, Spain.
  - Dr. Francisco Javier González Barcala from Complejo Hospitalario de Pontevedra, Spain.
  - Dr. Teresa Bazús González from Hospital Universitario Central de Asturias, Oviedo, Spain.
  - Dr. Luis Pérez de Llano from Hospital Lucus Augusti, Lugo, Spain.
  - Dr. Patrick Berger from Université Bordeaux 2, Bordeaux, France.
  - Dr. James G Martin from McGill University, Montreal, Canada.

## Active Grants

- ▶ Mercedes Mayos Pérez. Proyecto PASHOS:Plataforma Avanzada para el estudio del Síndrome de Apnea Hipopnea del Sueño (SAHS): Estudio de validación de un modelo de criba del SAHS en Atención Primaria. PI14/01985. Instituto de Salud Carlos III. Duration: 2015-2018. 19,400.00 €.
- ▶ David Ramos Barbón. Mecanismos patogénicos versus terapéuticos de las células madre mesenquimales sobre la remodelación bronquial en asma: prueba de concepto para subsiguiente desarrollo farmacéutico. PI14/00257. Instituto de Salud Carlos III. Duration: 2015-2019. 121,500.00 €.
- ▶ Oriol Sibila Vidal. El microbioma respiratorio en la EPOC; relación con la respuesta inmune pulmonar y sistémica. PI15/02042. Instituto de Salud Carlos III. Duration: 2016-2018. 72,000.00 €.
- ▶ Alfonso Torrego Fernández. Estudi dels mecanismes fisiopatològics i resultats de l'aplicació de termoplàstia bronquial en asma greu. BECA VIFOR - FUCAP 2015. Fundació Catalana de Pneumologia. Duration: 2015-2018. 10,363.65 €.
- ▶ Oriol Sibila Vidal. Respiratory Microbiome and COPD exacerbations. . RAMON PLA ARMENGOL 2015. Fundació Ramón Pla Armengol. Duration: 2015-2018. 63,636.36 €.
- ▶ David Ramos Barbón. Desarrollo clínico y validación de biomarcadores de un nuevo tratamiento oral para el asma a través de un ensayo de fase II. RTC-2016-4698-1. Ministeri d'Economia i Competitivitat. Duration: 2016-2018. 178,150.00 €.
- ▶ Astrid del Carmen Crespo Lessmann. Validación de la medición de la IgE total e IgE específica en el esputo inducido de pacientes con asma alérgica y no alérgica. BECA LETI 2016. Fundació Catalana de Pneumologia. Duration: 2016-2018. 10,909.08 €.
- ▶ Diego Castillo Villegas. Caracterización genética y funcional de la histiocitosis pulmonar de células de langerhans: Implicaciones diagnósticas y terapéuticas. EPID-FUTURO 2013. Societat Espanyola de Pneumologia i Cirugia Toràcica. Duration: 2013-2017. 5,291.00 €.
- ▶ Oriol Sibila Vidal. Infección bronquial en pacientes con EPOC y agudizaciones frecuentes; papel de la inmunidad innata y utilidad de una nariz electrónica para su diagnóstico. ASTRAZENECA 2015-1. Fundació AstraZeneca. Duration: 2015-2017. 20,000.00 €.
- ▶ Oriol Sibila Vidal. Infección bronquial en pacientes con EPOC y agudizaciones frecuentes; papel de la inmunidad innata y utilidad de una nariz electrónica para su diagnóstico. SEPAR 2014. Societat Espanyola de Pneumologia i Cirugia Toràcica. Duration: 2016-2017. 12,847.61 €.
- ▶ Guillermo Rafael Suarez Cuartín. Infección bronquial en pacientes con bronquiectasias NO-FQ: papel de los mecanismos de defensa pulmonar y utilidad de una nariz electrónica para su diagnóstico. BECA BECAR SOCAP 2016. Societat Catalana de Pneumologia. Duration: 2016-2017. 13,090.91 €.
- ▶ Oriol Sibila Vidal. Infección bronquial en pacientes con bronquiectasias No-FQ: Papel de los mecanismos de defensa pulmonar y utilidad de una nariz electrónica para su diagnóstico. SEPAR 2015 - BECAR. Societat Espanyola de Pneumologia i Cirugia Toràcica. Duration: 2016-2017. 17,100.00 €.
- ▶ Ana María Rodrigo Troyano. El microbioma respiratorio en la EPOC; relación con la respuesta inmune pulmonar y sistémica. IR16-R2. Fundació Privada Hospital de la Santa Creu i Sant Pau. Duration: 2016-2017. 35,500.00 €.
- ▶ Oriol Sibila Vidal. Impacto del tabaquismo sobre los mecanismos de defensa pulmonar y la infección bronquial en pacientes con EPOC y agudizaciones frecuentes. FUCAP 2015 (La Caixa). Fundació Catalana de Pneumologia. Duration: 2015-2018. 13,300.00 €.

Note: Total amount granted to PI. It does not include indirect costs.

## Grants Awarded in 2017

- ▶ Ana María Rodrigo Troyano, El microbioma respiratorio en la EPOC; relación con la respuesta inmune pulmonar y sistémica. BECA BECAR SOCAP 2017. Societat Catalana de Pneumologia. Duration: 2017-2018. 14,400.00 €.
- ▶ Vicente Plaza Moral, Asma Neutrofílica y/o No Eosinofílica. Proyecto ANNE. PI17/01950. Instituto de Salud Carlos III. 2018-2020. 87,000.00 €.

Note: Total amount granted to PI. It does not include indirect costs.

# Chronic Respiratory Diseases

**\*TIF: 183.351 \*\*MIF: 5.093**

Barcelo A., Morell-Garcia D., Salord N., Esquinas C., Perez G., Perez A., Monasterio C., Gasa M., Fortuna A.M., Montserrat J.M., Mayos M., A randomized controlled trial: branched-chain amino acid levels and glucose metabolism in patients with obesity and sleep apnea (2017) *J SLEEP RES*, 26 (6), 773-781.

**IF: 3.433**

Ceccato A., Cilloniz C., Ranzani O.T., Menendez R., Agusti C., Gabarrus A., Ferrer M., Sibila O., Niederman M.S., Torres A., Treatment with macrolides and glucocorticosteroids in severe community-acquired pneumonia: A post-hoc exploratory analysis of a randomized controlled trial (2017) *PLOS ONE*, 12 (6).

**IF: 2.766**

Cepeda S., Pajares V., Trujillo-Reyes J.C., Torregó A., A New Cyanoacrylate Used as Bronchial Sealant in the Endoscopic Treatment of Bronchopleural Fistula Utilización de un nuevo cianoacrilato como sellante bronquial en el tratamiento endoscópico de la fistula broncopleural (2017) *ARCH BRONCONEUMOL*, 53 (3), 168-169.

**IF: 2.633**

Chalmers J.D., Moffitt K.L., Suarez-Cuartin G., Sibila O., Finch S., Furrie E., Dicker A., Wrobel K., Elborn J.S., Walker B., Martin S.L., Marshall S.E., Huang J.T.-J., Fardon T.C., Neutrophil elastase activity is associated with exacerbations and lung function decline in bronchiectasis (2017) *AM J RESP CRIT CARE*, 195 (10), 1384-1393.

**IF: 15.239**

Cosio B.G., De Llano L.P., Vina A.L., Torregó A., Lopez-Campos J.L., Soriano J.B., Moragon E.M., Izquierdo J.L., Bobolea I., Callejas J., Plaza V., Miravitles M., Soler-Catalunya J.J., Th2 signature in chronic airway diseases: Towards the extinction of asthma-COPD overlap syndrome? (2017) *EUR RESPIR J*, 49 (5).

**IF: 12.242**

Crespo-Lessmann A., Mateus E., Torrejón M., Belda A., Giner J., Vidal S., Sibila O., Plaza V., Asthma with bronchial hypersecretion: expression of mucins and toll-like receptors in sputum and blood. *J ASTHMA ALLERGY* 2017;10:269-276.

**IF: 1.59**

Crespo-Lessmann A., Plaza V., González-Barcala F.J., Fernández-Sánchez T., Sastre J., Concordance of opinions between patients and physicians and their relationship with symptomatic control and future risk in patients with moderate-severe asthma. *BMJ OPEN RESPIR RES*. 2017 Sep 13;4(1):e000189. PMID: 29018525.

**IF 1.188**

Faverio P., Sibila O., New biomarkers in community-acquired pneumonia: Another step

in improving outcome prediction (2017) *RESPIROLOGY*, 22 (3), 416-417.

**IF: 4.407**

Gimenez S., Romero S., Alonso J.F., Mananas M.A., Pujol A., Baxarias P., Antonjoan R.M., Monitoring sleep depth: analysis of bispectral index (BIS) based on polysomnographic recordings and sleep deprivation (2017) *J CLIN MONIT COMPUT*, 31 (1), 103-110.

**IF: 2.450**

Gonzalez A., Lluch A., Aba E., Albalen J., Anton A., Alvarez I., Ayala F., Barnadas A., Calvo L., Ciruelos E., Cortes J., de la Haba J., Lopez-Vega J.M., Martinez E., Munoz M., Pelaez I., Redondo A., Rodriguez A., Rodriguez C.A., Ruiz A., Llombart A., A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM) (2017) *CLIN TRANSL ONCOL*, 19 (5), 616-624.

**IF: 2.392**

Guell M.-R., Cejudo P., Ortega F., Puy M.C., Rodriguez-Trigo G., Pijoan J., Martinez-Indart L., Gorostiza A., Bdeir K., Celli B., Galdiz J.B., Benefits of long-term pulmonary rehabilitation maintenance program in patients with severe chronic obstructive pulmonary disease (2017) *AM J RESP CRIT CARE*, 195 (5), 622-629.

**IF: 15.239**

Huertas D., Monton C., Marin A., Solanes I., Lopez-Sanchez M., Pomares X., Munoz-Esquerra M., Dorca J., Santos S., Effectiveness of a Respiratory Day Hospital Program to Reduce Admissions for Exacerbation in Patients with Severe COPD: A Prospective, Multicenter Study (2017) *COPD*, 14 (3), 304-310.

**IF: 2.604**

Koo C.-Y., de la Torre A.S., Loo G., Torre M.S.D.L., Zhang J., Duran-Cantolla J., Li R., Mayos M., Sethi R., Abad J., Furlan S.F., Coloma R., Hein T., Ho H.-H., Jim M.-H., Ong T.-H., Tai B.-C., Turino C., Drager L.F., Lee C.-H., Barber F., Effects of Ethnicity on the Prevalence of Obstructive Sleep Apnoea in Patients with Acute Coronary Syndrome: A Pooled Analysis of the ISAACC Trial and Sleep and Stent Study (2017) *HEART LUNG CIRC*, 26 (5), 486-494.

**IF: 1.921**

Lopez-Vina A., Giner J., Molina J., Palicio J., Plaza J., Quintano J.A., Quirce S., Soria C., Urendez A.M., Plaza V., Multidisciplinary Consensus on the Nonadherence to Clinical Management of Inhaled Therapy in Spanish asthma patients (2017) *CLIN THER*, 39 (8), 1730-1745.e1.

**IF: 3.185**

Marquez-Rodas I., Pollan M., Escudero M.J., Ruiz A., Martin M., Santaballa A., Martinez del Prado P., Batista N., Andres R., Anton A.,

Llombart A., Fernandez Aramburu A., Adrover E., Gonzalez S., Segui M.A., Calvo L., Lizón J., Rodriguez Lescure A., Ramon y Cajal T., Llort G., Jara C., Carrasco E., Lopez-Tarruell S., Frequency of breast cancer with hereditary risk features in Spain: Analysis from GEICAM "El Álamo III" retrospective study (2017) *PLOS ONE*, 12 (10).

**IF: 2.766**

Martin M., Chacon J.I., Anton A., Plazaola A., Garcia-Martinez E., Segui M.A., Sanchez-Rovira P., Palacios J., Calvo L., Esteban C., Espinosa E., Barnadas A., Batista N., Guerrero A., Munoz M., Romio E., Rodriguez-Martin C., Caballero R., Casas M.I., Rojo F., Carrasco E., Antolin S., Neoadjuvant therapy with weekly nanoparticle albumin-bound paclitaxel for luminal early breast cancer patients: Results from the nabrax study (GEICAM/2011-02), a multicenter, non-randomized, phase ii trial, with a companion biomarker analysis (2017) *ONCOLOGIST*, 22 (11), 1301-1308.

**IF: 5.306**

Martinez-Garcia M.A., Riveiro-Falkenbach E., Rodriguez-Peralto J.L., Nagore E., Martorell-Calatayud A., Campos-Rodriguez F., Farre R., Hernandez Blasco L., Roca J.B., Vives E.C., Sanchez-De-La-Torre A., Capa J.A., Montserrat J.M., Almendros I., Perez-Gil A., Nuno V.C., Cano-Pumarega I., Penafiel J.C., Cambrales T.D., Mediano O., Arias J.D., Gozal D., Garcia Martin R.M., Herrera E.M., De Jaime M.N., Moreno S., Illa F.B., De La Torre M.S., De Eusebio E., Landete P., Gordon M.M., Arias E., Masa F., Herrada C.G., Carrera C., Ferrer A.M., Boada A., Fortuna A., Mayos M., Garcia J.G., A prospective multicenter cohort study of cutaneous melanoma: Clinical staging and potential associations with HIF-1α and VEGF expressions (2017) *MELANOMA RES*, 27 (6), 558-564.

**IF: 5.306**

Martinez-Moragon E., Plaza V., Torres I., Rosado A., Urrutia I., Casas X., Hinojosa B., Blanco-Aparicio M., Delgado J., Quirce S., Sabadell C., Cebollero P., Munoz-Fernandez A., Fibromyalgia as a cause of uncontrolled asthma: a case-control multicenter study (2017) *CURR MED RES OPIN*, 33 (12), 2181-2186.

**IF: 2.665**

Miravitles M., Alvarez-Gutierrez F.J., Calle M., Casanova C., Cosio BG, López-Viña A., Pérez de Llano L., Quirce S., Roman-Rodríguez M., Soler-Cataluña JJ, Plaza V., An algorithm for easy identification of ACO: Consensus between the Spanish COPD (GesEPOC) and asthma (GEMA) guidelines. *EUR RESPIR J* 2017;49(5).

**IF: 12.242**

Munoz-Cano R., Torregó A., Bartra J., Sanchez-Lopez J., Picado R.P., Valero A., Fol-

\*TIF: 183.351 \*\*MIF: 5.093

low-up of patients with uncontrolled asthma: Clinical features of asthma patients according to the level of control achieved (the COAS study) (2017) EUR RESPIR J, 49 (3).  
**IF: 12.242**

Pérez-de-Llano L, Cosio BG; CHACOS study group. Asthma-COPD overlap is not a homogeneous disorder: further supporting data. RESPIR RES. 2017;18(1):183.

**IF: 3.751**

Plaza V, Lopez-Vina A, Cosio B.G., Test of Adherence to Inhalers El test de adhesión a los inhaladores (2017) ARCH BRONCONEUMOL, 53 (7), 360-361.

**IF: 2.633**

Plaza V, Alvarez F, Calle M, Casanova C, Cosio B.G., Lopez-Vina A, Perez de Llano L, Quirce S, Roman-Rodriguez M, Soler-Cataluna JJ, Miravitles M, Consensus on the Asthma-COPD Overlap Syndrome (ACOS) Between the Spanish COPD Guidelines (GesEPOC) and the Spanish Guidelines on the Management of Asthma (GEMA) Consenso sobre el solapamiento de asma y EPOC (ACO) entre la Guía española de la EPOC (GesEPOC) y la Guía Española para el Manejo del Asma (GEMA) (2017) ARCH BRONCONEUMOL, 53 (8), 443-449.

**IF: 2.633**

Quirce S, Delgado J, Entrenas JL, Grande M, Llorente C, López Viña A, Martínez Moragón E, Mascarós E, Molina J, Olaguibel JM, Pérez de Llano LA, Perpiñá Tordera M, Quintano JA, Rodríguez M, Román-Rodriguez M, Sastre J, Trigueros JA, Valero AL, Zoni AC, Plaza V; ASMAFORUM II Group. Quality indicators of asthma care derived from the Spanish guideline for asthma management (GEMA 4.0): A multidisciplinary team report. J INVESTIG ALLERGOL CLIN IMMUNOL. 2017;27(1):69-73.

**IF 3.457**

Reyes L.F., Restrepo M.I., Hinojosa C.A., Soni N.J., Anzueto A., Babu B.L., Gonzalez-Juarbe N., Rodriguez A.H., Jimenez A., Chalmers J.D.,

Aliberti S, Sibila O, Winter V.T., Coalson J.J., Giavedoni L.D., Dela Cruz C.S., Waterer G.W., Witzenrath M, Suttorp N, Dube P.H., Orihuebla C.J., Severe pneumococcal pneumonia causes acute cardiac toxicity and subsequent cardiac remodeling (2017) AM J RESP CRIT CARE, 196 (5), 609-620.

**IF: 15.239**

Rodrigo G.J., Neffen H, Plaza V, Asthma-chronic obstructive pulmonary disease overlap syndrome: A controversial concept (2017) CURR OPIN ALLERGY CL, 17 (1), 36-41.

**IF: 3.544**

Rodrigo-Troyano A., Mediavilla M.M., Garin N, Guell R, Heart failure induced by itraconazole Insuficiencia cardíaca secundaria a tratamiento con itraconazol (2017) MED CLIN-BARCELONA, 148 (2), 69-70.

**IF: 1.168**

Rodrigo-Troyano A, Sibila O, The respiratory threat posed by multidrug resistant Gram-negative bacteria (2017) RESPIROLOGY, 22 (7), 1288-1299.

**IF: 4.407**

Roman-Rodriguez M, Ibarrola-Ruiz L, Mora F, Plaza V, Sastre J, Torrego A, Vega J.M., Sanchez-Herrero G, Motivational interviewing for adherence: Post-training attitudes and perceptions of physicians who treat asthma patients (2017) PATIENT PREFER ADHER, 11, 811-820.

**IF: 1.733**

Sellares J., Ferrer M., Anton A., Loureiro H., Bencosme C., Alonso R., Martinez-Olondris P., Sayas J., Penacoba P., Torres A., Discontinuing noninvasive ventilation in severe chronic obstructive pulmonary disease exacerbations: A randomised controlled trial (2017) EUR RESPIR J, 50 (1).

**IF: 12.242**

Serrano-Pariente J., Plaza V., Near-fatal asthma: A heterogeneous clinical entity (2017) CURR OPIN ALLERGY CL, 17 (1), 28-35.

**IF: 3.544**

Serrano-Pariente J., Plaza V., Soriano J.B., Mayos M, Lopez-Vina A, Picado C, Vigil L, Crespo-Lessmann A, Asthma outcomes improve with continuous positive airway pressure for obstructive sleep apnea (2017) ALLERGY, 72 (5), 802-812.

**IF: 6.048**

Soto Campos J.G., Rojas Villegas J., Padilla Galo A., Marina Malanda N., Garcia Rivero J.L., Pinedo Sierra C., Garcia Salmones M., Cabrera Galan C., Segura Molina E., Plaza V., Impacto del asma en la vida sexual de los pacientes. Un estudio de casos y controles Impact of Asthma on the Sexual Functioning of Patients. A Case-Control Study (2017) ARCH BRONCONEUMOL, 53 (12), 667-674.

**IF: 2.633**

Soto Campos J.G., Rojas Villegas J., Padilla Galo A., Marina Malanda N., Garcia Rivero J.L., Pinedo Sierra C., Garcia Salmones M., Cabrera Galan C., Segura Molina E., Plaza V., Pascual Erquicia S., Impact of Asthma on the Sexual Functioning of Patients. A Case-Control Study Impacto del asma en la vida sexual de los pacientes. Un estudio de casos y controles (2017) ARCH BRONCONEUMOL, 53 (12), 667-674.

**IF: 2.633**

Suarez-Cuartin G., Smith A., Abo-Leyah H., Rodrigo-Troyano A., Perea L., Vidal S., Plaza V., Fardon T.C., Sibila O., Chalmers J.D., Anti-Pseudomonas aeruginosa IgG antibodies and chronic airway infection in bronchiectasis (2017) RESP MED, 128, 1-6.

**IF: 3.230**

Xaubet A., Molina-Molina M., Acosta O., Bollo E., Castillo D., Fernandez-Fabrellas E., Rodriguez-Portal J.A., Valenzuela C., Ancochea J., Guidelines for the medical treatment of idiopathic pulmonary fibrosis Normativa sobre el tratamiento farmacológico de la fibrosis pulmonar idiopática (2017) ARCH BRONCONEUMOL, 53 (5), 263-269.

**IF: 2.633**

# Research Group in HIV and AIDS



## Coordinator

Domingo Pedrol, Pere FGS  
pdomingo@santpau.cat

## Members

Cadafalch Arpa, Josep	FGS
Castella Rovira, Marta	IR
Gutiérrez Macía, Maria del Mar	IR
Lamarca Soria, Maria Karuna	IR
Mateo García, Gracia María	IR
Muñoz Rodríguez, Jessica	IR
Ponte Márquez, Paola Helena	IR
Sambeat Domènech, Maria Antònia	FGS
Villarroja Terrade, Joan	IR

## Main Lines of Research

- ▶ Medical care projects.
- ▶ Study of pathogenic mechanisms altering body fat distribution.
- ▶ Study of metabolic disorders associated with antiretroviral treatment.
- ▶ Body composition changes.
- ▶ New antiretroviral drugs.

- ▶ Cardiovascular risk associated with antiretroviral treatment.
- ▶ Comorbid conditions associated with HIV-1 infection.
- ▶ Pharmacogenetics (toxicokinetics).
- ▶ Bacterial meningitis.

## Medical Care Projects

- ▶ Continuing with, expanding and, as appropriate, consolidating the care team for HIV-1 infected patients, consisting currently of 3 staff physicians, 4 grantaided research assistants (including a Río Hortega-funded research assistant) and 2 nurses.
- ▶ Continuing with participation in multi-centre projects (especially the AIDS network, Gesida, VACH, EuroSIDA and ART collaboration).
- ▶ Exploration of possible participation in clinical trials of new antiretroviral drugs.
- ▶ Increasing the number of HIV-1 infected patients attended to in our hospital (given current mortality rates, an estimated annual increase of 50 patients is required).
- ▶ Continuing with current clinical research and mixed basic research-clinical research lines.

## Pathogenic mechanisms altering body fat distribution

- ▶ Study of metabolism in pyrimidines and derivatives in the genesis of lipodystrophy associated with HIV-1 and antiretroviral treatment.
- ▶ Development of an animal (mouse) model of lipodystrophy.
- ▶ Development of in vitro models (adipocyte cultures) to study the adipose toxicity of antiretroviral drugs.
- ▶ Study of new manifestations of the lipodystrophy syndrome.
- ▶ Development of measurements for antiretroviral drug concentrations in adipose tissue.
- ▶ Exploration of the role of inflammation in the pathogenesis of lipodystrophy associated with HIV-1 and antiretroviral treatment.
- ▶ Metabolism of uridine and its role in the pathogenesis of lipodystrophy.

## Challenges

## Metabolic disorders associated with antiretroviral treatment

- ▶ In vivo assessment of metabolic toxicity associated with antiretroviral treatment.
- ▶ Development of in vitro models (adipocyte cultures) to study the adipose toxicity of antiretroviral drugs.
- ▶ Study of factors contributing to hepatic steatosis in patients receiving antiretroviral treatment.
- ▶ Study of the pathogenic role of FGF21 in insulin resistance in HIV-1 infected patients.
- ▶ Study of role of FABP4 in metabolic disorders associated with antiretroviral treatment.

## Body composition

- ▶ Definition of normal fat distribution in the general population.
- ▶ Establishment of abnormal fat distribution patterns.
- ▶ Development of a definition of lipodystrophy associated with HIV-1 and antiretroviral treatment.

## New antiretroviral drugs

- ▶ Clinical trials of new antiretroviral drugs (phases 2 and 3).
- ▶ Ritonavir and non-ritonavir pharmacokinetic potentiation of antiretroviral drugs.

## Cardiovascular risk associated with antiretroviral treatment

- ▶ Establishment of a multicentre cardiovascular risk cohort.
- ▶ Study of antiretroviral treatment-dependent and non-treatment-dependent factors in multicentre cohorts.
- ▶ Development of in vitro models (adipose cultures) to study adipose toxicity for antiretroviral drugs.

## Challenges

**Comorbid conditions associated with HIV-1 infection**

- ▶ Study of ageing in different tissues associated with HIV-1 infection and antiretroviral treatment.
- ▶ Study of fragility in patients with HIV-1 infection and the role of HAART.
- ▶ Evaluation of the neurocognitive function in patients with HIV-1 infection with and without antiretroviral treatment.
- ▶ Participation in multicentre cohort studies to determine the incidence of specific comorbidities (cancer, HCV, cardiovascular disease, osteogenesis/osteoporosis): EuroSIDA, ART Collaboration, Gesida, VACH, etc.
- ▶ Treatment of HCV in patients with HIV-1 and its prognostic significance.

**Pharmacogenetics (toxicogenetics)**

- ▶ Role of enzyme polymorphism of the pyrimidine pathways in the pathogenesis of lipodystrophy.
- ▶ Role of enzyme polymorphism of the pyrimidine pathways in the pathogenesis of clinical toxicity (neuropathy, pancreatitis).
- ▶ Role of IL28B polymorphism in spontaneous HCV clearance in the response to antiviral treatment based on interferon and ribavirin.

**Bacterial meningitis**

- ▶ Identification of prognostic factors in adult bacterial meningitis.
- ▶ Continuation with a cohort study of adult bacterial meningitis.
- ▶ Identification of host-intrinsic factors in the pathogenesis and prognosis of adult bacterial meningitis and meningococcal disease.

## Collaborations

**Collaborations with other IIB Sant Pau Groups**

- ▶ Microbiology and Infectious Diseases (Dr. Pere Coll).

## Active Grants

- ▶ Pere Domingo Pedrol. El sistema FGF23/alpha-Klotho como mediador de las comorbilidades no directamente relacionadas con la infección por VIH en el eje cardio-osteo-renal. PI14/00700. Instituto de Salud Carlos III. Duration: 2015-2017. 116,500.00 €.
- ▶ Joan Villarroya Terrade. Estudio de las alteraciones metabólicas y óseas en pacientes VIH bajo tratamiento antirretrovial. IJCI-2014-19681. Ministeri d'Economia i Competitivitat. Duration: 2016-2018. 64,000.00 €.

- ▶ Pere Domingo Pedrol. Prevalencia y progresión de la ateromatosis subclínica en pacientes con infección por VIH: correlación con marcadores de señalización inter-orgánica, disbiosis intestinal y estrés oxidativo. PI17/00498 Instituto de Salud Carlos III. 275,780.48 €

Note: Total amount granted to PI. It does not include indirect costs.

# Research Group in HIV and AIDS

**\*TIF: 93.933   \*\*MIF: 5.87**

Alvarez-Del Arco D., Fakoya I., Thomadakis C., Pantazis N., Touloumi G., Gennotte A.-F., Zuure F., Barros H., Staehelin C., Gopel S., et al., High levels of postmigration HIV acquisition within nine European countries (2017) AIDS, 31 (14), 1979-1988.

**IF: 5.0030**

Domingo P, Espinet J, Vidal F. ART regimes and fat: the healing hand wielding the sword. LANCET HIV. 2017 Jan; 4(1): e2-e3.

**IF: 11.355**

Gallego-Escuredo J.M., Lamarca M.K., Villarroya J., Domingo J.C., Mateo M.G., Gutierrez M.D.M., Vidal F., Villarroya F., Domingo P., Giralt M., High FGF21 levels are associated with altered bone homeostasis in HIV-1-infected patients (2017) METABOLISM, 71, 163-170.

**IF: 5.963**

Garin N., Zurita B., Velasco C., Feliu A., Gutierrez M., Masip M., Mangues M.A., Prevalence and clinical impact of recreational drug consumption in people living with HIV on treatment: A cross-sectional study (2017) BMJ OPEN, 7 (1).

**IF: 2.413**

Gatell J.M., Assoumou L., Moyle G., Waters L., Johnson M., Domingo P., Fox J., Martinez E., Stellbrink H.-J., Guaraldi G., Masia M., Gompels M., De Wit S., Florence E., Esser S., Raffi F., Pozniak A.L., Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk (2017) AIDS, 31 (18), 2503-2514.

**IF: 4.914**

Gomez-Ambrosi J., Gallego-Escuredo J.M., Catalan V., Rodriguez A., Domingo P., Moncada R., Valenti V., Salvador J., Giralt M., Villarroya F., Fruhbeck G., FGF19 and FGF21 serum concentrations in human obesity and type 2 diabetes behave differently after diet- or surgically-induced weight loss (2017) CLIN NUTR, 36 (3), 861-868.

**IF: 5.496**

Martinez-Sanchez N., Seoane-Collazo P., Contreras C., Varela L., Villarroya J., Rial-Pensado E., Buque X., Aurrekoetxea I., Delgado T.C., Vazquez-Martinez R., Gonzalez-Garcia I., Roa J., Whittle A.J., Gomez-Santos B., Vellagapudi V., Tung Y.C.L., Morgan D.A., Voshol P.J., Martinez de Morentin P.B., Lopez-Gonzalez T., Linares-Pose L., Gonzalez F., Chatterjee K., Sobrino T., Medina-Gomez G., Davis R.J., Casals N., Oresic M., Coll A.P., Vidal-Puig A.,

Mittag J., Tena-Sempere M., Malagon M.M., Dieguez C., Martinez-Chantar M.L., Aspichuela P., Rahmouni K., Nogueiras R., Sabio G., Villarroya F., Lopez M., Hypothalamic AMPK-ER Stress-JNK1 Axis Mediates the Central Actions of Thyroid Hormones on Energy Balance (2017) CELL METAB, 26 (1), 212-229.e12.

**IF: 20.565**

Masia M., Padilla S., Moreno S., Barber X., Iribarren J.A., Del Romero J., Gomez-Sirvent J.L., Rivero M., Vidal F., Campins A.A., et al., Prediction of long-term outcomes of HIV-infected patients developing non-AIDS events using a multistate approach (2017) PLOS ONE, 12 (9).

**IF: 2.766**

Negredo E., Estrada V., Domingo P., Gutierrez M.D., Mateo G.M., Puig J., Bonjoch A., Ornelas A., Echeverria P., Estany C., Toro J., Clotet B., Switching from a ritonavir-boosted PI to dolutegravir as an alternative strategy in virologically suppressed HIV-infected individuals (2017) J ANTIMICROB CHEMOTH, 72 (3), 844-849.

**IF: 5.217**

Perez-Molina J.A., Rubio R., Rivero A., Pasquau J., Suarez-Lozano I., Riera M., Estebanez M., Palacios R., Sanz-Moreno J., Troya J., et al., Simplification to dual therapy (atazanavir/ritonavir+lamivudine) versus standard triple therapy [atazanavir/ritonavir+two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study) (2017) J ANTIMICROB CHEMOTH, 72 (1), 246-253.

**IF: 5.217**

Pomar V., Benito N., Lopez-Contreras J., Coll P., Gurgui M., Domingo P., Characteristics and outcome of spontaneous bacterial meningitis in patients with cancer compared to patients without cancer (2017) MEDICINE, 96 (19).

**IF: 2.028**

Pulido F., Ribera E., Lagarde M., Perez-Valero I., Palacios R., Iribarren J.A., Payeras A., Domingo P., Sanz J., Cervero M., Curran A., Rodriguez-Gomez F.J., Tellez M.J., Ryan P., Barrafut P., Knobel H., Rivero A., Alejos B., Yllanes M., Arribas J.R., Dual Therapy with Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy with Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus

Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial (2017) CLIN INFECT DIS, 65 (12), 2112-2118.

**IF: 9.117**

Rivero A., Pérez-Molina JA, Blasco AJ, Arribas JR, Crespo M, Domingo P, Estrada V, Iribarren JA, Knobel H, Lázaro P, López-Aldeguer J, Lozano F, Moreno S, Palacios R, Pineda JA, Pulido F, Rubio R, de la Torre J, Tuset M, Gatell JM. Costs and cost-efficacy analysis of the 2016 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. Enferm Infect Microbiol Clin. 2017 Feb;35(2):88-99.

**IF: 1.707**

Rueda F., Eich C., Cordobilla B., Domingo P., Acosta G., Albericio F., Cruz L.J., Domingo J.C., Effect of TLR ligands co-encapsulated with multiepitopic antigen in nanoliposomes targeted to human DCs via Fc receptor for cancer vaccines (2017) IMMUNOBIOLOGY, 222 (11), 989-997.

**IF: 2.873**

Saumoy M., Llibre J.M., Terron A., Knobel H., Arribas J.R., Domingo P., Arroyo-Manzano D., Rivero A., Moreno S., Podzamczer D., Short Communication: Maraviroc Once-Daily: Experience in Routine Clinical Practice (2017) AIDS RES HUM RETROV, 33 (1), 29-32.

**IF: 1.935**

Saumoy M., Tiraboschi J.M., Ordóñez-Llanos J., Ribera E., Domingo P., Mallolas J., Curto J., Gatell J.M., Podzamczer D., Atherogenic properties of LDL particles after switching from Truvada or Kivexa plus lopinavir/r to lamivudine plus lopinavir/r: OLE-MET sub-study (2017) HIV CLIN TRIALS, 18 (2), 49-53.


**IF: 1.379**

Teira R., Vidal F., Muñoz-Sánchez P., Geijo P., Viciana P., Ribera E., Domingo P., Castaño M., Martínez E., Roca B., Puig T., Estrada V., Deig E., Galindo M., de la Fuente B., Lozano F., Montero M., Muñoz-Sanz A., Sanchez T., Terrón A., Romero-Palacios A., Lacalle J., Garrido M., Suárez-Lozano I., Very low level viraemia and risk of virological failure in treated HIV-1-infected patients (2017) HIV MED, 18 (3), 196-203.

**IF: 2.932**

Villarroya F., Gavalda-Navarro A., Peyrou M., Villarroya J., Giralt M., The Lives and Times of Brown Adipokines (2017) TRENDS ENDOCRIN MET, 28 (12), 855-867.

**IF: 10.769**



# Genome Instability and DNA Repair Syndromes



## Coordinator

Surrallés Calonge, Jordi FGS  
jsurrellas@santpau.cat

## Members

Bogliolo, Massimo	CIBERER
Castells Roca, Laia	UAB
Hernández Viedma, Gonzalo	UAB
Marín Vilar, María	UAB
Minguillón Pedreño, Jordi	UAB
Molina Romero, Ana	UAB
Montanuy Escribano, Helena	UAB
Muñoz Subirana, Núria	UAB
Peiró Navarro, Montserrat	UAB
Pujol Calvet, Roser	CIBERER
Ramírez de Haro, María José	CIBERER
Riera Armengol, Pau	IR
Steugerwald, Daniela	UAB

## Main Lines of Research

- ▶ Genetics and molecular biology of cancer-prone genetic syndromes with a focus in familiar breast cancer and Fanconi Anemia. Genetic characterization of Fanconi patients and identification of new genes involved in the disease and into hereditary breast cancer syndrome and its functions.
- ▶ Development of new diagnostic and therapeutic tools in Fanconi anemia, including gene therapy, regenerative medicine and drug repurposing.
- ▶ Mechanism of genomic instability and predisposition to cancer. Study of DNA repair and biological and clinical consequences of DNA repair failure.
- ▶ Fanconi/BRCA pathway in cancer. Implications of Fanconi genes in cancer and their use as therapeutic target against cancer.

## Challenges

- ▶ Our research interests are cancer-prone genetic syndromes with defective DNA repair with special focus in Fanconi anemia and familiar cancer syndromes. We perform genetic, molecular biology and therapeutic research including gene discovery, mechanisms of DNA repair, gene and cell therapy approaches and cell-based drug screening platforms. A long term goal is to understand the mechanisms that maintain genome stability and protect us from disease, cancer, and ageing to improve the diagnostics and find novel therapeutic strategies.

## Collaborations

### Collaborations with other IIB Sant Pau Groups

- ▶ Dr. Isabel Badell. Unit of Hematology, Oncology y Hematopoietic Stem Cell Transplant, Pediatrics Service, Hospital de la Santa Creu i Sant Pau.
- ▶ Dr. Csilla Krausz' team, Andrology Department, Fundació Puigvert, Universitat Autònoma de Barcelona, Institut d'Investigacions Biomèdiques Sant Pau (IIB-Sant Pau), Barcelona.

### External Collaborations

#### National collaborations

- ▶ Juan A. Bueren, CIEMAT, Madrid
- ▶ Luis A. Perez Jurado, UPF, Barcelona
- ▶ Joaquín Dopazo, CIPF, València
- ▶ Miquel Àngel Pujana, ICO, Hospitalet
- ▶ Csilla Krautz, Fundació Puigverd, Barcelona
- ▶ Cristina Diaz de Heredia, H. Vall Hebron, Barcelona
- ▶ Albert Català, H. Sant Joan de Déu, Barcelona
- ▶ Judith Balmaña, H. Vall Hebron, Barcelona
- ▶ Xose Puente, Universidad de Oviedo, Oviedo
- ▶ Javier Benítez, CNIO, Madrid

#### Collaborating external institutions

- ▶ Hereditary Cancer Programme, Catalan Institute of Oncology (ICO), Bellvitge In-

stitute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona.

- ▶ Breast Cancer and Systems Biology Laboratory, Program Against Cancer Therapeutic Resistance (ProCURE), ICO, IDIBELL, L'Hospitalet del Llobregat, Barcelona.
- ▶ Centro Andaluz de Biología Molecular y Medicina Regenerativa (CABIMER) and Departamento de Genética, Universidad de Sevilla, Spain.
- ▶ Hereditary Cancer Programme, ICO, Girona Biomedical Research Institute (IDIBGI), Girona, Spain.
- ▶ Oncogenetics Group, Hospital Universitari de la Vall d'Hebron; Vall d'Hebron Institute of Oncology (VHIO); Vall d'Hebron Institute of Research (VHIR); Universitat Autònoma de Barcelona, Barcelona, Spain.
- ▶ Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
- ▶ Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Preventive and Predictive Medicine, Fondazione IRCCS (Istituto Di Ricovero e Cura a Carattere Scientifico) Istituto Nazionale dei Tumori (INT), Milan, Italy.
- ▶ IFOM, Fondazione Istituto FIRC di Oncologia Molecolare and Unit of Molecular Bases of Genetic.

#### International collaborations

- ▶ Detlev Schindler, University of Würzburg, Germany
- ▶ Paolo Radice, Cancer Institute of Milan, Italy

**Collaborations**

- ▶ Paolo Peterlongo, Cancer Institute of Milan, Italy
- ▶ Jean Soulier, Saint Louis Hospital de Paris, France
- ▶ Fergus Couch, Clinica Mayo, USA
- ▶ Minoru Takata, University of Kyoto, Japan
- ▶ Toomo Ogi, University of Nagasaki, Japó
- ▶ Publications with more than 100 international co-autors

**Grants Awarded in 2017**

- ▶ Pau Riera Armengol. Marcadores farmacogenéticos de respuesta/resistencia a las terapias biológicas (anti-EGFR) en cáncer colorrectal. FPU16/04968, Ministerio de Educación, Cultura y Deporte. Duration: 2017-2020. 51,327.00 €.
- ▶ Jordi Surrallés. EUROFANCOLEN. Phase I/II Gene therapy trial of Fanconi anemia patients with a new Orphan Drug consisting of a lentiviral vector carrying the FANCA gene: A Coordinated International Action. European Commission. Duration: 2012-2017 (extended until 2018). HEALTH-F5-2012-305421. 260,424 €.
- ▶ Jordi Surrallés. Drug screening and repurposing in Fanconi anemia therapeutics. Fanconi Anemia Research Fundation (FARF). Duration: 2016-2018. 144,275 €.
- ▶ Jordi Surrallés. COFUND Project for a Postdoctoral Fellowship under the European Union's Horizon H2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No 665919 between UAB and the European Commission. Acronym: P-SPHERE. 2016. Research line of the host laboratory:

Targeting DNA repair in cancer and rare disease therapy. Recipient: Dr. Laia Roca.

- ▶ Jordi Surrallés. Reparación del DNA y anemia de Fanconi: Investigación genética y aplicaciones terapéuticas (REPAIR-FANC). SAF2015-64152-R. Convocatoria Ayudas a proyectos I+D+I, Programa Estatal de Investigación, Desarrollo e Innovación orientada a los Retos de la sociedad. Ministerio de Economía y Competitividad. Duration: 2016-2018. 278,300 €.
- ▶ Jordi Surrallés. Detección de mosaicismo clonal como marcador precoz de cáncer en pacientes con Anemia de Fanconi. Proyecto coordinado, CIBERER Acciones Cooperativas y Complementarias Intramurales (ACCI). Duration: 2016-2017. 34,500 €.
- ▶ Investigación terapéutica en tumores escamosos. CIBERER Acciones Cooperativas y Complementarias Intramurales (ACCI). Duration: 2017-2018. 36,500 €.

Note: Total amount granted to PI. It does not include indirect costs.

**Awards**

- ▶ Fanconi Anemia International Fund Discovery Award, Atlanta, USA, 2017.

**Theses**

- ▶ Helena Montanuy Escribano. Investigación terapéutica y cribados de fármacos en Anemia de Fanconi. Universitat Autònoma de Barcelona. Director: Jordi Surrallés. Date of defense: 14/11/2017.
- ▶ Cristina Camps. Targeting the Fanconi anemia/BRCA pathway in cancer treatment. Universitat Autònoma de Barcelona. Director: Jordi Surrallés. Date of defense: 03/04/2017.

- ▶ Daniela Steigerwald. Synthetic lethal interactions in cancer treatment. Universitat Autònoma de Barcelona. Director: Jordi Surrallés. Date of defense: 01/05/2017.

**Patents**

- ▶ J. Minguillón, J.Surrallés, C.Lázaro, M.A.Pujana, Nou biomarcador pronòstic i terapèutic en càncer de mama i ovari. Titular entity: UAB, ICO. Sol.14/03/2016. European extension: april 2017, Ref.163821739.1403, Biomarcador, 03/04/2017.

# Genome Instability and DNA Repair Syndromes

## Transfer Products

- ▶ Agreement with Intelligent Pharma (PYTHIA SERVICE AGREEMENT). February 2017.
- ▶ Agreement with intelligent Pharma (Project: Targeting the Fanconi anèmia pathway in drug discovery. March-july 2017.
- ▶ Research Agreement with Parioforma Limited. May 2017.
- ▶ Consulting agreement with Deerfield Management Company, L.P. January-december 2018.
- ▶ Research Agreement with Rocket Pharmaceuticals, USA. March 2018.
- ▶ Agreement with Boston Children's Hospital (Data and Material Use Agreement). USA. April 2018.
- ▶ The group hosts the Laboratory of Diagnosis of Chromosome Fragility of the Universitat Autònoma de Barcelona. <http://safcro.uab.es>. We performe service under invoice or signed agreement to more that 100 Spanish and European public and private hospitals and diagnostic and pharma companies.

## Scientific Production

Knies K, Inano S, Ramirez MJ, Ishiai M, Surrallés J, Takata M, and Schindler D. Biallelic mutations in the ubiquitin ligase RFWD3 cause Fanconi. *JCLIN INVEST*. May (2017);127; 8: 1-16.

**FI 13.251**

Reina-Castillón J, Pujol R, López-Sánchez M, Rodríguez-Santiago B, Aza-Carmona M, González JR, Casado JA, Bueren JA, Sevilla J, Badell I, Català A, Beléndez C, Dasi MA, Diaz de Heredia C, Soulier J, Schindler D, Pérez-Jurado LA, Surrallés J (2017) Detectable clonal mosaicism in blood as biomarker of cancer risk in Fanconi anemia. *BLOOD, ADVANCES* 1:319-329.

**FI 15.132**

Rio P, Navarro S., Guenechea G., Sanchez-Dominguez R., Lamana M.L., Yanez R., Casado J.A., Mehta P.A., Pujol M.R., Surrallés J., Charrier S., Galy A., Segovia J.C., Diaz De Heredia C., Sevilla J., Bueren J.A., Engraftment and in vivo proliferation advantage of gene-corrected mobilized CD34+ cells from Fanconi anemia patients (2017) *BLOOD*, 130 (13), 1535-1542.

**IF: 15.132**



AREA 3

# Haematological and Oncological D

**114** Clinical Oncology

**118** Oncogenesis and Antitumour Drugs

**122** Haematological Diagnosis

**124** Molecular Pathology of Gynaecologic Cancer

**126** Ear, Nose and Throat Cancers

**128** Oncology/Haematology and Transplantation

# iiseases



# Clinical Oncology



## Coordinator

Barnadas Molins, Agustí FGS  
abarnadas@sanpau.cat

## Members

Alfonso Ruiz, Rosa	IR
Andrés Granyo, Marta	IR
Arqueros Núñez, Cristina	FGS
Barba Joaquín, Andrés	IR
Bell Ramírez, Olga Lidia	IR
Buxó Orra, Elvira	FGS
Calvo Vergés, Núria	FGS
Casanova Bombardo, Clàudia	IR
Castells Tello, Diana	IR
Escuín Borràs, Daniel	IR
Fisas Masferrer, David	IR
Galceran Gallagher, Sara	IR
Gallego Rubio,	
Óscar Salvador	FGS
García Belinchón, Mercè	IR
Gisbert Beamud, Alexandra	IR
Lavernia Rosell, Laia	IR
Lladó Jordan, Gina	IR
Llobet Busquets, Mireia	IR
López Pousa, Antonio	FGS
Majem Tarruella, Margarita	FGS
Maroto Rey, José Pablo	FGS
Martín Lorente, Cristina	FGS
Martín Richard, Marta	FGS
Menéndez Cuervo,	
Dulce María	IR
Paez López-Bravo, David	FGS
Pallarès Curto, Maria Cinta	FGS
Pich Martínez, Olga	IR
Ramon y Cajal Asensio,	
Teresa	FGS
Ribas Carbonell, Romina	IR
Roca Gimeno, Llara	IR
Roca Solà, Marc	IR
Saavedra Bandera, Eduard	IR
Sebio García, Ana	FGS
Serra López, Jorgina	IR
Tibau i Martorell, Ariadna	FGS
Tijeras Pérez, Sandra	IR
Tobeña Puyal, María	FGS
Virgili Manrique, Anna Cristina	IR

## Main Lines of Research

### Clinical

- ▶ Development of new therapeutic strategies.
- ▶ Studies to improve tumour staging.
- ▶ Studies to detect residual disease.

### Translational

- ▶ Personalized anticancer therapy.
- ▶ Studies of predictive and prognostic molecular markers.

## Challenges

- ▶ Consolidate clinical research into cancer.
- ▶ Foster translational research into cancer in cooperation with other internal and external research groups.

- ▶ Consolidate the bank of tumours, DNA and serum for patients with cancer diagnosed and treated in our hospital.
- ▶ Develop new early-stage drugs (phase 0/1 studies).

## Collaborations

### Collaborations with other IIB Sant Pau Groups

- ▶ Oncogenesis and Antitumour Drugs (Dr. Ramon Mangues).
- ▶ Molecular Pathology of Urologic Cancer (Dr. F Algaba)
- ▶ Genetic Diseases (Dr. Montserrat Baiget).

- ▶ Breast Cancer (Dr. E Lerma).

### External Collaborations

- ▶ Tumoural progression modelling group at the Biomedical Research Institute (IRB) (Dr. A. Nebreda).
- ▶ Methylation and resistance to chemotherapy in ovarian cancer (Dr. M. Esteller).

## Active Grants

- ▶ Daniel Escuín Borràs. Perfil de expresión de miRNAs en tumor primario de mama y sus ganglios linfáticos centinela: implicaciones en los mecanismos de invasión y su valor como marcadores metastásicos. PI13/00110. Instituto de Salud Carlos III. Duration: 2014-2018. 76,000.00 €.

- ▶ Anna Cristina Virgili Manrique. Marcadores de células madre embrionarias y mesenquimales en la predicción de respuesta al tratamiento en sarcomas de tejidos blandos de alto riesgo. IR16-R3. Fundació Privada Hospital de la Santa Creu i Sant Pau. Duration: 2016-2017. 35,500.00 €.

- ▶ David Paez López-Bravo. La familia de los receptores tirosina kinasa ERBB y sus mecanismos reguladores: Identificación mediante NGS de variantes genéticas asociadas a las respuestas excepcionales a las terapias biológicas en cáncer colorrectal. AECC 2015-1. Asociación Española Contra el Cáncer. Duration: 2016-2018. 20,000.00 €.

- ▶ Margarita Majem Tarruella. Maneig dels pacients amb càncer de pulmó. IR16-E1. Fundació Privada Hospital de la Santa Creu i Sant Pau. Duration: 2017-2017. 2,200.00 €.
- ▶ Ana Sebio Garcia. Estancia para la investigación clínica y traslacional en la Unidad de Sarcomas del Hospital Royal Marsden de Londres. MV16/00043. Instituto de Salud Carlos III. Duration: 2017-2017. 8,000.00 €.

Note: Total amount granted to PI. It does not include indirect costs.

## Grants Awarded in 2017

- ▶ Ana Sebio Garcia. Evaluación de las alteraciones de la distrofina y proteínas afines como factores pronósticos en pacientes afectos de leiomiosarcoma. PI17/00143. Instituto de Salud Carlos III. Duration: 2018-2020. 61,500.00 €.

Note: Total amount granted to PI. It does not include indirect costs.

- ▶ Ivana Sullivan. Pharmacogenetic studies and prognostic factors in non-small cell lung cancer. Universitat Autònoma de Barcelona. Directors: Agustí Barnadas Molins, Juliana Salazar Blanco. Date of defense: 22/09/2017.

**\*TIF: 351.635 \*\*MIF: 7.0327**

Aapro M, De Laurentiis M, Rea D, Bargallo Rocha J.E., Elizalde R, Landherr L, Lindholm B, Mamounas E, Markopoulos C, Neven P, Petrovsky A, Rouzier R, Smit V, Svedman C, Schneider D, Thomassen C, Martin M, The MAGIC survey in hormone receptor positive (HR+), HER2-negative (HER2-) breast cancer: When might multi-gene assays be of value? (2017) BREAST, 33, 191-199.

**IF: 2.951**

Arqueros C, Salazar J, Arranz M.J., Sebio A, Mora J, Sullivan I, Tobena M, Martin-Richard M, Barnadas A, Baiget M, Paez D, SPARC gene variants predict clinical outcome in locally advanced and metastatic pancreatic cancer patients (2017) MED ONCOL, 34 (8).

**IF: 2.920**

Balana C, Capellades J, Pineda E, Estival A, Puig J, Domenech S, Verger E, Pujol T, Martinez-Garcia M, Oleaga L, Velarde J, Mesia C, Fuentes R, Marruecos J, Del Barco S, Villa S, Carrato C, Gallego O, Gil-Gil M, Craven-Bartle J, Alameda F, Pseudoprogression as an adverse event of glioblastoma therapy (2017) CANCER MED-US, 6 (12), 2858-2866.

**IF: 3.202**

Ballesteros M, Montero N, Lopez-Pousa A, Urrutia G, Sola I, Rada G, Pardo-Hernandez H, Bonfill X, Evidence mapping based on systematic reviews of therapeutic interventions for gastrointestinal stromal tumors (GIST) (2017) BMC MED RES METHODOL, 17 (1).

**IF: 2.524**

Buonadonna A, Benson C, Casanova J, Kasper B, Lopez Pousa A, Mazzeo F, Brodowicz T, Penel N, A noninterventional, multicenter, prospective phase IV study of trabectedin in patients with advanced soft tissue sarcoma (2017) ANTI-CANCER DRUG, 28 (10), 1157-1165.

**IF: 1.869**

Calvete O, Garcia-Pavia P, Dominguez F, Bougeard G, Kunze K, Braeuninger A, Teule A, Las A, Ramon Y Cajal T, Llort G, Fernandez V, Lazaro C, Urioste M, Benitez J, The wide spectrum of POT1 gene variants correlates with multiple cancer types (2017) EUR J HUM GENET, 25 (11), 1278-1281.

**IF: 3.636**

Capdevila J, Galofre J.C., Grande E, Zafon Llopis C, Ramon Y Cajal Asensio T, Navarro Gonzalez E, Jimenez-Fonseca P, Santamaría Sandi J, Gomez Saez J.M., Riesco Eizaguirre G., Consensus on the management of ad-

vanced radioactive iodine-refractory differentiated thyroid cancer on behalf of the Spanish Society of Endocrinology Thyroid Cancer Working Group (GTSEEN) and Spanish Rare Cancer Working Group (GETHI) (2017) CLIN TRANSL ONCOL, 19 (3), 279-287.

**IF: 2.392**

Capdevila J, Trigo J.M., Aller J, Manzano J.L, Adrian S.G, Llopis C.Z, Reig O, Bohn U, Cajal T.R.Y, Duran-Poveda M, Astorga B.G, Lopez-Alfonso A, Martinez J.M., Porras I, Reina J.J., Palacios N, Grande E, Cillan E, Matos I, Grau J.J., Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC) (2017) EUR J ENDOCRINOL, 177 (4), 309-317.

**IF: 4.333**

Casali P.G., Fumagalli E, Gronchi A, Zalcberg J, Kotasek D, Cesne A.L., Blay J.-Y, Italiano A, Reichardt P, Lindner L.H., Grunwald V, Judson I.R., Van Der Graaf W, Schoffski P, Litiere S, Marreaud S, Leyvraz S, Pousa A.L., Sleijfer S, Verweij J, Kerst J.M., Hogendoorn P, Van Der Graaf W, Rutkowski P, Ten-year progression-free and overall survival in patients with unresectable or metastatic GI stromal tumors: Long-term analysis of the European organisation for research and treatment of cancer, Italian sarcoma group, and Australasian gastrointestinal trials group intergroup phase III randomized trial on imatinib at two dose levels (2017) J CLIN ONCOL, 35 (15), 1713-1720.

**IF: 26.303**

Cinieri S, Chan A, Altundag K, Vandebroek A, Tubiana-Mathieu N, Barnadas A, Dodyk P, Lazzarelli S, Botha M, Rauch D, Villanova G, Coskun U, Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer (2017) CLIN BREAST CANCER, 17 (2), 91-99.e1.

**IF: 2.703**

Codony-Servat J, Cuatrecasas M, Asensio E, Montironi C, Martinez-Cardus A, Marin-Aguilar M, Horndler C, Martinez-Balibrea E, Rubini M, Jares P, Reig O, Victoria I, Gaba L, Martin-Richard M, Alonso V, Escudero P, Fernandez-Martos C, Feliu J, Mendez J.C., Mendez M, Gallego J, Salud A, Rojo F, Castells A., Prat A, Rosell R, Garcia-Albeniz X, Camps J, Maurel J, Nuclear IGF-1R predicts chemotherapy and targeted therapy resis-

tance in metastatic colorectal cancer (2017) BRIT J CANCER, 117 (12), 1777-1786.

**IF: 5.922**

de Castro J, Gonzalez-Larriba J.L, Vazquez S, Massuti B, Sanchez-Torres J.M., Domine M, Garrido P, Calles A., Artal A, Collado R, Garcia R, Sereno M, Majem M, Macias J.A., Juan O, Gomez-Codina J, Hernandez B, Lazaro M, Ortega A.L., Cobo M, Trigo J.M., Carcereny E, Rolfo C, Macia S, Munoz J, Diz P, Mendez M, Rosillo F, Paz-Ares L, Cardona J.V, Isla D, Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy (2017) CLIN TRANSL ONCOL, 19 (2), 219-226.

**IF: 2.392**

Duran I, Lambea J, Maroto P, Gonzalez-Larriba J.L, Flores L, Granados-Principal S, Graupera M, Saez B, Vivancos A, Casanovas O, Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action (2017) TARGET ONCOL, 12 (1), 19-35.

**IF: 3.877**

Echavarria I, Lopez-Tarruella S, Marquez-Rodas I, Jerez Y, Martin M, Neratinib for the treatment of HER2-positive early stage breast cancer (2017) EXPERT REV ANTICANC, 17 (8), 669-679.

**IF: 2.347**

Fischer S, Tandstad T, Wheater M, Porfiri E, Flechon A, Aparicio J, Klingbiel D, Skrbinc B, Basso U, Shamash J, Lorch A, Dieckmann K.-P, Cohn-Cedermark G, Stahl O, Chau C, Arriola E, Marti K, Hutton P, Laguerre B, Maroto P, Beyer J, Gillessen S, Outcome of men with relapse after adjuvant carboplatin for clinical stage I seminoma (2017) J CLIN ONCOL, 35 (2), 194-200.

**IF: 26.303**

Gonzalez A, Lluch A, Aba E, Albalen J, Anton A, Alvarez I, Ayala F, Barnadas A, Calvo L, Ciruelos E, Cortes J, de la Haba J, Lopez-Vega J.M., Martinez E, Munoz M, Pelaez I, Redondo A, Rodriguez A, Rodriguez C.A., Ruiz A, Lombart A, A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM) (2017) CLIN TRANSL ONCOL, 19 (5), 616-624.

**IF: 2.392**

Gonzalez del Alba A, Arranz J.A., Puente J, Mendez-Vidal M.J., Gallardo E, Grande E, Perez-Valderrama B, Gonzalez-Billalabeitia E, Lazaro-Quintela M, Pinto A, Lainez N,

# Clinical Oncology

\*TIF: 351.635 \*\*MIF: 7.0327

Piulats J.M., Esteban E., Maroto Rey J.P., Garcia J.A., Suarez C., Recent advances in genitourinary tumors: A review focused on biology and systemic treatment (2017) CRIT REV ONCOL HEMAT, 113, 171-190.

**IF: 4.495**

Gonzalez-Billalbeitia E., Castellano D., Sobrevilla N., Guma J., Hervas D., Luengo M.I., Aparicio J., Sanchez-Munoz A., Mellado B., Saenz A., Valverde C., Fernandez A., Margeli M., Duran I., Fernandez S., Sastre J., Ros S., Maroto P., Manneh R., Cerezuela P., Carmena-Bayonas A., Prognostic significance of venous thromboembolic events in disseminated germ cell cancer patients (2017) JN-CI-J NATL CANCER I, 109 (4).

**IF: 11.238**

Gonzalez-Larriba J.L., Maroto P., Duran I., Lambrea J., Flores L., Castellano D., Anido U., Basterrechea L., Casanova O., Chirivella I., Climent M.A., Dur I., Gallardo E., Garc R., Guix M., Lainez N., Marino A.M., Montesa A., Pinto A., Puente J., Romero G.R., Suarez C., Virizuela J.A., The role of mTOR inhibition as second-line therapy in metastatic renal carcinoma: clinical evidence and current challenges (2017) EXPERT REV ANTICANC, 17 (3), 217-226.

**IF: 2.347**

Grasselli J., Elez E., Caratu G., Matito J., Santos C., Macarulla T., Vidal J., Garcia M., Vieitez J.M., Paez D., Falco E., Lopez Lopez C., Aranda E., Jones F., Sikri V., Nuciforo P., Fasani R., Tabernero J., Montagut C., Azuara D., Dienstmann R., Salazar R., Vivancos A., Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer (2017) ANN ONCOL, 28 (6), 1294-1301.

**IF: 13.926**

Gronchi A., Ferrari S., Quagliuolo V., Broto J.M., Pousa A.L., Grignani G., Basso U., Blay J.-Y., Tendero O., Beveridge R.D., Ferraresi V., Lugowska I., Merlo D.F., Fontana V., Marchesi E., Donati D.M., Palassini E., Palmerini E., De Sanctis R., Morosi C., Stacchiotti S., Bagué S., Coindre J.M., Dei Tos A.P., Picci P., Bruzzi P., Casali P.G., Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial (2017) LANCET ONCOL, 18 (6), 812-822.

**IF: 36.418**

Irigoyen A., Gallego J., Guillen Ponce C., Vera R., Iranzo V., Ales I., Arevalo S., Pisa A., Martin M., Salud A., Falco E., Saenz A., Manzano Mozo J.L., Pulido G., Martinez Galan J., Pazo-Cid R., Rivera F., Garcia Garcia T., Serra O., Fernandez Parra E.M., Hurtado A., Gomez Reina M.J., Lopez Gomez L.J., Martinez Ortega E., Benavides M., Aranda E., Gemcitabine-

erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety results of a phase IIb randomised study from the Spanish TTD Collaborative Group (2017) EUR J CANCER, 75, 73-82.

**IF: 7.191**

Isla D., Majem M., Vinolas N., Artal A., Blasco A., Felip E., Garrido P., Remon J., Baquedano M., Borras J.M., Die Trill M., Garcia-Campelo R., Juan O., Leon C., Lianes P., Lopez-Rios F., Molins L., Planchuelo M.A., Cobo M., Paz-Ares L., Trigo J.M., de Castro J., A consensus statement on the gender perspective in lung cancer (2017) CLIN TRANSL ONCOL, 19 (5), 527-535.

**IF: 2.392**

Jimenez-Fonseca P., Gomez Saez J.M., Santamaría Sandi J., Capdevila J., Navarro Gonzalez E., Zafon Llopis C., Ramon Y Cajal Asensio T., Riesco-Eizaguirre G., Grande E., Galofre J.C., Spanish consensus for the management of patients with anaplastic cell thyroid carcinoma (2017) CLIN TRANSL ONCOL, 19 (1), 12-20.

**IF: 2.392**

Joensuu H., Blay J.-Y., Comandone A., Martin-Broto J., Fumagalli E., Grignani G., Del Muro X.G., Adenis A., Valverde C., Pousa A.L., Bouche O., Italiano A., Bauer S., Barone C., Weiss C., Crippa S., Camozzi M., Castellana R., Le Cesne A., Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib (2017) BRIT J CANCER, 117 (9), 1278-1285.

**IF: 5.922**

Manos M., Giralt J., Rueda A., Cabrera J., Martinez-Trufero J., Marruecos J., Lopez-Pousa A., Rodrigo J.P., Castelo B., Martinez-Galan J., Arias F., Chaves M., Herranz J.J., Arrazubi V., Baste N., Castro A., Mesia R., Multidisciplinary management of head and neck cancer: First expert consensus using Delphi methodology from the Spanish Society for Head and Neck Cancer (part 1) (2017) ORAL ONCOL, 70, 58-64.

**IF: 4.636**

Maroto P., Esteban E., Fernandez Parra E., Mendez-Vidal M.J., Domenech M., Perez-Valderrama B., Calderero V., Perez-Gracia J.L., Grande E., Algaba F., HIF pathway and c-Myc as biomarkers for response to sunitinib in metastatic clear-cell renal cell carcinoma (2017) ONCOTARGETS THER, 10, 4635-4643.

**IF: 2.656**

Marquez-Rodas I., Pollan M., Escudero M.J., Ruiz A., Martin M., Santaballa A., Martinez del Prado P., Batista N., Andres R., Anton A., Llombart A., Fernandez Aramburu A., Adrover E., Gonzalez S., Segui M.A., Calvo L., Lizón J., Rodriguez Lescure A., Ramon y Cajal T.,

Llort G., Jara C., Carrasco E., Lopez-Tarruella S., Frequency of breast cancer with hereditary risk features in Spain: Analysis from GEICAM "El Álamo III" retrospective study (2017) PLOS ONE, 12 (10).

**IF: 2.766**

Martin M., Chacon J.I., Anton A., Plazaola A., Garcia-Martinez E., Segui M.A., Sanchez-Rovira P., Palacios J., Calvo L., Esteban C., Espinosa E., Barnadas A., Batista N., Guerrero A., Munoz M., Romio E., Rodriguez-Martin C., Caballero R., Casas M.I., Rojo F., Carrasco E., Antolin S., Neoadjuvant therapy with weekly nanoparticle albumin-bound paclitaxel for luminal early breast cancer patients: Results from the nabrax study (GEICAM/2011-02), a multicenter, non-randomized, phase ii trial, with a companion biomarker analysis (2017) ONCOLOGIST, 22 (11), 1301-1308.

**IF: 5.306**

Martin M., Chan A., Dirix L., O'Shaughnessy J., Hegg R., Manikhas A., Shtivelband M., Krivorotko P., Batista Lopez N., Campone M., Ruiz Borrego M., Khan Q.J., Beck J.T., Ramos Vazquez M., Urban P., Goteti S., Di Tomaso E., Massacesi C., Delaloge S., A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4) (2017) ANN ONCOL, 28 (2), 313-320.

**IF: 13.926**

Martin-Broto J., Redondo A., Valverde C., Vaz M.A., Mora J., Garcia del Muro X., Gutierrez A., Tous C., Carnero A., Marcilla D., Carranza A., Sancho P., Martinez-Trufero J., Diaz-Beveridge R., Cruz J., Encinas V., Taron M., Moura D.S., Luna P., Hindi N., Lopez-Pousa A., Gemcitabine plus sirolimus for relapsed and progressing osteosarcoma patients after standard chemotherapy: A multicenter, single-arm phase II trial of Spanish Group for Research on Sarcoma (GEIS) (2017) ANN ONCOL, 28 (12), 2994-2999.

**IF: 13.926**

Mayo-de-las-Casas C., Jordana-Ariza N., Garzon-Ibanez M., Balada-Bel A., Bertran-Alamillo J., Viteri-Ramirez S., Reguart N., Munoz-Quintana M.A., Lianes-Barragan P., Camps C., Jantus E., Remon-Massip J., Calabuig S., Aguiar D., Gil M.L., Vinolas N., Santos-Rodriguez A.K., Majem M., Garcia-Pelaez B., Villatoro S., Perez-Rosado A., Monasterio J.C., Ovalle E., Catalán M.J., Campos R., Morales-Espinosa D., Martinez-Bueno A., Gonzalez-Cao M., Gonzalez X., Moya-Horno I., Sosa A.E., Karachaliou N., Rosell R., Molina-Vila M.A., Large scale, prospective screening of EGFR mutations in the blood of advanced NSCLC patients to guide treatment decisions (2017) ANN ONCOL, 28 (9), 2248-2255.

**IF: 13.926**

\*TIF: 351.635 \*\*MIF: 7.0327

Mestres J.A., IMolins A.B., Martinez LC., Lopez-Muniz J.I.C., Gil E.C., de Juan Ferre A., Del Barco Berron S., Perez Y.F., Mata J.G., Palomo A.G., Gregori J.G., Pardo P.G., Manas J.J.I., Hernandez A.L., de Duenas E.M., Janez N.M., Murillo S.M., Bofill J.S., Aunon P.Z., Sanchez-Rovira P., Defining the optimal sequence for the systemic treatment of metastatic breast cancer (2017) CLIN TRANSL ONCOL, 19 (2), 149-161.

**IF: 2.392**

Mocellin S., Baretta Z., Roque i Figuls M., Sola I., Martin-Richard M., Hallum S., Bonfill Cosp X., Second-line systemic therapy for metastatic colorectal cancer (2017) COCHRANE DB SYST REV, 2017 (1).

**IF: 6.754**

Montes A., Fernandez A., Camacho V., de Quintana C., Gallego O., Craven-Bartle J., Lopez D., Molet J., Gomez-Anson B., Carrio I., The usefulness of 18F-fluorocholine PET/CT in the detection of recurrence of central nervous system primary neoplasms Valor de la PET/TC cerebral con 18F-fluorocolina en la detección de recurrencias de neoplasias primarias del sistema nervioso central (2017) REV ESP MED NUCL IMA, 36 (4), 227-232.

**IF: 1.202**

Mora J., Castaneda A., Perez-Jaume S., Lopez-Pousa A., Maradiegue E., Valverde C., Martin-Broto J., Garcia Del Muro X., Cruz O., Cruz J., Martinez-Trufero J., Maurel J., Vaz M.A., De Alava E., De Torres C., GEIS-21: A multicentric phase II study of intensive chemotherapy including gemcitabine and docetaxel for the treatment of Ewing sarcoma of children and adults: A report from the Spanish sarcoma group (GEIS) (2017) BRIT J CANCER, 117 (6), 767-774.

**IF: 5.922**

Moran T., Palmero R., Provencio M., Insa A., Majem M., Reguart N., Bosch-Barrera J., Isla D., Costa E.C., Lee C., Puig M., Kraemer S., Schnell D., Rosell R., A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib (2017) LUNG CANCER, 108, 154-160.

**IF: 4.486**

Paez D., Salazar R., Tabernero J., DPYD genotype-guided fluoropyrimidines dose: Is it ready for prime time? (2017) ANN ONCOL, 28 (12), 2913-2914.

**IF: 13.926**

Perez-Gracia J.L., Sanmamed M.F., Bosch A., Patino-Garcia A., Schalper K.A., Segura V., Bellmunt J., Tabernero J., Sweeney C.J., Choueiri T.K., Martin M., Fusco J.P., Rodriguez-Ruiz M.E., Calvo A., Prior C., Paz-Ares L., Pio R., Gonzalez-Billalabertia E., Gonzalez

Hernandez A., Paez D., Piulats J.M., Gorpide A., Andueza M., de Velasco G., Pazo R., Grande E., Nicolas P., Abad-Santos F., Garcia-Donas J., Castellano D., Pajares M.J., Suarez C., Colomer R., Montuenga L.M., Melero I., Strategies to design clinical studies to identify predictive biomarkers in cancer research (2017) CANCER TREAT REV, 53, 79-97.

**IF: 8.122**

Puente J., Lainez N., Duenas M., Mendez-Vidal M.J., Esteban E., Castellano D., Martinez-Fernandez M., Basterretxea L., Juan-Fita M.J., Anton L., Leon L., Lambea J., Perez-Valderrama B., Vazquez S., Suarez C., del Muro X.G., Gallardo E., Maroto J.P., Luz Samaniego M., Suarez-Paniagua B., Sanz J., Paramio J.M., Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma (2017) ONCOTARGET, 8 (18), 30410-30421.

**IF: 5.1680**

Puente J., Grande E., Medina A., Maroto P., Lainez N., Arranz J.A., Docetaxel in prostate cancer: A familiar face as the new standard in a hormone-sensitive setting (2017) THER ADV MED ONCOL, 9 (5), 307-318.

**IF: 6.238**

Redondo A., Bague S., Bernabeu D., Ortiz-Cruz E., Valverde C., Alvarez R., Martinez-Trufero J., Lopez-Martin J.A., Correa R., Cruz J., Lopez-Pousa A., Santos A., Garcia Del Muro X., Martin-Broto J., Malignant bone tumors (other than Ewing's): clinical practice guidelines for diagnosis, treatment and follow-up by Spanish Group for Research on Sarcomas (GEIS) (2017) CANCER CHEMOTH PHARM, 80 (6), 1113-1131.

**IF: 2.808**

Remon J., Isla D., Garrido P., de Castro J., Majem M., Vinolas N., Artal A., Carcereny E., Garcia-Campelo M.R., Lianes P., Provencio M., Juan O., Diz P., Blanco R., Lopez-Castro R., Maestu I., Vadell C., Felip E., Efficacy of tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a real-world setting: the WORLD07 database (2017) CLIN TRANSL ONCOL, 19 (12), 1537-1542.

**IF: 2.392**

Rosell R., Dafni U., Felip E., Curioni-Fontecedro A., Gautschi O., Peters S., Massuti B., Palmero R., Aix S.P., Carcereny E., Fruh M., Pless M., Popat S., Kotsakis A., Cuffe S., Bidoli P., Favaretto A., Froesch P., Reguart N., Puente J., Coate L., Barlesi F., Rauch D., Thomas M., Camps C., Gomez-Codina J., Majem M., Porta R., Shah R., Hanrahan E., Kammler R., Ruepp B., Rabaglio M., Kassapian M., Karachaliou N., Tam R., Shames D.S., Molina-Vila M.A., Stahel R.A., Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international,

multicentre, single-arm, phase 2 trial (2017) LANCET RESP MED, 5 (5), 435-444.

**IF: 21.466**

Sepulveda-Sanchez J.M., Vaz M.A., Balana C., Gil-Gil M., Reynes G., Gallego O., Martinez-Garcia M., Vicente E., Quindos M., Luque R., Ramos A., Ruano Y., Perez-Segura P., Benavides M., Sanchez-Gomez P., Hernandez-Lain A., Phase II trial of dacitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification (2017) NEURO-ONCOLOGY, 19 (11), 1522-1531.

**IF: 9.384**

Sharma P., Lopez-Tarruella S., Garcia-Saenz J.A., Ward C., Connor C.S., Gomez H.L., Prat A., Moreno F., Jerez-Gilarranz Y., Barnadas A., Picornell A.C., Del Monte-Millan M., Gonzalez-Rivera M., Massarrah T., Pelaez-Lorenzo B., Palomero M.I., Gonzalez Del Val R., Cortes J., Rivera H.F., Morales D.B., Marquez-Rodas I., Perou C.M., Wagner J.L., Mammen J.M.V., McGinniss M.K., Klemp J.R., Amin A.L., Fabian C.J., Heldstab J., Godwin A.K., Jensen R.A., Kimler B.F., Khan Q.J., Martin M., Efficacy of neoadjuvant carboplatin plus docetaxel in triple-negative breast cancer: Combined analysis of two cohorts (2017) CLIN CANCER RES, 23 (3), 649-657.

**IF: 10.199**

Socinski M.A., Kaye F.J., Spigel D.R., Kudrik F.J., Ponce S., Ellis P.M., Majem M., Lorigan P., Gandhi L., Gutierrez M.E., Nepert D., Corral J., Ares L.P., Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage Disease (2017) CLIN LUNG CANCER, 18 (1), 68-76.

**IF: 4.486**

Sullivan I., Salazar J., Arqueros C., Andres M., Sebio A., Majem M., Szafrańska J., Martinez E., Paez D., Lopez-Pousa A., Baiget M., Barnadas A., KRAS genetic variant as a prognostic factor for recurrence in resectable non-small cell lung cancer (2017) CLIN TRANSL ONCOL, 19 (7), 884-890.

**IF: 2.392**

Tibau A., Diez-Gonzalez L., Navarro B., Galan-Moya E.M., Templeton A.J., Seruga B., Pandiella A., Amir E., Ocana A., Impact of Availability of Companion Diagnostics on the Clinical Development of Anticancer Drugs (2017) MOL DIAGN THER, 21 (3), 337-343.

**IF: 2.716**

Vinolas N., Garrido P., Isla D., Provencio M., Majem M., Artal A., Carcereny E., Garcia-Campelo R., Lianes P., De La Penas R., Felip E., Lung Cancer in Never-Smoking Women: A Sub-Analysis of the Spanish Female-Specific Database WORLD07 (2017) CANCER INVEST, 35 (5), 358-365.

**IF: 2.053**

# Oncogenesis and Antitumour Drugs



## Coordinator

Mangues Bafalluy, Ramon IR  
rmangues@santpau.cat

## Members

Álamo Vargas,	
Patricia Virginia	IR- EXTERNS
Arroyo Solera, Irene	IR
Boullosa Goberna,	
Ana María	CIBERBBN
Cabrera Rodríguez,	
María del Carmen	CIBERBBN
Carmona Gude, Sílvia	IR
Casanova Rigat, Isolda	CIBERBBN
Céspedes Navarro, Virtudes	IR
Falgàs Comamala, Aida	IR
Garcia León, Annabel	IR
Medina Gutiérrez, Esperanza	IR
Navas Jiménez, Luis Carlos	IR
Sala Faig, Rita	IR
Turrado Rodríguez, Victor	FGS
Unzueta Elorza, Ugutz	IR

## Main Lines of Research

- ▶ Development of novel animal models of disseminated disease in solid tumours and haematological neoplasms for the mechanistic study of metastases and preclinical drug development.

- ▶ Identification of prognostic biomarkers in head and neck squamous cell carcinoma and their functional validation *in vivo*.
- ▶ Development of nanoconjugates for targeted delivery of antitumour drugs or toxins to metastasis stem cells.

## Challenges

- ▶ Obtain funding to ensure stable employment of senior researchers, attract post-doctoral fellows and reinforce current collaborations with clinicians.
- ▶ Develop molecular markers for therapeutic decision-making in head and neck carcinomas.

- ▶ Achieve antimetastatic effects by targeting antitumour drugs to metastasis stem cells in solid tumors and haematological neoplasies.
- ▶ Enhance international collaboration and participation in EU networks and industrial projects.

## Collaborations

### Collaborations with other IIB Sant Pau Groups

- ▶ Collaboration with Dra. Isolda Casanova and Àida Falgàs in: Terapia dirigida de Aurstatina E o Ara-C a células de leucemia mieloide aguda que expresan CXCR4, receptor implicado en adhesión al estroma y quimiorresistencia. PI14/00450. IP: Jordi Sierra Gil. Instituto de Salud Carlos III. Duration: 2015-2018. 172,000.00 €.
- ▶ Collaboration of Dr. Irene Arroyo with the research group of the Otorhinolaryngology Service led by the Drs. Miquel Quer and Xavier Léon in the study of prognostic factors in head and neck cancer.
- ▶ Collaboration of Drs. María Virtudes Céspedes and Patricia Álamo and de Rita Sala with the research groups of the Services of Pharmacy (led by Dra. María Antonia Mangues), Pathological Anatomy (led by Drs. Enrique Lerma and Alberto Gallardo), Surgery (led by Dr. Manuel Trias) and Medical Oncology (led by Drs. Agustí Barnadas and Antonio López-Pousa), and Àlex Bayés and Marta Valle groups at IIB-Sant Pau. Project: Targeted nanoconjugates for the selective elimination of stem cells in disseminated cancer. PIE15/00028. IP: Ramon Mangues. Instituto de Salud Carlos III. Duration: 2016-2018. 423,912.00 €.

### National Collaborations

- ▶ Eduard Batlle, Biomedical Research Institute (IIRB) and Barcelona Scientific Park (PCB).
- ▶ Antonio Villaverde, Departament de Microbiología Aplicada, Universitat Autònoma de Barcelona (UAB).
- ▶ CB06/01/1031. Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN). Insti-

tuto de Salud Carlos III. 2008-2018. 90,000-117,000€/year.

- ▶ OncoCat. Member of the Catalonian Cancer Research Network. Xarxa ConnectEU, Biocat, Generalitat de Catalunya.
- ▶ NanoBioMed. Member of the Catalonian Network on Nanobiotechnology, Xarxa Connect-EU. Biocat.

### International Collaborations

- ▶ Achilea Bittencourt. Visiting Researcher, International Cooperation with Brasil, MCT/CNPq 046/2010.
- ▶ Paolo Micheli, Institute for Cancer Research and Treatment, Candiolo, Turin (Italy).
- ▶ Arne Östman, Cancer Center Karolinska, Karolinska Institutet, Stockholm (Sweden).
- ▶ Alberto Bardelli, University of Torino, Medical School, Turin (Italy).
- ▶ Ramon Mangues collaborates with the French Institute National du Cancer (INCa), by being Member of the Scientific Evaluation Committee of the Translational Cancer Research Programme (PRT-K) since 2016, Ministry of Health (DGOS) and
- ▶ ATMP-EATRIS, European Union. Member of the Working Group on Advanced therapies and biologicals of ATMP (Advanced Therapy Medicinal Products), EATRIS (European Infrastructure for Translational Medicine) Network.
- ▶ ETP Nanomedicine, European Union, Member of the European Technology Platform on Nanomedicine.
- ▶ TME-AACR member. Member of the Tumor Microenvironment Working Group, American Association for Cancer Research (AACR).

## Active Grants

- ▶ Ramon Mangues Bafalluy. Grup d'òncogènes i antitumorals (GOA). 2014 SGR 1041. Agència de Gestió d'Ajuts Universitaris i de Recerca. Duration: 2014-2017. 30,000.00 €.
- ▶ Ramon Mangues Bafalluy. Desenvolupament d'un nanoconjunt antimetastàtic dirigit a cèl·lules mare metastàtiques CXCR4+. 2014 PROD 00055. Agència de Gestió d'Ajuts Universitaris i de Recerca. Duration: 2015-2017. 89,500.00 €.
- ▶ Ramon Mangues Bafalluy. Prevención de metástasis en cáncer colorrectal mediante terapia dirigida a células madre metastásicas y estromales. PI15/00378. Instituto de Salud Carlos III. Duration: 2016-2018. 172,000.00 €.
- ▶ Virtudes Céspedes Navarro. Contratos Miguel Servet I 2015. MS15/00163. Instituto de Salud Carlos III. Duration: 2016-2021. 202,500.00 €.
- ▶ Virtudes Céspedes Navarro. Nanoconjugates for targeted therapy against CXCR4+ cancer stem cells in pancreatic cancer. CP15/00163. Instituto de Salud Carlos III. Duration: 2016-2018. 121,500.00 €.
- ▶ Ramon Mangues Bafalluy. Targeted nanoconjugates for the selective elimination of stem cells in disseminated cancer. PIE15/00028. Instituto de Salud Carlos III. Duration: 2016-2018. 423,912.00 €.
- ▶ Rita Sala Faig. Contractes predoctorals de formació en investigació en salut 2016. FI16/00017. Instituto de Salud Carlos III. Duration: 2017-2020. 82,400.00 €.
- ▶ Ramon Mangues Bafalluy. Papel de las células natural killer y del receptor CXCR4 en el desarrollo de metástasis en cáncer colorrectal. IR16-P2. Fundació Privada Hospital de la Santa Creu i Sant Pau. Duration: 2017-2017. 7,000.00 €.
- ▶ Ugutz Unzueta Elorza. Contractes "Sara Borrell" 2014. CD14/00055. Instituto de Salud Carlos III. Duration: 2015-2018. 86,598.00 €.
- ▶ Ramon Mangues Bafalluy. Genotoxic nanoparticles targeting colorectal cancer stem cells. 20132030. Fundació La Marató de TV3. Duration: 2014-2017. 142,000.00 €.
- ▶ Ramon Mangues Bafalluy. Grup d'Òncogènes i Antitumorals (GOA). 2017 SGR 865. Agència de Gestió d'Ajuts Universitaris i de Recerca. Duration: 2017-2019. 35,200.00 €.
- ▶ Carmen Cabrera Rodriguez. Ayudas para personal técnico de apoyo a infraestructuras. convocatoria 2013. Plataforma de Nanotoxicología. Centro de Investigación en Red en Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN). PTA2013-8426-I. MINECO. Duration: 2015-2017. 36,000 €.
- ▶ Ramón Mangues. Humanized antitumoral nanodrug for the treatment of CXCR4-positive cancers (CIBER-BBN Technology Transfer Program (coordinated project). Group PI and coordinator: Antonio Villaverde (NBT-UAB). Industrial Partner: Nanoligent SL. Finance Agencies: CIBER-BBN and Nanoligent SL. Nanotrac. BBN-TRF17. Duration: 2017-2018. 35,000 €.

Note: Total amount granted to PI. It does not include indirect costs.

## Grants Awarded in 2017

- ▶ Aida Falgas Comamala. Avaluació de l'activitat antitumoral de nous nanoconjunts dirigits al receptor CXCR4 en Limfoma Difús de Cèl·lules Grans B (LDCGB). 2017 FI\_B 00680. Agència de Gestió d'Ajuts Universitaris i de Recerca. Duration: 2017-2020. 40,806.00 €.
- ▶ Virtudes Céspedes Navarro. Terapia dirigida para la eliminación selectiva de células madre metastásicas CXCR4+ en cáncer de endometrio. FMM 2017. Fundación Mutua Madrileña. Duration: 2017-2020. 133,333.33 €.
- ▶ Virtudes Céspedes Navarro. Nanoterapia dirigida y radioterapia SBRT combinada para la eliminación selectiva de células madre tumorales en cáncer de páncreas. PI17/00150. Instituto de Salud Carlos III. Duration: 2018-2020. 123,000.00 €.

- ▶ Ramon Mangues Bafalluy. Émbolos tumorales circulantes hCX-CR4/SerpinE1 en el pronóstico del cáncer de cabeza y cuello. PI17/00584. Instituto de Salud Carlos III. Duration: 2018-2020. 90,000.00 €.
- ▶ Ramon Mangues Bafalluy. Implicación de la vía CXCR4/CXCL12/CXCR7 en la resistencia, recidiva y fenotipo de célula madre de la leucemia mieloide aguda. PI17/01246. Instituto de Salud Carlos III. Duration: 2018-2020. 108,000.00 €.

Note: Total amount granted to PI. It does not include indirect costs.

## Theses

- ▶ Irene Arroyo Solera. Estudio del valor pronóstico de Serpina E1 y su papel en el crecimiento y la diseminación metastásica del carcinoma escamoso de cabeza y cuello. Universitat de Barcelona. Directors: Ramon Mangues and Miguel Angel Pavón. Date of defense: 24/06/2017.

## Transfer Products

- ▶ Company: NANOLIGENT, SLU. (B-66970088). Spin-off of the Biomedical Research Institute Sant Pau. Founding members: M. Rodríguez-Mariscal, Ramon Mangues, Antonio Villaverde, and Esther Vázquez. Date of constitution: 03/13/2017.

# Oncogenesis and Antitumour Drugs

## Patents

- ▶ Inventors: Antonio Villaverde, Esther Vázquez, Ugutz Unzueta, Ramon Mangues, María Virtudes Céspedes, Isolda Casanova. Owner Companies: Universitat Autònoma de Barcelona, Fundació Privada Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau and Centro de Investigación Biomédica en Red. Therapeutic Nanoconjugates And Uses Thereof. European Patent Office. Application number: EP17382461, PCT. 14/07/2017.
- ▶ Inventors: Antonio Villaverde, Esther Vázquez, Naroa Serna, Laura Sánchez García, Ugutz Unzueta, Ramon Mangues, María Virtudes, Céspedes Isolda Casanova. Owner Companies: Universitat Autònoma de Barcelona, Fundació Privada Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau and Centro de Investigación Biomédica en Red. Nanostructured Proteins And Uses Thereof. European Patent Office. Application number: EP17169722.0 - 1401, PCT. 05/05/2017.
- ▶ Inventors: Esther Vázquez, Ugutz Unzueta, Neus Ferrer, Antonio P. Villaverde, María Virtudes Céspedes, Isolda Casanova and Ramon Mangues. Owner Companies: Universitat Autònoma de Barcelona, Fundació Privada Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau and Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN). Methods and reagents for efficient and targeted delivery of therapeutic molecules to CXCR4 cells. European Patent: EP2663336. Reference: P6461EPPC. European Patent, PCT. 17/09/2017.

**\*TIF: 74.365 \*\*MIF: 6.760**

## Scientific Production

Body S., Esteve-Arenys A., Miloudi H., Recasens-Zorzo C., Tchakarska G., Moros A., Bustany S., Vidal-Crespo A., Rodriguez V., Lavigne R., Com E., Casanova I., Mangues R., Weigert O., Sanjuan-Pla A., Menendez P., Marcq B., Picquenot J.-M., Perez-Galan P., Jardin F., Roue G., Sola B., Cytoplasmic cyclin D1 controls the migration and invasiveness of mantle lymphoma cells (2017) SCI REP-UK, 7 (1).

**IF: 4.122**

Mira A., Morello V., Cespedes M.V., Perera T., Comoglio P.M., Mangues R., Michieli P., Stromal-derived HGF drives metabolic adaptation of colorectal cancer to angiogenesis inhibitors (2017) ONCOTARGET, 8 (24), 38193-38213.

**IF: 5.1680**

Pallares V., Hoyos M., Chillon M.C., Barragan E., Conde M.I.P., Llop M., Cespedes M.V., Nomdedeu J.F., Brunet S., Sanz M.A., Gonzalez-Diaz M., Sierra J., Casanova I., Mangues R., NEDD 9 an independent good prognostic factor in intermediate-risk acute myeloid leukemia patients (2017) ONCOTARGET, 8 (44), 76003-76014.

**IF: 5.1680**

Pesarrodona M., Crosas E., Cubarsi R., Sanchez-Chardi A., Saccardo P., Unzueta U., Rueda F., Sanchez-Garcia L., Serna N., Mangues R., Ferrer-Miralles N., Vazquez E., Villaverde A., Intrinsic functional and architectonic het-

erogeneity of tumor-targeted protein nanoparticles (2017) NANOSCALE, 9 (19), 6427-6435.

**IF: 7.233**

Sanchez-Garcia L., Serna N., Mattanovich M., Cazzanelli P., Sanchez-Chardi A., Conchillo-Sole O., Cortes F., Daura X., Unzueta U., Mangues R., Villaverde A., Vazquez E., The fusogenic peptide HA2 impairs selectivity of CXCR4-targeted protein nanoparticles (2017) CHEM COMMUN, 53 (33), 4565-4568.

**IF: 6.290**

Sanchez-Garcia L., Serna N., Mattanovich M., Cazzanelli P., Sanchez-Chardi A., Conchillo-Sole O., Cortes F., Daura X., Unzueta U., Mangues R., Villaverde A., Vazquez E., The fusogenic peptide HA2 impairs selectivity of CXCR4-targeted protein nanoparticles (2017) CHEM COMMUN, 53 (33), 4565-4568.

**IF: 6.290**

Serna N., Cespedes MV., Unzueta U., Sala R., Sanchez-Chardi A., Sanchez-Garcia L., Cortés F., Ferrer-Miralles N., Mangues R., Vázquez E., Villaverde A., Peptide-based nanostructured materials with intrinsic pro-apoptotic activities in CXCR4+ solid tumors. Adv Funct Mat 2017.

**IF: 13.325**

Serna N., Sanchez-Garcia L., Sanchez-Chardi A., Unzueta U., Roldan M., Mangues R.,

Vazquez E., Villaverde A., Protein-only, antimicrobial peptide-containing recombinant nanoparticles with inherent built-in antibacterial activity (2017) ACTA BIOMATER, 60, 256-263.

**IF: 6.383**

Serna N., Sanchez-Garcia L., Unzueta U., Diaz R., Vazquez E., Mangues R., Villaverde A., Protein-Based Therapeutic Killing for Cancer Therapies (2017) TRENDS BIOTECHNOL.


**IF: 13.578**

Unzueta U., Seras-Franzoso J., Cespedes M.V., Saccardo P., Cortes F., Rueda F., Garcia-Fruitos E., Ferrer-Miralles N., Mangues R., Vazquez E., Villaverde A., Engineering tumor cell targeting in nanoscale amyloidal materials (2017) NANOTECHNOLOGY, 28 (1).

**IF: 3.404**

Unzueta U., Serna N., Sanchez-Garcia L., Roldan M., Sanchez-Chardi A., Mangues R., Villaverde A., Vazquez E., Engineering multifunctional protein nanoparticles by in vitro disassembling and reassembling of heterologous building blocks (2017) NANOTECHNOLOGY, 28 (50).

**IF: 3.404**



# Haematological Diagnosis



## Coordinator

Nomdedéu Guinot,  
Josep Francesc  
jnomdedeu@santpau.cat

FGS

## Members

Blanco, María Laura	FGS
Bussaglia Petrillo, Elena Mart	FGS
Carricundo Morcillo, Maite	FGS
Espadaler Pare, Montserrat	FGS
Estivill Riezu, María Camino	FGS
Fernández Rosales, María Nieves	FGS
Fuentes Hernández, Francisca	FGS
Hernández Campos, Carmen	FGS
Martínez Sánchez, Elisabeth	FGS
Martínez Valverde, Clara María	FGS
Ortin Quílez, Rosa	FGS
Pratcorona Canela, Marta	FGS
Remacha Sevilla, Ángel Francisco	FGS
Rubio Olmos, Miguel Ángel	IR
Sarda Vidal, María Pilar	FGS
Serra Ferrer, Marta	FGS
Úbeda Rodenas, Jose	FGS

## Main Lines of Research

- ▶ Hematologic malignancies: diagnostics (morphology, cytogenetics, flow cytometry, molecular diagnostics).
- ▶ Next generation sequencing, genomic (microarrays) and proteomic platforms for diagnosis.
- ▶ Patient's derived xenografts.
- ▶ Noncancerous haemopathologies
- ▶ Diagnosis and characterization of thrombocytopenias, thrombocytopathies and other platelet pathologies, especially

complex pathologies (of genetic, mixed or unknown origin) and including unusual presentations of common diseases.

- ▶ In the framework of the GAIT-2 (genetic analysis of idiopathic thrombophilia, phase 2) project, to seek new phenotypes that favour the development of thrombosis, specifically related to the structure and function of platelets and other blood cells.

## Challenges

- ▶ Consolidate characterization of haematological tumours and complex, rare and genetic noncancerous haemopathologies.
- ▶ Sampling management: isolation of neoplastic and non-neoplastic cells.
- ▶ Include the results of mass-analysis genomic and proteomic platforms in diagnostic algorithms and establish prognostic factors for haematological disorders, preferably complex or genetic neoplasms and noncancerous pathologies.
- ▶ Set up animal models in hematologic malignancies.

▶ Consolidate cooperation with the GAIT-2 project, especially regarding platelet and other blood cell participation in thrombosis generation.

- ▶ Promote interaction and stable links with internal groups (clinical hematology, pathology, gastrointestinal, hemostasis and thrombosis, complex disease genomics areas) and with other groups in Spain and abroad, especially those with complementary technologies.

## Collaborations

### Collaborations with other IIB Sant Pau Group

- ▶ Dr. Matilde Parreño:
  - Josep Francesc Nomdedéu Guinot, Matilde Parreño. Instituto de Salud Carlos III. PI/00940. Duration: 2017-2019. 80,465 €.
  - Support grants to the Research Groups of Catalonia. Grup de Diagnòstic Hematològic. AGAUR 2017. 2017-SGR-383. Duration: 2017-2019.
- ▶ Oncology/Haematology and Transplantation (PI: Jordi Sierra).
- ▶ Molecular Bases of Disease (PI: Pablo Fuentes).
- ▶ Dr. Ramon Mangues/Isolda Casanova.

### External Collaborations

- ▶ Dr. G. Saglio. Torino University.
- ▶ Dr. G. Gaidano. Novara University.
- ▶ Dr. Anna Bigas, IMIM (Hospital del Mar).
- ▶ Dr. Luciano di Croce. CRG. Barcelona.
- ▶ Dr. Pablo Menéndez. Josep Carreras Foundation (Hospital Clínic).
- ▶ Dr. Alberto Villanueva. IDIBELL-Bellvitge Biomedical Research Institute.
- ▶ Dr. G. Vassiliou. Sanger Center. Cambridge. UK

## Active Grants

- ▶ Josep Francesc Nomdedéu Guinot. Diagnostic Hematologic. 2014 SGR 383. Agència de Gestió d'Ajuts Universitaris i de Recerca. Duration: 2014-2017. 30,000.00 €.
- ▶ Josep Francesc Nomdedéu Guinot. Heterogeneidad clonal en leucemia mieloide aguda: caracterización inmunofenotípica, genotípica y mediante generación de xenografts. PI16/00940. Instituto de Salud Carlos III. Duration: 2017-2019. 66,500.00 €

Note: Total amount granted to PI. It does not include indirect costs.

## Scientific Production

Bosch R., Mora A., Vicente E.P., Ferrer G., Jansa S., Damle R., Gorlatov S., Rai K., Montserrat E., Nomdedeu J., Pratcorona M., Blanco L., Saavedra S., Garrido A., Esquirol A., Garcia I., Granell M., Martino R., Delgado J., Sierra J., Chiorazzi N., Moreno C., FcγRIIb expression in early stage chronic lymphocytic leukemia (2017) LEUKEMIA LYMPHOMA, 58 (11), 2642-2648.  
**IF: 2.644**

Diaz de la Guardia R., Lopez-Millan B., La-voie J.R., Bueno C., Castano J., Gomez-Casares M., Vives S., Palomo L., Juan M., Delgado J., Blanco M.L., Nomdedeu J., Chaparro A., Fuster J.L., Anguita E., Rosu-Myles M., Menendez P., Detailed Characterization of Mesenchymal Stem/Stromal Cells from a

**\*TIF: 18.71 \*\*MIF: 3.742**

Large Cohort of AML Patients Demonstrates a Definitive Link to Treatment Outcomes (2017) STEM CELL REP, 8 (6), 1573-1586.

**IF: 6.537**

Gomez Ramirez S., Remacha Sevilla A.F., Munoz Gomez M., Anaemia in the elderly Anemia del anciano (2017) MED CLIN-BARCELONA, 149 (11), 496-503.

**IF: 1.168**

Nomdedeu J.F., Puigdecanet E., Bussaglia E., Hernandez J.J., Carricondo M., Estivill C., Marti-Tutusaus J.M., Tormo M., Zamora L., Serrano E., Perea G., de Llano M.P.Q., Garcia A., Sanchez-Ortega I., Ribera J.M., Nonell L., Aventin A., Sole F., Brunet M.S., Sierra J.,

Feasibility of the AML profiler (Skyline™ Array) for patient risk stratification in a multi-centre trial: a preliminary comparison with the conventional approach (2017) HEMATOLOGY ONCOL, 35 (4), 778-788.

**IF: 3.193**

Pallares V., Hoyos M., Chillon M.C., Barragan E., Conde M.I.P., Llop M., Cespedes M.V., Nomdedeu J.F., Brunet S., Sanz M.A., Gonzalez-Diaz M., Sierra J., Casanova I., Mangues R., NEJD 9 an independent good prognostic factor in intermediately acute myeloid leukemia patients (2017) ONCOTARGET, 8 (44), 76003-76014.

**IF: 5.1680**

# Molecular Pathology of Gynaecologic Cancer



## Coordinator

Llerma Puertas, Enrique FGS  
ellerma@santpau.cat

## Members

Bagué, Silvia	FGS
Espinosa Mariscal, Iñigo	FGS
Gallardo Alcañiz, Alberto	FGS
García-Valdecasas Vilanova, Bárbara	FGS
González Vidal, Alan	FGS
López Vilaró, Laura	FGS
Muñoz Beatove, Josefina	FGS
Pons Pérez, Cristina	FGS
Prat Diaz de Losada, Jaime	FGS
Szafranska, Justyna	FGS

## Main Lines of Research

- ▶ Pathogenic mechanisms of cancer (endometrial/ovarian cancer and others).
- ▶ Molecular mechanisms of stromal response and immunosuppression in endometrial cancer.
- ▶ Clinical application of prognostic factors in common cancers.
- ▶ Clinical application of tumour markers.
- ▶ Molecular biology of uterine and extra-uterine sarcomas.

## Challenges

- ▶ Cooperate with other groups at the national and international levels.

## Collaborations

### Collaborations with other IIB Sant Pau Groups

- ▶ Experimental Immunology (Silvia Vidal).
- ▶ Estudio de las alteraciones del metabolismo intracelular del colesterol en el cáncer de mama y carcinoma epitelial de tiroides: Evaluación de estrategias terapéuticas basadas en la HDL. (Juan Carlos Escolà Gil). PI16/00139. Instituto de Salud Carlos III. Duration: 2017-2020.
- ▶ Endocrinology, Diabetes and Nutrition (Dra. Rosa Corcoy)

### External Collaborations

Molecular alterations related with progression in endometrial cancer (Spanish Association Against Cancer, AECC):

- ▶ Dr. Jaume Reventós. Vall d'Hebron Hospital Research Institute (VHIR), Barcelona, Spain.
- ▶ Dr. Xavier Matias-Guiu. Institute for Biomedical Research (IRB Lleida), Lleida, Spain.
- ▶ Dr. Miguel Abal. Santiago de Compostela University Hospital Complex (CHUS), Spain.
- ▶ Dr. Gema Moreno. Fundación MD Anderson Internacional, Madrid, Spain.

## Active Grants

- ▶ Jaime Prat Diaz De Losada. Red Temática de Investigación Cooperativa en Cáncer (RTICC). RD12/0036/0011. Instituto de Salud Carlos III. Duration: 2013-2017. 160,000.00 €.

Note: Total amount granted to PI. It does not include indirect costs.

**\*TIF: 77.0210 \*\*MIF: 7.0019**

Espinosa I., Lee C.-H., D'Angelo E., Palacios J., Prat J., Undifferentiated and Dedifferentiated Endometrial Carcinomas with POLE Exonuclease Domain Mutations Have a Favorable Prognosis (2017) AM J SURG PATHOL, 41 (8), 1121-1128.

**IF: 5.878**

Espinosa I., Serrat N., Zannoni G.F., Rovira R., D'Angelo E., Prat J., Endometrioid endometrial carcinomas with microcystic, elongated, and fragmented (MELF) type of myoinvasion: role of immunohistochemistry in the detection of occult lymph node metastases and their clinical significance (2017) HUM PATHOL, 70, 6-13.

**IF: 3.125**

Garcia J., Lopez M., Lopez L., Bague S., Granell E., Quer M., Leon X., Validation of the pathological classification of lymph node metastasis for head and neck tumors according to the 8th edition of the TNM Classification of Malignant Tumors (2017) ORAL ONCOL, 70, 29-33.

**IF: 4.636**

Garcia-Sanz P., Trivino J.C., Mota A., Perez Lopez M., Colas E., Rojo-Sebastian A., Garcia A., Gatius S., Ruiz M., Prat J., Lopez-Lopez R., Abal M., Gil-Moreno A., Reventos J., Matias-Guiu X., Moreno-Bueno G., Chromatin remodelling and DNA repair genes are frequently mutated in endometrioid endometrial carcinoma (2017) INT J CANCER, 140 (7), 1551-1563.

**IF: 7.360**

Gronchi A., Ferrari S., Quagliuolo V., Broto J.M., Pousa A.L., Grignani G., Basso U., Blay J.-Y., Tendero O., Beveridge R.D., Ferraresi V., Lugowska I., Merlo D.F., Fontana V., Marchesi E., Donati D.M., Palassini E., Palmerini E., De Sanctis R., Morosi C., Stacchiotti S., Bague S., Coindre J.M., Dei Tos A.P., Picci P., Bruzzi P., Casali P.G., Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial (2017) LANCET ONCOL, 18 (6), 812-822.

**IF: 36.418**

Martel M., Alemany L., Taberna M., Mena M., Tous S., Bague S., Castellsague X., Quer M., Leon X., The role of HPV on the risk of second primary neoplasia in patients with oropharyngeal carcinoma (2017) ORAL ONCOL, 64, 37-43.

**IF: 4.636**

Prat J., Pathology of borderline and invasive cancers (2017) BEST PRACT RES CL OB, 41, 15-30.

**IF: 2.710**

Redondo A., Bague S., Bernabeu D., Ortiz-Cruz E., Valverde C., Alvarez R., Martinez-Trufero J., Lopez-Martin J.A., Correa R., Cruz J., Lopez-Pousa A., Santos A., Garcia Del Muro X., Martin-Broto J., Malignant bone tumors (other than Ewing's): clinical practice guidelines for diagnosis, treatment and follow-up by Spanish Group for Research on

Sarcomas (GEIS) (2017) CANCER CHEMOTH PHARM, 80 (6), 1113-1131.

**IF: 2.808**

Sanchez E., Nieto J.C., Vidal S., Santiago A., Martinez X., Sancho F.J., Sancho-Bru P., Mirelis B., Corominola H., Juarez C., Manichanh C., Guarner C., Soriano G., Fermented milk containing Lactobacillus paracasei subsp. paracasei CNCMI-1518 reduces bacterial translocation in rats treated with carbon tetrachloride (2017) SCI REP-UK, 7.

**IF: 4.122**

Sanmartin E., Ortiz-Martinez F., Pomares-Navarro E., Garcia-Martinez A., Rodrigo-Banos M., Garcia-Escalano M., Andres L., Lerma E., Aranda F.I., Martinez-Peinado P., Sempero-Ortells J.M., Peiro G., CD44 induces FOXP3 expression and is related with favorable outcome in breast carcinoma (2017) VIRCHOWS ARCH, 470 (1), 81-90.

**IF: 2.936**

Sullivan I., Salazar J., Arqueros C., Andres M., Sebio A., Majem M., Szafranska J., Martinez E., Paez D., Lopez-Pousa A., Baiget M., Barnadas A., KRAS genetic variant as a prognostic factor for recurrence in resectable non-small cell lung cancer (2017) CLIN TRANSL ONCOL, 19 (7), 884-890.

**IF: 2.392**

# Ear, Nose and Throat Cancers



## Coordinator

Quer Agustí, Miquel  
mquer@santpau.cat

FGS

## Members

De Juan Beltran, Julia	FGS
García Lorenzo, Jacinto	FGS
Gras Cabrerizo, Juan Ramon	FGS
Kolanczak, Katarzyna Alicia	FGS
Leon Vintró, Xavier	FGS
López Vilas, Montserrat	FGS
Montserrat Gili, Joan Ramon	FGS
Orus Dotu, Cesar	FGS
Pujol Olmo, Albert	FGS
Venegas Pizarro, Maria del Prado	FGS



## Main Lines of Research

- ▶ Genetic and molecular predictors of response to head and neck cancer (with the Oncogenesis and Antitumour Drugs group).
- ▶ Molecular mechanisms of inflammation in head and neck cancer (with the Inflammation Laboratory).
- ▶ Nasosinal endoscopic surgery: innovations in skull base techniques.
- ▶ Internal ear: aspects related to severe deafness, cochlear implants and otoneurological surgery of tumours.

## Challenges

- ▶ Promote clinical and translational research into head and neck cancer with a very large database of head and neck cancers.
- ▶ Study relevant clinical issues in depth (second-third neoplasms, staging concerns, prognostic factors, etc) and investigate translational aspects such as genetic and molecular predictors.

## Collaborations

### Collaborations with other IIB Sant Pau Groups

- ▶ Angiology, Vascular Biology and Inflammation (Dr. Lluís Vila).
- ▶ Oncogenesis and Antitumour Drugs (Dr. Ramon Mangues).
- ▶ Translational Molecular Oncology (Dr. Matilde Parreño).

### External Collaborations

- ▶ Catalan Institute of Oncology: Epidemiology (Dr. X. Bosch).
- ▶ Catalan Institute of Oncology: Oncology (Dr. Ricard Mesia).
- ▶ Hospital Joan XXIII: Head and Neck Cancer (Dr. F.J. Avilés).
- ▶ Hospital Central de Asturias: Head and Neck Cancer (Dr. C. Suárez).

## Active Grants

- ▶ Xavier Leon Vintró. Herramienta de predicción de respuesta a la radioterapia basada en la expresión de genes relacionados con la transición epitelial-mesenquimal en cáncer de cabeza y cuello. PI14/01918. Instituto de Salud Carlos III. Duration: 2015-2018. 71,500.00 €.

Note: Total amount granted to PI. It does not include indirect costs.

## Grants Awarded in 2017

- ▶ Miquel Quer Agustí. Émbolos tumorales circulantes hCXCR4/SerpinE1 en el pronóstico del cáncer de cabeza y cuello. PI17/00584. Instituto de Salud Carlos III. Duration: 2018-2020. 2,000.00 €.

Note: Total amount granted to PI. It does not include indirect costs.

## Theses

- ▶ Ricard Simó. Intrathoracic goitres: comparative study of the transcervical approach versus the combined cervicothoracic. Universitat Autònoma de Barcelona. Directors: Miquel Quer and Xavier León. Date of defense: 11/05/2017.
- ▶ Jose Miguel Costa González. Impacto del carcinoma de cabeza y cuello en la actividad laboral de los pacientes. Universitat Autònoma de Barcelona. Directors: Miquel Quer, Xavier León and Montserrat López. Date of defense: 17/02/2017.

\*TIF: 44.781 \*\*MIF: 2.6364

Aviles-Jurado F.X., Flores J.C., Guma J., Cepe-ruelo-Mallafre V., Casanova-Marques R., Gomez D., Vendrell J.J., Leon X., Vilaseca I., Terra X., Prognostic relevance of insulin resistance on disease-free survival in head and neck squamous cell carcinomas: Preliminary results (2017) HEAD NECK-J SCI SPEC, 39 (12), 2501-2511.

**IF: 2.471**

Codina Aroca A., Gras Cabrerizo J.R., De Juan Delago M., Massegur Solench H., Spontaneous cerebrospinal fluid fistula in the clivus (2017) EUR ANN OTORHINOLARY, 134 (6), 431-434.

**IF: 1.036**

Garcia J., Lopez M., Lopez L., Bague S., Granell E., Quer M., Leon X., Validation of the pathological classification of lymph node metastasis for head and neck tumors according to the 8th edition of the TNM Classification of Malignant Tumors (2017) ORAL ONCOL, 70, 29-33.

**IF: 4.636**

Garcia Lorenzo J., Montoro Martinez V., Rigo Quera A., Codina Aroca A., Lopez Vilas M., Quer Agusti M., Leon Vintro X., Modifications in the treatment of advanced laryngeal cancer throughout the last 30 years (2017) EUR ARCH OTO-RHINO-L, 274 (9), 3449-3455.

**IF: 1.546**

Garcia-Lorenzo J., Farre N., Codina A., Gallego O., de Vega M., Leon X., Nasopharyngeal carcinoma: 30-year experience of a single institution in a non-endemic area (2017) CLIN TRANSL ONCOL, 19 (6), 777-783.

**IF: 2.392**

Lenarz T., Muller L., Czerniejewska-Wolska H., Valles Varela H., Orus Dotu C., Durko M., Huarte Irujo A., Piszcztowski B., Zadroziak M., Irwin C., Graham P.L., Wyss J., Patient-Related Benefits for Adults with Cochlear Implantation: A Multicultural Longitudinal Observational Study (2017) AUDIOL NEURO-OTOL, 22 (2), 61-73.

**IF: 2.078**

Leon X., Valero C., Rovira C., Rodriguez C., Lopez M., Garcia-Lorenzo J., Quer M., Relationship between response to induction chemotherapy and disease control in patients with advanced laryngeal carcinoma included in an organ preservation protocol (2017) EUR ARCH OTO-RHINO-L, 274 (6), 2581-2587.

**IF: 1.546**

Leon X., Rigo A., Farre N., Lopez M., Garcia J., de Juan J., Quer M., Prognostic significance of extracapsular spread in isolated neck recurrences in head and neck squamous cell carcinoma patients (2017) EUR ARCH OTO-RHINO-L, 274 (1), 527-533.

**IF: 1.546**

Lopez F., Williams M.D., Skalova A., Hellquist H., Suarez C., Nixon I.J., Rodrigo J.P., Cardesa A., Strojan P., Quer M., Hunt J.L., Rinaldo A., Ferlito A., How Phenotype Guides Management of the Most Common Malignant Salivary Neoplasms of the Larynx? (2017) ADV THER, 34 (4), 813-825.

**IF: 3.085**

Lopez F., Williams M.D., Cardesa A., Hunt J.L., Strojan P., Rinaldo A., Nixon I.J., Rodrigo J.P., Saba N.F., Mendenhall W.M., Quer M., Suarez C., Ferlito A., How phenotype guides management of non-conventional squamous cell carcinomas of the larynx? (2017) EUR ARCH OTO-RHINO-L, 274 (7), 2709-2726.

**IF: 1.546**

Martel M., Alemany L., Taberna M., Mena M., Tous S., Bague S., Castellsague X., Quer M., Leon X., The role of HPV on the risk of second primary neoplasia in patients with oropharyngeal carcinoma (2017) ORAL ONCOL, 64, 37-43.

**IF: 4.636**

Olsen K.D., Quer M., de Bree R., Vander Poorten V., Rinaldo A., Ferlito A., Deep lobe parotidectomy—why, when, and how? (2017) EUR ARCH OTO-RHINO-L, 274 (12), 4073-4078.

**IF: 1.546**

Pardo L., Valero C., Lopez M., Garcia J., Camacho M., Quer M., Leon X., The prognostic value of pretreatment platelet count in patients with head and neck squamous cell carcinoma (2017) AURIS NASUS LARYNX, 44 (3), 313-318.

**IF: 1.387**

Quer M., Vander Poorten V., Takes R.P., Silver C.E., Boedeker C.C., de Bree R., Rinaldo A., Sanabria A., Shah A.R., Pujol A., Zbaren P., Ferlito A., Surgical options in benign parotid tumors: a proposal for classification (2017) EUR ARCH OTO-RHINO-L, 274 (11), 3825-3836.

**IF: 1.546**

Rodrigo J.P., Villaronga M.A., Menendez S.T., Hermida-Prado F., Quer M., Vilaseca I., Allanca E., Pedregal Mallo D., Astudillo A., Garcia-Pedrero J.M., A Novel Role for Nanog As An Early Cancer Risk Marker in Patients with Laryngeal Precancerous Lesions (2017) SCI REP-UK, 7 (1).

**IF: 4.122**

Schroeder L., Boscolo-Rizzo P., Dal Cin E., Romeo S., Baboci L., Dyckhoff G., Hess J., Lucena-Porcel C., Byl A., Becker N., Alemany L., Castellsague X., Quer M., Leon X., Wiesenfarth M., Pawlita M., Holzinger D., Human papillomavirus as prognostic marker with rising prevalence in neck squamous cell carcinoma of unknown primary: A retrospective multicentre study (2017) EUR J CANCER, 74, 73-81.

**IF: 7.191**

Valero C., Pardo L., Lopez M., Garcia J., Camacho M., Quer M., Leon X., Pretreatment count of peripheral neutrophils, monocytes, and lymphocytes as independent prognostic factor in patients with head and neck cancer (2017) HEAD NECK-J SCI SPEC, 39 (2), 219-226.

**IF: 2.471**

# Oncology/Haematology and Transplantation



## Coordinator

Sierra Gil, Jordi FGS  
jsierra@santpau.cat

## Members

Aljarrilla Medina, Alba	IR
Álvarez Fernández, Carmen	IR
Barata Badiella, Anna	IR
Bosch Godia, Rosa Maria	IR
Briones Meijide, Javier	FGS
Brunet Mauri, Maria Salut	FGS
Caballero González, Ana Carolina	FGS
Cuellar García, Carolina	IR
De Rueda Gamboa, Maria Jèssica	IR
Escriba Garcia, Laura	IR
Garcia Cadenas, Irene	FGS
Garrido Díaz, Anna	IR
Granell Gorrochategui, Miguel	FGS
Hoyos Colell, Montserrat	IR
Martino Bofarull, Rodrigo	FGS
Miqueleiz Álamos, Sara	IR
Monter Rovira, Anna	FGS
Mora Raya, Alba	IR
Moreno Atanasio, Carolina	FGS
Novelli Canales, Silvana Ana Rina	FGS
Pallarés López, Manuel Víctor	IR
Rodríguez Fernández, Diana	IR
Rosal Muntadas-Prim, Maria Josefa	IR
Rovira Brugues, Sandra	IR
Rubio Olmos, Miguel Angel	IR
Saavedra Gerosa, Silvana Daniela	
Téllez Gabriel, Marta	IR

## Main Lines of Research

- ▶ Study of the molecular and cellular pathophysiology of haematological cancers.
- ▶ Study of the prognostic value of clinical and biological parameters in haematological malignancies.
- ▶ Design of new modalities of chemotherapy, biotherapy and drug treatment targeting molecular mechanisms.

## Challenges

- ▶ Identify new prognostic parameters for risk and therapeutic stratification.
- ▶ Evaluate targeted therapy in cell lines and animal models (with the Oncogenesis and Antitumour Drugs group).
- ▶ Reduce toxicity and increase availability of allogeneic transplants.
- ▶ Molecularly characterize acute myeloid leukaemia and determine the prognostic value of known genes and other genes of uncertain significance (with the Haematology Laboratory).

## Collaborations

### Collaborations with other IIB Sant Pau Groups

- ▶ Oncogenesis and Antitumour Drugs (Dr. Ramon Mangues).
- ▶ Haematological Diagnosis (Dr. Josep Nomdedéu).
- ▶ Microbiology and Infectious Diseases (Dr. Pere Coll).

### External Collaborations

- ▶ Carlos III Health Institute Cooperative Cancer Research Network (RTICC): J. Sierra, co-ordinator.

- ▶ Design of new modalities of haemopoietic stem-cell transplantation and cell therapy.
- ▶ Psychological intervention and quality of life in patients with haematological malignancies.

- ▶ European Research Initiative on Chronic Lymphocytic Leukemia (ERIC): C. Moreno, coordinator.
- ▶ Spanish lymphoma transplantation groups (GELTAMO): J. Briones, S. Novelli.
- ▶ Spanish hematologic malignancies consortium (PETHEMA): J. Sierra, M. Granell, S. Brunet.
- ▶ Spanish CETLAM acute myeloid leukaemia and myelodysplasia group hospitals: co-ordinator, S. Brunet.
- ▶ European Leukaemia Network of Excellence groups.

## Active Grants

- ▶ Jordi Sierra Gil. Red Temática de Investigación Cooperativa en Cáncer (RTICC). RD12/0036/0071. Instituto de Salud Carlos III. Duration: 2013-2017. 321,500.00 €.
- ▶ Javier Briones Meijide. Memory stem T cells transduced with a chimeric antigen receptor targeting CD30 for the treatment of hodgkin lymphoma. 20130710. Fundació La Marató de TV3. Duration: 2014-2017. 153,970.00 €.
- ▶ Jordi Sierra Gil. Grup de diagnòstic i tractament de les neoplàsies hematològiques. 2014 SGR 1281. Agència de Gestió d'Ajuts Universitaris i de Recerca. Duration: 2015-2017. 18,000.00 €.
- ▶ Jordi Sierra Gil. Terapia dirigida de Auristatina E o Ara-C a células de leucemia mieloide aguda que expresan CXCR4, receptor implicado en adhesión al estroma y quimiorresistencia. PI14/00450. Instituto de Salud Carlos III. Duration: 2015-2018. 191,500.00 €.
- ▶ Alba Mora Raya. Caracterització immunofenotípica i molecular de la malaltia residual en leucèmia limfàtica crònica. 2015 FI\_B 00295. Agència de Gestió d'Ajuts Universitaris i de Recerca. Duration: 2015-2018. 58,965.00 €.
- ▶ Javier Briones Meijide. Terapia génica 2.0: nueva generación de vectores virales episomales de alta bioseguridad y su desarrollo pre-industrial. RTC-2015-3393-1. Ministeri d'Economia i Competitivitat. Duration: 2015-2018. 112,138.60 €.
- ▶ Javier Briones Meijide. Advancecat: acceleradora pel desenvolupament de teràpies avançades a Catalunya. COMRDI15-1-0013. BIOCAT. Duration: 2016-2019. 39,927.96 €.
- ▶ Javier Briones Meijide. Celulas T de memoria "STEM" transducidas con un receptor químerico antígeno-específico (CAR) dirigido al antígeno BCMA en linfoma de Hodgkin. PI15/01383. Instituto de Salud Carlos III. Duration: 2016-2018. 51,500.00 €.
- ▶ Carolina Moreno Atanasio. Long-term survivors in Chronic Lymphocytic Leukemia. AECC 2015-2. Associació Espanyola Contra el Càncer. Duration: 2016-2018. 20,000.00 €.
- ▶ Javier Briones Meijide. Memory stem T cells with optimized chimeric antigen receptors targeting CD30 for the treatment of peripheral T cells lymphomas. DJCLS 10R/2016. Fundació Josep Carreras Internacional. Duration: 2017-2020. 135,000.00 €.
- ▶ Carolina Moreno Atanasio. Anàlisi de l'expressió i funció del FcγRIIb en cèl·lules B normals i en leucèmia limfàtica crònica. Conveni CELLEX-2. Fundació CELLEX. Duration: 2015-2018. 118,181.82 €.
- ▶ Javier Briones Meijide. Inmunoterapia mediante células T de memoria "stem" modificadas con receptores químericos antígeno-específicos (CARs) para tratamiento de pacientes con neoplasias linfoides. Conveni CELLEX-3. Fundació CELLEX. Duration: 2015-2018. 190,000.00 €.
- ▶ Jordi Sierra Gil. Red de Terapia Celular (TerCel). RD16/0011/0028. Instituto de Salud Carlos III. Duration: 2017-2021. 3,945.00 €.
- ▶ Carolina Moreno Atanasio. Geriatric assessment in elderly patients with chronic lymphocytic leukemia. GLD16/00153. Gilead Sciences, S.L.U. Duration: 2016-2018. 32,000.00 €.
- ▶ Manuel Víctor Pallarés López. Nanoconjungados para la terapia dirigida a células de leucemia mieloide aguda que expresan CXCR4, receptor implicado en adhesión al estroma y quimiorresistencia. FEHH 2016. Fundació Espanyola d'Hematologia i Hemoteràpia. Duration: 2017-2018. 36,000.00 €.
- ▶ Jordi Sierra Gil. EURE-CART EUROpean Endeavour for Chimeric Antigen Receptor Therapies. H2020-SC1-PM09-EURE-CART. Unió Europea. Duration: 2017-2020. 195,552.00 €.
- ▶ Manuel Víctor Pallarés López. Contratos Sara Borrell 2013. CD13/00074. Instituto de Salud Carlos III. Duration: 2014-2017. 80,598.00 €.
- ▶ Jordi Sierra Gil. Grup de Diagnòstic i Tractament de les Neoplàsies Hematològiques. 2017 SGR 1395. Agència de Gestió d'Ajuts Universitaris i de Recerca. Duration: 2017-2019. 35,200.00 €.

Note: Total amount granted to PI. It does not include indirect costs.

## Grants Awarded in 2017

- ▶ Jordi Sierra Gil, Estudio post-autorización prospectivo de terapia adaptada al riesgo en la leucemia mieloide aguda y síndromes mielodisplásicos de alto riesgo: importancia del perfil genómico y de la enfermedad residual mínima en la asignación del tratamiento. SLT002/16/00433. Departament de Salut. Duration: 2017-2019. 222,472.60 €.
- ▶ Carmen Álvarez Fernández, Inmunoterapia mediante linfocitos T de memoria STEM con receptores antígeno-específicos (CARs)
- ▶ Jordi Sierra Gil, Implicación de la vía CXCR4/CXCL12/CXCR7 en la resistencia, recidiva y fenotipo de célula madre de la leucemia mieloide aguda. PI17/01246. Instituto de Salud Carlos III. Duration: 2018-2020. 73,000,00 €.

Note: Total amount granted to PI. It does not include indirect costs.

## Theses

- ▶ Ana Barata Badiella. Quality of life in hematopoietic cell transplantation. Universitat Autònoma de Barcelona. Directors: Jordi Sierra and Rodrigo Martino. Date of defense: 15/03/2017.
- ▶ Irene Garcia Cádenas. Complicaciones del trasplante alógénico de progenitores hematopoyéticos: enfermedad de Injerto contra el Receptor y predisposición a infecciones. Estrategias de mejora. Universitat Autònoma de Barcelona. Directors: Jordi Sierra, Rodrigo Martino. Date of defense: 30/05/2017.
- ▶ Silvana Novelli Canales. Análisis epidemiológico, clínico y anatomo-patológico de los linfomas T cutáneos, Universitat Autònoma de Barcelona. Directors: Javier Briones. Date of defense: 08/11/2017.

# Oncology/Haematology and Transplantation

\*TIF: 386.142 \*\*MIF: 8.045

Almeida A.M., Prebet T., Itzykson R., Ramos F., Al-Ali H., Shammo J., Pinto R., Maurillo L., Wetzel J., Musto P., Van De Loosdrecht A.A., Costa M.J., Esteves S., Burgstaller S., Stauder R., Autzinger E.M., Lang A., Kripli P., Geissler D., Falantes J.F., Pedro C., Bargay J., Deben G., Garrido A., Bonanad S., Diez-Campelo M., Thepot S., Ades L., Sperr W.R., Valent P., Fenaux P., Sekeres M.A., Greil R., Pleyer L., Clinical outcomes of 217 patients with acute erythroleukemia according to treatment type and line: A retrospective multinational study (2017) *INT J MOL SCI*, 18 (4).

**IF: 3.687**

Alonso-Alvarez S., Magnano L., Alcoceba M., Andrade-Campos M., Espinosa-Lara N., Rodriguez G., Mercadal S., Carro I., Sancho J.M., Moreno M., Salar A., Garcia-Pallarols F., Arranz R., Cannata J., Terol M.J., Teruel A.I., Rodriguez A., Jimenez-Ubieto A., Gonzalez de Villambrosia S., Bello J.L., Lopez L., Monsalvo S., Novelli S., de Cabo E., Infante M.S., Pardal E., Garcia-Alvarez M., Delgado J., Gonzalez M., Martin A., Lopez-Guillermo A., Caballero M.D., Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group (2017) *BRIT J HAEMATOL*, 178 (5), 699-708.

**IF: 5.128**

Bahlis N.J., Corso A., Mugge L.-O., Shen Z.-X., Desjardins P., Stoppa A.-M., Decaux O., De Revel T., Granell M., Marit G., Nahi H., Demuyck H., Huang S.-Y., Basu S., Guthrie T.H., Ervin-Haynes A., Marek J., Chen G., Facon T., Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial (2017) *LEUKEMIA LYMPHO-MA*, 58 (11), 2642-2648.

**IF: 10.23**

Baptista MJ, Granada I, Morgades M, Calasanx MJ, Canals J, Robles De Castro D, Luño E, Ruiz-Xivillé N, Rodríguez-Hernández I, González T, Terol MJ, Valiente A, Ortúñoz F, García-Malo MD, Piñán MA, Oliveira AC, Talavera M, Buñó I, Batlle-López A, Moreno C, Ferra C, Solé F. Monosomal karyotype in chronic lymphocytic leukemia: Association with clinical and biological features and potential prognostic significance. *AM J HE-MATOL*. 2017 Jul; 92(7): E132-E135.

**IF: 5.303**

Barata A., Martino R., Gich I., Garcia-Cadenas I., Abella E., Barba P., Briones J., Brunet S., Esquirol A., Garcia-Pallarols F., Garrido A., Granell M., Martinez J., Mensa I., Novelli S., Sanchez-Gonzalez B., Valcarcel D., Sierra J., Do Patients and Physicians Agree When They Assess Quality of Life? (2017) *BIOL BLOOD MARROW TR*, 23 (6), 1005-1010.

**IF: 4.484**

Barr P.M., Brown J.R., Hillmen P., O'Brien S., Barrientos J.C., Reddy N.M., Coutre S., Mulligan S.P., Jaeger U., Furman R.R., Cymbalista F., Montillo M., Dearden C., Robak T., Moreno C., Pagel J.M., Burger J.A., Suzuki S., Sukbuntherng J., Cole G., James D.F., Byrd J.C., Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL (2017) *BLOOD*, 129 (19), 2612-2615.

**IF: 15.132**

Battipaglia G., Labopin M., Candoni A., Fanin R., El Cheikh J., Blaise D., Michallet M., Ruggeri A., Contentin N., Ribera J.M., Stadler M., Sierra J., Von Dem Borne P.A., Bloor A., Socie G., Nagler A., Mohty M., Risk of sinusoidal obstruction syndrome in allogeneic stem cell transplantation after prior gemtuzumab ozogamicin treatment: A retrospective study from the Acute Leukemia Working Party of the EBMT (2017) *BONE MARROW TRANSPL*, 52 (4), 592-599.

**IF: 4.497**

Bosch R., Mora A., Vicente E.P., Ferrer G., Jansa S., Damle R., Gorlatov S., Rai K.,Montserrat E., Nomdedeu J., Pratcorona M., Blanco L., Saavedra S., Garrido A., Esquirol A., Garcia I., Granell M., Martino R., Delgado J., Sierra J., Chiorazzi N., Moreno C., FcγRllb expression in early stage chronic lymphocytic leukemia (2017) *LEUKEMIA LYMPHO-MA*, 58 (11), 2642-2648.

**IF: 2.644**

Cabrero M., Martin A., Briones J., Gayoso J., Jarque I., Lopez J., Grande C., Heras I., Aranz R., Bernal T., Perez-Lopez E., Lopez-Godino O., Conde E., Caballero D., Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (with Melphalan, Fludarabine ± Thiotepa) for Allogeneic Transplantation in Relapsed or Refractory Aggressive B Cell Lymphoma: A GELTAMO Trial (2017) *BIOL BLOOD MARROW TR*, 23 (1), 53-59.

**IF: 4.484**

Castillo N., Garcia-Cadenas I., Barba P., Canals C., Diaz-Heredia C., Martino R., Ferra C., Badell I., Elorza I., Sierra J., Valcarcel D., Querol S., Early and Long-Term Impaired T Lymphocyte Immune Reconstitution after Cord Blood Transplantation with Antithymocyte Globulin (2017) *BIOL BLOOD MARROW TR*, 23 (3), 491-497.

**IF: 4.484**

Chen Y.-B., Wang T., Hemmer M.T., Brady C., Couriel D.R., Alousi A., Pidala J., Urbano-Ispizua A., Choi S.W., Nishihori T., Teshima T., Inamoto Y., Wirk B., Marks D.I., Abdel-Azim H., Lehmann L., Yu L., Bitan M., Cairo M.S., Qayed M., Salit R., Gale R.P., Martino R., Jaglowski S., Bajel A., Savani B., Frangoul H., Lewis I.D., Storek J., Askar M., Khar-

fan-Dabaja M.A., Aljurf M., Ringden O., Reshef R., Olsson R.F., Hashmi S., Seo S., Spitzer T.R., MacMillan M.L., Lazaryan A., Spellman S.R., Arora M., Cutler C.S., GvHD after umbilical cord blood transplantation for acute leukemia: An analysis of risk factors and effect on outcomes (2017) *BONE MARROW TRANSPL*, 52 (3), 400-408.

**IF: 4.497**

De Witte T., Bowen D., Robin M., Malcovati L., Niederwieser D., Yakoub-Agha I., Mufti G.J., Fenaux P., Sanz G., Martino R., Alessandrino E.P., Onida F., Symeonidis A., Passweg J., Kobbe G., Ganser A., Platzbecker U., Finke J., Van Gelder M., Van De Loosdrecht A.A., Ljungman P., Stauder R., Volin L., Deeg H.J., Cutler C., Saber W., Champlin R., Giralt S., Anasetti C., Kroger N., Allogeneic hematopoietic stem cell transplantation for MDS and CMML: Recommendations from an international expert panel (2017) *BLOOD*, 129 (13), 1753-1762.

**IF: 15.132**

Dimopoulos M.A., Trotman J., Tedeschi A., Matous J.V., Macdonald D., Tam C., Tournilhac O., Ma S., Oriol A., Heffner L.T., Shustik C., Garcia-Sanz R., Cornell R.F., de Larrea C.F., Castillo J.J., Granell M., Kyrtsonis M.-C., Leblond V., Symeonidis A., Kastritis E., Singh P., Li J., Graef T., Biliotti E., Treon S., Buske C., Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (INNOVATE): an open-label substudy of an international, multicentre, phase 3 trial (2017) *LANCET ONCOL*, 18 (2), 241-250.

**IF: 36.418**

Dohner H., Estey E., Grimwade D., Amadori S., Appelbaum F.R., Buchner T., Dombret H., Ebert B.L., Fenaux P., Larson R.A., Levine R.L., Lo-Coco F., Naoe T., Niederwieser D., Ossenkoppele G.J., Sanz M., Sierra J., Tallman M.S., Tien H.-F., Wei A.H., Lowenberg B., Bloomfield C.D., Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel (2017) *BLOOD*, 129 (4), 424-447.

**IF: 15.132**

Escribà-García L, Alvarez-Fernández C, Telléz-Gabriel M, Sierra J, Briones J. Dendritic cells combined with tumor cells and  $\alpha$ -galactosylceramide induce a potent, therapeutic and NK-cell dependent antitumor immunity in B cell lymphoma. *J TRANSL MED*. 2017 May 26;15(1):115.

**IF: 4.197**

Esquirol A., Pascual M.J., Ortiz M., Pinana J.L., Ferra C., Garcia Cadenas I., Vilades I., Brunet S., Martino R., Sierra J., Single-Agent GvHD prophylaxis with tacrolimus after post-Transplant high-dose cyclophosphamide is a valid option for haploidentical transplantation in adults with hematologi-

**\*TIF: 386.142 \*\*MIF: 8.045**

cal malignancies (2017) BONE MARROW TRANSPL, 52 (9), 1273-1279.

**IF: 4.497**

Gallardo D., Bosch-Vizcaya A., Rodriguez-Romanos R., Santos N., Buno I., de la Camara R., Brunet S., Jimenez-Velasco A., Gonzalez M., Nieto J.B., Martinez-Laperche C., Vallejo C., Ferra C., Sampol A., Lopez-Jimenez J., Perez-Simon J.A., Martinez C., Diez J.L., Donor CTLA-4 Genotype Modulates the Immune Response to Minor Histocompatibility Antigen Mismatches (2017) BIOL BLOOD MARROW TR, 23 (12), 2042-2047.

**IF: 4.484**

Garcia-Cadenas I., Rivera I., Martino R., Esquirol A., Barba P., Novelli S., Ortí G., Briones J., Brunet S., Valcarcel D., Sierra J., Patterns of infection and infection-related mortality in patients with steroid-refractory acute graft versus host disease (2017) BONE MARROW TRANSPL, 52 (1), 107-113.

**IF: 4.497**

Garcia-Noblejas A., Cannata-Ortiz J., Conde E., Gonzalez Barca E., Gutierrez N., Rojas R., Vidal M.J., Ramirez M.J., Jimenez-Ubieto A., Garcia-Ruiz J.C., Sancho J.M., Lopez A., Rios Rull P., Novelli S., Albo C., Deben G., Lopez-Guillermo A., Nicolas C., Gonzalez de Villambreria S., Mercadal S., Martin Garcia-Sancho A., Arranz R., Autologous stem cell transplantation (ASCT) in patients with mantle cell lymphoma: a retrospective study of the Spanish lymphoma group (GELTAMO) (2017) ANN HEMATOL, 96 (8), 1323-1330.

**IF 2.845**

Granell M., Calvo X., Garcia-Guinon A., Escoda L., Abella E., Martinez C.M., Teixido M., Teres Gimenez M., Senin A., Sanz P., Campoy D., Vicent A., Arenillas L., Rosinol L., Sierra J., Blade J., De Larrea C.F., Prognostic impact of circulating plasma cells in patients with multiple myeloma: Implications for plasma cell leukemia definition (2017) HAEMATOLOGICA, 102 (6), 1099-1104.

**IF: 9.090**

Herrera S., Perez-Lopez J., Molto-Abad M., Guerri-Fernandez R., Cabezudo E., Novelli S., Esteve J., Hernandez A., Roig I., Solanich X., Prieto-Alhambra D., Nogues X., Diez-Perez A., Assessment of Bone Health in Patients With Type 1 Gaucher Disease Using Impact Microindentation (2017) J BONE MINER RES, 32 (7), 1575-1581.

**IF: 6.314**

Jimenez-Ubieto A., Grande C., Caballero D., Yanez L., Novelli S., Hernandez-Garcia M.T., Manzanares M., Arranz R., Ferreiro J.J., Bobillo S., Mercadal S., Galeo A., Lopez Jimenez J., Moraleda J.M., Vallejo C., Albo C., Perez E., Marrero C., Magnano L., Palomera L., Jarque I., Martinez-Sanchez P., Martin A., Coria E., Lopez-Guillermo A., Salar A., Lahuerta J.J., Autologous Stem Cell Transplantation for Follicular Lymphoma: Favorable Long-Term Survival Irrespective of Pretransplantation Rituximab Exposure (2017) BIOL BLOOD MARROW TR, 23 (10), 1631-1640.

**IF: 4.484**

Jimenez-Ubieto A., Grande C., Caballero D., Yanez L., Novelli S., Hernandez M.T., Manzanares M., Arranz R., Ferreiro J.J., Bobillo S., Mercadal S., Galeo A., Jimenez J.L., Moraleda J.M., Vallejo C., Albo C., Perez E., Marrero C., Magnano L., Palomera L., Jarque I., Coria E., Rodriguez A., Martin A., Lopez-Guillermo A., Salar A., Lahuerta J.J., Progression-free survival at 2 years post-autologous transplant: a surrogate end point for overall survival in follicular lymphoma (2017) CANCER MED-US, 6 (12), 2766-2774.

**IF: 3.202**

Kharfan-Dabaja MA, Parody R, Perkins J, Lopez-Godino O, Lopez-Corral L, Vazquez L, Caballero D, Falantes J, Shapiro J, Ortí G, Barba P, Valcárcel D, Esquirol A, Martino R, Piñana JL, Solano C, Tsalatsanis A, Pidala J, Anasetti C, Perez-Simón JA. Tacrolimus plus sirolimus with or without ATG as GVHD prophylaxis in HLA-mismatched unrelated donor allogeneic stem cell transplantation. Bone Marrow Transplant. 2017 Mar; 52(3):m438-444.

**IF: 4.497**

Khoury H.J., Wang T., Hemmer M.T., Couriel D., Alousi A., Cutler C., Aljurf M., Battiwala M., Cahn J.-Y., Cairo M., Chen Y.-B., Gale R.P., Hashmi S., Hayashi R.J., Jagasia M., Juckett M., Kamble R.T., Kharfan-Dabaja M., Litzow M., Majhail N., Miller A., Nishihori T., Qayed M., Antin J.H., Schoemans H., Schouten H.C., Socie G., Storek J., Verdonck L., Vij R., Wood W.A., Yu L., Martino R., Carabasi M., Dandoy C., Gergis U., Hematti P., Solh M., Jamani K., Lehmann L., Savani B., Schultz K.R., Wirk B.M., Spellman S., Arora M., Pidala J., Improved survival after acute graft-versus-host disease diagnosis in the modern era (2017) HAEMATOLOGICA, 102 (5), 958-966.

**IF: 9.090**

Magnano L., Montoto S., Gonzalez-Barca E., Briones J., Sancho J.M., Muntanola A., Salar A., Besalduch J., Escoda L., Moreno C., Domingo-Domenech E., Estany C., Oriol A., Altes A., Pedro C., Gardella S., Asensio A., Vivancos P., Fernandez de Sevilla A., Ribera J.M., Colomer D., Campo E., Lopez-Guillermo A., Long-term safety and outcome of fludarabine, cyclophosphamide and mitoxantrone (FCM) regimen in previously untreated patients with advanced follicular lymphoma: 12 years follow-up of a

phase 2 trial (2017) ANN HEMATOL, 96 (4), 639-646.

**IF: 2.845**

Martino R., Henseler A., van Lint M., Schaap N., Finke J., Beelen D., Vigouroux S., Alessandrino E.P., Mufti G.J., Veelken J.H., Bruno B., Yakoub-Agha I., Volin L., Maertens J., Or R., Leblond V., Rovira M., Kalhs P., Alvarez A.F., Vitek A., Sierra J., Wagner E., Robin M., de Witte T., Kroger N., Long-term follow-up of a retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic transplantation from matched related donors in myelodysplastic syndromes (2017) BONE MARROW TRANSPL, 52 (8), 1107-1112.

**IF: 4.497**

Maziarz R.T., Brazauskas R., Chen M., McLeod A.A., Martino R., Wingard J.R., Aljurf M., Battiwala M., Dvorak C.C., Geroge B., Guinan E.C., Hale G.A., Lazarus H.M., Lee J.-W., Liesveld J.L., Ramanathan M., Reddy V., Savani B.N., Smith F.O., Strasfeld L., Taplitz R.A., Ustun C., Boeckh M.J., Gea-Banacloche J., Lindemans C.A., Auletta J.J., Riches M.L., Pre-existing invasive fungal infection is not a contraindication for allogeneic HSCT for patients with hematologic malignancies: A CIBMTR study (2017) BONE MARROW TRANSPL, 52 (2), 270-278.

**IF: 4.497**

Montalban C., Diaz-Lopez A., Dlouhy I., Rovira J., Lopez-Guillermo A., Alonso S., Martin A., Sancho J.M., Garcia O., Sanchez J.M., Rodriguez M., Novelli S., Salar A., Gutierrez A., Rodriguez-Salazar M.J., Bastos M., Dominguez J.F., Fernandez R., Gonzalez de Villambreria S., Queizan J.A., Cordoba R., de Ona R., Lopez-Hernandez A., Freue J.M., Garrote H., Lopez L., Martin-Moreno A.M., Rodriguez J., Abraira V., Garcia J.F., Validation of the NCCN-IPI for diffuse large B-cell lymphoma (DLBCL): the addition of  $\beta 2$ -microglobulin yields a more accurate GELTAMO-IPI (2017) BRIT J HAEMATOL, 176 (6), 918-928.

**IF: 5.128**

Motillo C., Ribera J.-M., Morgades M., Granda I., Montesinos P., Brunet S., Bergua J., Tormo M., Garcia-Boyero R., Sarra J., del Potro E., Grande C., Barba P., Bernal T., Amigo M.-L., Grau J., Cervera J., Feliu E., Frequency and prognostic significance of t(v;11q23)/KMT2A rearrangements in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocols (2017) LEUKEMIA LYMPHOMA, 58 (1), 145-152.

**IF: 2.644**

Muffy L., Pasquini M.C., Martens M., Brazauskas R., Zhu X., Adekola K., Aljurf M.,

# Oncology/Haematology and Transplantation

\*TIF: 386.142 \*\*MIF: 8.045

Ballen K.K., Bajel A., Baron F., Battiwala M., Beitinjaneh A., Cahn J.-Y., Carabasi M., Chen Y.-B., Chhabra S., Ciurea S., Copelan E., D'Souza A., Edwards J., Foran J., Freytes C.O., Fung H.C., Gale R.P., Giralt S., Hashmi S.K., Hildebrandt G.C., Ho V., Jakubowski A., Lazarus H., Luskin M.R., Martino R., Maziarz R., McCarthy P., Nishihori T., Olin R., Olsson R.F., Pawarode A., Peres E., Rezvani A.R., Rizzieri D., Savani B.N., Schouten H.C., Sabloff M., Seftel M., Seo S., Sorror M.L., Szer J., Wirk B.M., Wood W.A., Artz A., Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States (2017) *BLOOD*, 130 (9), 1156-1164.

**IF: 15.132**

Nomdedeu J.F., Puigdecanet E., Bussaglia E., Hernandez J.J., Carricondo M., Estivill C., Marti-Tutusaus J.M., Tormo M., Zamora L., Serrano E., Perea G., de Llano M.P.Q., Garcia A., Sanchez-Ortega I., Ribera J.M., Nonell L., Aventin A., Sole F., Brunet M.S., Sierra J., Feasibility of the AML profiler (Skyline™ Array) for patient risk stratification in a multi-centre trial: a preliminary comparison with the conventional approach (2017) *HEMATOL ONCOL*, 35 (4), 778-788.

**IF: 3.193**

Pallares V., Hoyos M., Chillón M.C., Barragan E., Conde M.I.P., Llop M., Cespedes M.V., Nomdedeu J.F., Brunet S., Sanz M.A., Gonzalez-Diaz M., Sierra J., Casanova I., Mangues R., NEDD 9 an independent good prognostic factor in intermediate-risk acute myeloid leukemia patients (2017) *ONCOTARGET*, 8 (44), 76003-76014.

**IF: 5.1680**

Paviglianiti A., Ruggeri A., Volt F., Sanz G., Milpied N., Furst S., Esquirol A., Arcese W., Picardi A., Ferra C., Ifrah N., Bourhis J.H., Raj K., von dem Borne P.A., Sica S., Menard A.-I., Bloor A., Kenzey C., Gluckman E., Rocha V., Evaluation of a disease risk index for adult patients undergoing umbilical cord blood transplantation for haematological malignancies (2017) *BRIT J HAEMATOL*, 179 (5), 790-801.

**IF: 5.128**

Picleanu A.M., Novelli S., Monter A., Garcia-Cadenas I., Caballero A.C., Martino R., Esquirol A., Briones J., Sierra J., Allogeneic hematopoietic stem cell transplantation for non-Hodgkin's lymphomas: a retrospective analysis of 77 cases (2017) *ANN HEMATOL*, 96 (5), 787-796.

**IF: 2.845**

Pinana J.L., Perez-Pitarch A., Garcia-cadenas I., Barba P., Hernandez-Boluda J.C., Esquirol A., Fox M.L., Terol M.J., Queralto J.M., Vima J., Valcarcel D., Ferriols-Lisart R., Sierra J., Solano C., Martino R., A Time-to-Event Model

for Acute Kidney Injury after Reduced-Intensity Conditioning Stem Cell Transplantation Using a Tacrolimus- and Sirolimus-based Graft-versus-Host Disease Prophylaxis (2017) *BIOL BLOOD MARROW TR*, 23 (7), 1177-1185.

**IF: 4.484**

Puiggros A., Collado R., Calasanz M.J., Ortega M., Ruiz-Xiville N., Rivas-Delgado A., Luno E., Gonzalez T., Navarro B., Garcia-Malo M., Valiente A., Hernandez J., Ardanaz M.T., Pinan M., Blanco M.L., Hernandez-Sanchez M., Batlle-Lopez A., Salgado R., Salido M., Ferrer A., Abrisqueta P., Gimeno E., Abella E., Ferra C., Terol M.J., Ortuno F., Costa D., Moreno C., Carbonell F., Bosch F., Delgado J., Espinet B., Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of TP53/ATM FISH deletions (2017) *ONCOTARGET*, 8 (33), 54297-54303.

**IF: 5.1680**

Rosinol L., Oriol A., Teruel A.I., de la Guia A.I., Blanchard M., de la Rubia J., Granell M., Sampol M., Palomera L., Gonzalez Y., Etxebeste M., Martinez-Martinez R., Hernandez M.T., de Arriba F., Alegre A., Cibeira M., Mateos M., Martinez-Lopez J., Lahuerta J.J., San Miguel J., Blade J., Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: A PETHEMA/GEM trial (2017) *LEUKEMIA*, 31 (9), 1922-1927.

**IF: 10.023**

Rosko A.E., Wang H.-L., de Lima M., Sandmaier B., Khouri H.J., Artz A., Brammer J., Bredeson C., Farag S., Kharfan-Dabaja M., Lazarus H.M., Marks D.I., Martino Bufarull R., McGuirk J., Mohty M., Nishihori T., Nivison-Smith I., Rashidi A., Ringden O., Seftel M., Weisdorf D., Bachanova V., Saber W., Reduced intensity conditioned allograft yields favorable survival for older adults with B-cell acute lymphoblastic leukemia (2017) *AM J HEMATOL*, 92 (1), 42-49.

**IF: 5.303**

Sanchez R., Ayala R., Alonso R.A., Martinez M.P., Ribera J., Garcia O., Sanchez-Pina J., Mercadal S., Montesinos P., Martino R., Barba P., Gonzalez-Campos J., Barrios M., Lavilla E., Gil C., Bernal T., Escoda L., Abella E., Amigo M.L., Moreno M.J., Bravo P., Guardia R., Hernandez-Rivas J.-M., Garcia-Guion A., Piernas S., Ribera J.-M., Martinez-Lopez J., Clinical characteristics of patients with central nervous system relapse in BCR-ABL1-positive acute lymphoblastic leukemia: the importance of characterizing ABL1 mutations in cerebrospinal fluid (2017) *ANN HEMATOL*, 96 (7), 1069-1075.

**IF: 2.845**

Sanz J., Kwon M., Bautista G., Sanz MA., Balsalobre P., Piñana JL., Solano C., Duarte R., Ferrá C., Lorenzo I., Martín C., Barba P., Pascual MJ., Martino R., Gayoso J., Buño I., Regidor C., de la Iglesia A., Montoro J., Díez-Martín JL., Sanz GF., Cabrera R., Single umbilical cord blood with or without CD34(+) cells from a third-party donor in adults with leukemia. *BLOOD ADV*. 2017 Jun 20;1(15):1047-1055.

**IF: 15.132**

Scheid C., De Wreede L., Van Biezen A., Koenneke C., Gohring G., Volin L., Maertens J., Finke J., Passweg J., Beelen D., Cornelissen JJ., Itala-Remes M., Chevallier P., Russell N., Petersen E., Milpied N., Richard Espiga C., Peniket A., Sierra J., Mufti G., Crawley C., Veelken J.H., Ljungman P., Cahn J.Y., Alessandrino E.P., De Witte T., Robin M., Kroger N., Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation: A retrospective analysis of the EBMT chronic malignancies working party (2017) *BONE MARROW TRANSPL*, 52 (11), 1519-1525.

**IF: 4.497**

Schetalig J., de Wreede L.C., van Gelder M., Andersen N.S., Moreno C., Vitek A., Karas M., Michallet M., Machaczka M., Gramatzki M., Beelen D., Finke J., Delgado J., Volin L., Passweg J., Dreger P., Henseler A., van Biezen A., Bornhauser M., Schonland S.O., Kroger N., Risk factors for treatment failure after allogeneic transplantation of patients with CLL: A report from the European Society for Blood and Marrow Transplantation (2017) *BONE MARROW TRANSPL*, 52 (4), 552-560.

**IF: 4.497**

Schetalig J., de Wreede L.C., Andersen N.S., Moreno C., van Gelder M., Vitek A., Karas M., Michallet M., Machaczka M., Gramatzki M., Beelen D., Finke J., Delgado J., Volin L., Passweg J., Dreger P., Schaap N., Wagner E., Henseler A., van Biezen A., Bornhauser M., Iacobelli S., Putter H., Schonland S.O., Kroger N., Centre characteristics and procedure-related factors have an impact on outcomes of allogeneic transplantation for patients with CLL: a retrospective analysis from the European Society for Blood and Marrow Transplantation (EBMT) (2017) *BRIT J HAEMATOL*, 178 (4), 521-533.

**IF: 5.128**

Stone R.M., Mandrekar S.J., Sanford B.L., Laumann K., Geyer S., Bloomfield C.D., Thiede C., Prior T.W., Dohner K., Marcucci G., Lo-Coco F., Klisovic R.B., Wei A., Sierra J., Sanz M.A., Brandwein J.M., De Witte T., Niederwieser D., Appelbaum F.R., Medeiros B.C., Tallman M.S., Krauter J., Schlenk R.F., Ganser A., Serve H., Ehninger G., Amadori

## Scientific Production

**\*TIF: 386.142 \*\*MIF: 8.045**

S., Larson R.A., Dohner H., Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 Mutation (2017) NEW ENGL J MED, 377 (5), 454-464.

**IF: 79.258**

Tellez-Gabriel M., Charrier C., Brounais-Le Royer B., Mullard M., Brown H.K., Verrecchia F., Heymann D., Analysis of gap junctional intercellular communications using a dielectrophoresis-based microchip (2017) EUR J CELL BIOL, 96 (2), 110-118.

**IF: 2.939**

Van Gelder M., De Wreede L.C., Bornhauser M., Niederwieser D., Karas M., Anderson N.S., Gramatzki M., Dreger P., Michallet M., Petersen E., et al., Long-term survival of patients with CLL after allogeneic transplantation: A report from the European Society for Blood and Marrow Transplantation (2017) BONE MARROW TRANSPL, 52 (3), 372-380.

**IF: 4.497**

Villegas A., Nunez R., Gaya A., Cuevas-Ruiz M.V., Bosch J.M., Carral A., Arrizabalaga B., Gomez-Roncero M.I., Mora A., Bravo P., Lavilla E., Monteserin C., Hernandez B., Mar-


tinez-Barranco P., Jarque I., Urquia M.A., Garcia-Donas G., Brunet S., Gonzalez F.A., Urbano A., Presence of acute and chronic renal failure in patients with paroxysmal nocturnal hemoglobinuria: results of a retrospective analysis from the Spanish PNH Registry (2017) ANN HEMATOL, 96 (10), 1727-1733.

**IF: 2.845**

## AREA 4

# Neurological, Mental and Ageing

- 136** Cerebrovascular Diseases
- 140** Neuromuscular Diseases
- 144** Parkinson Disease and Movement Disorders
- 148** Molecular Neuropharmacology
- 150** Pharmacological Research in Humans
- 152** Clinical Psychiatry
- 156** Genetics in Neurodegenerative Diseases



# tal Disorders



# Cerebrovascular Diseases



## Coordinator

Martí Fàbregas, Joan  
jmarti@santpau.cat

## Members

Camps Renom, Pol	IR
Delgado Mederos, Raquel	FGS
Guisado Alonso, Daniel	FGS
Jiménez Xarrie, Elena	IR
Marín Bueno, Rebeca	IR
Martínez Domeño, Alejandro	FGS
Maruccia, Federica	IR
Prats Sánchez, Luis Antonio	IR

## Main Lines of Research

- ▶ Brain neurorepair after stroke.
- ▶ Role of statins in ischemic and haemorrhagic stroke.
- ▶ Prevention of cerebral haemorrhage with anticoagulants.
- ▶ Endothelial progenitor cells in stroke.
- ▶ Aetiological classification of brain haemorrhage.
- ▶ Pathophysiology of hematoma growth in acute cerebral haemorrhage.

- ▶ Benefits and risks of intravenous thrombolysis.
- ▶ Non-invasive monitoring of cerebral flow with applied optic methods.
- ▶ Participation in clinical trials.
- ▶ Cancer and stroke.
- ▶ Vulnerability of the atherosclerotic plaque.
- ▶ Predictors of atrial fibrillation.

## Challenges

- ▶ Enhance cooperation with other groups in the framework of Spanish stroke research.
- ▶ Network (RETICS/INVICTUS) and also intra-hospital and extra-hospital cooperation.
- ▶ To obtain funding from FIS, regional authorities and private companies.

- ▶ Increase the number of contracted and grant-aided researchers and professionally develop existing researchers.

## Collaborations

### Collaborations with other IIB Sant Pau Groups

- ▶ Neuroradiology
- ▶ Thrombosis and Haemostasis
- ▶ Cardiovascular Biochemistry
- ▶ Neurobiology of Dementia
- ▶ Molecular Pathology and Therapeutic of Ischaemic and Atherothrombotic Diseases
- ▶ Stroke Pharmacogenomics and Genetics Group
- ▶ Genomics of Complex Diseases
- ▶ Clinical Epidemiology and Healthcare Services
- ▶ Inflammation and Vascular Remodelling
- ▶ Nuclear Medicine

- ▶ Dr. Blanca Fuentes. Hospital La Paz, Madrid, Spain.
- ▶ Dr. Ángel Chamorro. Hospital Clínico de Barcelona, Spain.
- ▶ Dr. Antonio Dávalos. Hospital Germans Trias i Pujol, Badalona, Spain.
- ▶ Dr. Jaume Roquer. Hospital del Mar, Barcelona, Spain
- ▶ Dr. Francesc Purroy. Hospital Arnau de Vilanova, Lleida, Spain.
- ▶ RETICS (cooperative health research network) / INVICTUS (ictus research)

- ▶ Clinical trials:
  - ASSENT
  - SWITCH
  - ENCHANTED
  - RESPECT-ESUS
  - NAVIGATE-ESUS
  - CONVINCE

- ▶ Dra. Jennifer Linn (SUSPECT study), University of Rochester, New York
- ▶ Dr. David Werring (HERO and CROMIS-2 study, Microbleeds consortium), National Hospital for Neurology and Neurosurgery, London.
- ▶ Dr. Peter Kelly (BIOVASC study, CONVINCE study), Mater University Hospital, Dublin.

### External Collaborations

- ▶ Dr. García-Verdugo. Universidad de Valencia, Spain.
- ▶ Dr. Carles Arús. Facultat de Ciències, Universitat Autònoma de Barcelona, Spain.
- ▶ Dr. Turgut Durduran. Instituto de Ciencias Fotónicas, Castelldefels, Barcelona, Spain.
- ▶ Dr. Tomás Sobrino. Hospital General Universitario, Santiago de Compostela, Spain.
- ▶ Dr. Exuperio Díez-Tejedor. Hospital La Paz, Madrid, Spain.

## Active Grants

- ▶ Joan Martí Fàbregas. INVICTUS. RD12/0014/0002. Instituto de Salud Carlos III. Duration: 2013-2017. 165,220.40 €.
- ▶ Joan Martí Fàbregas. Estudio de la progresión y la vulnerabilidad de la aterosclerosis carotidea: influencia del recuento de Células Endoteliales Progenitoras y del control de factores de riesgo vascular. PI15/00884. Instituto de Salud Carlos III. Duration: 2016-2018. 106,500.00 €.

- ▶ Joan Martí Fàbregas. REgenerative Stem cell therapy for STroke in Europe - RESSTORE. PHC-15-2015. Unió Europea. Duration: 2015-2020. 389.58 €.
- ▶ Joan Martí Fàbregas. Red de Enfermedades Vasculares Cerebrales. INVICTUS PLUS RD16/0019/0010. Instituto de Salud Carlos III. Duration: 2017-2021. 50,008.00 €.

Note: Total amount granted to PI. It does not include indirect costs.

## Grants Awarded in 2017

- ▶ Raquel Delgado Mederos. Cerebral blood flow-guided early rehabilitation intervention after stroke: a pilot randomized trial. MARATO 20170930. Fundació La Marató de TV3. Duration: 2018-2021. 114,900.00 €.

- ▶ Elena Jiménez Xarrie. Biomarcadors lipoproteics per determinar la inflamació de la placa carotida en l'ictus isquèmic., MARATO 20171610. Fundació La Marató de TV3. Duration: 2018-2021. 158,060.00 €.

Note: Total amount granted to PI. It does not include indirect costs.

## Theses

- ▶ Xavier Vidal Novellas. Eficacia de las ondas de choque radiales en comparación con la toxina botulínica tipo A para el tratamiento de la espasticidad en las extremidades inferiores en pacientes con parálisis cerebral. Ensayo clínico cruzado aleatorizado. Universitat Internacional de Catalunya. Director: Joan Martí Fàbregas. Date of defense: 10/02/2017.

**\*TIF: 104.3490 \*\*MIF: 5.7971**

Abilleira S., Ribera A., Cardona P., Rubiera M., Lopez-Cancio E., Amaro S., Rodriguez-Campello A., Camps-Renom P., Canovas D., De Miquel M.A., Tomasello A., Remollo S., Lopez-Rueda A., Vivas E., Perendreu J., Gallofre M., Outcomes after Direct Thrombectomy or Combined Intravenous and Endovascular Treatment Are Not Different (2017) STROKE, 48 (2), 375-378.

**IF: 6.2390**

Camps-Renom P., Alejandre-Monforte A., Delgado-Mederos R., Martinez-Domeno A., Prats-Sanchez L., Pascual-Goni E., Marti-Fabregas J., Does prior antiplatelet therapy influence hematoma volume and hematoma growth following intracerebral hemorrhage? Results from a prospective study and a meta-analysis (2017) EUR J NEUROL, 24 (2), 302-308.

**IF: 4.6210**

Camps-Renom P., Mendez J., Granell E., Cassoni F., Prats-Sanchez L., Martinez-Domeno A., Guisado-Alonso D., Marti-Fabregas J., Delgado-Mederos R., Transcranial duplex sonography predicts outcome following an intracerebral hemorrhage (2017) AM J NEURORADIOOL, 38 (8), 1543-1549.

**IF: 3.6530**

Chamorro A., Amaro S., Castellanos M., Gomis M., Urrea X., Blasco J., Arenillas J.F., Roman L.S., Munoz R., Macho J., Canovas D., Marti-Fabregas J., Leira E.C., Planas A.M., Uric acid therapy improves the outcomes of stroke patients treated with intravenous tis-

sue plasminogen activator and mechanical thrombectomy (2017) INT J STROKE, 12 (4), 377-382.

**IF: 3.8590**

Davalos A., Cobo E., Molina C.A., Chamorro A., de Miquel M.A., Roman L.S., Serena J., Lopez-Cancio E., Ribo M., Millan M., Urrea X., Cardona P., Tomasello A., Castano C., Blasco J., Aja L., Rubiera M., Gomis M., Renu A., Lara B., Marti-Fabregas J., Jankowitz B., Cerda N., Jovic T.G., Safety and efficacy of thrombectomy in acute ischaemic stroke (REVASCAT): 1-year follow-up of a randomised open-label trial (2017) LANCET NEUROL, 16 (5), 369-376.

**IF: 27.1380**

Fam M.D., Zeineddine H.A., Eliyas J.K., Stadnik A., Jesselson M., McBee N., Lane K., Cao Y., Wu M., Zhang L., Thompson R.E., John S., Ziai W., Hanley D.F., Awad I.A., Marti-Fabregas J., CSF inflammatory response after intraventricular hemorrhage (2017) NEUROLOGY, 89 (15), 1553-1560.

**IF: 7.6090**

Fayos-Vidal F., Arzamendi- Aizpurua D., Milian-Alvarez X., Guisado-Alonso D., Camps-Renom P., Prats-Sanchez L., Martinez-Domeno A., Delgado-Mederos R., Marti-Fabregas J., Left atrial appendage closure in patients with intracranial haemorrhage and atrial fibrillation (2017) NEUROLOGIA.

**IF: 1.9380**

Fernandez-Cadenas I., Mendioroz M., Giralt D., Nafria C., Garcia E., Carrera C., Galle-

go-Fabrega C., Domingues-Montanari S., Delgado P., Ribo M., Castellanos M., et al. The Use of Genetics to Predict the Vascular Recurrence after Stroke (2017) STROKE, 48 (5), 1147-1153.

**IF: 6.2390**

Fuentes B., Sanz-Cuesta B.E., Gutierrez-Fernandez M., Martinez-Sanchez P., Lisbona A., Madero-Jarabo R., Delgado-Mederos R., Gallego-Cullere J., Rodriguez-Yanez M., Martinez-Zabaleta M., Freijo M., Alonso de Lecinana M., Portilla J.C., Gil-Nunez A., Diez-Tejedor E., Glycemia in Acute Stroke II study: a call to improve post-stroke hyperglycemia management in clinical practice (2017) EUR J NEUROL, 24 (9), 1091-1098.

**IF: 4.6210**

Garcia-Pastor A., Gil-Nunez A., Ramirez-Moreno J.M., Gonzalez-Nafria N., Tejada J., Moniche F., Portilla-Cuenca J.C., Martinez-Sanchez P., Fuentes B., Gamero-Garcia M.A., Alonso de Lecinana M., Canovas-Verge D., Aladro Y., Parkhutik V., Lago-Martin A., de Arce-Borda A.M., Usero-Ruiz M., Delgado-Mederos R., Pampliega A., Ximenez-Carillo A., Bartulos-Iglesias M., Castro-Reyes E., Early risk of recurrent stroke in patients with symptomatic carotid near-occlusion: Results from CAOS, a multicenter registry study (2017) INT J STROKE, 12 (7), 713-719.

**IF: 3.8590**

Giralt-Steinhauer E., Ois A., Abilleira S., Urrea X., Cardona-Portela P., Gomis M., Castellanos M., Molina C., Marti-Fabregas J., Pellise A.,

## Scientific Production

# Cerebrovascular Diseases

\*TIF: 104.3490 \*\*MIF: 5.7971

Canovas D., Gomez-Choco M., Kuprinski J., Cocho D., Roquer J., Frequency and outcome of total anterior circulation strokes without intracranial large-vessel occlusion (2017) EUR J NEUROL, 24 (1), 11-17.

**IF: 4.6210**

Guisado-Alonso D., Fayos-Vidal F., Martí-Fabregas J., Prats-Sánchez L., Marín-Bueno R., Martínez-Doménech A., Delgado-Mederos R., Camps-Renom P., Reliability of point-of-care coagulometer measurements in patients with acute ischaemic stroke receiving intravenous fibrinolysis (2017) NEUROLOGIA.

**IF: 1.9380**

Jiménez-Xarrie E., Dávila M., Candiota A.P., Delgado-Mederos R., Ortega-Martorell S., Julia-Sape M., Arus C., Martí-Fabregas J., Brain metabolic pattern analysis using a magnetic resonance spectra classification software in experimental stroke (2017) BMC NEUROSCI, 18 (1).

**IF: 2.1730**

Korompoki E., Filippidis F.T., Nielsen P.B., Del Giudice A., Lip G.Y.H., Kuramatsu J.B., Huttner H.B., Fang J., Schulman S., Martí-Fabregas J., Gathier C.S., Viswanathan A., Biffi A., Poli D.,

Weimar C., Malzahn U., Heuschmann P., Veltkamp R., Long-term antithrombotic treatment in intracranial hemorrhage survivors with atrial fibrillation (2017) NEUROLOGY, 89 (7), 687-696.

**IF: 7.6090**

Morenas-Rodríguez E., Camps-Renom P., Pérez-Cordon A., Horta-Barba A., Simón-Talero M., Cortés-Vicente E., Guisado-Alonso D., Vilaplana E., García-Sánchez C., Gironell A., Roig C., Delgado-Mederos R., Martí-Fabregas J., Visual hallucinations in patients with acute stroke: a prospective exploratory study (2017) EUR J NEUROL, 24 (5), 734-740.

**IF: 4.6210**

Prats-Sánchez L., Martínez-Doménech A., Camps-Renom P., Delgado-Mederos R., Guisado-Alonso D., Marín R., Dorado L., Rudilloso S., Gomez-Gonzalez A., Purroy F., Gomez-Choco M., Canovas D., Cocho D., Garcés M., Abilleira S., Martí-Fabregas J., Risk factors are different for deep and lobar remote hemorrhages after intravenous thrombolysis (2017) PLOS ONE, 12 (6).

**IF: 2.7660**

Reig-Rosello G., Contreras M.M., Suárez-Fernández C., González-Hernández A., Cardona P., Pons-Amate J.M., Martí-Fabregas J., Vivancos J., Pose A., Diaz J.A., et al., Clinical profile and satisfaction with anticoagulated treatment in patients with non-valvular atrial fibrillation attended in internal medicine and neurology departments of Spain Perfil clínico y satisfacción con el tratamiento antiocoagulante en pacientes con fibrilación auricular no valvular atendidos en consultas de medicina interna y neurología de España (2017) REV NEUROLOGIA, 65 (8), 361-367.

**IF: 0.6010**

Shoamanesh A., Pearce L.A., Bazan C., Catañese L., McClure L.A., Sharma M., Martí-Fabregas J., Anderson D.C., Kase C.S., Hart R.G., Benavente O.R., Microbleeds in the Secondary Prevention of Small Subcortical Strokes Trial: Stroke, mortality, and treatment interactions (2017) ANN NEUROL, 82 (2), 196-207.

**IF: 10.2440**



# Neuromuscular Diseases



## Coordinator

Illa Sendra, Maria Isabel FGS  
illi@sanpau.cat

## Members

Araque Palacios, Josefa	CIBERER
Carrasco Rozas, Ana	IR
Cortés Vicente, Elena	IR
De Luna Salva, Noemí	CIBERER
Díaz Manera, Jorge Alberto	FGS
Gallardo Vigo, Eduard	IR
Piñol Júrado, Patricia	IR
Querol Gutiérrez, Luis Antonio	FGS
Rojas García, Ricardo	FGS
Segovia Simón, Sonia	CIBERER
Siles Gómez, Ana María	IR
Suarez Calvet, Xavier	IR
Vidal Fernández, Maria Nuria	IR

## Main Lines of Research

### Autoimmune neuromuscular diseases

- ▶ Characterization of new target antigens in Myasthenia Gravis (MG), and immune neuropathies (CIDP, GBS, MMN). Their use as diagnostic and therapeutic biomarkers.
- ▶ Pathogenesis of newly recognized antigens both in MG and in CIDP.
- ▶ Analysis of the innate immunity in inflammatory myopathies.
- ▶ Analysis of the impact of new immuno-modulating therapies on IgG4 mediated Neuromuscular Diseases (NMD).
- ▶ Functional aspects of immune system cells (response to ligands, production of antibodies, etc.).
- ▶ Phase 2 clinical trials in autoimmune neuromuscular diseases.
- ▶ IGOS data base for Guillain Barre syndrome.
- ▶ NMD-ES Spanish registry for neuromuscular diseases.

### Muscular dystrophy, dysferlinopathy and distal myopathies

- ▶ Muscle MRI analysis as a biomarker of different muscular dystrophies.
- ▶ Role of PDGF in muscular dystrophies fibrosis. Study of nintedanib as an antifibrotic drug in muscular dystrophies.
- ▶ Natural history of Dysferlinopathies. The international COS-study Jain Foundation.
- ▶ Study of proteasome inhibitors in dysferlin myopathy.
- ▶ Clinical trials in muscular dystrophies and metabolic muscle diseases.

### Amyotrophic lateral sclerosis

- ▶ Epidemiology of ALS in Catalonia.
- ▶ Gene profile of ALS patients in Spain.
- ▶ Biomarkers profile in different phenotypes of ALS.

## Challenges

- ▶ Advance in the knowledge of the immunological mechanisms involved in the pathogenesis of autoimmune neuromuscular diseases (MG, CIDP, MMN).
- ▶ Advance in the knowledge of the pathogenetic mechanisms of inflammatory myopathies (DM).
- ▶ Search for new antigens and develop diagnostic tests with new biomarkers in immune-mediated neuropathies and Myasthenia Gravis.
- ▶ Implement new diagnostic and disease follow-up methods for muscular dystrophies resulting from dysferlinopathy and other myopathies research (biomarkers (miRNA, secretome), MRI, etc.).

- ▶ Advance in the knowledge of the pathogenetic mechanisms involved in dysferlin deficiency and other muscular dystrophies.
- ▶ Search for new genes and biomarkers in the different phenotypes of ALS.
- ▶ Use of the NMD.ES registry to perform research in different NMD.

## Collaborations

### Collaborations with other IIB Sant Pau Groups

- ▶ Genetic Diseases
- ▶ Inflammatory Diseases

### External Collaborations

- ▶ Jerome Devaux, investigador CNRS (Institut de Neurosciences de Montpellier, U1051R1). France.
- ▶ Silvere van der Maarel, Leiden, The Netherlands.
- ▶ Xavier Navarro. Departament de Medicina, Institut de Neurociències. Universitat Autònoma de Barcelona, Spain.

▶ R. Martí, Elena Garcia Arumí. Vall d'Hebron Research Institute, Barcelona, Spain. CIBERER CB 06/07/015.

▶ Vilchez JJ. Hospital La Fe Valencia. CIBERER CB 06/05/ 091.

▶ Al Chalabi A. King's College, London, UK.

▶ Benveniste, O. Hopital Salpetriere, Paris, France.

▶ Nagaraju, K/ Jaiswal, J. Children's Hospital, Washington D.C. USA.

▶ Mouly, V. Institut de Myologie, Paris, France.

▶ Pinal I. National Institute of Health, Bethesda, MD, USA.

## Active Grants

- ▶ Maria Isabel Illa Sendra. Nuevas reactividades antigénicas y estudios de inmunidad innata en enfermedades neuromusculares autoinmunes. PI13/00937. Instituto de Salud Carlos III. Duration: 2014-2017. 160,250.00 €.
- ▶ Eduard Gallardo Vigo. Recerca en Malalties Neuromusculars. 2014 SGR 272. Agència de Gestió d'Ajuts Universitaris i de Recerca. Duration: 2014-2017. 30,000.00 €.
- ▶ Ricardo Rojas García. Biomarkers profile in different phenotypes of Motor Neuron Disease. MARATO 20143710. Fundació La Marató de TV3. Duration: 2015-2018. 120,500.00 €.
- ▶ Jorge Alberto Díaz Manera. PDGF como nuevo biomarcador y diana terapéutica en pacientes con distrofia muscular. PI15/01822. Instituto de Salud Carlos III. Duration: 2016-2018. 76,500.00 €.
- ▶ Eduard Gallardo Vigo. Influencia de factores inmunológicos y no inmunológicos en la patogenia de las miopatías inflamatorias PI15/01597. Instituto de Salud Carlos III. Duration: 2016-2018. 91,500.00 €.
- ▶ Ricardo Rojas Garcia. Identificación de biomarcadores diagnósticos en pacientes con Esclerosis Lateral Amiotrófica . PI15/01618. Instituto de Salud Carlos III. Duration: 2016-2018. 91,500.00 €.
- ▶ Luis Antonio Querol Gutiérrez. Identificación de autoanticuerpos en neuropatías inflamatorias y caracterización del fenotipo celular implicado en su desarrollo. PI16/00627. Instituto de Salud Carlos III. Duration: 2017-2019. 76,500.00 €.
- ▶ Maria Isabel Illa Sendra. Estudios moleculares y celulares en Miastenia Gravis: Correlaciones clínicas y terapéuticas PI16/01440. Instituto de Salud Carlos III. Duration: 2017-2019. 111,500.00 €.
- ▶ Elena Cortes Vicente. Ajuts per a contractes de formació "Río Hortega" 2016. CM16/00096. Instituto de Salud Carlos III. Duration: 2017-2018. 53,732.00 €.
- ▶ Maria Isabel Illa Sendra. Aproximaciones terapéuticas en distrofias musculares mediante modelos celulares y animales. GEMIO 2016. Fundació Isabel Gemio. Duration: 2016-2019. 160,908.99 €.
- ▶ Eduard Gallardo Vigo. El proteasoma com a diana terapèutica en distrofies musculars per déficit de disferlina. IR16-P4. Fundació Privada Hospital de la Santa Creu i Sant Pau. Duration: 2017-2017. 7,000.00 €.
- ▶ Noemi de Luna Salva. Activación de la inmunidad innata en células deficientes en disferlina: nuevas dianas terapéuticas F. RAMÓN ARECES 2016. Fundació Ramón Areces. Duration: 2017-2019.
- ▶ Xavier Suarez Calvet. New therapeutic targets in dermatomyositis. Research Grant Application 2014. The Myositis Association. Duration: 2015-2017. 83,586.64 €.

Note: Total amount granted to PI. It does not include indirect costs.

## Grants Awarded in 2017

- ▶ Elena Cortés Vicente. Antigen-specific regulatory networks to treat Myasthenia Gravis. MV17/00012. Instituto de Salud Carlos III. Duration: 2018. 11,960.00 €.

Note: Total amount granted to PI. It does not include indirect costs.

## Awards

- ▶ Extraordinary PhD award to Alba Ramos Franci for the thesis Nuevos marcadores diagnósticos y factores pronósticos en miastenia Gravis.
- ▶ Award to the best presentation of a young researcher on the treatments in the muscular dystrophy of Duchenne. Patricia Piñol. Nintedanib as a new therapeutic agent for Duchenne Muscular Dystrophy: preclinical and in vivo studies. 22nd World Muscle Society Meeting, St Malo, France.
- ▶ Elsevier WMS Membership Award. Alicia Alonso. Magnetic Resonance Image in Oculopharyngeal muscle dystrophy. 22nd World Muscle Society Meeting, St Malo, France.

## Patents

- ▶ RH Brown, MF Ho, I Illa, E Gallardo. Blood-Based Assay for Dysferlinopathies. US7172858B2. USA, Canada, Japan, 06/02/2007

# Neuromuscular Diseases

Books or chapters  
with ISBN

Scientific Production

**Eduardo Gutiérrez-Rivas (ed). Manual de Enfermedades Neuromusculares. 2017. ISBN: 978-84-16732-35-2**

- ▶ Chapter 17. Estudios inmunológicos. E Gallardo, X. Suárez, I. Illa. page 137
- ▶ Chapter 34. Neuropatías disimunes. L. Querol, R. Rojas. page 275
- ▶ Chapter 45. Distrofinopatías. J Diaz, E. Gallardo. page 375
- ▶ Chapter 67. Panorama de la Investigación sobre las enfermedades neuromusculares en España. R. Torrón, I. Illa, et al. page 581

**Medicina Interna Farreras Rozman (18th edition) ISBN 978-84-9022-996-5**

- ▶ Chapter 174. Ataxias y paraparesias espásticas. Enfermedades de la neurona motora. E. Muñoz, R. Rojas Garcia. page 1409.
- ▶ Chapter 182. Enfermedades de los nervios periféricos. J. Casademont y R. Rojas Garcia. page 1470.
- ▶ Chapter 184. Enfermedades de la unión neuromuscular: Miastenia Gravis y síndromes miasténicos. JM Grau y I. Illa. page 1496.

\*TIF: 127.542 \*\*MIF: 5.7974

Aragones J.M., Altimiras J., Roura P., Alonso F., Bufill E., Munmany A., Alfonso S., Illa I., Prevalence of myasthenia gravis in the Catalan county of Osona Prevalencia de miastenia gravis en la comarca de Osona (Barcelona, Cataluña) (2017) NEUROLOGIA, 32 (1), 1-5.

**IF: 1.938**

Cortes-Vicente E., Pradas J., Marin-Iahoz J., De Luna N., Clarimon J., Turon-Sans J., Gelpi E., Diaz-Manera J., Illa I., Rojas-Garcia R., Early diagnosis of amyotrophic lateral sclerosis mimic syndromes: pros and cons of current clinical diagnostic criteria (2017) AMYOTROPH LAT SCL FR, 18 (5-6), 333-340.

**IF: 2.982**

De Luna N., Suarez-Calvet X., Lleixa C., Diaz-Manera J., Olive M., Illa I., Gallardo E., Hypoxia triggers IFN-1 production in muscle: Implications in dermatomyositis (2017) SCI REP-UK, 7 (1).

**IF: 4.122**

Delmont E., Manso C., Querol L., Cortese A., Berardinelli A., Lozza A., Belghazi M., Malissart P., Labauge P., Taieb G., Yuki N., Illa I., Attarian S., Devaux JJ., Autoantibodies to nodal isoforms of neurofascin in chronic inflammatory demyelinating polyneuropathy (2017) BRAIN, 140 (7), 1851-1858.

**IF: 10.840**

Garibaldi M., Tasca G., Diaz-Manera J., Ottaviani P., Laschena F., Pantoli D., Gerevini S., Fiorillo C., Maggi L., Tasca E., D'Amico A., Musumeci O., Toscano A., Bruno C., Massa R., Angelini C., Bertini E., Antonini G., Pennisi E.M., Muscle MRI in neutral lipid storage disease (NLSD) (2017) J NEUROL, 264 (7), 1334-1342.

**IF: 3.783**

Howard J.F., Utsugisawa K., Benatar M., Murai H., Barohn R.J., Illa I., Jacob S., Vissing J., Burns T.M., Kissel J.T., et al., Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled,

multicentre study (2017) LANCET NEUROL, 16 (12), 976-986.

**IF: 27.138**

Illa I., ARTHUR ASBURY LECTURE: Chronic inflammatory demyelinating polyradiculoneuropathy: clinical aspects and new animal models of auto-immunity to nodal components (2017) J PERIPHER NERV SYST, 22 (4), 418-424.

**IF: 2.550**

Jacobs B.C., van den Berg B., Verboon C., Chavada G., Cornblath D.R., Gorson K.C., Harbo T., Hartung H.-P., Hughes R.A.C., Kusunoki S., et al., International Guillain-Barré Syndrome Outcome Study: protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillain-Barré syndrome (2017) J PERIPHER NERV SYST, 22 (2), 68-76.

**IF: 2.550**

Martinez-Martinez L., Lleixa M.C., Boera-Carnicer G., Cortese A., Devaux J., Siles A., Rajabally Y., Martinez-Pineiro A., Carvajal A., Parado J., Delmont E., Attarian S., Diaz-Manera J., Callegari I., Marchioni E., Franciotta D., Benedetti L., Lauria G., de la Calle Martin O., Juarez C., Illa I., Querol L., Anti-NF155 chronic inflammatory demyelinating polyradiculoneuropathy strongly associates to HLA-DRB15 (2017) J NEUROINFLAMM, 14 (1).

**IF: 5.193**

Morenas-Rodriguez E., Camps-Renom P., Perez-Cordon A., Horta-Barba A., Simon-Talero M., Cortes-Vicente E., Guisado-Alonso D., Vilaplana E., Garcia-Sanchez C., Gironell A., Roig C., Delgado-Mederos R., Marti-Fabregas J., Visual hallucinations in patients with acute stroke: a prospective exploratory study (2017) EUR J NEUROL, 24 (5), 734-740.

**IF: 4.621**

Natera-de Benito D., Topf A., Vilchez J.J., Gonzalez-Quereda L., Dominguez-Carral J., Diaz-Manera J., Ortez C., Bestue M., Gallano P., Dul M., Abicht A., Muller J.S., Senderek J.,

Garcia-Ribes A., Muelas N., Evangelista T., Azuma Y., McMacken G., Paipa Merchan A., Rodriguez Cruz P.M., Camacho A., Jimenez E., Miranda-Herrero M.C., Santana-Artiles A., Garcia-Campos O., Dominguez-Rubio R., Olive M., Colomer J., Beeson D., Lochmuller H., Nascimento A., Molecular characterization of congenital myasthenic syndromes in Spain (2017) NEUROMUSCULAR DISORD, 27 (12), 1087-1098.

**IF: 2.487**

Navas-Madronal M., Valero-Mut A., Martinez-Zapata M.J., Simon-Talero M.J., Figuerola S., Vidal-Fernandez N., Lopez-Gongora M., Escartin A., Querol L., Absence of antibodies against KIR4.1 in multiple sclerosis: A three-technique approach and systematic review (2017) PLOS ONE, 12 (4).

**IF: 2.766**

Pinol-Jurado P., Gallardo E., de Luna N., Suarez-Calvet X., Sanchez-Riera C., Fernandez-Simon E., Gomis C., Illa I., Diaz-Manera J., Platelet-Derived Growth Factor BB Influences Muscle Regeneration in Duchenne Muscle Dystrophy (2017) AM J PATHOL, 187 (8), 1814-1827.

**IF: 4.069**

Querol L., Devaux J., Rojas-Garcia R., Illa I., Autoantibodies in chronic inflammatory neuropathies: Diagnostic and therapeutic implications (2017) NAT REV NEUROL, 13 (9), 533-547.

**IF: 19.819**

Querol L., Siles A.M., Alba-Rovira R., Jauregui A., Devaux J., Faivre-Sarrailh C., Araque J., Rojas-Garcia R., Diaz-Manera J., Cortes-Vicente E., Nogales-Gadea G., Navas-Madronal M., Gallardo E., Illa I., Antibodies against peripheral nerve antigens in chronic inflammatory demyelinating polyradiculoneuropathy (2017) SCI REP-UK, 7 (1).

**IF: 4.122**

Rodriguez M.A., Barquero L.M.D.R., Ortez C.I., Jou C., Vigo M., Medina J., Febrer A., Ramon-Krauel M., Diaz-Manera J., Olive M.,

\*TIF: 127.542 \*\*MIF: 5.7974

Gonzalez-Mera L., Nascimento A., Jimenez-Mallebrera C., Differences in adipose tissue and lean mass distribution in patients with collagen VI related myopathies are associated with disease severity and physical ability (2017) FRONT AGING NEUROSCI, 9 (AUG).

**IF: 3.582**

Saxena A., Stevens J., Cetin H., Koneczny I., Webster R., Lazaridis K., Tzartos S., Vrolix K., Nogales-Gadea G., Machiels B., Molenaar P.C., Damoiseaux J., De Baets M.H., Simon-Keller K., Marx A., Vincent A., Losen M., Martinez-Martinez P., Characterization of an anti-fetal AChR monoclonal antibody isolated from a myasthenia gravis patient (2017) SCI REP-UK, 7 (1).

**IF: 4.122**

Scarpelli M., Carreno-Gago L., Russignan A., de Luna N., Carnicer-Caceres C., Ariatti A., Verriello L., Devigili G., Tonin P., Garcia-Arumi E., Pinos T., Identification and characterization of the novel m.8305C>T MTTK and m.4440G>A MTTM gene mutations causing mitochondrial myopathies (2017) NEUROMUSCULAR DISORD.

**IF: 2.487**

Sivera R., Frasquet M., Lupo V., Garcia-Sobrino T., Blanco-Arias P., Pardo J., Fernandez-Tor-

ron R., De Munain A.L., Marquez-Infante C., Villarreal L., Carbonell P., Rojas-Garcia R., Segovia S., Illa I., Frongia A.L., Nascimento A., Ortez C., Garcia-Romero M.D.M., Pascual S.I., Pelayo-Negro A.L., Berciano J., Guerrero A., Casasnovas C., Camacho A., Esteban J., Chumillas M.J., Barreiro M., Dlaz C., Palau F., Vilchez J.J., Espinosa C., Sevilla T., Distribution and genotype-phenotype correlation of GDAP1 mutations in Spain (2017) SCI REP-UK, 7 (1).

**IF: 4.122**

Suarez-Calvet X., Gallardo E., Pinal-Fernandez I., De Luna N., Lleixa C., Diaz-Manera J., Rojas-Garcia R., Castellvi I., Martinez M.A., Grau J.M., Selva-O'Callaghan A., Illa I., RIG-I expression in perifascicular myofibers is a reliable biomarker of dermatomyositis (2017) ARTHRITIS RES THER, 19 (1).

**IF: 4.269**

van der Ploeg A.T., Kruijshaar M.E., Toscano A., Laforet P., Angelini C., Lachmann R.H., Pascual Pascual S.I., Roberts M., Rosler K., Stuflig T., van Doorn P.A., Van den Bergh P.Y.K., Vissing J., Schoser B., Bembi B., Broomefield A., Boentert M., Desnuelle C., Findling O., Hahn A., Diaz-Manera J., Hundsberger T., Kornblum C., Labarthe F., Laforet P., Mengel K.-E., Mongini T., Muller-Felber W., Parenti G.,

Pijnappel W.P., Preisler N., Sacconi S., Talim B., Tardieu M., van der Beek N.A.M.E., Wenninger S., European consensus for starting and stopping enzyme replacement therapy in adult patients with Pompe disease: a 10-year experience (2017) EUR J NEUROL, 24 (6), 768-e31.

**IF: 4.621**

van der Zee J., Gijselinck I., Van Moesvelde S., Perrone F., Dillen L., Heeman B., Baumer V., Engelborghs S., De Bleeker J., Baets J., Gelpi E., Rojas-Garcia R., Clarimon J., Lleo A., Diehl-Schmid J., Alexopoulos P., Perneczkly R., Synofzik M., Just J., Schols L., Graff C., Thonberg H., Borroni B., Padovani A., Jordanova A., Sarafov S., Tournev I., de Mendonca A., Miltenberger-Miltenyi G., Simoes do Couto F., Ramirez A., Jessen F., Heneka M.T., Gomez-Tortosa E., Danek A., Cras P., Vandenberghe R., De Jonghe P., De Deyn P.P., Sleegers K., Cruts M., Van Broeckhoven C., TBK1 Mutation Spectrum in an Extended European Patient Cohort with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis (2017) HUM MUTAT, 38 (3), 297-309.

**IF: 5.359**

# Parkinson Disease and Movement Disorders



## Coordinator

Kulisevsky Bojarski, Jaime FGS  
jkulisevsky@santpau.cat

## Members

Aracil Bolanos, Ignacio	FGS
Bejr-Kasem Marco, Helena	
CIBERNED	
Botí González, María Ángeles	IR
Campolongo Perillo, Antonia	IR
Gironell Carrero, Alexandre	FGS
Horta Barba, Andrea	IR
Marín Lahoz, Juan	IR
Martínez Horta, Saul Indra	IR
Pagonabarraga Mora, Javier	FGS
Pascual Sedano, Berta Marta	FGS
Pérez Pérez, Jesús	IR
Sampedro Santaló,	
Frederic Vicenç	FGS

## Main Lines of Research

### Cognitive Impairment and Behavioural Dysfunctions in Parkinson Disease (PD)

- ▶ Study of the neural correlates of cognitive performance, mild cognitive impairment, dementia and behavioral alterations (apathy, visual hallucinations and impulse control disorders) in PD using neurophysiological techniques (event-related brain potentials), structural, functional and molecular neuroimaging.
- ▶ Characterization of the neurodegenerative process underlying cognitive impairment in PD through the study of cortical atrophy patterns related to genetic and biomarker indicators.
- ▶ Development and validation of PD-specific tools for cognitive and functional assessment to detect subtle changes in cognitive performance and treatment response.
- ▶ Prospective follow-up study of cognition and mood in PD patients with deep-brain stimulation of the subthalamic nucleus.
- ▶ Identification of blood-based, cognitive and neurophysiological biomarkers of cognitive deterioration in PD.
- ▶ Identification of genetic and neurophysiological biomarkers of apathy and impulse control disorders in PD.
- ▶ Data science applied to large PD databases such as PPMI.
- ▶ Surgery and treatments of continuous infusion of intraduodenal levodopa.
- ▶ Study of the effects of continuous infusion of intraduodenal levodopa on cognition and mood.
- ▶ Follow-up and etiologic study of weight loss in patients treated with continuous infusion of intraduodenal levodopa.

### Huntington Disease (HD)

- ▶ Clinical characterization of the natural course HD in large cohort and international studies (Enroll-HD).
- ▶ Study of the neural correlates of clinical progression, cognitive performance, mild

cognitive impairment, dementia and behavioral alterations in HD using neurophysiological techniques (event-related brain potentials), structural, functional and molecular neuroimaging.

- ▶ Identification of potential neuroimaging, blood-based, muscular tissue, CSF and clinical biomarkers of progression and phenotypic in premanifest and manifest HD.

- ▶ Study of the prevalence and neural substrates of behavioral alterations in premanifest and manifest HD.

- ▶ Development and validation of HD-specific tools for cognitive and functional assessment to detect subtle changes in cognitive performance and treatment response.

- ▶ Study of the effect of intermediate alleles and homozygosity on the clinical presentation of HD.

- ▶ Data science applied to large HD databases such as Enroll-HD and Registry.

- ▶ Identification of different cognitive phenotypes in HD.

### Progressive Supranuclear Palsy (PSP)

- ▶ Development of a PSP-specific cognitive rating scale.
- ▶ Development of a standarized eye movement evaluation.
- ▶ Study of the neural correlates of clinical progression, cognitive performance and behavioral alterations in PSP using structural and functional neuroimaging.

### Essential Tremor and Other Movement Disorders

- ▶ Molecular neuroimaging in essential tremor.
- ▶ Clinical, neurophysiological and neuroimaging assessment of patients with FXTAS (fragile X-associated tremor/ataxia syndrome).

**Challenges****Cognitive and Behavioural Dysfunctions in Parkinson Disease**

- ▶ Study and understanding of the neural substrates of cognitive impairment in Parkinson disease so as to improve diagnostic and therapeutic approaches.
- ▶ Development of specific tools to assess and track cognitive changes in Parkinson disease.
- ▶ Identification of the involvement of specific executive and reward-related brain systems in the etiology of apathy in PD

**Huntington's Disease**

- ▶ Study of the dynamics of mutant Htt protein aggregation and related neural and cognitive correlates along disease stages in Huntington's disease.
- ▶ Validation of new instruments to assess and track subtle cognitive changes in pre-manifested and early-stage Huntington's disease population.
- ▶ Identification of the structural and metabolic brain correlates of apathy in early and mild HD.

**Essential Tremor and Other Movement Disorders**

- ▶ Genetic studies and genotype-phenotype correlations in essential tremor.
- ▶ Development of new therapeutic interventions in essential tremor.
- ▶ Neurochemical and structural neuroimaging studies on the pathophysiological bases of essential tremor.

**Translational Research - Animal Models of Parkinsonism**

- ▶ Behavioural, physiological and pharmacological characterization of animal models of parkinsonism with combined dopaminoergic and noradrenergic lesions.
- ▶ Physiopathology of motor, cognitive and behavioural complications linked to antiparkinsonian drugs in animal models of parkinsonism.

**Collaborations****Collaborations with other IIB Sant Pau Groups**

- ▶ Active collaboration with the Reserach groups of Neuroradiology and Nuclear Medicine (Huntington's disease).

**External Collaborations**

- ▶ Active collaboration with the Cognition and Brain Plasticity Group at the Bellvitge Health Science Campus at the University of Barcelona adscribed to the Department of Basic Psychology, Faculty of Psychology - University of Barcelona and the IDIBELL (Institut d'Investigació Biomèdica de Bellvitge).
- ▶ Centro de Investigación Biomédica en Red de Enfermedades neurodegenerativas (CIBERNED), Instituto de Salud Carlos III.

- ▶ International Movement Disorders Society (MDS). Task Force for Developing Rating Scales in Parkinson's Disease (Subcomitee for Cognitive Evaluation).
- ▶ MDS Task Force for Mild Cognitive Impairment in Parkinson's Disease.
- ▶ MDS Task Force for Evidence Based Medicine in Huntington's Disease.
- ▶ Spanish Coordinator of the European Huntington Disease Network and the ENROLL Study (Cure for Huntington's Disease International - CHDI).
- ▶ Coordination of the Cognitive Phenotype Working Group of the European Huntington's Disease Network (EHDN).

**Active Grants**

- ▶ Jaime Kulisevsky Bojarski. Huntington's Disease Network EHDN. Duration: 2010-2021. 149,240.00 €.
- ▶ Jaime Kulisevsky Bojarski. Grup de Trastorns del Moviment de l'Hospital de la Santa Creu i Sant Pau. 2014 SGR 1203. Agència de Gestió d'Ajuts Universitaris i de Recerca. Duration: 2014-2017. 21,000.00 €.
- ▶ Jaime Kulisevsky Bojarski. Prediction of apathy and impulse control disorders in Parkinson's disease based on Feedback related negativity. MARATO 20142410. Fundació La Marató de TV3. Duration: 2015-2018. 159,686.00 €.
- ▶ Javier Pagonabarraga Mora. Blood-based and neurophysiological markers of cognitive deterioration and dementia in Parkinson's disease. MARATO 20142910. Fundació La Marató de TV3. Duration: 2015-2018. 159,589.00 €.
- ▶ Javier Pagonabarraga Mora. Marcadores en sangre y neurofisiológicos de la progresión del deterioro cognitivo en la enfermedad de Parkinson. PI14/02058. Instituto de Salud Carlos III. Duration: 2015-2018. 54,500.00 €.

- ▶ Juan Marin Lahoz. Contratos Río Hortega 2015. CM15/00071. Instituto de Salud Carlos III. Duration: 2016-2018. 53,732.00 €.
- ▶ Jaime Kulisevsky Bojarski. Correlatos anatómico-funcionales de los trastornos del control de impulsos y apatía en la enfermedad de Parkinson. PI15/00962. Instituto de Salud Carlos III. Duration: 2016-2018. 61.500,00 €.
- ▶ Jesus Perez Perez. Contratos Juan Rodés 2016. JR16/00034. Instituto de Salud Carlos III. Duration: 2017-2020. 135,000.00 €.
- ▶ Jaime Kulisevsky Bojarski. Desarrollo, validación y estudio de la sensibilidad al cambio de una versión alternativa de la Parkinson's Disease - Cognitive Rating Scale. PI12/03005. Instituto de Salud Carlos III. Duration: 2013-2017. 23,500.00 €.
- ▶ Ignacio Aracil Bolaños. Búsqueda de biomarcadores prodrómicos en la demencia asociada a la enfermedad de Parkinson (EP) y enfermedad por cuerpos de Lewy (ECL) IR16-R5. Fundació Privada Hospital de la Santa Creu i Sant Pau. Duration: 2017-2018. 30,477.44 €.

Note: Total amount granted to PI. It does not include indirect costs.

# Parkinson Disease and Movement Disorders

Grants  
Awarded  
in 2017

- ▶ Jesus Pérez Pérez. Estudio longitudinal de los correlatos clínicos y neuroradiológicos asociados a los niveles de huntingtina y otros biomarcadores en LCR y plasma en la enfermedad de Huntington. PI17/01885. Instituto de Salud Carlos III. Duration: 2018-2020. 97,000.00 €.
- ▶ Helena Bejr-Kasem Marco. Contractes de formació en recerca "Río Hortega" 2017., CM17/00209, Instituto de Salud Carlos III. Duration: 2018-2019. 53,732.00 €.

Note: Total amount granted to PI. It does not include indirect costs.

**\*TIF: 102.993 \*\*MIF: 5.4206**

Antonini A., Poewe W., Chaudhuri K.R., Jech R., Pickut B., Pirtosek Z., Szasz J., Valldeoriola F., Winkler C., Bergmann L., et al., Levodopa-carbidopa intestinal gel in advanced Parkinson's: Final results of the GLORIA registry (2017) PARKINSONISM RELAT D, 45, 13-20.

**IF: 4.426**

Ayala A., Trivino-Juarez J.M., Forjaz M.J., Rodriguez-Blazquez C., Rojo-Abuin J.-M., Martinez-Martin P., Aguilar M., Quilez-Ferrer P., Alvarez Sauco M., Bayes A., et al., Parkinson's disease severity at 3 years can be predicted from non-motor symptoms at baseline (2017) FRONT NEUROL, 8 (OCT).

**IF: 3.290**

Bellosta Diago E., Perez Perez J., Santos La-sosa S., Viloria Alebesque A., Martinez Horta S., Kulisevsky J., Lopez del Val J., Circadian rhythm and autonomic dysfunction in pre-symptomatic and early Huntington's disease (2017) PARKINSONISM RELAT D, 44, 95-100.

**IF: 4.426**

Carmona-Iragui M., Balasa M., Benejam B., Alcolea D., Fernandez S., Videla L., Sala I., Sanchez-Saudinos M.B., Morenas-Rodriguez E., Ribosa-Nogue R., Illan-Gala I., Gonzalez-Ortiz S., Clarimon J., Schmitt F., Powell D.K., Bosch B., Llado A., Rafii M.S., Head E., Molinuevo J.L., Blesa R., Videla S., Lleo A., Sanchez-Valle R., Fortea J., Cerebral amyloid angiopathy in Down syndrome and sporadic and autosomal-dominant Alzheimer's disease (2017) ALZHEIMERS DEMENT, 13 (11), 1251-1260.

**IF: 11.980**

Colom-Cadena M., Grau-Rivera O., Planellas L., Cerquera C., Morenas E., Helgueta S., Munoz L., Kulisevsky J., Marti M.J., Tolosa E., Clarimon J., Lleo A., Gelpi E., Regional overlap of pathologies in Lewy body disorders (2017) J NEUROPATH EXP NEUR, 76 (3), 216-224.

**IF: 3.271**

De Fabregues O., Gironell A., Rossello-Jimenez D., Movement disorders units and management of motor fluctuations in advanced parkinson's disease Unidades de trastornos del movimiento y tratamiento de las fluctuaciones motoras de la enfermedad de Parkinson avanzada (2017) REV NEUROLOGIA, 65 (9), 396-404.

**IF: 0.384**

Fernandez-Bobadilla R., Martinez-Horta S., Marin-Lahoz J., Horta-Barba A., Pagonabarraga J., Kulisevsky J., Garcia-Sanchez C., Gironell A., Roig C., Delgado-Mederos R., Marti-Fabregas J., Visual hallucinations in patients with acute stroke: a prospective exploratory study (2017) EUR J NEUROL, 24 (5), 734-740.

raga J., Kulisevsky J., Development and validation of an alternative version of the Parkinson's Disease-Cognitive Rating Scale (PD-CRS) (2017) PARKINSONISM RELAT D, 43, 73-77.

**IF: 4.426**

Garcia-Sanz P., Orgaz L., Bueno-Gil G., Espadas I., Rodriguez-Traver E., Kulisevsky J., Gutierrez A., Davila J.C., Gonzalez-Polo R.A., Fuentes J.M., Mir P., Vicario C., Moratala R., N370S-GBA1 mutation causes lysosomal cholesterol accumulation in Parkinson's disease (2017) MOVEMENT DISORD, 32 (10), 1409-1422.

**IF: 7.596**

Lopez-Mora D.A., Camacho V., Fernandez A., Fuentes F., Perez-Perez J., Carrio I., Value of 18F-FDG PET/CT in the diagnosis of chorea-acanthocytosis Valor de la 18F-FDG PET/TC en el diagnóstico de corea-acantocitosis (2017) REV ESP MED NUCL IMA.

**IF: 0.981**

Lopez-Mourelo O., Mur E., Madrigal I., Alvarez-Mora M.I., Gomez-Anson B., Pagonabarraga J., Rodriguez-Revenga L., Mila M., Social anxiety and autism spectrum traits among adult FMR1 premutation carriers (2017) CLIN GENET, 91 (1), 111-114.

**IF: 3.374**

Martinez-Castrillo J.C., Pena-Segura J.L., Sanz-Cartagena P., Alonso-Curro X., Arbelo-Gonzalez J.M., Arriola-Pereda G., Coll-Bosch M.D., Conejero-Casares J.A., Garcia-Ribes A., Jauma-Classen S., Pagonabarraga J., Vidal-Valls J., Garcia-Ruiz P.J., Myths and evidence on the use of botulinum toxin: Spasticity in adults and in children with cerebral palsy Mitos y evidencias en el empleo de la toxina botulínica: Espasticidad del adulto y del niño con parálisis cerebral (2017) REV NEUROLOGIA, 64 (10), 459-470.

**IF: 0.384**

Martinez-Horta S., Sampedro F., Pagonabarraga J., Fernandez-Bobadilla R., Marin-Lahoz J., Riba J., Kulisevsky J., Non-demented Parkinson's disease patients with apathy show decreased grey matter volume in key executive and reward-related nodes (2017) BRAIN IMAGING BEHAV, 11 (5), 1334-1342.

**IF: 3.719**

Morenas-Rodriguez E., Camps-Renom P., Perez-Cordon A., Horta-Barba A., Simon-Talero M., Cortes-Vicente E., Guisado-Alonso

D., Vilaplana E., Garcia-Sanchez C., Gironell A., Roig C., Delgado-Mederos R., Marti-Fabregas J., Visual hallucinations in patients with acute stroke: a prospective exploratory study (2017) EUR J NEUROL, 24 (5), 734-740.

**IF: 3.543**

Moss D.J.H., Tabrizi S.J., Mead S., Lo K., Pardinas A.F., Holmans P., Jones L., Langbehn D., Coleman A., Santos R.D., et al., Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study (2017) LANCET NEUROL, 16 (9), 701-711.

**IF: 26.619**

Pagonabarraga J., Kulisevsky J., Apathy in Parkinson's Disease. Int Rev Neurobiol. 2017;133:657-678. doi: 10.1016/bs.irn.2017.05.025. Epub 2017 Jul 10.

**IF: 2.371**

Pagonabarraga J., Kulisevsky J., Safinamide from daily clinical practice: First clinical steps Safinamide desde la práctica clínica diaria: Primeros pasos clínicos (2017) REV NEUROLOGIA, 65 (10), 433-438.

**IF: 0.384**

Sala I., Illan-Gala I., Alcolea D., Sanchez-Saudinos M.B., Salgado S.A., Morenas-Rodriguez E., Subirana A., Videla L., Clarimon J., Carmona-Iragui M., Ribosa-Nogue R., Blesa R., Fortea J., Lleo A., Diagnostic and Prognostic Value of the Combination of Two Measures of Verbal Memory in Mild Cognitive Impairment due to Alzheimer's Disease (2017) J ALZHEIMERS DIS, 58 (3), 909-918.

**IF: 3.071**

Schapira A.H.V., Fox S.H., Hauser R.A., Janikovic J., Jost W.H., Kenney C., Kulisevsky J., Pahwa R., Poewe W., Anand R., Assessment of safety and efficacy of safinamide as a levodopa adjunct in patients with Parkinson disease and motor fluctuations a randomized clinical trial (2017) JAMA NEUROL, 74 (2), 216-224.

**IF: 11.152**

Spataro N., Roca-Umbert A., Cervera-Carles L., Valles M., Anglada R., Pagonabarraga J., Pascual-Sedano B., Campolongo A., Kulisevsky J., Casals F., Clarimon J., Bosch E., Detection of genomic rearrangements from targeted resequencing data in Parkinson's disease patients (2017) MOVEMENT DISORD, 32 (1), 165-169.

**IF: 7.596**

Scientific Production

**Other Publications**

- ▶ Catalán MJ, Antonini A, Calopa M, Băjenaru O, de Fábregues O, Mínguez-Castellanos A, Odin P, García-Moreno JM, Pedersen SW, Pirtošek Z, Kulisevskyl J. Can suitable candidates for levodopa/carbidopa intestinal gel therapy be identified using current evidence? . *eNeurologicalSci.* 2017 Sep; 8: 44–53. Published online 2017 Jul 2. doi: 10.1016/j.ensci.2017.06.004 PMCID: PMC5730910 PMID: 29260038.
- ▶ Rosa-Grilo M , Qamar MA , Taddei RN , Pagonabarraga J, Kulisevsky J, Sauerbier A, Chaudhuri KR. Rotigotine transdermal patch and sleep in Parkinson's disease: where are we now?. *NPJ Parkinsons Dis.* 2017 Sep 5;3:28. doi: 10.1038/s41531-017-0030-4. eCollection 2017.

# Molecular Neuropharmacology



## Coordinator

Pol Rigau, Olga  
opol@santpau.cat

IR

## Members

Ferreria Chamorro,	
Pablo Aníbal	UAB
Leanez Morilla, Sergi	IR
Mendes Gomes, Joyce	UAB
Penelas Pintos, Irene	UAB
Redondo Arbós, Alejandro	UAB
Riego Sánchez, Gabriela	UAB

## Main Lines of Research

Chronic pain affects a high percentage of population and is difficult to treat even with the most potent analgesic compounds, which represents one of the main challenges in the current research of pain. Our main objective is to investigate new strategies for the treatment of chronic pain by using pharmacological, molecular and genetic approaches.

The main lines of research are to:

- Investigate new targets for the treatment of chronic pain. Identify new drugs capable to alleviate inflammatory, arthritic, and/or neuropathic pain and evaluate its mechanism of action in different animal pain models.
- Establish new strategies for the treatment of diabetic neuropathy. Identify new approaches for treating neuropathy and oxidative stress, two of the main

complications associated to diabetes, by evaluating the role played by the activation of transcription factor Nrf2/HO-1 signaling pathway in type I and II diabetic animals.

- Study the emotional disorders associated to chronic pain. Investigate the role played by gaseous neurotransmitters in the modulation of the anxiety- and depressive-like behaviors associated to chronic inflammatory and neuropathic pain in animals.
- Investigate the neuropharmacology of opioid and cannabinoid receptors. Establish new strategies to enhance the analgesic effects produced by opioids and cannabinoids during the treatment of chronic pain avoiding the development of side effects.

## Challenges

Our scientific challenges are to:

- Identify new pharmacological compounds that effectively abolish chronic pain without side effects and which use can be transferred to clinical practice and/or patentable.
- Develop new effective approaches for the treatment of diabetic neuropathy, oxidative stress and obesity associated to the development of type 2 diabetes in transgenic mice.

- Establish the role played by gaseous neurotransmitters in the modulation of anxiety and depression associated with the development of chronic inflammatory and neuropathic pain
- Advance in the knowledge of the molecular mechanisms involved in the increased analgesic actions produced by opioids and cannabinoids combined with Nrf2/HO-1 signaling pathway activators during chronic pain.

## Collaborations

### Collaborations with other IIB Sant Pau Groups

- Metabolic Bases of Cardiovascular Risk (PI: Francisco Blanco)

### External Collaborations

- Prof. Christie Ramos Andrade Leite-Panissi. University of São Paulo. Brazil.

- Prof. Luiz Guilherme de Siqueira Branco. University of São Paulo. Brazil.
- Prof. Roberto Motterlini. INSERM U955, University Paris-Est. France.
- Prof. Lydia Giménez-Lloret. Universitat Autònoma de Barcelona. Spain
- Prof. Gianfranco Balboni. University of Cal-gari. Italy

## Active Grants

- Olga Pol Rigau. Nuevas estrategias en el tratamiento de la neuropatía diabética PI14/00927. Instituto de Salud Carlos III. Duration: 2015-2018. 71,500.00 €.
- Olga Pol Rigau. Possible interaction CO-NO in the emotional and nociception modulation: role of locus coeruleus PVE 2014. Ciencia sin Fronteras. Duration: 2015-2018.

Note: Total amount granted to PI. It does not include indirect costs.

**Awards**

- The Molecular Neuropharmacology Group has been awarded with the Prize in basic area for its communication "The induction of the transcription factor Nrf2 inhibits hypersensitivity to pain and increases the analgesic action of morphine in animals with chronic inflammatory pain" in the XIV Congress National of the Spanish Society of Pain celebrated in Murcia, Spain. June 2017.

**Scientific Production**

McDonnell C., Leanez S., Pol O., The induction of the transcription factor Nrf2 enhances the antinociceptive effects of delta-opioid receptors in diabetic mice (2017) PLOS ONE, 12 (7).  
**IF: 2.766**

McDonnell C., Leanez S., Pol O., The inhibitory effects of cobalt protoporphyrin IX and cannabinoid 2 receptor agonists in type 2 diabetic mice (2017) INT J MOL SCI, 18 (11).  
**IF: 3.687**

Redondo A., Chamorro P.A.F., Riego G., Leanez S., Pol O., Treatment with sulforaphane produces antinociception and improves morphine effects during inflammatory pain in mice (2017) J PHARMACOL EXP THER, 363 (3), 293-302.  
**IF: 3.706**

# Pharmacological Research in Humans



## Coordinator

Antonieta Arbós,  
Rosa María  
antonijoana@santpau.cat

## Members

Ballester Verneda, María Rosa	IR
Castillo Ocaña, Marta	IR
Claramunt Giralt, Judit	IR
Clos Batet, Susana	IR
Coimbra Hurtado, Maria Jimena	IR
Coma Bolta, Sonia	IR
Ferrero Cafiero, Juan Manuel	IR
Funes Ungria, María Àngels	IR
Garcia Gea, Consuelo	IR
Garrido Sánchez, Maria Teresa	IR
Gich Saladich, Ignasi Josep	FGS
Giménez Badia, Sandra	IR
Gomis Pulgar, Ana María	IR
González Cuadros, Mireia	IR
Martínez Bonifacio, David	IR
Martínez Colomer, Juan	IR
Martínez Domínguez, Pura	IR
Martínez Martínez, Maria Isabel	IR
Mercader Seguí, Esteve	IR
Molina Perelló, Pol	IR
Mora Amargos, Sara	IR
Puntes Rodríguez, Montserrat	IR

## Main Lines of Research

### Clinical Trials with no Therapeutic Benefits to Volunteer Participants

- ▶ Phase I clinical trials (healthy volunteers) whose main objectives include: first-time-in- humans, safety and tolerability (local, systemic/dermatological, ophthalmological, vaginal), pharmacokinetics, bioavailability and bioequivalence (generic drugs), pharmacodynamics, interactions (drug-drug/drug-food), evaluation and characterization of biomarkers, proofs of concept, acceptability and preference studies.
- ▶ Follow-up studies in populations with the same or different characteristics (elderly, obese, postmenopausal, with liver or kidney failure).
- ▶ Collaboration with clinical services to conduct phase II/III studies.

### Neuro-Physio-Pharmacology of Sleep/Wake States

- ▶ Investigate human brain activity in sleep and wakefulness, mechanisms involved in these states, problems derived from sleep disturbances and possible interventions.
- ▶ Approach the phenomenon as a continuum: appropriate interpretation of the impact of a certain intervention, whether pharmacological or not, should take into account the complementarity of evaluations performed during sleep and during wakefulness.
- ▶ Develop studies that consider the 24-hour day/night cycle as the phenomenon under study cannot be evaluated without taking this interactivity into account.
- ▶ Develop psychomotor performance tests, subjective evaluation scales, neurophysiologic recordings (quantitative EEG, evoked-sensorial potentials and polysomnography), psychophysiological tests and pupillometric tests.

## Challenges

- ▶ Consolidate and strengthen leadership in this field in Spain, conserve relationships with the pharmaceutical industry on a national level and strengthen and extend relations abroad with multinational enterprises and industries from other sectors.
- ▶ Broaden the range of questions to address in research projects along the lines of the neuro-physio-pharmacology of sleep/wake states, focusing on pharmacotherapeutic objectives and also on physiopathologic objectives in related fields, such as dreams.
- ▶ Develop neurophysiologic recording performance in ambulatory conditions, simplifying participation of volunteers but not lowering the quality of data obtained (non-negotiable element of their application as a research variable).

- ▶ Promote dissemination of our activity with a dual objective: to return knowledge generated to society and demystify research in humans, bringing it closer to the community so as to foster participation in clinical trials (particularly in specific sectors of the populations, such as the elderly).
- ▶ Set up educational activities related to our two main research lines: the application of good clinical practices in clinical research into sleep medicine and its medical (pathology, and treatment) and social (quality of life, prevention of accident risk) consequences.

## Collaborations

### External Collaborations

- ▶ Phase I-II clinical trials for national and international pharmaceutical companies.

## Active Grants

- ▶ Rosa María Antonieta Arbós. Desarrollo de una combinación de sensibilizantes de la acción de la insulina y antiandrógenos para el tratamiento del síndrome de ovario poliquístico en adolescentes y mujeres jóvenes RTC-2016-5671-1. Ministeri d'Economia i Competitivitat. Duration: 2016-2019. 100,796.00 €.

Note: Total amount granted to PI. It does not include indirect costs.

**\*TIF: 22.251 \*\*MIF: 2.7813**

Alquezar A., Santalo M., Rizzi M., Gich I., Grau M., Sionis A., Ordonez-Llanos J., Merce J., Martin A., Munoz M., Povar J., Velilla J., Calmarza P., Temboury F., Ortiz C., Balaguer J., Carratala A., Combined high-sensitivity copeptin and troponin T evaluation for the diagnosis of non-ST elevation acute coronary syndrome in the emergency department Evaluación de una estrategia diagnóstica combinada con copeptina y troponina T ultrasensibles en el infarto de miocardio sin elevación del segmento ST en los servicios de urgencias (2017) EMERGENCIAS, 29 (4), 237-244.

**IF: 3.608**

Antonijuan R., Coimbra J., Garcia-Gea C., Puntes M., Gich I., Campo C., Valiente R., Labeaga L., Comparative efficacy of bilastine, desloratadine and rupatadine in the suppression of wheal and flare response induced by intradermal histamine in healthy volunteers (2017) CURR MED RES OPIN, 33 (1), 129-136.

**IF: 2.665**

Barata A., Martino R., Gich I., Garcia-Cadenas I., Abella E., Barba P., Briones J., Brunet S., Esquirol A., Garcia-Pallarols F., Garrido A., Granell M., Martinez J., Mensa I., Novelli S., Sanchez-Gonzalez B., Valcarcel D., Sierra J., Do Patients and Physicians Agree When They Assess Quality of Life? (2017) BIOL BLOOD MARROW TR, 23 (6), 1005-1010.

**IF: 4.484**

Diaz-Torné C., Moragues C., Toniolo E., Geli C., Castellví I., Moya P., Gich I., Llobet JM. Impact of ultrasonography on treatment decision in rheumatoid arthritis: the IMPULSAR study. (2017) RHEUMATOL INT 37 6 891-896.

**IF: 1.952**

Espinós JJ., Vanrell C., Gich I., Urgell E., Calaf J., Pituitary response profile following metoclopramide administration in women with different forms of hyperprolactinemia. (2017) GYNECOL ENDOCRINOL 33 2 148-151.

**IF: 1.453**

Gimenez S., Romero S., Alonso J.F., Mananas M.A., Pujol A., Baxarias P., Antonijuan R.M.,

Monitoring sleep depth: analysis of bispectral index (BIS) based on polysomnographic recordings and sleep deprivation (2017) J CLIN MONIT COMPUT, 31 (1), 103-110.

**IF: 2.450**

Ginovart G., Gich I., Gutierrez A., Verd S., A Fortified Donor Milk Policy is Associated with Improved In-Hospital Head Growth and Weight Gain in Very Low-Birth-Weight Infants (2017) ADV NEONAT CARE, 17 (4), 250-257.

**IF: 1.443**

Lambert C., Cubedo J., Padro T., Sanchez-Hernandez J., Antonijuan R.M., Perez A., Badimon L., Phytosterols and omega 3 supplementation exert novel regulatory effects on metabolic and inflammatory pathways: A proteomic study (2017) NUTRIENTS, 9 (6).

**IF: 4.196**

# Clinical Psychiatry



## Coordinator

Portella Moll, María Jesús      IR  
mportella@santpau.cat

## Members

Allende Leal, Saiko	CIBERSAM
Almenta Gallego, David	FGS
Alonso Solís, Anna	IR
Álvarez Martínez, Enric	FGS
Carceller Sindreu, María del Mar	IR
Carmona Farres, Cristina	IR
Corriño Collado, Iluminada	FGS
De Diego Adelño, Francisco Javier	FGS
Díaz Pérez, Anna María	FGS
Draganov, Metodi	IR
Fernández Vidal, Aina	FGS
García-Ribera Comdor, Carles	FGS
Grasa Bello, Eva María	CIBERSAM
Jubero Urgell, Miriam	IR
Pascual Mateos, Juan Carlos	FGS
Pérez Blanco, Josefina	FGS
Pérez Sola, Victor	FGS
Puigdemont Campos, Maria Dolors	FGS
Rabella Figueras, Mireia	IR
Soler Ribaudi, Joaquín	FGS
Soriano Pacheco, José Antonio	FGS
Tiana Sastre, Thaís	FGS
Vicent Gil, Muriel	IR

## Main Lines of Research

- ▶ Psychotic disorders (first episodes and persistent hallucinations).
- ▶ Affective disorders (major depression and validation of scales).
- ▶ Borderline personality disorder.

## Challenges

- ▶ Foster research that reduces the health-care, social and personal costs of mental illness by exploring areas such as epidemiology, etiopathogenesis, physiopathology, prevention and treatment.
- ▶ Foster research into mental health therapies.
- ▶ Foster research to improve quality of life of patients with mental disorders.

## Research into Psychotic Disorders

- ▶ Neuroimaging studies in first psychotic episodes.
- ▶ Study of environmental, biological and genetic factors in psychosis.
- ▶ Efficacy and effectiveness studies of antipsychotic drugs.
- ▶ Efficacy and effectiveness study of psychotherapy for hallucinations.
- ▶ Study of treatment resistance in schizophrenia.

## Collaborations

### Collaborations with other IIB Sant Pau Groups

- ▶ Addictive Behaviours.
- ▶ Neuroradiology.
- ▶ Neurosurgery.
- ▶ Hypophysis Diseases.
- ▶ CIM – Sant Pau.
- ▶ Pain Clinic Sant Pau.
- ▶ Genetics.
- ▶ Internal Medicine.

## Research into Affective Disorders

- ▶ Identification and evaluation of new therapeutic targets in depression.
- ▶ Neuroimaging studies in first psychotic episodes.
- ▶ Biological and genetic markers in affective disorders.
- ▶ Implementation of new therapeutic programmes, depression evaluation and social aspects of depression.

## Research into Personality Disorders

- ▶ Clinical trials regarding the usefulness of mixed treatment in patients with borderline personality disorder and validation of diagnostic instruments.
- ▶ Genetic-neuroimaging studies of borderline personality disorder (BPD).
- ▶ Efficacy and effectiveness studies of psychotherapy for treating borderline personality disorder

## External Collaborations

- ▶ Hospital Clínic de Barcelona, Psychiatry Department.
- ▶ Hospital Parc Taulí, Sabadell, Psychiatry Department.
- ▶ Universidad Complutense de Madrid, Medicine-Pharmacology Department.
- ▶ Hospital Universitario de la Princesa, Madrid, Psychiatry Department.
- ▶ Universidad de Valencia, Medicine-Psychiatry Department.
- ▶ Leipzig University, Medicine-Psychiatry Department.
- ▶ Universidad de Cádiz, Medicine-Pharmacology Department.
- ▶ Hospital Benito Menni – FIDMAG, Barcelona, Psychiatry Department.
- ▶ University of Oxford, Medicine-Psychiatry Department.

## Active Grants

- ▶ María Jesús Portella Moll. Estudio longitudinal de cambios cerebrales en pacientes con un primer episodio de depresión mayor. PI13/01057. Instituto de Salud Carlos III. Duration: 2014-2018. 56,300.00 €.
- ▶ Joaquín Soler Ribaudi. Efectos del Mindfulness en la Actividad y Conectividad Funcional de la Default Mode Network en Pacientes con Trastorno Límite de la Personalidad. PI13/00134. Instituto de Salud Carlos III. Duration: 2014-2017. 46,150.00 €.
- ▶ Iluminada Corripio Collado. Mobile Therapeutic Attention for Patients with Treatment Resistant Schizophrenia (m-RESIST). PHC26-2014 (2) - IR. Unió Europea. Duration: 2015-2017. 126,474.19 €.
- ▶ Juan Carlos Pascual Mateos. Estudio Epigenómico en el Trastorno Límite de la Personalidad: estudio del patrón de metilación (EWAS-Epigenome-wide association study) y su relación con antecedentes traumáticos. PI14/00214. Instituto de Salud Carlos III. Duration: 2015-2018. 81,500.00 €.
- ▶ Eva María Grasa Bello. Eficacia del Entrenamiento Metacognitivo Individualizado (EMC+) en personas con psicosis de breve evolución. PI14/00044 C. Instituto de Salud Carlos III. Duration: 2015-2017.
- ▶ Iluminada Corripio Collado. Mobile Therapeutic Attention for Patients with Treatment Resistant Schizophrenia (m-RESIST). PHC26-2014 (2) - FGS. Unió Europea. Duration: 2015-2017. 152,667.81 €.
- ▶ Francisco Javier de Diego Adeliño. Estudio longitudinal de predicción precoz de la respuesta en depresión con la combinación multimodal de biomarcadores epigenéticos, neurocognitivos y clínicos. PI16/00302. Instituto de Salud Carlos III. Duration: 2017-2019. 86,500.00 €.
- ▶ Enric Álvarez Martínez. Efectos de un análogo de la Ayahuasca sobre el reprocesamiento emocional en pacientes con Trastorno Límite de la Personalidad. PI16/00078. Instituto de Salud Carlos III. Duration: 2017-2019. 46,500.00 €.
- ▶ María Jesús Portella Moll. Contractes "Miguel Servet II" 2016. CPII16/00020. Instituto de Salud Carlos III. Duration: 2017-2020. 101,250.00 €.
- ▶ María Jesús Portella Moll. Convocatòria d'ajuts intramurals per cofinançar despeses pel desenvolupament de projectes actius 2016. IR16-P3. Fundació Privada Hospital de la Santa Creu i Sant Pau. Duration: 2017-2017. 7,000.00 €.
- ▶ Enric Álvarez Martínez. Estimulación Cerebral Profunda en el tratamiento de la esquizofrenia refractaria: Estudio piloto aleatorizado, controlado y cruzado. PI12/00042. Instituto de Salud Carlos III. Duration: 2013-2017. 91,500.00 €.
- ▶ María Jesús Portella Moll. Contracte SNS "M. SERVET" 2010. MS10/00393. Instituto de Salud Carlos III. Duration: 2011-2017. 151,875.00 €.
- ▶ María del Mar Carceller Sindreu. Contractes predoctorals de formació en investigació en salut 2014. FI14/00201. Instituto de Salud Carlos III. Duration: 2015-2019. 82,400.00 €.
- ▶ Francisco Javier de Diego Adeliño. Contratos Juan Rodés 2014. JR14/00011. Instituto de Salud Carlos III. Duration: 2015-2018. 135,000.00 €.
- ▶ Lorena Chanes Puiggrós. Contractes postdoctorals "Sara Borrell" 2016. CD16/00059. Instituto de Salud Carlos III. Duration: 2017-2019. 80,598.00 €.
- ▶ María Jesús Portella Moll. Grup de Recerca en Trastorns Psiquiàtrics de Sant Pau. 2017 SGR 1343. Agència de Gestió d'Ajuts Universitaris i de Recerca. Duration: 2017-2019. 16,250.00 €.

Note: Total amount granted to PI. It does not include indirect costs.

## Grants Awarded in 2017

- ▶ María Jesús Portella Moll. RIDEM: Rehabilitación Integral para Depresión Mayor. Estudio de eficacia de un programa de rehabilitación integral. PI17/00056. Instituto de Salud Carlos III. Duration: 2018-2020. 47,000.00 €.

Note: Total amount granted to PI. It does not include indirect costs.

## Theses

- ▶ Anna Barata Badiella. Qualitat de vida en el receptor de trasplante hematopoiètic. Universitat Autònoma de Barcelona. Directors: Jim Heather, Rodrigo Martino, Jordi Sierra and Enric Álvarez (tutor). Date of defense: 15/03/2017.

# Clinical Psychiatry

\*TIF: 95.2194 \*\*MIF: 2.9756

Alonso-Solis A., Vives-Gilabert Y., Portella M.J., Rabella M., Grasa E.M., Roldan A., Keymer-Gausset A., Molins C., Nunez-Marin F., Gomez-Anson B., Alvarez E., Corripio I., Altered amplitude of low frequency fluctuations in schizophrenia patients with persistent auditory verbal hallucinations (2017) SCHIZOPHR RES, 189, 97-103.

**IF: 3.649**

Alvarez-Tomas I., Soler J., Bados A., Martin-Blanco A., Elices M., Carmona C., Bauza J., Pascual J.C., Long-term course of borderline personality disorder: A prospective 10-year follow-up study (2017) J PERS DISORD, 31 (5), 590-605.

**IF: 2.471**

Bernardo M., Bioque M., Cabrera B., Lobo A., Gonzalez-Pinto A., Pina L., Corripio I., Sanjuan J., Mane A., Castro-Fornieles J., Vieta E., Arango C., Mezquida G., Gasso P., Parellada M., Saiz-Ruiz J., Cuesta M.J., Mas S., Modeling gene-environment interaction in first episodes of psychosis (2017) SCHIZOPHR RES, 189, 181-189.

**IF: 3.649**

Carceller-Sindreu M., de Diego-Adelino J., Portella M.J., Garcia-Moll X., Figueras M., Fernandez-Vidal A., Queralto J.M., Puigdemont D., Alvarez E., Lack of relationship between plasma levels of escitalopram and QTc-interval length (2017) EUR ARCH PSY CLIN N, 267 (8), 815-822.

**IF: 3.617**

Cebolla A., Campos D., Galiana L., Oliver A., Tomas J.M., Feliu-Soler A., Soler J., Garcia-Campayo J., Demarzo M., Banos R.M., Exploring relations among mindfulness facets and various meditation practices: Do they work in different ways? (2017) CONSCIOUS COGN, 49, 172-180.

**IF: 2.003**

Cebolla A., Demarzo M., Martins P., Soler J., Garcia-Campayo J., Unwanted effects: Is there a negative side of meditation? A multicentre survey (2017) PLOS ONE, 12 (9).

**IF: 2.600**

Elices M., Carmona C., Narvaez V., Seto V., Martin-Blanco A., Pascual J.C., Soriano J., Soler J., Direct experience while eating: Laboratory outcomes among individuals with eating disorders versus healthy controls (2017) EAT BEHAV, 27, 23-26.

**IF: 1.870**

Escandon-Nagel N., Dada G., Grau A., Soria-no J., Feixas G., Eating disorder patients evolution three years after intake in Day Hospital La evolución de los pacientes con trastorno de la conducta alimentaria tres años después de ingresar a Hospital de Día (2017) REV ARGENT CLIN PSIC, 16 (1), 59-69.

**IF: 0.436**

Estrada-Prat X., Alvarez-Guerrico I., Bleda-Hernandez M.J., Campodon-Rosanas E., Battle-Vila S., Pujals-Altes E., Nascimento-Osorio M.T., Martin-Lopez L.M., Alvarez-Martinez E., Perez-Sola V., Romero-Cela S., Sleep study in disruptive mood dysregulation disorder and bipolar children Estudio del sueño en niños con Trastorno de Disregulación Disruptivo del Estado de Ánimo y Bipolares (2017) ACTAS ESP PSIQUIATRI, 45 (1), 12-20.

**IF: 0.796**

Feliu-Soler A., Pascual J.C., Elices M., Martin-Blanco A., Carmona C., Cebolla A., Simon V., Soler J., Fostering Self-Compassion and Loving-Kindness in Patients With Borderline Personality Disorder: A Randomized Pilot Study (2017) CLIN PSYCHOL PSYCHOT, 24 (1), 278-286.

**IF: 2.263**

Fraguas D., Diaz-Caneja C.M., Corripio I., Gonzalez-Pinto A., Lobo A., Bioque M., Cuesta M.J., Sanjuan J., Rodriguez-Toscano E., Arias B., Sarro S., Cabrera B., Bulbena A., Vieta E., Castro-Fornieles J., Arango C., Bernardo M., Parellada M., Gene-environment interaction as a predictor of early adjustment in first episode psychosis (2017) SCHIZOPHR RES, 189, 196-203.

**IF: 3.649**

Franquesa A., Cebolla A., Garcia-Campayo J., Demarzo M., Elices M., Pascual J.C., Soler J., Meditation Practice Is Associated with a Values-Oriented Life: the Mediating Role of Decentering and Mindfulness (2017) MINDFULNESS, 8 (5), 1259-1268.

**IF: 2.474**

Garriga M., Sole E., Gonzalez-Pinto A., Selva-Vera G., Arranz B., Amann B.L., Saiz-Ruiz J., Perez-Blanco J., Vieta E., Efficacy of quetiapine XR vs. placebo as concomitant treatment to mood stabilizers in the control of subthreshold symptoms of bipolar disorder: Results from a pilot, randomized controlled trial (2017) EUR NEUROPSYCHOPHARM, 27 (10), 959-969.

**IF: 3.946**

Huerta-Ramos E., Marco-Garcia S., Soledad-Escobar-Villegas M., Rubio-Abadal E., Ochoa S., GrasaBello E.M., Solis A.A., Rabella M., Berdun J., Hospedales M., Corripio I., Usall J., M-RESIST, a complete m-Health solution for patients with treatment-resistant schizophrenia: A qualitative study of user needs and acceptability in the Barcelona metropolitan area M-RESIST, una solución m-health integral para personas con esquizofrenia resistente: Estudio cualitativo de necesidades y aceptabilidad de usuarios en el área de Barcelona (2017) ACTAS ESP PSIQUIATRI, 45 (6), 277-289.

**IF: 0.796**

Justicia A., Elices M., Cebria A.I., Palao D.J., Gorosabel J., Puigdemont D., de Diego-Adelino J., Gabilondo A., Iruin A., Hegerl U., Perez V., Rationale and methods of the iFightDepression study: A double-blind, randomized controlled trial evaluating the efficacy of an internet-based self-management tool for moderate to mild depression (2017) BMC PSYCHIATRY, 17 (1).

**IF: 2.419**

Justicia A., Elices M., Cebria A.I., Palao D.J., Gorosabel J., Puigdemont D., de Diego-Adelino J., Gabilondo A., Iruin A., Hegerl U., Perez V., Rationale and methods of the iFightDepression study: A double-blind, randomized controlled trial evaluating the efficacy of an internet-based self-management tool for moderate to mild depression (2017) BMC PSYCHIATRY, 17 (1).

**IF: 2.280**

Mane A., Berge D., Penzol M.J., Parellada M., Bioque M., Lobo A., Gonzalez-Pinto A., Corripio I., Cabrera B., Saiz-Ruiz J., Bernardo M., Cannabis use, COMT, BDNF and age at first-episode psychosis (2017) PSYCHIAT RES, 250, 38-43.

**IF: 2.223**

Martin-Blanco A., Patrizi B., Soler J., Gasol X., Elices M., Gasol M., Carmona C., Pascual J.C., Use of nalmefene in patients with comorbid borderline personality disorder and alcohol use disorder: A preliminary report (2017) INT CLIN PSYCHOPHARM, 32 (4), 231-234.

**IF: 2.284**

Martin-Blanco A., Ancochea A., Soler J., Elices M., Carmona C., Pascual J.C., Changes over the last 15 years in the psychopharmacological management of persons with borderline personality disorder (2017) ACTA PSYCHIAT SCAND, 136 (3), 323-331.

**IF: 4.772**

Mas S., Gasso P., Torra M., Bioque M., Lobo A., Gonzalez-Pinto A., Olmeda M.S., Corripio I., Vieta E., Castro-Fornieles J., Rodriguez-Jimenez R., Bobes J., Usall J., Llerena A., Saiz-Ruiz J., Bernardo M., Lafuente A., Intuitive pharmacogenetic dosing of risperidone according to CYP2D6 phenotype extrapolated from genotype in a cohort of first episode psychosis patients (2017) EUR NEUROPSYCHOPHARM, 27 (7), 647-656.

**IF: 3.946**

Mezquida G., Cabrera B., Bioque M., Amoretti S., Lobo A., Gonzalez-Pinto A., Espliego A., Corripio I., Vieta E., Castro-Fornieles J., Berge D., Escarti M.J., Ibanez A., Penades R., Sanchez-Torres A.M., Bernardo M., The course of negative symptoms in first-episode schizophrenia and its predictors: A prospective two-year follow-up study (2017) SCHIZOPHR RES, 189, 84-90.

**IF: 3.649**

\*TIF: 95.2194 \*\*MIF: 2.9756

Molins C., Carceller-Sindreu M., Navarro H., Carmona C., Pineiro M., Martinez E., Alvarez E., Portella M.J., Plasma ratio of clozapine to N-desmethylclozapine can predict cognitive performance in treatment-resistant psychotic patients (2017) PSYCHIAT RES, 258, 153-157.

**IF: 2.325**

Mora E., Portella M.J., Martinez-Alonso M., Teres M., Forcada I., Vieta E., Mur M., The impact of obesity on cognitive functioning in euthymic bipolar patients: A cross-sectional and longitudinal study (2017) J CLIN PSYCHIAT, 78 (8), e924-e932.

**IF: 4.058**

Ochoa S., Lopez-Carrilero R., Barrigon M.L., Pousa E., Barajas A., Lorente-Rovira E., Gonzalez-Higueras F., Grasa E., Ruiz-Delgado I., Cid J., Birules I., Esteban-Pinos I., Casanas R., Luengo A., Torres-Hernandez P., Corripio I., Montes-Gomez M., Beltran M., De Apraiz A., Dominguez-Sanchez L., Sanchez E., Llacer B., Pelaez T., Bogas J.L., Moritz S., Randomized control trial to assess the efficacy of meta-cognitive training compared with a psycho-educational group in people with a recent-onset psychosis (2017) PSYCHOL MED, 47 (9), 1573-1584.

**IF: 5.296**

Perez V., Salavert A., Espadaler J., Tuson M., Saiz-Ruiz J., Saez-Navarro C., Bobes J., Baca-Garcia E., Vieta E., Olivares J.M., et al., Efficacy of prospective pharmacogenetic testing in the treatment of major depressive

disorder: Results of a randomized, double-blind clinical trial (2017) BMC PSYCHIATRY, 17 (1).

**IF: 2.280**

Pousa E., Ochoa S., Cobo J., Nieto L., Usall J., Gonzalez B., Garcia-Ribera C., Perez Sola V., Ruiz A.-I., Banos I., Cobo J., Garcia-Ribera C., Gonzalez B., Massons C., Nieto L., Monserrat C., Ochoa S., Pousa E., Ruiz A.-I., Ruiz I., Sanchez-Cabezudo D., Usall J., A deeper view of insight in schizophrenia: Insight dimensions, unawareness and misattribution of particular symptoms and its relation with psychopathological factors (2017) SCHIZOPHR RES, 189, 61-68.

**IF: 3.649**

Puig O., Baeza I., De La Serna E., Cabrera B., Mezquida G., Bioque M., Lobo A., Gonzalez-Pinto A., Parellada M., Corripio I., et al., Persistent negative symptoms in first-episode psychosis: Early cognitive and social functioning correlates and differences between early and adult onset (2017) J CLIN PSYCHIAT, 78 (9), 1414-1422.

**IF: 4.058**

Sampedro F., Revenga M.D.L.F., Valle M., Roberto N., Dominguez-Clave E., Elices M., Luna L.E., Cripa J.A.S., Hallak J.E.C., Araujo D.B.D., Friedlander P., Barker S.A., Alvarez E., Soler J., Pascual J.C., Feilding A., Riba J., Assessing the psychedelic "after-glow" in ayahuasca users: Post-acute neurometabolic and functional connectivity changes are associated with enhanced mindfulness capac-

ities (2017) INT J NEUROPSYCHOPH, 20 (9), 698-711.

**IF: 3.875**

Sanchez-Torres A.M., Moreno-Izco L., Lorente-Omenaca R., Cabrera B., Lobo A., Gonzalez-Pinto A.M., Merchan-Naranjo J., Corripio I., Vieta E., de la Serna E., et al., Individual trajectories of cognitive performance in first episode psychosis: a 2-year follow-up study (2017) EUR ARCH PSY CLIN N, 1-13.

**IF: 3.390**

Santos A., Resmini E., Pascual J.C., Crespo I., Webb S.M., Psychiatric Symptoms in Patients with Cushing's Syndrome: Prevalence, Diagnosis and Management (2017) DRUGS, 77 (8), 829-842.

**IF: 4.633**

Sauras R., Keymer A., Alonso-Solis A., Diaz A., Molins C., Nunez F., Rabella M., Roldan A., Grasa E., Alvarez E., Portella M.J., Corripio I., Volumetric and morphological characteristics of the hippocampus are associated with progression to schizophrenia in patients with first-episode psychosis (2017) EUR PSYCHIAT, 45, 1-5.

**IF: 3.904**

Vega D., Torrubia R., Soto A., Ribas J., Soler J., Pascual J.C., Rodriguez-Fornells A., Marco-Pallares J., Exploring the relationship between non suicidal self-injury and borderline personality traits in young adults (2017) PSYCHIAT RES, 256, 403-411.

**IF: 2.015**

- Elices M., Soler J., Feliu-Soler A., Carmona C., Tiana T., Pascual JC., García-Palacios A., Alvarez E., Combining emotion regulation and mindfulness skills for preventing depression relapse: a randomized-controlled study. BORDERLINE PERSONAL DISORD EMOT DYSREGUL. 2017 Jul;5:4:13.

# Genetics in Neurodegenerative Diseases




## Coordinator

Jordi Clarimon Echavarria, IR  
jclarimon@santpau.cat

## Members

Cervera Carles, Laura IR  
Dols Icardo, Oriol IR  
Muñoz Llahuna, Laia CIBERNED



## Main Lines of Research

- ▶ Use of state-of-the-art genomic strategies to study the genetic architecture of complex diseases caused by neurodegenerative processes, including Alzheimer disease and other dementias, Parkinson disease, and amyotrophic lateral sclerosis (ALS), among others.
- ▶ Cloning and evaluation of novel genes associated with neurodegenerative disorders through genomic analyses on families with Mendelian pattern of inheritance.

- ▶ Study of the relationship between biomarkers and endophenotypes at the individual genetic background.

- ▶ Evaluation of the effect of novel genes related to neurodegenerative disorders in the Spanish population through multi-centre collaborative studies.

## Challenges

- ▶ Assemble a research team of excellence in the international field of genetics of neurodegenerative disorders.
- ▶ Increase our capacity of funding through EU support.

- ▶ Develop a comprehensive genomic database from well-characterized Spanish patients of European origin suffering from neurodegenerative disorders.

## Collaborations

### Collaborations with other IIB Sant Pau Groups

- ▶ Neurobiology of Dementia.
- ▶ Parkinson Disease and Movement Disorders.
- ▶ Neuromuscular Diseases.

- ▶ CIBER-Neurodegenerative Diseases (CIBER-NED)

### Collaborations with international centres

- ▶ Dr. John Hardy, University College of London, UK.
- ▶ Dr. Andrew Singleton, National Institutes of Health, USA.
- ▶ Dr. Jean-Charles Lambert, Directeur de recherche Inserm chez INSERM. Lille, France.
- ▶ Dr. Alfredo Ramírez, University of Bonn. Germany.
- ▶ Dr. Ekaterina Rogava, University of Toronto, Canada.
- ▶ Dr. Mikko Hiltunen, Kuopio University, Finland.
- ▶ Dr. Martin Ingelsson, Uppsala University, Sweden.
- ▶ Dr. Liana Fidani, Aristotle University of Thessaloniki, Greece.
- ▶ Dr. Christine Van Broekhoven, University of Antwerp, Belgium.

## Grants Awarded in 2017

- ▶ Oriol Dols Icardo. Estudi del paper de les variants genètiques rares en l'arquitectura genètica de la malaltia d'Alzheimer. SLT002/16/00040. Departament de Salut. Duration: 2017-2019. 88.376,57 €.
- ▶ Jordi Clarimon Echavarria, Estudio del splicing alternativo en ARN de muestras con diagnóstico neuropatológico de ELA asociada a TDP-43. FUNDELA 2017. Fundació Espanyola per al Foment de la Investigació de l'Esclerosis Lateral Amiotrófica. Duration: 2017-2018. 26.087,00 €.

Note: Total amount granted to PI. It does not include indirect costs.

## Active Grants

- ▶ Jordi Clarimon Echavarria. Estudio del perfil de expresión de microRNA exosomal en biofluídos para la identificación de biomarcadores de uso diagnóstico en la demencia frontotemporal. PI15/00026. Instituto de Salud Carlos III. Duration: 2016-2018. 101,500.00 €.
- ▶ Jordi Clarimon Echavarria. Unitat genètica malalties neurodegeneratives. IR16-P7. Fundació Privada Hospital de la Santa Creu i Sant Pau. Duration: 2017-2017. 7,000.00 €.
- ▶ Jordi Clarimon Echavarria. A comprehensive genomic analysis of patients with motor neuron disease and frontotemporal dementia to disentangle the missing genetic architecture of amyotrophic lateral sclerosis TODOS SOMOS RAROS 2014. Federación Española de Enfermedades Raras / Fundación Isabel Gemio / Federación Española de Enfermedades Neuromusculares. Duration: 2015-2017. 90,748.00 €.
- ▶ Jordi Clarimon Echavarria. Grup de Recerca en Demècies. 2014 SGR 235. Agència de Gestió d'Ajuts Universitaris i de Recerca. Duration: 2014-2017. 18,000.00 €.
- ▶ Jordi Clarimon Echavarria. Contratos Miguel Servet 2013 (II). MSII13/00005. Instituto de Salud Carlos III. Duration: 2014-2017. 101,250.00 €.
- ▶ Jordi Clarimon Echavarria. Grup de Recerca en Demècies: Sant Pau. 2017 SGR 547. Agència de Gestió d'Ajuts Universitaris i de Recerca. Duration: 2017-2019. 35,200.00 €.

Note: Total amount granted to PI. It does not include indirect costs.

**\*TIF: 122.507 \*\*MIF: 7.6566**

## Scientific Production

- Alcolea D., Vilaplana E., Suarez-Calvet M., Illan-Gala I., Blesa R., Clarimon J., Llado A., Sanchez-Valle R., Molinuevo J.L., Garcia-Ribas G., Compta Y., Marti M.J., Pinol-Ripoll G., Amer-Ferrer G., Noguera A., Garcia-Martin A., Fortea J., Lleo A., CSF sAPP $\beta$ , YKL-40, and neurofilament light in frontotemporal lobar degeneration (2017) NEUROLOGY, 89 (2), 178-188. **IF: 7.180**
- Carmona-Iragui M., Balasa M., Benejam B., Alcolea D., Fernandez S., Videla L., Sala I., Sanchez-Saudinos M.B., Morenas-Rodriguez E., Ribosa-Nogue R., Illan-Gala I., Gonzalez-Ortiz S., Clarimon J., Schmitt F., Powell D.K., Bosch B., Llado A., Rafii M.S., Head E., Molinuevo J.L., Blesa R., Videla S., Lleo A., Sanchez-Valle R., Fortea J., Cerebral amyloid angiopathy in Down syndrome and sporadic and autosomal-dominant Alzheimer's disease (2017) ALZHEIMERS DEMENT, 13 (11), 1251-1260. **IF: 11.980**
- Cervera-Carles L., Alcolea D., Estanga A., Ecay-Torres M., Izagirre A., Clerigue M., Garcia-Sebastian M., Villanua J., Escalas C., Blesa R., Martinez-Lage P., Lleo A., Fortea J., Clarimon J., Cerebrospinal fluid mitochondrial DNA in the Alzheimer's disease continuum (2017) NEUROBIOL AGING, 53, 192.e1-192.e4. **IF: 4.225**
- Colom-Cadena M., Grau-Rivera O., Planellas L., Cerquera C., Morenas E., Helgueta S., Muñoz L., Kulisevsky J., Marti M.J., Tolosa E., Clarimon J., Lleo A., Gelpi E., Regional overlap of pathologies in Lewy body disorders (2017) J NEUROPATH EXP NEUR, 76 (3), 216-224. **IF: 3.271**
- Compta Y., Ramos-Campoy O., Grau-Rivera O., Colom-Cadena M., Clarimon J., Marti M.J., Gelpi E., Conjoint FTLD-FUS of the neuronal intermediate filament inclusion disease type, progressive supranuclear palsy, and mild Alzheimer's pathology presenting as parkinsonism with early falls and late hallucinations, psychosis and dementia (2017) NEUROPATHOL
- APPL NEUROBIOL, 43 (4), 352-357. **IF: 6.059**
- Cortes-Vicente E., Pradas J., Marin-Iahoz J., De Luna N., Clarimon J., Turon-Sans J., Gelpi E., Diaz-Manera J., Illa I., Rojas-Garcia R., Early diagnosis of amyotrophic lateral sclerosis mimic syndromes: pros and cons of current clinical diagnostic criteria (2017) AMYOTROPH LAT SCL FR, 18 (5-6), 333-340. **IF: 2.467**
- De Roeck A., van Den Bossche T., van der Zee J., Verheijen J., de Coster W., van Dongen J., Dillen L., Baradaran-Heravi Y., Heeman B., Sanchez-Valle R., et al., deleterious ABCA7 mutations and transcript rescue mechanisms in early onset Alzheimer's disease (2017) ACTA NEUROPATHOL, 134 (3), 475-487. **IF: 15.248**
- Gelpi E., Carrato C., Grau-López L., Becerra JL., Garcia-Armengol R., Massuet A., Cervera-Carles L., Clarimon J., Beyer K., Alvarez R., Incidental neuronal intermediate filament inclusion pathology: unexpected biopsy findings in a 37-year old woman with epilepsy (2017) NEUROPATHOL APPL NEUROBIOL, 43 (7), 636-640. **IF: 6.059**
- Kun-Rodrigues C., Ross O.A., Orme T., Shepherd C., Parkkinen L., Darwent L., Hernandez D., Ansorge O., Clark L.N., Honig L.S., et al., Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodies (2017) NEUROBIOL AGING, 49, 214.e13-214.e15. **IF: 4.225**
- Pegueroles J., Vilaplana E., Montal V., Samperio F., Alcolea D., Carmona-Iragui M., Clarimon J., Blesa R., Lleo A., Fortea J., Longitudinal brain structural changes in preclinical Alzheimer's disease (2017) ALZHEIMERS DEMENT, 13 (5), 499-509. **IF: 11.980**
- Querol-Vilaseca M., Colom-Cadena M., Pegueroles J., San Martin-Paniello C., Clarimon J., Belbin O., Fortea J., Lleo A., YKL-40 (Chitinase 3-like 1) is expressed in a subset of astrocytes in Alzheimer's disease and other tauopathies (2017) J NEUROINFLAMM, 14 (1). **IF: 4.910**
- Sala I., Illan-Gala I., Alcolea D., Sanchez-Saudinos M.B., Salgado S.A., Morenas-Rodriguez E., Subirana A., Videla L., Clarimon J., Carmona-Iragui M., Ribosa-Nogue R., Blesa R., Fortea J., Lleo A., Diagnostic and Prognostic Value of the Combination of Two Measures of Verbal Memory in Mild Cognitive Impairment due to Alzheimer's Disease (2017) J ALZHEIMERS DIS, 58 (3), 909-918. **IF: 3.071**
- Sims R., Van Der Lee S.J., Naj A.C., Bellenguez C., Badarinarayan N., Jakobsdottir J., Kunkle B.W., Boland A., Raybould R., Bis J.C., et al., Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease (2017) NAT GENET, 49 (9), 1373-1384. **IF: 26.192**
- Spataro N., Roca-Umbert A., Cervera-Carles L., Valles M., Anglada R., Pagonabarraga J., Pascual-Sedano B., Campolongo A., Kulisevsky J., Casals F., Clarimon J., Bosch E., Detection of genomic rearrangements from targeted resequencing data in Parkinson's disease patients (2017) MOVEMENT DISORD, 32 (1), 165-169. **IF: 7.596**
- Tell-Marti G., Puig-Butille J.A., Potrony M., Plana E., Badenes C., Antonell A., Sanchez-Valle R., Molinuevo J.L., Lleo A., Alcolea D., Fortea J., Fernandez-Santiago R., Clarimon J., Llado A., Puig S., A Common Variant in the MC1R Gene (p.V92M) is associated with Alzheimer's Disease Risk (2017) J ALZHEIMERS DIS, 56 (3), 1065-1074. **IF: 3.071**
- Van der Zee J., Gijsselinck I., Van Moesvelde S., Perrone F., Dillen L., Heeman B., Baumer V., Engelborghs S., De Bleeker J., Baets J., et al., TBK1 Mutation Spectrum in an Extended European Patient Cohort with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis (2017) HUM MUTAT, 38 (3), 297-309. **IF: 4.973**


# Human Neuropsychopharmacology



## Coordinator

Riba Serrano, Jordi  
jriba@santpau.cat

IR



## Main Lines of Research

### General Neuropsychopharmacology

- ▶ Pharmacological modulation of the different neurotransmission systems to study the role of these systems in advanced cognitive functions (executive control) and emotions.

### Neuropsychopharmacology of Abused Substances

- ▶ Effects on the central nervous system of psychodysleptic drugs such as ayahuasca, salvinorin A, dimethyltryptamine and THC.
- ▶ Assessment of the impact of long-term drug use on brain function (fMRI) and structure (VBM, DTI).

## Challenges

- ▶ Consolidate and extend existing research lines through possible cooperation agreements with other groups and according to internal growth.
- ▶ Obtain stable funding and supporting technical staff.

- ▶ Establish new cooperation agreements within HSCSP RI.

## Collaborations

### Collaborations with other IIB Sant Pau Groups

- ▶ Pharmacokinetic/Pharmacodynamic Modelling and Simulation.
- ▶ Parkinson Disease and Movement Disorders.
- ▶ Clinical Psychiatry.

- ▶ Department of Psychopharmacology and Neuropsychology, Maastricht University, The Netherlands.

### External Collaborations

- ▶ Cognition and Brain Plasticity Group (IDIBELL Bellvitge Biomedical Research Institute), Spain.
- ▶ Biomedical Engineering Research Centre, Universitat Politècnica de Catalunya (UPC), Spain.

- ▶ Psychiatry and Behavioral Sciences Department, Johns Hopkins School of Medicine, USA.

- ▶ Department of Comparative Biomedical Sciences, Louisiana State University, USA.

- ▶ Brain Institute, Federal University of Rio Grande do Norte, Natal, Brazil.

- ▶ Neuroscience and Behaviour Department, Ribeirão Preto Medical School, University of São Paulo, Brazil.

## Active Grants

- ▶ Jordi Riba Serrano. Farmacología humana de la salvinorina-A: estudio farmacocinético, farmacodinámico y de mecanismo de acción mediante bloqueo farmacológico de los efectos. PI12/02758. Instituto de Salud Carlos III. Duration: 2013-2017. 66,500.00 €.
- ▶ Jordi Riba Serrano and Enrique Álvarez. Efectos de un análogo de la ayahuasca sobre el procesamiento emocional en pacientes con Trastorno Límite de la Personalidad. PI16/00078. Instituto de Salud Carlos III. Duration: 2016-2019. 46,500.00 €.

Note: Total amount granted to PI. It does not include indirect costs.

**\*TIF: 18.966 \*\*MIF: 3.7932**

Martinez-Horta S., Sampedro F., Pagonabarraga J., Fernandez-Bobadilla R., Marin-Lahoz J., Riba J., Kulisevsky J., Non-demented Parkinson's disease patients with apathy show decreased grey matter volume in key executive and reward-related nodes (2017) BRAIN IMAGING BEHAV, 11 (5), 1334-1342.

**IF: 3.543**

Morales-Garcia J.A., De La Fuente Revenga M., Alonso-Gil S., Rodriguez-Franco M.I., Feilding A., Perez-Castillo A., Riba J., The alkaloids of Banisteriopsis caapi, the plant source of the Amazonian hallucinogen Ayahuasca, stimulate adult neurogenesis in vitro (2017) SCI REP-UK, 7 (1).

**IF: 3.745**

Sampedro F., Revenga M.D.L.F., Valle M., Roberto N., Dominguez-Clave E., Elices M., Luna L.E., Crippa J.A.S., Hallak J.E.C., Araujo D.B.D., Friedlander P., Barker S.A., Alvarez E., Soler J., Pascual J.C., Feilding A., Riba J., Assessing the psychedelic "after-glow" in ayahuasca users: Post-acute neurometabolic and functional connectivity changes are associated with enhanced mindfulness capacities (2017) INT J NEUROPSYCHOPH, 20 (9), 698-711.

**IF: 3.875**

Santamaria E., Estevez J.A., Riba J., Izquierdo I., Valle M., Population pharmacokinetic modelling of rupatadine solution in 6-11 year olds and optimisation of the experimental design in younger children (2017) PLOS ONE, 12 (4).

**IF: 2.600**

Vaquero L., Camara E., Sampedro F., Perez de los Cobos J., Batlle F., Fabregas J.M., Sales J.A., Cervantes M., Ferrer X., Lazcano G., Rodriguez-Fornells A., Riba J., Cocaine addiction is associated with abnormal prefrontal function, increased striatal connectivity and sensitivity to monetary incentives, and decreased connectivity outside the human reward circuit (2017) ADDICT BIOL, 22 (3), 844-856.

**IF: 5.203**

# Neurobiology of Dementia



## Coordinator

Lleó Bisa, Alberto  
alleo@santpau.cat

FGS

## Members

Alcolea Rodríguez, Daniel Andrés	FGS
Belbin, Olivia	IR
Benejam,	
Bessy Rafaela	IR- EXTERNAL
Blasco Angell, Lucas	IR
Blesa González, Rafael	FGS
Carmona Iragui, María	FGS
Delaby, Constance Jeanne	IR
Fortea Ormaechea, Juan	FGS
García Losada, Lidia	IR
Illan Gala, Ignacio	IR
Montal Blancafort, Víctor	IR
Morenas Rodríguez, Estrella	IR
Núñez Llaves, Raúl	IR
Pegueroles Mollà, Jordi	IR
Querol Vilaseca, Marta	IR
Ribosa Nogué, Roser	IR
Sala Matavera, Isabel	FGS
Salinas Ayala, Marta	IR
Sánchez Saudinos,	
Maria Belén	IR
Sirisi Dolcet, Sonia	IR
Subirana Castillo, Andrea	IR
Torres Alcalá, Soraya	IR
Valldeneu Castells, Silvia	IR
Videla Toro, Laura	IR
Vilaplana Martínez, Eduard	CIBERNED

## Main Lines of Research

- ▶ Biomarkers in Alzheimer disease and other neurodegenerative dementias:
  - CSF biomarkers in Alzheimer disease, dementia with Lewy bodies and frontotemporal dementia.
  - Amyloid and tau imaging in neurodegenerative dementias.
  - Novel MRI markers in preclinical Alzheimer disease and frontotemporal dementia.

- Biomarkers of Alzheimer disease in Down syndrome.
- Molecular basis of neurodegenerative diseases.
- Clinical trials in Alzheimer disease and dementia with Lewy bodies.

## Challenges

- ▶ Maintain and increase scientific production and funding in the next 5 years.
- ▶ Develop a training plan for researchers entering the group while maintaining its translational nature.

- ▶ Establish new cooperation agreements to increase number of applications for European and international projects.
- ▶ Establish links with technological innovation groups and companies to foster additional patent applications and contracts.

## Collaborations

### Collaborations with other IIB Sant Pau Groups

- ▶ Genetics in Neurodegenerative Diseases (PI: Jordi Clarimon).
- ▶ Molecular Physiology of the Synapse (PI: Alex Bayés).
- ▶ Cerebrovascular Diseases (PI: Joan Martí-Fàbregas).
- ▶ Neuromuscular Diseases (PI: Isabel Illa, Ricardo Rojas).
- ▶ Parkinson Disease and Movement Disorders (PI: Jaime Kulisevsky).
- ▶ Nuclear Medicine (PI: Ignasi Carrió).

### External Collaborations

- ▶ Ellen Gelpi, José L. Molinuevo, Raquel Sánchez-Valle. Hospital Clínic-IDIBAPS, Barcelona, Spain.
- ▶ Martin Ingesson, MD, PhD, Uppsala University, Sweden.
- ▶ Tara Spires-Jones, University of Edinburgh, UK.
- ▶ Kaj Blennow, Göteborg, Sweden.
- ▶ Bos, I. Department of Psychiatry and Neuropsychology, Maastricht University, School for Mental Health and Neuroscience, Alzheimer Center Limburg. Maastricht, Netherlands. Collaboration in the article: Estudio de los factores de riesgo en EA prodromica.
- ▶ Collins, JA. Department of Neurology, Massachusetts General Hospital/Harvard Medical School, Charlestown, MA, USA. Collaboration in the article: Estudio de la atrofia focal temporal y la degeneración de redes en la APP semántica.
- ▶ Dekker, AD. Department of Neurology and Alzheimer Research Center, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. Collaboration in the article: Estudio sobre biomarcadores en LCR de EA en Down.
- ▶ De Leon, MJ. Department of Psychiatry, New York University School of Medicine, Center for Brain Health, New York. Collaboration in the article: Estudio del LCR en EA medido con PET.
- ▶ De Roeck, A. Neurodegenerative Brain Diseases Group, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium. Collaboration in the article: Estudio sobre mutaciones y mecanismos de transcripción en EA de inicio precoz.
- ▶ Engelborghs, S. Reference Center for Biological Markers of Dementia (BIODEM), Department of Biomedical Sciences, Institute Born-Bunge, University of Antwerp, Antwerp, Belgium. Collaboration in the article: Estudio sobre guía de consenso para punción lumbar en paciente neurológico.
- ▶ Hamlett, ED. Department of Neuroscience, Medical University of South Carolina, Charleston, SC, USA; The Knoebel Institute for Healthy Aging, University of Denver, Denver, CO, USA. Collaboration in the article: Estudio sobre la revelación de los exosomas neuronales de la enfermedad de Alzheimer en el síndrome de Down.
- ▶ Irwin, DJ and Grossman, M. Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. Collaboration in the article: Estudio sobre los niveles de tau en LCR ante mortem y su correlación con patología tau post mortem en demencia lobar frontotemporal.

## Collaborations

- ▶ Lewczuk, P. Department of Psychiatry and Psychotherapy, Universitätsklinikum Erlangen, and Friedrich-Alexander Universität Erlangen-Nürnberg , Erlangen , Germany. Estudio del LCR y biomarcadores de sangre para las demencias neurodegenerativas.
- ▶ McCallion, P. University at Albany, Albany, NY, USA. Working Group of the International Summit on Intellectual Disability and Dementia. Collaboration in the article: Estudio sobre el consenso de la "International Summit on Intellectual Disability and Dementia" relacionada con la atención primaria en el final de la vida en demencia avanzada.
- ▶ Riancho, J. Servicio de Neurología, Universidad Hospital Marqués de Valdecilla -IDIVAL; CIBERNED, Santander, Spain. Collaboration in the article: Estudio del perfil MicroRNA en pacientes con enfermedad de Alzheimer.
- ▶ Takada, LT. Department of Neurology, Cognitive and Behavioral Neurology Unit, University of São Paulo, São Paulo, Brazil. Collaboration in the article: Estudio sobre enfermedad prionica genética y la demencia rápidamente progresiva en un centro de EUA.
- ▶ Tort-Merino, A. Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clinic, Barcelona, Spain. Collaboration in the article: Estudio sobre la detección precoz de dificultades de aprendizaje de información nueva en la enfermedad de Alzheimer preclínica.
- ▶ van Waalwijk van Doorn, LJ. Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud Alzheimer Centre, Radboud University Medical Center, Nijmegen, The Netherlands. Collaboration in the article: Estudio sobre la mejora de la discriminación pacientes con Alzheimer-pacientes controles basada en el estudio de LCR.
- ▶ Verheijen, J. Neurodegenerative Brain Diseases group, VIB Center for Molecular Neurology, University of Antwerp, Antwerp, Belgium; Institute Born-Bunge, University of Antwerp, Antwerp, Belgium. Collaboration in the article: Estudio de las variantes de TBK1 en la enfermedad de Alzheimer de inicio precoz en una cohorte Europea.
- ▶ Spires-Jones, TL. The University of Edinburgh, UK Dementia Research Institute, Centre for Discovery Brain Sciences, Edinburgh Neuroscience, Euan MacDonald Centre, and Centre for Dementia Prevention, Edinburgh. Collaboration in the article: Estudio sobre la p-alpha-synuclein sináptica en demencia por cuerpos de Lewy.
- ▶ Nordberg, A. Department of Neurobiology, Care Sciences and Society (NVS), H1, Division of Clinical geriatrics. Karolinska Institutet, Sweden. Collaboration and stage: Estudio sobre la inflamación de astrocitos en la enfermedad de Alzheimer preclínica.
- ▶ DZNE-Munich, Alemania. Collaboration and stage: Estudio de biomarcadores relacionados con la actividad microglial en enfermedades neurodegenerativas: demencia con cuerpos de Lewy, demencia frontotemporal y enfermedad de Alzheimer.
- ▶ Trinity College of Dublin, Irlanda. Estudio de la Enfermedad de Alzheimer en el síndrome de Down. Collaboration and stage as "Atlantic Fellow", programme Global Brain Health Institute.

## Active Grants

- ▶ Rafael Blesa González. Enfermedad de Alzheimer y síndrome de Down. Estudios multimodales de líquido cefalorraquídeo, resonancia magnética y PET de amiloide. PI13/01532. Instituto de Salud Carlos III. Duration: 2014-2018. 107,500.00 €.
- ▶ Olivia Belbin. Contratos Miguel Servet 2013 - Tipo I. MS13/00091. Instituto de Salud Carlos III. Duration: 2014-2019. 202,500.00 €.
- ▶ Olivia Belbin. Search for synaptic biomarkers of Alzheimer's disease. CP13/00091. Instituto de Salud Carlos III. Duration: 2014-2017. 121,500.00 €.
- ▶ Alberto Lleó Bisa. Synaptic markers in preclinical Alzheimer's disease. MARATO 20142610. Fundació La Marató de TV3. Duration: 2015-2018. 159,903.00 €.
- ▶ Juan Fortea Ormaechea. Alzheimer's disease in Down's syndrome. CSF, MRI, EEG and PET multimodal studies. MARATO 20141210. Fundació La Marató de TV3. Duration: 2015-2018. 159,200.00 €.
- ▶ Juan Fortea Ormaechea. La estructura cerebral y el metabolismo en la enfermedad de Alzheimer preclínica. Interacciones entre "nuevos y viejos" biomarcadores. PI14/01126. Instituto de Salud Carlos III. Duration: 2015-2019. 101,500.00 €.
- ▶ Alberto Lleó Bisa. Marcadores sinápticos en la enfermedad de Alzheimer. PI14/01561. Instituto de Salud Carlos III. Duration: 2015-2019. 111,500.00 €.
- ▶ Olivia Belbin. Valoración y caracterización de biomarcadores del estadio preclínico de la enfermedad de Alzheimer. PI15/00058. Instituto de Salud Carlos III. Duration: 2016-2018. 56,500.00 €.
- ▶ Rafael Blesa González. Pre-clinical Alzheimer's disease and Type 2 diabetes and obesity. Effects of bariatric surgery: a multimodal study. MARATO 20161431. Fundació La Marató de TV3. Duration: 2017-2020. 142,700.00 €.
- ▶ Rafael Blesa González. Estudio del trazador de tomografía por emisión de positrones (PET) para Tau [18F]THK-5351 en pacientes con diferentes Taupatías. PI16/01825. Instituto de Salud Carlos III. Duration: 2017-2019. 101,500.00 €.
- ▶ Alberto Lleó Bisa. Study with the tau Positron Emission Tomography radiotracer (18F)THK-5351 in patients with different Tauopathies (TAUDEM) BBVA 2016. Fundació BBVA. Duration: 2016-2019. 107,900.00 €.
- ▶ Juan Fortea Ormaechea. Contractes per a intensificació de l'activitat investigadora en el SNS 2016. INT16/00171. Instituto de Salud Carlos III. Duration: 2017-2017. 18,000.00 €.
- ▶ Maria Carmona Iragui. Ajuts per a contractes de formació "Río Hortega" 2014 CM14/00029. Instituto de Salud Carlos III. Duration: 2015-2017. 53,732.00 €.
- ▶ Estrella Morenas Rodríguez. Estudi multimodal de biomarcadors en pacients amb demència amb cossos de Lewy 2015 FI\_B 00336. Agència de Gestió d'Ajuts Universitaris i de Recerca. Duration: 2015-2018. 57,465.00 €.
- ▶ Ignacio Illan Gala. Contratos i-PFIS: Doctorados IIS-Empresa en Ciencias y Tecnologías de la Salud 2015 IF15/00060. Instituto de Salud Carlos III. Duration: 2016-2017. 82,400.00 €.
- ▶ Estrella Morenas Rodríguez. Ajuts per a contractes de formació "Río Hortega" 2016 CM16/00054. Instituto de Salud Carlos III. Duration: 2017-2019. 53,732.00 €.
- ▶ Alberto Lleó Bisa. Contratos para la intensificación de la actividad en el Sistema Nacional de Salud 2015. INT15/00113. Instituto de Salud Carlos III. Duration: 2016-2017. 30,000.00 €.

Note: Total amount granted to PI. It does not include indirect costs.

# Neurobiology of Dementia

## Grants Awarded in 2017

- ▶ Raúl Nuñez Llaves. Valoración y caracterización de proteínas sinápticas como biomarcadores del daño sináptico relacionado con la enfermedad Alzheimer. SLT002/16/00099. Departament de Salut. Duration: 2017-2019. 60,783.66 €.
- ▶ Alberto Lleó Bisa. Estudio de biomarcadores y desarrollo de nuevas estrategias terapéuticas en una cohorte multicéntrica de Demencia Frontotemporal. SLT002/16/00408-01. Departament de Salut. Duration: 2017-2019. 251,426.53 €.
- ▶ Rafael Blesa González. Down Alzheimer Barcelona Neuroimaging Initiative (DABNI). LA CAIXA - DOWN ALZHEIMER, Fundació La Caixa. Duration: 2017-2020. 783,000.00 €.
- ▶ Maria Carmona Iragui. Domiciliary Alzheimer Visiting in Down syndrome. GBHI\_ALZ-18-543740, ALTUM. Duration: 2017-2019. 18,433.61 €.
- ▶ Estrella Morenas Rodríguez, Estudio de biomarcadores de neuroinflamación en demencia con cuerpos de Lewy y demencia frontotemporal. MV17/00026. Instituto de Salud Carlos III. Duration: 2017-2018. 11,960.00 €.
- ▶ Alberto Lleó Bisa, Estudio de biomarcadores y desarrollo de nuevas estrategias terapéuticas en una cohorte multicéntrica de Demencia Frontotemporal. SLT002/16/00408. Departament de Salut. Duration: 2017-2019. 123,280.20 €.
- ▶ Alberto Lleó Bisa, Aplicación de Tomografía de Array (AT) para el estudio sistemático a gran escala del daño sináptico en las demencias neurodegenerativas. PI17/01896. Instituto de Salud Carlos III. Duration: 2018-2020. 77,000.00 €.
- ▶ Juan Fortea Ormaechea, Estudios longitudinales de RM magnética, de difusión y funcional en la enfermedad de Alzheimer preclínica esporádica y asociada al síndrome de Down., PI17/01019, Instituto de Salud Carlos III, Duration: 2018-2020, 127,000.00 €.
- ▶ Ignacio Illan Gala, Contractes de formació en recerca "Río Hortega" 2017., CM17/00074, Instituto de Salud Carlos III, Duration: 2018-2019, 53,732.00 €.
- ▶ Sonia Sirisi Dolcet, Contractes postdoctorals "Sara Borrell" 2017., CD17/00055, Instituto de Salud Carlos III, Duration: 2018-2020, 80,598.00 €.
- ▶ Sonia Sirisi Dolcet, Daños sinápticos en la Deméncia Frontotemporal., FJCI-2016-30669, Ministeri d'Economia i Competitivitat, Duration: 2018-2019, 50,000.00 €.
- ▶ Cristina Guardia Laguarta, Efecto de las manipulaciones genéticas y farmacológicas sobre la actividad del complejo gamma-secretasa., 2016BP00112, Agència de Gestió d'Ajuts Universitaris i de Recerca. Duration: 2017-2019. 92,000.00 €.

Note: Total amount granted to PI. It does not include indirect costs.

## Theses

- ▶ Martí Colom Cadena. Neuropathology of Lewy body diseases: Confluence of multiple pathologies and role of synaptic p- $\alpha$ -synuclein. Universitat de Barcelona. Directors: Lleó A., Gelpí E., Ferer, I. Date of defense: 14/06/2017.
- ▶ María Carmona-Iragui. Sporadic cerebral amyloid angiopathy, beyond lobar intracerebral hemorrhage: multimodal biomarker studies of atypical presentations. Universitat Autònoma de Barcelona, Lleó A., Fortea J., Blesa R. Date of defense: 12/06/2017.
- ▶ Miguel Ángel Santos Santos. Clinicopathologic correlations and neuroimaging biomarkers in primary progressive aphasia. Universitat Autònoma de Barcelona. Directors: Fortea J., Escartín A., Gorno-Tempini M.L. Date of defense: 29/06/2017.
- ▶ Eduard Vilaplana Martínez, A biphasic model for cortical structural changes in preclinical AD: a multimodal MRI, CSF and PET study. Universitat Autònoma de Barcelona, Lleó A., Fortea J. Date of defense: 31/10/2017.

## Awards

- ▶ Daniel Alcolea. Award to the best PhD thesis in neurosciences. SEN (Sociedad Española de Neurología).
- ▶ Benejam B., Videla L, Carmona M, Alcolea D, Fernández González S, Videla S, Lleó A, Blesa R, Fortea J. Biomarcadores en líquido cefalorraquídeo y correlatos neuropsicológicos en una cohorte de personas con síndrome de Down. In: LXIX Reunión Anual de la Sociedad Española de Neurología. Valencia 21-24 nov 2017. Oral communication selected as stellar.
- ▶ Illán Gala I, Montal V, Vilaplana E, Pegueroles J, Alcolea D, Rojas R, Lladó A, Blesa R, Sánchez Valle R, Lleó A, Fortea J. Cortical Microstructural Changes in FTLD: A Novel Imaging Biomarker. In: XXI Reunió Anual de la Societat Catalana de Neurologia. Barcelona 04-05 may 2017. Oral communication awarded.
- ▶ Montal Blancafort V, Illán Gala I, Vilaplana E, Pegueroles J, Alcolea D, Borrego S, Sánchez Saudín MB, Subirana A, Clarimon J, Lladó A, Blesa R, Sánchez Valle R, Lleó A, Fortea J. Cambios micro-

estructurales corticales en los síndromes relacionados con la degeneración lobular frontal: un nuevo marcador de neuroimagen. In: LXIX Reunión Anual de la Sociedad Española de Neurología. Valencia 21-24 nov 2017. Oral communication selected as stellar.

- ▶ Vilaplana E, Montal V, Pegueroles J, Alcolea D, Carmona-Iragui M, Sampedro F, Camacho V, Clarimon J, Blesa R, Lleó A, Fortea J. Biphasic model of preclinical Alzheimer's disease: AV45 PET, CSF Tau and cortical thickness. In: Alzheimer Association International Conference 2017 (AAIC). London (United Kingdom) 16-20 jul 2017. Oral communication awarded with a fellowship.
- ▶ Vilaplana E, Montal V, Pegueroles J, Alcolea D, Illán I, Carmona-Iragui M, Clarimon J, Blesa R, Lleó A, Fortea J. PET de tau: envejecimiento sano y patológico. In: LXIX Reunión Anual de la Sociedad Española de Neurología. Valencia 21-24 nov 2017. Oral communication selected as stellar.

## Transfer Products

- ▶ FUJIRebio Europe N.V. Validación kits ELISA diagnóstico de tau y beta-amiloide con tecnología Lumipulse.
- ▶ Merck, Sharp & Dohme de España, S.A. Recursos humanos necesarios para llevar a cabo las tareas de entrada de preparación de las visitas de los pacientes.



**\*TIF: 322.347 \*\*MIF: 6.8584**

Alcolea D., Vilaplana E., Suarez-Calvet M., Illan-Gala I., Blesa R., Clarimon J., Llado A., Sanchez-Valle R., Molinuevo J.L., Garcia-Ribas G., Compta Y., Marti M.J., Pinol-Ripoll G., Amer-Ferrer G., Noguera A., Garcia-Martin A., Fortea J., Lleo A., CSF sAPP $\beta$ , YKL-40, and neurofilament light in frontotemporal lobar degeneration (2017) NEUROLOGY, 89 (2), 178-188.

**IF: 7.6090**

Bos I., Vos S.J., Frolich L., Kornhuber J., Wiltfang J., Maier W., Peters O., Ruther E., Engelborghs S., Niemantsverdriet E., et al., The frequency and influence of dementia risk factors in prodromal Alzheimer's disease (2017) NEUROBIOL AGING, 56, 33-40.

**IF: 4.4540**

Calabria M., Cattaneo G., Marne P., Hernandez M., Juncadella M., Gascon-Bayarri J., Sala I., Lleo A., Ortiz-Gil J., Ugas L., Blesa R., Rene R., Costa A., Language deterioration in bilingual Alzheimer's disease patients: A longitudinal study (2017) J NEUROLIN-GUIST, 43, 59-74.

**IF: 1.5470**

Carmona-Iragui M., Balasa M., Benejam B., Alcolea D., Fernandez S., Videla L., Sala I., Sanchez-Saudinos M.B., Morenas-Rodriguez E., Ribosa-Nogue R., Illan-Gala I., Gonzalez-Ortiz S., Clarimon J., Schmitt F., Powell D.K., Bosch B., Llado A., Rafii M.S., Head E., Molinuevo J.L., Blesa R., Videla S., Lleo A., Sanchez-Valle R., Fortea J., Cerebral amyloid angiopathy in Down syndrome and sporadic and autosomal-dominant Alzheimer's disease (2017) ALZHEIMERS DEMENT, 13 (11), 1251-1260.

**IF: 12.7400**

Carmona-Iragui M., Santos T., Videla S., Fernandez S., Benejam B., Videla L., Alcolea D., Blennow K., Blesa R., Lleo A., Fortea J., Feasibility of Lumbar Puncture in the Study of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Subjects with Down Syndrome (2017) J ALZHEIMERS DIS, 55 (4), 1489-1496.

**IF: 3.4760**

Cervera-Carles L., Alcolea D., Estanga A., Ecay-Torres M., Izagirre A., Clerigue M., Garcia-Sebastian M., Villanua J., Escalas C., Blesa R., Martinez-Lage P., Lleo A., Fortea J., Clarimon J., Cerebrospinal fluid mitochondrial DNA in the Alzheimer's disease continuum (2017) NEUROBIOL AGING, 53, 192.e1-192.e4.

**IF: 4.4540**

Collins J.A., Montal V., Hochberg D., Quimby M., Mandelli M.L., Makris N., Seeley W.W., Gorno-Tempini M.L., Dickerson B.C., Focal temporal pole atrophy and network degen-

eration in semantic variant primary progressive aphasia (2017) BRAIN, 140 (2), 457-471.

**IF: 10.8400**

Colom-Cadena M., Pegueroles J., Herrmann A.G., Henstridge C.M., Munoz L., Querol-Vilaseca M., Martin-Paniello C.S., Luque-Cabeceiras J., Clarimon J., Belbin O., Nunez-Llaves R., Blesa R., Smith C., McKenzie C.-A., Frosch M.P., Roe A., Fortea J., Andilla J., Loza-Alvarez P., Gelpi E., Hyman B.T., Spires-Jones T.L., Lleo A., Synaptic phosphorylated  $\alpha$ -synuclein in dementia with Lewy bodies (2017) BRAIN, 140 (12), 3204-3214.

**IF: 10.8400**

Colom-Cadena M., Grau-Rivera O., Planellas L., Cerquera C., Morenas E., Helgueta S., Munoz L., Kulisevsky J., Marti M.J., Tolosa E., Clarimon J., Lleo A., Gelpi E., Regional overlap of pathologies in Lewy body disorders (2017) J NEUROPATH EXP NEUR, 76 (3), 216-224.

**IF: 3.4900**

Compta Y., Ramos-Campoy O., Grau-Rivera O., Colom-Cadena M., Clarimon J., Marti MJ, Gelpi E. Conjoint FTLD-FUS of the neuronal intermediate filament inclusion disease type, progressive supranuclear palsy, and mild Alzheimer's pathology presenting as parkinsonism with early falls and late hallucinations, psychosis and dementia. Neuropathol Appl Neurobiol. 2017; 43(4): 352-357.

**IF: 6.0590**

Contreras F., Albacete A., Tebé C., Benejam B., Caño A., Menchón JM. Patients with schizophrenia activate behavioural intentions facilitated by counterfactual reasoning. PLoS One. 2017; 12(6): e0178860.

**IF: 2.7660**

Cosin-Tomas M., Antonell A., Llado A., Alcolea D., Fortea J., Ezquerre M., Lleo A., Marti M.J., Pallas M., Sanchez-Valle R., Molinuevo J.L., Sanfeliu C., Kaliman P., Plasma miR-34a-5p and miR-545-3p as Early Biomarkers of Alzheimer's Disease: Potential and Limitations (2017) MOL NEUROBIOL, 54 (7), 5550-5562.

**IF: 5.0760**

Cummings J., Scheltens P., McKeith I., Blesa R., Harrison J.E., Bertolucci P.H.F., Rockwood K., Wilkinson D., Wijker W., Bennett D.A., Shah R.C., Effect size analyses of souvenaid in patients with Alzheimer's disease (2017) J ALZHEIMERS DIS, 55 (3), 1131-1139.

**IF: 3.4760**

Dangla-Valls A., Molinuevo J.L., Altirriba J., Sanchez-Valle R., Alcolea D., Fortea J., Ramí L., Balasa M., Munoz-Garcia C., Ezquerre M., Fernandez-Santiago R., Lleo A., Llado A., Antonell A., CSF microRNA Profiling in Alz-

heimer's Disease: a Screening and Validation Study (2017) MOL NEUROBIOL, 54 (9), 6647-6654.

**IF: 5.0760**

Dekker AD, Fortea J, Blesa R, De Deyn PP. Cerebrospinal fluid biomarkers for Alzheimer's disease in Down syndrome. Alzheimers Dement (Amst.). 2017; 8: 1-10.

**IF: 12.7400**

De Leon M.J., Li Y., Okamura N., Tsui W.H., Saint-Louis L.A., Glodzik L., Osorio R.S., Fortea J., Butler T., Pirraglia E., Fossati S., Kim H.-J., Carare R.O., Nedergaard M., Benveniste H., Rusinek H., Cerebrospinal fluid clearance in Alzheimer disease measured with dynamic PET (2017) J NUCL MED, 58 (9), 1471-1476.

**IF: 7.4390**

De Roeck A., van Den Bossche T., van der Zee J., Verheijen J., de Coster W., van Dongen J., Dillen L., Baradarani-Heravi Y., Heeman B., Sanchez-Valle R., et al., deleterious ABCA7 mutations and transcript rescue mechanisms in early onset Alzheimer's disease (2017) ACTA NEUROPATHOL, 134 (3), 475-487.

**IF: 15.8720**

Engelborghs S., Niemantsverdriet E., Struyfs H., Blennow K., Brouns R., Comabella M., Djimovic I., van der Flier W., Fröhlich L., Galimberti D., Gnanapavan S., Hemmer B., Hoff E., Hort J., Jacobaeus E., Ingelsson M., Jan de Jong F., Jonsson M., Khalil M., Kuhle J., Lleó A., de Mendonça A., Molinuevo JL., Nagels G., Paquet C., Parnetti L., Roks G., Rosa-Neto P., Scheltens P., Skårgård C., Stomrud E., Tumani H., Visser PJ., Wallin A., Winblad B., Zetterberg H., Duits F., Teunissen CE. Consensus guidelines for lumbar puncture in patients with neurological diseases. Alzheimers Dement (Amst.). 2017; 8: 111-126.

**IF: 12.7400**

Estévez R., Elorza-Vidal X., Gaitán-Peña H., Pérez-Rius C., Armand-Ugón M., Alonso-Gardón M., Xicoy-Espaulella E., Sirisi S., Arnedo T., Capdevila-Nortes X., López-Hernández T., Montolio M., Duarri A., Tejido O., Barrallo-Gimeno A., Palacín M., Nunes V. Megalencephalic leukoencephalopathy with subcortical cysts: A personal biochemical retrospective. Eur J Med Genet. 2017.

**IF: 2.0040**

Ferrari R., Wang Y., Vandrovčová J., Guelfi S., Witeolar A., Karch C.M., Schork A.J., Fan C.C., Brewer J.B., Momeni P., et al., Genetic architecture of sporadic frontotemporal dementia and overlap with Alzheimer's and Parkinson's diseases (2017) J NEUROL NEUROSUR PS, 88 (2), 152-164.

**IF: 7.1440**

# Neurobiology of Dementia

## Scientific Production

Gamir-Morralla A., Belbin O., Fortea J., Alcolea D., Ferrer I., Lleo A., Iglesias T., Kidins220 Correlates with Tau in Alzheimer's Disease Brain and Cerebrospinal Fluid (2017) *J ALZHEIMERS DIS.*, 55 (4), 1327-1333.

**IF: 3.4760**

Garcia-Ayllon M.-S., Lopez-Font I., Boix C.P., Fortea J., Sanchez-Valle R., Lleo A., Molinuevo J.-L., Zetterberg H., Blennow K., Saez-Valero J., C-Terminal fragments of the amyloid precursor protein in cerebrospinal fluid as potential biomarkers for Alzheimer disease (2017) *SCI REP-UK*, 7 (1).

**IF: 4.1220**

Garrido-Pedrosa J., Sala I., Obradors N., Effectiveness of cognition-focused interventions in activities of daily living performance in people with dementia: A systematic review (2017) *BRIT J OCCUP THER*, 80 (7), 397-408.

**IF: 0.7540**

Hamlett E.D., Goetzl E.J., Ledreux A., Vasilevko V., Boger H.A., LaRosa A., Clark D., Carroll S.L., Carmona-Iragui M., Fortea J., Mufson E.J., Sabbagh M., Mohammed A.H., Hartley D., Doran E., Lott I.T., Granholm A.C., Neuronal exosomes reveal Alzheimer's disease biomarkers in Down syndrome (2017) *ALZHEIMERS DEMENT*, 13 (5), 541-549.

**IF: 12.7400**

Illán Gala I., Vilaplana E., Pegueroles J., Montal V., Alcolea D., Blesa R., Lleo A., Fortea J. The pitfalls of biomarker-based classification schemes. *Alzheimers Dement.* 2017; 13(9): 1072-1074.

**IF: 12.740**

Illán Gala I., Pérez Lucas J., Martín Montes A., Máñez Miró J., Arpa J., Ruiz Ares G. Long-term outcomes of adult chronic idiopathic hydrocephalus treated with a ventriculo-peritoneal shunt. *Neurologia*. 2017; 32(4): 205 - 212.

**IF: 1.938**

Irwin D.J., Lleo A., Xie S.X., Mcmillan C.T., Wolk D.A., Lee E.B., Van Deerlin V.M., Shaw L.M., Trojanowski J.Q., Grossman M., Ante mortem cerebrospinal fluid tau levels correlate with postmortem tau pathology in frontotemporal lobar degeneration (2017) *ANN NEUROL*, 82 (2), 247-258.

**IF: 10.2440**

Jimenez A., Pegueroles J., Carmona-Iragui M., Vilaplana E., Montal V., Alcolea D., Videla L., Gala I.I., Pane A., Casajoana A., Belbin O., Clarimon J., Moize V., Vidal J., Lleo A., Fortea J., Blesa R., Weight loss in the healthy elderly might be a non-cognitive sign of preclinical Alzheimer's disease (2017) *ONCOTARGET*, 8 (62), 104706-104716.

**IF: 4.6700**

Kun-Rodrigues C., Ross O.A., Orme T., Shepherd C., Parkkinen L., Darwent L., Hernandez D., Ansorge O., Clark L.N., Honig L.S., et al., Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodies (2017) *NEUROBIOLOGY AGING*, 49, 214.e13-214.e15.

**IF: 4.4540**

Lewczuk P., Riederer P., O'Bryant SE., Verbeek MM., Dubois B., Visser PJ., Jellinger KA., Engelborghs S., Ramirez A., Parnetti L., et al. Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. *World J Biol Psychiatry*. 2017; 27: 1-85.

**IF: 3.713**

Marquie M., Siao Tick Chong M., Anton-Fernandez A., Verwer E.E., Saez-Calveras N., Meltzer A.C., Ramanan P., Amaral A.C., Gonzalez J., Normandin M.D., Frosch M.P., Gomez-Isla T., [F-18]-AV-1451 binding correlates with postmortem neurofibrillary tangle Braak staging (2017) *ACTA NEUROPATHOL*, 134 (4), 619-628.

**IF: 15.8720**

McCallion P., Hogan M., Santos FH., McCarron M., Service K., Stemp D., Keller D., Fortea J., Bishop K., Watchman K., Janicki MP. Consensus statement of the International Summit on Intellectual Disability and Dementia related to end-of-life care in advanced dementia. *J. Appl. Res. Intellect. Disabil.* 2017; 30(6): 1160-1164.

**IF: 2.260**

Montal V., Vilaplana E., Alcolea D., Pegueroles J., Pasternak O., González-Ortiz S., Clarimon J., Carmona-Iragui M., Illán-Gala I., Morenas-Rodríguez E., Ribosa-Noguera R., Sala I., Sánchez-Saudinós MB., García-Sebastián M., Vilaplana J., Izagirre A., Estanga A., Eacay-Torres M., Iriondo A., Clerigue M., Tainta M., Pozueta A., González A., Martínez-Heras E., Llufrí S., Blesa R., Sánchez-Juan P., Martínez-Lage P., Lleo A., Fortea J. Cortical microstructural changes along the Alzheimer's disease continuum. *Alzheimers Dement.* 2017.

**IF: 12.740**

Morenas-Rodríguez E., Camps-Renom P., Perez-Cordon A., Horta-Barba A., Simon-Talero M., Cortes-Vicente E., Guisado-Alonso D., Vilaplana E., Garcia-Sánchez C., Gironell A., Roig C., Delgado-Mederos R., Martí-Fabregas J., Visual hallucinations in patients with acute stroke: a prospective exploratory study (2017) *EUR J NEUROL*, 24 (5), 734-740.

**IF: 4.6210**

Pegueroles J., Vilaplana E., Montal V., Sampedro F., Alcolea D., Carmona-Iragui M., Clarimon J., Blesa R., Lleo A., Fortea J., Lon-

gitudinal brain structural changes in pre-clinical Alzheimer's disease (2017) *ALZHEIMERS DEMENT*, 13 (5), 499-509.

**IF: 12.7400**

Querol-Vilaseca M., Colom-Cadena M., Pegueroles J., San Martin-Paniello C., Clarimon J., Belbin O., Fortea J., Lleo A., YKL-40 (Chitinase 3-like 1) is expressed in a subset of astrocytes in Alzheimer's disease and other tauopathies (2017) *J NEUROINFLAMM*, 14 (1).

**IF: 5.1930**

Riancho J., Vázquez-Higuera JL., Pozueta A., Lage C., Kazimierczak M., Bravo M., Calero M., Gonalezález A., Rodríguez E., Lleó A., Sánchez-Juan P. MicroRNA Profile in Patients with Alzheimer's Disease: Analysis of miR-9-5p and miR-598 in Raw and Exosome Enriched Cerebrospinal Fluid Samples. *J Alzheimers Dis.* 2017; 57(2): 483-491.

**IF: 3.476**

Sala I., Illán-Gala I., Alcolea D., Sanchez-Saudinós M.B., Salgado S.A., Morenas-Rodríguez E., Subirana A., Videla L., Clarimon J., Carmona-Iragui M., Ribosa-Noguera R., Blesa R., Fortea J., Lleo A., Diagnostic and Prognostic Value of the Combination of Two Measures of Verbal Memory in Mild Cognitive Impairment due to Alzheimer's Disease (2017) *J ALZHEIMERS DIS*, 58 (3), 909-918.

**IF: 3.4760**

Sims R., Van Der Lee S.J., Naj A.C., Bellenzquez C., Badarinarayan N., Jakobsdottir J., Kunkle B.W., Boland A., Raybould R., Bis J.C., et al., Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease (2017) *NAT GENET*, 49 (9), 1373-1384.

**IF: 27.1250**

Sintas C., Carreño O., Fernández-Castillo N., Corominas R., Vila-Pueyo M., Toma C., Cuenca-León E., Barroeta I., Roig C., Volpini V., Macaya A., Cormand B. Mutation Spectrum in the CACNA1A Gene in 49 Patients with Episodic Ataxia. *Sci Rep.* 2017; 7(1): 2514.

**IF: 4.122**

Sirisi S., Elorza-Vidal X., Arnedo T., Armand-Ugón M., Callejo G., Capdevila-Nortes X., López-Hernández T., Schulte U., Barrallo-Gimeno A., Nunes V., Gasull X., Estévez R. Depolarization causes the formation of a ternary complex between GlialCAM, MLC1 and CIC-2 in astrocytes: implications in megacephalic leukoencephalopathy. *Hum Mol Genet.* 2017; 26(13): 2436-2450.

**IF: 4.902**

Spataro N., Roca-Umbert A., Cervera-Carles L., Vallès M., Anglada R., Pagonabarraga J., Pascual-Sedano B., Campolongo A., Kulisevsky J., Casals F., Clarimon J., Bosch E. Detection of genomic rearrangements from

## Scientific Production

targeted resequencing data in Parkinson's disease patients. *Mov Disord.* 2017; 32(1): 165-169.

**IF: 8.324**

Takada L.T., Kim M.-O., Cleveland R.W., Wong K., Forner S.A., Gala I.I., Fong J.C., Geschwind M.D., Genetic prion disease: Experience of a rapidly progressive dementia center in the United States and a review of the literature (2017) *AM J MED GENET B*, 174 (1), 36-69.

**IF: 3.0160**

Tell-Martí G., Puig-Butille J.A., Potrony M., Plana E., Badenas C., Antonell A., Sanchez-Valle R., Molinuevo J.L., Lleo A., Alcolea D., Fortea J., Fernandez-Santiago R., Clarimon J., Llado A., Puig S., A Common Variant in the MC1R Gene (p.V92M) is asso-

ciated with Alzheimer's Disease Risk (2017) *J ALZHEIMERS DIS*, 56 (3), 1065-1074.

**IF: 3.4760**

Tort-Merino A., Valech N., Penaloza C., Gronholm-Nyman P., Leon M., Olives J., Estanga A., Ecay-Torres M., Fortea J., Martinez-Lage P., Molinuevo J.L., Laine M., Rodriguez-Fornells A., Rami L., Early Detection of Learning Difficulties when Confronted with Novel Information in Preclinical Alzheimer's Disease Stage 1 (2017) *J ALZHEIMERS DIS*, 58 (3), 855-870.

**IF: 3.4760**

Van der Zee J., Gijselinck I., Van Moesvelde S., Perrone F., Dillen L., Heeman B., Baumer V., Engelborghs S., De Bleecker J., Baets J., et al., TBK1 Mutation Spectrum in an Extended European Patient Cohort with Fronto-

temporal Dementia and Amyotrophic Lateral Sclerosis (2017) *HUM MUTAT*, 38 (3), 297-309.

**IF: 5.3590**

Van Waalwijk Van Doorn L.J.C., Gispert J.D., Kuiperij H.B., Claassen J.A.H.R., Arighi A., Baldeiras I., Blennow K., Bozzali M., Castello-Brando M., Cavedo E., et al., Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes (2017) *J ALZHEIMERS DIS*, 56 (2), 543-555.

**IF: 3.476**

## Books or chapters with ISBN

- ▶ Youssif C, Flix B, Belbin O, Comalada M. Measuring NLR Oligomerization IV: Using FRET-FLIM to Determine the Close Proximity of Inflammasome Components. En: Di Virgilio F, Pelegrín P, editors. *NLR Proteins: Methods and Protocols*. Springer: New York; 2017. pages 169-183.
- ▶ Lleó A, Blesa R. Clinical course of Alzheimer's disease. En: Waldemar G, editor. *Contribution towards Alzheimer's disease*. Oxford Neurology library: Oxford; 2017.

## Other Publications

- ▶ Ortiz B, Videla L, Gich I, Alcacer B, Torres D, Jover I, Sánchez E, Iglesias M, Fortea J, Videla S. Señales de alarma de trastornos del espectro autista en personas con Síndrome de Down. *Rev Med Int Sindr Down*. 2017; 21(1): 3-11.

# Neuroradiology



## Coordinator

Gómez Ansón, Beatriz María FGS  
bgomeza@santpau.cat

## Members

Gómez-Chiari, Marta	FGS
Granell, Esther	FGS
Lozano, Andrea	FGS
Medina, Victoria	FGS
Méndez, Jorge	FGS
Pires, Patricia	UAB

## Main Lines of Research

Ours is a multidisciplinary research group, which has the added value of combining neuroimaging skills of the members of the Neuroradiology clinical unit at Hospital de la Santa Creu i Sant Pau with technological knowledge from PIC/IFAE investigators at the Universitat Autònoma de Barcelona (Spain) and University College London (UCL, UK).

Our focus are: 1) Neuroimaging biomarkers in diseases involving the central nervous system, including neurodegenerative and neuropsychiatric conditions; 2) Automatic procedures and software tools, especially those of Deep Learning/Artificial Intelligence, in neuroradiology.

## Challenges

- ▶ To achieve visibility of our research group and of neuroradiology –often considered by clinicians more a technical tool rather than a discipline in itself– as a defined field of knowledge.
- ▶ To add knowledge in clinical Neuroradiology to the development and implementation of Artificial Intelligence in Diagnostic Imaging.

## Collaborations

### Collaborations with other IIB Sant Pau Groups

- ▶ Pituitary Gland Disorders, Digestive Diseases, Parkinson Disease and Movement Disorders, Cerebrovascular Diseases.
- ▶ Neuro-Oncology, Maternal Care/Obstetrics, Clinical Psychiatry, Head and neck Tumours/Otorhinolaringology.

### External Collaborations

- ▶ University College London (UCL), London, UK (B. Gómez-Anson is Hon Associate Lecturer).

- ▶ Translational Imaging Group, UCL (C. Sudre), and National Hospital for Neurology and Neurosurgery (R. Jäger), London, UK.
- ▶ The role of conventional radiological approach in machine learning. C. Sudre, B. Gómez-Anson, Prof. R. Jäger, M.J. Cardoso, et al. <http://cmictig.cs.ucl.ac.uk/the-role-of-conventional-radiological-approach-in-machine-learning>
- ▶ PIC (Information Science Port) / IFAE (Institute for High Energy Physics), Universitat Autònoma de Barcelona, Spain

## Theses

- ▶ Patricia Pires Encuentra. Análisis del estado e integridad de la sustancia blanca por cortisolismo endógeno en el Síndrome de Cushing. Directors: Beatriz Gómez Ansón, Susana Webb Youdale. Date of defense: 19/09/2017.

**\*TIF: 42.136 \*\*MIF: 3.010**

Aguilar EJ, Corripio I, García-Martí G, Grasa E, Martí-Bonmatí L, Gómez-Anson B, Sanjuán J, Núñez-Marín F, Lorente-Rovira E, Escartí MJ, Brabban A, Turkington D. Emotional fMRI auditory paradigm demonstrates normalization of limbic hyperactivity after cognitive behavior therapy for auditory hallucinations. *Schizophr Res.* 2017 Jul 15; pii: S0920-9964(17)30425-5. doi: 10.1016/j.schres.2017.07.024.

**IF: 3.958**

Alonso-Solis A., Vives-Gilabert Y., Portella M.J., Rabella M., Grasa E.M., Roldan A., Keymer-Gausset A., Molins C., Nunez-Marin F., Gomez-Anson B., Alvarez E., Corripio I., Altered amplitude of low frequency fluctuations in schizophrenia patients with persistent auditory verbal hallucinations (2017) SCHIZOPHR RES, 189, 97-103.

**IF: 3.958**

Balsa M.A., Camacho V., Garrastachu P., Garcia-Solis D., Gomez-Rio M., Rubi S., Setoain X., Arbizu J., A new era for Nuclear Medicine neuroimaging in Spain: Where do we start from in Spain? Nuevos tiempos para la neuroimagen de Medicina Nuclear en España: ¿de dónde partimos? (2017) REV ESP MED NUCL IMA, 36 (4), 219-226.

**IF: 1.202**

Camps-Renom P., Mendez J., Granell E., Cassoni F., Prats-Sánchez L., Martinez-Domeno A., Guisado-Alonso D., Martí-Fabregas J., Delgado-Mederos R., Transcranial duplex sonography predicts outcome following an intracerebral hemorrhage (2017) AM J NEURORADIOOL, 38 (8), 1543-1549.

**IF: 3.653**

Codina Aroca A., Gras Cabrerizo J.R., De Juan Delago M., Massegur Solench H., Spontaneous cerebrospinal fluid fistula in the clivus (2017) EUR ANN OTORHINOLARY, 134 (6), 431-434.

**IF: 1.036**

De Quintana Schmidt C., Leidinger, B Gomez, Granell E, O Gallego, J Craven et al. Practical application of intraoperative tractography on awake brain surgery. Neuro-Oncology 2017; 19(suppl\_3):iii110-iii110.

**IF: 9.384**

Garcia J., Lopez M., Lopez L., Bague S., Granell E., Quer M., Leon X., Validation of the pathological classification of lymph node metastasis for head and neck tumors according to the 8th edition of the TNM Classification of Malignant Tumors (2017) ORAL ONCOL, 70, 29-33.

**IF: 4.636**

Lopez-Mora D.A., Camacho V., Fernandez A., Fuentes F., Perez-Perez J., Carrio I., Value of 18F-FDG PET/CT in the diagnosis of chorea-acanthocytosis Valor de la 18F-FDG PET/CT en el diagnóstico de corea-acantocitosis (2017) REV ESP MED NUCL IMA.

**IF: 1.202**

Lopez-Mourelo O., Mur E., Madrigal I., Alvarez-Mora M.I., Gomez-Anson B., Pagonabaraga J., Rodriguez-Revenga L., Mila M., Social anxiety and autism spectrum traits among adult FMR1 permutation carriers (2017) CLIN GENET, 91 (1), 111-114.

**IF: 3.512**

Higueros E., Roe E., Granell E., Baselga E. Síndrome de Sturge-Weber: revisión ActasDermo-Sifiliográficas. Actas Dermosifiliogr. 2017 Jun; 108(5): 407-417.

**IF: 0.374**

Montes A., Fernandez A., Camacho V., de Quintana C., Gallego O., Craven-Bartle J., Lopez D., Molet J., Gomez-Anson B., Carrio I., The usefulness of 18F-fluorocholine PET/CT in the detection of recurrence of central nervous system primary neoplasms Valor de la PET/TC cerebral con 18F-fluorocolina en la detección de recurrencias de neoplasias primarias del sistema nervioso central (2017) REV ESP MED NUCL IMA, 36 (4), 227-232.

**IF: 1.202**

Pires P., Santos A., Vives-Gilabert Y., Webb S.M., Sainz-Ruiz A., Resmini E., Crespo I., de Juan-Delago M., Gomez-Anson B., White matter involvement on DTI-MRI in Cushing's syndrome relates to mood disturbances and processing speed: a case-control study (2017) PITUITARY, 20 (3), 340-348.

**IF: 2.730**

Santos A., Granell E., Gomez-Anson B., Crespo I., Pires P., Vives-Gilabert Y., Valassi E., Webb S.M., Resmini E., Depression and Anxiety Scores Are Associated with Amygdala Volume in Cushing's Syndrome: Preliminary Study (2017) BIOMED RES INT, 2017,

**IF: 2.583**

Sudre CH, Gomez Anson B, Davagnanam I, Schmitt A, Mendelson AF, Prados F, Smith L, Atkinson D, Hughes AD, Chaturvedi N, Cardoso MJ, Barkhof F, Jaeger HR, Ourselin S. Bullseye's representation of cerebral white matter hyperintensities. J Neuroradiol. 2017 Nov 11.

**IF: 2.706**

# Ageing Institute



## Coordinator

Salvà Casanovas,  
Antoni  
anton.i.salva@uab.cat

FSiE-UAB

## Members

Blancafort Alias, Sergi	FSiE-UAB
Coll Planas, Laura	FSiE-UAB
Domènec Pou, Sara	FSiE-UAB
Domingo Riu, Alexandre	FSiE-UAB
Fernández Maldonado, Laura	FSiE-UAB
Rivero Fernández, Antonio	FSiE-UAB
Rojano Luque, Xavier	FSiE-UAB
Roqué Figuls, Marta Cristina	FSiE-UAB

## Main Lines of Research

### Health promotion and prevention in older people

- ▶ Healthy ageing. Promotion of intrinsic capacities.
- ▶ Healthy habits: Physical activity, sedentary behaviour, healthy diet, cognition stimulation.
- ▶ Epidemiological studies.
- ▶ ICT applications to promote healthy ageing.

### Geriatric Syndromes and Health problems of older people

- ▶ Geriatric Syndromes and Health problems of older people

- ▶ Fragility and sarcopenia.

- ▶ Falls.

- ▶ Functional loss.

- ▶ Alzheimer Disease and other dementias.

- ▶ Malnutrition.

### Long Term Care

- ▶ Health and social services for older people.
- ▶ Personal Centered Care.
- ▶ Caregivers of older adults.
- ▶ ICT applications to health, social services.
- ▶ Functional assessment.

## Challenges

### Health promotion and prevention in older people

- ▶ Area mainly focused on health promotion and disability prevention to improve quality of life among older people. How we improve intrinsic capacities and functional capacity with age.
- ▶ Clinical and epidemiological research undertaken includes both observational and intervention studies, with the main lines of research referring to mobility, nutrition and cognition.
- ▶ ICT Solutions for promoting healthy ageing.

### Geriatric Syndromes and Health problems of older people

- ▶ Screening, diagnosis and intervention in geriatric syndromes.
- ▶ Screening of frailty and sarcopenia. How to apply in clinical practice.
- ▶ Identifying risk of falls and falls prevention in the community and nursing homes.

### Long Term Care

- ▶ How to apply Personal Centered Care in social centres is a key element to promote quality of social services.
- ▶ New models of services for older people with long term care needs.

## Collaborations

### Collaborations with other IIB Sant Pau Groups

- ▶ FRAPEM: FIS Fragilitat. EAP Sardenya.
- ▶ FIS Memory Workshops. Public Health Agency of Barcelona and EAP Sardenya.

### External Collaborations

- ▶ The group participates usually in CE-funded projects.

- ▶ The Group belongs to the Global Research Network of the International Association of Geriatrics and Gerontology.

- ▶ Participation in European groups. Currently:

- The group of nutrition and cognitive decline of the EUGMS (European Union Geriatric Medicine Society)

- MOBEX group: about mobility and falls

**Active Grants**

- ▶ AEQUALIS. Promovent l'autocura, l'alfabetització per a la salut i el capital social en persones grans de zones urbanes desafavorides socioeconòmicament. <http://salut-nvelliment.uab.cat/aequalis/>. Recercaixa. IP. Sergi Blancafortl.78.111,55 €
- ▶ SITLESS. Exercise Referral Schemes enhanced by Self-Management Strategies to battle sedentary behavior. H2020. (Coordinator Centre). IP. Antoni Salvà. Local grant: 789.684 € <http://sitless.eu>
- ▶ NESTORE. Novel Empowering Solutions and Technologies for Older people to Retain Everyday life activities. H2020. IP Giuseppe Andreoni. Local IP. Laura Fernández. 299.500,71 €. <https://nestore.ro/home>
- ▶ APTITUDE. Actuar per a la prevenció Transpirinència de la dependència en les persones grans. Programa Interreg-POCTEFA 2014-2020. IP. Bruno Vellas. Local IP. Antoni Salvà. 390.000 €
- ▶ INNOBRAIN. Noves tecnologies per a la innovació en rehabilitació i estimulació cognitiva COMRDI15-1-0017Ris3Cat. IP. Antoni Rivero. 42.370,39 €
- ▶ REMI en centres d'atenció social i sociosanitària per a persones grans. Obre Social La Caixa. IP: Antoni Rivero. 45.386 €. <http://salut-envelliment.uab.cat/remi/>
- ▶ LOMAPT. Prevention of cognitive decline in older adults with low DHA/EPA index in red blood cells. IP. Bruno Vellas. Up to 723.895 € (Max.).
- ▶ SUMAR. 16470,40 €: 1. Avaluació de l'impacte d'un model d'ACP en residències per a persones grans. IP. Antoni Salvà. 2. Constitució d'una eina per a l'avaluació de la satisfacció en residencies. IP Antoni Rivero.
- ▶ XARESS. Xarxa de recerca en centres sociosanitaris. Dep Salut. IP. Antoni Salvà.

Note: Total amount granted to PI. It does not include indirect costs.

**Theses**

- ▶ Laura Coll. Solitud, suport social i participació de les persones grans des d'una perspectiva de la salut. Universitat Autònoma de Barcelona. Directors: Maria Teresa Puig Reixach and Fredrica Nyqvist. Date of defense: 30/05/2017.
- ▶ Toni Rivero. Enveliment i productivitat científica individual: Evidència empírica pel professorat d'Economia i Empresa a Catalunya 2017. Universitat Autònoma de Barcelona. Director: Josep Lluís Raymond. Date of defense: 19/07/2017.

**Other Publications**

- ▶ Blancafort Alias S, Lobera Barendse A, González Fernández C, Ríos Maré A, González Riera A, Coll-Planas L. El ensayo clínico AEQUALIS para mejorar la salud autopercebida en personas mayores: evaluación de la intervención piloto Sentirnos Bien. Comunidad Julio 2017; 19(2): 4.
- ▶ Xavier Rojano. Prevalença de la fragilitat i la sarcopènia a l'atenció primària: relació amb l'estat cognitiu del pacient. Universitat Autònoma de Barcelona. Director: Rosa Monteserín. Date of defense: 15/09/2017.

# Ageing Institute

## Scientific Production

\*TIF: 73.775 \*\*MIF: 4.3397

Arevalo-Rodriguez I., Munoz L., Godoy-Casasbuenas N., Ciapponi A., Arevalo J.J., Boogaard S., Roquei Figuls M., Needle gauge and tip designs for preventing post-dural puncture headache (PDPH) (2017) COCHRANE DB SYST REV, 2017 (4).

**IF: 6.7540**

Arevalo-Rodriguez I., Munoz L., Godoy-Casasbuenas N., Ciapponi A., Arevalo J.J., Boogaard S., Roquei Figuls M., Needle gauge and tip designs for preventing post-dural puncture headache (PDPH) (2017) COCHRANE DB SYST REV, 2017 (4).

**IF: 6.7540**

Bonfill X., Urrutia G., Roque M., Martinez M.J., Pardo-Hernandez H., Osorio D., Pardo J., Seiron P., Tzanova M., Sola I., Latin American Clinical Epidemiology Network Series – Paper 3: Cochrane develops widely in Latin America and strengthens ties with Latin-CLEN (2017) J CLIN EPIDEMIOL, 86, 84-90.

**IF: 4.2450**

Coll-Planas L., del Valle Gomez G., Bonilla P., Masat T., Puig T., Monteserín R., Promoting social capital to alleviate loneliness and improve health among older people in Spain (2017) HEALTH SOC CARE COMM, 25 (1), 145-157.

**IF: 2.0390**

Coll-Planas L., Nyqvist F., Puig T., Urrutia G., Sola I., Monteserín R., Social capital interventions targeting older people and their impact on health: A systematic review (2017) J EPIDEMIOL COMMUN H, 71 (7), 663-672.

**IF: 3.9730**

Coll-Planas L., Watchman K., Domenech S., McGillivray D., O'Donnell H., Tolson D., Developing Evidence for Football (Soccer) Reminiscence Interventions Within Long-term Care: A Co-operative Approach Applied in Scotland and Spain (2017) J AM MED DIR ASSOC, 18 (4), 355-360.

**IF: 5.3250**

Giné-Garriga M., Coll-Planas L., Guerra M., Domingo Á., Roqué M., Caserotti P., Denkinger M., Rothenbacher D., Tully MA., Kee F., McIn-

tosh E., Martín-Borràs C., Oviedo GR., Jerez-Roig J., Santiago M., Sansano O., Varela G., Skjødt M., Wirth K., Dallmeier D., Klenk J., Wilson JJ., Blackburn NE., Deidda M., Lefebvre G., González D., Salvà A. The SITLESS project: exercise referral schemes enhanced by self-management strategies to battle sedentary behaviour in older adults: study protocol for a randomised controlled trial. Trials. 2017 May 18;18(1):221.

**IF: 2.067**

Hemmingsen B., Gimenez-Perez G., Mauricio D., Roque i Figuls M., Metzendorf M.-I., Richter B., Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus (2017) COCHRANE DB SYST REV, 2017 (12).

**IF: 6.7540**

Martinez Garcia L., Pardo-Hernandez H., Supercchi C., Nino de Guzman E., Ballesteros M., Ibargoyen Roteta N., McFarlane E., Posso M., Roque i Figuls M., Rotaetxe del Campo R., Sanabria A.J., Selva A., Sola I., Vernooij R.W.M., Alonso-Coello P., Methodological systematic review identifies major limitations in prioritization processes for updating (2017) J CLIN EPIDEMIOL, 86, 11-24.

**IF: 4.2450**

Masanes F., Rojano I., Luque X., Salva A., Serra-Rexach J.A., Artaza I., Formiga F., Cuesta F., Lopez Soto A., Ruiz D., Cruz-Jentoft A.J., Cut-off points for muscle mass — not grip strength or gait speed — determine variations in sarcopenia prevalence (2017) J NUTR HEALTH AGING, 21 (7), 825-829.

**IF: 2.8680**

Mocellin S., Baretta Z., Roque i Figuls M., Sola I., Martin-Richard M., Hallum S., Bonfill Cosp X., Second-line systemic therapy for metastatic colorectal cancer (2017) COCHRANE DB SYST REV, 2017 (1).

**IF: 6.7540**

Roque i Figuls M., Martinez-Zapata M.J., Scott-Brown M., Alonso-Coello P., Radioiso-

topes for metastatic bone pain (2017) COCHRANE DB SYST REV, 2017 (3).

**IF: 6.7540**

Sanchez-Garcia S., Garcia-Pena C., Salva A., Sanchez-Arenas R., Granados-Garcia V., Cuadros-Moreno J., Velazquez-Olmedo L.B., Cardenas-Bahena A., Frailty in community-dwelling older adults: Association with adverse outcomes (2017) CLIN INTERV AGING, 12, 1003-1011.

**IF: 2.5050**

Sanchez-Garcia S., Gallegos-Carrillo K., Espinel-Bermudez M.C., Doubova S.V., Sanchez-Arenas R., Garcia-Pena C., Salva A., Briseno-Fabian S.C., Comparison of quality of life among community-dwelling older adults with the frailty phenotype (2017) QUAL LIFE RES, 26 (10), 2693-2703.

**IF: 2.3920**

Wirth K., Klenk J., Brefka S., Dallmeier D., Faehling K., Roque i Figuls M., Tully M.A., Gine-Garriga M., Caserotti P., Salva A., Rothenbacher D., Denkinger M., Stubbs B., Biomarkers associated with sedentary behaviour in older adults: A systematic review (2017) AGEING RES REV, 35, 87-111.

**IF: 8.9730**

Bullrich-Marín I., Sánchez-Ferrín P., Cabanes-Duran C., Salvà-Casanovas A. [Social and health resources in Catalonia. Current situation]. Rev Esp Geriatr Gerontol. 2017 Nov - Dec;52(6):342-347.

**IF: 0.225**

Coll-Planas L., Monteserín R., Cob E., Blanchfort S. [What are primary health care teams doing about loneliness?] Aten Primaria. 2017 Mar 30.

**IF: 1.148**

A close-up photograph of two hands, likely belonging to an elderly person, holding a piece of torn, light-colored paper. The hands are weathered and wrinkled. The paper has the words "AGED CARE" printed on it in a dark, sans-serif font. The background is a warm-toned wooden surface.

AGED  
CARE

# Addictive Behaviours



## Coordinator

Pérez de los Cobos Peris,  
José Carlos FGS  
jperezc@santpau.cat

## Members

Alcaraz García, Saül	FGS
Batlle Batlle, Francesca	FGS
Costa Juste, Silvia María	IR
De Andres Muñoz, Sandra	FGS
Duran-Sindreu Terol, Santiago Francisco	FGS
Guardia Sereigni, Josep	FGS
Muñoz Hurtado, Laura	IR
Pinet Ogue, María Cristina	FGS
Ragull Puig, Miquel	FGS
Ribalta Corona, Elisa	FGS
Siñol Llosa, Nuria	FGS
Tejero Pociello, Antonio	FGS
Trujols Albet, Joan	FGS
Valdeperez Toledo, Ana	FGS

## Main Lines of Research

### Alcohol

- Pharmaco-epidemiological, non-interventional, prospective, multicenter study with Selincro® in alcohol dependence, to determine patterns of use and consumption of alcohol in routine clinical practice in Spain.
- Prospective observational study for reducing the negative consequences associated with excessive alcohol use (RINCA) through the treatment program to reduce alcohol consumption with nalmefene.

### Cocaine

- Evaluation of cocaine craving during hospitalization conditions.

### Smoking

- Evaluation of the neuropsychiatric safety and efficacy of varenicline and bupropion

hydrochloride for smoking cessation in subjects with and without a history of psychiatric disorders.

- Non-treatment follow-up for cardiac assessments following use of smoking cessation treatments in subjects with and without a history of psychiatric disorders.
- Effectiveness of a telephone intervention for smoking cessation in patients with mental disorder: a pragmatic clinical trial

### Opiates

- Patient satisfaction concerning maintenance treatment with opioid agonists (methadone and buprenorphine/naloxone).
- Satisfaction of the heroin-dependent patient regarding methadone and methadone pharmacogenetics.

## Challenges

- Establish bidirectional links between clinical practice and investigation both to suggest hypotheses and incorporate recent advances.
- Participate in controlled clinical trials on the treatment of addictive disorders.
- Develop clinical research studies into the perspective of patients with addictions.

- Integrate clinical research in routine medical practice to assess the effectiveness of procedures.
- Evaluate the validity and reliability of frequently used clinical evaluation procedures.

## Collaborations

### Collaborations with other IIB Sant Pau Groups

- Clinical Epidemiology and Healthcare Services.
- Clinical Psychiatry.
- Genetic Diseases.

### External Collaborations

- DeustoPsych, R+D+I in Psychology and Health, University of Deusto, Bilbao, Spain.
- Joan Trujols. Calidad de vida y satisfacción con el tratamiento en pacientes dependientes de opioides en mantenimiento con metadona: Desarrollo y estudio piloto de dos autoinformes centrados en la perspectiva del paciente (13BICIBE08). Internal call CIBERSAM. 4,050 €.

## Awards

- Pérez de los Cobos J, Trujols J, Alcaraz S, Siñol N, Lozano O, González-Saiz F, Buprenorphine/Naloxone Survey Group. Propiedades psicométricas de la Escala para Valorar la Satisfacción con los Medicamentos para Tratar las Adicciones – Buprenorfina/Naloxona para la Adicción a la Heroína (SASMAT-BUNHER). Best Poster in Neuropsychopharmacology XX Congreso Nacional de Psiquiatría. Barcelona, November 2017.

## Active Grants

- ▶ José Carlos Pérez de los Cobos Peris. Hacia la identificación de los mecanismos que permiten inhibir el craving de cocaína: valoración de factores motivacionales y cognitivos potencialmente relacionados con la ausencia de craving PI12/00105. Instituto de Salud Carlos III. Duration: 2013-2017. 74,500.00 €.
- ▶ Joan Trujols Albet. Calidad de vida desde la perspectiva del paciente en tratamiento con agonistas opioides: síntesis de estudios cualitativos y desarrollo de una escala centrada en el paciente PI16/00056. Instituto de Salud Carlos III. Duration: 2017-2019. 28,500.00 €.
- ▶ José Carlos Pérez de los Cobos Peris. Efecto de los polimorfismos de genes implicados en el perfil farmacodinámico y farmaco-

cinético de la metadona sobre la satisfacción con este medicamento en pacientes dependientes de heroína con mala respuesta terapéutica 2016 I036. Ministeri de Sanitat, Serveis Socials i Igualtat. Duration: 2017-2019. 24,480.00 €.

- ▶ Joan Trujols Albet. Satisfacción con el tratamiento de mantenimiento con agonistas opioides: Revisión sistemática de instrumentos de medida y síntesis cuantitativa de las diferencias en los niveles de satisfacción en función del medicamento y de la escala 2013 I060. Ministeri de Sanitat i Política Social. Duration: 2014-2017. 15,630.00 €.

Note: Total amount granted to PI. It does not include indirect costs.

**\*TIF: 18.628 \*\*MIF: 2.6611**

## Scientific Production

Alcaraz S., Garcia-Barrachina M., Stop&Go - Promoting healthy lifestyles during inpatient detoxification treatment: Rationale, intervention design, methodology (2017) REV PSICOL DEPORTE, 26, 81-87.

**IF: 0.7890**

Alcaraz S., Trujols J., Sinol N., Duran-Sindreu S., Batlle F., Perez de los Cobos J., Exploring predictors of response to methadone maintenance treatment for heroin addiction: The role of patient satisfaction with methadone as a medication (2017) HEROIN ADDICT REL CL, 19 (4), 35-40.

**IF: 0.6810**

Del Pino-Gutierrez A., Fernandez-Aranda F., Granero R., Tarrega S., Valdeperez A., Aguera Z., Hakansson A., Sauvaget A., Aymami N., Gomez-Pena M., Moragas L., Bano M., Honrubia M., Menchon J.M., Jimenez-Murcia S., Impact of alcohol consumption on clinical aspects of gambling disorder (2017) INT J MENT HEALTH NU, 26 (2), 121-128.

**IF: 2.033**

Del Pino-Gutierrez A., Jimenez-Murcia S., Fernandez-Aranda F., Aguera Z., Granero R., Hakansson A., Fagundo A.B., Bolao F., Valdeperez A., Mestre-Bach G., Steward T., Penelo E., Moragas L., Aymami N., Gomez-Pena M., Rigol-Cuadras A., Martin-Romera V., Menchon J.M., The relevance of personality traits in impulsivity-related disorders: From substance use disorders and gambling disorder to bulimia nervosa (2017) J BEHAV ADDICT, 6 (3), 396-405.

**IF: 3.6280**

Pérez de los Cobos J., Alcaraz S., Siñol N., Aranz MJ., Trujols J., Batlle F., Calafell F., Durán-Sindreu S., Salazar J., Satisfaction with methadone and opioid receptor genes polymorphisms in treatment-refractory heroin-dependent patients. J CLIN PSYCHO-PHARMACOL. (2017). 37 (3), 378–380.

**IF: 3.134**

Trujols J., Gonzalez-Saiz F., Manresa M.J., Alcaraz S., Batlle F., Duran-Sindreu S., Perez de los Cobos J., Patient perception of methadone dose adequacy in methadone mainte-

nance treatment: The role of perceived participation in dosage decisions (2017) PATIENT EDUC COUNS, 100 (5), 981-986.

**IF: 2.7850**

Vaquero L., Camara E., Sampedro F., Perez de los Cobos J., Batlle F., Fabregas J.M., Sales J.A., Cervantes M., Ferrer X., Lazcano G., Rodriguez-Fornells A., Riba J., Cocaine addiction is associated with abnormal prefrontal function, increased striatal connectivity and sensitivity to monetary incentives, and decreased connectivity outside the human reward circuit (2017) ADDICT BIOL, 22 (3), 844-856.

**IF: 5.5780**

## Other Publications

- ▶ Trujols J., Guardia-Olmos J., Iraurgi I., Pérez de los Cobos J., Approaches to the perspective of the individual receiving methadone maintenance treatment: Reflections on 10 years of research (2017). Aloma, 35 (2) 39-50.

# Molecular Physiology of the Synapse




## Coordinator

Bayés Puig, Alejandro  
abayesp@santpau.cat

IR

## Members

Gou Alsina, Gemma IR  
Ramos Vicente, David IR  
Reig Viader, Rita IR



## Main Lines of Research

- ▶ Molecular and cellular analyses of the vertebrate synapse.
- ▶ Molecular and cellular dysfunctions underlying intellectual disability and autism.
- ▶ Research into animal models of mental and behavioural disorders.
- ▶ Development of new biochemical methods to study the synapse.

## Challenges

- ▶ Characterize the molecular roots of cognition and behaviour.
- ▶ Identify the synaptic molecules and mechanisms involved in mental and behavioural disorders, mainly intellectual disabilities and autism spectrum disorders.
- ▶ Identify drugs which might help treat mental and behavioural disorders.
- ▶ Study the reversibility after birth of neurodevelopmental disorders affecting cognition.

## Collaborations

### Collaborations with other IIB Sant Pau Groups

- ▶ Neurobiology of Dementias (PI: Alberto Lleó)
- ▶ Oncogenesis and Antitumour Drugs (PI: Ramón Mangues)
- ▶ Molecular Bases of Disease (PI: Pablo Fuentes-Prior)
- ▶ Neurosurgery (PI: Joan Molet)

### External Collaborations

- ▶ Prof. Seth GN Grant. University of Edinburgh, UK.
- ▶ Dr. Noboru Komiyama. University of Edinburgh, UK.
- ▶ Dr. Gavin Rumbaugh. Scripps Research Institute, USA.
- ▶ Dr. Richard Emes. University of Nottingham, UK.
- ▶ Dr. Maksym Kopanitsa. Charles River Laboratories, Finland.
- ▶ Dr. Hector Escribà. Sorbonne Universités, UPMC Univ Paris 06, CNRS, France.

- ▶ Dr. Nael Nadif-Kasri. Radboud University. The Netherlands.
- ▶ Dr. Jyoti S. Choudhari. The Wellcome Trust Sanger Institute, UK.
- ▶ Dr. Mark Collins. University of Sheffield, UK.
- ▶ Dra. Àngels García-Cazorla. Hospital Sant Joan de Déu, Barcelona.
- ▶ Dra. Nerea Roher. Universitat Autònoma de Barcelona, Bellaterra.
- ▶ Dr. Jordi García Fernández. Universitat de Barcelona, Barcelona.
- ▶ Dr. Carles Sindreu. Universitat de Barcelona, Barcelona.
- ▶ Dr. David Soto. Universitat de Barcelona, Barcelona.
- ▶ Dr. Xavier Altafaj. Bellvitge Biomedical Research Institute (IDIBELL), Barcelona
- ▶ Dra. Liset Menéndez de la Prida. Instituto Cajal, Madrid.
- ▶ Dr. Angel Barco. Instituto de Neurociencias, Alicante.
- ▶ Dr. Andres Ozaita. Universitat Pompeu Fabra, Barcelona.

## Active Grants

- ▶ Gemma Gou Alsina. Contratos Predoctorales para la Formación de Doctores 2013 BES-2013-063720. Ministerio de Economía y Competitividad. Duration: 2013-2017. 83,900.00 €.
- ▶ Alejandro Bayés Puig. Red para el estudio de la sinapsis en el contexto de la disfunción cognitiva SAF2014-52624-REDT. Ministerio de Economía y Competitividad. Duration: 2014-2017. 32,000.00 €.
- ▶ Alejandro Bayés Puig. Looking into the dynamics of synaptic molecular machines to learn about the basis of cognition and intellectual disability BFU2015-69717-P. Ministerio de Economía y Competitividad. Duration: 2016-2019. 156,800.00 €.

▶ Alejandro Bayés Puig. Targeted nanoconjugates for the selective elimination of stem cells in disseminated cancer PIE15/00028. Instituto de Salud Carlos III. Duration: 2016-2018. 93,448.00 €.

▶ Alejandro Bayés Puig. Subvenciones del Programa Ramón y Cajal concedidas por la Resolución 05/12/2011. RYC-2011-08391. Ministerio de Economía y Competitividad. Duration: 2012-2017. 168,600.00 €.

Note: Total amount granted to PI. It does not include indirect costs.

## Grants Awarded in 2017

- ▶ Gemma Gou Alsina. Estudio de los mecanismos moleculares de la sinapsis implicados en procesos cognitivos y en la discapacidad cognitiva no sindromica. EEBB-I-17-11996. Ministerio de Economía y Competitividad. Duration: 2017-2017. 6,280.00 €.
- ▶ Alejandro Bayés Puig. Synaptic Dysfunction in Intellectual Disability Caused by SYNGAP1. Translational Research to Develop Human Models and Advance Pharmacological Treatments. AC17/00005. Instituto de Salud Carlos III. Duration: 2018-2020. 123,500.00 €.
- ▶ Alejandro Bayés Puig. Ayudas para la incorporación estable de doctores 2017. IEDI-2017-00822. Ministerio de Economía y Competitividad. Duration: 2018-2020. 100,000.00 €.

Note: Total amount granted to PI. It does not include indirect costs.

## Awards

- ▶ F1000 recommended our publication: Àlex Bayés, Mark O Collins, Rita Reig-Viader, Gemma Gou, David Goulding, Abril Izquierdo, Jyoti S Choudhary, Richard D Emes and Seth GN Grant. Evolution of complexity in the zebrafish synapse proteome. *Nature Communications* 2017 Mar 2; 8: 14613.

## Books or chapters with ISBN

- ▶ Rita Reig-Viader and Àlex Bayés. Quantitative In-Depth profiling of the Postsynaptic Density Proteome to Understand the Molecular Mechanisms Governing Synaptic Physiology and Pathology. Current Proteomic Approaches Applied to Brain Function. 2017 Human Press, Springer Protocols. ISBN 978-1-4939-7119-0.

## Scientific Production

**\*TIF: 12.353 \*\*MIF: 12.353**

Bayes A., Collins M.O., Reig-Viader R., Gou G., Goulding D., Izquierdo A., Choudhary J.S., Emes R.D., Grant S.G.N., Evolution of complexity in the zebrafish synapse proteome (2017) *NAT COMMUN*, 8.

**IF: 12.353**

AREA 5

# Uronephrology and Experimental S

**178** General and Digestive Surgery

**180** Neurosurgery

**182** Nephrology

**188** Women and Perinatal Health Research Group

# Surgery



# General and Digestive Surgery


**Coordinator**

Trias Folch, Manel  
mtrias@santpau.cat

**Members**

Artigas Raventós, Vicenç	FGS
Balaguer Ponz,	
María Carmen	FGS
Bollo Rodríguez,	
Jesús Manuel	FGS
Caballero Mestres, Ferran	FGS
Cerdan Riart, Gemma	FGS
Clos Enríquez, Montserrat	FGS
De la Fuente Hernández,	
Noa	FGS
Fernández Ananín, Sonia	FGS
Garay Sola, Meritxell	FGS
González López,	
Jose Antonio	FGS
Hernández Casanovas,	
Maria Pilar	FGS
Martín Arnau, Ana Belén	FGS
Martínez Sánchez,	
María del Carmen	FGS
Medrano Caviedes,	
Rodrigo Gustavo	FGS
Moral Duarte, Antonio	FGS
Pérez García, José Ignacio	FGS
Rodríguez Blanco, Manuel	FGS
Rofin Serra, Silvia	FGS
Targarona Soler,	
Eduardo María	FGS

**Main Lines of Research**
**Gastrointestinal Surgery**

- ▶ Application of laparoscopic surgery in diseases of the spleen.
- ▶ Application of laparoscopic surgery in disorders of the oesophagogastric junction.
- ▶ Advanced application of colorectal laparoscopy.
- ▶ New stratification and treatment options in colorectal cancer.

**Oncological and Hepatobiliarypancreatic Surgery**

- ▶ Surgery for liver metastasis in colorectal cancer.
- ▶ Development of diagnostic and therapeutic techniques in the global context of treatment for liver metastasis in colorectal carcinoma.
- ▶ Surgery for primary hepatic tumours: determination of efficient prognostic parameters for surgical

**Challenges**
**Gastrointestinal Surgery**

- ▶ Design, develop and manage a dry laboratory for endoscopic surgery, creating a multifunctional research and teaching space to conduct applied technological research in minimally invasive surgery.

**Hepatobiliarypancreatic Surgery**

- ▶ Development of techniques to study liver volume and function.
- ▶ Development of experimental studies on the function and healing of bilio-intestinal sutures.
- ▶ Studies of the value of nutrition in patients undergoing aggressive surgery for highly debilitating cancer.
- ▶ Suitable stratification of GIST tumours in accordance with an anatomopathological classification.

**Books or chapters with ISBN**

- ▶ Monclova, Targarona, EM, Balague, C, R Luppi, C. Minimally invasive splenectomy for oncological diseases of the spleen. In: MA Cuesta. Minimally Invasive Upper Abdominal Surgery, Ed. Springer, 2017. ISBN 978-3-319-54301-7.

resection of hepatocarcinoma and likelihood of tumour recurrence after resection.

- ▶ Introduction of the laparoscopic methodology to biliary lithiasis.
- ▶ Surgery for sarcomas: participation in GIST research through the Spanish Sarcoma Research Group (GEIS) and other entities.
- ▶ Surgery for sarcomas: participation in the development and results of surgery for retroperitoneal tumours.

**Emergency Care**

- ▶ Collaborative project on clinical safety for the introduction of safe practices for polytraumatized patients.

- ▶ Viability of surgical interventions considering the likelihood of disease recurrence.

**Emergency Surgery**

- ▶ Consolidation of a multidisciplinary group for polytraumatized patient care.

**Breast Surgery**

- ▶ Technological innovations in surgery.
- ▶ Possible role of genetic studies in diagnosis and follow-up.

**Endocrinial and Cervical Surgery**

- ▶ Technical innovations in surgery.

- ▶ Targarona, EM. Manual of the European Association of Endoscopic Surgery (EAES). Laparoscopic surgery of the spleen, In: Bonjer J. Surgical Principles of Minimally Invasive Procedures. Eds. Springer 2017. ISBN : 978-3-319-43194-9

## Scientific Production

## Other Publications

Arezzo A., Balague C., Targarona E., Borghi F., Giraudo G., Ghezzo L., Arroyo A., Sola-Vera J., de Paolis P., Bossotti M., Bannone E., Forcignano E., Bonino M.A., Passera R., Morino M., Colonic stenting as a bridge to surgery versus emergency surgery for malignant colonic obstruction: results of a multicentre randomised controlled trial (ESCO trial) (2017) SURG ENDOOSC, 31 (8), 3297-3305.

**IF: 3.117**

Arezzo A., Passera R., Lo Secco G., Verra M., Bonino M.A., Targarona E., Morino M., Stent as bridge to surgery for left-sided malignant colonic obstruction reduces adverse events and stoma rate compared with emergency surgery: results of a systematic review and meta-analysis of randomized controlled trials (2017) GASTROINTEST ENDOSC, 86 (3), 416-426.

**IF: 7.204**

Balla A., Batista Rodriguez G., Buonomo N., Martinez C., Hernandez P., Bollo J., Targarona E.M., Perineal hernia repair after abdominoperineal excision or extralevator abdominoperineal excision: a systematic review of the literature (2017) TECH COLOPROCTOL, 21 (5), 329-336.

**IF: 2.378**

Balla A., Batista Rodriguez G., Corradetti S., Balague C., Fernandez-Ananin S., Targarona E.M., Outcomes after bariatric surgery ac-

cording to large databases: a systematic review (2017) LANGENBECK ARCH SURG, 402 (6), 885-899.

**IF: 2.296**

Ordieres C., Navascues C.A., Gonzalez-Dieguez M.L., Rodriguez M., Cadahia V., Varela M., Rodrigo L., Rodriguez M., Prevalence and epidemiology of hepatitis D among patients with chronic hepatitis B virus infection: A report from Northern Spain (2017) EUR J GASTROEN HEPAT, 29 (3), 277-283.

**IF: 2.014**

Rodriguez de Lope C., Reig M., Matilla A., Ferrer M.T., Duenas E., Minguez B., F. Castroagudin J., Ortiz I., Pascual S., Lledo J.L., et al., Clinical characteristics of hepatocellular carcinoma in Spain. Comparison with the 2008-2009 period and analysis of the causes of diagnosis out of screening programs. Analysis of 686 cases in 73 centers Características clínicas del carcinoma hepatocelular en España. Comparación con el período 2008-2009 y análisis de las causas del diagnóstico fuera de cribado. Estudio de 686 casos en 73 centros (2017) MED CLIN-BARCELONA, 149 (2), 61-71.

**IF: 1.168**

Rodriguez-Otero Luppi C., Targarona Soler E.M., Balague Ponz C., Pantoja Millan J.P., Turrado Rodriguez V., Pallares Segura J.L., Bollo Rodriguez J., Trias Folch M., Clinical,

Anatomical, and Pathological Grading Score to Predict Technical Difficulty in Laparoscopic Splenectomy for Non-traumatic Diseases (2017) WORLD J SURG, 41 (2), 439-448.

**IF: 2.766**

Sanchez Santos R., Corcelles R., Vilallonga Puy R., Delgado Rivilla S., Ferrer J.V., Foncillas Corvinos J., Masdevall Noguera C., Socas Macias M., Gomes P., Balague Ponz C., et al., Prognostic factors of weight loss after sleeve gastrectomy: Multi centre study in Spain and Portugal Factores predictivos de pérdida ponderal tras la gastrectomía vertical. Estudio multicéntrico hispano-portugués (2017) CIR ESPAN, 95 (3), 135-142.

**IF: 0.841**

Targarona E.M., Frasson M., Balibrea J.M., Lopez-Cano M., Rios A., Ferrer J., CIRUGÍA ESPAÑOLA: Evolution and continuity CIRUGÍA ESPAÑOLA: evolución y continuidad (2017) CIR ESPAN, 95 (5), 243-244.

**IF: 0.841**

Van der Pas M.H.G.M., Deijen C.L., Abis G.S.A., de Lange-de Klerk E.S.M., Haglind E., Furst A., Lacy A.M., Cuesta M.A., Bonjer H.J., D'Hoore A., et al., Conversions in laparoscopic surgery for rectal cancer (2017) SURG ENDOOSC, 31 (5), 2263-2270.

**IF: 3.117**

- ▶ Domínguez, R., Medrano, R., Rofin, S., Caballero, F., & Trias, M. Cirugía urgente de la pared abdominal. Rev Hispanoam Hernia. 2017; 5(3): 91-94.
- ▶ Hernández Casanovas MP, Martínez MC, Bollo J, Balla A, Batista Rodríguez G, Balagué C, Targarona EM. Laparoscopic approach for retrorectal tumors-results of a series of 11 cases. Ann Laparosc Endosc Surg 2017; 2: 126.
- ▶ Martín, B., Medrano, R., Caballero, F., Rofin, S., & Trias, M. (2017). Intestinal Obstruction Complicated by Large Morgagni Hernia. Archives of Surgery and Clinical Research, 1(1), 016-020.

# Neurosurgery



## Coordinator

Molet Teixidó, Joan  
jmolet@santpau.cat

## Members

Aibar Duran, Juan Ángel	FGS
Álvarez Holzapfel,	
Maria Jesús	FGS
Asencio Cortés, Carlos	FGS
De Quintana Schmidt,	
Cristian Jose	FGS
Muñoz Hernández,	
Fernando	FGS
Rico Pereira, Marta	FGS
Rodríguez Rodríguez,	
Rodrigo	FGS
Salgado López, Laura	FGS
Sánchez Casas, Marc	FGS
Tresserras Ribó, Pere	FGS



## Main Lines of Research

- ▶ Biomaterials: comparative study of two different cranial bone fixations.
- ▶ Tumour biology: gliomas (prognostic value of different mutations in anaplastic astrocytoma and GBM), pituitary gland adenomas.
- ▶ Biomarkers in anaplastic astrocytomas and glioblastoma multiforme.

## Challenges

- ▶ Monitor the clinical trial on treatment-resistant depression treated using deep brain stimulation techniques (jointly with psychiatry).
- ▶ Evaluate neurostimulation for other disorders: cluster headache.

## Collaborations

### Collaborations with other IIB Sant Pau Groups

- ▶ Fernando Muñoz, Ignasi Català. IMPACT-24 study. Effects of pterygopalatine ganglion stimulation on cerebral perfusion in patients with stroke, Brainsgate. Principal researcher: Joan Martí.
- ▶ Fernando Muñoz, Cristian de Quintada, Ignasi Català, Carles Asencio. CLEAR III. Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage Phase III. John Hопpinkgs Hospital. Principal researcher: Joan Martí.
- ▶ Fernández Muñoz, Carlos Asencio. Estudi MISTIE III. Minimally Invasive Surgery Plus rt-PA for Intracerebral Hemorrhage Evacuation. Principal researcher: Fernando Muñoz Hernández.

- ▶ Fernando Muñoz, Carlos Asencio. SWITCH Trial. Swiss Trial of Decompressive Craniectomy versus Best Medical Treatment of Spontaneous Intracerebral Hemorrhage. A Randomized Controlled Trial. Principal researcher: Fernando Muñoz.

### External Collaborations

- ▶ Joan Molet. MOBI-KITS study. Prospective multicentre worldwide study of the relationship between cell phone use and brain tumour development in the youth population, 7th Framework Programme. ENV-2008-226873. Coordinators Spain: Carlos Díaz Acedo and Sandra Plans. Coordinator Catalonia: CREAL.

## Theses

- ▶ Fernando Muñoz Hernández. Estudi comparatiu entre cirurgia endoscòpica transesfenoïdal versus cirurgia tradicional transesfenoïdal amb microscopi per l'exèresi d'adenomes hipofisaris. Universitat Autònoma de Barcelona. Directors: Xavier Rius Cornadó, Pere Tresserras Ribó. Date of defense: 19/04/2017.

## Scientific Production

Casanova M.J., Chaparro M., Garcia-Sanchez V., Nantes O., Leo E., Rojas-Feria M., Jauregui-Amezaga A., Garcia-Lopez S., Huguet J.M., Arguelles-Arias F., et al., Evolution after Anti-TNF Discontinuation in Patients with Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study (2017) AM J GASTROENTEROL, 112 (1), 120-131.

**IF: 10.231**

Montes A., Fernandez A., Camacho V., de Quintana C., Gallego O., Craven-Bartle J., Lopez D., Molet J., Gomez-Anson B., Carrio I.,

**\*TIF: 21.664 \*\*MIF: 3.4582**

The usefulness of 18F-fluorocholine PET/CT in the detection of recurrence of central nervous system primary neoplasms Valor de la PET/TC cerebral con 18F-fluorocolina en la detección de recurrencias de neoplasias primarias del sistema nervioso central (2017) REV ESP MED NUCL IMA, 36 (4), 227-232.

**IF: 1.202**

Ordas I., Domenech E., Manosa M., Garcia-Sánchez V., Iglesias-Flores E., Penalva M., Canas-Ventura A., Merino O., Fernández-Banares F., Gomollón F., Vera M., Gutier-

rez A., Garcia-Planella E., Chaparro M., Aguas M., Gento E., Munoz F., Aguirresarobe M., Munoz C., Fernandez L., Calvet X., Jimenez C.E., Montoro M.A., Mir A., De Castro M.L., Garcia-Sepulcre M.F., Bermejo F., Panes J., Esteve M., Long-Term Efficacy and Safety of Cyclosporine in a Cohort of Steroid-Refractory Acute Severe Ulcerative Colitis Patients from the ENEIDA Registry (1989-2013): A Nationwide Multicenter Study (2017) AM J GASTROENTEROL, 112 (11), 1709-1718.

**IF: 10.231**

# Nephrology



## Coordinator

Ballarín Castán, José F. Puigvert  
jballarin@fundacio-puigvert.es

## Members

Ars Criach, Elisabeth	F. Puigvert
Bardají de Quixano, Beatriz	F. Puigvert
Bover Sanjuan, Jordi	F. Puigvert
Bullrich Vilanova, Gemma	F. Puigvert
Coll Piera, Elisabet	F. Puigvert
Da Silva Santos, Iara Karlla	F. Puigvert
Díaz Encarnación, Montserrat Mercedes	F. Puigvert
Díaz Gómez, Joan Manel	F. Puigvert
Fernández de la Llama, Patricia	F. Puigvert
Furlano, Mónica María	F. Puigvert
Gràcia García, Silvia	F. Puigvert
Guillén Gómez, Elena	F. Puigvert
Guirado Perich, Lluís	F. Puigvert
Lorente Grandoso, Laura	F. Puigvert
Sanmiguel Amigo, Luz	F. Puigvert
Silva Torres, Irene	F. Puigvert
Torra Balcells, Roser	F. Puigvert

## Main Lines of Research

Fundació Puigvert's Nephrology Research Group has been part of the IIB since its very beginning. The group carries out translational research within the field of renal diseases along different lines from hypertension, hereditary diseases, glomerular diseases and renal fibrosis, to transplants and dialysis.

Those different lines are analysed in detail below:

- ▶ Dra. Torra is the head researcher of the hereditary diseases line she and Dra. Ars have leaded many research projects on these diseases, and both have supervised several doctoral theses. The hereditary renal diseases team is currently analysing phenotype variability of those diseases, both in its genomic and its clinical dimension. Dra. Torra coordinates both the Catalan and the Spanish hereditary renal diseases teams, and is a member of the homonymous European board of the EDTA (European Dialysis and Transplant Association).
- ▶ Dra. Ars heads the molecular genetics laboratory; she has optimised the Next generation sequencing tools for hereditary renal diseases, in collaboration with Dra. Gemma Bullrich. Dra. Ars coordinates the Sant Pau IIB's Fundació Puigvert's On-line Biobank node belonging to the National Biobanks Platform. She is also the person responsible for organising an European Molecular Quality Network (EMQN) outline for quality control of the genetic diagnoses of ADPKD by European laboratories. Currently she is leading a research project for applying this outline to kidney and urinary tract congenital abnormalities.
- ▶ Jointly with Dra. Díaz, Dr. Ballarín leads a series of clinical trials, both national and international, on glomerular and systemic diseases affecting the kidneys. They also participate in registries at a Catalan, Spanish and European level.
- ▶ Dra. Díaz leads the studies on renal inflammation and fibrosis. Renal grafts from cadaveric donors are an apt model for her study due to their less-good prognosis and to a high probability of inflammation and ensuing fibrosis as compared to living donor grafts. Dra. Díaz and Dra. Guillén have identified the activation of purinergic elements, both in cell cultures and in grafts from cadaver donors. This activation participates in inflammation and fibrosis, triggered by the phenotype change of macrophages into anti-inflammatory and pro-fibrotic, and interacting with other pro-fibrotic classical pathways. This new role of the purinergic pathways could be the key for the detection of new markers and new therapeutic targets associated with renal graft dysfunction after transplant.
- ▶ Dra. Fernández-Llama is participating in the development of a prototype of a multiplex system for flow cystometry focused on a new multi-parametric etio-pathogenic diagnosis of acute renal damage. As an expert in hypertension, she participates in a collaborative trial for evaluating 24-hour central blood pressure, its circadian rhythms and its relationship with organic damage.
- ▶ Dr. Bover is also a member of the EDTA work force board on bone metabolism, this being his primary research subject.
- ▶ Dr. Díaz leads the dialysis research line. Currently the two major research lines are concerned with the appropriateness of peritoneal dialysis, and the investigation for biomarkers of the acute renal failure.
- ▶ Dra. Coll, who belongs in the dialysis team, heads the research of genomic damage in patients on renal replacement therapy, either transplant or dialysis. She analyses the differences of oxidative stress in transplanted vs. dialysis patients. She also analyses the effect of different antioxidants on genomic damage of dialysis patients.
- ▶ The transplant team, leaded by Dr. Guiraldo, either participates or heads over 15 studies, amongst them clinical trials with drugs against kidney rejection or for treating associated viral infections. His active participation and his leadership in the investigation of biochemical, serologic and genomic biomarkers of both rejection and viral infections associated with renal transplant, are outstanding.
- ▶ Ms. Luz San Miguel and Ms. Judith Ballart are the coordinators of clinical studies and trials. Their work is essential and of the utmost importance for carrying out the high number of clinical trials performed by the group.

**Challenges**

- ▶ Maintain the level of national and international publication.
- ▶ Continue with both clinical and basic research in all the previously described areas.
- ▶ Participate in the elaboration of clinical nephrology guidelines.
- ▶ Continue with active collection of research samples from CKD and transplant patients.

- ▶ Maintain participation in national working groups and increase international cooperation.
- ▶ Engage in new pharmaceutical clinical studies, including clinical trials.

**Collaborations****Collaborations with other IIB Sant Pau Groups****Active collaborations in basic and clinical research projects**

- ▶ Inflammatory Diseases Group: renal fibrosis.
- ▶ Anaesthesiology Group (in collaboration with the Catalan ANES-CARDIOCAT Group): risk of major adverse cardiovascular and cerebrovascular events in non-cardiac surgery associated with the preoperative estimated glomerular filtration rate.
- ▶ Paediatrics Group: nephrotic syndrome evolution, Ig A nephropathy and inherited kidney diseases.
- ▶ Andrology Group: infertility.
- ▶ Urology Group: genetic predisposition to prostate cancer and transplant.
- ▶ Gynecology: High risk pregnancies, prenatal diagnosis, preimplantation diagnosis.
- ▶ Multidisciplinary teams for inherited kidney diseases: collaboration with most specialities from Sant Pau Hospital for different inherited kidney diseases (data bases, articles, protocols...)

**Platforms**

- ▶ Biobank platform.

**External Collaborations****National academic collaborations**

- ▶ Department of Biochemistry and Molecular Biology, Universitat de Barcelona, Institute of Biomedicine and Oncology Programme, National Biomedical Research Institute of Liver and Gastrointestinal Diseases (CIBER EHD): renal fibrosis.
- ▶ Laboratory of Proteomics CSIC/Universitat Autònoma de Barcelona: diabetic nephropathy.
- ▶ Mutagenesis Department of Universitat Autònoma de Barcelona: renal impairment in chronic kidney disease.
- ▶ Genomic Regulation Center (CRG): inherited kidney diseases.
- ▶ Universidad de Salamanca: acute kidney injury.
- ▶ Universitat de Lleida: chronic kidney disease.

- ▶ National Scientific Societies (such as Sociedad Española de Nefrología) and investigators of other centres: basic and clinical studies (including public grants, clinical trials, observational studies...) promoted by them.

**International academic collaborations**

- ▶ Biochemistry and Microbiology Institute UACH (Chile): renal fibrosis and diabetic nephropathy.
- ▶ Mayo Clinic (Rochester, USA): Autosomal Dominant Polycystic Kidney Disease (ADPKD).
- ▶ Hospital Tenon (Paris, France): Nephrotic syndrome.
- ▶ EURenOms Platform: membranous nephropathy and nephrotic syndrome.
- ▶ Toronto General Hospital (Canada): molecular genetics of idiopathic nephrotic syndrome.
- ▶ University of Melbourne (Australia): Alport syndrome.
- ▶ University Medicine Goettingen (Germany): Alport syndrome.
- ▶ EDTA (multinational, Europe): inherited kidney diseases and chronic kidney disease-mineral and bone disorders.
- ▶ Addenbrooke's Hospital, Cambridge University Hospitals NHS (United Kingdom): vasculitis.
- ▶ EUVAS Group (multinational collaborative Group): vasculitis.

**Private national and international collaborations**

- ▶ Participation in clinical studies including clinical trials and post-authorisation studies promoted by national and international pharmaceutical companies.
- ▶ Research Joint-Venture with VU Medisch Centrum (Amsterdam, The Netherlands); Medizinische Klinik I (Aachen, Germany) and San Paolo Hospital (Milan, Italy) sponsored by Abbvie Co on effects of vitamina D derivatives in CKD-MBD.

**Other collaborations**

- ▶ Tient organisations: inherited diseases (AIRG), lupus (ACLECA) and chronic kidney disease (ALCER).

# Nephrology

## Active Grants

- ▶ Roser Torra Balcells. Nefropatías familiares no filiadas: genes implicados en su causa y su variabilidad fenotípica.. PI15/01824. Instituto de Salud Carlos III. Duration: 2016-2018. 115,500.00 €.
- ▶ Elisabeth Ars Criach. Estudio genómico de nefropatías de inicio temprano.. PI16/01998. Instituto de Salud Carlos III. Duration: 2017-2019. 107,500.00 €.
- ▶ Elisabeth Ars Criach. Enfermedades renales hereditarias quísticas y glomerulares: secuenciación masiva de un panel de genes para mejorar su diagnóstico y del exoma para identificar nuevos genes.. PI13/01731. Instituto de Salud Carlos III. Duration: 2014-2017. 68,000.00 €.
- ▶ Lluís Guirado Perich. Estudi multicèntric, aleatoritzat per avaluar l'eficàcia de la individualització del risc immunològic basat en biomarcadors selectius (disparitat d'eplets HLA i ELISPOT IFN-Y), per optimitzar el tractament immunosupressor en pacients trasplantats renals de donant viu (BIOIMMUN). Generalitat de Catalunya PERIS 2016. SLT002/16/00089. Duration: 2017-2019. 30,589.14 €.
- ▶ José Ballarín Castán. Red de Investigación Renal. ISCIII. RD16/0009/0019. Duration: 2017-2020. 121,379.50 €.
- ▶ José Ballarín Castán. Grup d'Investigació en Nefrologia. AGAUR. 2017 SGR 676. Duration: 2017-2019.

Note: Total amount granted to PI. It does not include indirect costs.

## Grants Awarded in 2017

- ▶ Montserrat Mercedes Díaz Encarnación. Impacto de las vías purinérgicas sobre la activación de macrófagos en el donante cadáver: pieza clave en el desarrollo de fibrosis y disfunción en el trasplante renal. PI17/01566. Instituto de Salud Carlos III. Duration: 2018-2020. 44,000.00 €.

Note: Total amount granted to PI. It does not include indirect costs.

## Theses

- ▶ Carme Facundo. Avaluació del filtrat glomerular en el donant viu renal. Universitat Autònoma de Barcelona. Director: Lluís Guirado. Date of defense: 30/10/2017.
- ▶ Cristina Canal. Supervivència d'empelt i pacient a llarg termini en el trasplantament renal a Catalunya. Universitat Autònoma de Barcelona. Director: Lluís Guirado. Date of defense: 13/12/2017.
- ▶ Nadia Ayasreh. Nefropatía tubulointersticial autosómica dominante. Universitat Autònoma de Barcelona. Director: R. Torra and E. Ars. Date of defense: 02/06/2017.
- ▶ Helena Marco Rusiñol, El Rituximab como tratamiento en las enfermedades autoinmunes. Universitat Autònoma de Barcelona. Directors: J. Ballarín, DJayne, M. Díaz-Encarnación. Date of defense: 14/07/2017.

## Awards

- ▶ Dra R Torra. Recognition of research, clinical outreach and the spread of rare diseases and / or orphan drugs. Best clinical career. Madrid, 27th November. Award from the Asociación Española de Laboratorios de medicamentos huérfanos y ultrahuérfanos (AELMHU).

## Transfer Products

- ▶ "Talking about Dominant Kidney Poliquistosis. Patient and familiars information session". Direction: Dr J.Ballarin and ALCER Patient Association. Barcelona, 17th October.
- ▶ "Living with kidney disease (VI edition meeting for patients)". Direction: Dr J.Ballarin. Barcelona, 16th November.

## Other Publications

- ▶ Vincenti F, Fervenza FC, Campbell KN, Díaz M, Gesualdo L, Nelson P, Praga M, Radhakrishnan J, Sellin L, Singh A, Thornley-Brown D, Veronese FV, Accomando B, Engstrand S, Ledbetter S, Lin J, Neylan J, Tumlin J. A phase 2, double blind, placebo controlled, randomized study of fresolimumab in patients with steroid-resistant primary focal segmental glomerulosclerosis. (2017) Kidney Int Rep 2 5 800-810.

**\*TIF: 155.648 \*\*MIF: 3,9909**

Arroyo D., Betriu A., Valls J., Gorri J.L., Pal-lares V., Abajo M., Gracia M., Valdivielso J.M., Fernandez E., Aladren Regidor M.J., et al., Factors influencing pathological ankle-brachial index values along the chronic kidney disease spectrum: The NEFRONA study (2017) NEPHROL DIAL TRANSPL, 32 (3), 513-520.

**IF: 4.600**

Ars E., Torra R. Rare diseases, rare presentations: recognizing atypical inherited kidney disease phenotypes in the age of genomics. (2017) clin kidney J 10 5 632-638.

**IF: 4.470**

Ayares N., Miquel R., Matamala A., Ars E., Torra R. Revisión de la nefropatía tubulointersticial autosómica dominante. (2017) NEFROLOGÍA 37 3 352-354.

**IF: 1.167**

Bover J., Bailone L., Lopez-Baez V., Benito S., Ciceri P., Galassi A., Cozzolino M., Osteoporosis, bone mineral density and CKD-MBD: treatment considerations (2017) J NEPHROL, 30 (5), 677-687.

**IF: 2.724**

Braun DA., Rao J., Mollet G., Shapiro D., Daugeron MC., Tan W., Gribouval O., Boyer O., Revy P., Furlano M., Mane S., Lifton RP., Bouchard M., Kannu P., Chitayat D., Magen D., Callewaert B., Van Tilbeurgh H., Zenker M., Antignac C., Hildebrandt F. Mutations in keops-complex genes cause nephrotic syndrome with primary microcephaly. (2017) NAT GENET 49, 10, 1529-1538.

**IF: 27.125**

Breda A., Territo A., Gausa L., Rodríguez-Faba O., Caffaratti J., de León P., Guirado L., Facundo C., Guazzieri M., Guttila A., Villavicencio H. Robotic kidney transplantation: one year after the beginning. (2017) WORLD J UROL 35, 10, 1507-1515.

**IF: 2.981**

Bruj MJ., Martí T., Torra R., Villacampa F. Recommendations for imaging-based diagnosis and management of renal angiomyolipoma associated with tuberous sclerosis complex. (2017) CLIN KIDNEY J 10, 7, 728-737.

**IF: 4.470**

Bullich G., Vargas I., Trujillano D., Mendizabal S., Pinero-Fernandez J.A., Fraga G., Garcia-Solano J., Ballarin J., Estivill X., Torra R., Ars E., Contribution of the TTC21B gene to glomerular and cystic kidney diseases (2017) NEPHROL DIAL TRANSPL, 32 (1), 151-156.

**IF: 4.600**

Butragueño L., Ars E., Martínez López AB., Alvarez O., Tejado JJ., Luque de Pablos A. Alteración genética no descrita previamente en 2 pacientes pediátricos con síndrome de

Alport. Influencia pronóstica del genotipo. (2017) NEFROLOGÍA 37, 1, 87-92.

**IF: 1.167**

Carmona A., Agüera ML., Luna C., Buendia P., Calleros L., Garcia Jerez A., Rodriguez Puyol M., Arias M., De Arriba G., Ballarin J., Poch E., Portoles JM., Rodriguez Puyol D., Sanchez Villanueva R., Sarro F., Torres A., Martin Malo A., Aljama A., Ramirez P. Markers of endothelial damage in patients with chronic kidney disease on hemodialysis. (2017) AM J PHYSIOL RENAL PHYSIOL 312, 4, F673-F681.

**IF: 3.164**

Collado S., Coll E., Nicolau C., Azqueta M., Pons M., Cruzado J.M., De La Torre B., Deulofeu R., Mojáil S., Pascual J., Cases A., Serum osteoprotegerin in prevalent hemodialysis patients: Associations with mortality, atherosclerosis and cardiac function (2017) BMC NEPHROL, 18 (1), -.

**IF: 2.395**

Corredor Z., Rodriguez-Ribera L., Coll E., Silva I., Diaz J.M., Ballarin J., Marcos R., Pastor S., DNA damage in kidney transplant patients. Role of organ origin (2017) ENVIRON MOL MUTAGEN, 58 (9), 712-718.

**IF: 3.254**

DaSilva I., Huerta A., Quintana L., Redondo B., Iglesias E., Draibe J., Praga M., Ballarin J., Diaz-Encarnacion M., Rituximab for Steroid-Dependent or Frequently Relapsing Idiopathic Nephrotic Syndrome in Adults: A Retrospective, Multicenter Study in Spain (2017) BIODRUGS, 31 (3), 239-249.

**IF: 3.825**

David C., Bover J., Voiculet C., Peride I., Petcu L.C., Niculae A., Covic A., Checherita I.A., Coronary risk score for mineral bone disease in chronic non-diabetic hemodialysis patients: results from a prospective pilot study (2017) INT UROL NEPHROL, 49 (4), 689-700.

**IF: 1.692**

de la Sierra A., Pareja J., Fernandez-Llama P., Armario P., Yun S., Acosta E., Calero F., Vazquez S., Blanch P., Sierra C., Oliveras A., Twenty-four-hour central blood pressure is not better associated with hypertensive target organ damage than 24-h peripheral blood pressure (2017) J HYPERTENS, 35 (10), 2000-2005.

**IF: 4.092**

Dominguez-Gil B., Coll E., Elizalde J., Herrero J.E., Pont T., Quindos B., Marcelo B., Bodí M.A., Martínez A., Nebra A., Guerrero F., Mancino J.M., Galán J., Lebrón M., Minambres E., Matéstan R., Expanding the Donor Pool Through Intensive Care to Facilitate Organ Donation: Results of a Spanish Multicenter Study (2017) TRANSPLANTATION, 101 (8), e265-e272.

**IF: 3.960**

Fernandez-Llama P., Pareja J., Yun S., Vazquez S., Oliveras A., Armario P., Blanch P., Calero F., Sierra C., de la Sierra A., Cuff-Based Oscillometric Central and Brachial Blood Pressures Obtained Through ABPM are Similarly Associated with Renal Organ Damage in Arterial Hypertension (2017) KIDNEY BLOOD PRESS R, 1068-1077.

**IF: 3.000**

Furlano M., Barreiro Y., Martí T., Facundo C., Ruiz-García C., DaSilva I., Ayasreh N., Cabrerizo-Lopez C., Ballarin J., Ars E., Torra R., Renal angiomyolipoma bleeding in a patient with TSC2/PKD1 contiguous gene syndrome after 17 years of renal replacement therapy Sangrado de angiomiolipoma renal en paciente con síndrome de genes contiguos (TSC2/PKD1) tras 17 años de tratamiento renal sustitutivo (2017) NEFROLOGIA, 37 (1), 87-92.

**IF: 1.167**

Furlano M., Barreiro Y., Martí T., Facundo C., Ruiz-García C., DaSilva I., Ayasreh N., Cabrerizo-Lopez C., Ballarin J., Ars E., Torra R., Renal angiomyolipoma bleeding in a patient with TSC2/PKD1 contiguous gene syndrome after 17 years of renal replacement therapy (2017) NEFROLOGIA, -,.

**IF: 1.167**

Gross O., Kashtan C.E., Rheault M.N., Flinter F., Savage J., Miner J.H., Torra R., Ars E., Deltas C., Savva I., Perin L., Renieri A., Ariani F., Mari F., Baigent C., Judge P., Knebelman B., Heidet L., Lagas S., Blatt D., Ding J., Zhang Y., Gale D.P., Prunotto M., Xue Y., Schachter A.D., Morton L.C.G., Blem J., Huang M., Liu S., Vallee S., Renault D., Schifter J., Skelding J., Gear S., Friede T., Turner A.N., Lennon R., Advances and unmet needs in genetic, basic and clinical science in Alport syndrome: Report from the 2015 International Workshop on Alport Syndrome (2017) NEPHROL DIAL TRANSPL, 32 (6), 916-924.

**IF: 4.600**

Guillen-Gomez E., Dasilva I., Silva I., Arce Y., Facundo C., Ars E., Breda A., Ortiz A., Guirado L., Ballarin J.A., Diaz-Encarnacion M.M., Early Macrophage Infiltration and Sustained Inflammation in Kidneys From Deceased Donors Are Associated With Long-Term Renal Function (2017) AM J TRANSPLANT, 17 (3), 733-743.

**IF: 4.493**

Kuebler B., Aran B., Miquel-Serra L., Munoz Y., Ars E., Bullich G., Furlano M., Torra R., Martí M., Veiga A., Raya A., Generation of integration-free induced pluripotent stem cell lines derived from two patients with X-linked Alport syndrome (XLAS) (2017) STEM CELL RES, 25, 291-295.

**IF: 1.829**

# Nephrology

\*TIF: 155.648 \*\*MIF: 3,9909

Kuebler B., Aran B., Miquel-Serra L., Munoz Y., Ars E., Bullich G., Furlano M., Torra R., Martí M., Veiga A., Raya A., Integration-free induced pluripotent stem cells derived from a patient with autosomal recessive Alport syndrome (ARAS) (2017) STEM CELL RES, 25, 1-5.

**IF: 1.829**

Macaya A., Torra, R. Recomendaciones para el abordaje multidisciplinar del complejo esclerosis tuberosa. Med Clin 2017, 149, 322. **IF:1.168**

Massy, ZA; Nistor, I; Apretii, M; Brandenburg, VM; Bover, J; Evenepoel, P; Goldsmith, D; Mazzaferro, S; Ureña, P; Vervloet, M; Cozzolino, M; Covic, A. ERA-EDTA ob. Magnesium-based interventions for normal kidney function and chronic kidney disease. (2017) MAGNES RES 29, 4, 126-140.

**IF: 1.281**

Mateos Rodriguez A.A., Andres Belmonte A., Del Rio Gallegos F, Coll E., Factors affecting the survival of transplants from donors after prehospital cardiac death Factores que influyen en la evolución de los injertos de donantes tras muerte cardiaca extrahospitalaria (2017) EMERGENCIAS, 29 (3), 167-172. **IF: 3.608**

Matesanz R., Dominguez-Gil B., Coll E., Mabillo B., Marazuela R., How Spain Reached 40 Deceased Organ Donors per Million Population (2017) AM J TRANSPLANT, 17 (6), 1447-1454.

**IF: 6.493**

Millan O., Budde K., Sommerer C., Aliart I., Rissling O., Bardaji B., Matz M., Zeier M., Silva I., Guirado L., Brunet M., Urinary miR-155-5p and CXCL10 as prognostic and predictive biomarkers of rejection, graft outcome and treatment response in kidney transplantation (2017) BRIT J CLIN PHARMACO, 83 (12), 2636-2650.

**IF: 3.838**

Molina P., Carrero JJ., Bover J., Chauveau P., Mazzaferro S., Torres P.U., Vitamin D, a modulator of musculoskeletal health in chronic kidney disease (2017) J CACHEXIA SARCO-PENI, 8 (5), 686-701.

**IF: 12.511**

Nube M.J., Peters S.A.E., Blankestijn P.J., Canaud B., Davenport A., Grooteman M.P.C., Ascí G., Locatelli F., Maduell F., Morena M., et al., Mortality reduction by post-dilution online-hemodiafiltration: A cause-specific analysis (2017) NEPHROL DIAL TRANSPL, 32 (3), 548-555. **IF: 4.600**

Pimentel A., Urena-Torres P., Zillikens M.C., Bover J., Cohen-Solal M., Fractures in patients with CKD—diagnosis, treatment, and prevention: a review by members of the European Calcified Tissue Society and the European Renal Association of Nephrology Dialysis and Transplantation (2017) KIDNEY INT, 92 (6), 1343-1355. **IF: 8.429**

Rodriguez Faba O., Palou J., Vila Reyes H., Guirado L., Palazzetti A., Gontero P., Vigués F., Garcia-Olaverri J., Fernandez Gomez J.M., Olsburg J., Terrone C., Figueiredo A., Burgos J., Lledo E., Breda A., Treatment options and predictive factors for recurrence and cancer-specific mortality in bladder cancer after renal transplantation: A multi-institutional analysis Opciones terapéuticas y factores predictivos de recurrencia y mortalidad cáncer-específica en pacientes con tumor vesical después de trasplante renal: análisis multiinstitucional (2017) ACTAS UROL ESP, 41 (10), 639-645. **IF: 1.260**

Rodríguez-Ribera L., Corredor Z., Silva I., Diaz J.M., Ballarin J., Marcos R., Pastor S., Coll E., Vitamin E-coated dialysis membranes reduce the levels of oxidative genetic damage in hemodialysis patients (2017) MUTAT RES-GEN TOX EN, 815, 16-21. **IF: 1.996**

Rodríguez Ribera L., Pastor S., Corredor Z., Silva I., Diaz, JM., Ballarín J., Marcos R., Coll E., Genetic damage in patients moving from hemodialysis to online hemodiafiltration. (2017) MUTAGENESIS 31, 2 131-135. **IF: 2.507**

Sandoval D., Poveda R., Draibe J., Perez Oller I., Diaz M., Ballarin J., Saurina A., Marco H., Bonet J., Barros X., Fulladosa X., Torras J., Cruzado JM. Efficacy of mycophenolate

treatment in adults with steroid-dependent/frequently relapsing idiopathic nephrotic syndrome. (2017) CLIN KIDNEY J 10, 5, 632-638. **IF: 4.470**

Sans L., Radosevic A., Quintian C., Montanes R., Gracia S., Vilaplana C., Mojá S., Ballarín J.A., Fernandez-Llama P., Torra R., Pascual J., Cystatin C estimated glomerular filtration rate to assess renal function in early stages of autosomal dominant polycystic kidney disease (2017) PLOS ONE, 12 (3), -. **IF: 2.766**

Tebe C., Arcos E., Comas J., Espallargues M., Pons JMV., Díaz JM., Tort J., Martínez-Castañao A. Atlas de variaciones sistemáticas en el tratamiento sustitutivo renal en Catalunya (2002-2012). (2017) NEFROLOGÍA 37, 2, 164-171. **IF:1,1830**

Torres P.A.U., Bover J., Cohen-Solal M., Etelcalcetide: Injectable calcimimetic for the treatment of secondary hyperparathyroidism in hemodialysis-dependent patients (2017) DRUG TODAY, 53 (9), 489-500. **IF: 1.325**

Vervloet M.G., Brandenburg V.M., Bover J., Brandenburg V., Covic A., Cozzolino M., Evenepoel P., Goldsmith D., Massy Z., Mazzaferro S., Urena-Torres P., Vervloet M., Circulating markers of bone turnover (2017) J NEPHROL, 30 (5), 663-670. **IF: 2.724**

Wadström J., Erizcon BG., Halloran PF., Bechstein WO., Opelz G., Serón D., Grinyó J., Loupy A., Kuypers D., Mariat C., Clancy M., Jardine AG., Guirado L., Fellström B., O'Grady J., Pirenne J., O'Leary JG., Aluvihare V., Trunečka P., Baccarani U., Neuberger J., Soto-Gutierrez A., Geissler EK., Metzger M., Gray M. Advancing Transplantation: New Questions, New Possibilities in Kidney and Liver Transplantation. (2017) TRANSPLANTATION 101 Suppl 2S, S1-S41. **IF: 3.6780**



# Women and Perinatal Health Research Group


**Coordinator**

Llurba Olivé, Elisa  
ellurba@santpau.cat

FGS

**Members**

Porta Roda, Josep Oriol  
Sánchez García, Olga

FGS

IR


**Main Lines of Research**

- ▶ Prediction and prevention of complications arising from placental insufficiency, intrauterine growth restriction / pre-eclampsia (IUGR / PE)
- ▶ Placental insufficiency and maternal cardiovascular risk later in life.

- ▶ Role of the oxygen transport deficit in the placental insufficiency.

- ▶ Development of predictive methods based on the integration of pre and postnatal factors for the detection of abnormal neurodevelopment in congenital heart diseases.

**Challenges**

- ▶ To study novel placental biomarkers in the diagnosis and prognosis of preeclampsia (PE) and intrauterine growth restriction (IUGR) in order to generate future hypothesis for target prevention and therapeutic interventions in these pathologies.
- ▶ To determine the usefulness of novel placental biomarkers (sFlt-1/PIGF ratio) in the diagnosis and prognosis of preeclampsia (PE) in order to change policies and improve maternal and neonatal health.
- ▶ To study novel maternal cardiovascular risk biomarkers after placental insufficiency and to explore potential preventive strategies in order to identify mother at risk for cardiovascular disease later in life.

- ▶ To study the role of placental insufficiency and hypoxia in congenital heart disease in order to gain insights into the relationships between hypoxia-dependent placental morphogenesis, placental function and effects on oxygen metabolism in the fetus.

- ▶ To develop biomarkers in fetal and neonatal life that help to predict postnatal neurological risk in congenital heart diseases.

**Active Grants**

- ▶ Elisa Llurba Olivé. Incorporación del ratio sFlt1/PIGF en el diagnóstico y clasificación de preeclampsia: Ensayo clínico randomizado (EuroPE estudio). PI16/00375. Instituto de Salud Carlos III. Duration: 2017-2019. 92,500.00 €.
- ▶ Elisa Llurba Olivé. Women and Perinatal Health Research Group.. 2017 SGR 1267. Agència de Gestió d'Ajuts Universitaris i de Recerca. Duration: 2017-2019. 10,000.00 €.

Note: Total amount granted to PI. It does not include indirect costs.

**Grants Awarded in 2017**

- ▶ Elisa Llurba Olivé. Red de salud materno-infantil y del desarrollo. RD16/0022/0015. Instituto de Salud Carlos III. Duration: 2017-2021. 71,412.00 €.
- ▶ Josep Oriol Porta Roda. Estudio de las propiedades biológicas de una matriz dérmica de origen humano para su aplicación en cirugía de corrección del prolapse de órganos pérvicos e incontinencia urinaria femenina. CONVENI BST 2017-3. Banc de Sang i Teixits. Duration: 2017-2020. 136,904.00 €.

Note: Total amount granted to PI. It does not include indirect costs.

**Theses**

- ▶ Míriam Bella Bustamante. Heparina de Bajo Peso Molecular (HBPM) para la prevención de complicaciones derivadas de la insuficiencia placentaria en las pacientes de riesgo sin trombofilia. Universitat Autònoma de Barcelona. Director: Elisa Llurba Olivé. Date of defense: 20/07/2017.

- ▶ Aina Ruíz Romero. Impacto de las cardiopatías congénitas en el sistema nervioso central. Universitat Autònoma de Barcelona. Director: Elisa Llurba Olivé. Date of defense: 18/09/2017.

## Collaborations

### **Collaborations with other IIB Sant Pau Groups**

- ▶ Genetic Research (Dr. Jordi Surrallés)
- ▶ Oncogenesis and Antitumour Drugs (Dra. Virtudes Céspedes)
- ▶ Reproductive Health (Dr. Joaquim Calaf)
- ▶ Anesthesiology (Dra. M Victoria Moral)
- ▶ General and Digestive Surgery (Dr. Antonio Moral)
- ▶ Endocrinology, Diabetes and Nutrition (Dra. Rosa Corcón)
- ▶ Paediatrics (Dr. Eduard Carreras)
- ▶ Clinical Epidemiology and Healthcare Services (DR. Xavier Bonfill)
- ▶ Clinical Biochemistry Service (Dr. Francisco Blanco)
- ▶ Image Diagnostic Service, Neuroradiology Section (Dra. Beatriz Gómez-Anson)

### **External Collaborations**

#### **International collaborations**

- ▶ Project: Role of Placental Insufficiency and Hypoxia in Congenital Heart Defects. Principal investigator: Steven A. Fisher, M.D.; Professor of Medicine and Physiology S-012a HSF II, 20 Penn St. Univ of Maryland School of Medicine (Baltimore MD 212) Hypothesis: There is an inter-relationship between mother and fetus in the genesis of CHD. Main objective: To develop new models to address these questions using genetically engineered mice is highly innovative and certainly will lead to new insights into the relationships between hypoxia-dependent placental morphogenesis, placental function and effects on oxygen metabolism in the fetus. Collaborator: Elisa Llurba.
- ▶ Project: Accuracy of clinical characteristics, biochemical and ultrasound markers in the prediction of preeclampsia: an Individual Patient Data (IPD) Meta-analysis. Principal Investigator: Shakila Thangaratinam, PhD; Professor in maternal and perinatal health at Queen Mary University of London, of Mile End Road, London, E1 4NS with administrative offices at QM Innovation Centre, 5 Walden Street, Whitechapel. (London E1 2EF) (the 'Recipient'). Main Objective: To develop, externally validate and update separate prediction models for (i) early (<34 weeks' gestation), (ii) late (> 34 weeks) and (iii) any onset preeclampsia and to estimate the prognostic value of individual clinical, biochemical and ultra-

sound markers for predicting preeclampsia by IPD meta-analysis. Collaborator: Elisa Llurba.

### **National collaborations**

- ▶ Maternal and Infant Health and Development Network (SAMID Network).
- ▶ RD16/0022/0015. Principal investigator: Elisa Llurba. Objective: The main objective is to study the different pathological processes, nutritional and environmental conditions of perinatal and postnatal period, by addressing the study of factors of prematurity, prevention and patient safety, environmental and pathogenetic factors, nutrition and child development as well as promoting research into new products and therapeutic procedures. It is also their aim to study the long-term consequences and its relationship with certain disorders of high prevalence in later stages of life, such as neuropsychiatric diseases, obesity and its complications. Collaborator: Olga Sánchez.
- ▶ Project: Breast cancer during pregnancy. Neurologic and cardiologic outcomes after chemotherapy exposition during fetal period. Principal Investigator: Dr. Octavi Córdoba (Hospital Universitari Vall d'Hebron, Barcelona). Hypothesis: The incidence of breast cancer during pregnancy is increasing worldwide. Optimal chemotherapy may be given during pregnancy. However a high level of pregnancy complications is still observed and a high percentage of preterm deliveries is observed because those complications. Main objective: To gain insight into the effect on placental function and fetal development of fetal period exposition to chemotherapy, especially on the impact on neurological development and cardiac function. Collaborator: Olga Sánchez.
- ▶ Project: Angiogenic factors during pregnancy and cardiovascular risk in the medium to long term in patients with preeclampsia. Clinical and experimental approach. Principal Investigator: Dr. Lluís Cabero Roura (Hospital Universitario de la Vall d'Hebron, Barcelona). Hypothesis: There is a relationship between anti-angiogenic factors and the incidence of cardiovascular injury to medium-long term in patients with preeclampsia (PE) or intrauterine growth restriction (IUGR). Main objective: The aim is to establish measures that might be appropriate to reduce cardiovascular risk in patients with a history of PE / IUGR during pregnancy. The project consists of two studies, one in humans, and the other in sFlt-1-induced preeclampsia rat model. Collaborators: Olga Sánchez.
- ▶ The Banc de Sang i Teixits (Blood and Tissue Bank) is a public agency of the Catalan Department of Health whose mission is to guarantee the supply and proper use of human blood and tissue in Catalonia. Collaborator: Elisa Llurba.

**\*TIF: 1.168 \*\*MIF: 1.168**

## Scientific Production

Alijotas-Reig J, Esteve-Valverde E, Ferrer-Olivares R, Llurba E, Ruffatti A, Tincani A, Lefkou E, Bertero M.a.T, Espinosa G, de Carolis S, Rovere-Querini P, Lundelin K., Picardo E, Mekinian A, Comparative study

between obstetric antiphospholipid syndrome and obstetric morbidity related with antiphospholipid antibodies (2017) MED CLIN-BARCELONA.

**IF: 1.168**

## Other Publications

- ▶ I Herraiz, E Llurba, S Verloren , A. Galindo, en nombre del Grupo español para el estudio de los marcadores angiogénicos en la preeclampsia, revista PROGRESOS. Actualización del diagnóstico y el pronóstico de la preeclampsia con la ayuda del cociente sFlt-1/PIGF en embarazos únicos.

AREA T1

# Epidemiology, Pub Healthcare Service

**192** Clinical Epidemiology and Healthcare Services

**198** Evaluation of Public Health Policies and Programmes

**202** Transport and Health: Injuries and Mobility

**204** Transmissible Diseases

**210** Health Inequalities

**214** Epidemiology of Addictions

**218** Primary Care Research

# Public Health and

S



# Clinical Epidemiology and Healthcare Services



## Coordinator

Bonfill Cosp, Xavier FGS  
xbonfill@santpau.cat

## Members

Acosta Isaac, Francisco René	IR
Aguilar López, Raúl	IR
Alonso Coello, Pablo Ignacio	IR
Álvarez Bustins, Gerard	ACCIB
Ballesteros Silva, Mónica Patricia	ACCIB
Barriomuevo Rosas, Leslie Margaret	ACCIB
Bolíbar Ribas, Ignasi	FGS
Canelo Aybar, Carlos Gilberto	ACCIB
Cánoyas Martínez, L eonor Esther	ACCIB
Cervera Alepuz, Andrea	ACCIB
Gich Saladich, Ignasi Josep	FGS
Girós Boixadós, Meritxell	IR
Gorgues Sendra, Marta	FGS
Martínez García, Laura	FGS
Martínez Zapata, María José	IR
Muñoz Galarín, María Trinidad	ACCIB
Niño De Guzman Guispe, Ena Pery	ACCIB
Pardo Hernández, Héctor	CIBERESP
Popova, Ekaterina	IR
Posso Rivera, Margarita	ACCIB
Puchol Sánchez, Cristina	ACCIB
Puig Reixach, María Teresa	FGS
Quintana Ruiz, María Jesús	FGS
Rabassa Bonet, Montserrat	IR
Requeijo Lorenzo, Carolina	FGS
Rigau Comas, David	ACCIB
Robleda Font, Gemma	ACCIB
Roqué Fíguls, Marta Cristina	IR
Salas Gama, Karla Rocio	FGS
Solà Arnaud, Ivan	FGS
Solà Roca, Judit	ACCIB
Song, Yang	UAB
Urrutia Cuchí, Gerard	FGS
Valli, Claudia	ACCIB

## Main Lines of Research

- ▶ Evidence-based medicine: systematic reviews, clinical practice guidelines and clinical trials.
- ▶ Health service evaluations.
- ▶ Methodological research.

## Areas of interest

- ▶ Evidence-based medicine.
- ▶ Cancer.
- ▶ Perioperative medicine.
- ▶ Cardiovascular medicine.
- ▶ Public health.
- ▶ Appropriateness.

## Challenges

- ▶ To develop and promote systematic-review production about the effects of healthcare interventions, in order to contribute to healthcare and clinical decision-making based on the best available scientific evidence.
- ▶ To promote national and international clinical and applied research projects that will contribute with new knowledge to solve clinical or healthcare problems that are relevant to the needs of the system (applied clinical studies, healthcare services assessment studies, clinical trials).
- ▶ To foster, organise and/or conduct training activities in order to promote healthcare professionals' acquisition of skills and knowledge on evidence-based Medicine (EBM) tools.
- ▶ To promote methodological research projects aiming to provide guidance and tools to improve scientific information analysis, interpretation and communication.
- ▶ To develop knowledge transfer activities (clinical practice guidelines) and scientific-knowledge dissemination tools.

## Collaborations

### Collaborations with other IIB Sant Pau Groups

- ▶ Addictive Behaviours
- ▶ Anaesthesiology
- ▶ Angiology, Vascular Biology and Inflammation
- ▶ Blood and Tissue Bank
- ▶ Central Clinical Research and Clinical Trials Unit
- ▶ Clinical and Translational Cardiology
- ▶ Evaluation of Public Health Policies and Programmes - Public Health Agency of Barcelona
- ▶ Locomotor System Research
- ▶ Palliative Care
- ▶ Plastic Surgery
- ▶ Primary Care Research - EAP Sardenya
- ▶ Thrombosis and Haemostasis
- ▶ Urology

### External Collaborations

- ▶ Population Health Research Institute, Mc-Master University (Canada).
- ▶ Clinical Trial Service Unit and Epidemiological Studies Unit, University of Oxford (United Kingdom).
- ▶ European Respiratory Society.
- ▶ Facultad de Ciencias de la Salud, Universidad Tecnológica Equinoccial (Ecuador).
- ▶ GRADE Working Group.
- ▶ Guidelines International Network.
- ▶ Cochrane Collaboration.
- ▶ Joint Research Centre - European Commission.
- ▶ Applied Health Research Center - Saint Michael's Hospital (Canada).
- ▶ Cochrane Collaboration.
- ▶ Joint Research Centre - European Commission.
- ▶ Applied Health Research Center - Saint Michael's Hospital (Canada).

## Active Grants

- ▶ Xavier Bonfill Cosp. Análisis y mejora del grado de adecuación de la cirugía programada del aneurisma de aorta abdominal. PI12/02530. Instituto de Salud Carlos III. Duration: 2013-2017. 48,500.00 €.
- ▶ Pablo Ignacio Alonso Coello. La toma de decisiones compartida en cáncer de pulmón. PROYECTOS SINGULARES 2013. Associació Espanyola Contra el Càncer. Duration: 2014-2018. 54,000.00 €.
- ▶ Xavier Bonfill Cosp. Grup de Recerca Clínica i Sanitària Aplicada. 2014 SGR 673. Agència de Gestió d'Ajuts Universitaris i de Recerca. Duration: 2014-2017. 21,000.00 €.
- ▶ Pablo Ignacio Alonso Coello. Contratos Miguel Servet II 2015. MSII15/00034. Instituto de Salud Carlos III. Duration: 2016-2019. 101,250.00 €.
- ▶ Xavier Bonfill Cosp. Estudio de adecuación de la terapia hormonal intermitente en pacientes con cáncer de próstata. PI15/00886. Instituto de Salud Carlos III. Duration: 2016-2018. 81,500.00 €.
- ▶ Laura Martínez García. Elaboración de una herramienta de priorización para la actualización de preguntas clínicas y aplicación a las guías de práctica clínica del Sistema Nacional de Salud. PI15/00325. Instituto de Salud Carlos III. Duration: 2016-2018. 50,000.00 €.
- ▶ María José Martínez Zapata. Contratos Miguel Servet I 2015. MS15/00116. Instituto de Salud Carlos III. Duration: 2016-2021. 202,500.00 €.
- ▶ María José Martínez Zapata. International, multi-centre, randomized controlled trial to assess transfusion thresholds in patients undergoing cardiac surgery (TRICS III). CP15/00116. Instituto de Salud Carlos III. Duration: 2016-2018. 114,350.00 €.
- ▶ Pablo Ignacio Alonso Coello. Perioperative myocardial ischemia: implementation of troponin monitoring, economic analysis and further insights in pathophysiology. MARATO 20150110. Fundació La Marató de TV3. Duration: 2016-2019. 159,202.88 €.
- ▶ Laura Martínez García. Contratos Juan Rodés 2015. JR15/00004. Instituto de Salud Carlos III. Duration: 2016-2018. 135,000.00 €.
- ▶ Ekaterine Popova. Mecanismos implicados en la lesión miocárdica perioperatoria: estudio mediante angiografía coronaria computarizada y resonancia magnética cardíaca. PI16/01162. Instituto de Salud Carlos III. Duration: 2017-2019. 74.500,00 €.
- ▶ María José Martínez Zapata. Ensayo clínico aleatorizado multicéntrico paralelo en pacientes antiagregados con fractura peritrocantérea de fémur que evalúa una estrategia para acortar el tiempo hasta la cirugía. PI16/01879. Instituto de Salud Carlos III. Duration: 2017-2019. 71.500,00 €.
- ▶ Montserrat Rabassa Bonet. Contractes postdoctorals "Sara Borrell" 2016. CD16/00157. Instituto de Salud Carlos III. Duration: 2017-2019. 80.598,00 €.
- ▶ Pablo Ignacio Alonso Coello. Isquemia miocárdica perioperatoria: aplicación de monitorización de troponina, análisis económico y más conocimientos sobre fisiopatología. IR16-P1. Fundació Privada Hospital de la Santa Creu i Sant Pau. Duration: 2017-2017. 7.000,00 €.

Note: Total amount granted to PI. It does not include indirect costs.

## Grants Awarded in 2017

- ▶ Pablo Ignacio Alonso Coello. COMPAR-EU - Comparing effectiveness of self-management interventions in 4 high priority chronic diseases in Europe. 754936-IR. European Union. Duration: 2018-2022. 456,109.00 €.
- ▶ Gerard Urrutia Cuchi. The effect of additional core stability exercises on improving dynamic sitting balance, trunk control and functional rehabilitation for subacute stroke patients: A randomized controlled trial. MARATO 20173710, Fundació La Marató de TV3. Duration: 2018-2021. 159,530.00 €.
- ▶ Ena Pery Niño de Guzman Guispe. Contractes de formació en recerca "Río Hortega" 2017. CM17/00199. Instituto de Salud Carlos III. Duration: 2018-2019. 53,732.00 €.
- ▶ Pablo Ignacio Alonso Coello. La toma de decisiones compartida de la terapia tromboprofiláctica durante el embarazo: el valor añadido del método de Análisis de Decisión. PI17/01874. Instituto de Salud Carlos III. Duration: 2018-2020. 52,000.00 €.
- ▶ Pablo Ignacio Alonso Coello. COMPAR-EU - Comparing effectiveness of self-management interventions in 4 high priority chronic diseases in Europe. 754936-FGS. European Union. Duration: 2018-2022. 180,120.00 €.

Note: Total amount granted to PI. It does not include indirect costs.

## Theses

- ▶ Héctor Alexander Pardo Hernández. Estrategias para prevenir y controlar el sesgo de diseminación de los ensayos clínicos con distribución aleatoria. Universitat Autònoma de Barcelona. Directors: Xavier Bonfill Cosp, Gerard Urrutia Cuchi. Date of defense: 20/12/2017.
- ▶ Margarita Posso Rivera. Cribado poblacional del cáncer de mama: aspectos relacionados con la efectividad y coste-efectividad, Universitat Autònoma de Barcelona. Directors: Xavier Bonfill Cosp, M. Teresa Puig Reixach. Date of defense: 18/12/2017.
- ▶ Lluís Campins Bernadas. Evaluación del impacto clínico y económico de una intervención farmacéutica orientada a disminuir la medicación inadecuada en personas mayores de 70 años polimedicadas. Universitat Autònoma de Barcelona. Directors: Ignasi Bolíbar Ribas, Mateu Serra Prat. Date of defense: 28/09/2017.
- ▶ Laura Coll Planas. Solitud, suport social i participació de les persones grans des d'una perspectiva de la salut., Universitat Autònoma de Barcelona. Directors: M. Teresa Puig Reixach, Fredrica Nyqvist. Date of defense: 30/05/2017.
- ▶ Xavier Rojano Luque. Prevalença de la fragilitat i la sarcopènia a l'atenció primària. Relació amb l'estat cognitiu del pacient. Universitat Autònoma de Barcelona. Directors: Rosa Monteserín Nadal, Ignasi Bolíbar Ribas (tutor). Date of defense: 15/06/2017.
- ▶ Marcos Jordán Sales, Prevención del sangrado postoperatorio en las fracturas subcapitales de fémur tratadas mediante sustitución protésica: eficacia y seguridad del ácido tranexámico y la cola de fibrina, Universitat Autònoma de Barcelona. Directors: M. José Martínez Zapata, Enrique Caceres Palou, Fernando Celaya Ibañez. Date of defense: 25/10/2017.

# Clinical Epidemiology and Healthcare Services

**\*TIF: 466.655 \*\*MIF: 6.392**

Agarwal A., Johnston B.C., Vernooyj R.W.M., Carrasco-Labra A., Brignardello-Petersen R., Neumann I., Akl E.A., Sun X., Briel M., Busse J.W., Ebrahim S., Granados C.E., Iorio A., Irfan A., Martinez Garcia L., Mustafa R.A., Ramirez-Morera A., Selva A., Sola I., Sanabria A.J., Tikkinen K.A.O., Vandvik P.O., Zhang Y., Zazueta O.E., Zhou Q., Schunemann H.J., Guyatt G.H., Alonso-Coello P., Authors seldom report the most patient-important outcomes and absolute effect measures in systematic review abstracts (2017) *J CLIN EPIDEMIOL*, 81, 3-12.

**IF: 4.245**

Akl E.A., Welch V., Pottie K., Eslava-Schmalbach J., Darzi A., Sola I., Katikireddi S.V., Singh J., Murad M.H., Meerpolh J., Stanev R., Lang E., Matovinovic E., Shea B., Agoritas T., Alexander P.E., Snellman A., Brignardello-Petersen R., Gloss D., Thabane L., Shi C., Stein A.T., Sharaf R., Briel M., Guyatt G., Schunemann H., Tugwell P., GRADE equity guidelines 2: considering health equity in GRADE guideline development: equity extension of the guideline development checklist (2017) *J CLIN EPIDEMIOL*, 90, 68-75.

**IF: 4.245**

Alarcon J.D., Rubiano A.M., Okonkwo D.O., Alarcon J., Martinez-Zapata M.J., Urrutia G., Bonfill Cosp X., Elevation of the head during intensive care management in people with severe traumatic brain injury (2017) CO-CHRANE DB SYST REV, 2017 (12).

**IF: 6.754**

Almirall J., Serra-Prat M., Bolíbar I., Balasso V., Risk Factors for Community-Acquired Pneumonia in Adults: A Systematic Review of Observational Studies (2017) *RESPIRATION*, 94 (3), 299-311.

**IF: 2.591**

Alonso-Coello P., Cook D., Xu S.C., Sigamani A., Berwanger O., Sivakumaran S., Yang H., Xavier D., Martinez L.X., Ibarra P., Rao-Melacini P., Pogue J., Zarnke K., Paniagua P., Ostlander J., Yusuf S., Devereaux P.J., Predictors, prognosis, and management of new clinically important atrial fibrillation after noncardiac surgery: A prospective cohort study (2017) *ANESTH ANALG*, 125 (1), 162-169.

**IF: 3.463**

Alquezar A., Santalo M., Rizzi M., Gich I., Grau M., Sionis A., Ordóñez-Llanos J., Merce J., Martín A., Muñoz M., Povar J., Velilla J., Calmarza P., Temboury F., Ortiz C., Balaguer J., Carratalá A., Combined high-sensitivity copeptin and troponin T evaluation for the diagnosis of non-ST elevation acute coronary syndrome in the emergency department Evaluación de una estrategia diagnóstica combinada con copeptina y troponina T ultrasensibles en el infarto de miocardio sin elevación del segmento ST en los servicios

de urgencias (2017) *EMERGENCIAS*, 29 (4), 237-244.

**IF: 3.609**

Alvarez-García J., Salamanca-Bautista P., Ferrero-Gregori A., Montero-Perez-Barqueró M., Puig T., Aramburu-Bodas O., Vazquez R., Formiga F., Delgado J., Arias-Jiménez J.L., Vives-Borras M., Cerqueiro Gonzalez J.M., Manzano L., Cinca J., Prognostic Impact of Physician Specialty on the Prognosis of Outpatients With Heart Failure: Propensity Matched Analysis of the REDINSCOR and RICA Registries Impacto pronóstico de la especialidad en el paciente ambulatorio con insuficiencia cardíaca: un análisis emparejado de los registros REDINSCOR y RICA (2017) *REV ESP CARDIOL*, 70 (5), 347-354.

**IF: 5.166**

Antoniojoan R., Coimbra J., García-Gea C., Puentes M., Gich I., Campo C., Valiente R., Labeaga L., Comparative efficacy of bilastine, desloratadine and rupatadine in the suppression of wheal and flare response induced by intradermal histamine in healthy volunteers (2017) *CURR MED RES OPIN*, 33 (1), 129-136.

**IF: 2.655**

Areosa Sastre A., Vernooyj R.W., Gonzalez-Colaco Harmand M., Martinez G., Effect of the treatment of Type 2 diabetes mellitus on the development of cognitive impairment and dementia (2017) COCHRANE DB SYST REV, 2017 (6).

**IF: 6.754**

Arevalo-Rodríguez I., Muñoz L., Godoy-Casasbuenas N., Ciapponi A., Arevalo J.J., Boogaard S., Roquei Figuls M., Needle gauge and tip designs for preventing post-dural puncture headache (PDPH) (2017) CO-CHRANE DB SYST REV, 2017 (4).

**IF: 6.754**

Arevalo-Rodríguez I., Muñoz L., Godoy-Casasbuenas N., Ciapponi A., Arevalo J.J., Boogaard S., Roquei Figuls M., Needle gauge and tip designs for preventing post-dural puncture headache (PDPH) (2017) CO-CHRANE DB SYST REV, 2017 (4).

**IF: 6.754**

Atala-Acevedo C., Abarca J., Martinez-Zapata M.J., Diaz J., Olate S., Zaror C., Success Rate of Autotransplantation of Teeth With an Open Apex: Systematic Review and Meta-Analysis (2017) *J ORAL MAXIL SURG*, 75 (1), 35-50.

**IF: 1.779**

Ballesteros M., Montero N., Lopez-Pousa A., Urrutia G., Sola I., Rada G., Pardo-Hernandez H., Bonfill X., Evidence mapping based on systematic reviews of therapeutic interventions for gastrointestinal stromal tumors (GIST) (2017) *BMJ MED RES METHODOL*, 17 (1).

**IF: 2.524**

Barata A., Martino R., Gich I., Garcia-Cadenas I., Abella E., Barba P., Briones J., Brunet S., Esquirol A., Garcia-Pallarols F., Garrido A., Granell M., Martinez J., Mensa I., Novelli S., Sanchez-Gonzalez B., Valcarcel D., Sierra J., Do Patients and Physicians Agree When They Assess Quality of Life? (2017) *BIOL BLOOD MARROW TR*, 23 (6), 1005-1010.

**IF: 4.484**

Bonfill X., Urrutia G., Roque M., Martinez M.J., Pardo-Hernandez H., Osorio D., Pardo J., Serón P., Tzanova M., Sola I., Latin American Clinical Epidemiology Network Series – Paper 3: Cochrane develops widely in Latin America and strengthens ties with Latin-CLEN (2017) *J CLIN EPIDEMIOL*, 86, 84-90.

**IF: 4.245**

Bonfill X., Rigau D., Esteban-Fuertes M., Barrera-Chacon J.M., Jauregui-Abrisqueta M.L., Salvador S., Aleman-Sanchez C.M., Borau A., Bea-Munoz M., Hidalgo B., Andrade M.J., Espinosa J.R., Martinez-Zapata M.J., Efficacy and safety of urinary catheters with silver alloy coating in patients with spinal cord injury: a multicentric pragmatic randomized controlled trial. The ESCALE trial (2017) *SPINE J*, 17 (11), 1650-1657.

**IF: 3.119**

Brandt L., Vandvik P.O., Alonso-Coello P., Akl E.A., Thornton J., Rigau D., Adams K., O'connor P., Guyatt G., Kristiansen A., Multilayered and digitally structured presentation formats of trustworthy recommendations: A combined survey and randomised trial (2017) *BMJ OPEN*, 7 (2).

**IF: 2.413**

Buron A., Posso M., Sivilia J., Grau J., Guayta R., Castells X., Castells A., Macia F., Analysis of participant satisfaction in the Barcelona colorectal cancer screening programme: Positive evaluation of the community pharmacy Análisis de la satisfacción de los participantes en el Programa de detección precoz de cáncer colorrectal de Barcelona: valoración positiva de la farmacia comunitaria (2017) *GASTROENT HEPAT-BARC*, 40 (4), 265-275.

**IF: 1.078**

Cabanas-Valdés R., Bagur-Calafat C., Caballero-Gómez F.M., Cervera-Cuenca C., Moya-Valdés R., Rodriguez-Rubio P.R., Urrutia G., Validation and reliability of the Spanish version of the Function in Sitting test (S-FIST) to assess sitting balance in subacute post-stroke adult patients (2017) *TOP STROKE REHABIL*, 24 (6), 472-478.

**IF: 1.771**

Cabanas-Valdés R., Bagur-Calafat C., Girabent-Farrés M., Caballero-Gómez F.M., du Port de Pontcharra-Serra H., German-Romero A., Urrutia G., Long-term follow-up of a randomized controlled trial on additional

**\*TIF: 466.655 \*\*MIF: 6.392**

core stability exercises training for improving dynamic sitting balance and trunk control in stroke patients (2017) CLIN REHABIL, 11, 1492-1499.

**IF: 2.930**

Camps L., Serra-Prat M., Palomera E., Bolíbar I., Martínez M.A., Gallo P., Reduction of pharmaceutical expenditure by a drug appropriateness intervention in polymedicated elderly subjects in Catalonia (Spain) (2017) GAC SANIT.

**IF: 1.581**

Coll-Planas L., del Valle Gomez G., Bonilla P., Masat T., Puig T., Monteserín R., Promoting social capital to alleviate loneliness and improve health among older people in Spain (2017) HEALTH SOC CARE COMM, 25 (1), 145-157.

**IF: 2.039**

Coll-Planas L., Nyqvist F., Puig T., Urrutia G., Sola I., Monteserín R., Social capital interventions targeting older people and their impact on health: A systematic review (2017) J EPIDEMIOL COMMUN H, 71 (7), 663-672.

**IF: 3.973**

Devereaux P.J., Biccard B.M., Sigamani A., Xavier D., Chan M.T.V., Srinathan S.K., Walsh M., Abraham V., Pearse R., Wang C.Y., et al., Association of postoperative high-sensitivity troponin levels with myocardial injury and 30-day mortality among patients undergoing noncardiac surgery (2017) JAMA-J AM MED ASSOC, 317 (16), 1642-1651.

**IF: 47.661**

Dorri M., Martínez-Zapata M.J., Walsh T., Marinho V.C.C., Sheiham A., Zaror C., Atraumatic restorative treatment versus conventional restorative treatment for managing dental caries (2017) COCHRANE DB SYST REV, 2017 (12).

**IF: 6.754**

Faillie J.-L., Ferrer P., Gouverneur A., Driot D., Berkemeyer S., Vidal X., Martínez-Zapata M.J., Huerta C., Castells X., Rottenkolber M., Schmiedl S., Sabate M., Ballarin E., Ibanez L., A new risk of bias checklist applicable to randomized trials, observational studies, and systematic reviews was developed and validated to be used for systematic reviews focusing on drug adverse events (2017) J CLIN EPIDEMIOL, 86, 168-175.

**IF: 4.245**

García L.M., Pardo-Hernández H., De Guzman E.N., Superchi C., Ballesteros M., McFarlane E., Penman K., Posso M., Figuls M.R., Sanabria A.J., Selva A., Vernooij R.W.M., Alonso-Coello P., Development of a prioritisation tool for the updating of clinical guideline questions: The UpPriority Tool protocol (2017) BMJ OPEN, 7 (8).

**IF: 2.413**

Ginovart G., Gich I., Gutierrez A., Verd S., A Fortified Donor Milk Policy is Associated with Improved In-Hospital Head Growth and Weight Gain in Very Low-Birth-Weight Infants (2017) ADV NEONAT CARE, 17 (4), 250-257.

**IF: 1.443**

Gonzalez-Osuna A., Videla S., Canovas E., Urrutia G., Rojas S., Lopez R., Murat J., Aguilera X., HESTAT: Study protocol for a phase II/III, randomized, placebo-controlled, single blind study to evaluate the new hemostatic agent TT-173 in total knee arthroplasty (2017) CONTEMP CLIN TRIALS, 61, 16-22.

**IF: 2.658**

Guix-Tula FX., Cabanas-Valdés R., Sitjà-Rabert M., Urrutia G., Gómarra-Toldrà N., The Efficacy of the proprioceptive neuromuscular facilitation (PNF) approach in stroke rehabilitation to improve basic activities of daily living and quality of life: a systematic review and meta-analysis protocol (2017) BMJ OPEN, 12, e016739.

**IF: 2.413**

Guyatt G.H., Ebrahim S., Alonso-Coello P., Johnston B.C., Mathioudakis A.G., Briel M., Mustafa R.A., Sun X., Walter S.D., Heels-Ans dell D., Neumann I., Kahale L.A., Iorio A., Meerpolh J., Schunemann H.J., Akl E.A., GRADE guidelines 17: assessing the risk of bias associated with missing participant outcome data in a body of evidence (2017) J CLIN EPIDEMIOL, 87, 14-22.

**IF: 4.245**

Hemmingsen B., Giménez-Pérez G., Mauricio D., Roque i Figuls M., Metzendorf M.-I., Richter B., Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus (2017) COCHRANE DB SYST REV, 2017 (12).

**IF: 6.754**

Joos G., Bush A., Burghuber O.C., Cordeiro C.R., Gaga M., Gibson G.J., Gratiou C., Rigau D., Rohde G., Smyth D., Stoltz D., Tonia T., Vestbo J., Welte T., Brusselle G., Miravitles M., Taken to task: What is and is not an appropriate response to an ERS guidelines task force? (2017) EUR RESPIR J, 50 (1).

**IF: 12.242**

Lafranconi A., Pylkkänen L., Deandrea S., Bramesfeld A., Lerda D., Neamtiu L., Saz-Parkinson Z., Posso M., Rigau D., Alonso-Coello P., Martínez-Zapata M.J., Intensive follow-up for women with breast cancer: Review of clinical, economic and patient's preference domains through evidence to decision framework (2017) HEALTH QUAL LIFE OUT, 15 (1).

**IF: 2.278**

Lanas F., Seron P., Munoz S., Margozzini P., Puig T., Latin American Clinical Epidemiology Network Series – Paper 7: Central obesity measurements better identified risk factors for coronary heart disease risk in the Chilean National Health Survey (2009–2010) (2017) J CLIN EPIDEMIOL, 86, 111-116.

**IF: 4.245**

Liang L., Abi Safi J., Gagliardi A.R., Armstrong M.J., Bernhardsson S., Brown J., Chakraborty S., Fleuren M., Lewis S.Z., Lockwood C., Pardo-Hernandez H., Vernooij R., Willson M., Number and type of guideline implementation tools varies by guideline, clinical condition, country of origin, and type of developer organization: Content analysis of guidelines (2017) IMPLEMENT SCI, 12 (1).

**IF: 4.345**

Lucas J.S., Barbato A., Collins S.A., Goutaki M., Behan L., Caudri D., Dell S., Eber E., Escudier E., Hirst R.A., Hogg C., Jorissen M., Latzin P., Legendre M., Leigh M.W., Midulla F., Nielsen K.G., Omran H., Papon J.-F., Pohunek P., Redfern B., Rigau D., Rindlisbacher B., Santamaría F., Shoemark A., Snijders D., Tonia T., Titiensi A., Walker W.T., Werner C., Bush A., Kuehni C.E., European Respiratory Society guidelines for the diagnosis of primary ciliary dyskinesia (2017) EUR RESPIR J, 49 (1).

**IF: 12.242**

Marti-Carvajal A.J., Sola I., Lathyris D., Dayer M., Homocysteine-lowering interventions for preventing cardiovascular events (2017) COCHRANE DB SYST REV, 2017 (8).

**IF: 6.754**

Martinez G., Vernooij R.W.M., Fuentes Padilla P., Zamora J., Flicker L., Bonfill Cosp X., 18F PET with flutemetamol for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI) (2017) COCHRANE DB SYST REV, 2017 (11).

**IF: 6.754**

Martinez G., Vernooij R.W.M., Fuentes Padilla P., Zamora J., Bonfill Cosp X., Flicker L., 18F PET with florbetapir for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI) (2017) COCHRANE DB SYST REV, 2017 (11).

**IF: 6.754**

Martinez G., Vernooij R.W., Fuentes Padilla P., Zamora J., Flicker L., Bonfill Cosp X., 18F PET with florbetaben for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI) (2017) COCHRANE DB SYST REV, 2017 (11).

**IF: 6.754**

Martinez Garcia L., Pardo-Hernández H., Superchi C., Nino de Guzman E., Ballesteros M., Ibargoyen Roteta N., McFarlane E., Posso M.,

# Clinical Epidemiology and Healthcare Services

## Scientific Production

\*TIF: 466.655 \*\*MIF: 6.392

Roque i Figuls M., Rotaeché del Campo R., Sanabria A.J., Selva A., Sola I., Vernooyj R.W.M., Alonso-Coello P., Methodological systematic review identifies major limitations in prioritization processes for updating (2017) *J CLIN EPIDEMIOL*, 86, 11-24.

**IF: 4.245**

Mas Dalmau G., Sant Arderiu E., Enfedaque Montes M.B., Sola I., Pequeno Saco S., Alonso Coello P., Patients' and physicians' perceptions and attitudes about oral anticoagulation and atrial fibrillation: a qualitative systematic review (2017) *BMC FAM PRACT*, 18 (1), 1-11.

**IF: 2.032**

Mazer CD., Whitlock RP., Ferguson DA., Hall J., Belley-Cote E., Connolly K., Khanykin B., Gregory AJ., de Médicis É., McGuinness S., Royse A., Carrier FM., Young PJ., Villar JC., Grocott HP., Seeberger MD., Fremen S., Leliouche F., Syed S., Byrne K., Bagshaw SM., Hwang NC., Mehta C., Painter TW., Royse C., Verma S., Hare GMT., Cohen A., Thorpe KE., Jüni P., Shehata N.; TRICS Investigators and Perioperative Anesthesia Clinical Trials Group. Restrictive or Liberal Red-Cell Transfusion for Cardiac Surgery (2017) *N ENG J MED*, 377, 2133-2144.

**IF: 79.258**

Miravitles M., Soler-Cataluna J.J., Calle M., Molina J., Almagro P., Quintano J.A., Trigueros J.A., Cosio B.G., Casanova C., Simonet P., Rigau D., Soriano J.B., Ancochea J., Spanish Guidelines for Management of Chronic Obstructive Pulmonary Disease (GesEPOC) 2017. Pharmacological Treatment of Stable Phase Guía española de la enfermedad pulmonar obstructiva crónica (GesEPOC) 2017. Tratamiento farmacológico en fase estable (2017) *ARCH BRONCONEUMOL*, 53 (6), 324-335.

**IF: 2.633**

Miravitles M., Urrutia G., Mathioudakis A.G., Ancochea J., Efficacy and safety of tiotropium and olodaterol in COPD: A systematic review and meta-analysis (2017) *RESP RES*, 18 (1).

**IF: 3.751**

Mocellin S., Baretta Z., Roque i Figuls M., Sola I., Martin-Richard M., Hallum S., Bonfill Cosp X., Second-line systemic therapy for metastatic colorectal cancer (2017) *COCHRANE DB SYST REV*, 2017 (1).

**IF: 6.754**

Morral A., Urrutia G., Bonfill X., Placebo effect and therapeutic context: A challenge in clinical research Efecto placebo y contexto terapéutico: un reto en investigación clínica (2017) *MED CLIN-BARCELONA*, 149 (1), 26-31.

**IF: 1.168**

Murad M.H., Guyatt G.H., Domecq J.P., Vernooyj R.W.M., Erwin P.J., Meerpohl J.J., Prutsky G.J., Akl E.A., Mueller K., Bassler D., Schandlmaier S., Walter S.D., Busse J.W., Kasenda B., Pagano G., Pardo-Hernandez H., Montori V.M., Wang Z., Briel M., Randomized trials addressing a similar question are commonly published after a trial stopped early for benefit (2017) *J CLIN EPIDEMIOL*, 82, 12-19.

**IF: 4.245**

Navas-Madronal M., Valero-Mut A., Martínez-Zapata M.J., Simon-Talero M.J., Figueiroa S., Vidal-Fernandez N., Lopez-Gongora M., Escartin A., Querol L., Absence of antibodies against KIR4.1 in multiple sclerosis: A three-technique approach and systematic review (2017) *PLOS ONE*, 12 (4).

**IF: 2.766**

Oliveros M.J., Gaete-Mahn M.C., Lanas F., Martínez-Zapata M.J., Seron P., Interval training exercise for hypertension (2017) *CO-CHRANE DB SYST REV*, 2017 (1).

**IF: 6.754**

Parmelli E., Amato L., Oxman A.D., Alonso-Coello P., Brunetti M., Moberg J., Nonino F., Pregno S., Saitto C., Schunemann H.J., Davoli M., Grade evidence to decision (etd) framework for coverage decisions (2017) *INT J TECHNOL ASSESS*, 33 (2), 176-182.

**IF: 1.333**

Polverino E., Goeminne P.C., McDonnell M.J., Aliberti S., Marshall S.E., Loebinger M.R., Murris M., Canton R., Torres A., Dimakou K., De Soyza A., Hill A.T., Haworth C.S., Vendrell M., Ringshausen F.C., Subotic D., Wilson R., Vilaro J., Stallberg B., Welte T., Rohde G., Blasi F., Elborn S., Almagro M., Timothy A., Ruddy T., Tonia T., Rigau D., Chalmers J.D., European Respiratory Society guidelines for the management of adult bronchiectasis (2017) *EUR RESPIR J*, 50 (3).

**IF: 12.242**

Posso M., Corominas J.M., Serrano L., Roman M., Tora-Rocamora I., Domingo L., Romero A., Quintana M.J., Vernet-Tomas M., Bare M., Vidal C., Sanchez M., Saladie F., Natal C., Ferrer J., Servitja S., Sala M., Castells X., Biomarkers expression in benign breast diseases and risk of subsequent breast cancer: a case-control study (2017) *CANCER MED-US*, 6 (6), 1482-1489.

**IF: 3.202**

Posso M., Puig T., Carles M., Rue M., Canale-Aybar C., Bonfill X., Effectiveness and cost-effectiveness of double reading in digital mammography screening: A systematic review and meta-analysis (2017) *EUR J RADIOL*, 96, 40-49.

**IF: 2.843**

Pottie K., Welch V., Morton R., Akl E.A., Eslava-Schmalbach J.H., Katikireddi V., Singh J., Moja L., Lang E., Magrini N., Thabane L.,

Stanev R., Matovinovic E., Snellman A., Briel M., Shea B., Tugwell P., Schunemann H., Guyatt G., Alonso-Coello P., GRADE equity guidelines 4: considering health equity in GRADE guideline development: evidence to decision process (2017) *J CLIN EPIDEMIOL*, 90, 84-91.

**IF: 4.245**

Pottie K., Mayhew A.D., Morton R.L., Greenaway C., Akl E.A., Rahman P., Zenner D., Pareek M., Tugwell P., Welch V., Meerpohl J., Alonso-Coello P., Hui C., Biggs B.-A., Requena-Mendez A., Agbata E., Noori T., Schunemann H.J., Prevention and assessment of infectious diseases among children and adult migrants arriving to the European Union/European Economic Association: A protocol for a suite of systematic reviews for public health and health systems (2017) *BMJ OPEN*, 7 (9).

**IF: 2.413**

Ramos A., Mendoza L.C., Rabasa F., Bolíbar I., Puig T., Corcòy R., Case-control studies in diabetes. Do they really use a case-control design? (2017) *ACTA DIABETOL*, 54 (7), 631-634.

**IF: 3.126**

Reques L., Bolíbar I., Chazelle E., Gomes L., Prikazsky V., Banza F., Keita M., Diallo B., Evaluation of contact tracing activities during the Ebola virus disease outbreak in Guinea, 2015. (2017) *INT HEALTH*, 9, 131-133.

**IF: 1.797**

Roman M., Quintana M.J., Ferrer J., Sala M., Castells X., Cumulative risk of breast cancer screening outcomes according to the presence of previous benign breast disease and family history of breast cancer: Supporting personalised screening (2017) *BRIT J CANCER*, 116 (11), 1480-1485.

**IF: 5.922**

Roque i Figuls M., Martinez-Zapata M.J., Scott-Brown M., Alonso-Coello P., Radioisotopes for metastatic bone pain (2017) *CO-CHRANE DB SYST REV*, 2017 (3).

**IF: 6.754**

Selva A., Sanabria A.J., Pequeno S., Zhang Y., Sola I., Pardo-Hernandez H., Selva C., Schunemann H., Alonso-Coello P., Incorporating patients' views in guideline development: a systematic review of guidance documents (2017) *J CLIN EPIDEMIOL*, 88, 102-112.

**IF: 4.245**

Selva A., Sola I., Zhang Y., Pardo-Hernandez H., Haynes R.B., Martinez Garcia L., Navarro T., Schunemann H., Alonso-Coello P., Development and use of a content search strategy for retrieving studies on patients' views and preferences (2017) *HEALTH QUAL LIFE OUT*, 15 (1).

**IF: 2.278**

**\*TIF: 466.655 \*\*MIF: 6.392**

Simancas-Racines D, Franco J.V., Guerra C.V., Felix M.L., Hidalgo R, Martinez-Zapata M.J., Vaccines for the common cold (2017) CO-CHRANE DB SYST REV, 2017 (5).

**IF: 6.754**

Torres A, Niederman M.S., Chastre J., Ewig S., Fernandez-Vandellós P, Hanberger H, Kollef M, Bassi G.L., Luna C.M., Martin-Lloeches I, Paiva J.A., Read R.C., Rigau D, Timo J.F., Welte T, Wunderink R, International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia (2017) EUR RESPIR J, 50 (3).

**IF: 12.242**

Turrillas M, Sitja-Rabert M, Pardo H, Vilarr Casamitjana J, Fort-Vanmeirhaeghe A, Morral Fernandez A, Cebria i Iranzo M.A., Bonfill Cosp X, Identification and description of controlled clinical trials published in Physiotherapy journals in Spain (2017) J EVAL CLIN PRACT, 23 (1), 29-36.

**IF: 1.483**

Vernooij R.W.M., Alonso-Coello P, Brouwers M, Martinez Garcia L, Reporting Items for Updated Clinical Guidelines: Checklist for the Reporting of Updated Guidelines (CheckUp) (2017) PLOS MED, 14 (1).

**IF: 11.675**

Vernooij R.W.M., Garcia L.M., Florez I.D., Hildago Armas L, Poorthuis M.H.F., Brouwers M, Alonso-Coello P, Updated clinical guidelines experience major reporting limitations (2017) IMPLEMENT SCI, 12 (1).

**IF: 4.345**

Wedzicha J.A., Calverley P.M.A., Albert R.K., Anzueto A, Criner G.J., Hurst J.R., Miravitles M, Papi A, Rabe K.F., Rigau D, Sliwinski P, Tonia T, Vestbo J, Wilson K.C., Krishnan J.A., Prevention of COPD exacerbations: A European Respiratory Society/ American Thoracic Society guideline (2017) EUR RESPIR J, 50 (3).

**IF: 12.242**

Wedzicha J.A., Miravitles M., Hurst J.R., Calverley P.M.A., Albert R.K., Anzueto A., Criner G.J., Papi A., Rabe K.F., Rigau D., Sliwinski P., Tonia T., Vestbo J., Wilson K.C., Krishnan J.A., Management of COPD exacerbations: A European Respiratory Society/American Thoracic Society guideline (2017) EUR RESPIR J, 50 (4).

**IF: 12.242**

Welch V.A., Akl E.A., Pottie K, Ansari M.T., Briel M, Christensen R, Dans A, Dans L, Eslava-Schmalbach J, Guyatt G, Hultcrantz M, Jull J, Katikireddi S.V., Lang E, Matovinovic E, Meerpohl J.J., Morton R.L., Mosdol A, Murad M.H., Petkovic J, Schunemann H, Sharaf R, Shea B, Singh J.A., Sola I, Stanev R,

Stein A, Thabaneii L, Tonia T, Tristan M, Vitols S, Watine J, Tugwell P, GRADE equity guidelines 3: considering health equity in GRADE guideline development: rating the certainty of synthesized evidence (2017) J CLIN EPIDEMIOL, 90, 76-83.

**IF: 4.245**

Willson M.L., Vernooij R.W.M., Gagliardi A.R., Questionnaires used to assess barriers of clinical guideline use among physicians are not comprehensive, reliable, or valid: a scoping review (2017) J CLIN EPIDEMIOL, 86, 25-38.

**IF: 4.245**

Wirth K, Klenk J, Brefka S, Dallmeier D, Faehling K, Roque i Figuls M, Tully M.A., Gine-Garriga M, Caserotti P, Salva A, Rothenbacher D, Denkinger M, Stubbs B, Biomarkers associated with sedentary behaviour in older adults: A systematic review (2017) AGEING RES REV, 35, 87-111.

**IF: 8.973**

Yepes-Nuñez JJ, Zhang Y, Xie F, Alonso-Coello P, Selva A, Schünemann H, Guyatt G, Forty-two systematic reviews generated 23 items for assessing the risk of bias in values and preferences/studies (2017) J CLIN EPIDEMIOL, 85, 21-31.

**IF: 4.245**

# Evaluation of Public Health Policies and Programmes



## Coordinator

Ariza Cardenal, Carles ASPB  
cariza@aspb.cat

## Members

Centrich Escarpenter, Francesc	ASPB
Continente García, Xavier	ASPB
Cortés Francisco, Núria	ASPB
García Altés, Anna	ASPB
León Pujadas, Gabriel	ASPB
López Medina, María José	ASPB
Muñoz Hurtado, Laura	IR
Pérez Giménez, Anna	ASPB
Puigpinós Riera, Rosa	ASPB
Sánchez Martínez, Francesca	ASPB
Serral Cano, Gemma	ASPB
Villalbí Hereter, Joan Ramon	ASPB



## Main Lines of Research

### Evaluation of Public Health Policies and Programmes

- ▶ Monitoring of behaviours and other health risk factors such as environmental exposure.
- ▶ Process and impact evaluation of public health programmes and services (school-

based prevention programmes for obesity, smoking, alcohol and cannabis consumption, breast cancer screening programmes and memory training workshops for elderly people).

- ▶ Evaluation of ICT innovation in public health.
- ▶ Evaluation of food contaminants.

## Challenges

- ▶ Promote research into the evaluation of policies and programmes.
- ▶ Support the debate on conceptual and methodological aspects of results evaluation in prevention and health promotion.
- ▶ Consolidate the group's research, fostering less developed aspects such as financial assessment and evaluation of health protection interventions.

▶ Develop a theoretical corpus of concepts, principles, methods and examples that contribute to filling the gap in undergraduate and postgraduate teaching regarding the design and evaluation of risk prevention and health promotion interventions.

## Collaborations

### Collaborations with other IIB Sant Pau Groups

- ▶ Clinical Epidemiology and Healthcare Services (PI: Xavier Bonfill).
- ▶ Transport and Health: Injuries and Mobility (PI: Catherine Pérez).
- ▶ Health Inequalities (PI: Carme Borrell).
- ▶ Epidemiology of Addictions (PI: M. Teresa Brugal).

▶ Foreign universities: Johns Hopkins University, USA.

▶ Spanish universities: Universitat Pompeu Fabra, Universitat Ramon Llull, Universitat de Vic, Universitat Internacional de Catalunya, Universitat Oberta de Catalunya, Universidad de Santiago de Compostela.

▶ Primary care centres: Ciutat Meridiana, Roquetes, Sant Rafael and Sardenya (Barcelona).

▶ Catalan Institute of Oncology (ICO).

▶ Municipal bodies: Barcelona Sports Institute (IBE), Barcelona Municipal Institute of Education (IME).

▶ Regional bodies: Public Health Agency of Catalonia (Promoting Health through Physical Activity and Healthy Eating Plan) and Catalan Health Information and Quality Agency (AQUAS).

▶ Other bodies: Catalan Recreation Foundation (FCE).

▶ Companies: Fontvella and Danone (Health Affairs Departments).

### External Collaborations

- ▶ CIBER-Epidemiology and Public Health (Group 18: Evaluation of public health policies and programmes).
- ▶ CIBER-Obesity and Nutrition (Group PI: Fernando Fernández de Aranda)
- ▶ AGAUR Consolidated Research Group (Evaluation of public health policies and programmes).
- ▶ Tobacco Working Group of the Spanish Epidemiology Society.
- ▶ Social Determinants Group of the Spanish Epidemiology Society.

**Active Grants**

- ▶ Rosa Puigpinós Riera. Influencia de determinantes sociales, estilos de vida, bienestar emocional y uso de terapias no convencionales en la evolución del cáncer de mama en una cohorte de mujeres diagnosticadas. PI13/01977. Instituto de Salud Carlos III. Duration: 2014-2018. 64,470.00 €.
- ▶ Carles Ariza Cardenal. Diseño y evaluación de la efectividad de una intervención de prevención selectiva del consumo de alcohol y cannabis en jóvenes vulnerables en el ámbito comunitario. 2015I070. Ministeri de Sanitat, Serveis Socials i Igualtat. Duration: 2016-2018. 61,773.00 €.
- ▶ Carles Ariza Cardenal. Evaluación de un proyecto de prevención integral de la obesidad infantil en la etapa pre-escolar en Barcelona (proyecto POIBA-2ª fase). PI16/00701. Instituto de Salud Carlos III. Duration: 2017-2019. 66,500.00 €.
- ▶ María José López. Exposición al humo ambiental de tabaco en menores de 12 años: estimación de la prevalencia y medición de marcadores en hogares y vehículos (PI13/02734). Duration: 2014-2017. 93,000 €.
- ▶ María José López. Tackling secondhand tobacco smoke and e-cigarette emissions: exposure assessment, novel interventions, impact on lung diseases and economic burden in diverse European populations (project ID: 681040). European Commission (H2020). Duration/2015-2019. 343,152.78 €.

Note: Total amount granted to PI. It does not include indirect costs.

**Grants Awarded in 2017**

- ▶ María José López Medina, Exposición al humo ambiental y residual del tabaco en niños y niñas: cohorte HUMO. PI17/01359. Instituto de Salud Carlos III. Duration: 2018-2020. 73,000.00 €.

Note: Total amount granted to PI. It does not include indirect costs.

**Books or chapters with ISBN**

- ▶ Ariza C. La salut conculcada. Editorial Claret. 2017. ISBN: 9788491360049.
- ▶ Ariza C, Sánchez-Martínez F, Pérez A. School-Based Cannabis Prevention Programs. In: Handbook of Cannabis and Related Pathologies. Elsevier. 2017. ISBN: 9780128007563.

**Awards**

- ▶ Francesc Freixa Prize at the SOCIDROGALCOHOL Symposium held in Oviedo, for the poster on visibility of alcohol in the urban environment of Barcelona. Villalbí, J.R.; Espelt, A.; Sureda, X.; Bosque Prous, M.; Teixidó Compañó, E.; Puigcorbé, S.; Franco, M.; Brugal, M.T. "Disponibilidad, promoción y visibilidad del consumo de alcohol en el entorno urbano. Un estudio en barrios de Barcelona"

**Theses**

- ▶ Gemma Serral. Desigualdades en el control mamográfico: el papel de los programas de cribado. Universitat Pompeu Fabra. Director: Rosa Puigpinós. Date of defense: 09/02/2017.

**Other Publications**

- ▶ Serral G, Puigpinós-Riera R. Desigualdades en la realización de mamografías y citologías cervicales en las mujeres españolas según las encuestas nacionales de salud. Revista de Senología y Patología Mamaria. 2017 30: 110-8.
- ▶ Puigpinós-Riera R, Continente X, Serral G, Bargalló X, Doménech M, Espinosa-Bravo M, Grau J, Macià F, Manzanera R, Pla M, Quintana MJ, Sala M, Vidal E. Influence of Social Determinants, Lifestyle, Emotional Well-Being and the Use of Unconventional Therapies in Breast Cancer Progression in a Cohort of Women in Barcelona: Protocol for the DAMA Cohort. JMIR Research Protocols. 2017 Dec 18; 6(12): e249.

# Evaluation of Public Health Policies and Programmes

\*TIF: 55.749 \*\*MIF: 2.3229

Alberto Vella V, Garcia-Altes A, Segura Garcia L, Ibanez Martinez N, Colom Farran J, Systematic review of guidelines in estimating social costs on drugs (2017) GAC SANIT.

**IF: 1.5810**

Arechavala T, Continente X, Pérez-Ríos M, Schiaffino A, Fernandez E, Cortés-Francisco N, Centrich F, Muñoz G, López MJ. Alcohol consumption recommendations in the dietary guidelines for the Spanish population. A very ambiguous message. (2017) NUTRICIÓN HOSPITALARIA Jul 28; 34(4): 1004-1005.

**IF: 0.747**

Ariza C, Arechavala T, Valmayor S, Serral G, Moncada A, Rajmil L, Schiaffino A, Sánchez-Martínez F. Validation of 'POIBA-How do we eat?' questionnaire in 9-10 years old schoolchildren. (2017) FOOD & NUTRITION RESEARCH Oct 30; 61(1): 1391665.

**IF: 2.086**

Barrio P, Reynolds J, Garcia-Altes A, Gual A, Anderson P, Social costs of illegal drugs, alcohol and tobacco in the European Union: A systematic review (2017) DRUG ALCOHOL REV, 36 (5), 578-588.

**IF: 2.8550**

Bosque-Prous M., Brugal M.T., Lima K.C., Villalbi J.R., Bartrolí M., Espelt A., Hazardous drinking in people aged 50 years or older: a cross-sectional picture of Europe, 2011–2013 (2017) INT J GERIATR PSYCH, 32 (8), 817-828.

**IF: 2.940**

Cabrera-Leon A, Daponte Codina A, Mateo I, Arroyo-Borrell E, Bartoll X, Bravo M.J., Dominguez-Berjon M.F., Renart G, Alvarez-Dardet C, Mari-Dell'Olmo M., Bolivar Munoz J, Saez M, Escriba-Aguir V, Palencia L, Lopez MJ, Saurina C, Puig V, Martin U, Gotsens M, Borrell C, Serra Saurina L, Sordo L, Bacigalupe A, Rodriguez-Sanz M, Perez G, Espelt A, Ruiz M, Bernal M, Contextual indicators to assess social determinants of health and the Spanish economic recession Indicadores contextuales para evaluar los determinantes sociales de la salud y la crisis económica española (2017) GAC SANIT, 31 (3), 194-203.

**IF: 1.5810**

Continente X, Perez A., Espelt A., Lopez MJ., Media devices, family relationships and sleep patterns among adolescents in an urban area (2017) SLEEP MED, 32, 28-35.

**IF: 3.395**

Continente X, Perez A., Espelt A., Ariza C, Lopez MJ., Multiple lifestyle risk behaviours and excess weight among adolescents in Barcelona, Spain Múltiples conductas de riesgo y exceso de peso en adolescentes de Barcelona, España (2017) GAC SANIT, 31 (4), 332-335.

**IF: 1.5810**

Espelt A, Villalbi J.R., Bosque-Prous M., Pares-Badell O, Mari-Dell'Olmo M., Brugal M.T., The impact of harm reduction programs and police interventions on the number of syringes collected from public spaces. A time series analysis in Barcelona, 2004–2014 (2017) INT J DRUG POLICY, 50, 11-18.

**IF: 4.2440**

Fernandez E, Fu M., Perez-Rios M, Schiaffino A., Sureda X, Lopez MJ., Changes in second-hand smoke exposure after smoke-free legislation (Spain, 2006-2011) (2017) NICOTINE TOB RES, 19 (11), 1390-1394.

**IF: 4.2910**

Fuentes S, Bilal U, Galan I, Villalbi J.R., Espelt A., Bosque-Prous M., Franco M., Lazo M., Binge drinking and well-being in European older adults: Do gender and region matter? (2017) EUR J PUBLIC HEALTH, 27 (4), 692-699.

**IF: 2.7820**

León-Gómez BB, Colell E, Villalbí JR, Barrio G, Domingo-Salvany A. Impact of smoke-free regulations on smoking prevalence trends in Spain (2017) EUROPEAN JOURNAL OF PUBLIC HEALTH Feb 1; 27(1): 123-128.

**IF: 2.782**

Lineros-Gonzalez C., Marcos-Marcos J., Ariza C., Hernan-Garcia M., The importance of the process in evaluating the effectiveness of a childhood obesity campaign Importancia del proceso en la evaluación de la efectividad de una intervención sobre obesidad infantil (2017) GAC SANIT, 31 (3), 238-241.

**IF: 1.5810**

Lopez MJ., Continente X, Sanchez E, Bartrolí M., Activities using websites and social networks: tools and indicators for evaluation Intervenciones que incluyen webs y redes sociales: herramientas e indicadores para su evaluación (2017) GAC SANIT, 31 (4), 346-348.

**IF: 1.5810**

Puigpinos-Riera R, Serral G, In favour of the pink ribbon and breast cancer prevention: various points of view A favor del lazo rosa y la prevención del cáncer de mama: diferentes puntos de vista (2017) GAC SANIT, 31 (3), 253-254.

**IF: 1.5810**

Rando-Matos Y., Pons-Vigues M., Lopez MJ., Cordoba R, Ballve-Moreno J.L., Puigdomenech-Puig E, Benito-Lopez V.E., Arias-Agudelo O.L., Lopez-Grau M., Guardia-Riera A, Trujillo J.M., Martin-Cantera C., Smokefree legislation effects on respiratory and sensory disorders: A systematic review and meta-analysis (2017) PLOS ONE, 12 (7).

**IF: 2.7660**

Ruiz-Trasserra A., Perez A., Continente X, O'Brien K., Bartrolí M., Teixido-Compano E, Espelt A., Patterns of physical activity and as-

sociated factors among teenagers from Barcelona (Spain) in 2012 Los patrones de actividad física y sus factores asociados en adolescentes de Barcelona en 2012 (2017) GAC SANIT, 31 (6), 485-491.

**IF: 1.5810**

Stillman FA, Soong A, Pang Y, Zheng L, Garcia-Esquinas E, Lopez MJ, Navas-Acien A. Tobacco Smoke Exposure in Indoor and Outdoor Locations in Airports Across Europe and the United States: A Cross-Sectional Study. (2017) Nicotine & Tobacco Research Nov 7; 19(12): 1482-1490.

**IF: 4.291**

Sureda X, Carreño V, Espelt A, Villalbí JR, Pearce J, Franco M. Alcohol in the city: whenever and wherever. (2017) GACETA SANITARIA Jul-Aug; 31(4): 332-335.

**IF: 1.5810**

Sureda X, Villalbí J.R., Espelt A., Franco M., Living under the influence: normalisation of alcohol consumption in our cities Bajo la influencia del alcohol: la normalización de su consumo en nuestras ciudades (2017) GAC SANIT, 31 (1), 66-68.

**IF: 1.5810**

Sureda X, Espelt A., Villalbí J.R., Cebrecos A., Baranda L, Pearce J, Franco M., Development and evaluation of the OHCTIES instrument: Assessing alcohol urban environments in the Heart Healthy Hoods project (2017) BMJ OPEN, 7 (10).

**IF: 2.4130**

Turino C, Bertran S, Gavalda R, Teixido I, Woehrle H, Rue M, Solsona F, Escarrabill J, Colls C, Garcia-Altes A, De Batlle J, Sanchez De-La-Torre M, Barbe F, Characterization of the CPAP-treated patient population in Catalonia (2017) PLOS ONE, 12 (9).

**IF: 2.7660**

Vela E, Clries M., Vella V.A., Adroher C, Garcia-Altes A, Population-based analysis of the Healthcare expenditure in Catalonia (Spain): What and who consumes more resources? (2017) GAC SANIT.

**IF: 1.5810**

Villalbi J.R., Borrell C., Macia M., Subirana T, Lopez M.J., Portana S, Llebaria X, Casas C, Adapting the service portfolio of a public health organisation to shrinking resources Adaptación de los servicios de una organización de salud pública a la disminución de los recursos (2017) GAC SANIT, 31 (3), 242-245.

**IF: 1.5810**



public health

# Transport and Health: Injuries and Mobility



## Main Lines of Research

- ▶ Public health injury surveillance.
- ▶ Evaluation of road safety strategies at the urban level.
- ▶ Evaluation of road safety strategies in Spain.
- ▶ Indicators of mobility exposure and risk of traffic injuries.
- ▶ Determinants of walking as a mode of transport.

- ▶ Health impact assessment of active transport (walking and cycling).
- ▶ Record linkage of health and police registers to study road traffic injury determinants.
- ▶ Inter-sector policies in transport: impact on sustainable environment, health and equity.

## Challenges

- ▶ Study of the nature of injuries and their severity according to the characteristics of the collision and the vehicles involved, particularly in urban settings.
- ▶ Evaluate road safety policies and interventions.

- ▶ Calculation of risk indicators using mobility exposure.
- ▶ Health impact of urban, air pollution interventions.

## Collaborations

### Collaborations with other IIB Sant Pau Groups

- ▶ Health Inequalities (PI: Carme Borrell).

### External Collaborations

- ▶ All members of the group are members of the Working Group for Health Impact Evaluation of Injuries in Spain (Sociedad Española de Epidemiología), which is leaded by the IP of the group (Catherine Pérez).
- ▶ All members of the group are members of the group of Social Inequalities of CIBERESP (Consorcio de Investigación Biomédica de Epidemiología y Salud Pública).
- ▶ The IP of the group is member of the European Committee of The Transport and Health Study Group (THSG) (UK).
- ▶ Joint action on monitoring injuries in Europe (JAMIE) (European Agency for Health and Consumers).

▶ Member of the Scientific Comitee of the Institut Français des Sciences et Technologies des Transports, de l'Aménagement et de Réseaux (IFSTTAR). From 2016.

▶ Safer City Streets IRTAD Cities (Joint Transport Research Centre of the OECD and the International Transport Forum, JTRC).

▶ Marta Olabarria, Elena Santamaría. Collaboration with Carmen Miralles (UAB) in: Movilidad cotidiana activa y saludable en entornos urbanos de proximidad. Enfoques multimedodológicos: tracking living labs, encuestas de movilidad y estudios cualitativos. Ministerio de Economía y Competitividad. CSO2016-74904-R. Duration: 2017-2019 43,000 €.

▶ Marta Olabarria, Elena Santamaría. Collaboration with Carmen Miralles (UAB) in: Ciudad, calidad de vida y movilidad activa en la tercera edad. Un análisis multimedológico a través de Tracking Living Labs. Recercaixa 2016. Duration: 2016-2018. 95,688.33 €.

## Active Grants

- ▶ Caterine Pérez. Safety CaUsation, Benefits and Efficiency (SafetyCube). H2020 N. 633485. European Commission. Duration: 2015-2018. 120,000 €.
- ▶ Caterine Pérez, Carme Borrell. Participatory Urban Living for Sustainable Environments (PULSE). Horizon 2020 H2020 N. 727816. European Commission. Duration: 2016-2018. 309,625 €.

Note: Total amount granted to PI. It does not include indirect costs.

## Awards

- Katherine Pérez and Elena Santamaría-Rubio. Are Barcelona's Advanced Zones for Motorcycles Effective? High Abstract Award Winners. Practitioner Category. II International Conference on Transport and Health. Barcelona, July 2017.

## Scientific Production

Cryer C., Miller T.R., Lyons R.A., Macpherson A.K., Perez K., Petridou E.T., Dessypris N., Davie G.S., Gulliver P.J., Lauritsen J., Boufous S., Lawrence B., de Graaf B., Steiner C.A., Towards valid 'serious non-fatal injury' indicators for international comparisons based on probability of admission estimates (2017) INJURY PREV, 23 (1), 47-57.

**IF: 2.420**

Llimona P., Perez G., Rodriguez-Sanz M., Novoa A.M., Espelt A., Garcia de Olalla P., Borrell C., Infobarris: an interactive tool to monitor and disseminate information on health and its determinants in the neighbourhoods of Barcelona (Spain) Infobarris: una herramienta interactiva para monitorizar y divulgar información sobre la salud y sus determinantes en los barrios de Barcelona (2017) GAC SANIT, 31 (5), 427-431.

**IF: 1.581**

**\*TIF: 12.835 \*\*MIF: 1.8335**

Mari-Dell'Olmo M., Novoa A.M., Camprubi L., Peralta A., Vasquez-Vera H., Bosch J., Amat J., Diaz F., Palencia L., Mehdiapanah R., Rodriguez-Sanz M., Malmusi D., Borrell C., Housing Policies and Health Inequalities (2017) INT J HEALTH SERV, 47 (2), 207-232.

**IF: 1.292**

Novoa A.M., Amat J., Malmusi D., Diaz F., Darnell M., Trilla C., Bosch J., Borrell C., Changes in Health Following Housing Improvement in a Vulnerable Population in Spain (2017) INT J HEALTH SERV, 47 (1), 83-107.

**IF: 1.292**

Novoa A.M., Perez G., Espelt A., Echave C., de Olalla P.G., Calvo M.J., Pasarin M., Diez E., Borrell C., Calvo M.J., Cormenzana B., Cortes I., Diez E., Echave C., Espelt A., de Olalla P.G., Gomez J., Novoa A.M., Pallares M., Perez G., Rodriguez-Sanz M., The Experience of Implementing Urban HEART Barcelona: a Tool for Action (2017) J URBAN HEALTH, 1-15.

**IF: 1.738**

Perez K., Olabarria M., Rojas-Rueda D., Santamaría-Rubio E., Borrell C., Nieuwenhuijsen M., The health and economic benefits of active transport policies in Barcelona (2017) J TRANSP HEALTH, 4, 316-324.

**IF: 2.774**

## Other Publications

- López-Ruiz M, Mancebo Fernández N, Pérez K, Serra Saurina L, G Benavides F. [Work-Related Fatal Traffic Injuries in Spain According to Travelling Reasons and Sex (2010-2013)]. REV ESP SALUD PUBLICA. 2017 Jan 23;91. pii: e201701013. Spanish. PubMed PMID: 28112714.
- Katherine Pérez, Anna Gómez-Gutiérrez. La qualitat de l'aire i la salut com a nous factors en la definició de polítiques de mobilitat. Revisa Papers. N.59 – Nous reptes en la mobilitat quotidiana. Polítiques públiques per a un model més equitatiu i sostenible. pages 26-32. Institut d'Estudis Regionals i Metropolitans de Barcelona. Barcelona Novembre 2017. ISSN: 1888-3621.

# Transmissible Diseases



## Coordinator

Rius Gibert, Cristina      ASPB  
crius@aspb.cat

## Members

Álamo Junquera,	
M. Dolores	ASPB
Bruguera Torrella, Sílvia	ASPB
Camprubí Garreta, Esteve	ASPB
Casals Toquero, Martí	ASPB
Caylà Buqueras,	
Joan Arturo	ASPB
De Andrés Aguayo, Anna	ASPB
De Benito Langa, Javier	ASPB
García Carrasco, Mireia	ASPB
Garcia de Olalla Rizo,	
Patricia	ASPB
Gil Simon, Sonia	ASPB
Manzanares, Sandra	ASPB
Martín Valle, Silvia	ASPB
Masdéu Corcoll, Eva	ASPB
Mercuriali, Lilas	FGS
Millet Vilanova, Joan Pau	ASPB
Molinero Ruiz, Emilia	ASPB
Montalvo Porro, Tomás	ASPB
Moreno Martínez, Antonio	ASPB
Orcau Palau, Àngels	ASPB
Ospina Valencia, Jesús E.	ASPB
Rodrigo Sanz, María Teresa	ASPB
Ros Samso, Míriam	ASPB
Simón Viván, Pere	ASPB

## Main Lines of Research

### Line 1: Tuberculosis prevention and treatment adherence

Investigate the impact of the incorporation of new technologies and circuits to favor the control of TB transmission, treatment adherence and TB contact tracing (Farma TITL project, Video DOT, etc.). To describe the incidence and epidemiological characteristics of multidrug resistant TB and TB in people infected with HIV in Europe (Study groups: TB-Net and EuroTB are carrying out observational epidemiological studies to get a more accurate view of this illness). Develop network information tools with different people in charge of the control of TB in other European cities, which allow developing strategies of assistance and control of the disease most suitable for large cities. We participate in the group "TB in Big Cities" promoted by the European CDC and with which we have made a document of consensus on control strategies in large cities. Describe socio-demographic, epidemiological and clinical characteristic of certain vulnerable groups that suffers from TB such as children, immigrants, homeless, etc.

economic crisis. We always try to strengthen the prevention and control measures in order to prevent the appearance of new cases. 2. To describe the temporal evolution of measles and parotiditis in relation to the systematic vaccination policies developed in Catalonia. 3. To investigate the transmission lines during the epidemic measles periods promoting the identification of strains due to molecular epidemiology. 4. To investigate the lines of transmission of pertussis during periods of epidemic in order to establish the discussion about different strategies for preventing the disease. 5. To investigate the sources of infection and the intrafamily secondary transmission rates of the pertussis, and establish the lines of transmission of pertussis within the family nucleus. 6. To know the epidemiological pattern of malaria in order to identify previously possible cases of autochthonous transmission of disease. 7. In hepatitis we are dealing with the European project, Hepscreen, which objective is to compare 2 strategies: passive (prevalence of infection is seen in immigrants who consult) and active (prevalences are studied from immigrants recruited by community health workers).

### Line 2: HIV and other STI surveillance and control

Evaluation of interventions based on reducing diagnostic delay of HIV and other sexual transmitted infections (STI): study of sexual contacts, especially vulnerable groups (men who have sex with men, immigrant population) and offers the HIV and STI tests. The aims are: 1. To offer the HIV test, and other STIs for men who have sex with men and other users of gays saunas, 2. To increase the vaccination coverage of hepatitis A and B in this group, 3. To improve the awareness of the users and workers of the saunas about the risk of exposing themselves to situations that favor the transmission and the need to take prevention measures and facilitate the access of preventive materials for HIV/STI/Hepatitis, 4. To involve entrepreneurs and employees of these centers in the implementation of this initiative. 5. To inform about access to other prevention services outside of saunas.

### Line 3: Research in other notifiable diseases

It focuses on the study of the temporal evolution and transmission patterns of parotiditis, pertussis, other STI, epidemic outbreaks and other emerging diseases, both in Spanish and Foreign-born. The aims are: 1. To describe the epidemiological pattern of these diseases in the last 10 years with the objective of detecting possible changes during the period 2014-2018 and its relationship with the

### Line 4: Community health workers and notifiable disease control among foreign born patients

For more than fifteen years, we have a team of Community Health Workers (CHW) that acts as sociocultural mediators and translators. They are from six different regions worldwide and collaborate within the team of epidemiologists and public health nursing team. Based on a strategy of complementary profiles, they are responsible for carrying out accompaniment in the diagnosis and treatment of diseases such as TB, hepatitis or HIV in populations with language barriers or the risk of social exclusion (undocumented immigrants). With their cultural and idiomatic profile, can treat patients from Eastern Europe, Asian countries with high incidence of communicable diseases such as China and India, Latin American, Maghreb countries and of sub-Saharan Africa. The aims are: 1. To evaluate the impact of their intervention in prevention and control of communicable diseases (HIV, TB and STI) in immigrant, 2. To adapt and disseminate information for the prevention and the promotion of healthy habits 3. To increase knowledge of the risk factors among these groups, as well as adequate access to the Catalan health system. 4. To reinforce patient's social relations into the communities so that they can become a useful resource in the fight against HIV, other STI and TB.

**Main Lines of Research****Line 5: Vaccine hesitancy**

To identify attitudes, beliefs, and knowledge about vaccines among the health care workers who are involved in the administration of systematic childhood vaccines in the public primary care setting in Barcelona, Spain. To describe and compare knowledge, attitudes, and beliefs regarding the vaccination calendar of pediatric primary care teams (doctors and nurses) and determine the factors associated with vaccine hesitancy in Barcelona in 2016-17.

**Line 6: Vector born transmitted diseases**

Arboviruses and other arthropod born disease such as malaria, are a group of diseases transmitted through arthropods. Many of them are capable of producing infection in humans. Some of the arboviruses such as West Nile Virus (WNV), Chikungunya (CHK), Dengue or Zika Virus (ZV) are emerging and have a high potential of generating epidemic outbreaks in European non-endemic countries. The threat of arbovirosis emergence and re-emergence has created a risk scenario for global public health. ZV as CHK, dengue and

WNV are mandatory notification diseases in Spain. Furthermore, in Barcelona an active epidemiological surveillance system is carried out based on a close relationship with the doctors in charge of imported diseases and in the electronic notification system for notification diseases. It is precisely this concern that has led several countries to adopt new protocols and procedures that adapt to these new situations to respond to this public health problem. After the diagnostic of the first cases of imported arbovirosis in the city, it was seen that they could pose a risk to public health since A.albopictus is endemic in our setting. That is the reason why a system of active epidemiological and entomological surveillance of notifiable diseases records (EDO) for each detected case, has been implemented and the Epidemiology and Entomological Surveillance Service, both from the Public Health Agency of Barcelona are working very close for minimizing the risk of having an autochthonous case. The aims are: 1. To explain the epidemiological and entomological surveillance that took place against the vector born transmitted diseases. 2. To identify the possible areas of improvement in the procedures in order to control ZV and other emerging arbovirosis that could be transmitted by local competent vectors.

**Challenges**

- ▶ Prevent sexually transmitted infections and other transmissible diseases.
- ▶ Evaluate HIV screening programs in gay saunas.
- ▶ Improve detection and research into causes of C hepatitis.
- ▶ Improve detection and control measures of outbreaks.
- ▶ Improve adherence of tuberculosis and latent tuberculosis infection.
- ▶ STD/HIV and TB contact tracing.
- ▶ Cost effective analysis on public health interventions.
- ▶ Describe the threats and improve the procedures of vector born transmitted diseases.

**Collaborations****External Collaborations**

- ▶ HEPSCREEN: Screening for hepatitis Project. <http://hepscreen.eu/>
- ▶ CASCADE
- ▶ GEMES
- ▶ COHERE
- ▶ GESIDA: grupo de estudio del SIDA de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC). <http://gesida-seimc.org/>
- ▶ PII-TB SEPAR: Programa integrado de investigación en Tuberculosis de la Sociedad Española de Patología Torácica.
- ▶ AGAUR: Agència de gestió d'ajuts Universitaris i de Recerca. <http://agaur.gencat.cat/ca/inici>
- ▶ TB-NET: Tuberculosis European Network. <http://www.tb-net.org/>
- ▶ CIBERESP: CIBER of Epidemiology and Public Health. <http://www.ciberesp.es/>
- ▶ UITB: Unitat d'Investigació en Tuberculosi de Barcelona.

**Awards**

- ▶ Sentís A, Martín M, Arando M, Armengol P, Barberà MJ, Martí G, Ocaña I, Gil S, García de Olalla P, and group of ITS of Barcelona. Infecciones de transmisión sexual en jóvenes entre 15 y 24 años, Barcelona, 2007-2015. VII Award of the Sociedad Española de Epidemiología (SEE) and Escuela Andaluza de Salud Pública to the best senior communication presented at the XXXV Reunión Científica de la SEE. Barcelona, 6-8 Sept 2017.
- ▶ Alarcón M, García de Olalla P, Fernández M. "Promoción de la prueba de VIH a hombres que tienen sexo con hombres a través de aplicaciones móviles". VI Award of the Sociedad Española de Epidemiología to the best dissertation in epidemiology and public health. Barcelona, 6-8 Sept 2017.

# Transmissible Diseases

## Active Grants

- ▶ Patricia García de Olalla Rizo. Uso de las aplicaciones para telefonía móvil en la promoción de las pruebas del VIH y otras infecciones de transmisión sexual en hombres que tienen sexo con hombres. PI16/02025. Instituto de Salud Carlos III. Duration: 2017-2019. 46,500.00 €.
- ▶ Antonio Moreno Martínez. Asociación de diabetes y tuberculosis en un distrito con alta incidencia de tuberculosis. Estudio de casos y controles, 2007-2016. PI16/01751. Instituto de Salud Carlos III. Duration: 2017-2019. 46,500.00 €.
- ▶ Joan Arturo Caylà Buqueras. Cribado de las enfermedades transmisibles en población inmigrante de un barrio con bajo nivel socioeconómico: comparación de dos estrategias. PI12/02573. Instituto de Salud Carlos III. Duration: 2013-2017. 43,500.00 €.
- ▶ Joan A. Caylà. TBTC Estudio 36: Plataforma para la evaluación de resultados de tratamiento de tuberculosis: un estudio observacional de personas tratadas de tuberculosis pulmonar. CDC-EEUU. Duration: 2015-2017. 310,000 €.
- ▶ Fernando Alcaide. Estudio de las resistencias a los fármacos y los mecanismos moleculares más frecuentes en *Mycobacterium tuberculosis* en España (Estudio REMOTUBES). SEPAR. Duration: 2015-2018. 18,000 €.
- ▶ Sandra Manzanares. Smartphone application for aging HIV-infected men who have sex with men to prevent sexually transmitted infections. GILEAD. Duration: 2016-2017. 69,250 €.
- ▶ Vinicio Israel Molina. Recaídas en Tuberculosis: ¿reinfección exógena o reactivación endógena? SEPAR. Duration: 2016-2017. 12,000 €.
- ▶ Héctor Javier Sánchez. Evaluación de nano-partículas magnéticas eléctricamente activas (NP-MEAS) para detectar, capturar y concentrar células de *Mycobacterium tuberculosis* de muestras clínicas. SEPAR. 2016-2017. 9,000 €.
- ▶ Joan A Caylà. Factores asociados a los brotes de gastroenteritis aguda por norovirus en instituciones cerradas y semicerradas. FIS PI16/02005. Duration: 2016-2018. 116,765 €.
- ▶ Àngels Orcau. Incidencia de tuberculosis entre contactos infectados por *Mycobacterium tuberculosis* en una gran ciudad. SEPAR. Duration: 2017-2018. 18,000 €.
- ▶ Joan Pau Millet. Barcelona Tb Photovoices Project. Duration: 2016-2019.
- ▶ Tomás M. Pérez Porcuna. Estudio observacional de la infección tuberculosa en niños VFR (visiting Friends and relatives) que viajan a países con elevada incidencia de tuberculosis. FIS PI16/00314. Duration: 2017-2019. 50,215 €.
- ▶ Israel Molina. PICAT (Plataforma integral para el control de arbovirosis en Cataluña). Departament de Salut. Duration: 2017-2019. 599,934 €.
- ▶ Àngels Orcau. Estudio de mejora de la adherencia y seguimiento del tratamiento de la infección tuberculosa latente mediante un programa de dispensación y seguimiento en farmacias comunitarias. SEPAR. Duration: 2018-2019. 6,000 €.

Note: Total amount granted to PI. It does not include indirect costs.

## Grants Awarded in 2017

- ▶ Sandra Manzanares Laya, Prueba rápida de hepatitis C en hombres que tienen sexo con hombres: conocimientos, prevalencia e implicaciones para el cribado en VIH negativos. PI17/02077. Instituto de Salud Carlos III. Duration: 2018-2020. 32,200.00 €.

Note: Total amount granted to PI. It does not include indirect costs.

## Transfer Products

- ▶ Technological transfer product. Innovation in Epidemiology and Public Health. Project financed by GILEAD: Smartphone application for aging HIV-infected men who have sex with men to prevent sexually transmitted infections. Creation of an App for smartphones whose objective is to promote sexual health and provide knowledge about ITS among men who have sex with other men (MSM) who live with HIV through the use of messages with or without geolocation. 13/01/2016.
- ▶ Technological transfer product. Innovation in Epidemiology and Public Health. Use of applications for mobile telephony in the promotion of HIV testing and other sexually transmitted infections in men who have sex with men. Use of profiles in Apps of contacts such as Grindr or Gay Romeo to launch messages offering HIV and other ITS tests for free and confidential. These messages are launched individually or in mass campaigns. A cohort has been created for this initiative to carry out tests of ITS and HIV. 10/01/2016.

## Other Publications

- ▶ Maurino J, Molina-Pinargote IV, Forcada N, Gónzalez-Díaz Y, Montes M, Ruiz M, Montoro M, Maldonado J, Soteras J, Altet N, Millet JP. Tuberculosis multirresistente y diabetes mellitus: la confluencia de dos pandemias genera casos complicados. REV ENF EMERG 2017; 16(1): 36-39.
- ▶ González R, Montalvo T, Camprubí E, Fernández L, Millet JP, Peracho V, Gorriño P, Avellanés I, Romero A, Caylà JA. Confirmed Dengue, Chikungunya and Zika Cases during the Period 2014 to 2016 in Barcelona, Spain. REV ESP SALUD PÚBLICA. 2017 Mar 7;91. pii: e201701027.

**\*TIF: 145.99 \*\*MIF: 4.8663**

Alvarez-Del Arco D, Fakoya I, Thomadakis C, Pantazis N, Touloumi G, Gennotte A.-F., Zuur F, Barros H, Staehelin C, Gopel S, et al, High levels of postmigration HIV acquisition within nine European countries (2017) AIDS, 31 (14), 1979-1988.

**IF: 4.914**

Balbuena S.F., Hoyos J., Belza M.J., Pujol F., Alvarez J., Zulaica D., Zamora C., Rifa B., Garcia-de-Olalla P., Esteso R., et al, HIV Rapid Testing Programs in Non-Clinical Settings have the Potential to Constitute a Major Diagnostic Option for MSM in Spain (2017) AIDS BEHAV, 21 (2), 525-533.

**IF: 3.017**

Belknap R, Holland D, Feng P-J, Millet J-P, Cayla J.A., Martinson N.A., Wright A, Chen M.P., Moro R.N., Scott N.A., Arevalo B., Miro J.M., Villarino M.E., Weiner M., Borisov A.S., Self-administered versus directly observed once-weekly isoniazid and rifapentine treatment of latent tuberculosis infection (2017) ANN INTERN MED, 167 (10), 689-697.

**IF: 19.384**

Bothamley GH, Lange C, TBNET (Millet JP). Infection control, genetic assessment of drug resistance and drug susceptibility testing in the current management of multi-drug/extensively-resistant tuberculosis (M/XDR-TB) in Europe: A tuberculosis network European Trialsgroup (TBNET) study. Respir Med. 2017 Nov;132:68-75.

**IF: 3.230**

Bouton TC, Phillips PPJ, Mitnick CD, Peloquin CA, Eisenach K, Patientia RF, Lecca L, Gotuzzo E, Gandhi NR, Butler D, Diacon AH, Martel B, Santillan J, Hunt KR, Vargas D, von Groote-Bidlingmaier F, Seas C, Dianis N, Moreno-Martinez A, Horsburgh CR Jr. An optimized background regimen design to evaluate the contribution of levofloxacin to multidrug-resistant tuberculosis treatment regimens: study protocol for a randomized controlled trial. Trials. 2017 Nov;25(1):563.

**IF: 2.067**

Caminero J.A., Cayla J.A., Garcia-Garcia J.-M., Garcia-Perez F.J., Palacios J.J., Ruiz-Manzano J., Diagnóstico y tratamiento de la tuberculosis con resistencia a fármacos Diagnosis and Treatment of Drug-Resistant Tuberculosis (2017) ARCH BRONCONEUMOL, 53 (9), 501-509.

**IF: 2.633**

Caminero J.A., Cayla J.A., Garcia-Garcia J.-M., Garcia-Perez F.J., Palacios J.J., Ruiz-Manzano J., Diagnosis and Treatment of Drug-Resistant Tuberculosis Diagnóstico y tratamiento de la tuberculosis con resistencia a fármacos (2017) ARCH BRONCONEUMOL, 53 (9), 501-509.

**IF: 2.633**

Casals M, Finch CF. Sports Biostatistician: a critical member of all sports science and medicine teams for injury prevention. Inj Prev 2017;23(6):423-427.

**IF: 2.420**

Chereau F, Madec Y, Sabin C, Obel N, Ruiz-Mateos E, Chrysos G, Fidler S, Lehmann C, Zangerle R, Wittkop L, et al, Impact of CD4 and CD8 dynamics and viral rebounds on loss of virological control in HIV controllers (2017) PLOS ONE, 12 (4).

**IF: 2.766**

Dominguez A., Soldevila N., Toledo D., Godoy P., Espejo E., Fernandez M.A., Mayoral J.M., Castilla J., Egurrola M., Tamames S., et al, The effectiveness of influenza vaccination in preventing hospitalisations of elderly individuals in two influenza seasons: A multicentre case-control study, Spain, 2013/14 and 2014/15 (2017) EUROSURVEILLANCE, 22 (34).

**IF: 7.127**

Dominguez A., Soldevila N., Cayla J.A., Garcia-Cenoz M., Ferrus G., Sala-Farre M.R., Alvarez J., Carol M., Barrabeig I., Camps N., Coronas L., Munoz-Almagro C., Godoy P., Assessment of clinical symptoms in household contacts of confirmed pertussis cases (2017) J INFECTION, 75 (5), 426-432.

**IF: 4.603**

Dominguez A., Soldevila N., Toledo D., Torner N., Force L., Perez M.J., Martin V., Rodriguez-Rojas L., Astray J., Egurrola M., et al, Effectiveness of 23-valent pneumococcal polysaccharide vaccination in preventing community-acquired pneumonia hospitalization and severe outcomes in the elderly in Spain (2017) PLOS ONE, 12 (2).

**IF: 2.766**

Garcia-Goez J.F., Munera G.A., Rojas V., Pacheco R., Cayla J.A., Miro J.M., Tuberculosis in recipients of solid-organ transplants during 1995–2015 in Cali, Colombia (2017) INT J TUBERC LUNG D, 21 (11).

**IF: 2.392**

Garriga C., Manzanares-Laya S., Garcia De Olalla P., Gorriundo P., Lens S., Sola R., Martinez-Rebollar M., Laguno M., Navarro J., Torras X., Gurgui M., Barbera M.-J., Quer J., Masdeu E., Simon P., Ros M., De Andres A., Cayla J.A., Evolution of acute hepatitis C virus infection in a large European city: Trends and new patterns (2017) PLOS ONE, 12 (11).

**IF: 2.766**

Ghosn J, Bayan T, Meixenberger K, Tran L, Frange P, d'Arminio Monforte A, Zangerle R, de Mendoza C, Krastinova E, Porter K, Meyer L, Chaix ML; CASCADE Collaboration in Euro-Coord (García de Olalla P.). CD4 T cell decline following HIV seroconversion in individuals with and without CXCR4-tropic virus. J Anti-

microb Chemother. 2017 Oct 1;72(10):2862-2868.

**IF: 5.217**

Jimenez-Britez G., Freixa X., Flores-Umanzor E, San Antonio R., Caixal G., Garcia J., Hernandez-Enriquez M., Andrea R., Regueiro A., Masotti M., Brugaletta S., Martin V., Sabate M., Out-of-hospital cardiac arrest and stent thrombosis: Ticagrelor versus clopidogrel in patients with primary percutaneous coronary intervention under mild therapeutic hypothermia (2017) RESUSCITATION, 114, 141-145.

**IF: 5.683**

Kunst H, Burman M., Arnesen T.M., Fiebig L., Hergens M.-P., Kalkouni O., Klinkenberg E., Orcau A., Soini H., Sotgiu G., Zenner D., De Vries G., Tuberculosis and latent tuberculous infection screening of migrants in Europe: Comparative analysis of policies, surveillance systems and results (2017) INT J TUBERC LUNG D, 21 (8), 840-851.

**IF: 2.392**

Llimona P, Perez G., Rodriguez-Sanz M., Novoa A.M., Espelt A., Garcia de Olalla P., Borrell C., Infobarris: an interactive tool to monitor and disseminate information on health and its determinants in the neighbourhoods of Barcelona (Spain) Infobarris: una herramienta interactiva para monitorizar y divulgar información sobre la salud y sus determinantes en los barrios de Barcelona (2017) GAC SANIT, 31 (5), 427-431.

**IF: 1.581**

Meije Y., Martinez-Montauti J., Cayla J.A., Loureiro J., Ortega L., Clemente M., Sanz X., Ricart M., Santoma M.J., Coll P., Sierra M., Calsina M., Vaque M., Ruiz-Camps I., Lopez-Sanchez C., Montes M., Ayestaran A., Carratala J., Orcau A., Healthcare-Associated Mycobacterium bovis -Bacille Calmette-Guérin (BCG) Infection in Cancer Patients Without Prior BCG Instillation (2017) CLIN INFECT DIS, 65 (7), 1136-1143.

**IF: 9.117**

Millet JP, Montalvo T, Bueno-Marí R, Romero-Tamarit A, Prats-Uribe A, Fernández L, Camprubí E, Del Baño L, Perachón V, Figuerola J, Sulleiro E, Martínez MJ, Caylà JA; Zika Working Group in Barcelona. Imported Zika Virus in a European City: How to Prevent Local Transmission?. Front Microbiol. 2017 Jul 18;8:1319.

**IF: 4.019**

Nielsen R.O., Chapman C.M., Louis W.R., Stovitz S.D., Mansournia M.A., Windt J., Moller M., Parner E.T., Hulme A., Bertelsen M.L., Finch C.F., Casals M., Verhagen E., Seven sins when interpreting statistics in sports injury science (2017) BRIT J SPORT MED.

**IF: 7.867**

# Transmissible Diseases

\*TIF: 145.99 \*\*MIF: 4.8663

Novoa A.M., Perez G., Espelt A., Echave C., de Olalla P.G., Calvo M.J., Pasarin M., Diez E., Borrell C., Calvo M.J., Cormenzana B., Cortes I., Diez E., Echave C., Espelt A., de Olalla P.G., Gomez J., Novoa A.M., Pallares M., Perez G., Rodriguez-Sanz M., The Experience of Implementing Urban HEART Barcelona: a Tool for Action (2017) *J URBAN HEALTH*, 1-15.

**IF: 1.738**

Parron I., Planas C., Godoy P., Manzanares-Laya S., Martinez A., Sala M.R., Mingueu S., Torner N., Jane M., Dominguez A., Effectiveness of hepatitis A vaccination as post-exposure prophylaxis (2017) *HUM VACC IMMUNOTHER*, 13 (2), 423-427.

**IF: 2.229**

Rius C., Baselga E., Tizon J., Fuentes P., Muñoz-Garza F.Z., Roige G., Llebaria X., Cayla J.A., Investigation of a suspected outbreak of lipoatrophia semicircularis in children Investigación de una sospecha de brote de lipotrofia semicircular en niños (2017) *MED CLIN-BARCELONA*, 149 (3), 101-106.

**IF: 1.168**

Ruhwald M., Aggerbeck H., Gallardo R.V., Hoff So.T., Villate J.I., Borregaard B., Martinez

J.A., Kromann I., Penas A., Anibarro LL., de Souza-Galvao M.L., Sanchez F., Rodrigo-Pendas J.A., Noguera-Julian A., Martinez-Lacasa X., Tunez M.V., Fernandez V.L., Millet J.P., Moreno A., Cobos N., Miro J.M., Roldan L., Orcau A., Andersen P., Cayla J.A., Safety and efficacy of the C-Tb skin test to diagnose Mycobacterium tuberculosis infection, compared with an interferon  $\gamma$  release assay and the tuberculin skin test: a phase 3, double-blind, randomised, controlled trial (2017) *LANCET RESP MED*, 5 (4), 259-268.

**IF: 21.466**

Smolen-Dzirba J., Rosinska M., Janiec J., Beniowski M., Cycon M., Bratosiewicz-Wasik J., Wasik T.J., Kelleher T., Cooper D., Grey P., et al., HIV-1 infection in persons homozygous for CCR5-Δ32 allele: The next case and the review (2017) *AIDS REV*, 19 (4), 219-230.

**IF: 2.775**

Valencia S., León M., Losada I., Sequera VG., Fernández Quevedo M., García-Basteiro AL., How do we measure adherence to anti-tuberculosis treatment?. Expert Rev Anti Infect Ther. 2017 Feb;15(2):157-165.

**IF 3.141**

Valero N., De Simon M., Galles P., Izquierdo N., Arimon J., Gonzalez R., Manzanares-Laya S., Avellanes I., Gomez A., Street cleaning trucks as potential sources of *Legionella pneumophila* (2017) *EMERG INFECT DIS*, 23 (11), 1880-1882.

**IF: 7.422**

Vashakidze S., Despuig A., Gogishvili S., Nikolashvili K., Shubladze N., Avaliani Z., Tukvadze N., Casals M., Cayla J.A., Cardona P.-J., Vilaplana C., Retrospective study of clinical and lesion characteristics of patients undergoing surgical treatment for Pulmonary Tuberculosis in Georgia (2017) *INT J INFECT DIS*, 56, 200-207.

**IF: 3.202**

Vergara A., Pitart C., Montalvo T., Roca I., Sabaté S., Hurtado JC., Planell R., Marco F., Ramírez B., Perachó V., de Simón M., Vila J., Prevalence of Extended-Spectrum-β-Lac-amase and/or Carbapenemase-Producing *Escherichia coli* Isolated from Yellow-Legged Gulls from Barcelona, Spain. *Antimicrob Agents Chemother*. 2017 Jan 24;61(2). pii: e02071-16.

**IF 4.255**



# Health Inequalities



## Coordinator

Borrell Thió, Carme  
cborrell@aspb.cat

ASPB

## Members

Artazcoz Lazcano, Lucía	ASPB
Bartoll Roca, Xavier	ASPB
Cortés Franch, Immaculada	ASPB
Díez David, Elia	ASPB
Gotsens Miquel, Mercè	ASPB
Mari Dell'Olmo, Marc	ASPB
Oliveras Puig, Laura	IR
Palencia Fernández, Laia	ASPB
Pasarín Rua, María Isabel	ASPB
Pérez Albaracín, Gloria	ASPB
Rodríguez Sanz, Maica	ASPB
Salvador Peral, Joaquín	ASPB

## Main Lines of Research

### Social class and geographical inequalities in health

- ▶ Study of health inequalities according to social class in Spain and worldwide.
- ▶ Exploitation of information at the census section level as the maximum disaggregation unit and at higher geographic aggregation levels such as the neighbourhood, town and region.

### Gender Inequalities in Health

- ▶ Sexual division between productive and reproductive work (gender roles) and differences in male and female identities as the 2 main structural factors that generate gender inequalities in health.

### Social and Political Determinants of Health and Their Impact on Policy Building and Interventions

- ▶ Evidence of the macroeconomic determinants of health inequalities between countries.
- ▶ The impact of the political context on the health of the population and the conclusion that countries with better developed welfare states have better levels of health.

## Challenges

### Health-Inequalities According to Different Inequality Axes

- ▶ Study of social determinants of health in terms of social class and gender, with the purpose of integrating these 2 axes and analysing inequalities among immigrants.
- ▶ Research into the impact of area of residence, especially smaller urbanized areas, on the health of the population.

### Gender Inequalities in Health

- ▶ Further explore the theoretical framework and explanatory charts developed to guide comprehension of the gender determinants that affect health.

### Social and Political Determinants of Health and Their Impact on Policy Building and Interventions

- ▶ Study the influence of policies on the health of populations and on social inequalities in health.

### Sex and Reproductive Inequalities in Health

- ▶ Establish a line of research to investigate different aspects of sexual and reproductive health (sexuality, contraception, pregnancy, birth, miscarriage, abortion, birth rates, etc).

## Awards

- ▶ Best Dissertation Award in Epidemiology and Public Health 2017 of the Sociedad Española de Epidemiología. Natalia López. Evolution of socioeconomic inequalities in mortality due to suicides in Barcelona during the period 2006-2016 (directed by Mercè Gotsens).

## Transfer Products

- ▶ Pla d'acció sobre drogues 2017-2020 (Drug Action Plan 2017-2020). Available at: <http://www.aspb.cat/documents/pla-dacio-sobre-drogues-barcelona-2017-20/>
- ▶ Report "La salut a Barcelona 2016" (Health in Barcelona 2016). Available at: [https://www.aspb.cat/wp-content/uploads/2017/11/Informe\\_Salut\\_2016.pdf](https://www.aspb.cat/wp-content/uploads/2017/11/Informe_Salut_2016.pdf)
- ▶ Report "La salut i els seus determinants en l'alumnat adolescent de Barcelona. Enquesta de Factors de Risc en Estudiants de Secundària. FRESC 2016" (The health and

its determinants in the adolescent students of Barcelona. Survey of Risk Factors in Secondary Students. FRESC 2016). Available at: <http://www.aspb.cat/wp-content/uploads/2017/05/salut-i-els-seus-determinants-en-alumnat-adolescent-Barcelona-FRESC-2016.pdf>

## Collaborations

## Active Grants

**External Collaborations**

- ▶ Vlaamse Instelling Voor Technologisch Onderzoek N.V. (VITO), established in Boeretang 200, MOL 2400, Belgium.
- ▶ Meteotest Societe Cooperative (METEOTEST), established in FABRIKSTRASSE 14, BERN 3012, Switzerland.
- ▶ GISAT S.R.O. (GISAT), established in Milady Horakove 1523/57A, PRAHA 7 170 00, Czech Republic.
- ▶ Katholieke Universiteit Leuven (KU Leuven), established in Oude Markt 13, LEUVEN 3000, Belgium.
- ▶ Fundacion Privada Instituto de Salud Global Barcelona (ISGLOBAL) established in C Rosselló 132 planta 05, Barcelona 08036, Spain.
- ▶ Joanneum Research Forschungsgesellschaft MBH (JR), established in Leonhardstrasse 59, GRAZ 8010, Austria.
- ▶ T6 Ecosystems SRL (T6ECO), established in Via Genova 30, Roma 00184, Italy.
- ▶ ARCTIK SPRL (ARCTIK), established in Avenue Emile de Beco 12 bte 2/3, Bruxelles 1050, Belgium.
- ▶ STAD ANTWERPEN, established in GROTE MARKT 1, Antwerpen 2000, Belgium.
- ▶ Bikecityguide Apps GMBH (BikeCityGuide), established in Kinkgasse 7, GRAZ 8020, Austria.
- ▶ Soprintendenza Speciale Colosseo MNR e Area Archeologica Di Roma (SSColosseo), established in Piazza dei Cinquecento 67, Roma 00185, Italy.
- ▶ Ines Energieplanung GMBH (INES), established in Laupenstrasse 20, Bern 3008, Switzerland.
- ▶ IURS - Institut Pro Udrzitelny Rozvoj Sidel ZS (IURS), established in Bulharska 1424/25, Ostrava Poruba 708 00, Czech Republic.
- ▶ Universidade de Coimbra, 1290, established in Paco das Escolas, Coimbra 3001 451, Portugal.
- ▶ Department of Health (DH), -, established in Quarry House, Quarry Hill, Leeds LS2 7UE, United Kingdom.
- ▶ Universite Paris Ouest Nanterre La Defense (UPO), 199212044, established in 200 Avenue de la Republique, Nanterre CEDEX 92001, France.
- ▶ Instituto Superior Tecnico (IST), 931400, established in Avenida Rovisco Pais 1, Lisboa 1049-001, Portugal.
- ▶ Universiteit Maastricht, WHW Artikel 1.8 LID, established in Minderbroedersberg 4-6, Maastricht 6200 MD, Netherlands.
- ▶ University College London (UCL), RC000631, established in Gower Street, London WC1E 6BT, United Kingdom.
- ▶ Karolinska Institutet (KI), 2021002973, established in Nobels Vag 5, Stockholm 17177, Sweden.
- ▶ Beuth-Hochschule Fuer Technik Berlin, established in Luxemburger Strasse 10, Berlin 13353, Germany.
- ▶ Univerzita Karlova V Praze (Univerzita Karlova v Praze), 00216208, established in Ovocny trh 5, Praha 1 11636, Czech Republic.
- ▶ Ethniko Kai Kapodistriako Panepistimio Athinon (UoA), established in 6 Christou Lada STR, Athina 10561, Greece.
- ▶ Consorzio Per Il Sistema Informativo (CSI PIEMONTE) IT4, 538244/CF01995120019, established in Corso Unione Sovietica 216, Torino 10134, Italy.
- ▶ Ekonomicka Univerzita V Bratislave (EUBA), 00399957, established in Dolnozemská Cesta 1, Bratislava 85235, Slovakia.
- ▶ Vrije Universiteit Brussel (VUB), 449012406, established in Pleinlaan 2, Brussels 1050, Belgium.
- ▶ Universitat Pompeu Fabra. Departament de Polítiques Públiques i Departament de Ciències Experimentals i de la Salut. Barcelona. Spain.
- ▶ Departamento de Salud del Gobierno Vasco. Vitoria. Spain.
- ▶ Departamento de Salud de la Comunidad de Madrid. Madrid. Spain.
- ▶ Escuela Andaluza de Salud Pública. Granada. Spain.
- ▶ IGOB. Barcelona. Spain.
- ▶ Universidad de Antioquia. Medellín. Colombia.

- ▶ Maica Rodríguez Sanz. Evolución de las desigualdades socioeconómicas y medioambientales en la distribución geográfica de la mortalidad en Barcelona (1996-2015): MEDEA3. PI16/00961. Instituto de Salud Carlos III. Duration: 2017-2019. 27,000.00 €.
- ▶ Marc Marí Dell'Olmo. Pobreza energética y salud desde múltiples perspectivas: análisis individual, geográfico y temporal. PI15/02006. Instituto de Salud Carlos III. Duration: 2016-2018. 84,150.00 €.
- ▶ M. Isabel Pasarín. Evaluación de un proyecto de prevención integral de la obesidad infantil en la etapa pre-escolar en Barcelona (POIBA-2a fase). PI16/00701. Instituto de Salud Carlos III. Duration: 2016-2019. 80,465.00 €.
- ▶ Carme Borrell and Catherine Pérez. Participatory Urban Living for Sustainable Environments (PULSE) 727816. Comisión Europea H2020-EU.3.1.5 Duration: 2016-2019. 309,625.00 €.
- ▶ Marc Marí Dell'Olmo. Pan-european urban climate services (PUCS) 730004-2 Vlaamse Instelling Voor Technologisch (leading institution). Duration: 2017-2019. 2,936,600.63 €.

- ▶ Catherine Pérez González. Safety CaUsation, Benefits and Efficiency – SAFETYCUBE. 633485 Horizon 2020. European Commission. 120,000.00 €.
- ▶ Carme Borrell. WP2 - "Shaping EUROpean policies to promote HEALTH equitY" (Euro-Healthy) 643398. European Commission. Duration: 2014-2017. 268,777.00 €.
- ▶ Lucía Artazcoz. Estado de bienestar y salud: un análisis epidemiológico en base a una cohorte de afiliados a la seguridad social (EBISA). PI14/00057. Instituto de Salud Carlos III. Duration: 2014-2017. 84,095.00 €.
- ▶ Carme Borrell. Evaluación de efectos en salud del programa Treball als Barris. CB087541 RecerCaixa 2014. La Caixa. Duration: 2014-2017. 78,359,71 €.

Note: Total amount granted to PI. It does not include indirect costs.

# Health Inequalities

## Scientific Production

- \*TIF: 49.902 \*\*MIF: 1.9193**
- Abajo M., Rodriguez-Sanz M., Malmusi D., Salvador M., Borrell C., Gender and socio-economic inequalities in health and living conditions among co-resident informal caregivers: a nationwide survey in Spain (2017) *J ADV NURS*, 73 (3), 700-715.  
**IF: 2.267**
- Aguilar-Palacio I., Martinez-Beneito M.A., Rabanaque M.J., Borrell C., Cirera L., Daponte A., Dominguez-Berjon M.F., Gendarillas A., Gotsens M., Lorenzo-Ruano P., Mari-Dell'Olmo M., Nolasco A., Saez M., Sanchez-Villegas P., Saurina C., Martos C., Diabetes mellitus mortality in Spanish cities: Trends and geographical inequalities (2017) *PRIM CARE DIABETES*, 11 (5), 453-460.  
**IF: 1.7020**
- Borrell C., Mari-Dell'Olmo M., Gotsens M., Calvo M., Rodriguez-Sanz M., Bartoll X., Esnaola S., Socioeconomic inequalities in suicide mortality before and after the economic recession in Spain (2017) *BMC PUBLIC HEALTH*, 17 (1).  
**IF: 2.4200**
- Borrell C., Malmusi D., Muntaner C., Introduction to the "evaluating the Impact of Structural Policies on Health Inequalities and Their Social Determinants and Fostering Change" (SOPHIE) Project (2017) *INT J HEALTH SERV*, 47 (1), 10-17.  
**IF: 1.2920**
- Cabrera-Leon A., Daponte Codina A., Mateo I., Arroyo-Borrell E., Bartoll X., Bravo M.J., Dominguez-Berjon M.F., Renart G., Alvarez-Dardet C., Mari-Dell'Olmo M., Bolivar Munoz J., Saez M., Escriba-Aguir V., Palencia L., Lopez M.J., Saurina C., Puig V., Martin U., Gotsens M., Borrell C., Serra Saurina L., Sordo L., Bacigalupe A., Rodriguez-Sanz M., Perez G., Espelt A., Ruiz M., Bernal M., Contextual indicators to assess social determinants of health and the Spanish economic recession Indicadores contextuales para evaluar los determinantes sociales de la salud y la crisis económica española (2017) *GAC SANIT*, 31 (3), 194-203.  
**IF: 1.5810**
- Espelt A., Villalbi J.R., Bosque-Prous M., Pares-Badell O., Mari-Dell'Olmo M., Brugal M.T., The impact of harm reduction programs and police interventions on the number of syringes collected from public spaces. A time series analysis in Barcelona, 2004–2014 (2017) *INT J DRUG POLICY*, 50, 11-18.  
**IF: 3.4790**
- Julia M., Olle-Espluga L., Vanroelen C., De Moortel D., Mousaid S., Vinberg S., Puig-Barachina V., Sanchez E., Muntaner C., Artazcoz L., Benach J., Employment and Labor Market Results of the SOPHIE Project: Concepts, Analyses, and Policies (2017) *INT J HEALTH SERV*, 47 (1), 18-39.  
**IF: 1.1350**
- Kulhanova I., Menville G., Hoffmann R., Eikemo T.A., Kulik M.C., Toch-Marquardt M., Deboosere P., Leinsalu M., Lundberg O., Regidor E., et al., The role of three lifestyle risk factors in reducing educational differences in ischaemic heart disease mortality in Europe (2017) *EUR J PUBLIC HEALTH*, 27 (2), 203-210.  
**IF: 2.4310**
- Limona P., Perez G., Rodriguez-Sanz M., Novoa A.M., Espelt A., Garcia de Olalla P., Borrell C., Infobarris: an interactive tool to monitor and disseminate information on health and its determinants in the neighbourhoods of Barcelona (Spain) Infobarris: una herramienta interactiva para monitorizar y divulgar información sobre la salud y sus determinantes en los barrios de Barcelona (2017) *GAC SANIT*, 31 (5), 427-431.  
**IF: 1.5810**
- Lopez-Ruiz M., Benavides F.G., Vives A., Artazcoz L., Informal employment, unpaid care work, and health status in Spanish-speaking Central American countries: a gender-based approach (2017) *INT J PUBLIC HEALTH*, 62 (2), 209-218.  
**IF: 2.6170**
- Malmusi D., Palencia L., Ikram U.Z., Kunst A.E., Borrell C., Inequalities by immigrant status in depressive symptoms in Europe: the role of integration policy regimes (2017) *SOC PSYCH PSYCH EPID*, 52 (4), 391-398.  
**IF: 2.9180**
- Mari-Dell'Olmo M., Novoa A.M., Camprubi L., Peralta A., Vasquez-Vera H., Bosch J., Amat J., Diaz F., Palencia L., Mehdipanah R., Rodriguez-Sanz M., Malmusi D., Borrell C., Housing Policies and Health Inequalities (2017) *INT J HEALTH SERV*, 47 (2), 207-232.  
**IF: 1.2920**
- Marinacci C., Demaria M., Melis G., Borrell C., Corma D., Dell'Olmo M.M., Rodriguez M., Costa G., The Role of Contextual Socioeconomic Circumstances and Neighborhood Poverty Segregation on Mortality in 4 European Cities (2017) *INT J HEALTH SERV*, 47 (4), 636-654.  
**IF: 1.2920**
- Marin-Gonzalez E., Malmusi D., Camprubi L., Borrell C., The Role of Dissemination as a Fundamental Part of a Research Project: Lessons Learned from SOPHIE (2017) *INT J HEALTH SERV*, 47 (2), 258-276.  
**IF: 1.292**
- Merino-Salazar P., Artazcoz L., Cornelio C., Iñiguez M.J.I., Rojas M., Martinez-Ingido D., Vives A., Funcasta L., Benavides F.G., Work and health in Latin America: Results from the working conditions surveys of Colombia, Argentina, Chile, Central America and Uruguay (2017) *OCCUP ENVIRON MED*, 74 (6), 432-439.  
**IF: 3.9650**
- Novoa A.M., Amat J., Malmusi D., Diaz F., Darnell M., Trilla C., Bosch J., Borrell C., Changes in Health Following Housing Improvement in a Vulnerable Population in Spain (2017) *INT J HEALTH SERV*, 47 (1), 83-107.  
**IF: 1.2920**
- Novoa A.M., Perez G., Espelt A., Echave C., de Olalla P.G., Calvo M.J., Pasarin M., Diez E., Borrell C., Calvo M.J., Cormenzana B., Cortes I., Diez E., Echave C., Espelt A., de Olalla P.G., Gomez J., Novoa A.M., Pallares M., Perez G., Rodriguez-Sanz M., The Experience of Implementing Urban HEART Barcelona: a Tool for Action (2017) *J URBAN HEALTH*, 1-15.  
**IF: 1.7380**
- Ostergren O., Lundberg O., Artnik B., Bopp M., Borrell C., Kalediene R., Leinsalu M., Martikainen P., Regidor E., Rodriguez-Sanz M., De Gelder R., Mackenbach J.P., Educational expansion and inequalities in mortality — A fixed-effects analysis using longitudinal data from 18 European populations (2017) *PLOS ONE*, 12 (8).  
**IF: 2.7660**
- Palencia L., De Moortel D., Artazcoz L., Salvador-Piedrafita M., Puig-Barachina V., Hagqvist E., Perez G., Ruiz M.E., Trujillo-Aleman S., Vanroelen C., Malmusi D., Borrell C., Gender Policies and Gender Inequalities in Health in Europe: Results of the SOPHIE Project (2017) *INT J HEALTH SERV*, 47 (1), 61-82.  
**IF: 1.2920**
- Peralta A., Camprubi L., Rodriguez-Sanz M., Basagana X., Borrell C., Mari-Dell'Olmo M., Impact of energy efficiency interventions in public housing buildings on cold-related mortality: A case-crossover analysis (2017) *INT J EPIDEMIOL*, 46 (4), 1192-1201.  
**IF: 8.3600**
- Perez K., Olabarria M., Rojas-Rueda D., Santamarina-Rubio E., Borrell C., Nieuwenhuijsen M., The health and economic benefits of active transport policies in Barcelona (2017) *J TRANSP HEALTH*, 4, 316-324.  
**IF: 2.7740**
- Salvador-Piedrafita M., Malmusi D., Borrell C., Time trends in health inequalities due to care in the context of the Spanish Dependency Law Evolución de las desigualdades en salud debidas al cuidado en el contexto de la Ley de Dependencia española (2017) *GAC SANIT*, 31 (1), 11-17.  
**IF: 1.7680**

**Scientific Production****\*TIF: 49.902 \*\*MIF: 1.9193**

Salvador-Piedrafita M., Malmusi D., Mehdiapanah R., Rodriguez-Sanz M., Espelt A., Perez C., Solf E., Abajo Del Rincon M., Borrell C., Views on the Effects of the Spanish Dependency Law on Caregivers' Quality of Life Using Concept Mapping (2017) INT J HEALTH SERV, 47 (2), 233-257.

**IF: 1.2920**

Vasquez-Vera H., Palencia L., Magna I., Mena C., Neira J., Borrell C., The threat of home eviction and its effects on health through

the equity lens: A systematic review (2017) SOC SCI MED, 175, 199-208.

**IF: 3.0070**

Vazquez N., Molina M.C., Ramos P., Artazcoz L., Effectiveness of a parent-training program in Spain: Reducing the Southern European evaluation gap (2017) GAC SANIT.

**IF: 1.5810**

Villalbi J.R., Borrell C., Macia M., Subirana T., Lopez M.J., Portana S., Llebaria X., Casas C.,

Adapting the service portfolio of a public health organisation to shrinking resources Adaptación de los servicios de una organización de salud pública a la disminución de los recursos (2017) GAC SANIT, 31 (3), 242-245.

**IF: 1.5810**

# Epidemiology of Addictions



## Coordinator

Brugal Puig, Maria Teresa ASPB  
tbrugal@aspb.cat

## Members

Barbaglia Navarro, Gabriela	ASPB
Bartrolí Checa, Montse	ASPB
Bosque Prous, Marina	ASPB
Bruguera Guitart, Anna Maria	ASPB
Espelt Fernández, Albert	ASPB
Jiménez Dueñas, Miriam	ASPB
Moreno España, Jose	ASPB
Parés Badell, Oleguer	ASPB
Pérez Guitart, Aina	ASPB
Puertolas Gracia, Beatriz	ASPB
Puigcorbé Alcalà, Susanna	IR
Sanz Asín, Pedro	ASPB
Serrano Jordan, Jaime	ASPB
Vázquez Vázquez, José María	ASPB

## Main Lines of Research

### Epidemiology of Drug Consumption and Patterns of Use

- ▶ Estimating cocaine use incidence and consumption patterns.
- ▶ Estimating heroin incidence and consumption patterns.
- ▶ Estimating the prevalence of problematic cocaine, heroin and alcohol users.

### Health Problems Associated with Drug Use

- ▶ Quality of life and psychiatric comorbidity in cocaine users.
- ▶ Service use in cocaine and alcohol users.
- ▶ Factors associated with cocaine addict and alcoholic retention in treatment programmes.
- ▶ Violent behaviour and aggressive attitudes in young cocaine consumers.

## Challenges

### Epidemiology of Drug Consumption and Patterns of Use

- ▶ Determine incidence and patterns of cocaine use.
- ▶ Determine incidence and patterns of heroin use.
- ▶ Determine prevalence of cocaine, heroin and alcohol use.

### Health Problems Associated with Drug Use

- ▶ Analyse aggressive and violent attitudes and behaviour in young cocaine users.
- ▶ Assess quality of life in users with psychiatric comorbidity.
- ▶ Determine use of services among young heroin, cocaine and alcohol users.
- ▶ Analyse factors associated with retention in treatment programmes for cocaine and alcohol addiction.

## Collaborations

### Collaborations with other IIB Sant Pau Groups

- ▶ Evaluation of Public Health Policies and Programmes (PI: Carlos Ariza)
- ▶ Health Inequalities (PI: Carme Borrell)

- ▶ Mortality and its determinants in cohorts with substance abuse disorders (alcohol, heroin and cocaine).

- ▶ Factors associated with acute health problems developing after cocaine and heroin use.

- ▶ Social and health discrepancies between immigrants and native drug users.

### Health Policies

- ▶ Social inequalities in the evaluation of results and adherence to treatment.
- ▶ Infectious diseases related to drug use.
- ▶ Brief motivational intervention programs as a treatment alternative for teenage users of psychoactive substances.
- ▶ Role of the workplace in drug consumption.

### Health Policies

- ▶ Evaluate supervised drug consumption rooms and other policies to reduce harm.
- ▶ Study social inequalities in evaluating results and adherence to treatment.
- ▶ Evaluate brief motivational intervention programmes as an alternative to disciplinary measures in teenage users of psychoactive substances.

### External Collaborations

- ▶ Several CIBERSAM and CIBERESP groups.

## Active Grants

- Maria Teresa Brugal Puig. Evaluación del tratamiento en una cohorte de pacientes con trastorno por uso de alcohol y/o cocaína: Análisis del impacto de la Comorbilidad Psiquiátrica, Uso de Servicios y Análisis Costes. PI16/01075. Instituto de Salud Carlos III. Duration: 2017-2019. 66,500.00 €.
- Maria Teresa Brugal Puig. Red de Trastornos Adictivos. RD16/0017/0013. Instituto de Salud Carlos III. Duration: 2017-2021. 40,790.00 €.
- Albert Espelt Fernández. Disponibilidad, accesibilidad, visibilidad de consumo, promoción y publicidad del alcohol en el entorno urbano y su relación con el consumo de alcohol en adolescentes. 2016I029. Ministerio de Sanidad Servicios Sociales e Igualdad. Duration: 2017-2019. 37,000.00 €.
- Marina Bosque Prous. Disponibilidad, accesibilidad, visibilidad de consumo, promoción y publicidad del alcohol en el entorno urbano y su relación con el consumo de alcohol en adolescentes. 2016I029. Ministerio de Sanidad Servicios Sociales e Igualdad. Duration: 2017-2019. 37,000.00 €.
- Maria Teresa Brugal Puig. Estudio transversal y multicéntrico para el desarrollo de un modelo de predicción clínico y farmacogenético de la satisfacción del paciente dependiente de heroína con la metadona como un medicamento. SLT006/17/179. Generalitat de Catalunya. PERIS 2017. 170,627.11 €.

Note: Total amount granted to PI. It does not include indirect costs.

**\*TIF: 91.876 \*\*MIF: 3.0625**

Alonso I, Vallejo F, Regidor E, Belza MJ, Sordo L, Otero-García L, Barrio G. Changes in directly alcohol-attributable mortality during the great recession by employment status in Spain: a population cohort of 22 million people. *J Epidemiol Community Health.* 2017 Aug;71(8):736-744.

**IF: 3.973**

Arribas-Ibar E, Suelves JM, Sanchez-Niubò A, Domingo-Salvany A, Brugal MT. Suicidal behaviours in male and female users of illicit drugs recruited in drug treatment facilities. *Gac Sanit.* 2017 Jul - Aug; 31(4): 292-298.

**IF: 1.581**

Bosque-Prous M., Brugal M.T., Lima K.C., Vilalbi J.R., Bartrolí M., Espelt A., Hazardous drinking in people aged 50 years or older: a cross-sectional picture of Europe, 2011–2013 (2017) *INT J GERIATR PSYCH,* 32 (8), 817-828.

**IF: 2.940**

Bosque-Prous M., Kunst A.E., Brugal M.T., Espelt A., Changes in alcohol consumption in the 50- to 64-yearold European economically active population during an economic crisis (2017) *EUR J PUBLIC HEALTH,* 27 (4), 711-716.

**IF: 2.940**

Bosque-Prous M., Kuipers M.A.G., Espelt A., Richter M., Rimpela A., Perelman J., Federico B., Brugal M.T., Lorant V., Kunst A.E., Adolescent alcohol use and parental and adolescent socioeconomic position in six European cities (2017) *BMC PUBLIC HEALTH,* 17 (1).

**IF: 2.420**

Cabrera-Leon A., Daponte Codina A., Mateo I., Arroyo-Borrell E., Bartoll X., Bravo M.J., Dominguez-Berjon M.F., Renart G., Alvarez-Dardet C., Mari-Dell'Olmo M., Bolivar Munoz J., Saez M., Escriba-Aguir V., Palencia L., Lopez M.J., Saurina C., Puig V., Martin U., Gotsens M., Borrell C., Serra Saurina L., Sordo L., Bacigalupe A., Rodriguez-Sanz M., Perez G., Espelt A., Ruiz M., Bernal M., Contextual indicators to assess social determinants of

health and the Spanish economic recession Indicadores contextuales para evaluar los determinantes sociales de la salud y la crisis económica española (2017) *GAC SANIT,* 31 (3), 194-203.

**IF: 1.581**

Continente X., Perez A., Espelt A., Lopez M.J., Media devices, family relationships and sleep patterns among adolescents in an urban area (2017) *SLEEP MED,* 32, 28-35.

**IF: 3.395**

Continente X., Perez A., Espelt A., Ariza C., Lopez M.J., Multiple lifestyle risk behaviours and excess weight among adolescents in Barcelona, Spain Múltiples conductas de riesgo y exceso de peso en adolescentes de Barcelona, España (2017) *GAC SANIT,* 31 (4), 332-335.

**IF: 1.581**

Domingo-Salvany A., Herrero MJ., Fernandez B., Perez J., Del Real P., González-Luque JC., de la Torre R. Prevalence of psychoactive substances, alcohol and illicit drugs, in Spanish drivers: A roadside study in 2015. *Forensic Sci Int.* 2017 Sep;278:253-259.

**IF: 1.974**

Espelt A., Mari-Dell'olmo M., Penelo E., Bosque-Prous M., Applied prevalence ratio estimation with different regression models: An example from a cross-national study on substance use research Estimación de la Razón de Prevalencia con distintos modelos de Regresión: Ejemplo de un estudio internacional en investigación de las adicciones (2017) *ADICCIONES,* 29 (2), 105-112.

**IF: 2.021**

Espelt A., Villalbi J.R., Bosque-Prous M., Pares-Badell O., Mari-Dell'Olmo M., Brugal M.T., The impact of harm reduction programs and police interventions on the number of syringes collected from public spaces. A time series analysis in Barcelona, 2004–2014 (2017) *INT J DRUG POLICY,* 50, 11-18.

**IF: 4.244**

Espelt A., Bosque-Prous M., Folch C., Sarasá-Renedo A., Majo X., Casabona J., Brugal M.T., Esteve A., Montoliu A., Munoz R., Gonzalez V., Ausina V., Vecino C., Colom J., Moreno M., Altabas A., Is systematic training in opioid overdose prevention effective? (2017) *PLOS ONE,* 12 (10).

**IF: 2.766**

Fuentes S., Bilal U., Galan I., Villalbi J.R., Espelt A., Bosque-Prous M., Franco M., Lazo M., Binge drinking and well-being in European older adults: Do gender and region matter? (2017) *EUR J PUBLIC HEALTH,* 27 (4), 692-699.

**IF: 2.782**

Herrero MJ., Domingo-Salvany A., de la Torre R. Data from roadside screening for psychoactive substances, alcohol and illicit drugs, among Spanish drivers in 2015. *DATA BRIEF.* 2017 Sep 20; 15: 160-162.

León-Gómez BB., Colell E., Villalbí JR., Barrio G., Domingo-Salvany A. Impact of smoke-free regulations on smoking prevalence trends in Spain. *EUR J PUBLIC HEALTH.* 2017 Feb 1; 27(1): 123-128.

**IF: 2.782**

Llimona P., Perez G., Rodriguez-Sanz M., Novoa A.M., Espelt A., Garcia de Olalla P., Borrell C., Infobarris: an interactive tool to monitor and disseminate information on health and its determinants in the neighbourhoods of Barcelona (Spain) Infobarris: una herramienta interactiva para monitorizar y divulgar información sobre la salud y sus determinantes en los barrios de Barcelona (2017) *GAC SANIT,* 31 (5), 427-431.

**IF: 1.581**

Lopez M.J., Continente X., Sanchez E., Bartrolí M., Activities using websites and social networks: tools and indicators for evaluation Intervenciones que incluyen webs y redes sociales: herramientas e indicadores para su evaluación (2017) *GAC SANIT,* 31 (4), 346-348.

**IF: 1.581**

## Scientific Production

# Epidemiology of Addictions

## Scientific Production

\*TIF: 91.876 \*\*MIF: 3.0625

Martín-Rodríguez MDM, Pulido J, Jiménez-Mejías E, Hoyos J, Lardelli-Claret P, Barrio G. Consistent association between hypnotics/sedatives and non-traffic injuries. Results from a national household survey. ACCID ANAL PREV. 2017 Sep; 106: 379-384.

**IF: 2.571**

Molist G, Brugal MT, Barrio G, Messías B, Bosque-Prous M, Parés-Badell O, de la Fuente L; Spanish Working Group for the Study of Mortality among Drug Users. Effect of ageing and time since first heroin and cocaine use on mortality from external and natural causes in a Spanish cohort of drug users. INT J DRUG POLICY. 2017 Dec 18;53:8-16.

**IF: 4.244**

Novoa A.M., Perez G., Espelt A., Echave C., de Olalla P.G., Calvo M.J., Pasarin M., Diez E., Borrell C., Calvo M.J., Cormenzana B., Cortes I., Diez E., Echave C., Espelt A., de Olalla P.G., Gomez J., Novoa A.M., Pallares M., Perez G., Rodriguez-Sanz M., The Experience of Implementing Urban HEART Barcelona: a Tool for Action (2017) J URBAN HEALTH, 1-15.

**IF: 1.738**

O'Brien KS, Forrest W, Greenlees I, Rhind D, Jowett S, Pinsky I, Espelt A, Bosque-Prous M, Sonderlund AL, Vergani M, Iqbal M. Alcohol consumption, masculinity, and alcohol-related violence and anti-social behaviour in sportspeople. J SCI MED SPORT. 2017 Jul 4. pii: S1440-2440(17)30936-2.

**IF: 3.929**

Pares-Badell O., Espelt A., Folch C., Majo X., Gonzalez V., Casabona J., Brugal M.T., Undiagnosed HIV and Hepatitis C infection in people who inject drugs: From new evidence to better practice (2017) J SUBST ABUSE TREAT, 77, 13-20.

**IF: 2.602**

Pernambuco L., Espelt A., Costa de Lima K., Screening for Voice Disorders in Older Adults (RAVI)—Part III: Cutoff Score and Clinical Consistency (2017) J VOICE, 31 (1), 117.e17-117.e22.

**IF: 1.3810**

Pernambuco L., Espelt A., Gois A.C.B., de Lima K.C., Voice Disorders in Older Adults Living in Nursing Homes: Prevalence and Associated Factors (2017) J VOICE, 31 (4), 510.e15-510.e21.

**IF: 1.3810**

Pulido J, Vallejo F, Alonso-López I, Regidor E, Villar F, de la Fuente L, Domingo-Salvany A, Barrio G. Directly alcohol-attributable mortality by industry and occupation in a Spanish Census cohort of economically active population. DRUG ALCOHOL DEPEND. 2017 Nov 1; 180: 93-102.

**IF: 3.322**

Ruiz-Trasserra A., Perez A., Continente X., O'Brien K., Bartroli M., Teixido-Compano E., Espelt A., Patterns of physical activity and associated factors among teenagers from Barcelona (Spain) in 2012 Los patrones de actividad física y sus factores asociados en

adolescentes de Barcelona en 2012 (2017) GAC SANIT, 31 (6), 485-491.

**IF: 1.581**

Salvador-Piedrafita M., Malmusi D., Mehdiapanah R., Rodriguez-Sanz M., Espelt A., Perez C., Solf E., Abajo Del Rincon M., Borrell C., Views on the Effects of the Spanish Dependency Law on Caregivers' Quality of Life Using Concept Mapping (2017) INT J HEALTH SERV, 47 (2), 233-257.

**IF: 1.292**

Sordo L, Barrio G, Bravo MJ, Indave BI, Degehardt L, Wiessing L, Ferri M, Pastor-Barriuso R. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017 Apr 26;357:j1550.

**IF: 23.259**

Sureda X, Villalbi J.R., Espelt A., Franco M., Living under the influence: normalisation of alcohol consumption in our cities Bajo la influencia del alcohol: la normalización de su consumo en nuestras ciudades (2017) GAC SANIT, 31 (1), 66-68.

**IF: 2.413**

Torrens M, Mestre-Pintó JI, Montanari L, Vicente J, Domingo-Salvany A. Dual diagnosis: an European perspective. ADICCIONES. 2017 Jan 1;29(1):3-5.

**FI 2.021**



# Primary Care Research



## Coordinator

Brotons Cuixart,  
Carles EAP Sardenya  
cbrotons@eapsardenya.cat

## Members

Aguado Jodar, María Alba	External*
Agustí Roca, Berta	EAP**
Balaguer Galito, Enriqueta	EAP**
Blasi Codinach, Anna	External*
Cabriano Canga, Lorena	IR
Casasa Plana, Albert	EAP**
Coderch Aris, Marta	EAP**
Cuixart Costa, Lluís	External*
De la Figuera Von	
Wichmann, Mariano	EAP**
Delgado Álvarez, Beatriz	EAP**
Fernández Valverde,	
Diana Elizabeth	IR
Fuentes García, Rubén	IR
Galán Díez, María Luisa	EAP**
Gallego Francisco, Rut	EAP**
Gil Calvo, Joan Josep	External*
Ichazo Tobella, Begoña	EAP**
Jiménez Muñoz, Beatriz	External*
Martí Braso, Agnes	External*
Martínez Gil, Mireia	EAP**
Monteserín Nadal, Rosa	EAP**
Moral Peláez, Irene	EAP**
Muñoz Pena, Aser	EAP**
Palasi Bargallo, Carme	EAP**
Pedro Pijoan, Anna Maria	External*
Peix Sambola, Maria Amor	EAP**
Puig Palma, Mireia	EAP**
Rayo Martínez, Elisabet	EAP**
Rivero Morcillo, Ana Belén	IR
Sellarès Sallas, Jaume	EAP**
Serrano Pons, Helena	EAP**
Verdú Arnal, Montserrat	External*
Vila García, Judit	EAP**

\* External entity

\*\* EAP Sardenya

## Main Lines of Research

- ▶ Cardiovascular disease prevention in primary care.
- ▶ Diabetes.
- ▶ Health promotion in primary care.
- ▶ Immunization.
- ▶ Ageing.
- ▶ Hypertension.

## Challenges

- ▶ Cooperate with other research teams of the IIB Sant Pau.
- ▶ Cooperate with other European institutions in implementing projects on risk prevention and health promotion in primary care.
- ▶ Encourage research into medical ethics in family medicine training.

## Collaborations

### Collaborations with other IIB Sant Pau Groups

- ▶ Clinical Epidemiology and Health Care Services.
- ▶ Ageing Institute.
- ▶ Lipids and Cardiovascular Pathology Research, Sant Pau Hospital.
- ▶ Molecular Biology Laboratory, Fundació Puigvert.
- ▶ Agency of Public Health of Barcelona.

### External Collaborations

- ▶ Ibermutuamur, a nationwide mutual company of workplace accidents that collaborates with the social security.

## Active Grants

- ▶ Carles Brotons Cuixart. Desarrollo de una ecuación de riesgo cardiovascular de por vida en población laboral. PI14/01177. Instituto de Salud Carlos III. Duration: 2015-2017. 45,500.00 €.
- ▶ Carles Brotons Cuixart. Performance of the SCORE (Systematic Coronary Risk Evaluation) model for European low risk countries and the new US American College of Cardiology (ACC)/American Heart Association (AHA) Risk Equation in a Spanish Cohort:

the VALID study. MARATO 20150310. Fundació La Marató de TV3. Duration: 2016-2019. 92,300.00 €.

- ▶ Carles Brotons Cuixart. Evaluació del risc cardiovascular en la gen gran. PREMI MUTUAM CONVIURE 2015. Fundació Mutuam Conviure. Duration: 2015-2017. 6,000.00 €.

Note: Total amount granted to PI. It does not include indirect costs.

## Books or chapters with ISBN

- ▶ Brotons C. 100 Preguntas clave en Cardiolipidología. In: Zamorano JL. Capítulo: Dieta y ejercicio. ISBN 978-84-17221-17-1.

- ▶ Carles Brotons Cuixart. Ensayo clínico multicéntrico, aleatorizado y abierto, para evaluar la eficacia en la reducción del riesgo cardiovascular de una intervención dirigida a mejorar la información a los pacientes con riesgo cardiovascular alto. Estudio INFORISK. SLT002/16/00313. Departament de Salut. Duration: 2017-2019. 93,831.62 €.
- ▶ Mariano de la Figuera Von Wichmann. Prueba piloto de un programa de cribado poblacional de aneurisma de aorta abdominal realizada en atención primaria mediante ecografía. SLT002/16/00441. Departament de Salut. Duration: 2017-2019. 52,737.31 €.
- ▶ Diana Elizabeth Fernández Valverde, Evaluació de l'eficàcia de la telemedicina en la insuficiència cardíaca: programa @tendidos. ACADEMIA 2017. Acadèmia de Ciències Mèdiques. Duration: 2017-2019. 22,727.27 €.
- ▶ Carles Brotons Cuixart. Ensayo clínico multicéntrico, aleatorizado y abierto, para evaluar la eficacia en la reducción del riesgo cardiovascular de una intervención dirigida a mejorar la información a los pacientes con riesgo cardiovascular alto. Estudio INFORISK. SLT002/16/00313-01. Departament de Salut. Duration: 2017-2019. 46,034.03 €.
- ▶ Mariano de la Figuera Von Wichmann. Prueba piloto de un programa de cribado poblacional de aneurisma de aorta abdominal realizada en atención primaria mediante ecografía. SLT002/16/00441-01. Departament de Salut. Duration: 2017-2019. 61,591.76 €.
- ▶ Carles Brotons Cuixart. Validación externa de una ecuación de riesgo cardiovascular de por vida. PI17/01031. Instituto de Salud Carlos III. Duration: 2018-2020. 41.000,00 €.

Note: Total amount granted to PI. It does not include indirect costs.

### \*TIF: 32.221 \*\*MIF: 2.6851

Aguilà Q, Ramón MÀ, Matesanz S, Vilatimò R, Del Moral I, Brotons C, Ulied À. Assessment study of the nutritional status, eating habits and physical activity of the schooled population of Centelles, Hostalets de Balenyà and Sant Martí de Centelles (ALIN 2014 Study). ENDOCRINOL DIABETES NUTR 2017 Mar;64(3):138-145.

**IF: 1.268**

Brotons Cuixart C., Lobos Bejarano J.M., New European guidelines for cardiovascular prevention and its Spanish adaptation Nuevas guías europeas de prevención cardiovascular y su adaptación española (2017) ATEN PRIM, 49 (4), 201-203.

**IF: 1.1480**

Brotons C, Moral I, Fernández D, Cuixart L, Muñoz A, Soteras A, Puig M, Joaniquet X, Casasa A. Erratum to "Clinical consequences of using the new cardiovascular risk tables SCORE OP in patients aged over 65 years". MED CLIN (BARC). 2017 Mar 3;148(5):241.

**IF: 1.1680**

Calvo-Bonacho E., Catalina-Romero C., Cabrera M., Fernandez-Labandera C., Sanchez Chaparro M.A., Brotons C., Ruilope L.M., Association Between Improvement in Cardiovascular Risk Profile and Changes in Sickness Absence: Results of the ICARIA Study Asociación entre la mejora en el perfil de riesgo cardiovascular y los cambios en la incapacidad temporal: resultados del estudio ICARIA (2017) REV ESP CARDIOL, 70 (11), 941-951.

**IF: 5.1660**

Coll-Planas L, del Valle Gomez G., Bonilla P., Masat T, Puig T, Monteserín R, Promoting social capital to alleviate loneliness and improve health among older people in Spain (2017) HEALTH SOC CARE COMM, 25 (1), 145-157.

**IF: 2.0390**

Coll-Planas L, Monteserín R, Cob E, Blancafort S. What are primary health care teams doing about loneliness?. Fundació Salut i Enveliment-Universitat Autònoma de Barcelona i EAP Sardenya-Barcelona. ATEN PRIMARIA. 2017 Oct; 49(8): 501-502.

**IF: 1.148**

Coll-Planas L, Nyqvist F, Puig T, Urrutia G., Sola I., Monteserín R., Social capital interventions targeting older people and their impact on health: A systematic review (2017) J EPIDEMIOL COMMUN H, 71 (7), 663-672.

**IF: 3.9730**

Godycki-Cwirko M., Panasiuk L, Brotons C., Bulc M., Zakowska I., Perception of preventive care and readiness for lifestyle change in rural and urban patients in poland: A questionnaire study (2017) ANN AGR ENV MED, 24 (4), 732-738.

**IF: 1.1160**

Marquez-Contreras E., Martell-Claros N., Gil-Guillen V., De la Figuera-Von Wichmann M., Sanchez-Lopez E., Gil-Gil I., Marquez-Rivero S., Quality of life with rivaroxaban in patients with non-valvular atrial fibrillation by therapeutic compliance (2017) QUAL LIFE RES, 26 (3), 647-654.

**IF: 2.3920**

Rehm J., Anderson P., Prieto J.A.A., Armstrong I., Aubin H.-J., Bachmann M., Bastus N.B., Brotons C., Burton R., Cardoso M., Colom J., Duprez D., Gmel G., Gual A., Kraus L., Kreutz R., Liira H., Manthey J., Moller L., Okruhlicka L., Roerecke M., Scafato E., Schulte B., Segura-Garcia L., Shield K.D., Sierra C., Vyshinskiy K., Wojnar M., Zarco J., Towards new recommendations to reduce the burden of alcohol-induced hypertension in the European Union (2017) BMC MED, 15 (1).

**IF: 9.0880**

Royo-Bordonada M.A., Armario P., Lobos Bejarano J.M., Pedro-Botet J., Villar Alvarez F., Elosua R., Brotons Cuixart C., Cortes O., Serrano B., Camafont Babkowski M., Gil Nunez A., Perez A., Maiques A., de Santiago Nocito A., Castro A., Alegria E., Baeza C., Herranz M., Sans S., Campos P., Spanish adaptation of the 2016 European Guidelines on cardiovascular disease prevention in clinical practice Adaptación española de las guías europeas de 2016 sobre prevención de la enfermedad cardiovascular en la práctica clínica (2017) GAC SANIT, 31 (3), 255-268.

**IF: 1.5810**


Ruiz Morilla M.D., Sans M., Casasa A., Gimenez N., Implementing technology in healthcare: Insights from physicians (2017) BMC MED INFORM DECIS, 17 (1).

**IF: 2.1340**

# Primary Care Research

## Other Publications

- ▶ Cabellos Sánchez A, Madueño Garro C, Campos Lizcano AM, Aguado Jodar A. Diario comunitario: ¿Qué actividades comunitarias se realizan en nueve centros de Atención Primaria? EL METGE DIGITAL 10 May 2017.
- ▶ F. López-Simarro, I. Moral, A. Aguado-Jodar, C. Cols-Sagarra, J. Mancera-Romero, Alonso-Fernández, S. Miravet-Jiménez, y C. Brotons. The impact of therapeutic inertia and the degree of the medication adherence on the control goals for patients with diabetes. SEMERGEN 2017 Nov 21. pii: S1138-3593(17)30301-5.
- ▶ Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney MT, Corrà U, Cosyns B, Deaton C, Graham I, Hall MS, Hobbs FDR, Løchen ML, Löllgen H, Marques-Vidal P, Perk J, Prescott E, Redon J, Richter DJ, Sattar N, Smulders Y, Tiberi M, van der Worp HB, van Dis I, Verschuren WMM. 2016 European guidelines on cardiovascular disease prevention in clinical practice. The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts. Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation]. G ITAL CARDIOL (ROME). 2017 Jul-Aug;18(7):547-612.



AREA T2

# Molecular, Genomic Kinetic-Dynamic Bases and their Treatment

**224** Genomics of Complex Diseases

**226** Molecular Bases of Disease

**228** Pharmacokinetic/Pharmacodynamic Modelling and Simulation

**230** Generation of Advanced Therapy Medicines

**232** Regenerative Medicine & Tissue Bioengineering

# ic, Cellular and ases for Diseases

## nt



# Genomics of Complex Diseases



## Coordinator

Soria Fernández, José Manuel IR  
jsoria@santpau.cat

## Members

Cárdenas Yebra, Antonio	IR
López Moreno, Sonia	IR
Martín Fernández, Laura	IR- external
Martínez Pérez, Ángel	IR
Muñoz Lozano, Concepción	IR
Rodríguez Rius, Alba	IR
Vázquez Santiago, Miguel	IR

## Main Lines of Research

### Complex Diseases and Epigenomics

#### Thrombosis Research:

- ▶ GAIT Project: Genetic Analysis of Idiopathic Thrombophilia
- ▶ RETROVE Project: Risk of Venous Thromboembolic Disease
- ▶ GOLIATH Project: Epigenomics of thrombosis

#### Research on Thrombosis and Cancer:

- ▶ OncoThromb Project: New biomarkers in Thrombosis and Cancer
- ▶ MIRTO Project: Modeling the Individual Risk of Thrombosis in Oncology

#### Osteoporosis: GAO Project

#### Aortic aneurysms: TAGA Project

### Chronic Obstructive Disease: GEPOC Project

### Genomics in Sports Medicine

#### Performance, effort and recovery:

- ▶ SUMMIT Project (Health in sport and its limits): Marathons and Ultras

#### Exposure to hypoxia in extreme environments:

- ▶ SHERPA\_Everest'2017 Project

### Bioinformatics

#### Analysis of data - patients of complex diseases:

- ▶ Salambó Project: Bioinformatics Platform

## Challenges

- ▶ Analysis of Omics data (Genomics, transcriptomics, epigenomics) in the field of complex diseases with transversal and translational approach in cooperation with clinical groups.
- ▶ Identify new biomarkers (genetic, epigenetic and/or plasmatic) that determine the susceptibility to complex diseases.
- ▶ Identify new mechanisms involved in the development and progression of complex diseases.

- ▶ Development of predictive algorithms that integrate the genetic, biological and clinical information of the patients (Personalized Medicine).

The achievement of these objectives will directly affect the improvement of Diagnosis, Prognosis, Prevention and Treatment of diseases with complex genetic basis.

## Active Grants

- ▶ José Manuel Soria Fernández, Sonia López Moreno. Identificación de Mecanismos de Regulación de la Expresión Génica (microRNAs) en la Enfermedad Tromboembólica Venosa. PI14/00582. Instituto de Salud Carlos III. Duration: 2015-2018. 111,500.00 €.
- ▶ José Manuel Soria Fernández. Modeling the Individual Risk of Thrombosis in Oncology (MIRTO). ESC 2015. European Society of Cardiology. Duration: 2016-2017. 268,253.00 €.

- ▶ José Manuel Soria Fernández. Unitat de Genòmica de Malalties Complexes. IR16-P5. Fundació Privada Hospital de la Santa Creu i Sant Pau. Duration: 2017. 7,000.00 €.

Note: Total amount granted to PI. It does not include indirect costs.

## Theses

- ▶ Laura Martín Fernández. Determinantes Genéticos de la Vía Intrínseca de la Coagulación. Universitat de Barcelona. Dr. José Manuel Soria Fernández. Date of defense: 13/06/2017.

## Patents

- ▶ Eduardo Salas, Andrés Muñoz, José Manuel Soria. Cancer-associated venous thromboembolic events. Application number: EP17382297.4, UE. 10/01/2017.

## Collaborations

**Collaborations with other IIB Sant Pau Groups**

- ▶ Thrombosis and Haemostasis, Dr. JC. Souto: GAIT, MIRTO, RETROVE Projects.
- ▶ Internal Medicine, Dr. J. Casademont: GAO Project.
- ▶ Angiology, Vascular Biology and Inflammation, Dr. JR. Escudero, Dra. M. Camacho: TAGA, GAIT Projects.
- ▶ Neurology, Dr. J. Martí: MIRTO Project.
- ▶ Medical Oncology, Dr. Barnadas: MIRTO Project.
- ▶ Clinical Hematology, Dr. J. Sierra: MIRTO Project.
- ▶ Neumology, Dr. O. Sibila: SUMMIT, SHERPA Projects

**External Collaborations**

- ▶ Clinical Oncology Department, Hospital Gregorio Marañón, Madrid, Dr. A. Muñoz: ONCOTHROMB Project.
- ▶ Centre de Recerca en Enginyeria Biomèdica, Universitat Politècnica de Catalunya, Barcelona, Dr. A. Perera: SUMMIT Project.
- ▶ Laboratory Haematology, Hospital Timone Marseille, France, Dr. P. Morange: GAIT, VEREMA Projects.

- ▶ Department of Genetic, University of Genève, Switzerland, Dr. M. Dermitzakis and Dr Ana Viñuela: GAIT Project.
- ▶ Department of Cardiology, Karolinska Institut, Sweden, Dra. M. Sabater: GAIT Project.
- ▶ INSERM UMR\_S1219 - Bordeaux Public Health Center. Bordeaux, France. Dr. DA. Tregouet: GAIT, VEREMA Projects.
- ▶ Haematology Department, Karolinska Hospital, Sweden, Dr. J. Odeberg: VEREMA Project.
- ▶ Institute of Biological Psychiatry, Sankt Hans Hospital. Roskilde, Denmark, Dr. A. Buil: Bioinformatics of Complex diseases, GAIT Project.
- ▶ Department of Internal Medicine. Clinical Department of Hematology and Hemostasis. University of Wien, Austria. Dra. Ingrid Pabinger. OncoThromb, MIRTO Projects.
- ▶ Ferrer Incode. Development of Genetic Diagnostics in Thrombosis.
- ▶ Leo-Pharma. Prediction of Thrombosis Risk in cancer patients.
- ▶ STAGO. Development of New Biomarkers in Thrombosis.
- ▶ Boehringer Ingelheim. Modeling the Individual Risk of Thrombosis in Oncology (MIRTO).

## Grants Awarded in 2017

- ▶ Alba Rodríguez Rius. Identificación de Mecanismos de Regulación de la Expresión Génica (microRNAs) en la Enfermedad Tromboembólica Venosa. 2017 FI\_B 00673. Agència de Gestió d'Ajuts Universitaris i de Recerca. Duration: 2017-2020. 40,806.00 €.
- ▶ José Manuel Soria Fernández. Exposición a la hipoxia ambiental extrema y su efecto sobre la respuesta inflamatoria y cardiopulmonar: Impacto biológico, genético y clínico. SHERPA EVEREST 2017. Fundació Bancària Caixa d'Estalvis i Pensions. Duration: 2017-2018. 97,000.00 €.
- ▶ José Manuel Soria Fernández. Validación del Proyecto MIRTO (Modeling the Individual Risk of Thrombosis in Oncology).

PI17/00059. Instituto de Salud Carlos III. Duration: 2018-2020. 112,000.00 €.

- ▶ Maria Sabater Lleal. Identification of novel biomarkers and genetic pathways involved in Abdominal Aortic Aneurysm. CP17/00142(P). Instituto de Salud Carlos III. Duration: 2018-2020. 99,000.00 €.
- ▶ Maria Sabater Lleal. Contratos de investigadores Miguel Servet tipo I 2017. CP17/00142. Instituto de Salud Carlos III. Duration: 2018-2023. 202,500.00 €.

Note: Total amount granted to PI. It does not include indirect costs.

**\*TIF: 15.981 \*\*MIF: 3.1962**

Esteban J., de la Morena-Barrio M.E., Sal-loum-Asfar S., Padilla J., Minano A., Roldan V., Soria J.M., Vidal F., Corral J., Vicente V., High incidence of FXI deficiency in a Spanish town caused by 11 different mutations and the first duplication of F11: Results from the Yecla study (2017) HAEMOPHILIA, 23 (6), e488-e496.

**IF: 2.768**

Maqueda M., Roca E., Brotons D., Soria J.M., Perera A., Affected pathways and transcriptional regulators in gene expression response to an ultra-marathon trail: Global and independent activity approaches (2017) PLOS ONE, 12 (10): e0180322, e0180322, eCollection 2017.

**IF: 2.766**

Martin-Fernandez L., Gavidia-Bovadilla G., Corrales I., Brunel H., Ramirez L., Lopez S., Souto J.C., Vidal F., Soria J.M., Next generation sequencing to dissect the genetic architecture of KNG1 and F11 loci using factor XI levels as an intermediate phenotype of thrombosis (2017) PLOS ONE, 12 (4): e0176301, eCollection 2017.

**IF: 2.766**

Sennblad B., Basu S., Mazur J., Suchon P., Martinez-Perez A., Vlieg A.H., Truong V., Li Y., Gadin J.R., Tang W., Grossman V., de Haan H.G., Handin N., Silveira A., Souto J.C., Franco-Cereceda A., Morange P-E., Gagnon F., Soria J.M., Eriksson P., Hamsten A., Maegdefessel L., Rosendaal F.R., Wild P., Folsom A.R., Tregouet D-A., Sabater-Lleal M., Ge-

nome-wide association study with additional genetic and post-transcriptional analyses reveals novel regulators of plasma factor XI levels (2017) HUM MOL GENET, 26 (3), 637-649.

**IF: 4.902**

Vázquez-Santiago M., Vilalta N., Ziyatdinov A., Cuevas B., Macho R., Pujol-Moix N., Carrasco M., Mateo J., Fontcuberta J., Soria JM., Souto JC., Platelet count and plateletcrit are associated with an increased risk of venous thrombosis in females. Results from the RETROVE study. Thromb Res. 2017 Jul 23;157:162-164.

**IF: 2.779**

## Scientific Production

# Molecular Bases of Disease


**Coordinator**

Fuentes Prior, Pablo  
pfuentes@santpau.cat

IR

**Members**

Acosta Andrade, Carlos	IR
Anton López, Rosa	IR
Nadal Rovira, Marta	IR
Vencesla García, Adoración	IR

**Main Lines of Research**
**Cancer**

- ▶ Structural and functional analysis of the androgen receptor (AR). Design and structure-function characterization of AR homodimerization inhibitors.
- ▶ Analysis of mutations and SNPs that affect the TET2 gene and implications for hematopoietic and lymphoid neoplasms.

**Neurodegenerative Diseases**

- ▶ Analysis of the structural bases of exon-7 exclusion from SMN2 and implications for the pathobiology of spinal muscular atrophy (SMA).

- ▶ Structural and functional investigations of the kinase, PINK1, and implications for Parkinson's disease.

**Thrombosis and Haemostasis**

- ▶ Structural and functional investigations of blood coagulation factors, with emphasis on thrombin interactions with physiological substrates (factor VIII and protease-activated receptors).

**Lipid Metabolism and Dyslipidemias**

- ▶ Bioinformatics analysis of STAP1 mutations identified in individuals with hypercholesterolemia.

**Challenges**

- ▶ Consolidate and extend research within the HSCSP Research Institute and the rest of the IIB Sant Pau in a context of limited access to financial support. To this end, the group needs to participate in at least one financed structure-and-function project in each of three major research areas (cardiovascular diseases, neurodegenerative diseases and cancer and innate immune responses).

**Collaborations**
**Collaborations with other IIB Sant Pau Groups**

- ▶ Metabolic Bases of Cardiovascular Risk
- ▶ Parkinson Disease and Movement Disorders
- ▶ Haematological Diagnosis
- ▶ Genetic Diseases
- ▶ Molecular Physiology of the Synapse

**External Collaborations**

- ▶ Dra. Eva Estébanez-Perpiña, UBIB, Universitat de Barcelona
- ▶ Dr. Jun Xu, Sun Yat-Sen University, Guangzhou, China

**Active Grants**

- ▶ Pablo Fuentes Prior. Estudio de las interacciones de la trombina con sustratos e inhibidores y su aplicación al diseño de nuevos pro- y anticoagulantes. SAF2014-57994-R. Ministerio de Economía y Competitividad. Duration: 2015-2018. 100,000.00 €.
- ▶ Pablo Fuentes Prior. A novel splicing therapeutic approach for Spinal Muscular Atrophy. Daniel Bravo 2015. Fundación Privada Daniel Bravo-Andreu. Duration: 2016-2019. 157,717.00 €.

- ▶ Pablo Fuentes Prior. Modulating SMN2 splicing with dual inhibitors of Sam68 and hnRNP A1: A novel therapeutic approach for Spinal Muscular Atrophy. SMA Europe. Spinal Muscular Atrophy (SMA Europe). Duration: 2014-2017. 117,500.00 €.

Note: Total amount granted to PI. It does not include indirect costs.

**Scientific  
Production****\*TIF: 12.353 \*\*MIF: 12.353**

Nadal M., Prekovic S., Gallastegui N., Helsen C., Abella M., Zielinska K., Gay M., Vilaseca M., Taules M., Houtsmuller A.B., Van Royen M.E., Claessens F., Fuentes-Prior P., Estebanez-Perpina E., Structure of the homodimeric androgen receptor ligand-binding domain (2017)  
NAT COMMUN, 8.  
**IF: 12.353**

# Pharmacokinetic/Pharmacodynamic Modelling and Simulation

**Coordinator**

Valle Cano, Marta  
mvallec@santpau.cat

IR

**Members**

Pla Juncà, Francesc

IR

## Main Lines of Research

- ▶ Population pharmacokinetic analysis aimed at establishing the pharmacokinetic characteristics of drugs and at differentiating and quantifying the degree of intra- and inter-variability.
- ▶ Pharmacokinetic/pharmacodynamic analysis of continuous response aimed at the analysis of effects (in the presence or absence of drugs) where the variable being evaluated changes values gradually.
- ▶ Pharmacokinetic/pharmacodynamic analysis of non-continuous response for responses most frequently observed in

clinical practice, such as categorical responses, survival, frequency and censored responses.

- ▶ Simulation of clinical trials and therapeutic dosage selection aimed at assisting with the design of clinical trials to help the development of new drugs (for pharmaceutical companies) and at improving the design of clinical trials (basic research and non-profit clinical studies) and to help in applications of daily clinical practice.

## Challenges

- ▶ Maintain existing external cooperation agreements.
- ▶ Establish new cooperation agreements within the Research Institute of the Hospital de la Santa Creu i Sant Pau.
- ▶ Generate sufficient financial resources to maintain and expand group staffing.
- ▶ Communicate the group's activities.

## Collaborations

### Collaborations with other IIB Sant Pau Groups

- ▶ Human Neuropsychopharmacology and Psychiatry. Active grant PI16/00078. Principal investigators: Jordi Riba and Enrique Álvarez. Title: Efectos de un análogo de la ayahuasca sobre el procesamiento emocional en pacientes con Trastorno Límite de la Personalidad. Instituto de Salud Carlos III. Total amount: 56,265 €
- ▶ Pharmacological Research in Humans.
- ▶ Pharmacy service. Developing the project "population pharmacokinetics of busulfan".
- ▶ Epidemiology and Traumatology Services: Developing the project "pharmacokinetics of tranexamic acid".

### External Collaborations

- ▶ Lluita Contra la SIDA Foundation, Germans Trias i Pujol Hospital, Badalona, Spain.
- Active grant: "Efficacy and safety of the HIVcons vaccine with romidepsine in the reduction of the virus reservoir and the viral control after stopping CART. Population PK/PD analysis". Fondo de investigación sanitaria (Instituto Carlos III). (PI15/). Beatriz Mothe/José Moltó, Investigator responsible at Sant Pau (Marta Valle)
- Developing the project: "Population pharmacokinetics of dolutegravir in HIV infected patients"
- ▶ Pharmacy Service, Hospital Quiron, Mallorca, Spain. Developing the PhD thesis: "Antimicrobial use in a small-medium size hospital"
- ▶ Department of Pharmacology, Torino University, Italy. Developing the project: "population pharmacokinetics of dolutegravir in HIV infected patients"
- ▶ Department of oncology. Hospital Valle Hebrón. Developing the PhD thesis: "Pharmacokinetics of oncologic drugs in patients with hepatic or renal impairment"



## Active Grants

- Marta Valle Cano. Targeted nanoconjugates for the selective elimination of stem cells in disseminated cancer. PIE15/00028. Instituto de Salud Carlos III. Duration: 2016-2018. 82,640.00 €.

Note: Total amount granted to PI. It does not include indirect costs.

## Scientific Production

Moltó J, Rajoli R, Back D, Valle M, Miranda C, Owen A, Clotet B, Sicardi M. Use of a physiologically based pharmacokinetic model to simulate drug-drug interactions between antineoplastic and antiretroviral drugs. *J Antimicrob Chemother.* 2017 Mar 1; 72(3): 805-811.

**IF: 5.217**

**\*TIF: 11.964 \*\*MIF: 3.988**

Sampedro F, Revenga M.D.L.F., Valle M., Roberto N., Dominguez-Clave E., Elices M., Luna L.E., Crippa J.A.S., Hallak J.E.C., Araujo D.B.D., Friedlander P., Barker S.A., Alvarez E., Soler J., Pascual J.C., Fielding A., Riba J., Assessing the psychedelic "after-glow" in ayahuasca users: Post-acute neurometabolic and functional connectivity changes are associated with enhanced mindfulness capacities (2017) *INT J NEUROPSYCHOPH,* 20 (9), 698-711.

**IF: 3.981**

Santamaría E., Estevez J.A., Riba J., Izquierdo I., Valle M., Population pharmacokinetic modelling of rupatadine solution in 6-11 year olds and optimisation of the experimental design in younger children (2017) *PLOS ONE,* 12 (4), -.

**IF: 2.766**

# Generation of Advanced Therapy Medicines



## Coordinator

García López, Joan  
joangarcia@bst.cat

## Members

Azqueta Molluna, Carme	BST
Blanco Garcia, Margarita	BST
Cabrera Pérez, Raquel	BST
Caro Oleas, José Luis	BST
Castillo Flores, Nerea	BST
Codinach Creus, Margarita	BST
Coll Bonet, Ruth	BST
Del Mazo Bárbara Ana	BST
Enrich Rande, Emma	BST
Frago Orduña, Clara	BST
Garcia Gomez, Susana	BST
Grau Vorster, Marta	BST
Lopez Montañés, María Inmaculada	BST
Martinez Llonch, Nuria	BST
Martorell Cedres, Lluís	BST
Medina Marrero, Laura	BST
Mirabel, Clementine	BST
Oliver Vila, Irene	BST
Querol Giner, Sergio Luis*	BST
Reyes Moreno, Blanca	BST
Rodríguez Gómez, Luciano	BST
Rudilla Salvador, Francesc	BST
Samarkanova, Dinara	BST
Torrabadella Reynoso, Marta	BST
Torrents Zapata, Sílvia	BST
Valdivia Garcia, Elena	BST
Vivas Pradillo, Daniel	BST
Vives Armengol, Joaquim	BST

\* During 2017 Dr. Querol assumed the direction of the group

## Main Lines of Research

- ▶ Bioprocessing for cell and tissue production.
- ▶ Regeneration of locomotor systems.
- ▶ Stem cell therapy for the lymphohaematopoietic system.
- ▶ Stem cell therapy for multiple sclerosis.

## Challenges

- ▶ Create a section within the Blood and Tissue Bank (BST) with the structure of a pharmaceutical enterprise, capable of developing, trialling, registering and commercializing advanced therapeutic drugs.

## Collaborations

### External Collaborations

- ▶ Phase III, randomised, open-label, multi-centre trial of ruxolitinib versus the best therapy available in patients with chronic corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation. Novartis. 2016-004432-38. Duration: 2017-2018. (Isabel Sanchez Ortega, ICO)
- ▶ Prospective, randomised trial comparing spinal fusion in patients with degenerative pathology of the lumbar spine, using autologous mesenchymal cells immobilised in human bone particles, with respect to the autologous iliac crest graft from the patient. Ministerio de Sanidad, Servicios Sociales e Igualdad. EC10-209. Duration: 2012- 2018. (Bagó Granell, Hospital Vall d'Hebron)
- ▶ Transplantation of autologous bone marrow-derived mesenchymal stem cells as a potential therapeutic strategy for the treatment of multiple sclerosis. Ministerio de Sanidad, Servicios Sociales e Igualdad. EC10-266. Duration: 2012-2018. (Xavier Montalbán Gairin, Hospital Vall d'Hebron)
- ▶ Autologous cell therapy with adult stem cells in osteonecrosis of the femoral head. Ministerio de Sanidad, Servicios Sociales e Igualdad. EC10-208. Duration: 2012 to 2018. (Màrius Aguirre Canyadell, Hospital Vall d'Hebron)
- ▶ Phase I / IIA pilot clinical safety and efficacy trial in the repair of meniscus injury by infiltration of autologous mesenchymal cells. Ministerio de Sanidad, Servicios Sociales e Igualdad. EC11-436. Duration: 2012-2017. (Joan Carles Monllau Garcia, ICATME)
- ▶ Phase IIa, single-centre, prospective, randomised, parallel, two treatment arm, open with blind evaluation and single-dose pilot clinical trial for the evaluation of adult autologous 'ex vivo' expanded mesenchymal stem cells conjugated on bone matrix of allogeneic origin in the treatment of non-hypertrophic non-union of long bones. ASEPEYO and BST. 2013-005025-23. Duration: 2016-2017. (Fernando Granell Escobar, Hospital ASEPEYO)
- ▶ Use of third party specific T lymphocytes against viral antigens, from a registry of voluntary donors, for the treatment of CMV, EBV and adenovirus infections in an allogeneic haematopoietic cell transplant recipient. Instituto de Salud Carlos III. PI16/01433 Duration: 2017-2019. (Pere Barba Suñol, Hospital Vall d'Hebron)
- ▶ FANCOSTEM: Phase I / II clinical trial to evaluate the safety and efficacy of mobilisation and collection of CD34 cells after treatment with plerixafor and filgrastim in patients with Fanconi anaemia for later use in gene therapy trials. Ministerio de Sanidad, Servicios Sociales e Igualdad. EC11-559. Duration: 2012-2018. (Cristina Diaz Heredia, Hospital Vall d'Hebron)
- ▶ Sergi Querol Giner (BST)
- ▶ TK008: Randomised phase III trial on haplo identical haematopoietic cell transplantation with or without a support strategy with donated HSV-TK lymphocytes in patients with acute high-risk leukaemia. Molmed. 2009-012973-37 Duration: 2017-2018. (Jordi Sierra Gil, Hospital de Sant Pau)
- ▶ Expanded treatment protocol for relapsed/refractory paediatric/young adult acute lymphoblastic leukaemia patients to be treated with CTL019. Novartis. 2016-001991-31. Duration: 2017- 2018. (Susana Rives Solà, Hospital Sant Joan de Déu)

## Active Grants

- ▶ Sergi Querol Giner. Prophylactic infusion of donor lymphocytes in cord blood transplant. Marató de TV3 Foundation. 20133230. Duration: 2014-2017.
- ▶ Sergi Querol Giner. Clinical efficacy of umbilical cord blood platelet gel in diabetic foot ulcers. BST. 2015-000510-22. Duration: 2015-2017.
- ▶ Luciano Rodríguez Gómez. Validation of manufacturing and quality control, according to good manufacturing practices of a tissue engineering drug for the treatment of myocardial injury after infarction. BST. I.2017.041. Duration: 2017-2018.
- ▶ Francesc Rudilla Salvador. Use of "third party" T-specific lymphocytes against viral antigens, from a registry of voluntary donors, for the treatment of CMV, EBV and ADV infections in allogeneic haematopoietic progenitor cell transplant recipients. BST. I.2017.042. Duration: 2017-2019.
- ▶ Joaquim Vives Armengol. Fibrin Sealant Grifols as scaffold in advanced therapies. 3D printing scaffolds for advanced trauma applications. In vitro study. Grifols. I.2016.035. Duration: 2017-2018.
- ▶ Joaquim Vives Armengol. Evaluation of Albix as a cryoprotector agent of MSC Albix® as stabiliser agent for T lymphocytes. Albulomedix. I.2017.023. Duration: 2017-2018.
- ▶ Ruth Coll Bonet. Safety of a double infusion of Wharton's jelly mesenchymal stem cells in spinal cord injury. BST. I.2017.052. Duration: 2017-2020.
- ▶ Sergi Querol Giner. Phase I / II, multicentre, randomised, open clinical trial of two treatment arms to evaluate the safety and efficacy of umbilical cord blood drop in the treatment of neurotrophic keratitis. BST. I.2016.010. Duration: 2017-2019.
- ▶ Joaquim Vives Armengol. Study of the anti-inflammatory and immunomodulatory properties of the advanced therapy drugs developed in the Cell Therapy Service. I.2015.012. BST. Duration: 2016-2018.
- ▶ José Luís Caro Oleas. Development and validation of a protocol for KIR genotyping using NGS technology and its application in different areas of the hospital care. BST. I.2017.035. Duration: 2017-2019.
- ▶ Josep Maria Canals Coll (Universitat de Barcelona), Joan Garcia López (BST). ADVANCE(CAT) Accelerator for the development of advanced therapies in Catalonia. COMRDI15-1-0013. ACCIÓ. Duration: 2016-2019.
- ▶ Antoni Bayés Genís (Hospital Germans Trias i Pujol), Joaquim Vives Armengol (BST). Cardiopoiesis with biomatrix to regenerate post-infarct scar: From bench to bedside (first-in-man trial). Departament de Salut. SLT002/16/00234. Duration: 2017-2019.

Note: Total amount granted to PI. It does not include indirect costs.

## Theses

- ▶ Nerea Castillo Flores. Kinetics and predictive factors of the study of the kinetics of immune reconstitution and its predictive factors in umbilical cord blood transplantation. Universitat Autònoma de Barcelona. Directors: Sergi Querol Giner and Josep Maria Ribera. Date of defense: 24/04/2017.

## Scientific Production

**\*TIF: 23.073 \*\*MIF: 3.8455**

Caminal M., Velez R., Rabanal R.M., Vivas D., Batlle-Morera L., Aguirre M., Barquiner J., García J., Vives J., A reproducible method for the isolation and expansion of ovine mesenchymal stromal cells from bone marrow for use in regenerative medicine preclinical studies (2017) J TISSUE ENG REGEN M, 11 (12), 3408-3416.

**IF: 4.089**

Casamayor-Genesca A., Pla A., Oliver-Vila I., Pujals-Fonts N., Marin-Gallen S., Caminal M., Pujol-Autonell I., Carrascal J., Vives-Pi M., Garcia J., Vives J., Clinical-scale expansion of CD34+ cord blood cells amplifies committed progenitors and rapid scid repopulation cells (2017) NEW BIOTECHNOL, 35, 19-29.

**IF: 3.733**

Chaverri D., Vives J. Towards the clinical use of circulating biomarkers predictive of bone

union. BIOMARK MED 2017 2017 Dec;11(12):1125-1133.

**IF: 2.179**

Nikolajeva O., Rocha V., Danby R., Ruggeri A., Volt F., Baudoux E., G. Gomez S., Kögler G., Larghero J., Lecchi L., Martinez MS., Navarrete C., Pouthiers F., Querol S., Kenzey C., Szydlo R., Gluckman E., Madrigal A., Umbilical Cord Blood Cytomegalovirus Serostatus Does Not Have an Impact on Outcomes of Umbilical Cord Blood Transplantation for Acute Leukaemia. BIOL BLOOD MARROW TRANSPLANT 2017 Oct;23(10):1729-1735.

**IF: 4.484**

Reyes B., Coca M.I., Codinach M., Lopez-Lucas M.D., del Mazo-Barbara A., Caminal M., Oliver-Vila I., Cabanas V., Lope-Piedrafita S., Garcia-Lopez J., Moraleda J.M., Fontecha C.G., Vives J., Assessment of biodistribution

using mesenchymal stromal cells: Algorithm for study design and challenges in detection methodologies (2017) CYROTHERAPY, 19 (9), 1060-1069.

**IF: 3.625**

Roura S., Galvez-Monton C., Mirabel C., Vives J., Bayes-Genis A., Mesenchymal stem cells for cardiac repair: Are the actors ready for the clinical scenario? (2017) STEM CELL RES THER, 8 (1), -.

**IF: 4.963**

Joshi N., Rodríguez L., Reverté-Vinaixa MM., Navarro A., Platelet-Rich Plasma Injections for Advanced Knee Osteoarthritis: A Prospective, Randomized, Double-Blinded Clinical Trial. THE ORTHOPAEDIC JOURNAL OF SPORTS MEDICINE 2017 2017 Feb 13;5(2):2325967116689386.

# Regenerative Medicine & Tissue Bioengineering



## Coordinator

Casaroli Marano, Ricardo P. BST  
rcasaroli@ub.edu

## Members

Aloy Reverte, Caterina	BST
Buitrago, Paola Andrea	BST
Fariñas Barbera, Oscar	BST
Genís Planella, Xavier	BST
López Chicón, Patricia	BST
Martínez Conesa, Eva María	BST
Otero Areitio, Nausica	BST
Piteira, Rita	BST
Riba Tietz, Tatiana	BST
Tabera, Jaime	BST
Trias Adroher, Esteve	BST
Vilarrodonà Serrat, Anna	BST

## Main Lines of Research

- ▶ Tissue procurement, clinical application, ethics and regulation.
- ▶ Tissue decellularization approaches for clinical applications.
- ▶ Cell-based therapy for ocular diseases.
- ▶ 3D bioimpression and biocompatible substrates.
- ▶ Ex-vivo cell expansion for regenerative purposes.

## Challenges

- ▶ Optimization and improvement of technical procedures related to the donor and tissues.
- ▶ Advances in the elaboration of criteria, regulation and ethics for donor and tissues.
- ▶ Technical excellence related to the processing cells, tissues and advanced therapies medical products (ATMP).
- ▶ The development of new approaches and ATMPs for regenerative medicine.

## Collaborations

### Collaborations with other IIB Sant Pau Groups

- ▶ Service of Ophthalmology (José Antonio Buil / Zoraida del Campo)
- ▶ Service of Traumatology (Pablo Gelber)
- ▶ Service of Gynecology & Obstetric (Oriol Porta, Elisa Llurba)

### External Collaborations

#### National

- ▶ University of Barcelona, Department of Surgery and Medical-Surgical Specialties
- ▶ University of Barcelona, Biophysics and Bioengineering Unit
- ▶ Institute for Bioengineering of Catalonia (IBEC)
- ▶ Center of Regenerative Medicine (CMR), Barcelona

- ▶ Center of Genomic Regulation (CRG), Barcelona
- ▶ Image Diagnostic Institute (IDI), Barcelona
- ▶ Vall d'Hebron Research Institute (VHIR)
- ▶ Advanced Therapies Committee – Hospital Clínic de Barcelona
- ▶ ICREC Group - Hospital Germans Trias i Pu-jol (Badalona)

#### International

- ▶ National Health Service Blood and Tissue (Liverpool, UK)
- ▶ Veneto Eye and Multitissue Bank (Mestre-Treviso, Italy)
- ▶ Irish Blood and Tissue Bank (Dublin, Ireland)
- ▶ Croatia National Tissue Bank (Zagreb, Croatia)
- ▶ EFS-National Blood Service (Paris, France)

## Awards

- ▶ Ricardo P Casaroli-Marano: Professor Joaquín Barraquer Price, Catalonia Royal Academy of Medicine. Barcelona 2017.
- ▶ Ricardo P Casaroli-Marano: Special Visiting Researcher, program "Science Without Frontiers", National Council for Scientific and Technological Development (CNPq, Brazil). Grant 401096/2014-9 (Mar 2015-Mar 2019).

## Theses

- ▶ Nuria Nieto Nicolau. Terapia celular para la reparación y regeneración de la superficie ocular: potencial terapéutico de las células progenitoras mesenquimales. University of Barcelona. Director: Ricardo P. Casaroli-Marano. Date of defense: 27/01/2017.

## Patents

- ▶ Casaroli Marano RP, Reina M, Vilaró S, Parente Duena A, García Antón JM. Use of glycoprotein NF3 (Pseudoalteromas antartica) for the treatment and re-epithelialization of wounds. 02738185.4-2107-ES0200281. European Patent Office (Patent), 07/06/2002.
- ▶ Parente Duena A, Garces Garces J, Guinea Sánchez J, García Antón JM, Casaroli Marano RP, Reina M, Vilaró S. Use of glycoprotein produced by Pseudoalteromonas antartica and having fibroblast adhesion and keratinocyte growth promoting action in topical compositions for wound treatment and re-epithelialization. WO2002102406-A1 / EP1402898-A1 / EP1402898-B1. International Patent Classification (Patent), 27/12/2002.
- ▶ Parente Duena A, Garces Garces J, Guinea Sánchez J, García Antón JM, Casaroli Marano RP, Reina M, Vilaró S. Use of a glycoprotein for the treatment and re-epithelialization of wounds. US07022668, US Patent and Trademark Office Patents (Patent), 04/04/2006.
- ▶ Benet Ferrus D, Corcostegui Guraya B, Prieto García J, (Casaroli-Marano RP). Conjunto de moléculas anti-angiogénicas y su uso. P200801291, Oficina Española de Patentes y Marcas (Licence). 01/09/2011.
- ▶ Benet Ferrus D, Corcostegui Guraya B, Prieto García J, (Casaroli-Marano RP). Set of antiangiogenic molecules and use thereof. PCT/ES2009/000236 / WO2009138533. European Patent Office (Licence). 26/11/2010.

# Associated Groups

**236** Emerging Processes in Prevalent Diseases

**238** Radiophysics and Radioprotection

**240** Paediatrics

**244** Ophthalmology

**246** Nuclear Medicine

**250** Intensive Medicine

**252** Pharmacy

**254** Dermatology

**258** Anaesthesiology

**260** Plastic Surgery

**262** Palliative Care

- 
- 264** Andrology
- 266** Urology
- 272** Radiation Oncology
- 274** Locomotor System Research
- 276** Pain and Neurosciences
- 278** Nursing Care Research
- 280** Reproductive Health
- 282** Translational Molecular Oncology
- 284** Cardiac Surgery
- 286** Inflammation and Vascular Remodelling

# Emerging Processes in Prevalent Diseases



## Coordinator

Benito Vales, Salvador FGS  
sbenito@santpau.cat

## Members

Agra Montava, Iván	FGS
Alquézar Arbe, Aitor	FGS
Álvarez Albarran, Maria Teresa	FGS
Barcons Pujol, Miquel	FGS
Blázquez Andion, Marta	FGS
Caballero Flores, Francisco	FGS
Ceresuela Lobera, Andrés	FGS
Díaz Rodríguez, Ivan	FGS
Díez Díez, Verónica	FGS
Fernández Castaño, Irene	FGS
García Sarasola, Ana	FGS
Gil Olivas, Eva	FGS
Guardiola Tey, José María	FGS
Hernández Ontiveros, Héctor	FGS
Herrera Mateo, Sergio Antonio	FGS
Higa Sansone,	
Jorge Leopoldo	FGS
López Matas, Mara	FGS
Lozano Polo, Laura	FGS
Mateo Roca, Miriam	FGS
Mauri Plana, Albert	FGS
Moliné Pareja, Antoni	FGS
Montiel Dacosta, Josep Antoni	FGS
Moreno Pinillos, Rosa	FGS
Mur Arizon, Isabel	FGS
Puig Campmany, Mireia	FGS
Ris Romeu, Josep	FGS
Rizzi, Miguel Alberto	FGS
Santaló Bel, Miguel	FGS
Serés Roig, Montserrat	FGS
Serradell Arranz, Sonia	FGS
Trejo Gutierrez, Olga Maria	FGS
Turbau Valls, Miquel	FGS

## Main Lines of Research

### Emerging Processes in Prevalent Diseases

- ▶ Study and analysis of processes frequently observed in emergency departments so as to transfer the results to clinical practice and provide better care to patients.

### Clinical Organization and Management (Mireia Puig and Josep Ris)

- ▶ Patient safety and emergency service quality. PI: Maite Álvarez.
- ▶ Nosocomial infection. PI: Albert Mauri.
- ▶ Short-stay unit. PI: J.M. Guardiola.
- ▶ Undergraduate teaching. PI: J.A. Montiel.

### Organ Donation and Coordination (Francisco Caballero and Jesús Leal)

### Respiratory System Disorders (Salvador Benito)

- ▶ Acute Respiratory Failure. PI: A. Moliné.
- ▶ Ventilatory pattern analysis in heart failure. PI: Sergio Herrera.
- ▶ Pneumonia in the emergency department. PI: Míriam Mateo.

- ▶ Noninvasive ventilation. PI: Miquel Turbau.
- ▶ Pulmonary embolism. PI: Laura Lozano.

### Cardiovascular System (Miquel Santaló)

- ▶ Acute coronary syndrome PI: Ivan Díaz.
- ▶ Acute coronary syndrome in women. PI: Marta Blázquez.
- ▶ Ultrasensitive markers in acute coronary syndrome. PI: Aitor Alquézar.
- ▶ Cardiac failure. PI: Miguel Rizzi.
- ▶ Supraventricular arrhythmias. PI: Olga Trejo.

### Community Disorders

- ▶ Diabetes care in emergency departments. PI: Iván Agra.
- ▶ Infection in emergency departments. PI: J.M. Guardiola.
- ▶ Sepsis syndrome. PI: Ivan Díaz.
- ▶ Elderly patients. PI: Leopoldo Higa.
- ▶ Sexes transmitted disease. PI: Montse Seres.
- ▶ Haematology disease. PI: Marta Blázquez.

## Active Grants

- ▶ Miquel Turbau Valls. Training stage at Fundació de Medicina Tropical Doutor Heitor Vieira Dourado de Manaus. IR16-E2. Fundació Privada Hospital de la Santa Creu i Sant Pau. Duration: 2017-2017. 1,200.00 €.

Note: Total amount granted to PI. It does not include indirect costs.

## Awards

- ▶ Prize Best in Class 2017 for the best Emergency Service in patient care.
- ▶ Prize Unió Catalana d'Hospitals en Innovació en Gestió 2017 for the Program of Attention to the Fragility of the Emergency Service.
- ▶ Finalist of the Excellence Award for Leadership and Management in Healthcare category of the 2017 International Awards of the International Hospital Federation, 41st IHF World Hospital Congress.
- ▶ Prize Mutuam Conviure 2017 to the best research project: Atenció Geriàtrica Integral en un Servei d'Urgències Hospitalari. Repercussió sobre la salut dels pacients i la gestió de fluxos després de la implantació a Urgències i la Unitat d'Estada Curta.
- ▶ Accreditation for methodological quality and the positive impact generated in the organization of the continuous improvement methodology promoted by the Urgent Care Process (2017, Observatori d'Innovació en Gestió en Salut, Agència de Qualitat i Avaluació Sanitàries de Catalunya – AquAS, del Departament de Salut de la Generalitat de Catalunya).

**\*TIF: 66.4780 \*\*MIF: 3.6932**

Alquezar A., Santalo M., Rizzi M., Gich I., Grau M., Sionis A., Ordóñez-Llanos J., Merce J., Martín A., Muñoz M., Povar J., Velilla J., Calmarza P., Temboury F., Ortiz C., Balaguer J., Carratalá A., Combined high-sensitivity copeptin and troponin T evaluation for the diagnosis of non-ST elevation acute coronary syndrome in the emergency department. *Evaluación de una estrategia diagnóstica combinada con copeptina y troponina T ultrasensibles en el infarto de miocardio sin elevación del segmento ST en los servicios de urgencias* (2017) *EMERGENCIAS*, 29 (4), 237-244.

**IF: 3.6080**

Alquezar-Arbe A., Sionis A., Ordóñez-Llanos J., Cardiac troponins: 25 years on the stage and still improving their clinical value (2017) *CRIT REV CL LAB SCI*, 54 (7-8), 551-571.

**IF: 6.4810**

Ambavane A., Lindahl B., Giannitis E., Roiz J., Mendifví J., Frankenstein L., Body R., Christ M., Bingisser R., Alquezar A., Mueller C., Economic evaluation of the one-hour rule-out and rule-in algorithm for acute myocardial infarction using the high-sensitivity cardiac troponin T assay in the emergency department (2017) *PLOS ONE*, 12 (11).

**IF: 2.766**

Berenguer J., Rodriguez-Castellano E., Carretero A., Wichmann M.A.V., Montero M., Galindo M.J., Mallolas J., Crespo M., Tellez M.J., Quereda C., Sanz J., Barros C., Tural C., Santos I., Pulido F., Guardiola J.M., Rubio R., Ortega E., Montes M.L., Jusdado J.J., Gaspar G., Esteban H., Bellon J.M., Gonzalez-Garcia J., Eradication of hepatitis C virus and non-liver-related non-acquired immune deficiency syndrome-related events in human immunodeficiency virus/hepatitis C virus coinfection (2017) *HEPATOLOGY*, 66 (2), 344-356.

**IF: 14.0790**

Bover J., Bailone L., Lopez-Baez V., Benito S., Ciceri P., Galassi A., Cozzolino M., Osteoporosis, bone mineral density and CKD-MBD: treatment considerations (2017) *J NEPHROL*, 30 (5), 677-687.

**IF: 2.7240**

Dominguez-Rodriguez A., Burillo-Putze G., Garcia-Saiz M.M., Aldea-Perona A., Harmand M.G.-C., Miro O., Abreu-Gonzalez P., Pinillos-Echeverria M.A., Rizzi M.A., Martin-Sánchez F.J., Suero-Mendez C., Calvo-Rodriguez R., Carballo-Carmona C., Gil V., Herrero P., Bajo A.A.B., Salmeron P.P., Study Design and Rationale of "A Multicenter, Open-Labeled, Randomized Controlled Trial Comparing Midazolam Versus Morphine in Acute Pulmonary Edema": MIMO Trial (2017) *CARDIO-VASC DRUG THER*, 31 (2), 209-213.

**IF: 2.7710**

Ferre C., Llopis F., Martin-Sánchez F.J., Semperé G., Llorens P., Navarro C., Martinez-Ortiz M., Juan A., Sanpedro F., Guardiola J.M., Guzman M., Alvarez A., Arranz M., Daza M., Cortes E., Perez V., Rua M.A., Serra P., Guerrero F., Nunez J.C., Illull J.A., Almela A., Anduiza J., Martin A., Juarez R., Gil J., Ferreira A., Lapuerta L., Castro C., Porras A., Valentín P.M., General Characteristics and Activity of Emergency Department Short-Stay Units in Spanish Hospitals (2017) *J EMERG MED*, 52 (5), 764-768.

**IF: 1.2070**

Garde A., Sornmo L., Laguna P., Jane R., Benito S., Bayes-Genis A., Giraldo B.F., Assessment of respiratory flow cycle morphology in patients with chronic heart failure (2017) *MED BIOL ENG COMPUT*, 55 (2), 245-255.

**IF: 1.9710**

Jacob J., Roset A., Miro O., Alquezar A., Herereo P., Martin-Sánchez F.J., Mockel M., Muller C., Llorens P., EAHFE-TROPICA2 study. Prognostic value of troponin in patients with acute heart failure treated in Spanish hospital emergency departments (2017) *BIO-MARKERS*, 22 (3-4), 337-344.

**IF: 1.9760**

Juanes A., Garin N., Mangues M.A., Herrera S., Puig M., Faus M.J., Baena M.I., Impact of a pharmaceutical care programme for patients with chronic disease initiated at the emergency department on drug-related negative outcomes: A randomised controlled trial (2017) *EUR J HOSP PHARM-S P*.

**IF: 0.5380**

Marquez P.H.P., Torres O.H., San-Jose A., Vidal X., Agusti A., Formiga F., Lopez-Soto A., Ramirez-Duque N., Fernandez-Moyano A., Garcia-Moreno J., et al., Potentially Inappropriate Antihypertensive Prescriptions to Elderly Patients: Results of a Prospective, Observational Study (2017) *DRUG AGING*, 34 (6), 453-466.

**IF: 2.3810**

Martin-Sánchez F.J., Rodriguez-Adrada E., Mueller C., Vidan M.T., Christ M., Frank Peacock W., Rizzi M.A., Alquezar A., Pinera P., Aragues P.L., Llorens P., Herrero P., Jacob J., Fernandez C., Miro O., The Effect of Frailty on 30-day Mortality Risk in Older Patients With Acute Heart Failure Attended in the Emergency Department (2017) *ACAD EMERG MED*, 24 (3), 298-307.

**IF: 2.6120**

Martin-Sánchez F.J., Rodriguez-Adrada E., Vidan M.T., Llopis Garcia G., Gonzalez del Castillo J., Rizzi M.A., Alquezar A., Pinera P., Lazaro Aragues P., Llorens P., Herrero P., Jacob J., Gil V., Fernandez C., Bueno H., Miro O., Impact of Frailty and Disability on 30-Day

Mortality in Older Patients With Acute Heart Failure (2017) *AM J CARDIOL*, 120 (7), 1151-1157.

**IF: 3.1710**

Mccord J., Cabrera R., Lindahl B., Giannitis E., Evans K., Nowak R., Frisoli T., Body R., Christ M., DeFilippi C.R., Christenson R.H., Jacobsen G., Alquezar A., Panteghini M., Melki D., Plebani M., Verschuren F., French J., Bendig G., Weiser S., Mueller C., Ordóñez-Llanos J., Prognostic utility of a modified HEART score in chest pain patients in the emergency department (2017) *CIRC-CARDIOVASC QUAL*, 10 (2).

**IF: 5.0360**

Miro O., A. Rizzi M., Herrero P., Jacob J., Martin-Sánchez F.J., Gil V., Alquezar A., Escoda R., Llorens P., OBESICA study: Relationship between BMI and acute heart failure outcome (2017) *EUR J EMERG MED*, 24 (5), 326-332.

**IF: 1.7290**

Navarro J., Laguno M., Vilchez H.H., Guardiola J.M., Carrion J.A., Force L., Cairo M., Cifuentes C., Vilaro J., Cucurull J., Marco A., Roget M., Erice E., Crespo M., Ortiz J., Aparicio C., Mallolas J., Rebollar M.M., Carrion J.A., Puigvehi M., Barrufet P., Sempere G., Perez M., Sarriera C., Valls I., Efficacy and safety of direct antiviral agents in a cohort of cirrhotic HCV/HIV-coinfected patients (2017) *J ANTIMICROB CHEMOTH*, 72 (10), 2850-2856.

**IF: 5.2170**

Prim N., Turbau M., Rivera A., Rodriguez-Navarro J., Coll P., Mirelis B., Prevalence of colistin resistance in clinical isolates of Enterobacteriaceae: A four-year cross-sectional study (2017) *J INFECTION*, 75 (6), 493-498.

**IF: 4.6030**

Torres Bonafonte O.H., Gil Olivas E., Perez Macho E., Pacho Pacho C., Mateo Roca M., Casademont Pou J., Ruiz Hidalgo D., Predictors of drug-resistant pathogens in community-onset pneumonia: Are factors considered in health-care-associated pneumonia useful in the emergency department? Predictores de patógenos resistentes en las neumonías procedentes de la comunidad: ¿Es útil en urgencias el concepto de neumonía asociada a cuidados sanitarios? (2017) *EMERGENCIAS*, 29 (5), 306-312.

**IF: 3.6080**

# Radiophysics and Radioprotection



## Coordinator

Ribas Morales, Montserrat FGS  
mribas@santpau.cat

## Members

Carrasco de Fez, Pablo	FGS
Eudaldo Puell, Teresa	FGS
Jornet Sala, Núria	FGS
Latorre Musoll, Arthur	FGS
Lizondo Gisbert, Maria	IR
Pallerol Pinzano, Rosa M.	FGS
Ruiz Martínez, Agustín	FGS

## Main Lines of Research

### External beam radiotherapy

- ▶ Characterization of various in vivo dose measurement detectors for radiation therapy treatments with intensity modulation (IMRT).
- ▶ Validation of dose calculation algorithms for external beam radiotherapy planning systems.

- ▶ Optimization of QA procedures for IMRT, stereotactic body radiation therapy (SBRT) and gating respiratory treatments.

- ▶ Skin dose in IMRT and SBRT techniques.

### Radiology

- ▶ Evaluation of a digital scatter correction for bedside chest radiographs.

## Collaborations

### External Collaborations

- ▶ Grup d'estudis citogenètics i moleculars dels efectes de les radiacions ionitzants i del càncer. 2017 SGR 255. UAB. Joan Francesc Barquiner (IP), HSCSP: Pablo Carrasco, Montserrat Ribas, Teresa Eudaldo, Núria Jornet, Artur Latorre, Agustín Ruiz, Paula Delgado, Carla Cases, P. Itziar Valverde. 2017-2019.

- ▶ Institut de Tècniques Energètiques de Catalunya (INTE), UPC. Ongoing research and knowledge transfer projects: development of thermoluminescence in vivo dosimetry for external beam radiotherapy use. Application of the Monte Carlo simulation method for radiation transport in a clinical environment and especially for testing and improving treatment planning systems algorithms used in external beam radiation therapy.

## Active Grants

- ▶ Montserrat Ribas Morales. Estudis Citogenètics i Moleculars dels efectes de les radiacions Montserrat Ribas Morales. Precisión y seguridad en SBRT: evaluación del efecto del movimiento respiratorio y dosimetría "in vivo" mediante dosimetría portal. PI15/00788. Instituto de Salud Carlos III. Duration: 2016-2018. 81,500.00 €.
- ▶ Pablo Carrasco de Fez. Dosimetría en piel en técnicas de IMRT y SBRT. Proyectos Singulares 2015. Asociación Española Contra el Cáncer. Duration: 2015-2018. 25,500.00 €.
- ▶ María Lizondo Gisbert. Evaluación de las nuevas estrategias de irradiación en el tratamiento del cáncer de mama y su implementación en la clínica. AIO 2016. Asociación Española Contra el Cáncer. Duration: 2016-2019. 135,000.00 €.

Note: Total amount granted to PI. It does not include indirect costs.


## Scientific Production

**\*TIF: 4.942 \*\*MIF: 4.942**

Jurado-Bruggeman D., Hernandez V., Saez J., Navarro D., Pino F., Martinez T., Alayrach M.-E., Ailleres N., Melero A., Jornet N., Multi-centre audit of VMAT planning and pre-treatment verification (2017) RADIOTHER ONCOL, 124 (2), 302-310.

**IF: 4.942**

\*Total Impact Factor \*\*Mean Impact Factor



# Paediatrics



## Coordinator

Carreras González, Eduard FGS  
ecarrerasg@santpau.cat

## Members

Álvarez Pérez, Roser	FGS
Amat Giménez, María Isabel	FGS
Badell Serra, Isabel	FGS
Betancourt Castellanos, Jocelyn Cristina	FGS
Brió Sanagustín, Sonia	FGS
Carreras González, Gemma	FGS
Coca Fernández, Elisabet	FGS
Curbelo, Madai	FGS
Febles González, Patricia	FGS
Fraga Rodríguez, Gloria María	FGS
García Boraú, María José	FGS
Ginovart Galiana, Gemma	FGS
López Bernal, Ester	FGS
Moliner Calderón, Elisenda	FGS
Serna, Vicente	FGS
Tirado Capistros, Mireia	FGS
Tobajas Torrubiano, Eva	FGS
Torrent Español, Montserrat	FGS
Turón Viñas, Eulàlia	FGS
Valle Figueras José María	FGS

## Main Lines of Research

- ▶ Erythropoietin as an alternative to transfusion in paediatrics.
- ▶ Clinical application of peritoneal drainage in the treatment of enterocolitis in infants.
- ▶ Chronic functional constipation: treatment with PEG.

- ▶ Creation of a Catalan diagnostic and clinical monitoring network for rare anaemias due to major haemoglobinopathies.
- ▶ Minimal residual disease in risk assessment in the treatment of children with acute lymphoblastic leukaemia in the SHOP protocol (in collaboration with the HSCSP Haematology Department).

## Challenges

- ▶ Transplant haematopoietic progenitor cells from alternative donors.
- ▶ Make pre-implant genetic diagnoses.
- ▶ Transplant haematopoietic progenitor cells in congenital immunodeficiencies.
- ▶ Transplant haematopoietic progenitor cells in congenital metabolic pathologies.
- ▶ Research congenital immunodeficiencies.
- ▶ Research Fanconi anaemia (group recognized by the UAB, Barcelona).

- ▶ Apply adaptive cell immunotherapy to tumours.
- ▶ Intervention in postasphyxia neuronal damage in infants with asphyxia by applying therapeutic hypothermia (in the context of a Catalan network).
- ▶ Polytraumatized patient care programme. PPT implementation code in HSCSP and in CatSalut central register.
- ▶ Implement a multidisciplinary institutional massive transfusion protocol in the HSCSP.

## Collaborations

### Collaborations with other IIB Sant Pau Groups

- ▶ Dra. Gloria María Fraga collaborates in the project of Dra. Roser Torra Balcells (PI) FIS award, PI15/01824: Nefropatías familiares no filiadas: genes implicados en su causa y su variabilidad fenotípica. 2016-2018.
- ▶ Dra. Gloria María Fraga collaborates in the project of Dra. Elisabeth Ars Criach (PI) PI16/01998: Estudio genómico de nefropatías de inicio temprano.
- ▶ Dra. Gloria María Fraga collaborates in the project of Dra. Elisa Llurba Olivé (PI) RD16/0022: Red de Salud Materno Infantil y del Desarrollo (SAMID). Duration: 2017-2021. RD 16/0002/0015. RETICS funded by PN I+D+I 2013-2016, ISCIII - Subdirección General de Evaluación y Fomento de la Investigación y el Fondo Europeo de Desarrollo Regional (FEDER).

### External Collaborations

- ▶ Clinical research group linked to Centro de Investigación Biomédica en la Red de Enfermedades Raras (CIBERER).
- ▶ G. Fraga (collaborator). Multicenter European study (París, Roma, Barcelona): estudio de Asociación de Genoma Completo (GWAS) para la identificación de factores genéticos de riesgo en pacientes con síndrome nefrótico córtico-sensible (SNCS)/ síndrome nefrótico por lesiones mínimas (SNLM).

- ▶ Workgroup of the Guía de Práctica Clínica sobre Manejo del Paciente con Reflujo Vesicoureteral primario o esencial. Guía de Práctica Clínica. Manejo del Paciente con Reflujo Vesicoureteral primario o esencial. Actualización. Asociación Española de Nefrología Pediátrica. 2014.

- ▶ Project “Compromiso por la Calidad de las Sociedades Médicas” (coordinated by Ministerio de Sanidad, Servicios Sociales e Igualdad, Sociedad Española de Medicina Interna and GuíaSalud).

- ▶ E. Carreras, S. Brió, E. Moliner. Programa VINCat. Resultats de la vigilància estandarditzada de la incidència de bacterièmia relacionada amb catèter venòs central (BRCVC) a les Unitats de Cures Intensives Pediàtriques (UCIP) i Neonatais (UCIN) dels Hospitals de Catalunya.

- ▶ J.M. Valle T-Figueras, collaborator in the multicenter work “Infecciones osteoarticulares en pediatría. Estudio prospectivo multicéntrico” de la Red de Infecciones Osteoarticulares Pediatricas (RIOPed).

**\*TIF: 53.108 \*\*MIF: 3.124**

Abras A., Munoz C., Ballart C., Berenguer P., Llovet T., Herrero M., Tebar S., Pinazo M.-J., Posada E., Martí C., Fumado V., Bosch J., Coll O., Juncosa T., Ginovert G., Armengol J., Gascon J., Portus M., Gallego M., Towards a new strategy for diagnosis of congenital Trypanosoma cruzi infection (2017) *J CLIN MICROBIOl*, 55 (5), 1396-1407.

**IF: 4.054**

Alsina Casanova M., Monteagudo-Sánchez A., Rodríguez Guérineau L., Court F., Gazquez Serrano I., Martorell L., Rovira Zurriaga C., Moore G.E., Ishida M., Castañon M., Moliner Calderón E., Monk D., Moreno Hernando J., Maternal mutations of FOXF1 cause alveolar capillary dysplasia despite not being imprinted (2017) *HUM MUTAT*, 38 (6), 615-620.

**IF: 5.359**

Belfort M.A., Whitehead W.E., Shamshirsaz A.A., Bateni Z.H., Olutoye O.O., Olutoye O.A., Mann D.G., Espinoza J., Williams E., Lee T.C., Keswani S.G., Ayres N., Cassady C.I., Mehollin-Ray A.R., Cortes M.S., Carreras E., Peiro J.L., Ruano R., Cass D.L., Fetoscopic open neural tube defect repair: Development and refinement of a two-port, carbon dioxide insufflation technique (2017) *OBSTET GYNECOL*, 129 (4), 734-743.

**IF: 4.982**

Bullrich G., Vargas I., Trujillano D., Mendizabal S., Pinero-Fernandez J.A., Fraga G., García-Solano J., Ballarin J., Estivill X., Torra R., Ars E., Contribution of the TTC21B gene to glomerular and cystic kidney diseases (2017) *NEPHROL DIAL TRANSPL*, 32 (1), 151-156.

**IF: 4.600**

Castillo N., García-Cadenas I., Barba P., Canals C., Diaz-Heredia C., Martino R., Ferrer C., Badell I., Elorza I., Sierra J., Valcarcel D., Querol S., Early and Long-Term Impaired T Lymphocyte Immune Reconstitution after Cord Blood Transplantation with Antithymocyte Globulin (2017) *BIOL BLOOD MARROW TR*, 23 (3), 491-497.

**IF: 4.484**

Di Cataldo A., Agodi A., Balaguer J., Garaventa A., Barchitta M., Segura V., Bianchi M., Castel V., Castellano A., Cesaro S., Cousello J.M., Cruz O., D'Angelo P., de Bernardi B., Donat J., de Andoin N.G., Hernandez M.I., la Spina M., Lillo M., Lopez-Almaraz R., Luksch R., Mastrangelo S., Mateos E., Molina J.,

Moscheo C., Mura R., Porta F., Russo G., Tondio A., Torrent M., Vetrella S., Villegas J.A., Viscardi E., Zanazzo G.A., Canete A., Metastatic neuroblastoma in infants: are survival rates excellent only within the stringent framework of clinical trials? (2017) *CLIN TRANSL ONCOL*, 19 (1), 76-83.

**IF: 2.392**

Esteban E., Belda S., García-Soler P., Rodríguez-Núñez A., Calvo C., Gil-Antón J., Bustín A., Iglesias-Bouzas M.I., Pujol-Joye M., de Carlos JC., García-Iñiguez JP., Pérez-Iranzo A., Téllez C., Ortiz I., Pérez R., Bonil V., Brió S., Concha A., López JD., Murga V., Flores JC., Trujillo A., Felipe A., Abadesso C., Pino M., León J., Martínez MC., Gómez F., Pérez-Montejano R., Tapia R., Jordan I., Ferrer R.A multifaceted educational intervention shortened time to antibiotic administration in children with severe sepsis and septic shock: ABISSE Edusepsis pediatric study. *INTENSIVE CARE MED*. 2017 Dec;43(12):1916-1918.

**IF: 2.514**

Ginovert G., Gich I., Gutierrez A., Verd S., A Fortified Donor Milk Policy is Associated with Improved In-Hospital Head Growth and Weight Gain in Very Low-Birth-Weight Infants (2017) *ADV NEONAT CARE*, 17 (4), 250-257.

**IF: 1.443**

Lin JC., Spinella PC., Fitzgerald JC., Tucci M., Bush JL., Nadkarni VM., Thomas NJ., Weiss SL.; Sepsis Prevalence, Outcomes, and Therapy Study Investigators (S. Brió). New or Progressive Multiple Organ Dysfunction Syndrome in Pediatric Severe Sepsis: A Sepsis Phenotype With Higher Morbidity and Mortality. *PEDIATR CRIT CARE MED*. 2017 Jan;18(1):8-16.

**IF: 3.092**

Maroto A., Illescas T., Meléndez M., Arevalo S., Rodo C., Peiro J.L., Belfort M., Cuxart A., Carreras E., Ultrasound functional evaluation of fetuses with myelomeningocele: study of the interpretation of results (2017) *J MATERN-FETAL NEO M*, 30 (19), 2301-2305.

**IF: 1.493**

Marotta M., Fernandez-Martin A., Oriá M., Fontecha C.G., Gine C., Martinez-Ibanez V., Carreras E., Belfort M.A., Pelizzetti G., Peiro J.L., Isolation, characterization, and differentiation of multipotent neural progenitor cells

from human cerebrospinal fluid in fetal cystic myelomeningocele (2017) *STEM CELL RES*, 22, 33-42.

**IF: 1.829**

Murillo M., Bel J., Perez J., Corripio R., Carreras G., Herrero X., Mengibar J.-M., Rodriguez-Arjona D., Ravens-Sieberer U., Raat H., Rajmil L., Health-related quality of life (HRQOL) and its associated factors in children with Type 1 Diabetes Mellitus (T1DM) (2017) *BMC PEDIATR*, 17 (1).

**IF: 2.042**

Murillo M., Bel J., Perez J., Corripio R., Carreras G., Herrero X., Mengibar J.-M., Rodriguez-Arjona D., Ravens-Sieberer U., Raat H., Rajmil L., Impact of monitoring health-related quality of life in clinical practice in children with type 1 diabetes mellitus (2017) *QUAL LIFE RES*, 26 (12), 3267-3277.

**IF: 2.392**

Porta R., Capdevila E., Botet F., Verd S., Ginovert G., Moliner E., Nicolas M., Rios J., Morbidity and mortality of very low birth weight multiples compared with singletons (2017) *J MATERN-FETAL NEO M*, 1-9.

**IF: 1.493**

Rodo C., Arevalo S., Lewi L., Couck I., Hollwitz B., Hecher K., Carreras E., Arabin cervical pessary for prevention of preterm birth in cases of twin-to-twin transfusion syndrome treated by fetoscopic LASER coagulation: The PECEP LASER randomised controlled trial (2017) *BMC PREGNANCY CHILDB*, 17 (1).

**IF: 2.331**

Ruiz A., Cruz-Lemini M., Masoller N., Sanz-Cortes M., Ferrer Q., Ribera I., Martinez J.M., Crispí F., Arevalo S., Gomez O., Perez-Hoyos S., Carreras E., Gratacos E., Llurba E., Longitudinal changes in fetal biometry and cerebro-placental hemodynamics in fetuses with congenital heart disease (2017) *ULTRASOUND OBST GYN*, 49 (3), 379-386.

**IF: 5.654**

Sanchez-Luna M., Medrano C., Lirio J., Suazo J.A.H., Pena M., Lopez E.N., Fernandez J.U., Jover E.B., Perales A.B., Delgado J.D., et al., Down syndrome as risk factor for respiratory syncytial virus hospitalization: A prospective multicenter epidemiological study (2017) *INFLUENZA OTHER RESP*, 11 (2), 157-164.

**IF: 2.954**

# Paediatrics

## Other Publications

- ▶ Escribano J, Ibars Z, Gonzalez JD, Parada E, Fraga G, Samper M, Ferre N, Cardona V. Predictive factors of pyelonephritis in infants and children. *Pediatr Nephrol* (2017) 32: 905-915.
- ▶ Fraga-Rodríguez GM, Brió-Sanagustin S, Turón-Viñas E, Brdely P Dixon, Carreras-González E. Eculizumab in a child with atypical haemolytic uraemic síndrome and haemophagocytic lymphohistiocytosis triggered by cytomegalovirus infection. *BMJ Case Reports* 2017.
- ▶ García-Reymundo M, Demestre X, Calvo MJ, Ginovart G, Jimenez A, Hurtado JA. Prematuro tardío en España: experiencia del Grupo SEN34-36. *AN PEDIATR (BARC)*. 2017.
- ▶ Valls Guallar C, Pujol Abajo M, López Bernal E, Armengol Santacreu J, Ginovart Galiana G, Vila Solé M, Carreras Gonzales E, Calaf Alsina J. Programa "Cap a casa". Part hospitalari amb mínim ingrés. *ANNALS DE MEDICINA* 2017; 100 (1): 14-17.
- ▶ Verd S, Ginovart G. Neonatal Weight Gain on Minute or Large Amounts of Donor Milk. Letter. *CLIN THER*. 2017 Dec; 39(12): 2450.



# Ophthalmology



## Coordinator

Buil Calvo, José Antonio FGS  
jbuil@santpau.cat

## Members

Bassaganyas Vilarrasa,	
María Francisca	IR
Conte Visus, María Àngels	FGS
Crespi Vilimelis, Jaume	FGS
Del Campo Carrasco,	
Zoraida	FGS
Díaz Cascajosa, Jesús	FGS
García Parés, Eva	FGS
Gil Arnal,	
Julián Miguel Ángel	FGS
Luna Marine, María Sabina	FGS
Marieges Jubany,	
Maria Teresa	FGS
Mingorance Moya, Ester	IR
Rodríguez Álvarez,	
Fernando	FGS
Sánchez Espallargas,	
Fernando	FGS
Solans Barri, Teresa	FGS
Téllez Vázquez, Jesús María	FGS
Vela Segarra, José Ignacio	FGS

## Main Lines of Research


- ▶ Optimization of the functional rehabilitation of patients after cataract surgery using multifocal intraocular lens, and evaluation of vision quality in terms of parameters such as visual acuity, sensitivity to contrast and aberrometry.
- ▶ Ocular repercussions of allogeneic medullary transplants and evaluation of the different clinical manifestations and response to treatment in graft-versus-host disease.
- ▶ Comparison of the effectiveness and safety of intravitreal injection of ranibizumab vs laser photocoagulation in patients with visual alteration due to diabetic macular edema.

\*TIF: 3.0220 \*\*MIF: 3.0220

## Scientific Production

Garay Sanchez S.A., Rodriguez Alvarez F.J., Zavala-Padilla G., Mejia-Cristobal L.M., Cruz-Rangel A., Costas M., Fernandez Velasco D.A., Melendez-Zajgla J., Del Pozo-Yauner L., Stability and aggregation propensity do not fully account for the association of various germline variable domain gene segments with light chain amyloidosis (2017) BIOL CHEM, 398 (4), 477-489.

IF: 3.0220



# Nuclear Medicine



## Coordinator

Carrió Gasset, Ignasi FGS  
icarrio@santpau.cat

## Members

Achury Murcia, Carlos	FGS
Camacho Martí, Maria del Valle	FGS
Domènech Vilardell, Anna	FGS
Duch Renom, Joan	FGS
Estorch Cabrera, Montserrat	FGS
Fernández León, Alejandro	FGS
Flotats Giralt, Albert	FGS
Jaller Vanegas, Rafael Enrique	FGS
López Mora, Diego Alfonso	FGS
Montes Graciano, Alberto	FGS

## Main Lines of Research

### Oncology

- ▶ New diagnostic methods based on the identification and visualization of molecular targets employing metabolic mechanisms, receptor systems, hypoxia, angiogenesis and apoptosis.
- ▶ New applications for sentinel node detection and radioguided surgery models.

### Cardiovascular Research

- ▶ New methods for non-invasive assessment of ischaemic heart disease and heart failure.

- ▶ Cardiovascular functional studies.

- ▶ New methods for assessing cardiac innervation.

### Functional Neuroimaging

- ▶ Development of new functional imaging methods for evaluating neurodegenerative diseases (Parkinson, Parkinson-Plus, Alzheimer, MCI).
- ▶ Dopaminergic system studies using IBZM and Datscan.

## Challenges

- ▶ Introduce new technologies to clinical research (given that imaging techniques are evolving very rapidly towards multimodal systems that integrate biological, molecular, anatomical and functional information in a single examination) and include these technologies, mainly PET/CT and PET/MR, in the group and hospital's research activities.

### New Molecular Imaging Techniques

- ▶ Develop new hybrid molecular imaging technologies, mainly PET/CT and PET/MR,

building on pre-clinical and clinical molecular imaging models developed using

- ▶ SPECT and conventional nuclear medicine technologies.

### PET Imaging Biomarkers

- ▶ Develop new PET radioactive tracers to be used as biomarkers in new imaging technologies building on our experience with radioactive tracers to view *in vivo* diagnostic and therapeutic targets.

## Collaborations

### Collaborations with other IIB Sant Pau Groups

- ▶ Neuroradiology: research into neurological and mental disorders and ageing (Dr. Camacho, member).
- ▶ Oncology, Gynaecology, Surgery, Radiology, Radiotherapy, Nuclear Medicine and Pathology: evaluation of the usefulness of PET CT with 18F-FDG in the staging of locally advanced breast carcinoma (Dr. Duch, PI).
- ▶ Cerebrovascular Diseases (Dr. Carrió, member).

### External Collaborations

- ▶ Zhejiang University, Hangzhou, China. Molecular imaging (Prof. Hong Zhang, Prof. Mei Tian).
- ▶ Hospital Clínico Universitario de Chile, Santiago de Chile. (Prof. P.Gonzalez, Prof. T. Massardo).
- ▶ QIMP team, Center of Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, Austria. (Prof. T. Beyrer).

## Theses

- ▶ Ana Paula Caresia. PET/CT en el cáncer de ovario: Estadificación inicial, valoración de la resecabilidad primaria y la respuesta a la quimioterapia neoadyuvante. Universitat Autònoma de Barcelona. Director: Ignasi Carrió. Date of defense: 26/05/2017.

- ▶ Frederic Sampedro Santaló. Automatic image quantification strategies in clinical nuclear medicine and neuroradiology. Universitat Autònoma de Barcelona. Director: Ignasi Carrió. Date of defense: 20/04/2017.

## Active Grants

- ▶ María del Valle Camacho Martí. PET en malalties neurodegeneratives. IR16-E6. Fundació Privada Hospital de la Santa Creu i Sant Pau. Duration: 2017-2017. 1,200.00 €.
- ▶ María del Valle Camacho. Philips Healthcare Master Research Agreement. Assessment of Advanced Technologies for Molecular Imaging.
- ▶ María del Valle Camacho. ROCHE protocol WN25203-PET-substudy: Sub-study to study WN25203, using positron emission tomography (PET) with an amyloid tracer to assess changes in amyloid load over time in subjects with prodromal Alzheimer's disease.
- ▶ María del Valle Camacho. ROCHE protocol WN28745-PET Sub-study. PET imaging substudy associated with: a phase III, randomized, double-blind, placebo-controlled, parallel-group, multicenter, efficacy, and safety study of gantenerumab in patients with mild Alzheimer's disease.
- ▶ Montserrat Estorch. MK-8931-019: Ensayo clínico de fase III, aleatorizado, controlado con placebo, de grupos paralelos, doble ciego, para estudiar la eficacia y la seguridad de MK-8931 (SCH900931) en pacientes con deterioro cognitivo leve amnésico debido a la enfermedad de Alzheimer (EA prodrómica)
- ▶ Montserrat Estorch. MK-8931-017: Estudio aleatorizado, doble ciego, controlado con placebo y de grupos paralelos de la eficacia y la seguridad de MK-8931 en sujetos con enfermedad de Alzheimer leve o moderada.
- ▶ María del Valle Camacho. D5010C00009: A 24 month, multi-center, randomized, double-blind, placebo-controlled, parallel-group, efficacy, safety, tolerability, biomarker, and pharmacokinetic study of AZD3293 in outpatients with early Alzheimer's disease.
- ▶ María del Valle Camacho. 221AD-301 & 302: A Phase 3 Multi-center, Randomized, Double-Blind, PlaceboControlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIIB037) in Subjects with Early Alzheimer's Disease.
- ▶ Albert Flotats. 1289.5: A multi-centre, double-bind, parallel-group, randomized controlled study to investigate the efficacy, safety and tolerability of orally administered BI409306 during a 12 week treatment period compared to placebo in patients with Alzheimer's disease.
- ▶ Albert Flotats. I8D-MC-AZET. A randomized, double-blind, placebo-controlled and delayed start study of LY3314841 in Mild alzheimer's disease dementia.
- ▶ Albert Flotats. ACT14820. Multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of GZ/SAR402671 in patients with early-stage Parkinson's disease carrying a GBA mutation or other pre-specified variant.
- ▶ Albert Flotats. E2606-G000-302. A placebo controlled, double blind, parallel group, 24 month study to evaluate the efficacy and safety of E2609 in subjects with early Alzheimer's disease.

Note: Total amount granted to PI. It does not include indirect costs.

## Books or chapters with ISBN

- ▶ A. Flotats, I. Carrió. Dysautonomia: From the Brain Disorders to Neuropathies and Including Diabetes. Atlas of Cardiac Innervation. Dil-sizian and Narula Eds. Springer Verlag 2017, pp147-168.

## Scientific Production

## \*TIF: 51.583 \*\*MIF: 3.439

Balsa M.A., Camacho V., Garrastachu P., García-Solis D., Gomez-Rio M., Rubí S., Setoain X., Arbizu J., A new era for Nuclear Medicine neuroimaging in Spain: Where do we start from in Spain? Nuevos tiempos para la neuroimagen de Medicina Nuclear en España: ¿de dónde partimos? (2017) REV ESP MED NUCL IMA, 36 (4), 219-226.

**IF: 1.2020**

Biswas S., Better N., Pascual T.N.B., Mercuri M., Vitola J.V., Karthikeyan G., Westcott J., Alexander E., Allam A.H., Al-Mallah M.H., Bom H.H.S., Bouyoucef S.E., Flotats A., Jerome S., Kaufman P.A., Lele V., Luxenburg O., Mahmalian J.J., Shaw L.J., Underwood S.R., Rehani M., Kashyap R., Dondi M., Paez D., Einstein A.J., Nuclear Cardiology Practices and Radiation Exposure in the Oceania Re-

gion: Results From the IAEA Nuclear Cardiology Protocols Study (INCAPS) (2017) HEART LUNG CIRC, 26 (1), 25-34.

**IF: 1.9210**

du Y., Carrio I., de Vincentis G., Fanti S., İlhan H., Mommsen C., Nitzsche E., Sundram F., Vogel W., Oyen W., Lewington V., Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer (2017) EUR J NUCL MED MOL I, 44 (10), 1671-1678.

**IF: 7.7040**

Estorch M., Treatment with 177Lu-DOTATATE: Past, present and future Tratamiento con 177Lu-DOTATATE: pasado, presente y futuro (2017) REV ESP MED NUCL IMA, 36 (2), 69-71.

**IF: 1.2020**

Flotats A., Carriño I., 123I-mIBG and the phantom tollbooth (2017) J NUCL CARDIOL, 1-3.

**IF: 3.8470**

García-Bermudez M., Moustafa A.-H., Barros-Membrilla A., Tizon-Marcos H., Repeated Loss of Consciousness in a Young Woman: A Suspicious SMAD3 Mutation Underlying Spontaneous Coronary Artery Dissection (2017) CAN J CARDIOL, 33 (2), 292.e1-292.e3.

**IF: 4.5240**

García-Ribas G., Arbizu J., Carriño I., Garrastachu P., Martínez-Lage P., PET biomarkers: Use of imaging techniques in Alzheimer disease and neurodegeneration clinical diagnosis Biomarcadores por tomografía por emisión de positrones (PET): imagen de la patología de Alzheimer y la neurodegeneración al

# Nuclear Medicine

**\*TIF: 51.583 \*\*MIF: 3.439**

servicio del diagnóstico clínico (2017) NEUROLOGIA, 32 (5), 275-277.

**IF: 1.9380**

Lopez-Mora D.A., Camacho V., Fernandez A., Fuentes F., Perez-Perez J., Carrio I., Value of 18F-FDG PET/CT in the diagnosis of chorea-acanthocytosis Valor de la 18F-FDG PET/TC en el diagnóstico de corea-acantocitosis (2017) REV ESP MED NUCL IMA.

**IF: 1.2020**

Montes A., Fernandez A., Camacho V., de Quintana C., Gallego O., Craven-Bartle J., Lopez D., Molet J., Gomez-Anson B., Carrio I., The usefulness of 18F-fluorocholine PET/CT in the detection of recurrence of central nervous system primary neoplasms Valor de la PET/TC cerebral con 18F-fluorocolina en la detección de recurrencias de neoplasias primarias del sistema nervioso central (2017) REV ESP MED NUCL IMA, 36 (4), 227-232.

**IF: 1.2020**

Sampedro F., Domenech A., Escalera S., Carrio I., Computing quantitative indicators of structural renal damage in pediatric DMSA scans Cómputo de indicadores cuantitativos de daño renal estructural en imágenes

DMSA pediátricas (2017) REV ESP MED NUCL IMA, 36 (2), 72-77.

**IF: 1.2020**

Sestini S., Pestelli F., Leoncini M., Bellandi F., Mazzeo C., Mansi L., Carrio I., Castagnoli A., The natural history of takotsubo syndrome: a two-year follow-up study with myocardial sympathetic and perfusion G-SPECT imaging (2017) EUR J NUCL MED MOL I, 44 (2), 267-283.

**IF: 7.7040**

Travin M.I., Carrio I., Henzlova M.J., van Eck-Smit B.L.F., Jain D., Carrio I., Folks R.D., Garcia E.V., Jacobson A.F., Verberne H.J., Assessment of 123I-mIBG and 99mTc-tetrofosmin single-photon emission computed tomographic images for the prediction of arrhythmic events in patients with ischemic heart failure: Intermediate severity innervation defects are associated with higher arrhythmic risk (2017) J NUCL CARDIOL, 24 (2), 377-391.

**IF: 3.8470**

Vidal-Bralo L., Perez-Pampin E., Regueiro C., Montes A., Varela R., Boveda M.D., Gomez-Reino J.J., Gonzalez A., Anti-carbamyl-

ated protein autoantibodies associated with mortality in Spanish rheumatoid arthritis patients (2017) PLOS ONE, 12 (7).


**IF: 3.8470**

Vives-Borras M., Moustafa A.-H., Alvarez-Garcia J., Ferrero-Gregori A., Balcells J., Garcia-Picart J., Serra-Penaranda A., Sionis A., Cinca J., Clinical and Prognostic Value of the Electrocardiogram in Patients With Acute Occlusion of the Left Circumflex Coronary Artery (2017) AM J CARDIOL, 120 (9), 1487-1494.


**IF: 3.171**

von Gall C., Maniawski P., Verzijlbergen F., Carrio I., Beyer T., Kalemis A., Saving costs in cancer patient management through molecular imaging (2017) EUR J NUCL MED MOL I, 1-5.

**IF: 7.7040**



# Intensive Medicine


**Coordinator**

Mancebo Cortés, Jordi FGS  
jmancebo@santpau.cat

**Members**

Aguirre Bermeo,	FGS
Hernán Marcelo	
Baldírà Martínez de Irujo,	
Jaume	FGS
Betbese Roig, Antoni Jordi	FGS
Izura Gómez, Marta	FGS
Morán Chorro, Indalecio	FGS
Parrilla Gómez,	
Francisco José	FGS
Roche Campo, Ferran	FGS
Romero Pastor, Mónica	FGS
Santos Rodríguez,	
José Alberto	FGS
Suárez Montero,	
Juan Carlos	FGS
Vera Artazcoz, Paula	FGS
Zapata Fenor, Luís	FGS

**Main Lines of Research**
**Acute Respiratory Failure and Artificial Ventilation**

- ▶ Non-invasive ventilation.
- ▶ New ventilation modes: proportional-assist ventilation and NAVA.
- ▶ Prone decubitus in acute respiratory dysfunction syndrome (ARDS).
- ▶ Artificial ventilation withdrawal.
- ▶ Expert ventilation systems.
- ▶ Sleep and artificial ventilation.
- ▶ Early and active mobilization of the critical patient.
- ▶ Extracorporeal CO<sub>2</sub> removal in ARDS patients.
- ▶ High-flow oxygen administration by nasal cannula in postextubation phase.
- ▶ Prevalence of drug interactions in critical care unit.

**Study of the Usefulness of New Biomarkers in Critically Ill Patients**

- ▶ BNP in weaning from mechanical ventilation.
- ▶ Use of the NGAL protein in the renal prognosis of critically ill patients.
- ▶ Strict control of blood glucose in critically ill patients.
- ▶ Prophylaxis of acute gastric mucosal injury in critically ill patients.
- ▶ Study of the haemodynamic effects of different antipyretic drugs in critically ill patients.
- ▶ Influence of position change to supine decubitus position in intra-abdominal pressure.

**Challenges**

- ▶ Consolidate clinical and physiological research into ventilation in critically ill patients through multicentre and multinational networking.

- ▶ Create a stable and well-trained group of researchers in this discipline.

**Collaborations**
**Collaboration with other IIB Sant Pau Groups**

- ▶ Pharmacological Research in Humans.

## Scientific Production

## Other Publications

- \*TIF: 118.1690 \*\*MIF: 7.3855**
- Ballus J., Lopez-Delgado J.C., Sabater-Riera J., Perez-Fernandez X.L., Betbese A.J., Roncal J.A., Factors Associated with the Development of Tertiary Peritonitis in Critically Ill Patients (2017) SURG INFECT, 18 (5), 588-595.  
**IF: 1.6890**
- Beduneau G., Pham T., Schortgen F., Piquiloud L., Zogheib E., Jonas M., Grelon F., Runge I., Terzi N., Grange S., Barberet G., Guitard P.-G., Frat J.-P., Constan A., Chretien J.-M., Mancebo J., Mercat A., Richard J.-C.M., Brochard L., Epidemiology of weaning outcome according to a new definition the WIND study (2017) AM J RESP CRIT CARE, 195 (6), 772-783.  
**IF: 15.239**
- Chiumello D., Brochard L., Marini J.J., Slutsky A.S., Mancebo J., Ranieri V.M., Thompson B.T., Papazian L., Schultz M.J., Amato M., Gattinoni L., Mercat A., Pesenti A., Talmor D., Vincent J.-L., Respiratory support in patients with acute respiratory distress syndrome: An expert opinion (2017) CRIT CARE, 21 (1).  
**IF: 6.425**
- Cuartero M., Ballus J., Sabater J., Perez X., Nin N., Ordonez-Llanos J., Betbese A.J., Cell-cycle arrest biomarkers in urine to predict acute kidney injury in septic and non-septic critically ill patients (2017) ANN INTENSIVE CARE, 7 (1).  
**IF: 3.771**
- Fan E., Del Sorbo L., Goligher E.C., Hodgson C.L., Munshi L., Walkey A.J., Adhikari N.K.J., Amato M.B.P., Branson R., Brower R.G., Ferguson N.D., Gajic O., Gattinoni L., Hess D., Mancebo J., Meade M.O., McAuley D.F., Pesenti A., Ranieri V.M., Rubenfeld G.D., Rubin E., Seckel M., Slutsky A.S., Talmor D., Thompson B.T., Wunsch H., Uleryk E., Brozek J., Brochard L.J., An official American Thoracic Society/European Society of intensive care medicine/society of critical care medicine clinical practice guideline: Mechanical ventilation in adult patients with acute respiratory distress syndrome (2017) AM J RESP CRIT CARE, 195 (9), 1253-1263.  
**IF: 15.239**
- Ferrarini A., Righetti L., Martinez M.P., Fernandez-Lopez M., Mastrangelo A., Horcajada J.P., Betbese A., Esteban A., Ordonez J., Gea J., Cabello J.R., Pellati F., Lorente J.A., Nin N., Ruperez F.J., Discriminant biomarkers of acute respiratory distress syndrome associated to H1N1 influenza identified by metabolomics HPLC-QTOF-MS/MS platform (2017) ELECTROPHORESIS, 38 (18), 2341-2348.  
**IF: 2.5690**
- Jaber S., Bellani G., Blanch L., Demoule A., Esteban A., Gattinoni L., Guerin C., Hill N., Laffey J.G., Maggiore S.M., Mancebo J., Mayo P.H., Mosier J.M., Navalesi P., Quintel M., Vincent J.L., Marini J.J., The intensive care medicine research agenda for airways, invasive and noninvasive mechanical ventilation (2017) INTENS CARE MED, 43 (9), 1352-1365.  
**IF: 15.239**
- Mehta S., Burns K.E.A., Machado F.R., Fox-Robichaud A.E., Cook D.J., Calfee C.S., Ware L.B., Burnham E.L., Kissoon N., Marshall J.C., Mancebo J., Finfer S., Hartog C., Reinhart K., Maitland K., Stapleton R.D., Kwizera A., Amin P., Abroug F., Smith O., Laake J.H., Shrestha G.S., Herridge M.S., Gender parity in critical care medicine (2017) AM J RESP CRIT CARE, 196 (4), 425-429.  
**IF: 15.239**
- Perez-Fernandez X., Sabater-Riera J., Sileanu F.E., Vazquez-Reveron J., Ballus-Noguera J., Cardenas-Campos P., Betbese-Roig A., Kellogg J.A., Clinical variables associated with poor outcome from sepsis-associated acute kidney injury and the relationship with timing of initiation of renal replacement therapy (2017) J CRIT CARE, 40, 154-160.  
**IF: 2.8720**
- Perez-Fernandez X., Sabater-Riera J., Ballus-Noguera J., Cardenas-Campos P., Moreno-Gonzalez G., Alonso-Juste V., Corral-Velez V., Gutierrez-Arambula D., Gumucio-Sanguino V., Betbese-Roig A., Liu K.D., No impact of surviving sepsis campaign care bundles in reducing sepsis-associated acute kidney injury (2017) CLIN NEPHROL, 88 (2), 105-111.  
**IF: 1.3520**
- Ramos A., Zapata L., Vera P., Betbese A., Pérez A., Transition from intravenous insulin to subcutaneous long-acting insulin in critical care patients receiving continuous enteral or parenteral nutrition. Endocrinol Diabetes Nutr. 2017. Endocrinol Diabetes Nutr. 2017 Dec;64(10):552-556.  
**IF: 1.106**
- Rialp Cervera G., Raurich Puigdevall J.M., Moran Chorro I., Martin Delgado M.C., Heras la Calle G., Mas Serra A., Vallverdu Perapoch I., Effects of early administration of acetazolamide on the Duration of mechanical ventilation in patients with chronic obstructive pulmonary disease or obesity-hypoventilation syndrome with metabolic alkalosis. A randomized trial (2017) PULM PHARMACOTHER, 44, 30-37.  
**IF: 2.4060**
- Rittayamai N., Beloncle F., Goligher E.C., Chen L., Mancebo J., Richard J.-C.M., Brochard L., Effect of inspiratory synchronization during pressure-controlled ventilation on lung distension and inspiratory effort (2017) ANN INTENSIVE CARE, 7 (1).  
**IF: 3.771**
- Rochwerg B., Brochard L., Elliott M.W., Hess D., Hill N.S., Nava S., Navalesi P., Antonelli M., Brozek J., Conti G., Ferrer M., Guntupalli K., Jaber S., Keenan S., Mancebo J., Mehta S., Raoof S., Official ERS/ATS clinical practice guidelines: Noninvasive ventilation for acute respiratory failure (2017) EUR RESPIR J, 50 (4).  
**IF: 12.242**
- Sahetya S.K., Mancebo J., Brower R.G., Fifty years of research in ARDS VT selection in acute respiratory distress syndrome (2017) AM J RESP CRIT CARE, 196 (12), 1519-1525.  
**IF: 15.239**
- Yebenes J.C., Ruiz-Rodriguez J.C., Ferrer R., Cleries M., Bosch A., Lorencio C., Rodriguez A., Nuvials X., Martin-Loeches I., Artigas A, et al., Epidemiology of sepsis in Catalonia: analysis of incidence and outcomes in a European setting (2017) ANN INTENSIVE CARE, 7 (1).  
**IF: 3.771**

- Munshi L., Del Sorbo L., Adhikari N., Hodgson C., Wunsch H., Meade M., Uleryk E., Mancebo J., Pesenti A., Ranieri M., Fan E. Prone position for acute respiratory distress syndrome. A systematic review and Meta-Analysis. ANN AM THORAC SOC 2017; 14(s4): S280-S288.
- Bellingan G., Brealey D., Mancebo J., Mercat A., Patroniti N., Pettila V., Quintel M., Vincent J-L., Maksimow M., Jalkanen M., Piippo I., Ranieri M. Comparison of the efficacy and safety of FP-1201-lyo (intravenously administered recombinant human interferon beta-1a) and placebo in the treatment of patients with moderate or severe acute respiratory distress syndrome: study protocol for a randomized controlled trial. TRIALS 2017; 18:536.

# Pharmacy



## Coordinator

Mangues Bafalluy,  
Maria Antònia  
mmangues@santpau.cat

## Members

Berga Garrote, Nuria	IR
Cardenete Ornaque, Juana	FGS
Cardona Pera, Daniel	FGS
De Pourcq, Jan Thomas	FGS
Feliu Ribera, Anna	FGS
Fernández de Gamarra Martínez, Edurne	FGS
Fonts Serra, Núria	FGS
Gámez Lechuga, María	FGS
Garin Escrivà, Noé	FGS
Gomis Pastor, Mar	FGS
Juanes Borrego, Ana María	FGS
Juanes Borrego, María Elena	IR
Masip Torne, Montserrat	FGS
Moreno Martinez, Maria Estela	FGS
Pagès Puigdemont, Neus	IR
Riba Solé, Mireia	FGS
Rodríguez-Arias Pal, Ainhoa	IR
Rodríguez Murphy, Esther	FGS
Villamarín Vallejo, Laura	FGS

## Main Lines of Research

- ▶ Pharmaceutical care
- ▶ Clinical epidemiology and public health
- ▶ Artificial nutrition
- ▶ Pharmaceutical formulation

- ▶ Oncohaematology
- ▶ Independent clinical trials

## Challenges

- ▶ Evaluate the impact of different pharmaceutical care programmes on the effectiveness and the safety of pharmacological treatments: personalized medicine (clinical pharmacokinetics & pharmacogenetics), health education, medication reconciliation, identification and prevention of drug related health problems, m-Health and e-Health.
- ▶ Use of clinical epidemiology to gain evidence in patient care: association between risk factors and health outcomes, study of drug interactions, adherence to medication, assessment of regular clinical practice.

- ▶ Evaluate the impact of artificial nutrition on the clinical evolution of patients.
- ▶ Study the stability of cytostatics in different pharmaceutical forms.
- ▶ Determine the stability and the PK-PD of protein nanoparticles with antimetastatic activity.
- ▶ Actively cooperate in independent clinical trials performed in Sant Pau.

## Collaborations

### Collaboration with other IIB Sant Pau Groups

- ▶ Oncogenesis and Antitumour Drugs- CIBER-BBN
- ▶ Clinical Haematology
- ▶ Medical Oncology
- ▶ Intensive Care Medicine
- ▶ Emergency
- ▶ Cardiology
- ▶ Infectious Diseases (HIV)
- ▶ Genetics

### External Collaborations

- ▶ Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN). Instituto de Salud Carlos III.
- ▶ Centro de Investigación en Salud Mental (CIBERSAM). Instituto de Salud Carlos III.
- ▶ Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy, University of Barcelona.
- ▶ Spanish Society of Hospital Pharmacy.
- ▶ Catalan Society of Clinical Pharmacy

## Active Grants

- ▶ Maria Antònia Mangues. Papel de las células natural killer y del receptor CXCR4 en el desarrollo de metástasis en cáncer colorectal. Roche Pharma S.A. Duration: 2016-2017. 40,000 €.
- ▶ Jorge Sierra. Terapia dirigida de Aurostatina E o Ara-C a células de leucemia mieloide aguda que expresan CXCR4, receptor implicado en adhesión al estroma y quimiorresistencia. PI14/00450. Instituto de Salud Carlos III, FIS . Duration: 2015-2017. 231,715 €.
- ▶ José Guerra Ramon. Caracterización genética del síndrome de QT largo asociado a fármacos. PI17/00980. Instituto de

- Salud Carlos III, FIS. Duration: 2017-2018. 95,227 €.
- ▶ Mireia Puig. Atenció geriàtrica integral en un Servei d'Urgències Hospitalari. Recursió sobre la salut dels pacients i la gestió de fluxos després de la implantació a Urgències i la Unitat d'Estada Curta. Duration: 2017-2018.
- ▶ Mar Gomis-Pastor. Improvement in Clinical Practice Using mHealth Technology. ID MHEART: NCT02554578. Duration: 2016-2019.

Note: Total amount granted to PI. It does not include indirect costs.

## Theses

- ▶ Ana María Juanes Borrego. Ensayo clínico randomizado de un programa de atención farmacéutica en pacientes con insuficiencia cardíaca y/o enfermedad pulmonar obstructiva crónica usuarios del servicio de urgencias del hospital de la Santa Creu i Sant Pau de Barcelona. Universidad de Granada. Directors: Maria Antònia Mangues Bafalluy, María Isabel Baena Parejo, María José Faus Dáder. Date of defense: 09/06/2017.
- ▶ Neus Pagès Puigdemont. Abordaje cualitativo y cuantitativo de la adherencia a los tratamientos farmacológicos. Universidad de Granada. Directors: Maria Antònia Mangues Bafalluy, Laura Tuneu Valls. Date of defense: 09/06/2017.

## Awards

- ▶ A. Juanes (IP: M Puig). Research prize of the Fundació Mutuam Convire Mutuam 2017- Atenció geriàtrica integral en un Servei d'Urgències Hospitalari. Repercusió sobre la salut dels pacients i la gestió de fluxos després de la implantació a Urgències i la Unitat d'Estada Curta.

## Scientific Production

**\*TIF: 4.8660 \*\*MIF: 1.2165**

Garin N, Zurita B, Velasco C, Feliu A, Gutierrez M, Masip M, Mangues M.A., Prevalence and clinical impact of recreational drug consumption in people living with HIV on treatment: A cross-sectional study (2017) BMJ OPEN, 7 (1).  
**IF: 2.4130**

Juanes A., Garin N., Mangues M.A., Herrera S., Puig M., Faus M.J., Baena M.I., Impact of a pharmaceutical care programme for patients with chronic disease initiated at the emer-

gency department on drug-related negative outcomes: A randomised controlled trial (2017) EUR J HOSP PHARM-S P.

**IF: 0.5380**

Rodrigo-Troyano A., Mediavilla M.M., Garin N., Guell R., Heart failure induced by itraconazole Insuficiencia cardíaca secundaria a tratamiento con itraconazol (2017) MED CLIN-BARCELONA, 148 (2), 69-70.

**IF: 1.1680**

Wanden-Berghe C., Luengo L.M., Alvarez J., Burgos R., Cuerda C., Matia P., Candela C.G., Olmos M.A.M., Gonzalo M., Calleja A., et al, Spanish home enteral nutrition registry of the year 2014 and 2015 from the NADYA-SENPE group Registro del Grupo NADYA-SENPE de nutrición enteral domiciliaria en España, años 2014 y 2015 (2017) NUTR HOSP, 34 (1), 15-18.  
**IF: 0.7470**

## Other Publications

- ▶ Garin N, Zurita B, Velasco C. Impacto clínico del chemsex en las personas con VIH. Revista Multidisciplinar del Sida (2017) 5 (11), 21-31.

# Dermatology



## Coordinator

Puig Sanz, Luis FGS  
lpuig@santpau.cat

## Members

Baselga Torres, Eulàlia	FGS
Dalmau Arias, Joan	FGS
Díaz-Salazar Monreal, María	IR
Garcés Gatnau, Joan Ramon	FGS
García Muret, María Pilar	FGS
López Ferrer, Anna	FGS
Margarit de Miguel, Esther	IR
Mir Bonafe, Juan Francisco	FGS
Morales Munuera, Caridad Elena	FGS
Paz del Río, Rocío	FGS
Roe Crespo, Esther	FGS
Ros Abarca, Sandra	IR
Ruiz Salas, Verónica	FGS
Serra Baldrich, Esther	FGS
Spertino, Jorge Luis	FGS
Villarrasa Rull, Eva	

## Main Lines of Research

- ▶ Biologic therapy in dermatology.
- ▶ Genome-wide association studies in psoriasis.
- ▶ Medical and physical treatment options for vascular tumours.
- ▶ Psychopathological studies of patients with chronic dermatological disorders.
- ▶ Innate and acquired immunity-mediated dermatological diseases.

## Challenges

- ▶ Ensure a stable clinical research infrastructure and staff.
- ▶ Foster interdepartmental collaborative research.

## Collaborations

### Collaborations with other IIB Sant Pau Groups

- ▶ Parkinson Disease and Movement Disorders.
- ▶ Inflammatory Diseases

**\*TIF: 139.633 \*\*MIF: 3.879**

Adsit S., Zaldivar E.R., Sofen H., Dei-Cas I., Garcia C.M., Penaranda E.O., Puig L., Meng X., Fox T., Guana A., Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials (2017) ADV THER, 34 (6), 1327-1339.

**IF: 3.085**

Amyere M., Revencu N., Helaers R., Pairet E., Baselga E., Cordisco M.R., Chung W., Dubois J., Lacour J.-P., Martorell L., et al., Germline loss-of-function mutations in EPHB4 cause a second form of capillary malformation-arteriovenous malformation (CM-AVM2) deregulating RAS-MAPK signaling (2017) CIRCULATION, 136 (11), 1037-1048.

**IF: 2.895**

Armstrong A., Puig L., Langley R., Tsai TF., Song M., Wasfi Y., Jiang J., Li S., Han C., Validation of psychometric properties and development of response criteria for the Psoriasis Symptoms and Signs Diary (PSSD): results from a phase III clinical trial. J DERMATOLOG TREAT. 2017 Aug 11:1-31.

**IF: 1.8900**

Augustin M., Blome C., Paul C., Puig L., Luger T., Lambert J., Chimenti S., Girolomoni G., Kragballe K., Naessens D., Bergmans P., Smirnov P., Barker J., Reich K., Quality of life and patient benefit following transition from methotrexate to ustekinumab in psoriasis (2017) J EUR ACAD DERMATOL, 31 (2), 294-303.

**IF: 4.287**

Blauvelt A., Papp K.A., Griffiths C.E.M., Puig L., Weisman J., Dutronc Y., Kerr L.F., Ilo D., Mallbris L., Augustin M., Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3) (2017) AM J CLIN DERMATOL, 18 (2), 273-280.

**IF: 3.018**

Blauvelt A., Puig L., Chimenti S., Vender R., Rajagopalan M., Romiti R., Skov L., Zachariae C., Young H., Prens E., Cohen A., van der Walt J., Wu J.J., Biosimilars for psoriasis: clinical studies to determine similarity (2017) BRIT J DERMATOL, 177 (1), 23-33.

**IF: 6.129**

Bronckers I.M.G.J., Seyger M.M.B., West D.P., Lara-Corrales I., Tollefson M., Tom W.L., Hollgeling M., Belazarian L., Zachariae C., Mahe E., Siegfried E., Philipp S., Szalai Z., Vleugels R.A., Holland K., Murphy R., Baselga E., Cordero K., Lambert J., Alexopoulos A., Mrowietz U., Kievit W., Paller A.S., Safety of systemic agents for the treatment of pediatric psoriasis (2017) JAMA DERMATOL, 153 (11), 1147-1157.

**IF: 8.107**

Checchio T., Ahadieh S., Gupta P., Mandema J., Puig L., Wolk R., Valdez H., Tan H., Krishnaswami S., Tallman A., Kaur M., Ito K., Quantitative Evaluations of Time-Course and Treatment Effects of Systemic Agents for Psoriasis: A Model-Based Meta-Analysis (2017) CLIN PHARMACOL THER, 102 (6), 1006-1016.

**IF: 6.544**

Cohen A.D., Wu J.J., Puig L., Chimenti S., Vender R., Rajagopalan M., Romiti R., de la Cruz C., Skov L., Zachariae C., Young H.S., Foley P., van der Walt J.M., Naldi L., Prens E.P., Blauvelt A., Biosimilars for psoriasis: worldwide overview of regulatory guidelines, uptake and implications for dermatology clinical practice (2017) BRIT J DERMATOL, 177 (6), 1495-1502.

**IF: 6.129**

Elewski B.E., Puig L., Mordin M., Gilloteau I., Sheriff B., Fox T., Gnanasakthy A., Papavassilis C., Strober B.E., Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75-89 response: results from two phase 3 studies of secukinumab (2017) J DERMATOL TREAT, 28 (6), 492-499.

**IF: 2.144**

Feldman S.R., Vrijens B., Gieler U., Piaserico S., Puig L., van de Kerkhof P., Treatment Adherence Intervention Studies in Dermatology and Guidance on How to Support Adherence (2017) AM J CLIN DERMATOL, 18 (2), 253-271.

**IF: 3.018**

Garces J.R., Garza-Rodriguez V., Alegre M., Repair of a Complex Forehead Defect Involving the Brow (2017) DERMATOL SURG, 43 (3), 443-445.

**IF: 2.471**

Garcia-Montero P., Del Boz J., Sanchez-Martinez M., Santos I.M.E., Baselga E., Microcystic lymphatic malformation successfully treated with topical rapamycin (2017) PEDIATRICS, 139 (5).

**IF: 5.515**

Girolomoni G., Strohal R., Puig L., Bachelez H., Barker J., Boehncke W.H., Prinz J.C., The role of IL-23 and the IL-23/TH17 immune axis in the pathogenesis and treatment of psoriasis (2017) J EUR ACAD DERMATOL, 31 (10), 1616-1626.

**IF: 4.287**

Lopez-Ferrer A., Laiz A., Puig L., The safety of ustekinumab for the treatment of psoriatic arthritis (2017) EXPERT OPIN DRUG SAF, 16 (6), 733-742.

**IF: 3.156**

Mull J.L., Chamlin S.L., Lai J.-S., Beaumont J.L., Cella D., Rancour E.A., Baselga E., Haggstrom A.N., Utility of the Hemangioma Severity

Scale as a Triage Tool and Predictor of Need for Treatment (2017) PEDIATR DERMATOL, 34 (1), 78-83.

**IF: 1.041**

Nagore E., Puig L., European Academy of Dermatology and Venereology (EADV) membership is worthwhile for Spanish dermatologists. ACTAS DERMOSIFILIOGR. 2017 Sep;108(7):605.

**IF: 0.374**

Navarini A.A., Burden A.D., Capon F., Mrowietz U., Puig L., Koks S., Kingo K., Smith C., Barker J.N., Bachelez H., Chiricozzi A., Costanzo A., Eyerich K., French L.E., Ghoreschi K., Gilliet M., Girolomoni G., Gniadecki R., Griffiths C., Koh H.Y., Lipsker D., Naldi L., Prans E., Prinz J., Reich K., Rocken M., Skov L., Sorin G., Stahle M., Stingl G., Van de Kerkhof P., Warren R., European consensus statement on phenotypes of pustular psoriasis (2017) J EUR ACAD DERMATOL, 31 (11), 1792-1799.

**IF: 4.287**

Planas-Ciudad S., Roe Crespo E., Sanchez-Carpintero I., Frieden I.J., Martin-Santiago A., Redondo Bellon P., Moreno Artero E., Osier E., Puig Sanz L., Baselga Torres E., Infantile hemangiomas with minimal or arrested growth associated with soft tissue hypertrophy: a case series of 10 patients (2017) J EUR ACAD DERMATOL, 31 (11), 1924-1929.

**IF: 4.287**

Puig L., Thom H., Mollon P., Tian H., Ramakrishna G.S., Clear or almost clear skin improves the quality of life in patients with moderate-to-severe psoriasis: a systematic review and meta-analysis (2017) J EUR ACAD DERMATOL, 31 (2), 213-220.

**IF: 4.287**

Puig L., The role of biologics in the treatment of moderate-to-severe plaque psoriasis (2017) GIORN ITAL DERMAT V, 152 (1), 28-35.

**IF: 1.327**

Puig L., Putrik P., Psoriasis: inequality or individualized care? (2017) BRIT J DERMATOL, 176 (5), 1111-1113.

**IF: 6.129**

Puig L., Brodalumab: The first anti-IL-17 receptor agent for psoriasis (2017) DRUG TODAY, 53 (5), 283-297.

**IF: 1.325**

Puig L., van de Kerkhof P.C.M., Reich K., Bachelez H., Barker J., Girolomoni G., Paul C., A European subset analysis from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis shows country-specific features: results from psoriasis patients in Spain (2017) J EUR ACAD DERMATOL, 31 (7), 1176-1182.

**IF: 4.287**

Puig L., Notario J., Jimenez-Morales A., Moreno-Ramirez D., Lopez-Ferrer A., Gozalbo I.,

# Dermatology

## Scientific Production

\*TIF: 139.633 \*\*MIF: 3.879

Prades M., Lizan L., Blanch C., Secukinumab is the most efficient treatment for achieving clear skin in psoriatic patients: a cost-consequence study from the Spanish National Health Service (2017) *J DERMATOL TREAT*, 28 (7), 623-630.

**IF: 2.144**

Puig L., The role of IL 23 in the treatment of psoriasis (2017) *EXPERT REV CLIN IMMU*, 13 (6), 525-534.

**IF: 3.436**

Puig L. Cardiometabolic Comorbidities in Psoriasis and Psoriatic Arthritis. *Int J Mol Sci.* 2017 Dec 25;19(1). Review.

**IF: 3.226**

Puig L. Choice of first-line biologic therapy in psoriasis: understanding the past and shaping the future? *Br J DERMATOL.* 2017 Sep;177(3):623-624.

**IF: 6.129**

Reich K., Puig L., Mallbris L., Zhang L., Osuntokun O., Leonardi C., The effect of body-weight on the efficacy and safety of ixekizumab: results from an integrated database of three randomised, controlled Phase 3 studies of patients with moderate-to-severe plaque psoriasis (2017) *J EUR ACAD DERMATOL*, 31 (7), 1196-1207.

**IF: 4.287**

Reich K., Zschocke I., Bachelez H., de Jong E.M.G.J., Gisondi P., Puig L., Warren R.B., Ortland C., Mrowietz U., A Topical Treatment

Optimization Programme (TTOP) improves clinical outcome for calcipotriol/betamethasone gel in psoriasis: results of a 64-week multinational randomized phase IV study in 1790 patients (PSO-TOP) (2017) *BRIT J DERMATOL*, 177 (1), 197-205.

**IF: 6.129**

Rius C., Baselga E., Tizon J., Fuentes P., Muñoz-Garza F.Z., Roige G., Llebaria X., Cayla J.A., Investigation of a suspected outbreak of lipoatrophia semicircularis in children Investigación de una sospecha de brote de lipoatrofia semicircular en niños (2017) *MED CLIN-BARCELONA*, 149 (3), 101-106.

**IF: 1.168**

Sampogna F., Puig L., Spuls P., Girolomoni G., Radtke M., Kirby B., Brunori M., Bergmans P., Smirnov P., Rundle J., Lavie F., Paul C., Prevalence of alexithymia in patients with psoriasis and its association with disease burden: a multicentre observational study (2017) *BRIT J DERMATOL*, 176 (5), 1195-1203.

**IF: 6.129**

Saunte D.M., Mrowietz U., Puig L., Zachariae C., Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management (2017) *BRIT J DERMATOL*, 177 (1), 47-62.

**IF: 6.129**

Theiler M., Baselga E., Gerth-Kahlert C., Mathes E.F., Schwieger-Briel A., Chaloupka

K., Weibel L., Frieden I.J., Infantile hemangiomas with conjunctival involvement: An underreported occurrence (2017) *PEDIATR DERMATOL*, 34 (6), 681-685.

**IF: 1.041**

Wan J., Steiner J., Baselga E., Blei F., Cordisco M., Garzon M.C., Goddard D.S., Haggstrom A., Krol A., Frieden I.J., Metry D., Morel K.D., Verhagen J.M.A., Wargon O., Drolet B.A., Siegel D.H., Prenatal Risk Factors for PHACE Syndrome: A Study Using the PHACE Syndrome International Clinical Registry and Genetic Repository (2017) *J PEDIATR-US*, 190, 275-279.

**IF: 3.667**

Zouboulis C.C., Tzellos T., Kyrgidis A., Jemec G.B.E., Bechara F.G., Giamarellos-Bourboulis E.J., Ingram J.R., Kanni T., Karagiannidis I., Martorell A., et al., Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity (2017) *BRIT J DERMATOL*, 177 (5), 1401-1409.

**IF: 6.129**



# Anaesthesiology


**Coordinator**

Moral Garcia, Maria Victoria FGS  
vmoralg@santpau.cat

**Members**

Anaya Camacho, Rafael	FGS
Argilaga Nogués, Marta	FGS
Azparren Cabezón, Gonzalo	FGS
Baños Lapuente, Victoria	FGS
Batalla González, Astrid María	FGS
Bastitta, Micaela	FGS
Bausili Ribera, Marc	FGS
Bauta Sanjuan, Javier	FGS
Bueno Izquierdo, Ana	FGS
Cegarra Sanmartín, Virginia	FGS
Cueva Castro, Luisa Fernanda	FGS
Díaz Jover, Rubén	FGS
Espinosa López Davalillo, Nieves	FGS
Felipe Correoso, María Mar	FGS
Fernández Núñez, José Anton	FGS
Ferrández Mach, Marta	FGS
Font Gual, Adrià	FGS
Galán Serrano, Josefa	FGS
García Álvarez, María Mercedes	FGS
García Muret, Albert	FGS
Genové Cortada, María Mercè	FGS
Gil de Bernabé Sala, Maria Àngels	FGS
Gil Sánchez, José María	FGS
Giné Serven, Marta	FGS
Gómez Caro, Ana M.	FGS
González Carrasco, Francisco Javier	FGS
González Rodríguez, Raúl	FGS
Guadalupe Fernández, Nerea	FGS
Herranz Pérez, Gracia	FGS
Hoffmann, Rolf Dieter	FGS
Illa Ribera, Susanna	FGS
India Aldana, Inmaculada	FGS
Italiano, Stefano	FGS

Koller, Tobias Bernhard	FGS	Paniagua Iglesias, Pilar	FGS
Maestre Hittinger, María Luz	FGS	Parera Ruiz, Ana	FGS
Martín Huerta, María Beatriz	FGS	Peláez Vaamonde, Xavier	FGS
Martínez Pérez, Selene	FGS	Piñol Sapena, Santiago	FGS
Melo Cruz, Martha Cristina	FGS	Revuelta Rizo, Miren Eli	FGS
Merten, Alfredo R.	FGS	Rivilla Lizano, María Teresa	FGS
Miralles Bagan, Jordi	FGS	Rodríguez Prieto, Mireia	FGS
Moreno Bueno, Marisa	FGS	Santeularia Vergés, María Teresa	FGS
Múñoz Andrade, G. Rolando	FGS	Unzueta Merino, María Carmen	FGS
Pablo Fernández, Rosa	FGS		

**Main Lines of Research**
**Perioperative medicine**

- ▶ Epidemiologic and clinical studies of perioperative morbidity and mortality in collaboration with the Epidemiology Department of HSCSP and external scientific organisations.
- ▶ Cost-benefit study of cardiac surgery in patients older than 80 years.
- ▶ Prevalence of postoperative pain.
- ▶ Prediction of cronification of postoperative pain.

**Rationalization of perioperative fluid therapy and blood products**

- ▶ Improvement of efficiency of massive transfusions.
- ▶ Monitoring of critical perioperative coagulopathy.
- ▶ Identification and recovery from preoperative anaemia.

**Challenges**

- ▶ Critical analysis of new clinical technologies.
- ▶ Patient blood management.
- ▶ Perioperative medicine.

- ▶ Study of the prevalence of perioperative transfusions.
- ▶ Monitoring of perioperative fluid therapy.

**New health service delivery systems**

- ▶ Improvement of perioperative care of patients with knee fracture.
- ▶ Optimization of preoperative evaluations in cataract surgery.
- ▶ Professional team preoperative evaluations.
- ▶ Zero preoperative stay.

**Physiology, pharmacology and anaesthetic techniques**

- ▶ Intraoperative respiratory physiology.
- ▶ Management of preoperative anxiety in Pediatric Anesthesia and Surgery.
- ▶ Improvement of intraoperative hypothermia in general surgery

**Active Grants**

- ▶ María Carmen Unzueta Merino. Reducción de las complicaciones postoperatorias y de la estancia hospitalaria con una estrategia perioperatoria individualizada de ventilación de protección pulmonar. Estudio comparativo, prospectivo, multicéntrico, aleatorizado y controlado. PI14/00829 C. Instituto de Salud Carlos III. Duration: 2015-2017.
- ▶ Pilar Paniagua Iglesias. Evaluación del grado de cumplimiento e impacto clínico

de los protocolos de transfusión masiva (PTM). PI16/01134. Instituto de Salud Carlos III. Duration: 2017-2019. 82,000.00 €.

- ▶ Astrid María Batalla González. Adecuación del medio perioperatorio al paciente pediátrico como método de ansiolisis. IR16-E5. Fundació Privada Hospital de la Santa Creu i Sant Pau. Duration: 2017-2017. 1,200.00 €.

Note: Total amount granted to PI. It does not include indirect costs.

### Collaborations with other IIB Sant Pau Groups

- ▶ PALLAPUPAS. Influencia de la intervención de pallapupas sobre la ansiedad preoperatoria infantil medida por niveles de cortisol salival. CEIC HSCSP, IR HSCSP. Duration: 2016-2018.
- ▶ IPROVE-O2. Reducción de la infección de la herida quirúrgica con ventilación de protección pulmonar y FiO2 elevada. Incluye EUDRAC: 2016: 002934-34. Instituto Carlos III. Duration: 2017-2018.
- ▶ ALBUMINA-CEC. Influencia de la albúmina en CEC sobre el desarrollo de disfunción renal aguda postoperatoria asociada a la cirugía cardíaca bajo circulación extracorpórea. CEIC HSCSP. Duration: 2017-2019.
- ▶ HIPOTERMIA QUIR. Análisis de la eficacia de los sistemas de calentamiento por convección en la prevención de la hipotermia intraoperatoria no deseada. IR HSC. Duration: 2017-2019.

### External Collaborations

- ▶ POPULAR (Postanesthesia PULmonary complications After use of muscle Relaxants in Europe), multicentre observational study. European Society of Anaesthesiology (ESA).
- ▶ Analysis of the Hemostatic Potential of Coagulation Factor Concentrates in an In Vitro Model of Extreme Hemodilution. Heimbürger Grant.

- ▶ Collaboration in Competitive, International and Multicenter Study titled TRICS (Restrictive or liberal red-cell transfusion for cardiac surgery). Population Health Research Institute. Hamilton General Hospital Canada. NCT 02042898.
- ▶ Collaboration in Competitive, International and Multicenter Study titled MANAGE (Management of myocardial injury after noncardiac surgery) - Population Health Research Institute. Hamilton General Hospital Canada. NCT 01661101 / 2014-2017
- ▶ Collaboration in Competitive, International and Multicenter Study titled AFFECT (Ensayo clínico aleatorizado multicéntrico paralelo en pacientes antiagregados con fractura pectorocántrea de fémur que evalúa una estrategia para acortar el tiempo hasta la cirugía) PI16/01879 - Instituto Carlos III, 2017-2019
- ▶ Collaboration in Competitive, International and Multicenter Study titled HIP-ATTACK (Hip fracture accelerated surgical care and Treatment Track)- Population Health Research Institute. Hamilton General Hospital Canada CEIC 15/294 - Population Health Research Institute. Hamilton General Hospital Canada. NCT 01661101.
- ▶ IPEGASUS (Individualized Perioperative goal- directed Therapy in Major Abdominal Surgery). NCT 030221525 - Hamburg University, Deutchland. Duration: 2017-2019.

\*TIF: 102.863 \*\*MIF: 11.4292

Alonso-Coello P, Cook D, Xu S.C., Sigamani A., Berwanger O, Sivakumaran S., Yang H., Xavier D, Martinez L.X., Ibarra P, Rao-Melacini P., Pogue J., Zarnke K., Paniagua P., Ostendar J., Yusuf S., Devereaux P.J., Predictors, prognosis, and management of new clinically important atrial fibrillation after noncardiac surgery: A prospective cohort study (2017) ANESTH ANALG, 125 (1), 162-169.

**IF: 3.463**

Colomina MJ, Basora M, Moral V, Llau JV. Crystalloids and hydroxyethyl starches in noncardiac surgical patients. EUR J ANAESTHESIOL. 2017; 34(1): 28-29.

**IF: 3.958**

Estadella J, Español P, Grandal B, Gine M, Parra. Laparoscopy during pregnancy: Case report and key points to improve laparoscopic management. J Eur J Obstet Gynecol Reprod Biol. 2017;217:83-88.

**IF: 1.666**

Ferrando C, Soro M, Unzueta C, Canet J., Tusman G, Suarez-Sipmann F, Librero J., Peiro S, Pozo N, Delgado C, Ibanez M, Aldecoa C, Garutti I, Pestana D, Rodriguez A, Garcia Del Valle S, Diaz-Cambronero O, Ballust J, Redondo F.J, De La Matta M, Gallego L, Granell M, Martinez P, Perez A, Leal S, Alday K, Garcia P, Monedero P, Gonzalez R, Mazzinari G, Aguilar G, Villar J, Belda F.J., Rationale and study design for an individu-

alised perioperative open-lung ventilatory strategy with a high versus conventional inspiratory oxygen fraction (IPROVE-O2) and its effects on surgical site infection: Study protocol for a randomised controlled trial (2017) BMJ OPEN, 7 (7).

**IF: 2.413**

LAS VEGAS investigators.(Moral V, Unzueta MC, Favá J, Puigbo C...). Epidemiology, practice of ventilation and outcome for patients at increased risk of postoperative pulmonary complications: LAS VEGAS - an observational study in 29 countries. Eur J Anaesthesiol. 2017; 34(8): 492-507.

**IF: 3.958**

Martín-Fumadó C, Gómez-Durán EL, Galán-Serrano J, Barberia-Macalain E, Arymany-Manso J, Parera-Ruiz A. Toma de decisiones al final de la vida y ante el diagnóstico de muerte encefálica. REV ESP MED. LEGAL 2017; 43: 123-126.

**IF: 0.231**

Mazer CD, Whitlock RP, Ferguson DA, Hall J, Belley-Cote E, Connolly K, Khanykin B, Gregory AJ, de Medicis É, McGuinness S, et al. Restrictive or Liberal Red-Cell Transfusion for Cardiac Surgery. NEW ENGL J MED. 2017;377(22):2133-2144.

**IF: 79.258**

Neto A.S., Campos P.P.Z.A., Hemmes S.N.T., Bos L.D., Bluth T., Ferner M., Guldner A., Hollmann M.W., India I., Kiss T., Laufenberg-Feldmann R., Sprung J., Sulemanji D., Unzueta C., Melo M.F.V., Weingarten T.N., Tuip-De Boer A.M., Pelosi P., Gama De Abreu M., Schultz M.J., Kinetics of plasma biomarkers of inflammation and lung injury in surgical patients with or without postoperative pulmonary complications (2017) EUR J ANAESTH, 34 (4), 229-238.

**IF: 3.958**

Serpa Neto A, Campos PP, Hemmes SN, Bos LD, Bluth T, Ferner M, Guldner A, Hollmann MW, India I, Kiss T, Laufenberg-Feldmann R, Sprung J, Sulemanji D, Unzueta C, Melo MF, Weingarten TN, Boer AM, Pelosi P, Gama de Abreu M, Schultz MJ; PROVE Network Investigators. Kinetics of plasma biomarkers of inflammation and lung injury in surgical patients with or without postoperative pulmonary complications. EUR J ANAESTHESIOL. 2017; 34(4): 229-238.

**IF: 3.958**

# Plastic Surgery



## Coordinator

Masia Ayala, Josep Jaume FGS  
jmasia@santpau.cat

## Members

Bernárdez, Débora	FGS
Fernández Garrido, Manuel	FGS
López Fernández, Susana	FGS
Olivares Domínguez, María de Leyre	FGS
Pons Playa, Gemma	FGS
Rodríguez Bauza, E Iena María	FGS
Sánchez-Porro Gil, Lidia	FGS
Vega García, María del Carmen	FGS

## Main Lines of Research

- ▶ Application of imaging techniques for intraoperative studies of perforator vessels with the aim to improve the design of flaps, evaluate the suitable blood perfusion and the viability of the flaps avoiding secondary postoperative complications secondary to vascular supply problems.
- ▶ Anatomical studies of the variability of perforator vessels in the following regions: internal mammary artery, inferior epigastric system and internal superficial circumflex system.
- ▶ Study of the perioperative and postoperative factors that influence on the viability of the microsurgical free flaps.
- ▶ Research by indocyanine green angiography of the concept of vascular blood balance after the dissection of a perforator flap.
- ▶ Research by indocyanine green angiography of the relationship between the different anatomical patterns of lymphatic vessels in the upper extremity and its readiness to develop lymphedema in the affected breast cancer patients.
- ▶ Feasibility of the research in animal models of major surgical and nonsurgical techniques existing today to treat secondary lymphatic insufficiency: fat transplant of autologous stem cells, stem cell transplantation autologous from bone marrow, lymphatic- venous anastomosis, free flap of vascularised autologous lymph nodes.
- ▶ Lymphangiogenesis studies in a comparative animal model between transplantation of adipose tissue stem cells vs bone marrow stem cells, lymphatic-venous anastomoses and transplantation of vascularized lymph nodes for lymphoedema treatment.
- ▶ Research in an experimental animal model on lymphangiogenesis and regeneration of the lymphatic system after a model of obstructive lymphoedema.
- ▶ Imaging studies using lymphography and indocyanine green, as well as lympho-magnetic resonance techniques.

## Challenges

- ▶ Improvement of the preoperative planning of perforator flaps with the help of advances in imaging techniques and knowledge of anatomy.
- ▶ Consolidate and optimize preoperative management techniques for locating the most suitable perforating vessels for each microsurgical flap.
- ▶ Minimize intra- and postoperative complications in perforator flaps using new imaging techniques to visualize intraoperatively patterns of vascularisation of the flaps and vascular blood supply dominance.
- ▶ Lymphedema prevention in those patients with mastectomy in which we perform searching procedures of sentinel node and/or axillaries lymph node dissections using new techniques of surgical treatment for this disease (lymphatic-venous anastomosis, transfer of vascularised lymph nodes).
- ▶ Identification by indocyanine green angiography for those patients affected with breast cancer with a major risk of developing secondary lymphedema.

## Collaborations

### Collaborations with other IIB Sant Pau Groups

- ▶ Advances in imaging techniques and therapy in muscle dystrophies: evaluation and treatment of the fibrosis. FISS. Clinical trial in conjunction with the Department of Neurology.

### External Collaborations

- ▶ Reporting clinical outcomes of prepectoral Braxton-assisted breast reconstruction: A 2-year Retrospective European Audit.
- ▶ A Double-Blind, Placebo- Controlled, Multicenter Study with an open-label extension to evaluate the efficacy and safety of SRP-4045 and SRP-4053 in Patients with Duchenne Muscular Dystrophy sponsored by Sarepta Therapeutics, Inc.

## Active Grants

- ▶ Josep Jaume Masia Ayala. Modelo experimental comparativo entre trasplante de células madre de tejido adiposo/médula ósea, anastomosis linfáticovenosas, trasplante de ganglios vascularizados en el linfedema. PI13/02793. Instituto de Salud Carlos III. Duration: 2014-2018. 29,000.00 €.

Note: Total amount granted to PI. It does not include indirect costs.

## Theses

- ▶ Manuel Fernández Garrido. Análisis descriptivo del pedículo vascular del colgajo SCIP. Constancia anatómica mediante estudio radiológico y ecográfico. Diseño y aplicación clínica. Universitat Autònoma de Barcelona. Directors: Jaume Masia Ayala, Xavier León Vintro. Date of defense: 27/07/2017.

## Scientific Production

**\*TIF: 13.0980 \*\*MIF: 2.6196**

Cheng M.-H., Koshima I., Chang D.W., Masia J., The 5th World Symposium for Lymphedema Surgery (2017) J SURG ONCOL, 115 (1), 5. **IF: 2.8860**

Loh C.Y.Y., Wu J.C.-W., Nguyen A., Dayan J., Smith M., Masia J., Chang D., Koshima I., Cheng M.-H., The 5th world symposium for lymphedema surgery—Recent updates in lymphedema surgery and setting up of a global knowledge exchange platform (2017) J SURG ONCOL, 115 (1), 6-12. **IF: 2.8860**

Miranda Garces M., Pons G., Mirapeix R., Masia J., Intratissue lymphovenous communications in the mechanism of action of vascularized lymph node transfer (2017) J SURG ONCOL, 115 (1), 27-31. **IF: 2.8860**

Tang J.B., Landin L., Cavadas P.C., Thione A., Chen J., Pons G., Masia J., Unique Techniques or Approaches in Microvascular and Microlymphatic Surgery (2017) CLIN PLAST SURG, 44 (2), 403-414. **IF: 2.0160**

Vidya R., Masia J., Cawthorn S., Berna G., Bozza F., Gardetto A., Kolacinska A., Dell'Antonia F., Tiengo C., Bassetto F., Caputo G.G., Governa M., Evaluation of the effectiveness of the prepectoral breast reconstruction with Braxton dermal matrix: First multicenter European report on 100 cases (2017) BREAST J, 23 (6), 670-676. **IF: 2.4240**

## Other Publications

- ▶ Garcia-Campo MJ, Quiles-Carrillo L, Masia J, Reig-Pérez MJ, Montanes N, Balart R. Environmentally Friendly Compatibilizers from Soybean Oil for Ternary Blends of Poly(lactic acid)-PLA, Poly(&ep-silon;-caprolactone)-PCL and Poly(3-hydroxybutyrate)-PHB. Materials (Basel). 2017 Nov 22;10(11).

# Palliative Care



## Coordinator

Pascual López, Antonio FGS  
apascual@santpau.cat

## Members

Collette, Nadia	IR
Fariñas Balaguer, Oscar	FGS
Güell Pérez, Ernest	FGS
Ramos Fernández, Adelaida	FGS

## Main Lines of Research

- ▶ Symptom evaluation and control: pain, dyspnoea, cognitive failure, complex situations.
- ▶ End-of-life ethical issues: sedation, expression of a desire for death, euthanasia.
- ▶ Psychosocial care for patients and families: adaptation to the terminal situation, grief, spiritual needs.

## Challenges

- ▶ Psychosocial care for patients and families.
- ▶ Counselling and hospital sensitization.
- ▶ Quality evaluation and control.
- ▶ Symptom evaluation and control.
- ▶ Integrated care: analysis and care of end-of-life emotional, social and spiritual dimensions and adequate ethical reflection in decision making.

## Grants Awarded in 2017

- ▶ Oscar Fariñas Balaguer. Ampliació criteri edat al-loempelts tendinosos. CONVENI BST 2017-1. Banc de Sang i Teixits. Duration: 2017-2018. 27,000.00 €.

Note: Total amount granted to PI. It does not include indirect costs.



# Andrology



## Coordinator

Ruiz Castañé, Eduard F. Puigvert  
eruiz@fundacio-puigvert.es

## Members

Bassas Arnau, Lluís	F. Puigvert
Krausz, Csilla	
Gabriella	F. Puigvert
Martínez Pasarell,	
Olga	F. Puigvert
Pedraza Godoy,	
M. Fernanda	F. Puigvert
Rajmil Marqueson,	
Osvaldo	F. Puigvert
Riera Escamilla,	
Antoni	F. Puigvert
Sánchez-Curbelo, J	
osvany	F. Puigvert
Vives Suñé, Alvarobar	F. Puigvert

## Main Lines of Research

- ▶ Genetics applied to male infertility.
- ▶ Male fertility preservation in oncological patients.
- ▶ Optimisation of preimplantation genetics diagnosis and in vitro fertilization techniques.

- ▶ Clinical research into new surgical procedures, drugs and medical devices applied to andrological diseases and conditions (male sexual dysfunction, hypogonadism, Peyronie disease, premature ejaculation, sexually transmitted diseases).

## Challenges

Our multidisciplinary team of professionals develops translational research in the field of diagnosis and treatment of andrological disorders. To improve our knowledge and thereby improve healthcare for patients, we seek to continue active projects, develop new lines of investigation, increase the number of interna-

tional publications, train professionals and enhance collaboration with hospital and university groups inside and outside the IIB Sant Pau.

## Collaborations

### Collaborations with other IIB Sant Pau Groups

- ▶ Nephrology Group.
- ▶ Urology Group.
- ▶ Gynecological Group.

### External Collaborations

#### National

- ▶ Medical and Molecular Genetics Centre (RI)-IDIBELL: genetics applied to infertility.
- ▶ Cellular Biology and Medical Genetics Unit-UAB: preimplantation genetic diagnosis techniques.

#### International

- ▶ Mario Serio Experimental and Clinical Biomedical Sciences Unit, University of Florence: genetics applied to male infertility.
- ▶ Reproductive Genomics Laboratory, Human Genetics Centre (KU Leuven): genetics applied to male infertility.
- ▶ New England Research Institutes: hypogonadism.
- ▶ European Academy of Andrology: radiology examinations of the male genital tract.

#### Private

- ▶ Participation in clinical studies including clinical trials and postauthorization studies sponsored by national and international pharmaceutical companies.

## Active Grants

- ▶ Csilla Gabriella Krausz . Estudio genético y genómico de subtipos específicos de azoospermia secretora: desarrollo de nuevas herramientas diagnósticas y pronósticas. PI14/01250. Instituto de Salud Carlos III. Duration: 2015-2018. 86,500.00 €.
- ▶ Krausz C. Evaluación del efecto de la terapia citostática sobre el genoma y el epigenoma del gameto masculino. Fundación Merck Salud: "Ayudas Merck de Investigación 2017 en el área de Investigación

Clinica en Fertilidad. Duration: 2017-2020. 30,000 €.

- ▶ Fundació Puigvert. Programa para el fomento de patentes y modelos de utilidad en el exterior. FPE-0701-00-20163. Oficina Española de Patentes y Marcas. Duration: 2017. 1,057.83 €.

Note: Total amount granted to PI. It does not include indirect costs.

## Grants Awarded in 2017

- ▶ Csilla Gabriella Krausz . Estudio genético y genómico en pacientes infériles y pacientes con tumor testicular de células germinales: desarrollo de nuevas herramientas para un diagnóstico precoz. PI17/01822. Instituto de Salud Carlos III. Duration: 2018-2020. 102,000.00 €.

Note: Total amount granted to PI. It does not include indirect costs.

## Awards

- ▶ Vinay, J.; Sarquella, J; Sánchez, J; Algaba, F; Gallegos, I; Rojas-Cruz, C; Palma, C. Sub-albuginean adipocyte accumulation is associated with erectile dysfunction: First clinical evidence and pathophysiological implications. Best poster in section "Last news in future treatments of erectile dysfunction". 31th EAU Annual Congress. Munich (Germany), 11-15 March.

## Theses

- ▶ Olga López Rodrigo. Caracterización biológica y molecular de síndromes teratozoospéricos causantes de la infertilidad masculina. Universidad de Barcelona. Directors: Ll. Bassas, R. Oliva. Date of defense: 21/09/2017.
- ▶ Antoni Riera-Escamilla. Genetic investigation in non-obstructive azoospermia: from the X chromosome to the whole exome , Università Degli Studi di Firenze. Director: Csilla Krausz. Date of defense: 10/03/2017.

## Transfer Products

- ▶ Diabetes and sexuality. Patient session. Director: MF Peraza with the collaboration of C. Regordosa (Catalonian Diabetic Patient Association). Barcelona, 16th November.

## Scientific Production

Bartolome E., Bozzo B., Sevilla P., Martínez-Pasarell O., Puig T., Granados X., ABS 3D printed solutions for cryogenic applications (2017) CRYOGENICS, 82, 30-37.

**IF: 1.196**

Casamonti E., Vinci S., Serra E., Fino M.G., Brilli S., Lotti F., Maggi M., Coccia M.E., Forti G., Krausz C., Short-term FSH treatment and sperm maturation: a prospective study in idiopathic infertile men (2017) ANDROLOGY-US, 5 (3), 414-422.

**IF: 2.734**

Cosentino M., Kanashiro A., Vives A., Sánchez J., Peraza MF., Moreno D., Perona J., De Marco V., Ruiz-Castañe E., Sarquella, J. Surgical treatment of Peyronie's disease with small intestinal submucosa graft patch. (2017) INT J IMPOT RES 28, 3, 106-109.

**IF: 1.517**

Espinós JJ., Polo A., Sanchez Henández J., Bordas JR., Parés P., Martínez-Passarell O., Calaf J. Weight decrease improves live birth rates in obese women undergoing IVF: A pilot study. (2017) REPROD BIOMED ONLINE 35 4 417-424.

**IF: 2.967**

**\*TIF: 27.196 \*\*MIF: 2.472**

Krausz C., Casamonti E., Spermatogenic failure and the Y chromosome (2017) HUM GENET, 136 (5), 637-655.

**IF: 3.930**

Romero Otero J., Rojas C., García Alonso F., García Gómez B., Sarquella J., Medina J., Ruiz-Castañe E., Rodriguez-Antolin A. Comparison of the patient and partner satisfaction with 700CX and titan penile prostheses. (2017) ASIAN J ANDROL 19, 3, 321-325.

**IF: 3.259**

Rosen R.C., Wu F., Behre H.M., Porst H., Meuleman E.J.H., Maggi M., Romero-Otero J., Martinez-Salamanca J.I., Jones T.H., Debruyne F.M.J., Kurth K.-H., Hackett G.I., Quinton R., Stroberg P., Reisman Y., Pescatori E.S., Morales A., Bassas L., Cruz N., Cunningham G.R., Wheaton O.A., Quality of Life and Sexual Function Benefits of Long-Term Testosterone Treatment: Longitudinal Results From the Registry of Hypogonadism in Men (RHYME) (2017) J SEX MED, 14 (9), 1104-1115.

**IF: 3.339**

Ruiz-Olvera S.F., Rajmil O., Sánchez-Curbelo J. R., Vinay J., Rodriguez-Espinosa J., Ruiz-Castañé E. Association of serum testoster-

one levels and testicular volume in adult patients. (2017) ANDROLOGY.

**IF: 2.734**

Vaszko T., Papp J., Krausz C., Casamonti E., Geczi, L., Olah E. Discrimination of deletion and duplication subtypes of the deleted in azoospermia gene family in the context of frequent interloci gene conversion. (2017) PLOS ONE 11, 10.

**IF: 2.766**

Vinay J., Sarquella J., Sanchez J., Algaba F., Gallegos I., Ruiz-Castañe E., Palma C., Adipocyte accumulation in corpus cavernosum: First clinical evidence and pathophysiological implications in erectile dysfunction Acumulación de adipocitos en el cuerpo cavernoso: primera evidencia clínica e implicaciones fisiopatológicas en la disfunción eréctil (2017) ACTAS UROL ESP, 41 (2), 97-102.

**IF: 1.260**

Vives A., Vázquez A., Rajmil O., Cosentino M. Urethral condylomas in men: experience in 123 patients without previous treatment. (2017) INT J STD & AIDS 27, 1, 39-43.

**IF: 1.494**

## Other Publications

- ▶ García-Cruz E., Monguet JM., Marrre D., González M., Peraza MF., Sánchez C., Susi C., Trejo A., Alcaraz A. A Multidisciplinary Approach to Sexual Behavior Profiles: The SEX360 P., Model. (2017) SEXUALITY & CULTURE 21(4): 941-52.

# Urology



## Coordinator

Villavicencio Maverich,  
Humberto F. Puigvert  
hvillavicencio@fundaciopuigvert.es

## Members

Algaba Arrea, Fernando	F. Puigvert
Arce Terroba, Yolanda	F. Puigvert
Breda, Alberto	F. Puigvert
Bujons Tur, Ana	F. Puigvert
Caffaratti Sfulcini, Jorge	F. Puigvert
Millán Rodríguez, Félix	F. Puigvert
Palou Redorta, Juan	F. Puigvert
Rodríguez Faba, Óscar	F. Puigvert

## Main Lines of Research

- ▶ Tissue engineering applied to urological oncology and congenital urogenital malformations.
- ▶ Genetic and immunohistochemistry analyses applied to urological cancers (diagnostic and prognostic biomarkers in urine, blood and tissues).

## Challenges

Translational research in the field of diagnosis and treatment of urological disorders. We seek to continue active projects, develop new lines of investigation, increase the number of international publications, train professionals and increase collaboration with hospital and university groups to improve our knowledge about kidney disorders and thereby improve healthcare for patients.

## Collaborations

### Collaborations with other IIB Sant Pau Groups

- ▶ Nephrology: genetic predisposition to prostate cancer.
- ▶ Clinical Epidemiology and Healthcare: epidemiological studies of urological cancers.
- ▶ Clinical Oncology: detection of prognosis biomarkers for drug response in kidney cancer.

### External Collaborations

#### National academic

- ▶ IDIBELL Molecular Genetics Laboratory: cystine lithiasis.
- ▶ CNIO: biomarkers in bladder cancer.
- ▶ National scientific societies (Spanish Urology Association, etc): clinical studies.

- ▶ Clinical research of new surgical procedures, drugs and medical device products applied to urological oncology, kidney transplantation and benign urogenital pathology (e.g. incontinence, benign hyperplasia of the prostate, lithiasis).

## International academic

- ▶ Aarhus University Molecular Genetics Department: bladder cancer.
- ▶ International Robotic Cystectomy Consortium: robotic cystectomy.
- ▶ International Renal Cell Carcinoma-Venous Thrombus Consortium: renal-cava thrombus in kidney cancer.

## Private national and international collaborations

- ▶ Clinical trials and postauthorization studies promoted by national and international pharmaceutical companies.

## Active Grants

- ▶ Ana Bujons Tur. Autologous enriched stem cell fat injection for the treatment of abdominal defects in patients with Exstrophy-Epispadias Complex. "Pedro Cifuentes Diaz" Research Grant. FIU. Duration: 2016-2017. 18,000 €.

Note: Total amount granted to PI. It does not include indirect costs.

## Books or chapters with ISBN

- ▶ Gaya JM, Emiliani E. Breda A. What is best port placement for urologic laparoscopy? In: Rane A., Turna B., Autorino R., Rassweiler JJ (Eds.). Practical Tips in Urology. Ed. Springer-Verlag London Limited, pages: 559-566. ISBN: 978-1-4471-4347-5.

## Awards

- ▶ Best Poster: Breda A., Territo A., Sanguedolce F., Manfredi M., Basile G., Gaya JM., Algaba F., Palou J., Villavicencio, H. Endomicroscopia Confocal (EC) en tumor urotelial de tracto urinario superior (TMTUS). Catalonian Society of Urology Congress. Barcelona, 30 Mars-1rst April.
- ▶ Best Case Award: Sabiote L., Mosquera M., Flores J., Català V., Emiliani F., Rousaud F., Sánchez-Martin F., Angerri O., Millan F., Villavicencio H. Litiasis ureteral en ectopia renal cruzada con fusión. Catalonian Society of Urology Congress. Barcelona, 30 Mars-1rst April.
- ▶ Joaquin Albarran 2nd Award to Best Poster: Breda A., Territo A., Gausa L., Manfredi M., Domenech F., Ponce De León X., Rodríguez Faba O., Gaya JM., Tu cu V., Decaestecker K., Stockle M., Fornara P., Olsburg J., Siena G., Doumerc N., Alcaraz A., Guirado LL., Facundo C., Villavicencio H. Transplante renal robotico: Resultados después de 1 año. Spansh Association of Urology- FIU Congress. Sevilla, 7-10 June.
- ▶ Best Poster. Breda A., Territo A., Manfredi M., Guttilla A., Quarisma L., Gaya J., Algaba F., Palou J., Villavicencio H. Confocal laser endomicroscopy in upper tract urothelial cancer (UTUC). American Urological Association Congress. Boston (Massachusetts-USA), 12-16 May.

## Transfer Products

- ▶ "What should we know about prostate cancer. Patient Session". Director: H. Villavicencio. Barcelona, 25 May.

## Scientific Production

**\*TIF: 313.184 \*\*MIF: 4.3498**

Angerri O., López JM., Sánchez-Martín F., Millán F., Rosales, A; Villavicencio H. Simple laparoscopic nephrectomy in stone disease: not always simple. *J ENDOUROL* 2017, 30(10): 1095-1098.

**IF: 2.038**

Babjuk M., Bohle A., Burger M., Capoun O., Cohen D., Comperat E.M., Hernandez V., Kaasinen E., Palou J., Roupert M., van Rhijn B.W.G., Sharif S.F., Soukup V., Sylvester R.J., Zigeuner R., EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016 (2017) *EUR UROL*, 71 (3), 447-461.

**IF: 17.581**

Breda A., Castellan P., Freitas RA., Schwartzmann I., Alvarez-Ossorio JL., Amon JH., Bellido JA., Ramos E., Rengifo D., Peña A., Villavicencio H. Renal and adrenal minimilaparoscopy: a prospective multicentric study. *UROLOGY* 2017, 92(6): 44-50.

**IF: 2.30**

Breda A., Emiliani E., Millán F., Scoffone C., Knoll T., Osther PJS., Liatsikos E. The new concept of ureteral access sheath with guide-wire disengagement: one wire does it all. *WORLD J UROL* 2017, 34(4): 603-606.

**IF: 2.981**

Breda A., Gausa LL., Territo A., López JM., Rodríguez Faba O., Caffaratti J., Ponce De León J., Guirado LL., Villavicencio H. Robotic-assisted kidney transplantation: our first case. *WORLD J UROL* 2017, 34(3): 443-447.

**IF: 2.981**

Breda A., Territo A., López JM. Benefits and risks of ureteral access sheaths for retrograde renal access. *CURR OPIN UROL* 2017, 26(1): 70-75.

**IF: 1.830**

Breda A., Territo A. Virtual reality simulators for robotassisted surgery. *EUR UROL* 2017, 69(6): 1081-1082.

**IF: 17.581**

Breda A., Territo A., Gausa LL., Rodriguez Faba O., Caffaratti J., Ponce de León X., Guirado LL., Facundo C., Guazzetti M., Guttilla A., Villavicencio H. Robotic kidney transplantation: one year after the beginning. *WORLD J UROL* 2017, 35(10): 1507-1515.

**IF: 2.981**

Bujons A., Lopategui DM., Rodríguez N., Centeno C., Caffaratti J., Villavicencio H. Quality of life in female patients with bladder exstrophy-epispadias complex: long-term-follow-up. *J PEDIATR UROL* 2017, 12(4): 210 E-210 6.

**IF: 1.935**

Bujons A., Millán F., Centeno C., Emiliani E., Sánchez-Martín F., Angerri O., Caffaratti J., Villavicencio H. Mini-percutaneous nephrolithotomy with high-power holmium yag laser in pediatric patients with staghorn and complex calculi. *J PEDIATR UROL* 2017, 12(4): 253 1-253 5.

**IF: 1.935**

Carpio Villanueva J., Rosales Bordes A., Ponce de Leon Roca J., Montllor Gonzalez M., Caparros Sariol J., Villavicencio Mavrich H., Laparoscopic adenomectomy: 10 years of experience (2017) *ACTAS UROL ESP*.

**IF: 1.260**

Catala V., Salas D., Esquena S., Mateu S., Algaba F., Palou J., De la Torre P. Questions and answers on prostate multiparameter magnetic resonance imaging: Everything a urologist should know. (2016) *ACTAS UROL ESP* 40, 6, 339-352.

**IF: 1.260**

Cindolo L., Castellan P., Scoffone C., Cracco C., Celia A., Paccaduscio A., Schips L., Proietti S., Breda A., Giusti G. Mortality and flexible ureteroscopy: analysis of six cases. *WORLD J UROL* 2017, 34(3): 305-310.

**IF: 2.981**

Corona Montes V.E., Pastore A.L., Gausa L., Rodriguez-Fa Ba O., Breda A., Palou J., Robot assisted retroperitoneal lymph-node dissection after adjuvant therapy: Different indications (2017) *MINERVA UROL NEFROL*, 69 (2), 153-158.

**IF: 1.449**

Dal Moro F., Haber G.P., Wiklund P., Canda A.E., Balbay M.D., Stenl A., Zattoni F., Palou J., Gill I., Catto J.W.F., Robotic intracorporeal urinary diversion: Practical review of current surgical techniques (2017) *MINERVA UROL NEFROL*, 69 (1), 14-25.

**IF: 1.449**

Dyrskjot L., Reinert T., Algaba F., Christensen E., Nieboer D., Hermann G.G., Mogensen K., Beukers W., Marquez M., Segersten U., Hoyer S., Ulhoi B.P., Hartmann A., Stohr R., Wach S., Nawroth R., Schwamborn K., Tulic C., Simic T., Junker K., Harving N., Petersen A.C., Jensen J.B., Keck B., Grimm M.-O., Horstmann M., Maurer T., Steyerberg E.W., Zwarthoff E.C., Real F.X., Malats N., Malmstrom P-U., Orntoft T.F., Prognostic Impact of a 12-gene Progression Score in Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Validation Study (2017) *EUR UROL*, 72 (3), 461-469.

**IF: 17.581**

Emiliani E., Gavrilov P., Mayordomo O., Salvador J., Palou J., Rosales A., Villavicencio H., Laparoscopic management of ureteroileal stenosis: Long term follow up Manejo laparoscópico de la estenosis uretero-ileal con

# Urology

## Scientific Production

\*TIF: 313.184 \*\*MIF: 4.3498

seguimiento a largo plazo (2017) ARCH ESP UROL, 70 (4), 487-491.

**IF: 0.465**

Faba O.R., Brookman-May S.D., Linares E., Breda A., Pisano F., Subiela J.D., Sanguedolce F., Braus M., Palou J., Cytoreductive nephrectomy in patients with metastatic renal cell carcinoma in the era of targeted therapy: a bibliographic review (2017) WORLD J UROL, 35 (12), 1807-1816.

**IF: 2.981**

Garat JM., Scivoli F., Bujons A. Novel plicating "wrap" technique for treating anterior urethral ballooning. UROLOGY 2017, 101: 119-122.

**IF: 2.300**

Gual Frau J., Palou J., Rodríguez O., Parada R., Breda A., Villavicencio H. Failure of Bacillus Calmette-Guérin therapy in non-muscle-invasive bladder cancer: Definition and treatment options. (2017) ARCH ESP UROL 69 7 423-433.

**IF: 0.465**

Golabek T., Palou J., Rodriguez O., Gaya J.M., Breda A., Villavicencio H., Is it possible to stop follow-up of patients with primary T1G3 urothelial carcinoma of the bladder managed with intravesical bacille Calmette-Guiérin immunotherapy? (2017) WORLD J UROL, 35 (2), 237-243.

**IF: 2.981**

Golabek T., Palou J., Rodriguez O., Parada R., Skrobot S., Pena J.A., Villavicencio H., Long-term Bladder and Upper Urinary Tract Follow-up Recurrence and Progression Rates of G1-2 Non-muscle-invasive Urothelial Carcinoma of the Bladder (2017) UROLOGY, 100, 145-150.

**IF: 2.300**

Gomis C., Sarquella J., Arce Y., Vinay J.I., Testicular intraepithelial neoplasia and infertility: Azoospermia associated with bilateral testicular intraepithelial neoplasia Neoplasia intratubular testicular e infertilidad: azoospermia asociada a neoplasia intratubular testicular bilateral (2017) REV INT ANDROL, 15 (4), 165-168.

**IF: 0.096**

Guillen-Gomez E., Dasilva I., Silva I., Arce Y., Facundo C., Ars E., Breda A., Ortiz A., Guirado L., Ballarin J.A., Diaz-Encarnacion M.M., Early Macrophage Infiltration and Sustained Inflammation in Kidneys From Deceased Donors Are Associated With Long-Term Renal Function (2017) AM J TRANSPLANT, 17 (3), 733-743.

**IF: 6.493**

Guiote I., Gaya JM., Gausa L., Rodríguez Faba O., Palou, J. Complicaciones de la cistectomía radical robótica: dónde estamos? ACTAS UROL ESP 2017, 40(2): 108-114.

**IF: 1.260**

Hedegaard J., Lamy P., Nordentoft I., Algaba F., Hoyer S., Ulhoi BP., Vang S., Reinert T., Hermann GG., Mogensen K., Thomsen MB., Nielsen MM., Marquez M., Jensen JB., Pedersen JS., Malmstrom PU., Malats N., Real FX., Zwarthoff E., Orntoft TF., Dyrskjot L. Comprehensive transcriptional analysis of early-stage urothelial carcinoma. CANCER CELL 2017, 30(1): 27-42.

**IF: 3.960**

Hussain A., May P.R., Ahmed H., Saar M., Wijburg C., Richstone L., Wagner A., Wilson T., Yuh B., Palou J., Dasgupta P., Kawa O., Khan M.S., Menon M., Peabody J., Hosseini A., Gaboardi F., Canda E., Balbay D., Wiklund P., Guru K.A. Development of a patient and institutional-based model for estimation of operative times for robot-assisted radical cystectomy: results from the international robotic cystectomy consortium. BJU INT 2017, 120 (5):695-701.

**IF: 4.688**

Hussain A., Saar M., May P.R., Wijburg C., Richstone L., Wagner A., Wilson T., Yuh B., Palou J., Dasgupta P., Khan M.S., Menon M., Peabody J., Hosseini A., Gaboardi F., Mottrie A., Rha K., Maatam T., Canda E., Wiklund P., Guru K.A. Early oncologic failure after robot assisted radical cystectomy: results from the international robotic cystectomy consortium. J UROL 2017, 197(6): 1427-1436.

**IF: 5.381**

Ingels A., Hew M., Algaba F., de Boer O.J., van Moorselaar R.J.A., Horenblas S., Zondervan P., de la Rosette J.J.M.C.H., Pilar Laguna Pes M., Vimentin over-expression and carbonic anhydrase IX under-expression are independent predictors of recurrence, specific and overall survival in non-metastatic clear-cell renal carcinoma: a validation study (2017) WORLD J UROL, 35 (1), 81-87.

**IF: 2.981**

Jessen J., Breda A., Brehmer M., Liatsikos E., Millán F., Osther P.J.S., Scoffone C., Knoll T. International collaboration in endourology: multicenter evaluation of presenting for ureterorenoscopy. J ENDOUROL 2017, 30(3): 268-273.

**IF: 2.0280**

Juárez del Dago P., Carpio J., Gaya, JM., Palou J. Manejo conservador y seguimiento en pacientes con carcinoma urotelial del tramo urinario superior: presente o futuro? ACTAS UROL ESP 2017, 40(7): 415-416.

**IF: 1.260**

Kamat A.M., Colombel M., Sundi D., Lamm D., Boehle A., Brausi M., Buckley R., Persad R., Palou J., Soloway M., Witjes J.A., BCG-unresponsive non-muscle-invasive bladder cancer: Recommendations from the IBCG (2017) NAT REV UROL, 14 (4), 244-255.

**IF: 8.089**

Kamat AM., Sylvester R., Böhle A., Palou J., Lamm D., Brausi M., Soloway M., Persad R., Buckley R., Colombel M., Witjes A. Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the international bladder cancer group. J CLIN ONCOL 2017, 34(16): 1935-1944.

**IF: 26.303**

Kanashiro A., Gaya J.M., Palou J., Gausa L., Villavicencio H., Robot-assisted radical cystoprostatectomy: Analysis of the complications and oncological and functional aspects Cistoprostatectomía radical robótica: análisis oncológico, funcional y de las complicaciones (2017) ACTAS UROL ESP, 41 (4), 267-273.

**IF: 1.260**

Kassouf W., Traboulsi SL., Schmitz-Dräger BJ., Palou J., Witjes A., Van Rhijn., Bas WG., Grossman HB., Kiemeney LA., Goebell PJ., Kamat AM. Follow-Up In Non-Muscle-Invasive Bladder Cancer. International Bladder Cancer Network Recommendations. UROL ONCOL 2017, 34(10): 460-468.

**IF: 3.397**

Kweldam CF., Nieboer D., Algaba F., Bostwick DG., Bubendorf L., Cheng L., Comperat E., Delahunt B., Egevad L., Evans AJ., Hansel DE., Humphrey P., Kristiansen G., Van Der Kwast TH., Magi-Galluzzi C., Montironi R., Netto GJ., Samaratunga H., Varma Zhou M., Van Leenders JLH. Gleason grade 4 prostate adenocarcinoma patterns: an interobserver agreement study among genitourinary pathologists. HISTOPATHOLOGY 2017, 69(3): 441-449.

**IF: 3.267**

Lammers RJ., Hendriks JC., Rodríguez Faba O., Witjes WPJ., Palou J., Witjes A. Prediction model for recurrence probabilities after intravesical chemotherapy in patients with intermediate-risk non-muscle invasive bladder cancer, including external validation. WORLD J UROL 2017, 34(2): 173-180.

**IF: 2.981**

Lazzeri M., Lughezzani G., Haese A., McNicholas T., De La Taille A., Buffi N., Cardone P., Hurle R., Casale P., Bini V., Palou J., Graefen M., Guazzoni G. Clinical performance of prostate health index in men with tpsa>10ng/ml: results from a multicentric european study. (2017) UROL ONCOL 34 9 415 EE19.

**IF: 3.397**

Mager R., Daneshmand S., Evans CP., Palou J., Martínez-Salamanca J., Master VA., McKernan M., Libertino J., Haferkamp A. Renal cell carcinoma with inferior vena cava involvement: prognostic effect of tumor thrombus consistency on cancer specific survival. J SURG ONCOL 2017, 114(6): 764-768.

**IF: 2.886**

**\*TIF: 313.184 \*\*MIF: 4.3498**

Mandalapu R.S., Remzi M., de Reijke T.M., Margulis V., Palou J., Kapoor A., Yossepowitch O., Coleman J., Traxer O., Anderson J.K., Catto J., de la Rosette J., O'Brien T., Zlotta A., Matin S.F., Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of low-risk upper tract urothelial carcinoma (2017) *WORLD J UROL*, 35 (3), 355-365.

**IF: 2.981**

Manikandan R., Rodriguez Faba O., Parada R., Palou J. Nonmuscle-invasive bladder cancer: what's changing and what has changed. *UROLOGIA* 2017, 84(1): 1-8.

**IF: 0.29**

Maroto P., Esteban E., Fernandez Parra E., Mendez-Vidal M.J., Domenech M., Perez-Valderrama B., Calderero V., Perez-Gracia J.L., Grande E., Algaba F., HIF pathway and c-Myc as biomarkers for response to sunitinib in metastatic clear-cell renal cell carcinoma (2017) *ONCOTARGETS THER*, 10, 4635-4643.

**IF: 2.656**

Naito S., Algaba F., Babjuk M., Bryan RT., Sun YH., Valiquette L., De La Rosette J. The clinical research office of the endourological society (CROES) multicentre randomised trial of narrow band imaging-assisted transurethral resection of bladder tumour (TURBT) versus conventional white light imaging-assisted turbt in primary non-muscle. *EUR UROL* 2017, 70(3): 506-515.

**IF: 17.581**

Palou J., Solsona E., Angulo J., Fernández JM., Madero R., Unda M., Martínez-Piñeiro JA., Portillo JA., Chantada V., Moyano JL. Estudio retrospectivo de diferentes opciones de tratamiento conservador con bacilo de Calmette-Guerin en el carcinoma urotelial vesical T1G3: terapia de mantenimiento. *ACTAS UROL ESP* 2017, 40(6): 370-377.

**IF: 1.260**

Pastore A.L., Mir A., Maruccia S., Palleschi G., Carbone A., Lopez C., Camps N., Palou J., Psychological distress in patients undergoing surgery for urological cancer: A single centre cross-sectional study (2017) *UROL ONCOL-SEMIN ORL*, 35 (12), 673.e1-673.e7.

**IF: 3.397**

Peña A., Schwartzmann I., Gavrilov P., Moncada E., López JM., Gaya JM., Oliveira M., Breda A., Rosales A., Palou J., Villavicencio H. Tumorectomía off-clamp por retroperitoneoscopia en tumores renales posteriores de complejidad media (Padua score 8-9). *ACTAS UROL ESP* 2017, 40(1): 11-16.

**IF: 1.260**

Ribal MJ., Mengual L., Lozano JJ., Ingelmo-Torres M., Palou J., Rodríguez Faba O., Witjes A., Van Der Heijden AG., Medina RA., Conde JM., Marberger M., Schmidbauer J., Fernández PL., Alcaraz A. Gene expression

test for the non-invasive diagnosis of bladder cancer: a prospective, blinded, international and multicenter validation study. *EUR J CANCER* 2017, 54(2): 131-138.

**IF: 7.191**

Ricciardulli S., Ding Q., Zhang X., Li H., Wang B., Yang G., Zhang P., Ma X., Breda A. Evaluation of padua score as predictor of warm ischemia time (WIT) during laparoscopic partial nephrectomy (LPN). (2017) *UROLOGIA* 83 4 194-199.

**IF: 0.29**

Rocco B., Grasso A.A.C., de Lorenzis E., Davis J.W., Abbou C., Breda A., Erdogru T., Gaston R., Gill I.S., Liatsikos E., Oktay B., Palou J., Piechaud T., Stolzenburg J.U., Sun Y., Albo G., Villavicencio H., Zhang X., Disanto V., Emilizzi P., Pansadoro V., Live surgery: highly educational or harmful? (2017) *WORLD J UROL*, 1-5.

**IF: 2.981**

Rodríguez Faba O., Akdogan B., Marszałek M., Langenhuijsen J., Brookman-May S., Stewart GD., Capitanio U., Sanguedolce F. Current status of focal cryoablation for small renal masses. *UROLOGY* 2017, 2017(90): 9-15.

**IF: 2.30**

Rodríguez Faba O., Brookman-May S., Linares E., Breda A., Pisano F., Subiela J., Sanguedolce F., Brausi M., Palou J. Cytoreductive nephrectomy in patients with metastatic renal cell carcinoma in the era of targeted therapy: a Bibliographic review. *WORLD J UROL* 2017, 35(12): 1807-1816.

**IF: 2.981**

Rodríguez Faba O., Gaya JM., Breda A., Juárez del Dago P., Pisano F., Salas D., Palou J. Resection of the intramural portion of the distal ureter during transurethral resection of bladder tumors: predictive factors for secondary stenosis and development of upper urinary tract recurrence. *J UROL* 2017, 196(1): 52-56.

**IF: 5.381**

Rodriguez Faba O., Palou J., Vila Reyes H., Guirado L., Palazzetti A., Gontero P., Vigues F., Garcia-Olaverri J., Fernandez Gomez J.M., Olsburg J., Terrene C., Figueiredo A., Burgos J., Lledo E., Breda A., Treatment options and predictive factors for recurrence and cancer-specific mortality in bladder cancer after renal transplantation: A multi-institutional analysis Opciones terapéuticas y factores predictivos de recurrencia y mortalidad cancer-específica en pacientes con tumor vesical después de trasplante renal: análisis multiinstitucional (2017) *ACTAS UROL ESP*, 41 (10), 639-645.

**IF: 1.260**

Rodríguez Faba O., Sanguedolce F., Grange P., Kooiman G., Bakavicius A., De La Torre P.,

Palou, J. Kidney cancer focal cryoablation trend: does location or approach matter? *WORLD J UROL* 2017, 34(7): 917-923.

**IF: 2.981**

Rosales A., Emiliani E., Salvador J., Peña A., Gaya JM., Palou J., Villavicencio H. Laparoscopic management of ureteroileal anastomosis strictures: initial experience. *EUR UROL* 2017, 70(3): 493-498.

**IF: 17.581**

Sanchez-Martin F.M., Angerri O., Emiliani E., Moncada E., Carpio J., Millan F., Villavicencio H., Epidemiology of urolithiasis in Spain: Review of published demographic data in the period 1977-2016 Epidemiología de la urolitiasis en España: Revisión de los datos demográficos publicados en el periodo 1977-2016 (2017) *ARCH ESP UROL*, 70 (2), 294-303.

**IF: 0.465**

Sánchez-Martín F., López JM., Kanashiro A., Moncada E., Angerri O., Millán F., Villavicencio H. Corinebacterium urealyticum: aumento de la incidencia de infección y uropatía incrustante. *ACTAS UROL ESP* 2017, 40(2): 102-107.

**IF: 1.260**

Schwartzmann I., Gaya JM., Breda, A. Cateterización tras ureteroscopia. Siempre? Nunca? Cuando? *ARCH ESP UROL* 2017, 69(8): 565-570.

**IF: 0.465**

Schwartzmann I., Pastore A.L., Sacca A., Territo A., Pisano F., Maruccia S., Breda A., Palou J., Upper Urinary Tract Urothelial Carcinoma Tumor Seeding along Percutaneous Nephrostomy Track: Case Report and Review of the Literature (2017) *UROL INT*, 98 (1), 115-119.

**IF: 1.508**

Secin F.P., Castillo O.A., Rozanec JJ., Featherston M., Holst P., Milfont J.C.A., Garcia Marchinena P., Jurado Navarro A., Autran A., Rovegno A.R., Faba O.R., Palou J., Teixeira Dubeux V., Nunez Bragayrac L., Sotelo R., Zequi S., Guimaraes G.C., Alvarez-Maestro M., Martinez-Pineiro L., Villoldo G., Villaronga A., Abreu Clavijo D., Decia R., Frota R., Vidal-Mora I., Finkelstein D., Monzo Gardiner J.I., Schatloff O., Hernandez-Porrás A., Santalla-Torres F., Quesada E.T., Sanchez-Salas R., Davila H., Mavric H.V., American Confederation of Urology (CAU) experience in minimally invasive partial nephrectomy (2017) *WORLD J UROL*, 35 (1), 57-65.

**IF: 2.981**

Seisen T., Peyronnet B., Dominguez-Escriv JL., Bruins HM., Yuan CY., Babjuk M., Böhle A., Burger M., Comperat E., Cowan N., Kaasinen E., Palou J., Van Rhijn Bas WG., Sylvester R., Zigeuner R., Shariat SF., Rouprét M. Oncologic outcomes of kidneysparing surgery versus radical nephroureterectomy for upper tract

# Urology

## Scientific Production

\*TIF: 313.184 \*\*MIF: 4.3498

urothelial carcinoma: a systematic review by the EAU nonmuscle invasive bladder cancer guidelines panel. EUR UROL 2017, 70(6): 1052-1068.

**IF: 17.581**

Soukup V., Capoun O., Cohen D., Hernandez V., Babjuk M., Burger M., Comperat E., Gonttero P., Lam T., MacLennan S., Mostafid A.H., Palou J., van Rhijn B.W.G., Roupert M., Shariat S.F., Sylvester R., Yuan Y., Zigeuner R., Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non-muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic Review (2017) EUR UROL, 72 (5), 801-813.

**IF: 17.581**

Territo A., Mottrie A., Abaza R., Rogers C., Menon M., Bhandari M., Ahlawat R., Breda A., Robotic kidney transplantation: Current status and future perspectives (2017) MINERVA UROL NEFROL, 69 (1), 5-13.

**IF: 1.449**

Tilki D., Chandrasekar T., Capitanio U., Ciancio G., Daneshmand S., Gontero P., Gonzalez J., Haferkamp A., Hohenfellner M., Huang W.C., et al., Impact of lymph node dissection at the time of radical nephrectomy with tumor thrombectomy on oncological outcomes: Results from the International Renal Cell Carcinoma-Venous Thrombus Consortium (IRCC-VTC) (2017) UROL ONCOL-SEMIN ORI.

**IF: 3.397**

Varma M., Egevad L., Algaba F., Berney DM., Bubendorf L., Camparo P., Comperat E., Ebersdobler A., Griffiths DF., Grobholz R., Langner C., Loftus B., López Beltran A., Mayer N., Nesi G., Oliveira P., Oxley J., Rioux-Leclercq

N., Seitz G., Shanks JK., Intraductal carcinoma of prostate reporting practice: a survey of expert european uropathologists. J CLIN PATHOL 2017, 69(10): 852-857.

**IF: 2.984**

Veneziano D., Ahmed K., Van Cleynenbreugel B., Gozen A., Palou J., Sarica K., Liatsikos E., Sanguedolce F., Honeck P., Alvarez-Maestro M., Papatsoris A., Kallidonis P., Greco F., Breda A., Somanı B.K., Development Methodology of the Novel Endoscopic Stone Treatment Step 1 Training/Assessment Curriculum: An International Collaborative Work by European Association of Urology Sections (2017) J ENDOUROL, 31 (9), 934-941.

**IF: 2.038**

Verrill C., Yilmaz A., Srigley J.R., Amin M.B., Comperat E., Egevad L., Ulbright T.M., Tickoo S.K., Berney D.M., Epstein J.I., Delahunt B., Magi-Galluzzi C., Algaba F., Oliva E., Montironi R., Young R.H., Idrees M.T., Williamson S.R., Zhou M., Humphrey P.A., Lopez-Beltran A., Perry-Keene J., Reporting and staging of testicular germ cell tumors: The international society of urological pathology (ISUP) testicular cancer consultation conference recommendations (2017) AM J SURG PATHOL, 41 (6), e22-e32.

**IF: 5.878**

Vinay J., Sarquella J., Sanchez J., Algaba F., Gallegos I., Ruiz-Castane E., Palma C., Adipocyte accumulation in corpus cavernosum: First clinical evidence and pathophysiological implications in erectile dysfunction Acumulación de adipocitos en el cuerpo cavernoso: primera evidencia clínica e implicaciones fisiopatológicas en la disfunción eréctil (2017) ACTAS UROL ESP, 41 (2), 97-102.

**IF: 1.260**

Williamson S.R., Delahunt B., Magi-Galluzzi C., Algaba F., Egevad L., Ulbright T.M., Tickoo S.K., Srigley J.R., Epstein J.I., Berney D.M., Amin M.B., Comperat E., Humphrey P.A., Idrees M.T., Lopez-Beltran A., Montironi R., Oliva E., Perry-Keene J., Verrill C., Yilmaz A., Young R.H., Zhou M., The World Health Organization 2016 classification of testicular germ cell tumours: a review and update from the International Society of Urological Pathology Testis Consultation Panel (2017) HISTOPATHOLOGY, 70 (3), 335-346.

**IF: 3.267**

Zequi S.C., Clavijo D.A., Nolazco A., Martinez P., Rozanec J., Ameri C., Vitagliano G., Pita H.R., Gueglio G., Jurado A., et al., The creation, development and diffusion of the larcglatin american renal cancer group (2017) INT BRAZ J UROL, 43 (1), 3-6.

**IF: 0.976**

Witjes A., Dallbagni G., Karnes RJ., Shariat SF., Joniau S., Palou, J., Serretta V., Larre., S; Di Stasi S., Colombo R., Babjuk M., Malmstrom PU., Malats N., Cha E., Ardeit P., Varkarakis J., Bartoletti R., Spahn M., Pisano F., Gontero P., Sylvester, R. The efficacy of BCG tice and BCG connaught in a cohort OF 2.099 patients with T1G3 non-muscle-invasive bladder cancer. UROL ONCOL 2017, 34(11): E19-E25.

**IF: 3.397**

Zondervan PJ., Wagstaff PG., Desai MM., De Bruin DM., Fraga, AF., Hadaschik BA., Kollermann J., Liehr UB., Paheznik SA., Schlemmer HP., Wendler JJ., Algaba F., De La Rosette J., Laguna P. Follow-up after focal therapy in renal masses: an international multidisciplinary delphi consensus project. WORLD J UROL 2017, 34(12): 1657-1665.

**IF: 2.981**



# Radiation Oncology



## Coordinator

Craven-Bartle Lamote  
de Grignon, Jordi  
jcraven@santpau.cat

## Members

Balart Serra, Josep

FGS

FGS

## Main Lines of Research

Research is partially conducted on the premises of the Translational Research Laboratory of the Catalan Oncology Institute (ICO)-Bellvitge Biomedical Research Institute (IDIBELL) under a framework agreement between Sant Pau and the ICO.

### Modulation of Radiosensitivity

- ▶ Modulation of radiosensitivity by SRC protein inhibitors in combination with anti-EGFR.
- ▶ Modulation of radiosensitivity by HMG-CoA reductase inhibitors in combination with anti- EGFR.

### SBRT for Patients with Lung Cancer and with Oligometastases

- ▶ Stereotactic body radiotherapy techniques in radical treatment of patients with early-stage non-surgical lung cancer and selected patients with non-surgical oligometastases.

## Radiation Therapy Based on PET/CT Functional Imaging of Tumours

- ▶ Implementation of planning techniques for radiotherapy treatment with PET/CT for chest locations and head and neck tumours squamous cell tumours.
- ▶ Image-guided radiotherapy and respiratory movement control.
- ▶ Salvage brachytherapy for local recurrence after external beam radiotherapy in prostate cancer.
- ▶ Hypofractionated intensity-modulated GRT in prostate cancer.

## Challenges

- ▶ Establish relatively radioresistant cell lines compared with the parental cells from which they derive (by clonal selection).
- ▶ Determine the resistant phenotype in cultures and xenografts.
- ▶ Determine molecular radioresistance.
- ▶ Evaluate the effect on carcinomas of SRC and HMG-CoA reductase inhibitors in combination with anti-EGFR.
- ▶ Explore signal transduction changes in the EGFR-MAPK pathway and SRC-EGFR/SRC-STAT3 cooperation induced by SRC and HMG-CoA reductase inhibitors.

## Scientific Production

Balana C., Capellades J., Pine-  
da E., Estival A., Puig J., Do-  
menech S., Verger E., Pujol T.,  
Martinez-Garcia M., Oleaga  
L., Velarde J., Mesia C., Fuent-  
es R., Marruecos J., Del Barco  
S., Villa S., Carrato C., Gallego  
O., Gil-Gil M., Craven-Bartle J.,  
Alameda F., Pseudoprogres-  
sion as an adverse event of  
glioblastoma therapy (2017)

\*TIF: 4.404 \*\*MIF: 2.202

CANCER MED-US, 6 (12),  
2858-2866.  
**IF: 3.202**

Montes A., Fernandez A.,  
Camacho V., de Quintana C.,  
Gallego O., Craven-Bartle J.,  
Lopez D., Molet J., Gomez-An-  
son B., Carrio I., The useful-  
ness of 18F-fluorocholine  
PET/CT in the detection of  
recurrence of central nervous

system primary neoplasms  
Valor de la PET/TC cerebral  
con 18F-fluorocolina en la  
detección de recurrencias de  
neoplasias primarias del  
sistema nervioso central  
(2017) REV ESP MED NUCL  
IMA, 36 (4), 227-232.  
**IF: 1.202**

\*Total Impact Factor \*\*Mean Impact Factor



# Locomotor System Research



**Coordinator**  
Crusi Sererols, Xavier FGS  
xcrusi@santpau.cat

**Members**

Aguilera Roig, Xavier	FGS
Almenara Fernández, Marta	FGS
Álvarez Gómez, Carlos	FGS
Jordan, Marcos	FGS
Millán Bili, Angélica	FGS
Velasco González, Laura	FGS
Pulido García, M. Carmen	FGS
Carrera Fernández, Ion	FGS
De Caso Rodríguez, Julio	FGS
Gelber Ghertner, Pablo Eduardo	FGS
Gamba, Carlo	FGS
González Rodríguez, José Carlos	FGS
Gracia Alegria, Isidre	FGS
Lamas Gómez, Claudia María	FGS
Monllau García, Joan Carles	FGS
Moya Gómez, Esther	FGS
Natera Cisneros, Luis Gerardo	FGS
Noguera Alonso, Laura	FGS
Pérez Romera, Ana Belén	FGS
Peiró Ibáñez, Ana	FGS
Proubasta Renart, Ignacio	FGS
Sarasquete, Juan	FGS
Soria Villegas, Laura	FGS
Vilà Canet, Gemma	FGS
Valera Pertegàs, Màrius	FGS
Velázquez Fragoso, Juan José	FGS

## Main Lines of Research

## Awards

### Antiresorptives in Orthopedic and Trauma Surgery

- ▶ Effect of zoledronic acid (Aclasta) on peri-prosthetic bone mineral density in patients undergoing total knee arthroplasty. Study approved by the HSCSP ethics committee and authorized by the Spanish Medicines and Health Products Agency (AEMPS) for the out-of-context indication of Aclasta.

### Knee

#### Haemostasis

- ▶ Blood loss control using tranexamic acid in primary prosthetic and knee revision surgery.
- ▶ Retrospective study of revision knee arthroplasty to compare the effects of intravenous tranexamic acid and normal haemostasis.
- ▶ Clinical trial comparing outcomes for intravenous tranexamic acid with fibrin glue (Tissucol) and normal haemostasis in primary knee prosthetic surgery.
- ▶ Observational study of blood loss in redon drainage over time in pectenotrochanteric hip fractures.
- ▶ Randomized multicenter parallel clinical trial in antiaggregated patients with proximal femur fracture that evaluates a strategy to shorten the time to surgery. AFFECT study.

#### Cartilage

- ▶ Regeneration of cartilage defects using tissue engineering and a matrix seeded with characterized allogeneic chondrocytes.

#### Cartilage

- ▶ Prospective study on fresh osteochondral allograft transplantation. CT, MRI and clinical outcomes.

#### Patella

- ▶ Prospective comparative study on patellar fractures. Metallic wiring versus suture fixation.

### Meniscus

- ▶ Effect of normal and growth-factor-enriched cell cultures on the meniscal collagen network and glycosaminoglycan expression.
- ▶ In vitro experimental study of the feasibility of a polyurethane replacement meniscus pre-seeded with stem cells.
- ▶ Evolution of allogeneic meniscal transplants and relationship with extrusion.

### Hip

- ▶ Coxarthrosis in young adults: etiological study of biomechanical factors.
- ▶ Biomechanics of coxarthrosis in young adults: finite element study.
- ▶ Influence of hip anatomy in early development of coxarthrosis: controlled, prospective radiographic study.
- ▶ Osteosynthesis with cannulated screws in non-displaced femoral neck fractures in elderly patients.
- ▶ Randomized clinical trial for capsular and rotator muscles suture in cemented bipolar hemiarthroplasties in patients with femur fracture.

### Foot and Ankle

- ▶ Prospective randomized clinical trial for the surgical treatment of Achilles tendon ruptures: repair with mini-invasive technique vs open tenorrhaphy.

### Upper Limb

- ▶ Anatomical study of stabilizing ligaments in the trapeziometacarpal joint: the role played by dorsoradial and anterior oblique ligaments in Bennett and Rolando fractures.
- ▶ Surgical treatment of middle-third clavicle fractures in high-energy trauma in young patients.
- ▶ Retrospective study of the use of vascularized bone graft using the 1,2-ICSR artery in the revascularization of proximal pole necrosis in scaphoid pseudarthrosis.

- ▶ Preize for the poster C. Lamas, H. Haro, I. Proubasta, I. Gich. Estudio comparativo de tres técnicas de reparación de la rotura aguda del ligamento colateral cubital del pulgar. XXIII Congreso de la Sociedad Española de Cirugía de la Mano (SECMA) and IV Congreso conjunto de la Sociedad Portuguesa de Cirugía de la Mano. Marbella 5-7 April 2017.

**Grants  
Awarded in  
2017**

- ▶ Pablo Eduardo Gelber Ghertner. Preservació en fresc al-loempelts osteocondrals. Conveni BST 2017-2. Banc de Sang i Teixits. Duration: 2017-2018. 44,500.00 €.

Note: Total amount granted to PI. It does not include indirect costs.

**\*TIF: 20.546 \*\*MIF: 2.2828**

Gomez C.L., Gondolbeu A.M., Marti R.M., Renart I.P., Perez M.L., The role of the carpo-metacarpal ligaments of the thumb in stability and the development of osteoarthritis lesions : An anatomical study (2017) ACTA ORTHOP BELG, 83 (3), 449-457.

**IF: 0.542**

Gonzalez-Osuna A., Videla S., Canovas E., Urrutia G., Rojas S., Lopez R., Murat J., Aguilera X., HESTAT: Study protocol for a phase II/III, randomized, placebo-controlled, single blind study to evaluate the new hemostatic agent TT-173 in total knee arthroplasty (2017) CONTEMP CLIN TRIALS, 61, 16-22.

**IF: 2.658**

Lizano-Diez X., Gines-Cespedosa A., Alentorn-Geli E., Perez-Prieto D., Gonzalez-Lucena G., Gamba C., de Zabala S., Solano-Lopez A., Rigol-Ramon P., Corticosteroid Injection for the Treatment of Morton's Neuroma: A Prospective, Double-Blinded, Randomized, Placebo-Controlled Trial (2017) FOOT ANKLE INT, 38 (9), 944-951.

**IF: 2.653**

Millan-Billi A., Gomez-Masdeu M., Ramirez-Bermejo E., Ibanez M., Gelber P.E., What is the most reproducible classification system to assess tibial plateau fractures? (2017) INT ORTHOP, 41 (6), 1251-1256.

**IF: 2.377**

Monllau J.C., Masferrer-Pino A., Ginovart G., Perez-Prieto D., Gelber P.E., Sanchis-Alfonso V., Clinical and radiological outcomes after a quasi-anatomical reconstruction of medial patellofemoral ligament with gracilis tendon autograft (2017) KNEE SURG SPORT TR A, 25 (8), 2453-2459.

**IF: 3.210**

Natera L., Valera M., Gomez E.M., Ibanez N., Crusi X., Sancho R., Survival of hydroxyapatite-coated cups: Acetabular screws involve a lower rate of revision surgery due to aseptic loosening (2017) HIP INT, 27 (2), 153-161.

**IF: 1.276**

Perez-Prieto D., Capurro B., Gelber P.E., Ginovart G., Reina F., Sanchis-Alfonso V., Monllau J.C., The anatomy and isometry of a qua-

si-anatomical reconstruction of the medial patellofemoral ligament (2017) KNEE SURG SPORT TR A, 25 (8), 2420-2423.

**IF: 3.210**

Perez-Prieto D., Portillo M.E., Gonzalez-Lucena G., Gines-Cespedosa A., Foot and ankle infections: Debridement, early fixation and rifampicin provide earlier recovery of function and quality of life (2017) FOOT ANKLE SURG.

**IF: 2.653**

Trigo L., Sarasquete J., Noguera L., Proubasta I., Lamas C., Radial nerve injury following elbow external fixator: report of three cases and literature review (2017) ARCH ORTHOP TRAUM SU, 137 (7), 953-957.

**IF: 1.967**

**Scientific  
Production**

**Other  
Publications**

- ▶ L. Trigo, C. Lamas, J. Sarasquete, J. De Caso, I. Proubasta. Luxación de codo con fractura ipsilateral del extremo distal del radio asociada a lesión de la arteria braquial. Una nueva entidad patológica de origen traumático. Revista Española de Cirugía Ortopédica y Traumatología 2017; 61 (3): 146.

# Pain and Neurosciences



## Coordinator

Català Puigbó, Elena FGS  
ecatala@santpau.cat

## Members

Díaz Jover, Rubén FGS  
Parera Ruiz, Ana FGS

## Main Lines of Research

- ▶ Involvement of brain areas and release of substances in acute and chronic neuropathic pain.
- ▶ Sleep disturbance on initiating systemic opioid treatment in patients with severe chronic pain and altered sleep patterns.
- ▶ Influence epidural corticosteroids treatment by different approach on the effectiveness of the radicular pain due to herniated lumbar disc.
- ▶ Profile in terms of demographics, comorbidities, kind of pain, physical and mental status and disability of patient.
- ▶ Look for a local and non pharmacological treatment for elderly patients with pain.

## Challenges

- ▶ Establish the possible differences in brain area involvement between acute and chronic pain.
- ▶ Determine the extent of chronic pain according to the involvement of different brain areas and if these alterations can improve with the relieve of pain.
- ▶ Determine whether the intensity of chronic neuropathic pain assessed by the patient is correlated with the patient's psychopathology, essentially anxiety, depression and catastrophizing.
- ▶ Determine the profile of patients who would benefit from treatment with major systemic opioids in relation to night rest and establish the recommendable opioid.
- ▶ Establish the recommended opioid dose to start a treatment and how to remove them.

## Collaborations

### Collaborations with other IIB Sant Pau Groups

- ▶ Psychiatry
- ▶ Anesthesiology
- ▶ Neurosurgery
- ▶ Neuroradiology

## Scientific Production


**\*TIF: 2.693 \*\*MIF: 2.693**

Videla S., Català E., Ribera M.-V., Montes A., Samper D., Fuentes J., Busquets C., Characteristics and outcomes of chronic pain patients referred to hospital pain clinics: A prospective observational study (2017) MINERVA ANESTESIOL, 83 (1), 12-22.  
**IF: 2.693**

\*Total Impact Factor \*\*Mean Impact Factor



# Nursing Care Research


**Coordinator**

López Ortega, Laura FGS  
llopez@santpau.cat

**Members**

Armora Verdú, Miriam	FGS
Berga Congost, Gemma	FGS
Cebrià Morales, Maria Queralt	FGS
Jover Sancho, Carmen	FGS
Marine Méndez, Albert	FGS
Márquez López, Adrián	FGS
Mas Dalmau, Gemma	IR
Ricart Basagaña, Maria Teresa	FGS
Roca Sarsanedas, Jaume	FGS
Romero Pastor, Mónica	FGS
Sillero Sillero, Amalia	FGS
Valverde Bernal, Jonatan	FGS
Vicente Pérez, Sílvia	FGS

**Main Lines  
of Research**

- ▶ Fall prevention and analysis of fall-related factors.
- ▶ Translation and validation of care evaluation questionnaires.
- ▶ Constipation and ageing.
- ▶ Quality of life related to nursing care.
- ▶ Development and application of health science methods: qualitative and qualita-

tive methods, text analysis and discourse analysis.

- ▶ Patient satisfaction with nursing care.
- ▶ Attention to the family.
- ▶ Pain.

**Challenges**

- ▶ Strengthen implemented research lines and disseminate the results of active projects.
- ▶ Explore the impact of nursing care for patients, strategies for care improvement and the application of results in cure models.

▶ Improve the development and understanding of qualitative research in the context of the health sciences and disseminate qualitative methods and analyses of text and discourse as tools in health science research.

- ▶ Create the synergies necessary to consolidate the group's activities.

**Collaborations**
**Collaborations with other IIB Sant Pau Groups**

- ▶ Collaboration with the Emergency group and Cardiology group to carry out the study: Gemma Berga, Adrian Marquez, Joñatan Valverde. Impact on reperfusion time after the elaboration and dissemination of an early diagnosis algorithm for acute myocardial infarction.
- ▶ Collaboration directing the final works of residence in resident nurses of mental health and paediatrics (2017) for Gemma Mas in:
  - Maria Pilar Rodríguez de Vera Escudero (R2 Mental Health). Mindfulness in parents of children with autism".

- Cristina Bonet Otero (R2 Paediatrics). Ulcers for pressure in ICU neonates.

- Paula Pasaro Fernández (R2 Paediatrics). Sexual education in children.

- José Alberto Tomé Pérez (R2 Mental Health). Prevalence of metabolic syndrome in patients with lithium treatment.

**External Collaborations**

- ▶ Collaboration with Hospital del Mar Research Institute (IMIM). Improving the therapeutic relationship in nursing care through the evidence multicentrical study in Catalonia psychiatry units. Queralt Cebrián Morales.

**Grants  
Awarded in 2017**

- ▶ Amalia Sillero Sillero. Impacte dels factors de l'entorn de la pràctica infermera en els resultats de les infermeres i dels pacients quirúrgics. SLT002/16/00033. Departament de Salut. Duration: 2017. 17,927.42 €.
- ▶ Adrián Márquez López. Desenvolupament i evaluació de l'impacte d'un llistat de verificació de seguretat adaptat a la cardiologia intervencionista. PR-235/17. Fundació Infermeria i Societat. Duration: 2018-2020. 4,000.00 €.

Note: Total amount granted to PI. It does not include indirect costs.

## Awards

- ▶ Adrián Márquez López. Young Talent Award in the category of Specialized Nursing Assistance. Association Catalano-Balear Nurses.
- ▶ Jonatan Valverde. How does an ischemic coronary event influence sexual activity? Award Oral communication Primary author. 38th Congress of the Spanish Association of Nursing in Cardiology (AEEC). Barcelona, 2017.
- ▶ Miriam Armora Verdú. Effectiveness of a smartphone application to major ambulatory surgery patients. Award at the III Jornades d'Infermeria to the Hospital of Santa Creu i Sant Pau. Barcelona 2017.

## Scientific Production

**\*TIF:2.0320 \*\*MIF: 2.0320**

Mas Dalmau G., Sant Arderiu E., Enfedaque Montes M.B., Sola I., Pequeno Saco S., Alonso Coello P., Patients' and physicians' perceptions and attitudes about oral anticoagulation and atrial fibrillation: a qualitative systematic review (2017) BMC FAM PRACT, 18 (1), 1-11.  
**IF: 2.0320**

## Other Publications

- ▶ Berga Congost G, Valverde Bernal J, Márquez López A, García Picart J. Factores clínicos predictores de retraso en la actuación del Código Infarto. ENFER CARDIOL. 2017; 71:63-71.
- ▶ Roca Sarsanedas J, Soler Candelas P, Martínez Suñé JM, Guerrero Moreno N, Rodríguez Lacabra D, Moreno Hernández M. Revisión de la seguridad en la administración del contraste yodado por vía endovenosa para los procedimientos de Tomografía Computerizada. REV. SOC. ESP. ENF. RADIOL. 2017; 14(3): 83-87.

# Reproductive Health



## Coordinator

Calaf Alsina, Joaquim FGS  
jcalaf@santpau.cat

## Members

Adelantado Pérez, FGS  
Juan María Espinosa Gómez, Juan José Estadella Tarriel, FGS  
Josep Ramón Guinot Gasull, Misericordia FGS  
Perelló Capo, Josep FGS  
Porta Roda, Josep Oriol FGS  
Rams Llop, Noelia FGS

## Main Lines of Research

- ▶ Qualitative study of foetal motility by means of 2D ultrasound in foetuses with spinal muscular atrophy.
- ▶ Value of foetal nuchal translucency as a marker of neuromuscular diseases and other monogenic diseases.
- ▶ Usefulness of Doppler ultrasound of the umbilical artery during the second trimester as a discriminator of pregnancies at high risk of poor perinatal outcomes.

## Challenges

- ▶ Consolidate a line of work with Sant Pau's genetics department concerning possible early clinical manifestations detectable using 2D and 4D ultrasound in foetuses affected by genetic diseases, particularly neuromuscular disorders, given that Sant Pau is a referral centre for a particular group of rare diseases.
- ▶ Screen for chromosomal abnormalities from the ultrasound and biochemistry points of view, investigating the potential usefulness of the markers used either alone or in combination as indicators of populations at risk of placental insufficiency.

- ▶ Cutoff point for foetal pyelectasis as a nephrourologic pathology discriminator.
- ▶ Value of ultrasound in the control of foetal anaemia.

**\*TIF: 22.249 \*\*MIF: 2.781**

Egan A.M., Vellinga A., Harreiter J., Simmons D., Desoye G., Corcoy R., Adelantado J.M., Devlieger R., van Assche A., Galjaard S., Damm P., Mathiesen E.R., Jensen D.M., Andersen L., Lapolla A., Dalfra M.G., Bertolotto A., Mantaj U., Wender-Ozegowska E., Zawiejska A., Hill D., Jelsma J.G.M., Snoek F.J., Worda C., Bancher-Todesca D., van Poppel M.N.M., Kautzky-Willer A., Dunne F.P., Epidemiology of gestational diabetes mellitus according to IADPSG/WHO 2013 criteria among obese pregnant women in Europe (2017) *DIABETOLOGIA*, 60 (10), 1913-1921.

**IF: 6.023**

Espinosa JJ., Vanrell C., Gich I., Urgell E., Calaf J., Pituitary response profile following metoclopramide administration in women with different forms of hyperprolactinemia (2017) *GYNECOL ENDOCRINOL*, 33 (2), 148-151.

**IF: 1.453**

Espinosa JJ., Polo A., Sanchez-Hernandez J., Bordas R., Pares P., Martinez O., Calaf J., Weight decrease improves live birth rates in obese women undergoing IVF: a pilot study (2017) *REPROD BIOMED ONLINE*, 35 (4), 417-424.

**IF: 2.967**

Estadella J., Espanol P., Grandal B., Gine M., Parra J., Laparoscopy during pregnancy: Case report and key points to improve laparoscopic management (2017) *EUR J OBSTET GYN R B*, 217, 83-88.

**IF: 1.809**

Monroy G., Tundidor D., Orellana I., Garcia-Patterson A., Adelantado J.M., Corcoy R., Antenatal oral glucose tolerance test in women with gestational diabetes mellitus: Fasting plasma glucose is the best predictor of both large for-gestational-age newborns and postpartum glucose tolerance (2017) *MINERVA ENDOCRINOL*, 42 (4), 311-317.

**IF: 1.260**

Pascual A., Guerriero S., Rams N., Juez L., Ajossa S., Graupera B., Hereter L., Cappai A., Pero M., Perniciano M., Errasti T., Parra J., Solis M., Alcazar J.L., Clinical and ultrasound features of benign, borderline, and malignant invasive mucinous ovarian tumors (2017) *EUR J GYNAECOL ONCOL*, 38 (3), 382-386.

**IF: 0.617**

Sattler M.C., Jelsma J.G.M., Bogaerts A., Simmons D., Desoye G., Corcoy R., Adelantado J.M., Kautzky-Willer A., Harreiter J., van Assche F.A., Devlieger R., Jans G., Galjaard S., Hill D., Damm P., Mathiesen E.R., Wender-Ozegowska E., Zawiejska A., Blumska K., Lapolla A., Dalfra M.G., Bertolotto A., Dunne F., Jensen D.M., Andersen L.L.T., Snoek F.J., van Poppel M.N.M., Correlates of poor mental health in early pregnancy in obese European women (2017) *BMC PREGNANCY CHILDB*, 17 (1).

**IF: 2.331**

Simmons D., Devlieger R., Van Assche A., Jans G., Galjaard S., Corcoy R., Adelantado J.M., Dunne F., Desoye G., Harreiter J., Kautzky-Willer A., Damm P., Mathiesen E.R., Jensen D.M., Andersen L., Lapolla A., Dalfra M.G., Bertolotto A., Wender-Ozegowska E., Zawiejska A., Hill D., Snoek F.J., Jelsma J.G.M., Van Poppel M.N.M., Effect of physical activity and/or healthy eating on gdmg risk: The dali lifestyle study (2017) *J CLIN ENDOCR METAB*, 102 (3), 903-913.

**IF: 5.789**

# Translational Molecular Oncology



## Coordinator

Parreño Gómez, Matilde IR  
mparreno@santpau.cat

## Members

Antoñón Rodríguez, Carlos IR- EXTERNAL  
Blanco, María Laura FGS

## Main Lines of Research

- ▶ In vitro and in vivo studies by genetic manipulation of putative biomarkers of prognosis in squamous cell carcinoma (SCC) in tumour progression, in radiotherapy and as potential therapeutic targets.
- ▶ Establiment of in vitro or in vivo models in leukomogenesis. Preclinical cancer models to study prognosis and alternative strategy of treatments in leukemia.

## Challenges

- ▶ Evaluate survival pathways, DNA damage response and epithelial-mesenchymal transition involving the studied genes.
- ▶ Improve a mouse model of cancer, based on implantation of human primary tumour.
- ▶ Reinforce and encourage translational research in tumour progression through collaboration with internal and external research groups

## Collaborations

### Collaborations with other IIB Sant Pau Groups


- ▶ Haematological Diagnosis (Josep Nomdedéu)
  - Establishment of "in vitro" and "in vivo" model of leukomogenesis.
- ▶ Support grants to the Research Groups of Catalonia. Grup de Diagnòstic Hematològic. AGAUR 2017. 2017-SGR-383. Duration: 2017-2019.
- ▶ Ear, Nose and Throat Cancers (Xavier Leon): studies of HNSCC.
- ▶ Angiology, Vascular Biology and Inflammation (Mercedes Camacho): studies of HNSCC.
- ▶ Implementation of Clean Room for advance therapeutic medicament production in collaboration with IR and BST (Eleena Serrano, Jordi Virgili, Jaume Kulisevsky)

## Active Projects

- ▶ Josep Francesc Nomdedéu Guinot, Matilde Parreño. Instituto de Salud Carlos III. PI/00940. Duration: 2017-2019. 80,465 €.

## External Collaborations

- ▶ Cell signalling and checkpoints, Faculty of Medicine, IDIBAPS (Neus Agell and Montserrat Jaumot).
- ▶ Translational Research Laboratory, Institut Català d'Oncologia (ICO) - IDIBELL (Alberto Villanueva): studies of mouse models.
- ▶ Master studies of Carlos Antoñón (Universitat de Barcelona) in the project: Designing of shRNA and production of lentiviral particles for gene infraexpression.
- ▶ PhD studies of Sabina Cisa from UAB Faculty of Medicine and Université Aix-Marseille (France)



# Cardiac Surgery



## Coordinator

Padró Fernández,  
Josep Maria  
jpadro@santpau.cat

## Members

Montiel Serrano, José  
Roselló Díez, Elena

FGS

FGS

## Main Lines of Research

- ▶ Off-pump coronary artery by-pass grafting surgery.
- ▶ Mitral repair surgery.
- ▶ Ascending aorta pathology.
- ▶ Pathogenesis of atrial fibrillation after cardiac surgery: electrophysiologic and mitochondrial analysis.
- ▶ Follow-up of sutureless aortic valve prosthesis: Perceval S.
- ▶ Follow-up of surgical check-list implementation.
- ▶ Use of erythropoietin before cardiac surgery.
- ▶ Participation in VISION study (Vascular events In Surgery patients cOhort evaluation)-Cardiac Surgery.

## Challenges

- ▶ Consolidation as a research group in different cardiac surgery-related fields, specific sutureless valve prosthesis-perioperative myocardial infarction.
- ▶ Participation in the assessment and validation of new products employed in cardiac surgery: haemostatics, sutures, systems for sternal closure...
- ▶ Collaboration with different national and international research teams involved in our lines of study.

## Collaborations

### Collaborations with other IIB Sant Pau Groups

- ▶ Leif Hove-Madsen, ICCC-CSIC.
- ▶ M. Luz Maestre Hittinger. Department of Anaesthesiology.

### External Collaborations

- ▶ Elena Domínguez Garrido. Unit of Molecular Diagnosis. Fundación Rioja Salud, La Rioja, Spain.
- ▶ Elisabeth Berastegui. Department of Cardiac Surgery. Hospital Germans Trias i Pujol, Badalona, Spain.
- ▶ Mercé Cladellas Capdevila. Department of Cardiology. Hospital del Mar, Barcelona, Spain.

## Scientific Production

Munoz-Guijosa C., Cortina Romero J.M., Aneurysm of both coronary buttons in a Marfan patient after Bentall-De Bono operation (2017) EUR J CARDIO-THORAC, 51 (4), 802.  
**IF: 3.504**


Ophof T., Remme C.A., Jorge E., Noriega F., Wiegerinck R.F.,

Tasiam A., Beekman L., Alvarez-Garcia J., Munoz-Guijosa C., Coronel R., Cinca J., Cardiac activation-repolarization patterns and ion channel expression mapping in intact isolated normal human hearts (2017) HEART RHYTHM, 14 (2), 265-272.  
**IF: 4.743**

Rossello X., Munoz-Guijosa C., Mena E., Camprecios M., Mendez A.B., Borras X., Padro J.M., Tricuspid valve replacement with mechanical prostheses: Short and long-term outcomes (2017) J CARDIAC SURG, 32 (9), 542-549.  
**IF: 1.179**

**\*TIF: 9.426 \*\*MIF: 3.142**

\*Total Impact Factor \*\*Mean Impact Factor



# Inflammation and Vascular Remodelling



## Coordinator

Rodríguez Sinovas,  
María Cristina  
crodriguezs@santpau.cat

## Members

Aguiló Nuñez, Silvia	ICCC
Cañes Esteve, Laia	ICCC
Segalés Aguilar, Estefanía	ICCC

## Main Lines of Research

- ▶ Inflammation and vascular remodelling: regulation of cardiovascular homeostasis by extracellular matrix components and modifying enzymes.
- ▶ Molecular and cellular mechanisms in atherosclerosis: identification of new therapeutic targets.
- ▶ Molecular basis of abdominal aortic aneurysm (AAA): new pharmacological strategies.
- ▶ Epigenetics in cardiovascular diseases.

## Challenges

- ▶ Identify new therapeutic targets, progression markers and biomarkers in atherosclerosis and AAA.
- ▶ Establish genetically modified animal models that could become useful disease models in atherosclerosis and AAA.
- ▶ Expand and consolidate the scientific staff.
- ▶ Increase regular funding through national and international calls.
- ▶ Set up new stable collaborations within IIB Sant Pau and with national and international groups and consolidate those already established.

## Collaborations

### Collaborations with other IIB Sant Pau Groups

- ▶ Angiology, Vascular Biology and Inflammation (PI: Luis Vila).
- ▶ Regulation of Cardiac Rhythm and Contraction (PI: Leif Hove-Madsen).
- ▶ Atherosclerosis and Vascular Biology (PI: José Martínez González).

### External Collaborations

- ▶ Alicia García Arroyo. Centro Nacional de Investigaciones Cardiovasculares (Spain)
- ▶ Nadia Mercader. University of Berna (Switzerland).
- ▶ Vicente Andrés. Centro Nacional de Investigaciones Cardiovasculares (Spain).
- ▶ E. Rodríguez-Boulan (Cornell University)

▶ Antonio Rodríguez-Sinovas/David García-Dorado. Hospital de la Vall d'Hebron (Spain).

▶ Roxana Carare (University of Southampton)

▶ Mercedes Salaices. Universidad Autónoma de Madrid (Spain).

▶ Victoria Cachofeiro. Universidad Complutense de Madrid (Spain).

▶ Francisco Marín. Department of Cardiology, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia (Spain).

▶ Francisco Sánchez-Madrid. Hospital de la Princesa (Madrid, Spain).

▶ Anna Planas (IIBB-CSIC).

## Active Grants

- ▶ María Cristina Rodríguez Sinovas. Remodelado de la matriz extracelular en el aneurisma de aorta abdominal y enfermedad arterial periférica. PI15/01016. Instituto de Salud Carlos III. Duration: 2016-2018. 156,500.00 €.
- ▶ María Cristina Rodríguez Sinovas. Remodelado de la matriz extracelular en la angio-arteriogenesis y la función vascular: impacto sobre la fisiopatología y el manejo clínico de la enfermedad arterial periférica. Sociedad Española de Cardiología. 20,000 €.

Note: Total amount granted to PI. It does not include indirect costs.

## Awards

- ▶ Special mention for the communication: Martí-Pàmies I, Cañes L, Alonso J, Romero JM, Rodríguez C, Martínez-González J. NOR1 en el aneurisma de aorta abdominal (AAA): generación de un nuevo modelo animal de AAA experimental. XXX Congreso de la Sociedad Española de Aterosclerosis. Cádiz, 31 May-2 June 2017.

## Theses

- ▶ Ingrid Martí Pàmies. NOR-1 en el remodelat cardiovascular: Identificació de gens diana i caracterització d'animals transgènics per a NOR-1 com a models en patologies cardiovasculars. Universitat de Barcelona. Directors: José Martínez-González, Cristina Rodríguez Sinovas. Date of defense: 10/03/2017.

## Patents

- ▶ José Martínez González, Cristina Rodríguez Sinovas, Ingrid Martí Pàmies, Modelo animal para aneurisma aórtico y sus usos, P201631548. Spanish patent. 07/12/2016.

## Scientific Production

**\*TIF: 21.8420 \*\*MIF: 5.4605**

Galan M., Varona S., Guadall A., Orriols M., Navas M., Aguiló S., De Diego A., Navarro M.A., García-Dorado D., Rodriguez-Sinovas A., Martínez-González J., Rodríguez C., Lysyl oxidase overexpression accelerates cardiac remodeling and aggravates angiotensin II-induced hypertrophy (2017) FASEB J, 31 (9), 3787-3799.

**IF: 5.5950**

Martínez-Revelles S., García-Redondo A.B., Avendano M.S., Varona S., Palao T., Orriols M.,

Roque F.R., Fortuno A., Touyz R.M., Martínez-González J., Salaices M., Rodríguez C., Briones A.M., Lysyl Oxidase Induces Vascular Oxidative Stress and Contributes to Arterial Stiffness and Abnormal Elastin Structure in Hypertension: Role of p38MAPK (2017) ANTONIO REDOX SIGN, 27 (7), 379-397.

**IF: 6.5300**

Marti-Pamies I., Canes L., Alonso J., Rodríguez C., Martínez-González J., The nuclear receptor NOR-1/NR4A3 regulates the multi-

functional glycoprotein vitronectin in human vascular smooth muscle cells (2017) FASEB J, 31 (10), 4588-4599.

**IF: 5.5950**

Soto B, Gallastegi-Mozos T, Rodríguez C, Martínez-González J, Escudero JR, Vila L, Camacho M. Circulating CCL20 as a New Biomarker of Abdominal Aortic Aneurysm. Sci Rep. 2017 Dec 11;7(1):17331.

**IF: 4.122**

## Other Publications

- ▶ Varona V, García-Redondo AB, Martínez-González J, Salaices M, Briones AM, Rodríguez C. La sobreexpresión vascular de la lisil oxidasa altera la estructura de la matriz extracelular e induce estrés oxidativo. Clin Investig Arterioscler. 2017; 29: 157-165.



Sant Pau  
Biomedical Research Institute

Sant Antoni Maria Claret, 167  
08025 Barcelona

iib@santpau.cat

[www.recercasantpau.cat](http://www.recercasantpau.cat)



CSB Consorci Sanitari  
de Barcelona

 Agència  
de Salut Pública

eap|sardenya

© Sant Pau Biomedical Research Institute (IIB Sant Pau), 2017

Hospital de la Santa Creu i Sant Pau

Sant Antoni Maria Claret, 167

08025 Barcelona

Spain

#### Photography

Hospital de la Santa Creu i Sant Pau Image bank

Sant Pau Biomedical Research Institute Image bank

Marta Jordi

Shutterstock